@prefix ns1: <https://1145.am/db/> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://1145.am/db/2201859/Rxvantage> a org:Organization ;
    ns1:buyer <https://1145.am/db/2201859/Repaccess_Acquisition> ;
    ns1:documentDate "2013-06-06T12:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "RxVantage Continues Rapid Growth with Acquisition of Competitor RepAccess" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/rxvantage-continues-rapid-growth-acquisition-competitor-repaccess> ;
    ns1:foundName "RxVantage" ;
    ns1:name "RxVantage" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2205089/Claremont_Creek_Ventures> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-06-26T13:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NuMedii Receives $3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/numedii-receives-3-5m-a-series-a-financing-from-claremont-creek-ventures-and-lightspeed-venture> ;
    ns1:foundName "Claremont Creek Ventures" ;
    ns1:investor <https://1145.am/db/2205089/Series_A_Investment_Claremont_Creek_Ventures_Life_Science_Angels_Lightspeed_Venture_Partners_Numedii_Completed> ;
    ns1:name "Claremont Creek Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1896192/Claremont_Creek_Ventures>,
        <https://1145.am/db/2326261/Claremont_Creek_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1830066/Claremont_Creek_Ventures>,
        <https://1145.am/db/1862378/Claremont_Creek_Ventures>,
        <https://1145.am/db/2295700/Claremont_Creek_Ventures>,
        <https://1145.am/db/2303734/Claremont_Creek_Ventures>,
        <https://1145.am/db/2308700/Claremont_Creek_Ventures>,
        <https://1145.am/db/2321658/Claremont_Creek_Ventures>,
        <https://1145.am/db/2342724/Claremont_Creek_Ventures>,
        <https://1145.am/db/2360088/Claremont_Creek_Ventures> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2205089/Life_Science_Angels> a org:Organization ;
    ns1:description "funding" ;
    ns1:documentDate "2013-06-26T13:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NuMedii Receives $3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/numedii-receives-3-5m-a-series-a-financing-from-claremont-creek-ventures-and-lightspeed-venture> ;
    ns1:foundName "Life Science Angels" ;
    ns1:investor <https://1145.am/db/2205089/Series_A_Investment_Claremont_Creek_Ventures_Life_Science_Angels_Lightspeed_Venture_Partners_Numedii_Completed> ;
    ns1:name "Life Science Angels" ;
    ns1:sameAsMedium <https://1145.am/db/2303734/Life_Science_Angels>,
        <https://1145.am/db/2318941/Life_Science_Angels>,
        <https://1145.am/db/2326159/Life_Science_Angels>,
        <https://1145.am/db/2329010/Life_Science_Angels>,
        <https://1145.am/db/2329011/Life_Science_Angels>,
        <https://1145.am/db/922439/Life_Science_Angels> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2206103/Buckhead_Investment_Partners> a org:Organization ;
    ns1:basedInLowRaw "Buckhead Investment Partners" ;
    ns1:description "investment" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "Buckhead Investment Partners" ;
    ns1:investor <https://1145.am/db/2206103/Investment_Buckhead_Investment_Partners_C___B_Capital_Council_Capital_Reach_Health_Silicon_Valley_Bank_Completed> ;
    ns1:name "Buckhead Investment Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2245807/Buckhead_Investment_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2206103/C___B_Capital> a org:Organization ;
    ns1:description "investment firms" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "C & B Capital" ;
    ns1:investor <https://1145.am/db/2206103/Investment_Buckhead_Investment_Partners_C___B_Capital_Council_Capital_Reach_Health_Silicon_Valley_Bank_Completed> ;
    ns1:name "C & B Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2234150/C___B_Capital> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2206103/Council_Capital> a org:Organization ;
    ns1:description "investment firms" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "Council Capital" ;
    ns1:investor <https://1145.am/db/2206103/Investment_Buckhead_Investment_Partners_C___B_Capital_Council_Capital_Reach_Health_Silicon_Valley_Bank_Completed> ;
    ns1:name "Council Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2234150/Council_Capital> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2206103/Silicon_Valley_Bank> a org:Organization ;
    ns1:basedInLowRaw "Silicon Valley" ;
    ns1:description "debt" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "Silicon Valley Bank" ;
    ns1:investor <https://1145.am/db/2206103/Investment_Buckhead_Investment_Partners_C___B_Capital_Council_Capital_Reach_Health_Silicon_Valley_Bank_Completed> ;
    ns1:name "Silicon Valley Bank" ;
    ns1:sameAsHigh <https://1145.am/db/1459827/Silicon_Valley_Bank>,
        <https://1145.am/db/1459870/Silicon_Valley_Bank> ;
    ns1:sameAsMedium <https://1145.am/db/1083805/Silicon_Valley_Bank>,
        <https://1145.am/db/1150348/Silicon_Valley_Bank>,
        <https://1145.am/db/1152132/Silicon_Valley_Bank>,
        <https://1145.am/db/1152410/Silicon_Valley_Bank>,
        <https://1145.am/db/1156520/Silicon_Valley_Bank>,
        <https://1145.am/db/1156858/Silicon_Valley_Bank>,
        <https://1145.am/db/1157082/Silicon_Valley_Bank>,
        <https://1145.am/db/1322428/Silicon_Valley_Bank>,
        <https://1145.am/db/1322978/Silicon_Valley_Bank>,
        <https://1145.am/db/1323008/Silicon_Valley_Bank>,
        <https://1145.am/db/1364929/Silicon_Valley_Bank>,
        <https://1145.am/db/1406733/Silicon_Valley_Bank>,
        <https://1145.am/db/1407485/Silicon_Valley_Bank>,
        <https://1145.am/db/1459745/Silicon_Valley_Bank>,
        <https://1145.am/db/1488514/Silicon_Valley_Bank>,
        <https://1145.am/db/1541570/Silicon_Valley_Bank>,
        <https://1145.am/db/1593099/Silicon_Valley_Bank>,
        <https://1145.am/db/1593638/Silicon_Valley_Bank>,
        <https://1145.am/db/1593923/Silicon_Valley_Bank>,
        <https://1145.am/db/1632797/Silicon_Valley_Bank>,
        <https://1145.am/db/1642059/Silicon_Valley_Bank>,
        <https://1145.am/db/1642619/Silicon_Valley_Bank>,
        <https://1145.am/db/1667921/Silicon_Valley_Bank>,
        <https://1145.am/db/1698574/Silicon_Valley_Bank>,
        <https://1145.am/db/1713202/Silicon_Valley_Bank>,
        <https://1145.am/db/1741357/Silicon_Valley_Bank>,
        <https://1145.am/db/1742374/Silicon_Valley_Bank>,
        <https://1145.am/db/1743415/Silicon_Valley_Bank>,
        <https://1145.am/db/1754583/Silicon_Valley_Bank>,
        <https://1145.am/db/1763293/Silicon_Valley_Bank>,
        <https://1145.am/db/1763925/Silicon_Valley_Bank>,
        <https://1145.am/db/1764096/Silicon_Valley_Bank>,
        <https://1145.am/db/1770095/Silicon_Valley_Bank>,
        <https://1145.am/db/1772737/Silicon_Valley_Bank>,
        <https://1145.am/db/1773924/Silicon_Valley_Bank>,
        <https://1145.am/db/1774323/Silicon_Valley_Bank>,
        <https://1145.am/db/1776688/Silicon_Valley_Bank>,
        <https://1145.am/db/1779266/Silicon_Valley_Bank>,
        <https://1145.am/db/1786720/Silicon_Valley_Bank>,
        <https://1145.am/db/1788937/Silicon_Valley_Bank>,
        <https://1145.am/db/1790917/Silicon_Valley_Bank>,
        <https://1145.am/db/1797945/Silicon_Valley_Bank>,
        <https://1145.am/db/1798154/Silicon_Valley_Bank>,
        <https://1145.am/db/1800466/Silicon_Valley_Bank>,
        <https://1145.am/db/1801332/Silicon_Valley_Bank>,
        <https://1145.am/db/1801801/Silicon_Valley_Bank>,
        <https://1145.am/db/1802212/Silicon_Valley_Bank>,
        <https://1145.am/db/1805339/Silicon_Valley_Bank>,
        <https://1145.am/db/1811789/Silicon_Valley_Bank>,
        <https://1145.am/db/1815709/Silicon_Valley_Bank>,
        <https://1145.am/db/1816776/Silicon_Valley_Bank>,
        <https://1145.am/db/1826128/Silicon_Valley_Bank>,
        <https://1145.am/db/1835585/Silicon_Valley_Bank>,
        <https://1145.am/db/1835823/Silicon_Valley_Bank>,
        <https://1145.am/db/1838850/Silicon_Valley_Bank>,
        <https://1145.am/db/1844083/Silicon_Valley_Bank>,
        <https://1145.am/db/1847903/Silicon_Valley_Bank>,
        <https://1145.am/db/1850081/Silicon_Valley_Bank>,
        <https://1145.am/db/1851311/Silicon_Valley_Bank>,
        <https://1145.am/db/1851910/Silicon_Valley_Bank>,
        <https://1145.am/db/1859520/Silicon_Valley_Bank>,
        <https://1145.am/db/1865990/Silicon_Valley_Bank>,
        <https://1145.am/db/1870276/Silicon_Valley_Bank>,
        <https://1145.am/db/1879085/Silicon_Valley_Bank>,
        <https://1145.am/db/1885748/Silicon_Valley_Bank>,
        <https://1145.am/db/1892674/Silicon_Valley_Bank>,
        <https://1145.am/db/1910560/Silicon_Valley_Bank>,
        <https://1145.am/db/1920478/Silicon_Valley_Bank>,
        <https://1145.am/db/1930908/Silicon_Valley_Bank>,
        <https://1145.am/db/1934634/Silicon_Valley_Bank_Uk_Limited>,
        <https://1145.am/db/1934658/Silicon_Valley_Bank>,
        <https://1145.am/db/1934735/Silicon_Valley_Bank>,
        <https://1145.am/db/1934736/Silicon_Valley_Bank>,
        <https://1145.am/db/1934742/Silicon_Valley_Bank_Uk>,
        <https://1145.am/db/1934843/Silicon_Valley_Bank>,
        <https://1145.am/db/1935125/Silicon_Valley_Bank>,
        <https://1145.am/db/1935154/Silicon_Valley_Bank>,
        <https://1145.am/db/1935871/Silicon_Valley_Bank>,
        <https://1145.am/db/1935994/Silicon_Valley_Bank>,
        <https://1145.am/db/1937022/Silicon_Valley_Bank>,
        <https://1145.am/db/1939035/Silicon_Valley_Bank>,
        <https://1145.am/db/1941577/Silicon_Valley_Bank>,
        <https://1145.am/db/1942037/Silicon_Valley_Bank>,
        <https://1145.am/db/1943030/Silicon_Valley_Bank>,
        <https://1145.am/db/1947358/Silicon_Valley_Bank>,
        <https://1145.am/db/1947401/Silicon_Valley_Bank>,
        <https://1145.am/db/1949094/Silicon_Valley_Bank>,
        <https://1145.am/db/1949839/Silicon_Valley_Bank>,
        <https://1145.am/db/1950157/Silicon_Valley_Bank>,
        <https://1145.am/db/1950194/Silicon_Valley_Bank>,
        <https://1145.am/db/1950239/Silicon_Valley_Bank>,
        <https://1145.am/db/1951636/Silicon_Valley_Bank>,
        <https://1145.am/db/1955045/Silicon_Valley_Bank>,
        <https://1145.am/db/2002123/Silicon_Valley_Bank>,
        <https://1145.am/db/2038928/Silicon_Valley_Bank>,
        <https://1145.am/db/2073939/Silicon_Valley_Bank>,
        <https://1145.am/db/2075411/Silicon_Valley_Bank>,
        <https://1145.am/db/2115567/Silicon_Valley_Bank>,
        <https://1145.am/db/2163392/Silicon_Valley_Bank>,
        <https://1145.am/db/2170076/Silicon_Valley_Bank>,
        <https://1145.am/db/2189022/Silicon_Valley_Bank>,
        <https://1145.am/db/2192716/Silicon_Valley_Bank>,
        <https://1145.am/db/2235296/Silicon_Valley_Bank>,
        <https://1145.am/db/2248746/Silicon_Valley_Bank>,
        <https://1145.am/db/2281936/Silicon_Valley_Bank>,
        <https://1145.am/db/2288016/Silicon_Valley_Bank>,
        <https://1145.am/db/2297263/Silicon_Valley_Bank>,
        <https://1145.am/db/2302085/Silicon_Valley_Bank>,
        <https://1145.am/db/2302707/Silicon_Valley_Bank>,
        <https://1145.am/db/2306687/Silicon_Valley_Bank>,
        <https://1145.am/db/2307820/Silicon_Valley_Bank>,
        <https://1145.am/db/2328616/Silicon_Valley_Bank>,
        <https://1145.am/db/2331928/Silicon_Valley_Bank>,
        <https://1145.am/db/2332435/Silicon_Valley_Bank>,
        <https://1145.am/db/2341774/Silicon_Valley_Bank>,
        <https://1145.am/db/2342734/Silicon_Valley_Bank>,
        <https://1145.am/db/2344593/Silicon_Valley_Bank>,
        <https://1145.am/db/2364404/Silicon_Valley_Bank>,
        <https://1145.am/db/2430644/Silicon_Valley_Bank>,
        <https://1145.am/db/2752043/Silicon_Valley_Bank>,
        <https://1145.am/db/2752829/Silicon_Valley_Bank>,
        <https://1145.am/db/366024/Silicon_Valley_Bank>,
        <https://1145.am/db/490152/Silicon_Valley_Bank>,
        <https://1145.am/db/490991/Silicon_Valley_Bank>,
        <https://1145.am/db/563676/Silicon_Valley_Bank>,
        <https://1145.am/db/596524/Silicon_Valley_Bank>,
        <https://1145.am/db/658338/Silicon_Valley_Bank>,
        <https://1145.am/db/714643/Silicon_Valley_Bank>,
        <https://1145.am/db/880050/Silicon_Valley_Bank>,
        <https://1145.am/db/941028/Silicon_Valley_Bank>,
        <https://1145.am/db/980498/Silicon_Valley_Bank>,
        <https://1145.am/db/996844/Silicon_Valley_Bank>,
        <https://1145.am/db/998845/Silicon_Valley_Bank> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2223723/406_Ventures> a org:Organization ;
    ns1:documentDate "2013-04-17T11:00:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iora Health Secures $14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/iora-health-secures-14-million-series-b-growth-financing-investor-group-includes-all> ;
    ns1:foundName ".406 Ventures" ;
    ns1:investor <https://1145.am/db/2223723/Growth_Investment_406_Ventures_Fidelity_Biosciences_Iora_Health_Polaris_Partners_Completed> ;
    ns1:name ".406 Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1139285/406_Ventures>,
        <https://1145.am/db/1142546/406_Ventures>,
        <https://1145.am/db/1142551/406_Ventures>,
        <https://1145.am/db/1163164/406_Ventures>,
        <https://1145.am/db/1166225/406_Ventures>,
        <https://1145.am/db/1397691/406_Ventures>,
        <https://1145.am/db/1578595/406_Ventures>,
        <https://1145.am/db/1580731/406_Ventures>,
        <https://1145.am/db/1711806/406_Ventures>,
        <https://1145.am/db/1714166/406_Ventures>,
        <https://1145.am/db/1776782/406_Ventures>,
        <https://1145.am/db/1796169/406_Ventures>,
        <https://1145.am/db/1824878/406_Ventures>,
        <https://1145.am/db/1834224/406_Ventures>,
        <https://1145.am/db/1841792/406_Ventures>,
        <https://1145.am/db/1846338/406_Ventures>,
        <https://1145.am/db/1980072/406_Ventures>,
        <https://1145.am/db/2182698/406_Ventures>,
        <https://1145.am/db/2186424/406_Ventures>,
        <https://1145.am/db/2320692/406_Ventures>,
        <https://1145.am/db/2321813/406_Ventures>,
        <https://1145.am/db/2441913/406_Ventures>,
        <https://1145.am/db/457409/406_Ventures>,
        <https://1145.am/db/593826/406_Ventures>,
        <https://1145.am/db/830293/406_Ventures>,
        <https://1145.am/db/935242/406_Ventures> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2223723/Fidelity_Biosciences> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-17T11:00:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iora Health Secures $14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/iora-health-secures-14-million-series-b-growth-financing-investor-group-includes-all> ;
    ns1:foundName "Fidelity Biosciences" ;
    ns1:industry "healthcare" ;
    ns1:investor <https://1145.am/db/2223723/Growth_Investment_406_Ventures_Fidelity_Biosciences_Iora_Health_Polaris_Partners_Completed> ;
    ns1:name "Fidelity Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/1023072/Bioiq>,
        <https://1145.am/db/1023890/Bioiq>,
        <https://1145.am/db/1092711/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1138485/Biote_Corp>,
        <https://1145.am/db/1139989/Biote_Corp>,
        <https://1145.am/db/1290497/Stagezero_Life_Sciences>,
        <https://1145.am/db/1480516/Biote_Corp>,
        <https://1145.am/db/1480603/Biote_Corp>,
        <https://1145.am/db/1588076/Biodesix>,
        <https://1145.am/db/1618778/Biote_Corp>,
        <https://1145.am/db/1619494/Biote_Corp>,
        <https://1145.am/db/1629263/Biote_Corp>,
        <https://1145.am/db/1630926/Biote_Corp>,
        <https://1145.am/db/1639548/Edp_Biotech>,
        <https://1145.am/db/1640735/Edp_Biotech>,
        <https://1145.am/db/1672932/Bioaffinity_Technologies>,
        <https://1145.am/db/2041484/Biocorp_Production_Sa>,
        <https://1145.am/db/2077341/Biocorp>,
        <https://1145.am/db/2198074/Verily>,
        <https://1145.am/db/2231348/Eclinicalworks>,
        <https://1145.am/db/2282460/Bioventus>,
        <https://1145.am/db/2293417/Biomimetic>,
        <https://1145.am/db/2296000/Bioclinica>,
        <https://1145.am/db/2301310/Big_Biotech>,
        <https://1145.am/db/2303275/Fidelity_Biosciences>,
        <https://1145.am/db/2308972/Genentech>,
        <https://1145.am/db/2331667/Bioscientia>,
        <https://1145.am/db/2337971/Fidelity_Biosciences>,
        <https://1145.am/db/2341842/Biotime>,
        <https://1145.am/db/2350891/Fidelity_Biosciences>,
        <https://1145.am/db/2351459/Pure_Bioscience>,
        <https://1145.am/db/2352128/Biocept_Inc>,
        <https://1145.am/db/2352350/Fidelity_Biosciences>,
        <https://1145.am/db/2361002/Advent_Life_Sciences>,
        <https://1145.am/db/2362166/Biovigil>,
        <https://1145.am/db/2367567/T2_Biosystems>,
        <https://1145.am/db/2539068/Bd_Life_Sciences>,
        <https://1145.am/db/2545409/Frontline_Bioventures>,
        <https://1145.am/db/405559/Myovant_Sciences>,
        <https://1145.am/db/412047/Stagezero_Life_Sciences>,
        <https://1145.am/db/448867/Stagezero_Life_Sciences>,
        <https://1145.am/db/560603/T2_Biosystems>,
        <https://1145.am/db/577663/Bioadvance>,
        <https://1145.am/db/622067/Bioiq>,
        <https://1145.am/db/649524/Stagezero_Life_Sciences>,
        <https://1145.am/db/656629/Stagezero_Life_Sciences>,
        <https://1145.am/db/690944/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/820574/Biocept>,
        <https://1145.am/db/865072/Stagezero_Life_Sciences>,
        <https://1145.am/db/876358/Stagezero_Life_Sciences>,
        <https://1145.am/db/890243/Biofrontera_Inc>,
        <https://1145.am/db/907480/2seventy_Bio>,
        <https://1145.am/db/907791/Biosig_Technologies>,
        <https://1145.am/db/951882/Bioventus_Inc>,
        <https://1145.am/db/976500/Gns_Healthcare>,
        <https://1145.am/db/989768/Biocentriq> ;
    ns1:sameAsMedium <https://1145.am/db/1801792/Fidelity_Biosciences>,
        <https://1145.am/db/1849746/Fidelity_Biosciences>,
        <https://1145.am/db/2304028/Fidelity_Biosciences>,
        <https://1145.am/db/2304044/Fidelity_Biosciences>,
        <https://1145.am/db/2306790/Fidelity_Biosciences>,
        <https://1145.am/db/2313305/Fidelity_Biosciences>,
        <https://1145.am/db/2316601/Fidelity_Biosciences>,
        <https://1145.am/db/2316605/Fidelity_Biosciences>,
        <https://1145.am/db/2317737/Fidelity_Biosciences>,
        <https://1145.am/db/2318905/Fidelity_Biosciences>,
        <https://1145.am/db/2325553/Fidelity_Biosciences>,
        <https://1145.am/db/2326576/Fidelity_Biosciences>,
        <https://1145.am/db/2336890/Fidelity_Biosciences>,
        <https://1145.am/db/2337972/Fidelity_Biosciences>,
        <https://1145.am/db/2339666/Fidelity_Biosciences>,
        <https://1145.am/db/2340581/Fidelity_Biosciences>,
        <https://1145.am/db/2341869/Fidelity_Biosciences>,
        <https://1145.am/db/2341897/Fidelity_Biosciences>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342771/Fidelity_Biosciences>,
        <https://1145.am/db/2344017/Fidelity_Biosciences>,
        <https://1145.am/db/2348149/Fidelity_Biosciences>,
        <https://1145.am/db/2349048/Fidelity_Biosciences>,
        <https://1145.am/db/2349050/Fidelity_Biosciences>,
        <https://1145.am/db/2352349/Fidelity_Biosciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2356048/Fidelity_Biosciences>,
        <https://1145.am/db/2356124/Fidelity_Biosciences>,
        <https://1145.am/db/2357722/Fidelity_Biosciences>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2359240/Fidelity_Biosciences>,
        <https://1145.am/db/2359287/Fidelity_Biosciences>,
        <https://1145.am/db/2359562/Fidelity_Biosciences>,
        <https://1145.am/db/2359683/Fidelity_Biosciences>,
        <https://1145.am/db/2361065/Fidelity_Biosciences>,
        <https://1145.am/db/2363510/Fidelity_Biosciences>,
        <https://1145.am/db/2366710/Fidelity_Biosciences>,
        <https://1145.am/db/2366712/Fidelity_Biosciences>,
        <https://1145.am/db/2367022/Fidelity_Biosciences>,
        <https://1145.am/db/2367023/Fidelity_Biosciences>,
        <https://1145.am/db/2367381/Fidelity_Biosciences>,
        <https://1145.am/db/2369644/Fidelity_Biosciences>,
        <https://1145.am/db/2549505/Fidelity_Biosciences>,
        <https://1145.am/db/2549507/Fidelity_Biosciences>,
        <https://1145.am/db/2551315/Fidelity_Biosciences>,
        <https://1145.am/db/2569831/Fidelity_Biosciences>,
        <https://1145.am/db/2587938/Fidelity_Biosciences>,
        <https://1145.am/db/2588372/Fidelity_Biosciences> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235248/Craig_Hospital> a org:Organization ;
    ns1:basedInHighGeoName "Denver" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5419384/about.rdf> ;
    ns1:basedInHighRaw "Denver" ;
    ns1:description "traumatic brain and spinal cord rehabilitative services" ;
    ns1:documentDate "2013-05-30T21:00:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Craig Hospital Undergoes State-of-the-Art Renovations With Support from Wells Fargo Securities" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/craig-hospital-undergoes-state-art-renovations-support-from-wells-fargo-securities> ;
    ns1:foundName "Craig Hospital" ;
    ns1:industry "Hospital" ;
    ns1:name "Craig Hospital" ;
    ns1:protagonist <https://1145.am/db/2235248/Investment_Craig_Hospital_Wells_Fargo_Securities_Has_Not_Happened> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235258/Davita> a org:Organization ;
    ns1:basedInLowRaw "Colombia" ;
    ns1:buyer <https://1145.am/db/2235258/Esensa_Sas_Interest_Acquisition> ;
    ns1:description "health care" ;
    ns1:documentDate "2013-06-03T13:00:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DaVita Expands Operations into Latin America" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/davita-expands-operations-into-latin-america> ;
    ns1:foundName "DaVita" ;
    ns1:name "DaVita" ;
    ns1:sameAsHigh <https://1145.am/db/1339012/Davita_Inc>,
        <https://1145.am/db/2186308/Davita_Medical_Group>,
        <https://1145.am/db/2190847/Davita_Medical_Group>,
        <https://1145.am/db/2191220/Davita_Medical_Group>,
        <https://1145.am/db/2191396/Davita_Medical_Group>,
        <https://1145.am/db/2197606/Davita_Medical_Group>,
        <https://1145.am/db/2197622/Davita_Medical_Group>,
        <https://1145.am/db/2331506/Davita_Healthcare_Partners>,
        <https://1145.am/db/964954/Davita_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2185708/Davita>,
        <https://1145.am/db/2186554/Davita>,
        <https://1145.am/db/2189671/Davita>,
        <https://1145.am/db/2189838/Davita>,
        <https://1145.am/db/2190142/Davita>,
        <https://1145.am/db/2227390/Davita_Inc>,
        <https://1145.am/db/2232720/Davita>,
        <https://1145.am/db/2234949/Davita_Inc>,
        <https://1145.am/db/2238943/Davita_Inc>,
        <https://1145.am/db/2239943/Davita_Inc>,
        <https://1145.am/db/2241773/Davita_Inc>,
        <https://1145.am/db/2246088/Davita>,
        <https://1145.am/db/2251771/Davita_Inc>,
        <https://1145.am/db/462169/Davita_Inc> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2247010/St_Lukes_Health_System> a org:Organization ;
    ns1:basedInHighGeoName "Boise" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5586437/about.rdf> ;
    ns1:basedInHighRaw "Boise" ;
    ns1:buyer <https://1145.am/db/2247010/Saltzer_Medical_Group_Acquisition> ;
    ns1:description "health care" ;
    ns1:documentDate "2013-03-14T17:01:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Despite increasing healthcare consolidation, FTC remains wary" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/despite-increasing-healthcare-consolidation-ftc-remains-wary> ;
    ns1:foundName "St. Luke's Health System" ;
    ns1:industry "health care" ;
    ns1:name "St. Luke's Health System" ;
    ns1:sameAsHigh <https://1145.am/db/2181757/St_Lukes>,
        <https://1145.am/db/2184701/St_Lukes_University_Health_Network>,
        <https://1145.am/db/2194425/Chi_St_Lukes_Health>,
        <https://1145.am/db/2237558/St_Lukes_Hospital_And_Health_Network>,
        <https://1145.am/db/2239082/St_Lukes_Health_System>,
        <https://1145.am/db/2239471/St_Lukes_Health_Initiatives>,
        <https://1145.am/db/2246455/St_Lukes_Hospital>,
        <https://1145.am/db/2253120/St_Lukes_Health_System>,
        <https://1145.am/db/2254888/St_Lukes_Health_System>,
        <https://1145.am/db/2254907/St_Lukes_Hospital>,
        <https://1145.am/db/2255710/St_Lukes>,
        <https://1145.am/db/2257072/St_Lukes_Health_System>,
        <https://1145.am/db/2257111/St_Lukes_Health_System>,
        <https://1145.am/db/2260588/St_Lukes>,
        <https://1145.am/db/2261433/St_Lukes_Health_System>,
        <https://1145.am/db/2262350/St_Lukes_Health_System>,
        <https://1145.am/db/2264918/St_Lukes_Health_System>,
        <https://1145.am/db/2267653/St_Lukes_Hospital>,
        <https://1145.am/db/2268178/St_Lukes_Health_System>,
        <https://1145.am/db/2271176/St_Lukes_Health_System>,
        <https://1145.am/db/2274631/St_Lukes_Health_System>,
        <https://1145.am/db/2276051/St_Lukes_Health_System>,
        <https://1145.am/db/2276051/St_Lukes_Hospital>,
        <https://1145.am/db/2276435/St_Lukes_Health_System-Saltzer_Medical_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2182171/Saint_Lukes_Health_System> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2249121/Lancaster_Pollard> a org:Organization ;
    ns1:basedInHighGeoName "Columbus" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4509177/about.rdf> ;
    ns1:basedInHighRaw "Columbus, Ohio" ;
    ns1:description "provides capital funding to health care, senior living and housing providers" ;
    ns1:documentDate "2013-04-02T21:27:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lancaster Pollard Completes $54 Million Refunding-Financing for Ohio Hospital" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/lancaster-pollard-completes-54-million-refunding-financing-for-ohio-hospital> ;
    ns1:foundName "Lancaster Pollard" ;
    ns1:industry "financial services" ;
    ns1:investor <https://1145.am/db/2249121/Investment_Lancaster_Pollard_Wood_County_Hospital_Completed> ;
    ns1:name "Lancaster Pollard" ;
    ns1:sameAsHigh <https://1145.am/db/2245274/Lancaster_Pollard>,
        <https://1145.am/db/2245275/Lancaster_Pollard>,
        <https://1145.am/db/2246263/Lancaster_Pollard>,
        <https://1145.am/db/2249120/Lancaster_Pollard>,
        <https://1145.am/db/2249123/Lancaster_Pollard>,
        <https://1145.am/db/2262898/Lancaster_Pollard>,
        <https://1145.am/db/2262900/Lancaster_Pollard> ;
    ns1:sameAsMedium <https://1145.am/db/2200609/Lancaster_Pollard> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2266902/Amerihealth> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:buyer <https://1145.am/db/2266902/Chartered_Health_Plan_Assets_Acquisition> ;
    ns1:description "health insurer" ;
    ns1:documentDate "2013-02-27T18:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AmeriHealth to buy embattled Medicaid plan" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/amerihealth-to-buy-embattled-medicaid-plan> ;
    ns1:foundName "AmeriHealth",
        "AmeriHealth Mercy" ;
    ns1:industry "health insurer" ;
    ns1:investor <https://1145.am/db/2266902/Chartered_Health_Plan_Assets_Acquisition> ;
    ns1:name "AmeriHealth" ;
    ns1:sameAsHigh <https://1145.am/db/1131734/Amerilife>,
        <https://1145.am/db/1288413/Amerilife>,
        <https://1145.am/db/1292642/Amerilife>,
        <https://1145.am/db/1295246/Amerilife>,
        <https://1145.am/db/1351641/Alerislife_Inc>,
        <https://1145.am/db/1352554/Alerislife_Inc>,
        <https://1145.am/db/1405429/Amerisure>,
        <https://1145.am/db/1444953/Amerilife>,
        <https://1145.am/db/1559252/Amerilife>,
        <https://1145.am/db/1592058/Amerisure_Companies>,
        <https://1145.am/db/1605340/Amerilife>,
        <https://1145.am/db/1616131/Ameritrust_Group>,
        <https://1145.am/db/1622344/Amerisafe>,
        <https://1145.am/db/1623019/Amerisafe>,
        <https://1145.am/db/1628444/Ambridge_Group>,
        <https://1145.am/db/1638835/Amerisure_Insurance>,
        <https://1145.am/db/1764038/Amenli>,
        <https://1145.am/db/1929770/Amerisure_Insurance>,
        <https://1145.am/db/2060787/Amerisure_Insurance>,
        <https://1145.am/db/2064233/Amerisafe>,
        <https://1145.am/db/2258956/Amerihealth>,
        <https://1145.am/db/2267701/Amerihealth>,
        <https://1145.am/db/468031/Amerisure_Companies>,
        <https://1145.am/db/468031/Amerisure_Mutual_Holdings>,
        <https://1145.am/db/567739/Amerilife>,
        <https://1145.am/db/669073/Amerisafe>,
        <https://1145.am/db/672095/Amerisafe>,
        <https://1145.am/db/678861/Amerilife>,
        <https://1145.am/db/682272/Ameritas_Mutual_Holding_Company>,
        <https://1145.am/db/747980/Amerilife>,
        <https://1145.am/db/768526/Amerilife>,
        <https://1145.am/db/868938/Amerilife_Group>,
        <https://1145.am/db/919301/Amerilife>,
        <https://1145.am/db/973581/Ameritrust_Group>,
        <https://1145.am/db/977845/Ameritrust_Group>,
        <https://1145.am/db/978302/Ameritrust_Group>,
        <https://1145.am/db/980292/Ameriway_Insurance_Company> ;
    ns1:sameAsMedium <https://1145.am/db/2258082/Amerihealth>,
        <https://1145.am/db/2266915/Amerihealth> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2294872/Series_D_Investment_Halt_Medical_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-04T13:17:37+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Halt Medical revealed Wednesday it has collected $ 15 million in Series D financing to market its Acessa System, a device approved by the FDA in November for treating uterine fibroids." ;
    ns1:documentTitle "UPDATED: Halt Medical snags $15M to launch uterine fibroid device" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/updated-halt-medical-snags-15m-to-launch-uterine-fibroid-device> ;
    ns1:foundName "market" ;
    ns1:name "market" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2294872/Halt_Medical> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 15 million" .

<https://1145.am/db/2294893/3x5_Special_Opportunity_Fund> a org:Organization ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "3x5 Special Opportunity Fund",
        "the 3x5 Special Opportunity Fund" ;
    ns1:investor <https://1145.am/db/2294893/Equity_Investment_3x5_Special_Opportunity_Fund_Ptv_Sciences_Rivervest_Venture_Partners_Spray_Venture_Partners_Tryton_Medical_Completed> ;
    ns1:name "3x5 Special Opportunity Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2355183/3x5_Special_Opportunity_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2294893/Ptv_Sciences> a org:Organization ;
    ns1:basedInLowRaw "Durham, NC" ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "PTV Sciences" ;
    ns1:investor <https://1145.am/db/2294893/Equity_Investment_3x5_Special_Opportunity_Fund_Ptv_Sciences_Rivervest_Venture_Partners_Spray_Venture_Partners_Tryton_Medical_Completed> ;
    ns1:name "PTV Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/1831222/Ptv_Sciences>,
        <https://1145.am/db/2207078/Ptv_Sciences>,
        <https://1145.am/db/2288553/Ptv_Sciences>,
        <https://1145.am/db/2288899/Ptv_Sciences>,
        <https://1145.am/db/2296606/Ptv_Sciences>,
        <https://1145.am/db/2303769/Ptv_Sciences>,
        <https://1145.am/db/2310099/Ptv_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2294893/Spray_Venture_Partners> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "Spray Venture Partners" ;
    ns1:investor <https://1145.am/db/2294893/Equity_Investment_3x5_Special_Opportunity_Fund_Ptv_Sciences_Rivervest_Venture_Partners_Spray_Venture_Partners_Tryton_Medical_Completed> ;
    ns1:name "Spray Venture Partners" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2295809/Founders_Fund> a org:Organization ;
    ns1:documentDate "2013-01-28T15:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J kicks off oral arguments in all-metal hip trial; Cook Medical launches ureteral access sheath;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/j-j-kicks-off-oral-arguments-all-metal-hip-trial-cook-medical-launches-ureteral> ;
    ns1:foundName "Founders Fund" ;
    ns1:investor <https://1145.am/db/2295809/Series_A_Investment_Direct_Flow_Medical_Founders_Fund_Tribogenics_Completed> ;
    ns1:name "Founders Fund" ;
    ns1:sameAsMedium <https://1145.am/db/1014718/Founders_Fund>,
        <https://1145.am/db/1015489/Founders_Fund>,
        <https://1145.am/db/1048355/Founders_Fund>,
        <https://1145.am/db/1119433/Founders_Fund>,
        <https://1145.am/db/1297417/Founders_Fund>,
        <https://1145.am/db/1323598/Founders_Fund>,
        <https://1145.am/db/1376203/Founders_Fund>,
        <https://1145.am/db/1481368/Founders_Fund>,
        <https://1145.am/db/1488858/Founders_Fund>,
        <https://1145.am/db/1494028/Founders_Fund>,
        <https://1145.am/db/1512079/Founders_Fund>,
        <https://1145.am/db/1635018/Founders_Fund>,
        <https://1145.am/db/1694637/Founders_Fund>,
        <https://1145.am/db/1697296/Founders_Fund>,
        <https://1145.am/db/1707285/Founders_Fund>,
        <https://1145.am/db/1708523/Founders_Fund>,
        <https://1145.am/db/1710313/Founders_Fund>,
        <https://1145.am/db/1722513/Founders_Fund>,
        <https://1145.am/db/1723683/Founders_Fund>,
        <https://1145.am/db/1725305/Founders_Fund>,
        <https://1145.am/db/1734908/Founders_Fund>,
        <https://1145.am/db/1737944/Founders_Fund>,
        <https://1145.am/db/1738602/Founders_Fund>,
        <https://1145.am/db/1740000/Founders_Fund>,
        <https://1145.am/db/1740701/Founders_Fund>,
        <https://1145.am/db/1743093/Founders_Fund>,
        <https://1145.am/db/1743316/Founders_Fund>,
        <https://1145.am/db/1743873/Founders_Fund>,
        <https://1145.am/db/1745995/Founders_Fund>,
        <https://1145.am/db/1745998/Founders_Fund>,
        <https://1145.am/db/1747001/Founders_Fund>,
        <https://1145.am/db/1747457/Founders_Fund>,
        <https://1145.am/db/1748490/Founders_Fund>,
        <https://1145.am/db/1748969/Founders_Fund>,
        <https://1145.am/db/1751632/Founders_Fund>,
        <https://1145.am/db/1753641/Founders_Fund>,
        <https://1145.am/db/1759004/Founders_Fund>,
        <https://1145.am/db/1760986/Founders_Fund>,
        <https://1145.am/db/1761460/Founders_Fund>,
        <https://1145.am/db/1764689/Founders_Fund>,
        <https://1145.am/db/1765550/Founders_Fund>,
        <https://1145.am/db/1766096/Founders_Fund>,
        <https://1145.am/db/1772199/Founders_Fund>,
        <https://1145.am/db/1773361/Founders_Fund>,
        <https://1145.am/db/1776563/Founders_Fund>,
        <https://1145.am/db/1779848/Founders_Fund>,
        <https://1145.am/db/1780288/Founders_Fund>,
        <https://1145.am/db/1787451/Founders_Fund>,
        <https://1145.am/db/1797416/Founders_Fund>,
        <https://1145.am/db/1802109/Founders_Fund>,
        <https://1145.am/db/1803147/Founders_Fund>,
        <https://1145.am/db/1806982/Founders_Fund>,
        <https://1145.am/db/1809707/Founders_Fund>,
        <https://1145.am/db/1818475/Founders_Fund>,
        <https://1145.am/db/1827081/Founders_Fund>,
        <https://1145.am/db/1829422/Founders_Fund>,
        <https://1145.am/db/1829549/Founders_Fund>,
        <https://1145.am/db/1834173/Founders_Fund>,
        <https://1145.am/db/1834221/Founders_Fund>,
        <https://1145.am/db/1846718/Founders_Fund>,
        <https://1145.am/db/1847739/Founders_Fund>,
        <https://1145.am/db/1849884/Founders_Fund>,
        <https://1145.am/db/1850812/Founders_Fund>,
        <https://1145.am/db/1852869/Founders_Fund>,
        <https://1145.am/db/1857306/Founders_Fund>,
        <https://1145.am/db/1858452/Founders_Fund>,
        <https://1145.am/db/1858742/Founders_Fund>,
        <https://1145.am/db/1871784/Founders_Fund>,
        <https://1145.am/db/1890157/Founders_Fund>,
        <https://1145.am/db/1892099/Founders_Fund>,
        <https://1145.am/db/1896530/Founders_Fund>,
        <https://1145.am/db/1909651/The_Founders_Fund>,
        <https://1145.am/db/1915630/Founders_Fund>,
        <https://1145.am/db/1916189/Founders_Fund>,
        <https://1145.am/db/1924201/Founders_Fund>,
        <https://1145.am/db/2008515/Founders_Fund>,
        <https://1145.am/db/2029836/Founders_Fund>,
        <https://1145.am/db/2058874/Founders_Fund>,
        <https://1145.am/db/2079011/Founders_Fund>,
        <https://1145.am/db/2087734/Founders_Fund>,
        <https://1145.am/db/2151717/Founders_Fund>,
        <https://1145.am/db/2183141/Founders_Fund>,
        <https://1145.am/db/2185522/Founders_Fund>,
        <https://1145.am/db/2188497/Founders_Fund>,
        <https://1145.am/db/2197248/Founders_Fund>,
        <https://1145.am/db/219754/Founders_Fund>,
        <https://1145.am/db/2246579/Founders_Fund>,
        <https://1145.am/db/2251834/Founders_Fund>,
        <https://1145.am/db/2285971/Founders_Fund>,
        <https://1145.am/db/2291004/Founders_Fund>,
        <https://1145.am/db/2349764/Founders_Fund>,
        <https://1145.am/db/2365279/Founders_Fund>,
        <https://1145.am/db/424834/Founders_Fund>,
        <https://1145.am/db/426637/Founders_Fund>,
        <https://1145.am/db/435549/Founders_Fund>,
        <https://1145.am/db/437536/Founders_Fund>,
        <https://1145.am/db/437556/Founders_Fund>,
        <https://1145.am/db/438632/Founders_Fund>,
        <https://1145.am/db/475105/Founders_Fund>,
        <https://1145.am/db/478867/Founders_Fund>,
        <https://1145.am/db/561809/Founders_Fund>,
        <https://1145.am/db/563972/Founders_Fund>,
        <https://1145.am/db/642123/Founders_Fund>,
        <https://1145.am/db/665662/Founders_Fund>,
        <https://1145.am/db/684792/Founders_Fund>,
        <https://1145.am/db/708842/Founders_Fund>,
        <https://1145.am/db/710123/Founders_Fund>,
        <https://1145.am/db/812291/Founders_Fund>,
        <https://1145.am/db/893359/Founders_Fund>,
        <https://1145.am/db/894233/Founders_Fund>,
        <https://1145.am/db/918904/Founders_Fund>,
        <https://1145.am/db/922498/Founders_Fund>,
        <https://1145.am/db/922613/Founders_Fund>,
        <https://1145.am/db/925994/Founders_Fund>,
        <https://1145.am/db/935448/Founders_Fund>,
        <https://1145.am/db/936245/Founders_Fund>,
        <https://1145.am/db/970382/Founders_Fund>,
        <https://1145.am/db/974922/Founders_Fund>,
        <https://1145.am/db/988084/Founders_Fund>,
        <https://1145.am/db/995137/Founders_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2296302/Burrill___Company> a org:Organization ;
    ns1:basedInLowRaw "India" ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:foundName "Burrill & Company" ;
    ns1:investor <https://1145.am/db/2296302/Investment_Burrill___Company_Has_Not_Happened>,
        <https://1145.am/db/2296302/Investment_Burrill___Company_Strand_Life_Sciences_Completed> ;
    ns1:name "Burrill & Company" ;
    ns1:sameAsMedium <https://1145.am/db/1872338/Burrill___Company>,
        <https://1145.am/db/1877768/Burrill_And_Company>,
        <https://1145.am/db/2300466/Burrill___Company>,
        <https://1145.am/db/2301901/Burrill___Company>,
        <https://1145.am/db/2303022/Burrill___Company>,
        <https://1145.am/db/2307824/Burrill___Company>,
        <https://1145.am/db/2307829/Burrill___Company>,
        <https://1145.am/db/2308855/Burrill___Company>,
        <https://1145.am/db/2311011/Burrill___Co>,
        <https://1145.am/db/2311069/Burrill___Company>,
        <https://1145.am/db/2311075/Burrill___Company>,
        <https://1145.am/db/2311076/Burrill___Company>,
        <https://1145.am/db/2313114/Burrill___Company>,
        <https://1145.am/db/2318577/Burrill___Company>,
        <https://1145.am/db/2318781/Burrill___Company>,
        <https://1145.am/db/2318796/Burrill___Company>,
        <https://1145.am/db/2318797/Burrill___Company>,
        <https://1145.am/db/2321150/Burrill___Co>,
        <https://1145.am/db/2321861/Burrill___Company>,
        <https://1145.am/db/2321870/Burrill___Company>,
        <https://1145.am/db/2339516/Burrill___Company>,
        <https://1145.am/db/2342348/Burrill___Company>,
        <https://1145.am/db/2358271/Burrill___Company>,
        <https://1145.am/db/2358272/Burrill___Company>,
        <https://1145.am/db/2364468/Burrill___Company>,
        <https://1145.am/db/2364471/Burrill___Company>,
        <https://1145.am/db/2364505/Burrill>,
        <https://1145.am/db/2364508/Burrill___Company> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2296302/Investment_Gold_Standard_Diagnostics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Gold Standard Diagnostics raised $ 1 million in new equity investment, according to a recent filing." ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2296302/Gold_Standard_Diagnostics> ;
    ns1:valueRaw "$ 1 million" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2297264/Life_Technologies_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-03-05T23:31:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The hot and cold rumors over a potential Life Technologies ($ LIFE) sale have swung back toward the former, as Bloomberg's sources say a team of private equity outfits are exploring an offer for the sequencing giant." ;
    ns1:documentTitle "Report: Life Tech may have found a buyer after all" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-life-tech-may-have-found-a-buyer-after-all> ;
    ns1:foundName "offer",
        "sale" ;
    ns1:name "offer",
        "sale" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2297264/Life_Technologies> ;
    ns1:targetName "Life Technologies" .

<https://1145.am/db/2297756/Athyrium_Opportunities_Fund> a org:Organization ;
    ns1:basedInLowRaw "Arizona" ;
    ns1:documentDate "2013-03-20T14:19:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "SynCardia snags $19M for artificial heart" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/syncardia-snags-19m-for-artificial-heart> ;
    ns1:foundName "Athyrium Opportunities Fund" ;
    ns1:investor <https://1145.am/db/2297756/Investment_Athyrium_Opportunities_Fund_Syncardia_Has_Not_Happened> ;
    ns1:name "Athyrium Opportunities Fund" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2299629/Investment_Nasoform_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T12:53:23+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Nasoform, a Menlo Park, CA - based device startup, raised $ 6 million in new venture funding toward development of a minimally invasive device designed to treat collapsed nasal valves." ;
    ns1:documentTitle "Tough market for venture-backed Dx outfits; Medtronic launches spinal tech;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tough-market-for-venture-backed-dx-outfits-medtronic-launches-spinal-tech> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2299629/Nasoform> ;
    ns1:targetDetails "venture" ;
    ns1:valueRaw "$ 6 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2299645/Orbimed> a org:Organization ;
    ns1:basedInLowRaw "Sweden" ;
    ns1:documentDate "2013-04-30T14:50:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Asthma devicemaker Aerocrine nabs $50M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asthma-devicemaker-aerocrine-nabs-50m> ;
    ns1:foundName "OrbiMed" ;
    ns1:investor <https://1145.am/db/2299645/Investment_Aerocrine_Novo_Orbimed_Has_Not_Happened> ;
    ns1:name "OrbiMed" ;
    ns1:sameAsMedium <https://1145.am/db/1004121/Orbimed>,
        <https://1145.am/db/1042080/Orbimed>,
        <https://1145.am/db/1086582/Orbimed>,
        <https://1145.am/db/1089269/Orbimed>,
        <https://1145.am/db/1140378/Orbimed>,
        <https://1145.am/db/1213048/Orbimed>,
        <https://1145.am/db/1334863/Orbimed>,
        <https://1145.am/db/1340338/Orbimed>,
        <https://1145.am/db/1426073/Orbimed>,
        <https://1145.am/db/1426943/Orbimed>,
        <https://1145.am/db/1608803/Orbimed>,
        <https://1145.am/db/1690914/Orbimed>,
        <https://1145.am/db/194149/Orbimed>,
        <https://1145.am/db/2032047/Orbimed>,
        <https://1145.am/db/2080575/Orbimed>,
        <https://1145.am/db/2151717/Orbimed>,
        <https://1145.am/db/2192716/Orbimed>,
        <https://1145.am/db/2198716/Orbimed>,
        <https://1145.am/db/2280770/Orbimed>,
        <https://1145.am/db/2281204/Orbimed>,
        <https://1145.am/db/2281272/Orbimed>,
        <https://1145.am/db/2283935/Orbimed>,
        <https://1145.am/db/2286207/Orbimed>,
        <https://1145.am/db/2286245/Orbimed>,
        <https://1145.am/db/2286541/Orbimed>,
        <https://1145.am/db/2288436/Orbimed>,
        <https://1145.am/db/2288529/Orbimed>,
        <https://1145.am/db/2290069/Orbimed>,
        <https://1145.am/db/2290337/Orbimed>,
        <https://1145.am/db/2290766/Orbimed>,
        <https://1145.am/db/2292284/Orbimed>,
        <https://1145.am/db/2293503/Orbimed>,
        <https://1145.am/db/2293508/Orbimed>,
        <https://1145.am/db/2293540/Orbimed>,
        <https://1145.am/db/2293893/Orbimed>,
        <https://1145.am/db/2295525/Orbimed>,
        <https://1145.am/db/2295713/Orbimed>,
        <https://1145.am/db/2297224/Orbimed>,
        <https://1145.am/db/2297507/Orbimed>,
        <https://1145.am/db/2297514/Orbimed>,
        <https://1145.am/db/2297930/Orbimed>,
        <https://1145.am/db/2298642/Orbimed>,
        <https://1145.am/db/2299411/Orbimed>,
        <https://1145.am/db/2300061/Orbimed>,
        <https://1145.am/db/2300653/Orbimed>,
        <https://1145.am/db/2301464/Orbimed>,
        <https://1145.am/db/2304258/Orbimed>,
        <https://1145.am/db/2318134/Orbimed>,
        <https://1145.am/db/2323243/Orbimed>,
        <https://1145.am/db/2330389/Orbimed>,
        <https://1145.am/db/2335764/Orbimed>,
        <https://1145.am/db/2337043/Orbimed>,
        <https://1145.am/db/2337667/Orbimed>,
        <https://1145.am/db/2340942/Orbimed>,
        <https://1145.am/db/2341484/Orbimed>,
        <https://1145.am/db/2341487/Orbimed>,
        <https://1145.am/db/2343545/Orbimed>,
        <https://1145.am/db/2344044/Orbimed>,
        <https://1145.am/db/2344045/Orbimed>,
        <https://1145.am/db/2347103/Orbimed>,
        <https://1145.am/db/2347885/Orbimed>,
        <https://1145.am/db/2348149/Orbimed>,
        <https://1145.am/db/2348857/Orbimed>,
        <https://1145.am/db/2349834/Orbimed>,
        <https://1145.am/db/2349838/Orbimed>,
        <https://1145.am/db/2350720/Orbimed>,
        <https://1145.am/db/2353515/Orbimed>,
        <https://1145.am/db/2355023/Orbimed>,
        <https://1145.am/db/2361337/Orbimed>,
        <https://1145.am/db/2362768/Orbimed>,
        <https://1145.am/db/236388/Orbimed>,
        <https://1145.am/db/2363947/Orbimed>,
        <https://1145.am/db/2368872/Orbimed>,
        <https://1145.am/db/2369135/Orbimed>,
        <https://1145.am/db/2369140/Orbimed>,
        <https://1145.am/db/2369202/Orbimed>,
        <https://1145.am/db/2369548/Orbimed>,
        <https://1145.am/db/2369982/Orbimed>,
        <https://1145.am/db/2369999/Orbimed>,
        <https://1145.am/db/2370208/Orbimed>,
        <https://1145.am/db/2370295/Orbimed>,
        <https://1145.am/db/2370694/Orbimed>,
        <https://1145.am/db/2370782/Orbimed>,
        <https://1145.am/db/2370799/Orbimed>,
        <https://1145.am/db/2371160/Orbimed>,
        <https://1145.am/db/2371163/Orbimed>,
        <https://1145.am/db/2547469/Orbimed>,
        <https://1145.am/db/2548437/Orbimed>,
        <https://1145.am/db/2718732/Orbimed>,
        <https://1145.am/db/2787561/Orbimed>,
        <https://1145.am/db/402604/Orbimed>,
        <https://1145.am/db/474852/Orbimed>,
        <https://1145.am/db/581662/Orbimed>,
        <https://1145.am/db/583614/Orbimed>,
        <https://1145.am/db/676857/Orbimed>,
        <https://1145.am/db/713335/Orbimed>,
        <https://1145.am/db/714498/Orbimed>,
        <https://1145.am/db/770684/Orbimed>,
        <https://1145.am/db/791742/Orbimed>,
        <https://1145.am/db/867907/Orbimed>,
        <https://1145.am/db/912732/Orbimed> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300074/Investment_Good_Start_Genetics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-08T10:45:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Massachusetts' Good Start Genetics has hauled in $ 28 million in financing, money the company will use to expand its sequencing - based carrier screening technology." ;
    ns1:documentTitle "Good Start Genetics raises $28M for carrier Dx" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/good-start-genetics-raises-28m-for-carrier-dx> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2300074/Good_Start_Genetics> ;
    ns1:valueRaw "$ 28 million" ;
    ns1:whereGeoName "Massachusetts" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6254926/about.rdf> ;
    ns1:whereRaw "Massachusetts" .

<https://1145.am/db/2300131/Equity_Investment_Daktari_Diagnostics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-15T14:43:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Daktari Diagnostics reeled in $ 7 million to fuel growth, expand plant in Scotland to manufacture its portable HIV diagnostic.-Courtesy of Daktari.",
        "Daktari Diagnostics reeled in another $ 7 million in equity financing, an amount likely to help fuel the company's overall expansion as well as the construction of a new plant in Scotland for its point-of-care HIV tests." ;
    ns1:documentTitle "Daktari Diagnostics reels in $7M as it preps for Scotland expansion" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/daktari-diagnostics-reels-7m-as-it-preps-for-scotland-expansion> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2300131/Daktari_Diagnostics> ;
    ns1:targetDetails "equity" ;
    ns1:valueRaw "$ 7 million" ;
    ns1:whereGeoName "Scotland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2638360/about.rdf> ;
    ns1:whereRaw "Scotland" .

<https://1145.am/db/2307564/Shangpharma_Merger_Sub_Limited> a org:Organization ;
    ns1:basedInLowRaw "China" ;
    ns1:documentDate "2013-01-01T23:20:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ShangPharma Corporation Enters into Definitive Merger Agreement for Going Private Transaction" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/shangpharma-corporation-enters-into-definitive-merger-agreement-for-going-private-transaction> ;
    ns1:foundName "ShangPharma Merger Sub Limited" ;
    ns1:industry "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:name "ShangPharma Merger Sub Limited" ;
    ns1:protagonist <https://1145.am/db/2307564/Shangpharma_Corporation_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/2310766/Shangpharma_Merger_Sub_Limited> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307565/Aberdare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:description "venture financing" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "Aberdare Ventures" ;
    ns1:investor <https://1145.am/db/2307565/Venture_Investment_Aberdare_Ventures_Edbi_Qualcomm_Ventures_West_Health_Investment_Fund_Gobalto_Completed> ;
    ns1:name "Aberdare Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1297270/Alate_Partners>,
        <https://1145.am/db/1298072/Alate_Partners>,
        <https://1145.am/db/1640340/Avanta_Ventures>,
        <https://1145.am/db/1735248/Aleph_Oceans_Ventures>,
        <https://1145.am/db/1739053/Anzi_Ventures>,
        <https://1145.am/db/1743285/Aleph_Venture_Capital>,
        <https://1145.am/db/1743395/Altair_Capital>,
        <https://1145.am/db/1759554/Alphalab_Capital>,
        <https://1145.am/db/1805034/Altair_Capital>,
        <https://1145.am/db/1813906/Altair_Capital>,
        <https://1145.am/db/1815712/Anthemis_Group>,
        <https://1145.am/db/1828930/Advent_Venture_Partners>,
        <https://1145.am/db/1840957/Vaizra_Investments>,
        <https://1145.am/db/1857635/Almi>,
        <https://1145.am/db/1866032/Seraph_Group>,
        <https://1145.am/db/1873136/Advent_Venture_Partners>,
        <https://1145.am/db/1874937/Vaizra_Investments>,
        <https://1145.am/db/1875469/Advent_Venture_Partners>,
        <https://1145.am/db/1879760/Advent_Venture_Partners>,
        <https://1145.am/db/1882907/Adinvest>,
        <https://1145.am/db/1895118/Azullo>,
        <https://1145.am/db/1910490/Advent_Venture_Partners>,
        <https://1145.am/db/2060003/Alphalab_Capital>,
        <https://1145.am/db/2154431/Alychlo>,
        <https://1145.am/db/2303656/Advent_Venture_Partners>,
        <https://1145.am/db/2331946/Advent_Venture_Partners>,
        <https://1145.am/db/2370239/Aurum_Ventures>,
        <https://1145.am/db/2638432/Advent_Venture_Partners>,
        <https://1145.am/db/2657775/Aurinvest>,
        <https://1145.am/db/2765030/Archangel_Ventures>,
        <https://1145.am/db/364370/Acadian_Capital_Ventures>,
        <https://1145.am/db/365337/Anterra_Capital>,
        <https://1145.am/db/464808/Accel_Avataar_Ventures>,
        <https://1145.am/db/562996/Altair_Capital>,
        <https://1145.am/db/704753/Aqton_Partners>,
        <https://1145.am/db/823971/Ad_Astra_Ventures>,
        <https://1145.am/db/922066/Anthemis_Group>,
        <https://1145.am/db/929712/Armilar_Venture_Partners>,
        <https://1145.am/db/956190/Ayon_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1856457/Aberdare_Ventures>,
        <https://1145.am/db/1857326/Aberdare_Ventures>,
        <https://1145.am/db/2292334/Aberdare_Ventures>,
        <https://1145.am/db/2292353/Aberdare_Ventures>,
        <https://1145.am/db/2318708/Aberdare_Ventures>,
        <https://1145.am/db/2323531/Aberdare_Ventures>,
        <https://1145.am/db/2329550/Aberdare_Ventures>,
        <https://1145.am/db/2330876/Aberdare_Ventures>,
        <https://1145.am/db/2343723/Aberdare_Ventures>,
        <https://1145.am/db/2343724/Aberdare_Ventures>,
        <https://1145.am/db/2343744/Aberdare_Ventures>,
        <https://1145.am/db/2346534/Aberdare_Ventures>,
        <https://1145.am/db/2350491/Aberdare_Ventures>,
        <https://1145.am/db/2362035/Aberdare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307565/Edbi> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:description "global investment arm of Singapore's Economic Development Board" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "EDBI" ;
    ns1:investor <https://1145.am/db/2307565/Venture_Investment_Aberdare_Ventures_Edbi_Qualcomm_Ventures_West_Health_Investment_Fund_Gobalto_Completed> ;
    ns1:name "EDBI" ;
    ns1:sameAsMedium <https://1145.am/db/1042080/Edbi>,
        <https://1145.am/db/1443192/Edbi>,
        <https://1145.am/db/1444350/Edbi>,
        <https://1145.am/db/1739285/Edbi>,
        <https://1145.am/db/1751683/Edbi>,
        <https://1145.am/db/1751800/Edbi>,
        <https://1145.am/db/1752458/Edbi>,
        <https://1145.am/db/1754541/Edbi>,
        <https://1145.am/db/1756901/Edbi>,
        <https://1145.am/db/1764169/Edbi>,
        <https://1145.am/db/1764789/Edbi>,
        <https://1145.am/db/1765880/Edbi>,
        <https://1145.am/db/1766255/Edbi>,
        <https://1145.am/db/1772722/Edbi>,
        <https://1145.am/db/1838511/Edbi>,
        <https://1145.am/db/1880208/Edbi>,
        <https://1145.am/db/2052769/Edbi>,
        <https://1145.am/db/2126175/Edbi>,
        <https://1145.am/db/2281648/Edbi>,
        <https://1145.am/db/2286665/Edbi>,
        <https://1145.am/db/969990/Edbi> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307565/Qualcomm_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "Qualcomm's investment group" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "Qualcomm Life Fund" ;
    ns1:investor <https://1145.am/db/2307565/Venture_Investment_Aberdare_Ventures_Edbi_Qualcomm_Ventures_West_Health_Investment_Fund_Gobalto_Completed> ;
    ns1:name "Qualcomm Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1282835/Qualcomm_Ventures>,
        <https://1145.am/db/1696426/Qualcomm>,
        <https://1145.am/db/1714583/Qualcomm_Ventures>,
        <https://1145.am/db/1748274/Qualcomm_Ventures>,
        <https://1145.am/db/1756547/Qualcomm_Ventures>,
        <https://1145.am/db/1762040/Qualcomm_Ventures>,
        <https://1145.am/db/1772381/Qualcomm_Ventures>,
        <https://1145.am/db/1777306/Qualcomm_Ventures>,
        <https://1145.am/db/1794935/Qualcomm_Ventures>,
        <https://1145.am/db/1803094/Qualcomm_Ventures>,
        <https://1145.am/db/1805165/Qualcomm_Ventures>,
        <https://1145.am/db/1818730/Qualcomm_Ventures>,
        <https://1145.am/db/1831659/Qualcomm_Ventures>,
        <https://1145.am/db/1835088/Qualcomm_Ventures>,
        <https://1145.am/db/1854510/Qualcomm_Ventures>,
        <https://1145.am/db/1858337/Qualcomm_Ventures>,
        <https://1145.am/db/1858346/Qualcomm_Ventures>,
        <https://1145.am/db/1895968/Qualcomm_Ventures>,
        <https://1145.am/db/2007150/Qualcomm_Ventures>,
        <https://1145.am/db/2117114/Qualcomm_Ventures>,
        <https://1145.am/db/2198716/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/2264763/Qualcomm_Ventures>,
        <https://1145.am/db/2296328/Qualcomm>,
        <https://1145.am/db/2420013/Qualcomm_Ventures>,
        <https://1145.am/db/2650349/Qualcomm>,
        <https://1145.am/db/522730/Qualcomm>,
        <https://1145.am/db/897722/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/936448/Qualcomm_Ventures>,
        <https://1145.am/db/938975/Qualcomm_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1512188/Qualcomm_Ventures>,
        <https://1145.am/db/1697179/Qualcomm_Ventures>,
        <https://1145.am/db/1734783/Qualcomm_Ventures>,
        <https://1145.am/db/1735722/Qualcomm_Ventures>,
        <https://1145.am/db/1773381/Qualcomm_Ventures>,
        <https://1145.am/db/1790641/Qualcomm_Ventures>,
        <https://1145.am/db/1800929/Qualcomm_Ventures>,
        <https://1145.am/db/1803893/Qualcomm_Ventures>,
        <https://1145.am/db/1807344/Qualcomm_Ventures>,
        <https://1145.am/db/1811619/Qualcomm_Ventures>,
        <https://1145.am/db/1813330/Qualcomm_Ventures>,
        <https://1145.am/db/1822501/Qualcomm_Ventures>,
        <https://1145.am/db/1825633/Qualcomm_Ventures>,
        <https://1145.am/db/1830613/Qualcomm_Ventures>,
        <https://1145.am/db/1837903/Qualcomm_Ventures>,
        <https://1145.am/db/1847633/Qualcomm_Ventures>,
        <https://1145.am/db/1848084/Qualcomm_Ventures>,
        <https://1145.am/db/1848444/Qualcomm_Ventures>,
        <https://1145.am/db/1865079/Qualcomm_Ventures>,
        <https://1145.am/db/1879716/Qualcomm_Ventures>,
        <https://1145.am/db/1911076/Qualcomm_Ventures>,
        <https://1145.am/db/1978877/Qualcomm_Ventures>,
        <https://1145.am/db/2008446/Qualcomm_Ventures>,
        <https://1145.am/db/2148662/Qualcomm_Ventures>,
        <https://1145.am/db/2228252/Qualcomm_Ventures>,
        <https://1145.am/db/2273257/Qualcomm_Ventures>,
        <https://1145.am/db/2299881/Qualcomm_Ventures>,
        <https://1145.am/db/2384477/Qualcomm_Ventures>,
        <https://1145.am/db/2406304/Qualcomm_Ventures>,
        <https://1145.am/db/2630274/Qualcomm_Ventures>,
        <https://1145.am/db/2630325/Qualcomm_Ventures>,
        <https://1145.am/db/2650366/Qualcomm_Ventures>,
        <https://1145.am/db/2650755/Qualcomm_Ventures>,
        <https://1145.am/db/2670192/Qualcomm_Ventures>,
        <https://1145.am/db/2670194/Qualcomm_Ventures>,
        <https://1145.am/db/415668/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/443441/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/528278/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/711232/Qualcomm_Ventures>,
        <https://1145.am/db/742087/Qualcomm_Ventures_Llc>,
        <https://1145.am/db/798865/Qualcomm_Ventures>,
        <https://1145.am/db/905476/Qualcomm_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307565/West_Health_Investment_Fund> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:description "health" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "West Health Investment Fund" ;
    ns1:investor <https://1145.am/db/2307565/Venture_Investment_Aberdare_Ventures_Edbi_Qualcomm_Ventures_West_Health_Investment_Fund_Gobalto_Completed> ;
    ns1:name "West Health Investment Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2209419/West_Health_Investment_Fund>,
        <https://1145.am/db/2323531/West_Health_Investment_Fund>,
        <https://1145.am/db/2362035/West_Health_Investment_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2309242/National_Research_Council_Industrial_Research_Assistance_Program> a org:Organization ;
    ns1:basedInLowRaw "Canada" ;
    ns1:description "assisting in networking the NICAM program with key global partners" ;
    ns1:documentDate "2013-06-20T18:20:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/isotechnika-pharma-receives-additional-funding-from-government-of-canada-for-preclinical> ;
    ns1:foundName "National Research Council Industrial Research Assistance Program" ;
    ns1:investor <https://1145.am/db/2309242/Investment_Isotechnika_Pharma_Inc_National_Research_Council_Industrial_Research_Assistance_Program_Has_Not_Happened> ;
    ns1:name "National Research Council Industrial Research Assistance Program" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335249/Investment_Salk_Institute_For_Biological_Studies_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-24T19:48:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK, Jan. 23, 2013 /PRNewswire/ - The Salk Institute for Biological Studies has received a $ 42 million gift-the largest in the Institute's history-to establish the Helmsley Center for Genomic Medicine (HCGM) , a research center dedicated to decoding the common genetic factors underlying many complex chronic human diseases." ;
    ns1:documentTitle "Salk Institute Awarded Historic $42 Million Grant From the Helmsley Charitable Trust" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/salk-institute-awarded-historic-42-million-grant-from-helmsley-charitable-trust> ;
    ns1:foundName "gift" ;
    ns1:name "gift" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2335249/Helmsley_Center_For_Genomic_Medicine>,
        <https://1145.am/db/2335249/Salk_Institute_For_Biological_Studies> ;
    ns1:targetName "Helmsley Center for Genomic Medicine" ;
    ns1:valueRaw "$ 42 million" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "NEW YORK" .

<https://1145.am/db/2335882/Activartis_Gmbh_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-06-18T13:03:03+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy.",
        "Vienna, Austria, June 17, 2013 / B3C newswire / - AOP Orphan Pharmaceuticals AG today announced the spin off of its 80 % stake in Activartis GmbH, a Vienna - based biotech company with a strong platform for immune - based cancer vaccines, to a group of private investors." ;
    ns1:documentTitle "AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aop-orphan-spins-off-its-stake-activartis-and-outlines-business-strategy> ;
    ns1:foundName "Spins Off",
        "spin off" ;
    ns1:name "Spins Off",
        "spin off" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2335882/Activartis_Gmbh> ;
    ns1:targetDetails "Stake",
        "stake" ;
    ns1:targetName "Activartis",
        "Activartis GmbH" ;
    ns1:vendor <https://1145.am/db/2335882/Aop_Orphan_Pharmaceuticals_Ag> ;
    ns1:when "2013-06-17T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 17, 2013" ;
    ns1:whereGeoName "Republic of Austria" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2782113/about.rdf> ;
    ns1:whereRaw "Austria" .

<https://1145.am/db/2336410/Bayern_Kapital> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "Bayern Kapital" ;
    ns1:investor <https://1145.am/db/2336410/Series_F_Investment_Bayern_Kapital_Entrepreneurs_Fund_Hanseatic_Asset_Management_Lbg_Heidelbergcapital_Private_Equity_Vasopharm_Gmbh_Completed> ;
    ns1:name "Bayern Kapital" ;
    ns1:sameAsMedium <https://1145.am/db/1023024/Bayern_Kapital>,
        <https://1145.am/db/1023822/Bayern_Kapital>,
        <https://1145.am/db/1226523/Bayern_Kapital>,
        <https://1145.am/db/1523031/Bayern_Kapital>,
        <https://1145.am/db/1749066/Bayern_Kapital>,
        <https://1145.am/db/2307886/Bayern_Kapital_Gmbh>,
        <https://1145.am/db/679562/Bayern_Kapital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336410/Entrepreneurs_Fund> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "Business" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "Entrepreneurs Fund (EF Investments S..r.l.)" ;
    ns1:investor <https://1145.am/db/2336410/Series_F_Investment_Bayern_Kapital_Entrepreneurs_Fund_Hanseatic_Asset_Management_Lbg_Heidelbergcapital_Private_Equity_Vasopharm_Gmbh_Completed> ;
    ns1:name "Entrepreneurs Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2358747/Entrepreneurs_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1428371/Entrepreneurs_Equity_Fund>,
        <https://1145.am/db/1782629/Entrepreneurs_Fund>,
        <https://1145.am/db/1796967/Entrepreneurs_Investment_Fund>,
        <https://1145.am/db/2356685/Entrepreneurs_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336410/Hanseatic_Asset_Management_Lbg> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "Hanseatic Asset Management LBG" ;
    ns1:investor <https://1145.am/db/2336410/Series_F_Investment_Bayern_Kapital_Entrepreneurs_Fund_Hanseatic_Asset_Management_Lbg_Heidelbergcapital_Private_Equity_Vasopharm_Gmbh_Completed> ;
    ns1:name "Hanseatic Asset Management LBG" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336410/Heidelbergcapital_Private_Equity> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "HeidelbergCapital Private Equity" ;
    ns1:investor <https://1145.am/db/2336410/Series_F_Investment_Bayern_Kapital_Entrepreneurs_Fund_Hanseatic_Asset_Management_Lbg_Heidelbergcapital_Private_Equity_Vasopharm_Gmbh_Completed> ;
    ns1:name "HeidelbergCapital Private Equity" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Biotech_Fund_Flanders> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "life sciences" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Biotech Fund Flanders" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Biotech Fund Flanders" ;
    ns1:sameAsHigh <https://1145.am/db/2302549/Biotech_Fund_Flanders> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/CRP-Sant> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "CRP-Sant" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "CRP-Sant" ;
    ns1:sameAsMedium <https://1145.am/db/2336927/CRP-Sant> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Gimv> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Belgium" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:basedInHighRaw "Belgium" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Gimv",
        "Gimv (Belgium)",
        "Gimv)" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Gimv" ;
    ns1:sameAsHigh <https://1145.am/db/1747873/Foresite_Capital>,
        <https://1145.am/db/2346397/PMV>,
        <https://1145.am/db/426688/LSP> ;
    ns1:sameAsMedium <https://1145.am/db/1724232/Gimv>,
        <https://1145.am/db/1806589/Gimv>,
        <https://1145.am/db/1830149/Gimv>,
        <https://1145.am/db/1854030/Gimv>,
        <https://1145.am/db/1866824/Gimv>,
        <https://1145.am/db/1883525/Gimv>,
        <https://1145.am/db/1914674/Gimv>,
        <https://1145.am/db/1919300/Gimv>,
        <https://1145.am/db/2154009/Gimv>,
        <https://1145.am/db/2280718/Gimv>,
        <https://1145.am/db/2281044/Gimv>,
        <https://1145.am/db/2286782/Gimv>,
        <https://1145.am/db/2294771/Gimv>,
        <https://1145.am/db/2299772/Gimv>,
        <https://1145.am/db/2301160/Gimv>,
        <https://1145.am/db/2302541/Gimv>,
        <https://1145.am/db/2302549/Gimv>,
        <https://1145.am/db/2316478/Gimv>,
        <https://1145.am/db/2328763/Gimv>,
        <https://1145.am/db/2328769/Gimv>,
        <https://1145.am/db/2346030/Gimv>,
        <https://1145.am/db/2352436/Gimv>,
        <https://1145.am/db/2352441/Gimv>,
        <https://1145.am/db/2352442/Gimv>,
        <https://1145.am/db/2356685/Gimv>,
        <https://1145.am/db/2365748/Gimv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Omnes_Capital> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "OMNES Capital" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "OMNES Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1337949/Omnes_Capital>,
        <https://1145.am/db/1338318/Omnes_Capital>,
        <https://1145.am/db/1771762/Omnes_Capital>,
        <https://1145.am/db/1936366/Omnes_Capital>,
        <https://1145.am/db/2288699/Omnes_Capital>,
        <https://1145.am/db/2294502/Omnes_Capital>,
        <https://1145.am/db/2295014/Omnes_Capital>,
        <https://1145.am/db/2295805/Omnes_Capital>,
        <https://1145.am/db/2300680/Omnes_Capital>,
        <https://1145.am/db/2301320/Omnes_Capital>,
        <https://1145.am/db/2301536/Omnes_Capital>,
        <https://1145.am/db/2336716/Omnes_Capital>,
        <https://1145.am/db/2336927/Omnes_Capital>,
        <https://1145.am/db/2351312/Omnes_Capital>,
        <https://1145.am/db/2580665/Omnes_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336944/Clarus_Ventures> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-06-27T15:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/heptares-raises-us-21-million-to-advance-novel-gpcr-medicines-into-clinical-development> ;
    ns1:foundName "Clarus Ventures" ;
    ns1:investor <https://1145.am/db/2336944/Series_B_Investment_Clarus_Ventures_Heptares_Therapeutics_Stanley_Family_Foundation_Takeda_Ventures_Completed> ;
    ns1:name "Clarus Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1696744/Cloquet_Capital_Partners>,
        <https://1145.am/db/2294202/Clarus_Funds>,
        <https://1145.am/db/2354295/Clarus_Ventures>,
        <https://1145.am/db/2366049/Clarus_Ventures>,
        <https://1145.am/db/2366055/Clarus_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Clarus_Ventures>,
        <https://1145.am/db/2302292/Clarus_Ventures>,
        <https://1145.am/db/2302994/Clarus_Ventures>,
        <https://1145.am/db/2303563/Clarus_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304261/Clarus_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2306754/Clarus_Ventures>,
        <https://1145.am/db/2311011/Clarus_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2312277/Clarus_Ventures>,
        <https://1145.am/db/2312288/Clarus_Ventures>,
        <https://1145.am/db/2312945/Clarus_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2315059/Clarus_Ventures>,
        <https://1145.am/db/2317145/Clarus_Ventures>,
        <https://1145.am/db/2318851/Clarus_Ventures>,
        <https://1145.am/db/2321137/Clarus_Ventures>,
        <https://1145.am/db/2324936/Clarus_Ventures>,
        <https://1145.am/db/2325880/Clarus_Ventures>,
        <https://1145.am/db/2327405/Clarus_Ventures>,
        <https://1145.am/db/2329773/Clarus_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335928/Clarus_Ventures>,
        <https://1145.am/db/2336313/Clarus_Ventures>,
        <https://1145.am/db/2341003/Clarus_Ventures>,
        <https://1145.am/db/2341600/Clarus_Ventures>,
        <https://1145.am/db/2342624/Clarus_Ventures>,
        <https://1145.am/db/2342629/Clarus_Ventures_Llc>,
        <https://1145.am/db/2343722/Clarus_Ventures>,
        <https://1145.am/db/2343725/Clarus_Ventures>,
        <https://1145.am/db/2343737/Clarus_Ventures>,
        <https://1145.am/db/2347389/Clarus_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2349120/Clarus_Ventures>,
        <https://1145.am/db/2349717/Clarus_Ventures>,
        <https://1145.am/db/2349722/Clarus_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2351958/Clarus_Ventures>,
        <https://1145.am/db/2352808/Clarus_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2353771/Clarus_Ventures>,
        <https://1145.am/db/2353789/Clarus_Ventures>,
        <https://1145.am/db/2355435/Clarus_Ventures>,
        <https://1145.am/db/2356084/Clarus_Ventures>,
        <https://1145.am/db/2357858/Clarus_Ventures>,
        <https://1145.am/db/2359654/Clarus_Ventures>,
        <https://1145.am/db/2360756/Clarus_Ventures>,
        <https://1145.am/db/2360758/Clarus_Ventures>,
        <https://1145.am/db/2364468/Clarus_Ventures>,
        <https://1145.am/db/2364471/Clarus_Ventures>,
        <https://1145.am/db/2365171/Clarus_Ventures>,
        <https://1145.am/db/2365184/Clarus_Ventures>,
        <https://1145.am/db/2368297/Clarus_Ventures>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2584561/Clarus_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336944/Stanley_Family_Foundation> a org:Organization ;
    ns1:description "Neuroscience disease" ;
    ns1:documentDate "2013-06-27T15:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/heptares-raises-us-21-million-to-advance-novel-gpcr-medicines-into-clinical-development> ;
    ns1:foundName "the Stanley Family Foundation" ;
    ns1:investor <https://1145.am/db/2336944/Series_B_Investment_Clarus_Ventures_Heptares_Therapeutics_Stanley_Family_Foundation_Takeda_Ventures_Completed> ;
    ns1:name "Stanley Family Foundation" ;
    ns1:sameAsMedium <https://1145.am/db/2336948/Stanley_Family_Foundation>,
        <https://1145.am/db/2336954/Stanley_Family_Foundation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336944/Takeda_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-06-27T15:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/heptares-raises-us-21-million-to-advance-novel-gpcr-medicines-into-clinical-development> ;
    ns1:foundName "Takeda Ventures" ;
    ns1:investor <https://1145.am/db/2336944/Series_B_Investment_Clarus_Ventures_Heptares_Therapeutics_Stanley_Family_Foundation_Takeda_Ventures_Completed> ;
    ns1:name "Takeda Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1115103/Takeda_Ventures>,
        <https://1145.am/db/2066938/Takeda_And_Quan_Capital>,
        <https://1145.am/db/564585/Takeda_Ventures_Inc>,
        <https://1145.am/db/566971/Takeda_Ventures_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1116076/Takeda_Ventures>,
        <https://1145.am/db/1469013/Takeda_Ventures>,
        <https://1145.am/db/1476658/Takeda_Ventures>,
        <https://1145.am/db/2280896/Takeda_Ventures>,
        <https://1145.am/db/2284001/Takeda_Ventures>,
        <https://1145.am/db/2341074/Takeda_Ventures>,
        <https://1145.am/db/2353283/Takeda_Ventures>,
        <https://1145.am/db/2363593/Takeda_Ventures>,
        <https://1145.am/db/2363597/Takeda_Ventures>,
        <https://1145.am/db/2364827/Takeda_Ventures>,
        <https://1145.am/db/2365444/Takeda_Ventures>,
        <https://1145.am/db/2544087/Takeda_Ventures>,
        <https://1145.am/db/2555545/Takeda_Ventures>,
        <https://1145.am/db/847865/Takeda_Ventures>,
        <https://1145.am/db/979509/Takeda_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336957/Bioscience_Managers_Pty_Ltd> a org:Organization ;
    ns1:basedInLowRaw "Australia" ;
    ns1:description "Investing in life science" ;
    ns1:documentDate "2013-06-27T16:09:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ampliphi Biosciences Corp : AmpliPhi Closes $7 Million Private Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ampliphi-biosciences-corp-ampliphi-closes-7-million-private-placement> ;
    ns1:foundName "BioScience Managers Pty Ltd" ;
    ns1:investor <https://1145.am/db/2336957/Investment_Ampliphi_Biosciences_Corp_Bioscience_Managers_Pty_Ltd_Ra_Capital_Management_Third_Security_Llc_Completed> ;
    ns1:name "BioScience Managers Pty Ltd" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336957/Ra_Capital_Management> a org:Organization ;
    ns1:description "life-sciences investors" ;
    ns1:documentDate "2013-06-27T16:09:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ampliphi Biosciences Corp : AmpliPhi Closes $7 Million Private Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ampliphi-biosciences-corp-ampliphi-closes-7-million-private-placement> ;
    ns1:foundName "RA Capital Management" ;
    ns1:investor <https://1145.am/db/2336957/Investment_Ampliphi_Biosciences_Corp_Bioscience_Managers_Pty_Ltd_Ra_Capital_Management_Third_Security_Llc_Completed> ;
    ns1:name "RA Capital Management" ;
    ns1:sameAsMedium <https://1145.am/db/1134574/Ra_Capital_Management_Lp>,
        <https://1145.am/db/1164709/Ra_Capital_Management>,
        <https://1145.am/db/1166452/Ra_Capital_Management>,
        <https://1145.am/db/1198548/Ra_Capital_Management>,
        <https://1145.am/db/1219334/Ra_Capital_Management>,
        <https://1145.am/db/1219771/Ra_Capital_Management>,
        <https://1145.am/db/1293978/Ra_Capital_Management>,
        <https://1145.am/db/1294718/Ra_Capital_Management>,
        <https://1145.am/db/1334624/Ra_Capital_Management>,
        <https://1145.am/db/1503165/Ra_Capital_Management>,
        <https://1145.am/db/1735850/Ra_Capital_Management>,
        <https://1145.am/db/1926411/Ra_Capital_Management>,
        <https://1145.am/db/1928388/Ra_Capital_Management>,
        <https://1145.am/db/2011094/Ra_Capital_Management>,
        <https://1145.am/db/2075754/Ra_Capital_Management>,
        <https://1145.am/db/2089412/Ra_Capital_Management>,
        <https://1145.am/db/2109798/Ra_Capital_Management>,
        <https://1145.am/db/2153910/Ra_Capital_Management>,
        <https://1145.am/db/2155505/Ra_Capital_Management>,
        <https://1145.am/db/2280400/Ra_Capital_Management>,
        <https://1145.am/db/2282268/Ra_Capital_Management>,
        <https://1145.am/db/2282806/Ra_Capital_Management>,
        <https://1145.am/db/2285762/Ra_Capital_Management>,
        <https://1145.am/db/2286204/Ra_Capital_Management>,
        <https://1145.am/db/2298395/Ra_Capital_Management>,
        <https://1145.am/db/2298642/Ra_Capital_Management>,
        <https://1145.am/db/2335743/Ra_Capital_Management>,
        <https://1145.am/db/2336510/Ra_Capital_Management>,
        <https://1145.am/db/2336511/Ra_Capital_Management_Llc>,
        <https://1145.am/db/2337599/Ra_Capital_Management_Llc>,
        <https://1145.am/db/2338126/Ra_Capital_Management>,
        <https://1145.am/db/2338127/Ra_Capital_Management>,
        <https://1145.am/db/2339214/Ra_Capital_Management>,
        <https://1145.am/db/2339223/Ra_Capital_Management>,
        <https://1145.am/db/2339666/Ra_Capital_Management>,
        <https://1145.am/db/2340942/Ra_Capital_Management>,
        <https://1145.am/db/2346773/Ra_Capital_Management_Llc>,
        <https://1145.am/db/2346775/Ra_Capital_Management_Llc>,
        <https://1145.am/db/2347043/Ra_Capital_Management>,
        <https://1145.am/db/2348149/Ra_Capital_Management>,
        <https://1145.am/db/2355029/Ra_Capital_Management>,
        <https://1145.am/db/2356216/Ra_Capital_Management>,
        <https://1145.am/db/2357144/Ra_Capital_Management>,
        <https://1145.am/db/2357566/Ra_Capital_Management>,
        <https://1145.am/db/2360277/Ra_Capital_Management>,
        <https://1145.am/db/2360682/Ra_Capital_Management>,
        <https://1145.am/db/2363391/Ra_Capital_Management_Llc>,
        <https://1145.am/db/2363442/Ra_Capital_Management>,
        <https://1145.am/db/2366735/Ra_Capital_Management>,
        <https://1145.am/db/2367678/Ra_Capital_Management>,
        <https://1145.am/db/2368322/Ra_Capital_Management>,
        <https://1145.am/db/2369974/Ra_Capital_Management>,
        <https://1145.am/db/2370436/Ra_Capital_Management>,
        <https://1145.am/db/2371160/Ra_Capital_Management>,
        <https://1145.am/db/2371163/Ra_Capital_Management>,
        <https://1145.am/db/2570481/Ra_Capital_Management>,
        <https://1145.am/db/2570483/Ra_Capital_Management>,
        <https://1145.am/db/387629/Ra_Capital_Management>,
        <https://1145.am/db/425953/Ra_Capital_Management>,
        <https://1145.am/db/441151/Ra_Capital_Management>,
        <https://1145.am/db/509733/Ra_Capital_Management>,
        <https://1145.am/db/572554/Ra_Capital_Management>,
        <https://1145.am/db/633100/Ra_Capital_Management>,
        <https://1145.am/db/677591/Ra_Capital_Management>,
        <https://1145.am/db/681970/Ra_Capital_Management>,
        <https://1145.am/db/820519/Ra_Capital_Management_Lp>,
        <https://1145.am/db/922552/Ra_Capital_Management>,
        <https://1145.am/db/923335/Ra_Capital_Management>,
        <https://1145.am/db/941871/Ra_Capital_Management>,
        <https://1145.am/db/979509/Ra_Capital_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338289/Chiesi_Farmaceutici_Spa> a org:Organization ;
    ns1:basedInLowRaw "Italy" ;
    ns1:buyer <https://1145.am/db/2338289/Acquisition_Chiesi_Farmaceutici_Spa_Cornerstone_Therapeutics_Inc_Has_Not_Happened>,
        <https://1145.am/db/2338289/Cornerstone_Therapeutics_Inc_Acquisition> ;
    ns1:description "Chiesi Farmaceutici SpA is involved in" ;
    ns1:documentDate "2013-02-20T17:03:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cornerstone-therapeutics-inc-announces-receipt-of-take-private-proposal-from-its-majority> ;
    ns1:foundName "Chiesi",
        "Chiesi Farmaceutici SpA" ;
    ns1:name "Chiesi Farmaceutici SpA" ;
    ns1:sameAsMedium <https://1145.am/db/1626867/Chiesi_Farmaceutici>,
        <https://1145.am/db/1627110/Chiesi_Farmaceutici_Spa>,
        <https://1145.am/db/1633105/Chiesi_Farmaceutici_Spa>,
        <https://1145.am/db/1633172/Chiesi_Farmaceutici_Spa>,
        <https://1145.am/db/1683116/Chiesi_Farmaceutici_Spa>,
        <https://1145.am/db/2289850/Chiesi_Farmaceutici>,
        <https://1145.am/db/2304396/Chiesi_Farmaceutici>,
        <https://1145.am/db/2319710/Chiesi_Farmaceutici>,
        <https://1145.am/db/2353129/Chiesi_Farmaceutici>,
        <https://1145.am/db/2566352/Chiesi_Farmaceutici> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339099/Series_B_Investment_Brickell_Biotech_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-26T14:13:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Brickell Biotech Announces $ 7M Series B Financing to Fund Development of Novel Dermatology Treatments.",
        "Brickell Biotech, Inc. (\"Brickell\") , a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, today announced a $ 7 million Series B financing round." ;
    ns1:documentTitle "Brickell Biotech Announces $7M Series B Financing to Fund Development of Novel Dermatology Treatments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/brickell-biotech-announces-7m-series-b-financing-to-fund-development-of-novel-dermatology> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2339099/Brickell_Biotech> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 7 million",
        "$ 7M" ;
    ns1:whereGeoName "Miami" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4164138/about.rdf> ;
    ns1:whereRaw "MIAMI" .

<https://1145.am/db/2339108/Invesco_Perpetual> a org:Organization ;
    ns1:basedInLowRaw "U.K." ;
    ns1:documentDate "2013-02-26T16:41:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Glide gets $21M round for drug/device work; Vivus shares battered on weak sales results for Qsymia;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/glide-gets-21m-round-for-drug-device-work-vivus-shares-battered-on-weak-sales-results-for> ;
    ns1:foundName "Invesco Perpetual" ;
    ns1:investor <https://1145.am/db/2339108/Investment_Glide_Pharma_Invesco_Perpetual_Completed> ;
    ns1:name "Invesco Perpetual" ;
    ns1:sameAsMedium <https://1145.am/db/2302961/Invesco_Perpetual>,
        <https://1145.am/db/2302965/Invesco_Perpetual>,
        <https://1145.am/db/2304832/Invesco_Perpetual>,
        <https://1145.am/db/2304844/Invesco_Perpetual>,
        <https://1145.am/db/2311597/Invesco_Perpetual>,
        <https://1145.am/db/2318529/Invesco_Perpetual>,
        <https://1145.am/db/2318537/Invesco_Perpetual>,
        <https://1145.am/db/2339111/Invesco_Perpetual>,
        <https://1145.am/db/2340559/Invesco_Perpetual>,
        <https://1145.am/db/2341738/Invesco_Perpetual>,
        <https://1145.am/db/2341760/Invesco_Perpetual>,
        <https://1145.am/db/2348796/Invesco_Perpetual>,
        <https://1145.am/db/2363947/Invesco_Perpetual>,
        <https://1145.am/db/2363950/Invesco_Perpetual>,
        <https://1145.am/db/2366154/Invesco_Perpetual>,
        <https://1145.am/db/2366156/Invesco_Perpetual>,
        <https://1145.am/db/2366434/Invesco_Perpetual>,
        <https://1145.am/db/2367043/Invesco_Perpetual>,
        <https://1145.am/db/2544138/Invesco_Perpetual> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339108/Ipo_Vivus_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2013-02-26T16:41:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Shares of Vivus ($ VVUS) took a beating after the company reported that sales of its weight drug Qsymia amounted to only $ 2 million in the fourth quarter." ;
    ns1:documentTitle "Glide gets $21M round for drug/device work; Vivus shares battered on weak sales results for Qsymia;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/glide-gets-21m-round-for-drug-device-work-vivus-shares-battered-on-weak-sales-results-for> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:vendor <https://1145.am/db/2339108/Vivus> ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "U.K." .

<https://1145.am/db/2339932/Innovus_Pharmaceuticals> a org:Organization ;
    ns1:basedInLowRaw "U.S" ;
    ns1:buyer <https://1145.am/db/2339932/Acquisition_Centric_Research_Institute_Innovus_Pharmaceuticals_Has_Not_Happened> ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "Innovus Pharmaceuticals" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Innovus Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2287533/Enthera_Pharmaceuticals>,
        <https://1145.am/db/2302750/Neomed>,
        <https://1145.am/db/2305797/Immtech_Pharmaceuticals>,
        <https://1145.am/db/2310229/Inex_Pharmaceuticals>,
        <https://1145.am/db/2314563/Inex_Pharmaceuticals>,
        <https://1145.am/db/2324024/Insmed>,
        <https://1145.am/db/2325476/Inex_Pharmaceuticals>,
        <https://1145.am/db/2325715/Insmed>,
        <https://1145.am/db/2326771/Insmed>,
        <https://1145.am/db/2328330/Medpointe_Inc>,
        <https://1145.am/db/2328409/Insmed>,
        <https://1145.am/db/2329586/Insmed>,
        <https://1145.am/db/2329589/Insmed_Inc>,
        <https://1145.am/db/2337212/Insmed_Incorporated>,
        <https://1145.am/db/2341500/Insmed_Incorporated>,
        <https://1145.am/db/2342375/Insmed_Incorporated>,
        <https://1145.am/db/2346991/Insmed_Incorporated>,
        <https://1145.am/db/2351060/Innovus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354167/Innovus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358957/Insmed_Incorporated>,
        <https://1145.am/db/2360593/Innovus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364627/Innovus_Pharmaceuticals>,
        <https://1145.am/db/2539113/Invagen_Pharmaceuticals_Inc>,
        <https://1145.am/db/2544054/Invagen_Pharmaceuticals>,
        <https://1145.am/db/2550554/Invagen_Pharmaceuticals_Inc>,
        <https://1145.am/db/2551522/Invagen_Pharmaceuticals>,
        <https://1145.am/db/2560781/Invagen_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339933/Agentschap_Nl> a org:Organization ;
    ns1:basedInLowRaw "Dutch" ;
    ns1:description "Economic Affairs" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "Agentschap NL" ;
    ns1:investor <https://1145.am/db/2339933/Series_A_Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_Completed> ;
    ns1:name "Agentschap NL" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2340819/Adage_Capital_Management> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "finance" ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "Adage Capital Management" ;
    ns1:investor <https://1145.am/db/2340819/Investment_Adage_Capital_Management_Brookside_Capital_Partners_Fund_Jennison_Associates_Llc_Longwood_Fund_Ptc_Therapeutics_Inc_Completed> ;
    ns1:name "Adage Capital Management" ;
    ns1:sameAsHigh <https://1145.am/db/2339223/Adage_Capital>,
        <https://1145.am/db/2364492/Adage_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1770748/Adage_Capital_Management>,
        <https://1145.am/db/2285893/Adage_Capital_Management>,
        <https://1145.am/db/2307845/Adage_Capital_Management>,
        <https://1145.am/db/2307846/Adage_Capital_Management>,
        <https://1145.am/db/2327488/Adage_Capital_Management_Lp>,
        <https://1145.am/db/2335748/Adage_Capital_Management>,
        <https://1145.am/db/2338428/Adage_Capital_Management>,
        <https://1145.am/db/2356216/Adage_Capital_Management>,
        <https://1145.am/db/2360266/Adage_Capital_Management>,
        <https://1145.am/db/2368322/Adage_Capital_Management>,
        <https://1145.am/db/2369974/Adage_Capital_Management>,
        <https://1145.am/db/281538/Adage_Capital_Management_Lp>,
        <https://1145.am/db/341984/Adage_Capital_Management>,
        <https://1145.am/db/341990/Adage_Capital_Management>,
        <https://1145.am/db/683988/Adage_Capital_Management>,
        <https://1145.am/db/888513/Adage_Capital_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2340819/Jennison_Associates_Llc> a org:Organization ;
    ns1:basedInLowRaw "N.J." ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "Jennison Associates L.L.C." ;
    ns1:investor <https://1145.am/db/2340819/Investment_Adage_Capital_Management_Brookside_Capital_Partners_Fund_Jennison_Associates_Llc_Longwood_Fund_Ptc_Therapeutics_Inc_Completed> ;
    ns1:name "Jennison Associates L.L.C." ;
    ns1:sameAsMedium <https://1145.am/db/2336221/Jennison_Associates_Llc>,
        <https://1145.am/db/2340942/Jennison_Associates>,
        <https://1145.am/db/2346773/Jennison_Associates_Llc>,
        <https://1145.am/db/2346775/Jennison_Associates_Llc>,
        <https://1145.am/db/2348148/Jennison_Associates>,
        <https://1145.am/db/2348149/Jennison_Associates>,
        <https://1145.am/db/2355023/Jennison_Associates_Llc>,
        <https://1145.am/db/2359683/Jennison_Associates>,
        <https://1145.am/db/2360277/Jennison_Associates_Llc>,
        <https://1145.am/db/2368070/Jennison_Associates_Llc>,
        <https://1145.am/db/2368579/Jennison_Associates>,
        <https://1145.am/db/2370694/Jennison_Associates>,
        <https://1145.am/db/378585/Jennison_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2340819/Longwood_Fund> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "top-tier institutional investors" ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "Longwood Fund" ;
    ns1:investor <https://1145.am/db/2340819/Investment_Adage_Capital_Management_Brookside_Capital_Partners_Fund_Jennison_Associates_Llc_Longwood_Fund_Ptc_Therapeutics_Inc_Completed> ;
    ns1:name "Longwood Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2152752/Longwood_Fund>,
        <https://1145.am/db/545988/Longwood_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1150529/Longwood_Fund>,
        <https://1145.am/db/1156304/Longwood_Fund>,
        <https://1145.am/db/1325968/Longwood_Fund>,
        <https://1145.am/db/2073480/Longwood_Fund>,
        <https://1145.am/db/207823/Longwood_Fund>,
        <https://1145.am/db/2153759/Longwood_Fund>,
        <https://1145.am/db/2289515/Longwood_Fund>,
        <https://1145.am/db/2291882/Longwood_Fund>,
        <https://1145.am/db/2349437/Longwood_Fund>,
        <https://1145.am/db/2362553/Longwood_Fund>,
        <https://1145.am/db/2363330/Longwood_Fund>,
        <https://1145.am/db/979509/Longwood_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342842/Ampersand_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:buyer <https://1145.am/db/2342842/Bioclinica_Investment> ;
    ns1:description "private equity" ;
    ns1:documentDate "2013-03-14T16:17:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BioClinica and CoreLab Partners Are One" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bioclinica-and-corelab-partners-are-one> ;
    ns1:foundName "Ampersand Capital Partners" ;
    ns1:industry "private equity" ;
    ns1:investor <https://1145.am/db/2342842/Bioclinica_Investment> ;
    ns1:name "Ampersand Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1006449/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1006707/One_Equity_Partners>,
        <https://1145.am/db/1007136/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1007761/One_Equity_Partners>,
        <https://1145.am/db/1008666/Abry_Partners>,
        <https://1145.am/db/1014464/Red_Door_Capital_Partners>,
        <https://1145.am/db/1016038/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1021/Sun_Capital_Partners>,
        <https://1145.am/db/1031030/Godspeed_Capital>,
        <https://1145.am/db/1042790/Atlantic_Street_Capital>,
        <https://1145.am/db/1051317/Ocean_Avenue_Capital_Partners>,
        <https://1145.am/db/1059981/Kline_Hill_Partners>,
        <https://1145.am/db/1060630/Kline_Hill_Partners>,
        <https://1145.am/db/1064824/Cvc_Capital_Partners>,
        <https://1145.am/db/1079016/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1079209/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1083961/Atlantic_Street_Capital>,
        <https://1145.am/db/1084696/Prospect_Hill_Growth_Partners>,
        <https://1145.am/db/1085856/Atlantic_Street_Capital>,
        <https://1145.am/db/1086147/Prospect_Hill_Growth_Partners>,
        <https://1145.am/db/1087313/Westview_Capital_Partners>,
        <https://1145.am/db/1101220/Aterian_Investment_Partners>,
        <https://1145.am/db/1103243/Aterian_Investment_Partners>,
        <https://1145.am/db/1112352/Victor_Capital_Partners>,
        <https://1145.am/db/1113141/Capital_Partners>,
        <https://1145.am/db/1114794/One_Equity_Partners>,
        <https://1145.am/db/1114821/One_Equity_Partners>,
        <https://1145.am/db/1116308/Ampersand_Capital_Partners>,
        <https://1145.am/db/1119554/Attain_Capital_Partners>,
        <https://1145.am/db/1128071/Cvc_Capital_Partners>,
        <https://1145.am/db/1137320/Sole_Source_Capital>,
        <https://1145.am/db/1140742/Sole_Source_Capital>,
        <https://1145.am/db/1149388/Great_Hill_Partners>,
        <https://1145.am/db/1150373/Sole_Source_Capital>,
        <https://1145.am/db/1151233/Great_Hill_Partners>,
        <https://1145.am/db/1152236/Sole_Source_Capital>,
        <https://1145.am/db/1152296/Triwest_Capital_Partners>,
        <https://1145.am/db/1157792/Bc_Partners>,
        <https://1145.am/db/1196066/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1196661/Court_Square_Capital_Partners>,
        <https://1145.am/db/1197316/Court_Square_Capital_Partners>,
        <https://1145.am/db/1197858/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1199020/Bc_Partners_Ltd>,
        <https://1145.am/db/1203996/One_Rock_Capital_Partners>,
        <https://1145.am/db/1212984/Sole_Source_Capital>,
        <https://1145.am/db/1213136/Godspeed_Capital>,
        <https://1145.am/db/1213476/Sole_Source_Capital>,
        <https://1145.am/db/1217982/New_Capital_Partners>,
        <https://1145.am/db/1223533/Granite_Creek_Capital_Partners>,
        <https://1145.am/db/123062/Pacific_Equity_Partners>,
        <https://1145.am/db/1233600/South_Street_Partners>,
        <https://1145.am/db/124264/Pacific_Equity_Partners>,
        <https://1145.am/db/1244678/Godspeed_Capital>,
        <https://1145.am/db/1244776/Arkview_Capital>,
        <https://1145.am/db/1245183/Great_Hill_Partners>,
        <https://1145.am/db/1245418/Godspeed_Capital>,
        <https://1145.am/db/1245688/Arkview_Capital>,
        <https://1145.am/db/1252784/Isleworth_Capital_Partners>,
        <https://1145.am/db/1253079/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1254864/Isleworth_Capital_Partners>,
        <https://1145.am/db/1262739/One_Equity_Partners>,
        <https://1145.am/db/1264347/Sfw_Capital_Partners>,
        <https://1145.am/db/1265089/Sfw_Capital_Partners>,
        <https://1145.am/db/1265498/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1265754/One_Equity_Partners>,
        <https://1145.am/db/1266311/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1272244/One_Rock_Capital_Partners>,
        <https://1145.am/db/1272478/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1273195/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1278526/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1278671/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1278904/Godspeed_Capital>,
        <https://1145.am/db/1278970/One_Equity_Partners>,
        <https://1145.am/db/1279638/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1279964/One_Equity_Partners>,
        <https://1145.am/db/1281384/Thompson_Street_Capital_Partners_Vi_Lp>,
        <https://1145.am/db/1281913/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1282353/L2_Capital>,
        <https://1145.am/db/1282744/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/128762/Pacific_Equity_Partners>,
        <https://1145.am/db/128784/Pacific_Equity_Partners>,
        <https://1145.am/db/1296402/Cvc_Capital_Partners>,
        <https://1145.am/db/1298503/Incline_Equity_Partners>,
        <https://1145.am/db/1300330/Primary_Capital>,
        <https://1145.am/db/1310799/One_Equity_Partners>,
        <https://1145.am/db/1312018/One_Equity_Partners>,
        <https://1145.am/db/1318669/Eagletree_Capital>,
        <https://1145.am/db/1319084/Thayer_Street_Partners>,
        <https://1145.am/db/1322337/Comvest_Partners>,
        <https://1145.am/db/1322965/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/1323023/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/1335299/Sfw_Capital_Partners>,
        <https://1145.am/db/1335427/Sfw_Capital_Partners>,
        <https://1145.am/db/1336622/Court_Square_Capital_Partners>,
        <https://1145.am/db/1337998/Court_Square_Capital_Partners>,
        <https://1145.am/db/1345729/Cvc_Capital_Partners>,
        <https://1145.am/db/1347521/Oak_Street>,
        <https://1145.am/db/1351608/Nonantum_Capital_Partners>,
        <https://1145.am/db/1352481/Nonantum_Capital_Partners>,
        <https://1145.am/db/1358651/Cvc_Capital_Partners>,
        <https://1145.am/db/1369951/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1370181/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1370710/One_Equity_Partners>,
        <https://1145.am/db/1375792/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1376070/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1386921/Sfw_Capital_Partners>,
        <https://1145.am/db/1387409/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1388089/Court_Square_Capital_Partners>,
        <https://1145.am/db/1388102/Sfw_Capital_Partners>,
        <https://1145.am/db/1388168/Oak_Hill_Capital_Partners>,
        <https://1145.am/db/1390496/Oak_Hill_Capital_Partners>,
        <https://1145.am/db/1406030/One_Equity_Partners>,
        <https://1145.am/db/1406481/One_Equity_Partners>,
        <https://1145.am/db/1408755/Advantary_Capital_Partners>,
        <https://1145.am/db/1422536/Godspeed_Capital>,
        <https://1145.am/db/1422557/Sole_Source_Capital>,
        <https://1145.am/db/1423290/Godspeed_Capital>,
        <https://1145.am/db/1423361/Sole_Source_Capital>,
        <https://1145.am/db/1432350/Oaktree_Capital_Management>,
        <https://1145.am/db/1432465/Kps_Capital_Partners>,
        <https://1145.am/db/1440951/Aliph_Capital>,
        <https://1145.am/db/1451844/Grant_Avenue_Capital>,
        <https://1145.am/db/1454855/Grant_Avenue_Capital>,
        <https://1145.am/db/1459712/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1495886/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1503057/One_Equity_Partners>,
        <https://1145.am/db/1507816/Aliph_Capital>,
        <https://1145.am/db/1509925/Centerfield_Capital_Partners>,
        <https://1145.am/db/1553037/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1553107/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1553362/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1554188/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1554304/Ascend_Capital_Partners>,
        <https://1145.am/db/156114/Towerbrook_Capital_Partners>,
        <https://1145.am/db/1561967/Arlington_Capital_Partners>,
        <https://1145.am/db/1562363/Arlington_Capital_Partners>,
        <https://1145.am/db/157827/Towerbrook_Capital_Partners>,
        <https://1145.am/db/157887/Towerbrook_Capital_Partners>,
        <https://1145.am/db/1581927/Bc_Partners_Ltd>,
        <https://1145.am/db/1581979/Altamont_Capital_Partners>,
        <https://1145.am/db/158241/Citic_Capital>,
        <https://1145.am/db/1609462/Bc_Partners>,
        <https://1145.am/db/1614023/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/1614865/Long_Ridge_Equity_Partners>,
        <https://1145.am/db/1615372/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/1616193/Long_Ridge_Equity_Partners>,
        <https://1145.am/db/1618787/Nonantum_Capital_Partners>,
        <https://1145.am/db/1618787/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1619234/Arlington_Capital_Partners>,
        <https://1145.am/db/1619465/Nonantum_Capital_Partners>,
        <https://1145.am/db/1619465/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1620909/Arlington_Capital_Partners>,
        <https://1145.am/db/1628687/M_C_Partners>,
        <https://1145.am/db/1631042/Exeter_Street_Capital_Partners>,
        <https://1145.am/db/164592/Pai_Partners>,
        <https://1145.am/db/1651532/Cvc_Capital_Partners>,
        <https://1145.am/db/1656903/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1658060/Llr_Partners>,
        <https://1145.am/db/1659093/Morgan_Stanley_Capital_Partners>,
        <https://1145.am/db/1659786/Ridgemont_Equity_Partners>,
        <https://1145.am/db/1659810/Morgan_Stanley_Capital_Partners>,
        <https://1145.am/db/1663459/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1667839/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1679207/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/169901/Cvc_Capital_Partners>,
        <https://1145.am/db/1711603/Oak_Hlll_Capital_Partners>,
        <https://1145.am/db/173152/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1735717/Hillhouse_Capital>,
        <https://1145.am/db/1740266/Great_Hill_Partners>,
        <https://1145.am/db/1746574/Hillhouse_Capital>,
        <https://1145.am/db/1748133/Crosspoint_Capital>,
        <https://1145.am/db/1748887/Francisco_Partners>,
        <https://1145.am/db/1749326/Sixth_Street_Partners>,
        <https://1145.am/db/179472/Hillhouse_Capital_Group>,
        <https://1145.am/db/1847894/Adams_Street_Partners>,
        <https://1145.am/db/1853872/Cvc_Capital_Partners>,
        <https://1145.am/db/1856857/Charterhouse_Capital_Partners>,
        <https://1145.am/db/1882372/Great_Hill_Partners>,
        <https://1145.am/db/1924169/Silver_Lake_Partners>,
        <https://1145.am/db/1926409/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/1926489/Sole_Source_Capital_Llc>,
        <https://1145.am/db/1929486/Cvc_Capital_Partners>,
        <https://1145.am/db/1938642/Cvc_Capital_Partner>,
        <https://1145.am/db/1939279/Court_Square_Capital_Partners>,
        <https://1145.am/db/1959321/Arkview_Capital>,
        <https://1145.am/db/1968065/Cvc_Capital_Partners>,
        <https://1145.am/db/196960/Bc_Partners>,
        <https://1145.am/db/1982583/Great_Hill_Partners>,
        <https://1145.am/db/1994494/One_Equity_Partners>,
        <https://1145.am/db/1997896/Court_Square_Capital_Partners>,
        <https://1145.am/db/2003857/Alpinvest_Partners>,
        <https://1145.am/db/2003857/One_Equity_Partners>,
        <https://1145.am/db/2019700/Godspeed_Capital>,
        <https://1145.am/db/2020777/Francisco_Partners>,
        <https://1145.am/db/2029386/Hillhouse_Capital_Group>,
        <https://1145.am/db/2033906/Grovecourt_Capital_Partners>,
        <https://1145.am/db/2033932/One_Equity_Partners>,
        <https://1145.am/db/2039782/Guardian_Capital_Partners>,
        <https://1145.am/db/204108/Ridgemont_Equity_Partners>,
        <https://1145.am/db/204704/Cvc_Capital_Partners>,
        <https://1145.am/db/2050172/Great_Hill_Partners>,
        <https://1145.am/db/2051486/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/2052015/Congruent_Investment_Partners>,
        <https://1145.am/db/2067945/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/2071921/Bluestone_Equity_Partners>,
        <https://1145.am/db/2072708/Bc_Partners>,
        <https://1145.am/db/2075548/Monroe_Street_Partners>,
        <https://1145.am/db/2075760/Arlington_Capital_Partners>,
        <https://1145.am/db/2083882/Grovecourt_Capital_Partners>,
        <https://1145.am/db/2093468/Francisco_Partners>,
        <https://1145.am/db/2094328/Francisco_Partners>,
        <https://1145.am/db/2096894/Sole_Source_Capital_Llc>,
        <https://1145.am/db/2099375/Grovecourt_Capital_Partners>,
        <https://1145.am/db/2109892/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2110563/Grant_Avenue_Capital>,
        <https://1145.am/db/2126826/Cvc_Capital_Partners>,
        <https://1145.am/db/2130279/Great_Hill_Partners>,
        <https://1145.am/db/2132436/Arlington_Capital_Partners>,
        <https://1145.am/db/2133887/Arlington_Capital_Partners>,
        <https://1145.am/db/2134320/Ascend_Capital_Partners>,
        <https://1145.am/db/2138702/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/2146633/A___M_Capital_Partners>,
        <https://1145.am/db/2159187/Bc_Partners>,
        <https://1145.am/db/2162895/Francisco_Partners>,
        <https://1145.am/db/2165613/Oak_Hill_Capital_Management_Llc>,
        <https://1145.am/db/2171577/Abry_Partners>,
        <https://1145.am/db/2177813/Hawk_Capital_Partners>,
        <https://1145.am/db/2205136/Francisco_Partners>,
        <https://1145.am/db/2209892/Francisco_Partners>,
        <https://1145.am/db/2220218/Francisco_Partners>,
        <https://1145.am/db/2230367/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/2231954/Francisco_Partners>,
        <https://1145.am/db/2240189/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/2247487/Francisco_Partners>,
        <https://1145.am/db/2249162/Francisco_Partners>,
        <https://1145.am/db/2249242/Llr_Partners>,
        <https://1145.am/db/227023/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/2273269/Oak_Hill_Capital_Partners>,
        <https://1145.am/db/2279411/Sfw_Capital_Partners>,
        <https://1145.am/db/2309719/Ampersand_Capital_Partners>,
        <https://1145.am/db/2329/Sun_Capital_Partners>,
        <https://1145.am/db/2344192/Ridgemont_Equity_Partners>,
        <https://1145.am/db/237583/One_Rock_Capital_Partners>,
        <https://1145.am/db/2443308/Comvest_Partners>,
        <https://1145.am/db/2477142/Ksl_Capital_Partners>,
        <https://1145.am/db/2527/Sun_Capital_Partners>,
        <https://1145.am/db/2545370/Chryscapital>,
        <https://1145.am/db/2546740/Ampersand_Capital_Partners>,
        <https://1145.am/db/2549919/Bc_Partners>,
        <https://1145.am/db/2550394/Bc_Partners>,
        <https://1145.am/db/2553166/Catalyst_Principal_Partners>,
        <https://1145.am/db/2558911/Cvc_Capital_Partners>,
        <https://1145.am/db/2561042/Cvc_Capital_Partners>,
        <https://1145.am/db/2578302/Ancor_Capital_Partners>,
        <https://1145.am/db/2580802/Prospect_Partners>,
        <https://1145.am/db/2591584/Bc_Partners>,
        <https://1145.am/db/2592707/Bc_Partners>,
        <https://1145.am/db/259821/Kps_Capital_Partners>,
        <https://1145.am/db/2599816/Abry_Partners>,
        <https://1145.am/db/2601139/Canyon_Bridge_Capital_Partners>,
        <https://1145.am/db/2601907/Oak_Hill_Capital_Partners>,
        <https://1145.am/db/2603843/Cvf_Capital_Partners>,
        <https://1145.am/db/2605285/Abry_Partners>,
        <https://1145.am/db/2608284/Abry_Partners>,
        <https://1145.am/db/2610972/Bc_Partners>,
        <https://1145.am/db/2612445/Silver_Lake_Partners>,
        <https://1145.am/db/2615297/Abry_Partners>,
        <https://1145.am/db/2615411/Oak_Hill_Capital_Partners>,
        <https://1145.am/db/2615505/Francisco_Partners>,
        <https://1145.am/db/2626198/Francisco_Partners>,
        <https://1145.am/db/2631300/Francisco_Partners>,
        <https://1145.am/db/2633244/One_Equity_Partners>,
        <https://1145.am/db/2646338/Harbinger_Capital_Partners_Funds>,
        <https://1145.am/db/2647818/Cvc_Partners>,
        <https://1145.am/db/2662265/Silver_Lake_Partners>,
        <https://1145.am/db/2666624/Francisco_Partners>,
        <https://1145.am/db/2668916/Cvc_Capital_Partners>,
        <https://1145.am/db/2674903/Harbinger_Capital_Partners>,
        <https://1145.am/db/2695499/Ksl_Capital_Partners>,
        <https://1145.am/db/2697469/Ksl_Capital_Partners>,
        <https://1145.am/db/2698337/Ksl_Capital_Partners>,
        <https://1145.am/db/270061/Charterhouse_Capital_Partners>,
        <https://1145.am/db/2704736/Sixth_Street_Partners>,
        <https://1145.am/db/2731857/Hillhouse_Capital>,
        <https://1145.am/db/2754699/Hillhouse_Capital>,
        <https://1145.am/db/2766777/Ridgemont_Equity_Partners>,
        <https://1145.am/db/2783050/Performant_Capital>,
        <https://1145.am/db/2798666/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/2820/Sun_Capital_Partners>,
        <https://1145.am/db/301841/Francisco_Partners>,
        <https://1145.am/db/303188/Kps_Capital_Partners>,
        <https://1145.am/db/308877/Oaktree_Capital_Group>,
        <https://1145.am/db/309966/Oaktree_Capital_Group>,
        <https://1145.am/db/348360/Ace_Capital_Partners>,
        <https://1145.am/db/352877/Oaktree_Capital_Group>,
        <https://1145.am/db/356927/__R>,
        <https://1145.am/db/360351/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/365378/Oak_Hill_Capital>,
        <https://1145.am/db/367654/Oak_Hill_Capital>,
        <https://1145.am/db/370212/Kps_Capital_Partners>,
        <https://1145.am/db/389665/Pai_Partners>,
        <https://1145.am/db/390812/Cvc_Capital_Partners>,
        <https://1145.am/db/413383/Charter_Oak_Equity>,
        <https://1145.am/db/413607/Nonantum_Capital_Partners>,
        <https://1145.am/db/421409/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/422483/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/428733/West_Lane_Capital_Partners_Llc>,
        <https://1145.am/db/430577/Arlington_Capital_Partners>,
        <https://1145.am/db/431676/Westview_Capital_Partners>,
        <https://1145.am/db/435888/Oaktree_Capital>,
        <https://1145.am/db/443026/Hillhouse_Capital>,
        <https://1145.am/db/446074/Towerbrook_Capital_Partners>,
        <https://1145.am/db/446156/Investcorp>,
        <https://1145.am/db/452368/Petershill_Partners>,
        <https://1145.am/db/452938/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/457990/Llr_Partners>,
        <https://1145.am/db/481161/Gatewood_Capital_Partners_Llc>,
        <https://1145.am/db/482784/Gatewood_Capital_Partners_Llc>,
        <https://1145.am/db/486414/Ci_Capital_Partners>,
        <https://1145.am/db/488333/Partners_Group_Holding>,
        <https://1145.am/db/488637/Great_Hill_Partners>,
        <https://1145.am/db/490196/One_Rock_Capital_Partners>,
        <https://1145.am/db/526463/Ridgelake_Partners>,
        <https://1145.am/db/526978/Arlington_Capital_Partners>,
        <https://1145.am/db/526978/Cm_Equity_Partners>,
        <https://1145.am/db/527649/Arlington_Capital_Partners>,
        <https://1145.am/db/527649/Cm_Equity_Partners>,
        <https://1145.am/db/540664/Ridgemont_Equity_Partners>,
        <https://1145.am/db/544578/Francisco_Partners>,
        <https://1145.am/db/555969/Ridgemont_Equity_Partners>,
        <https://1145.am/db/555987/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/556134/Aterian_Investment_Partners_Iv>,
        <https://1145.am/db/564781/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/567133/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/581473/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/582350/Eagletree_Capital>,
        <https://1145.am/db/583034/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/590254/Eagletree_Capital>,
        <https://1145.am/db/591820/Britehorn_Partners>,
        <https://1145.am/db/607097/Eagletree_Capital>,
        <https://1145.am/db/607534/Ridgemont_Equity_Partners>,
        <https://1145.am/db/607558/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/619175/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/619244/Great_Hill_Partners>,
        <https://1145.am/db/629527/Partners_Group>,
        <https://1145.am/db/633069/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/638283/Cvc_Capital_Partners>,
        <https://1145.am/db/641201/Godspeed_Capital>,
        <https://1145.am/db/641409/Blue_Wolf_Capital_Partners_Llc>,
        <https://1145.am/db/641642/Godspeed_Capital>,
        <https://1145.am/db/642369/Oak_Hill_Capital>,
        <https://1145.am/db/643839/Cvc_Capital_Partners>,
        <https://1145.am/db/656827/Francisco_Partners>,
        <https://1145.am/db/659858/Pacific_Equity_Partners>,
        <https://1145.am/db/661224/Pacific_Equity_Partners>,
        <https://1145.am/db/664344/Investcorp>,
        <https://1145.am/db/685346/Cvc_Capital_Partners>,
        <https://1145.am/db/688739/Cvc_Capital_Partners>,
        <https://1145.am/db/693284/Northleaf_Capital_Partners>,
        <https://1145.am/db/695148/Northleaf_Capital_Partners>,
        <https://1145.am/db/6994/Arlington_Capital_Partners>,
        <https://1145.am/db/701660/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/711394/Capitalworks>,
        <https://1145.am/db/713274/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/714376/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/730791/Great_Hill_Partners>,
        <https://1145.am/db/734544/Comvest_Partners>,
        <https://1145.am/db/739269/Great_Hill_Partners>,
        <https://1145.am/db/739579/One_Equity_Partners>,
        <https://1145.am/db/741241/Exeter_Street_Capital_Partners>,
        <https://1145.am/db/750161/Sole_Source_Capital_Llc>,
        <https://1145.am/db/750874/Arlington_Capital_Partners>,
        <https://1145.am/db/755740/Godspeed_Capital>,
        <https://1145.am/db/766278/Dl_Capital_Partners>,
        <https://1145.am/db/790064/Godspeed_Capital>,
        <https://1145.am/db/790455/Godspeed_Capital>,
        <https://1145.am/db/800128/Great_Hill_Equity_Partners_Viii>,
        <https://1145.am/db/800128/Great_Hill_Partners>,
        <https://1145.am/db/800849/Ci_Capital_Partners>,
        <https://1145.am/db/830349/Hildred_Equity_Partners_Ii>,
        <https://1145.am/db/832/Abry_Partners>,
        <https://1145.am/db/846826/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/865389/Kps_Capital_Partners>,
        <https://1145.am/db/866583/One_Equity_Partners>,
        <https://1145.am/db/866641/Morgan_Stanley_Capital_Partners>,
        <https://1145.am/db/866641/Sheridan_Capital_Partners>,
        <https://1145.am/db/866708/Sfw_Capital_Partners>,
        <https://1145.am/db/867837/Sfw_Capital_Partners>,
        <https://1145.am/db/867942/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/879952/One_Equity_Partners>,
        <https://1145.am/db/890845/Dc_Capital_Partners_Llc>,
        <https://1145.am/db/894004/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/895233/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/901012/One_Equity_Partners>,
        <https://1145.am/db/901053/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/901687/One_Equity_Partners>,
        <https://1145.am/db/901700/Northleaf_Capital_Partners>,
        <https://1145.am/db/901836/Blue_Wolf_Capital_Partners>,
        <https://1145.am/db/902992/Northleaf_Capital_Partners>,
        <https://1145.am/db/907800/Court_Square_Capital_Partners>,
        <https://1145.am/db/92671/One_Equity_Partners>,
        <https://1145.am/db/935223/Red_Door_Capital_Partners_Llc>,
        <https://1145.am/db/946632/Graham_Allen_Partners>,
        <https://1145.am/db/952891/One_Rock_Capital_Partners>,
        <https://1145.am/db/955109/Thompson_Street_Capital_Partners>,
        <https://1145.am/db/963101/Sole_Source_Capital>,
        <https://1145.am/db/963846/Seacrest_Capital>,
        <https://1145.am/db/972243/Godspeed_Capital_Management>,
        <https://1145.am/db/973727/One_Rock_Capital_Partners>,
        <https://1145.am/db/975556/Godspeed_Capital_Management_Lp>,
        <https://1145.am/db/983132/Investcorp>,
        <https://1145.am/db/985628/Investcorp>,
        <https://1145.am/db/993356/Congruent_Investment_Partners>,
        <https://1145.am/db/993436/Congruent_Investment_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1309309/Ampersand_Capital_Partners>,
        <https://1145.am/db/1486363/Ampersand_Capital_Partners>,
        <https://1145.am/db/1486654/Ampersand_Capital_Partners>,
        <https://1145.am/db/1615485/Ampersand_Capital_Partners>,
        <https://1145.am/db/2051134/Ampersand_Capital_Partners>,
        <https://1145.am/db/2550242/Ampersand_Capital_Partners>,
        <https://1145.am/db/2559395/Ampersand_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342842/Jll_Partners> a org:Organization ;
    ns1:basedInLowRaw "NEWTOWN, Pa" ;
    ns1:buyer <https://1145.am/db/2342842/Bioclinica_Investment> ;
    ns1:description "private equity" ;
    ns1:documentDate "2013-03-14T16:17:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BioClinica and CoreLab Partners Are One" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bioclinica-and-corelab-partners-are-one> ;
    ns1:foundName "JLL Partners" ;
    ns1:industry "private equity" ;
    ns1:investor <https://1145.am/db/2342842/Bioclinica_Investment> ;
    ns1:name "JLL Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1023568/Sk_Capital_Partners>,
        <https://1145.am/db/1027732/Sk_Capital_Partners>,
        <https://1145.am/db/1055198/Motive_Partners>,
        <https://1145.am/db/1061871/Sk_Capital_Partners>,
        <https://1145.am/db/1097309/A91_Partners>,
        <https://1145.am/db/1112482/Insight_Partners>,
        <https://1145.am/db/1247884/Sk_Capital_Partners>,
        <https://1145.am/db/1264790/Stepstone_Group_Inc>,
        <https://1145.am/db/1322337/Sk_Capital_Partners>,
        <https://1145.am/db/1425834/Jll_Partners>,
        <https://1145.am/db/1581363/Platinum_Equity>,
        <https://1145.am/db/1614882/O2_Investment_Partners>,
        <https://1145.am/db/1616190/O2_Investment_Partners>,
        <https://1145.am/db/166320/Platinum_Equity>,
        <https://1145.am/db/1774506/Insight_Partners>,
        <https://1145.am/db/1800086/Greycroft_Partners>,
        <https://1145.am/db/1828550/Providence_Equity_Partners>,
        <https://1145.am/db/1849355/Greycroft_Partners>,
        <https://1145.am/db/1951926/Kv_Capital>,
        <https://1145.am/db/1958910/Stepstone_Group>,
        <https://1145.am/db/1959233/Stepstone_Group>,
        <https://1145.am/db/1990567/Private_Equity_Partners>,
        <https://1145.am/db/2010581/Sk_Capital_Partners>,
        <https://1145.am/db/2050966/Thl_Partners>,
        <https://1145.am/db/2064429/Motive_Partners>,
        <https://1145.am/db/2070302/Sk_Capital_Partners>,
        <https://1145.am/db/2110027/Providence_Equity_Partners>,
        <https://1145.am/db/2112930/O2_Investment_Partners>,
        <https://1145.am/db/2114511/Pacific_Lake_Partners>,
        <https://1145.am/db/2116981/Sk_Capital_Partners>,
        <https://1145.am/db/2134045/Thl_Partners>,
        <https://1145.am/db/2135109/Sk_Capital_Partners>,
        <https://1145.am/db/2136452/Sk_Capital_Partners>,
        <https://1145.am/db/223643/Insight_Partners>,
        <https://1145.am/db/2307529/Kesa_Partners>,
        <https://1145.am/db/2308646/Jll_Partners>,
        <https://1145.am/db/2309471/Jll_Partners>,
        <https://1145.am/db/2309719/Jll_Partners>,
        <https://1145.am/db/2322813/Jll_Partners>,
        <https://1145.am/db/2333773/Jll_Partners>,
        <https://1145.am/db/2334335/Jll_Partners>,
        <https://1145.am/db/2561121/Kesa_Partners>,
        <https://1145.am/db/2562418/Sk_Capital_Partners>,
        <https://1145.am/db/260470/Kps_Capital_Partners>,
        <https://1145.am/db/260685/Kps_Capital_Partners>,
        <https://1145.am/db/261154/Kps_Capital_Partners>,
        <https://1145.am/db/2612445/Silver_Lake_Partners>,
        <https://1145.am/db/2621184/Stg_Partners>,
        <https://1145.am/db/2629313/Silver_Lake_Partners>,
        <https://1145.am/db/2662265/Silver_Lake_Partners>,
        <https://1145.am/db/2669352/Group>,
        <https://1145.am/db/2682270/Providence_Equity_Partners>,
        <https://1145.am/db/2682308/Providence_Equity_Partners>,
        <https://1145.am/db/2703242/Ksl_Capital_Partners>,
        <https://1145.am/db/303188/Kps_Capital_Partners>,
        <https://1145.am/db/304762/Platinum_Equity_Llc>,
        <https://1145.am/db/305672/Platinum_Equity_Llc>,
        <https://1145.am/db/329547/Kps_Capital_Partners>,
        <https://1145.am/db/348837/Insight_Partners>,
        <https://1145.am/db/353990/Platinum_Equity>,
        <https://1145.am/db/355252/Platinum_Equity>,
        <https://1145.am/db/370212/Kps_Capital_Partners>,
        <https://1145.am/db/371074/Platinum_Equity>,
        <https://1145.am/db/371503/Platinum_Equity>,
        <https://1145.am/db/371555/Platinum_Equity>,
        <https://1145.am/db/422368/Sk_Capital_Partners>,
        <https://1145.am/db/425684/Sk_Capital_Partners>,
        <https://1145.am/db/493083/Housatonic_Partners>,
        <https://1145.am/db/591820/Britehorn_Partners>,
        <https://1145.am/db/626988/Partners_Group>,
        <https://1145.am/db/704156/Sk_Capital_Partners>,
        <https://1145.am/db/730060/Sk_Capital_Partners>,
        <https://1145.am/db/731966/Sk_Capital_Partners>,
        <https://1145.am/db/734108/Graham_Partners>,
        <https://1145.am/db/764856/O2_Investment_Partners>,
        <https://1145.am/db/783251/Patrimonium_Private_Equity>,
        <https://1145.am/db/880899/Sk_Capital_Partners>,
        <https://1145.am/db/962899/Andera_Partners>,
        <https://1145.am/db/973804/Kayne_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2305471/Jll_Partners>,
        <https://1145.am/db/2305479/Jll_Partners>,
        <https://1145.am/db/2308650/Jll_Partners>,
        <https://1145.am/db/2336429/Jll_Partners>,
        <https://1145.am/db/2543530/Jll_Partners>,
        <https://1145.am/db/2545530/Jll_Partners>,
        <https://1145.am/db/2560288/Jll_Partners>,
        <https://1145.am/db/686779/Jll_Partners>,
        <https://1145.am/db/689702/Jll_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Angeli_Parvi> a org:Organization ;
    ns1:basedInHighGeoName "Lebanon" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5088597/about.rdf> ;
    ns1:basedInHighRaw "LEBANON, N.H." ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "Angeli Parvi" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "Angeli Parvi" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Borealis_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.H" ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "Borealis Ventures" ;
    ns1:investor <https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "Borealis Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1814854/Borealis_Ventures>,
        <https://1145.am/db/2153423/Borealis_Ventures>,
        <https://1145.am/db/2288209/Borealis_Ventures>,
        <https://1145.am/db/2319338/Borealis_Ventures>,
        <https://1145.am/db/2352489/Borealis_Ventures>,
        <https://1145.am/db/612707/Borealis_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Polaris_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "N.H" ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2343210/Polaris_Venture_Partners>,
        <https://1145.am/db/2344256/Polaris_Venture_Partners>,
        <https://1145.am/db/2345224/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344916/Versant_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "venture partner" ;
    ns1:documentDate "2013-03-25T13:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Novira Therapeutics Completes $25 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/novira-therapeutics-completes-25-million-series-a-financing-0> ;
    ns1:foundName "Versant Ventures" ;
    ns1:investor <https://1145.am/db/2344916/Series_A_Investment_Novira_Therapeutics_Versant_Ventures_Completed> ;
    ns1:name "Versant Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1928388/Versant_Ventures>,
        <https://1145.am/db/1975490/Versant_Ventures>,
        <https://1145.am/db/2110276/Versant_Ventures>,
        <https://1145.am/db/2154566/Versant_Ventures>,
        <https://1145.am/db/2288016/Versant_Ventures>,
        <https://1145.am/db/2290283/Versant_Ventures>,
        <https://1145.am/db/2291315/Versant_Ventures>,
        <https://1145.am/db/2294202/Versant_Ventures>,
        <https://1145.am/db/2300337/Versant_Ventures>,
        <https://1145.am/db/2303767/Versant_Ventures>,
        <https://1145.am/db/2304606/Versant_Ventures>,
        <https://1145.am/db/2305015/Versant_Ventures>,
        <https://1145.am/db/2308758/Versant_Ventures>,
        <https://1145.am/db/2313143/Versant_Ventures>,
        <https://1145.am/db/2318934/Versant>,
        <https://1145.am/db/2319784/Versant_Ventures>,
        <https://1145.am/db/2326361/Versant_Ventures>,
        <https://1145.am/db/2326373/Versant_Ventures>,
        <https://1145.am/db/2330852/Versant_Ventures>,
        <https://1145.am/db/2331754/Versant_Ventures>,
        <https://1145.am/db/2331868/Versant_Ventures>,
        <https://1145.am/db/2339886/Versant_Ventures>,
        <https://1145.am/db/2343184/Versant_Ventures>,
        <https://1145.am/db/2345769/Versant_Ventures>,
        <https://1145.am/db/2348857/Versant_Ventures>,
        <https://1145.am/db/2349233/Versant_Ventures>,
        <https://1145.am/db/2350915/Versant_Venture_Capital_V_Lp>,
        <https://1145.am/db/2362527/Versant_Ventures>,
        <https://1145.am/db/2362566/Versant_Ventures>,
        <https://1145.am/db/2364480/Versant_Ventures>,
        <https://1145.am/db/2365135/Versant_Ventures>,
        <https://1145.am/db/2367275/Versant_Ventures>,
        <https://1145.am/db/2371163/Versant_Ventures>,
        <https://1145.am/db/547640/Versant_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1540787/Versant_Ventures>,
        <https://1145.am/db/1541055/Versant_Ventures>,
        <https://1145.am/db/1571794/Versant_Ventures>,
        <https://1145.am/db/2069394/Versant_Ventures>,
        <https://1145.am/db/2151802/Versant_Ventures>,
        <https://1145.am/db/2154338/Versant_Ventures>,
        <https://1145.am/db/2281211/Versant_Ventures>,
        <https://1145.am/db/2287023/Versant_Ventures>,
        <https://1145.am/db/2291344/Versant_Ventures>,
        <https://1145.am/db/2293059/Versant_Ventures>,
        <https://1145.am/db/2293893/Versant_Ventures>,
        <https://1145.am/db/2296209/Versant_Ventures>,
        <https://1145.am/db/2298176/Versant_Ventures>,
        <https://1145.am/db/2299080/Versant_Ventures>,
        <https://1145.am/db/2299776/Versant_Ventures>,
        <https://1145.am/db/2304598/Versant_Ventures>,
        <https://1145.am/db/2304769/Versant_Ventures>,
        <https://1145.am/db/2310285/Versant_Ventures>,
        <https://1145.am/db/2310302/Versant_Ventures>,
        <https://1145.am/db/2311353/Versant_Ventures>,
        <https://1145.am/db/2317750/Versant_Ventures>,
        <https://1145.am/db/2317753/Versant_Ventures>,
        <https://1145.am/db/2318733/Versant_Ventures>,
        <https://1145.am/db/2322646/Versant_Ventures>,
        <https://1145.am/db/2323226/Versant_Ventures>,
        <https://1145.am/db/2324226/Versant_Ventures>,
        <https://1145.am/db/2325681/Versant_Ventures>,
        <https://1145.am/db/2326903/Versant_Ventures>,
        <https://1145.am/db/2330075/Versant_Ventures>,
        <https://1145.am/db/2330712/Versant_Ventures>,
        <https://1145.am/db/2335675/Versant_Ventures>,
        <https://1145.am/db/2335760/Versant_Ventures>,
        <https://1145.am/db/2339885/Versant_Ventures>,
        <https://1145.am/db/2342445/Versant_Ventures>,
        <https://1145.am/db/2343185/Versant_Ventures>,
        <https://1145.am/db/2343206/Versant_Ventures>,
        <https://1145.am/db/2343467/Versant_Ventures>,
        <https://1145.am/db/2343547/Versant_Ventures>,
        <https://1145.am/db/2343641/Versant_Ventures>,
        <https://1145.am/db/2343647/Versant_Ventures>,
        <https://1145.am/db/2344915/Versant_Ventures>,
        <https://1145.am/db/2344922/Versant_Ventures>,
        <https://1145.am/db/2344926/Versant_Ventures>,
        <https://1145.am/db/2347368/Versant_Ventures>,
        <https://1145.am/db/2348012/Versant_Ventures>,
        <https://1145.am/db/2349834/Versant_Ventures>,
        <https://1145.am/db/2350917/Versant_Ventures>,
        <https://1145.am/db/2351904/Versant_Ventures>,
        <https://1145.am/db/2354296/Versant_Ventures>,
        <https://1145.am/db/2360189/Versant_Ventures>,
        <https://1145.am/db/2360191/Versant_Ventures>,
        <https://1145.am/db/2360415/Versant_Ventures>,
        <https://1145.am/db/2362457/Versant_Ventures>,
        <https://1145.am/db/2362528/Versant_Ventures>,
        <https://1145.am/db/2362565/Versant_Ventures>,
        <https://1145.am/db/2365134/Versant_Ventures>,
        <https://1145.am/db/2368517/Versant_Ventures>,
        <https://1145.am/db/2370609/Versant_Ventures>,
        <https://1145.am/db/2370782/Versant_Ventures>,
        <https://1145.am/db/2370799/Versant_Ventures>,
        <https://1145.am/db/2371160/Versant_Ventures>,
        <https://1145.am/db/2541575/Versant_Ventures>,
        <https://1145.am/db/2584561/Versant_Ventures>,
        <https://1145.am/db/456081/Versant_Ventures>,
        <https://1145.am/db/488687/Versant_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346978/Augment_Investments_Ltd> a org:Organization ;
    ns1:basedInLowRaw "BRITISH COLUMBIA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Augment Investments Ltd",
        "Augment Investments Ltd." ;
    ns1:investor <https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> ;
    ns1:name "Augment Investments Ltd",
        "Augment Investments Ltd." ;
    ns1:sameAsHigh <https://1145.am/db/1251783/Venture_Mls>,
        <https://1145.am/db/1741685/Kb_Investment>,
        <https://1145.am/db/1758193/Fin_Venture_Capital>,
        <https://1145.am/db/1760108/Xyz_Venture_Capital>,
        <https://1145.am/db/1762992/Nice_Investment>,
        <https://1145.am/db/2011571/Open_Venture_Capital>,
        <https://1145.am/db/2056931/Kb_Investments>,
        <https://1145.am/db/2152360/Vc23>,
        <https://1145.am/db/2194249/Lowercase_Capital>,
        <https://1145.am/db/2302731/Morningside_Venture_Investments_Ltd>,
        <https://1145.am/db/2324671/Morningside_Venture_Investments>,
        <https://1145.am/db/2370022/Morningside_Venture_Investments>,
        <https://1145.am/db/694888/Kb_Investment>,
        <https://1145.am/db/823763/Fin_Venture_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346978/Baker_Brothers_Investments> a org:Organization ;
    ns1:basedInLowRaw "BRITISH COLUMBIA" ;
    ns1:description "venture-backed, pharmaceutical company" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Baker Brothers Investments" ;
    ns1:investor <https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> ;
    ns1:name "Baker Brothers Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2301824/Baker_Brothers_Investments>,
        <https://1145.am/db/2302890/Baker_Brothers_Investments>,
        <https://1145.am/db/2302897/Baker_Brothers_Investments>,
        <https://1145.am/db/2313221/Baker_Brothers_Investments>,
        <https://1145.am/db/2321856/Baker_Brothers_Investments>,
        <https://1145.am/db/2364457/Baker_Brothers_Investments>,
        <https://1145.am/db/2364458/Baker_Brothers_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346978/Ventures_West_Capital> a org:Organization ;
    ns1:basedInLowRaw "BRITISH COLUMBIA" ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Ventures West Capital" ;
    ns1:investor <https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> ;
    ns1:name "Ventures West Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1006252/Menlo_Ventures>,
        <https://1145.am/db/1006262/Com_Prelude_Ventures>,
        <https://1145.am/db/1006574/Integr8d_Capital>,
        <https://1145.am/db/1006880/Root_Ventures>,
        <https://1145.am/db/1007193/Capital_One_Ventures>,
        <https://1145.am/db/1007527/Integr8d_Capital>,
        <https://1145.am/db/1008085/Root_Ventures>,
        <https://1145.am/db/1008260/Servicenow_Ventures>,
        <https://1145.am/db/1010064/Greatpoint_Ventures>,
        <https://1145.am/db/1010064/Maverick_Ventures>,
        <https://1145.am/db/1010199/One9_Ventures>,
        <https://1145.am/db/102038/Allegion_Ventures>,
        <https://1145.am/db/102038/Pathbreaker_Ventures>,
        <https://1145.am/db/102038/West_Ventures>,
        <https://1145.am/db/1023252/Digitalbridge_Ventures>,
        <https://1145.am/db/1024247/Digitalbridge_Ventures>,
        <https://1145.am/db/1024483/Investbridge_Capital>,
        <https://1145.am/db/1026319/Able_Partners>,
        <https://1145.am/db/1034591/Valia_Ventures>,
        <https://1145.am/db/1041601/Kineo_Finance>,
        <https://1145.am/db/1042250/Kineo_Finance>,
        <https://1145.am/db/1043051/Sequoia_Capital>,
        <https://1145.am/db/1043259/Sequoia_Capital>,
        <https://1145.am/db/1043342/Root_Ventures>,
        <https://1145.am/db/1043516/Kineo_Finance>,
        <https://1145.am/db/1045242/Dipalo_Ventures>,
        <https://1145.am/db/1045384/Sequoia_Capital>,
        <https://1145.am/db/1051115/Dn_Capital>,
        <https://1145.am/db/1051644/Vestigo_Ventures>,
        <https://1145.am/db/1052155/Gate_Ventures>,
        <https://1145.am/db/1059993/Tera_Ventures>,
        <https://1145.am/db/1060146/Ulu_Ventures>,
        <https://1145.am/db/1061824/Bluebird_Ventures>,
        <https://1145.am/db/1061911/Ulu_Ventures>,
        <https://1145.am/db/1065366/Applied_Ventures_Llc>,
        <https://1145.am/db/1065544/Menlo_Ventures>,
        <https://1145.am/db/1066120/Crosslink_Capital>,
        <https://1145.am/db/1081175/Rse_Ventures>,
        <https://1145.am/db/1081490/Vinco_Ventures>,
        <https://1145.am/db/1081888/Ggv_Capital>,
        <https://1145.am/db/1082613/Rse_Ventures>,
        <https://1145.am/db/1082719/Dorilton_Ventures>,
        <https://1145.am/db/1082814/Cathexis_Ventures>,
        <https://1145.am/db/1082814/Promus_Ventures>,
        <https://1145.am/db/1082814/Type_One_Ventures>,
        <https://1145.am/db/1084014/Ret_Ventures>,
        <https://1145.am/db/1085867/Ret_Ventures>,
        <https://1145.am/db/1086604/Alerion_Ventures>,
        <https://1145.am/db/1086673/Wintrust_Ventures>,
        <https://1145.am/db/1089416/Nexo_Ventures>,
        <https://1145.am/db/1090643/Argon_Ventures>,
        <https://1145.am/db/1090643/Glasswing_Ventures>,
        <https://1145.am/db/1101244/Acequia_Capital>,
        <https://1145.am/db/1103270/Acequia_Capital>,
        <https://1145.am/db/1106082/Northpond_Ventures>,
        <https://1145.am/db/1106670/Sequoia_Capital>,
        <https://1145.am/db/1111505/Nissay_Capital>,
        <https://1145.am/db/1111505/Remiges_Ventures>,
        <https://1145.am/db/1112074/Nissay_Capital>,
        <https://1145.am/db/1112074/Remiges_Ventures>,
        <https://1145.am/db/1114979/Catapult_Ventures>,
        <https://1145.am/db/1115103/Northpond_Ventures>,
        <https://1145.am/db/1119456/Truist_Ventures>,
        <https://1145.am/db/1119699/Prelude_Ventures>,
        <https://1145.am/db/1120030/Morpheus_Ventures>,
        <https://1145.am/db/1120030/Point72_Ventures>,
        <https://1145.am/db/1120071/Morpheus_Ventures>,
        <https://1145.am/db/1120071/Point72_Ventures>,
        <https://1145.am/db/1122750/Prelude_Ventures>,
        <https://1145.am/db/1129561/Redbeard_Ventures>,
        <https://1145.am/db/1130744/Redbeard_Ventures>,
        <https://1145.am/db/1133003/Sequoia_Capital>,
        <https://1145.am/db/1134165/Boldstart_Ventures>,
        <https://1145.am/db/1136173/Boldstart_Ventures>,
        <https://1145.am/db/1137178/CRV>,
        <https://1145.am/db/1138154/Ggv_Capital>,
        <https://1145.am/db/1139703/Industry_Ventures>,
        <https://1145.am/db/1140286/Origin_Ventures>,
        <https://1145.am/db/1141736/Redpoint_Ventures>,
        <https://1145.am/db/1150154/Riv_Capital>,
        <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1150529/Solasta_Ventures>,
        <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1151736/True_Ventures>,
        <https://1145.am/db/1152929/Aperiamventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1154242/True_Ventures>,
        <https://1145.am/db/1163139/Sentiero_Ventures>,
        <https://1145.am/db/1163139/Skyriver_Ventures>,
        <https://1145.am/db/1164299/Lavrock_Ventures>,
        <https://1145.am/db/1164299/Progress_Ventures>,
        <https://1145.am/db/1164688/Abstract_Ventures>,
        <https://1145.am/db/1164688/Spacecadet_Ventures>,
        <https://1145.am/db/1164845/Lavrock_Ventures>,
        <https://1145.am/db/1164845/Progress_Ventures>,
        <https://1145.am/db/1165515/G2_Group_Ventures>,
        <https://1145.am/db/1166154/Allos_Ventures>,
        <https://1145.am/db/1166957/Seedil_Ventures>,
        <https://1145.am/db/1168757/Accomplice_Ventures>,
        <https://1145.am/db/1169687/Artiman_Ventures>,
        <https://1145.am/db/1169687/J_Ventures>,
        <https://1145.am/db/1169687/Nd_Capital>,
        <https://1145.am/db/1169815/Accomplice_Ventures>,
        <https://1145.am/db/1170971/Equinor_Ventures>,
        <https://1145.am/db/1173428/Equinor_Ventures>,
        <https://1145.am/db/1175576/Divcowest_Ventures>,
        <https://1145.am/db/1175576/Point72_Ventures>,
        <https://1145.am/db/1175576/Signia_Ventures>,
        <https://1145.am/db/1176018/First_Star_Ventures>,
        <https://1145.am/db/1187600/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/11887/Adv>,
        <https://1145.am/db/1190097/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/1190127/Animo_Ventures>,
        <https://1145.am/db/1190127/Chaac_Ventures>,
        <https://1145.am/db/1190127/Ulu_Ventures>,
        <https://1145.am/db/1196068/Arthur_Ventures>,
        <https://1145.am/db/1196728/Greatpoint_Ventures>,
        <https://1145.am/db/1199177/Greatpoint_Ventures>,
        <https://1145.am/db/1199182/Boxone_Ventures>,
        <https://1145.am/db/1202673/Basecamp_Ventures>,
        <https://1145.am/db/1203180/Basecamp_Ventures>,
        <https://1145.am/db/1206820/Tenoneten_Ventures>,
        <https://1145.am/db/1208519/Tappanhill_Ventures>,
        <https://1145.am/db/1208749/Industry_Ventures>,
        <https://1145.am/db/1208749/Keshif_Ventures>,
        <https://1145.am/db/1208749/Tenoneten_Ventures>,
        <https://1145.am/db/1213076/Equinor_Ventures>,
        <https://1145.am/db/1213076/Scf_Ventures>,
        <https://1145.am/db/1213119/Nevcaut_Ventures>,
        <https://1145.am/db/1215930/Northpond_Ventures>,
        <https://1145.am/db/1219982/Soma_Ventures>,
        <https://1145.am/db/1221237/C2_Ventures>,
        <https://1145.am/db/1222789/Glasswing_Ventures>,
        <https://1145.am/db/1232497/Droia_Ventures>,
        <https://1145.am/db/1232497/Gv>,
        <https://1145.am/db/1233314/Citta_Capital>,
        <https://1145.am/db/1236549/Adit_Ventures>,
        <https://1145.am/db/1247755/Sinewave_Ventures>,
        <https://1145.am/db/1247761/Clear_Ventures>,
        <https://1145.am/db/1248631/Sinewave_Ventures>,
        <https://1145.am/db/1252447/Gaingels>,
        <https://1145.am/db/1256269/Ampd_Ventures_Inc>,
        <https://1145.am/db/1264028/K3_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1268150/Pender_Ventures>,
        <https://1145.am/db/1269968/Abstract_Ventures>,
        <https://1145.am/db/1272468/Launchpad_Capital>,
        <https://1145.am/db/1279264/Roosh_Ventures>,
        <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1282820/Agya_Ventures>,
        <https://1145.am/db/1286872/Morevc>,
        <https://1145.am/db/1287476/Felicis_Ventures>,
        <https://1145.am/db/1297417/Bitkraft_Ventures>,
        <https://1145.am/db/1299578/Seedtob_Capital>,
        <https://1145.am/db/1307620/Inventus_Capital_Partners>,
        <https://1145.am/db/1311917/Avid_Ventures>,
        <https://1145.am/db/1311917/Canapi_Ventures>,
        <https://1145.am/db/1322441/Solana_Ventures>,
        <https://1145.am/db/1326376/Dexcom_Ventures>,
        <https://1145.am/db/1329887/Peter_Nagar>,
        <https://1145.am/db/1331691/Pelion_Ventures>,
        <https://1145.am/db/1332798/Acrobator_Ventures>,
        <https://1145.am/db/1334186/First_Ascent_Ventures>,
        <https://1145.am/db/1334193/Version_One_Ventures>,
        <https://1145.am/db/1334395/Gv>,
        <https://1145.am/db/1334895/Soleus_Capital>,
        <https://1145.am/db/1335073/Yl_Ventures>,
        <https://1145.am/db/1335080/Dorilton_Ventures>,
        <https://1145.am/db/1344240/Neotribe_Ventures>,
        <https://1145.am/db/1352420/Vamos_Ventures>,
        <https://1145.am/db/1353145/Infinity_Ventures>,
        <https://1145.am/db/1362743/Cobalt_Ventures>,
        <https://1145.am/db/1373683/BGV>,
        <https://1145.am/db/1375916/J2_Ventures>,
        <https://1145.am/db/1376353/J2_Ventures>,
        <https://1145.am/db/1378599/Menlo_Ventures>,
        <https://1145.am/db/1381832/Northpond_Ventures>,
        <https://1145.am/db/1382787/Northpond_Ventures>,
        <https://1145.am/db/1383818/Newlin_Ventures>,
        <https://1145.am/db/1387557/Naventures>,
        <https://1145.am/db/138878/Metacartel_Ventures>,
        <https://1145.am/db/1398057/Owen_Van_Natta_Temaris___Associates>,
        <https://1145.am/db/1398917/Trousdale_Ventures>,
        <https://1145.am/db/1407553/Sequoia_Capital>,
        <https://1145.am/db/1407614/C2_Ventures>,
        <https://1145.am/db/1411289/Sequoia_Capital>,
        <https://1145.am/db/1411934/Riptide_Ventures>,
        <https://1145.am/db/1425749/Menlo_Ventures>,
        <https://1145.am/db/1425749/Se_Ventures>,
        <https://1145.am/db/1433429/Crosslink_Capital>,
        <https://1145.am/db/1445378/Mvp_Ventures>,
        <https://1145.am/db/1445935/Verissimo_Ventures>,
        <https://1145.am/db/1449316/+Nd_Capital>,
        <https://1145.am/db/1449740/Mistral_Ventures>,
        <https://1145.am/db/1452107/Abstract_Ventures>,
        <https://1145.am/db/1455216/Engage_Ventures>,
        <https://1145.am/db/1455616/Abstract_Ventures>,
        <https://1145.am/db/1463829/1sharpe_Ventures>,
        <https://1145.am/db/1467693/Preseed_Ventures>,
        <https://1145.am/db/1467892/M_Ventures>,
        <https://1145.am/db/1467932/Sequoia_Capital_Gv>,
        <https://1145.am/db/1468981/Preseed_Ventures>,
        <https://1145.am/db/1476448/Origin_Ventures>,
        <https://1145.am/db/1480152/True_Ventures>,
        <https://1145.am/db/1480651/Glasswing_Ventures>,
        <https://1145.am/db/1480989/Infinity_Ventures>,
        <https://1145.am/db/1481875/Infinity_Ventures>,
        <https://1145.am/db/1482705/Oif_Ventures>,
        <https://1145.am/db/1484103/Boxone_Ventures>,
        <https://1145.am/db/1484857/Iu_Ventures>,
        <https://1145.am/db/1488858/Alkeon_Capital>,
        <https://1145.am/db/1490126/Seedtob_Capital>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490978/Seedtob_Capital>,
        <https://1145.am/db/1492889/Future_Ventures>,
        <https://1145.am/db/1492889/Radical_Ventures>,
        <https://1145.am/db/1494028/Alkeon_Capital>,
        <https://1145.am/db/1496360/Realist_Ventures>,
        <https://1145.am/db/1503768/Nevateam_Partners>,
        <https://1145.am/db/1508325/Aramco_Ventures>,
        <https://1145.am/db/1509462/F7_Ventures>,
        <https://1145.am/db/1512891/Acme_Capital>,
        <https://1145.am/db/1515109/Cmfg_Ventures>,
        <https://1145.am/db/1515916/Sequoia_Capital>,
        <https://1145.am/db/1520070/Menlo_Ventures>,
        <https://1145.am/db/1520070/Northpond_Ventures>,
        <https://1145.am/db/1520772/January_Ventures>,
        <https://1145.am/db/1537166/Catalio_Capital_Management>,
        <https://1145.am/db/1537970/Catalio_Capital_Management>,
        <https://1145.am/db/1541308/Panoramic_Ventures>,
        <https://1145.am/db/1541797/G1_Ventures>,
        <https://1145.am/db/1545833/Alerion_Ventures>,
        <https://1145.am/db/1545994/Noemis_Ventures>,
        <https://1145.am/db/1546945/Alerion_Ventures>,
        <https://1145.am/db/1546965/Citi_Ventures>,
        <https://1145.am/db/1546965/Truist_Ventures>,
        <https://1145.am/db/1547281/Noemis_Ventures>,
        <https://1145.am/db/1548592/Gopoint_Ventures>,
        <https://1145.am/db/1556397/Dnx_Ventures>,
        <https://1145.am/db/1556442/C16_Ventures>,
        <https://1145.am/db/1557877/Embark_Ventures>,
        <https://1145.am/db/1559824/Embark_Ventures>,
        <https://1145.am/db/1560704/Breaktrail_Ventures>,
        <https://1145.am/db/1563623/Amex_Ventures>,
        <https://1145.am/db/1564049/Amex_Ventures>,
        <https://1145.am/db/1571330/Seae_Ventures>,
        <https://1145.am/db/1571330/Venturesouth>,
        <https://1145.am/db/1572216/Seae_Ventures>,
        <https://1145.am/db/1572216/Venturesouth>,
        <https://1145.am/db/1574557/True_Ventures>,
        <https://1145.am/db/1574647/Vanterra_Ventures>,
        <https://1145.am/db/1575612/Interlace_Ventures>,
        <https://1145.am/db/1575612/Valia_Ventures>,
        <https://1145.am/db/1578178/N49p>,
        <https://1145.am/db/1578178/Naventures>,
        <https://1145.am/db/1578327/Crit_Ventures>,
        <https://1145.am/db/1578327/Nextview_Ventures>,
        <https://1145.am/db/1579770/Schams_Ventures>,
        <https://1145.am/db/1579792/Crit_Ventures>,
        <https://1145.am/db/1579792/Nextview_Ventures>,
        <https://1145.am/db/1580468/Cohort_Ventures>,
        <https://1145.am/db/1582024/Avalon_Ventures>,
        <https://1145.am/db/1582111/Forepont_Capital_Partners>,
        <https://1145.am/db/1583413/Navigare_Ventures>,
        <https://1145.am/db/1615195/Digitalis_Ventures>,
        <https://1145.am/db/1616990/Digitalis_Ventures>,
        <https://1145.am/db/1632002/Catalio_Capital_Management>,
        <https://1145.am/db/1632028/Catalio_Capital_Management>,
        <https://1145.am/db/1632131/Catalio_Capital_Management>,
        <https://1145.am/db/1632156/Catalio_Capital_Management>,
        <https://1145.am/db/1638640/1digi_Ventures>,
        <https://1145.am/db/1649691/Sequoia_Capital>,
        <https://1145.am/db/1653506/Ascendum_Capital>,
        <https://1145.am/db/1653506/Citta_Capital>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1664837/Civilization_Ventures>,
        <https://1145.am/db/1664948/Dreamit_Ventures>,
        <https://1145.am/db/1669908/Aviso_Ventures>,
        <https://1145.am/db/1670128/Primary_Ventures>,
        <https://1145.am/db/1676513/Connect_Ventures>,
        <https://1145.am/db/1685482/Lavrock_Ventures>,
        <https://1145.am/db/1690703/Arkam_Ventures>,
        <https://1145.am/db/1690703/Prosus_Ventures>,
        <https://1145.am/db/1691060/Veblen_Ventures>,
        <https://1145.am/db/1691364/Ts_Ventures>,
        <https://1145.am/db/1693592/Cventures>,
        <https://1145.am/db/1693668/Sunny_Side_Ventures>,
        <https://1145.am/db/1693981/Boldstart_Ventures>,
        <https://1145.am/db/1694241/True_Ventures>,
        <https://1145.am/db/1694301/Dn_Capital>,
        <https://1145.am/db/1694417/Sequoia_Capital>,
        <https://1145.am/db/1694448/Presidio_Ventures>,
        <https://1145.am/db/1694592/Credo_Ventures>,
        <https://1145.am/db/1694592/Susa_Ventures>,
        <https://1145.am/db/1694798/Udc_Ventures>,
        <https://1145.am/db/1694947/Intersouth_Partners>,
        <https://1145.am/db/1695849/Salesforce_Ventures>,
        <https://1145.am/db/1695885/True_Ventures>,
        <https://1145.am/db/1697044/Palomar_Ventures>,
        <https://1145.am/db/1697044/Sequoia_Capital>,
        <https://1145.am/db/1697373/Lerer_Ventures>,
        <https://1145.am/db/1697910/Entrepia_Ventures>,
        <https://1145.am/db/1697910/Innovacom>,
        <https://1145.am/db/1698516/Engage_Ventures>,
        <https://1145.am/db/1698516/Tyh_Ventures>,
        <https://1145.am/db/1698644/Inovia_Capital>,
        <https://1145.am/db/1699263/Contour_Venture_Partners>,
        <https://1145.am/db/1700565/Sequoia_Capital>,
        <https://1145.am/db/1700572/Contour_Venture_Partners>,
        <https://1145.am/db/1701414/Sequoia_Capital>,
        <https://1145.am/db/1702003/Ventures_West>,
        <https://1145.am/db/1702065/Kreos_Capital>,
        <https://1145.am/db/1702472/Chiratae_Ventures>,
        <https://1145.am/db/1702483/Sure_Ventures_Usvp>,
        <https://1145.am/db/1702517/Prime_Ventures>,
        <https://1145.am/db/1702871/Charles_River_Ventures>,
        <https://1145.am/db/1703120/Point72_Ventures>,
        <https://1145.am/db/1703551/People_Ventures>,
        <https://1145.am/db/1703907/T-Venture>,
        <https://1145.am/db/1704404/True_Ventures>,
        <https://1145.am/db/1704740/T-Venture>,
        <https://1145.am/db/1704842/Se_Ventures>,
        <https://1145.am/db/1704871/Yl_Ventures>,
        <https://1145.am/db/1705825/Ventures_Platform>,
        <https://1145.am/db/1707227/Schams_Ventures>,
        <https://1145.am/db/1707540/Prosus_Ventures>,
        <https://1145.am/db/1707567/Contour_Venture_Partners>,
        <https://1145.am/db/1707567/Reign_Ventures>,
        <https://1145.am/db/1707637/Resolute_Ventures>,
        <https://1145.am/db/1707736/Artiman_Ventures>,
        <https://1145.am/db/1708555/20vc>,
        <https://1145.am/db/1708903/Kaedan_Capital>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1710027/Contour_Venture_Partners>,
        <https://1145.am/db/1711208/Sequoia_Capital>,
        <https://1145.am/db/1711383/Aviso_Ventures>,
        <https://1145.am/db/1711383/Pelion_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1711790/CRV>,
        <https://1145.am/db/1711849/K20_Ventures>,
        <https://1145.am/db/1712471/Cervin_Ventures>,
        <https://1145.am/db/1713712/Grotech_Ventures>,
        <https://1145.am/db/1714098/Charles_River_Ventures>,
        <https://1145.am/db/1714148/Ulu_Ventures>,
        <https://1145.am/db/1714624/Abstract_Ventures>,
        <https://1145.am/db/1714630/January_Ventures>,
        <https://1145.am/db/1716124/Appian_Ventures>,
        <https://1145.am/db/1716168/Onset_Ventures>,
        <https://1145.am/db/1716667/Dag_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1718012/Dag_Ventures>,
        <https://1145.am/db/1718012/Presidio_Ventures>,
        <https://1145.am/db/1718018/Ggv_Capital>,
        <https://1145.am/db/1718081/Jafco_Ventures>,
        <https://1145.am/db/1718748/Truist_Ventures>,
        <https://1145.am/db/1718787/J_Ventures>,
        <https://1145.am/db/1719362/True_Ventures>,
        <https://1145.am/db/1719370/Bv_Capital>,
        <https://1145.am/db/1720145/Bessemer_Ventures>,
        <https://1145.am/db/1720182/Convivialit_Ventures>,
        <https://1145.am/db/1720441/Origin_Ventures>,
        <https://1145.am/db/1721171/Citi_Ventures>,
        <https://1145.am/db/1721392/Redpoint_Ventures>,
        <https://1145.am/db/1721393/Trinity_Ventures>,
        <https://1145.am/db/1721548/Ggv_Capital>,
        <https://1145.am/db/1721548/Menlo_Ventures>,
        <https://1145.am/db/1722252/Onset_Ventures>,
        <https://1145.am/db/1723165/Menlo_Ventures>,
        <https://1145.am/db/1723664/T-Venture>,
        <https://1145.am/db/1723932/Citi_Ventures>,
        <https://1145.am/db/1724979/Jafco_Ventures>,
        <https://1145.am/db/1724979/Sequoia_Capital>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726088/Zeev_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1726544/Ei_Ventures>,
        <https://1145.am/db/1727288/Sozo_Ventures>,
        <https://1145.am/db/1728569/Redpoint_Ventures>,
        <https://1145.am/db/1729186/Catamount_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1731419/Redpoint_Ventures>,
        <https://1145.am/db/1734104/Alpana_Ventures>,
        <https://1145.am/db/1734104/Highsage_Ventures>,
        <https://1145.am/db/1734728/Talis_Capital>,
        <https://1145.am/db/1735194/Eqt_Ventures>,
        <https://1145.am/db/1735248/Corigin_Ventures>,
        <https://1145.am/db/1735726/Nextview_Ventures>,
        <https://1145.am/db/1735755/Firebolt_Ventures>,
        <https://1145.am/db/1735774/Alpha4_Ventures>,
        <https://1145.am/db/1736136/Ggv_Capital>,
        <https://1145.am/db/1737278/Crosslink_Capital>,
        <https://1145.am/db/1737392/Moxxie_Ventures>,
        <https://1145.am/db/1737979/CRV>,
        <https://1145.am/db/1738162/3one4_Capital>,
        <https://1145.am/db/1738300/Chryscapital>,
        <https://1145.am/db/1738415/Capnamic_Ventures>,
        <https://1145.am/db/1738444/Prosus_Ventures>,
        <https://1145.am/db/1738776/Illuminate_Ventures>,
        <https://1145.am/db/1739022/Eventures>,
        <https://1145.am/db/1739042/Experior_Venture_Fund>,
        <https://1145.am/db/1739064/Jsw_Ventures>,
        <https://1145.am/db/1739106/Sequoia_Capital>,
        <https://1145.am/db/1739120/Sequoia_Capital>,
        <https://1145.am/db/1739285/Sequoia_Capital>,
        <https://1145.am/db/1739630/Redsea_Ventures>,
        <https://1145.am/db/1739719/Seedplus>,
        <https://1145.am/db/1739851/Signum_Capital>,
        <https://1145.am/db/1739909/Root_Ventures>,
        <https://1145.am/db/1739946/Dn_Capital>,
        <https://1145.am/db/1740077/3one4_Capital>,
        <https://1145.am/db/1740665/First_Bridge_Ventures>,
        <https://1145.am/db/1740832/J_Ventures>,
        <https://1145.am/db/1740832/Susa_Ventures>,
        <https://1145.am/db/1740859/Ggv_Capital>,
        <https://1145.am/db/1741357/Dn_Capital>,
        <https://1145.am/db/1741575/Addventure>,
        <https://1145.am/db/1741635/Zeev_Ventures>,
        <https://1145.am/db/1742267/Firebolt_Ventures>,
        <https://1145.am/db/1742267/Point72_Ventures>,
        <https://1145.am/db/1743271/Liil_Ventures>,
        <https://1145.am/db/1743348/Felicis_Ventures>,
        <https://1145.am/db/1743409/Dreamit_Ventures>,
        <https://1145.am/db/1743737/Regah_Ventures>,
        <https://1145.am/db/1744229/R7>,
        <https://1145.am/db/1744775/Point72_Ventures>,
        <https://1145.am/db/1744864/Sequoia_Capital>,
        <https://1145.am/db/1744922/Agla_Ventures>,
        <https://1145.am/db/1745326/Eqt_Ventures>,
        <https://1145.am/db/1745326/Lios_Ventures>,
        <https://1145.am/db/1745326/Prime_Ventures>,
        <https://1145.am/db/1745746/Garuda_Ventures>,
        <https://1145.am/db/1745746/Starling_Ventures>,
        <https://1145.am/db/1745920/Sequoia_Capital>,
        <https://1145.am/db/1747252/Citi_Ventures>,
        <https://1145.am/db/1747391/Sequoia_Capital>,
        <https://1145.am/db/1747400/Eqt_Ventures>,
        <https://1145.am/db/1747503/Brighteye_Ventures>,
        <https://1145.am/db/1747722/Shinhan_Capital>,
        <https://1145.am/db/1747943/Altai_Ventures>,
        <https://1145.am/db/1748417/Zeev_Ventures>,
        <https://1145.am/db/1749226/Dn_Capital>,
        <https://1145.am/db/1749425/Ac_Ventures>,
        <https://1145.am/db/1749651/Colle_Capital>,
        <https://1145.am/db/1749911/Khwarizmi_Ventures>,
        <https://1145.am/db/1750942/Celesta_Capital>,
        <https://1145.am/db/1750942/Chiratae_Ventures>,
        <https://1145.am/db/1751135/Inovia_Capital>,
        <https://1145.am/db/1751312/Abstract_Ventures>,
        <https://1145.am/db/1751361/Kreos_Capital>,
        <https://1145.am/db/1751506/Ggv_Capital>,
        <https://1145.am/db/1751551/Gaingels>,
        <https://1145.am/db/1751553/Canapi_Ventures>,
        <https://1145.am/db/1751743/Intudo_Ventures>,
        <https://1145.am/db/1751800/Morpheus_Ventures>,
        <https://1145.am/db/1751954/Novastar_Ventures>,
        <https://1145.am/db/1752102/Origin_Ventures>,
        <https://1145.am/db/1752403/Yl_Ventures>,
        <https://1145.am/db/1752998/Agla_Ventures>,
        <https://1145.am/db/1753704/Apex_Ventures>,
        <https://1145.am/db/1753721/Financial_Venture_Studio>,
        <https://1145.am/db/1753721/Resolute_Ventures>,
        <https://1145.am/db/1753745/2i_Ventures>,
        <https://1145.am/db/1754211/Citi_Ventures>,
        <https://1145.am/db/1754211/Menlo_Ventures>,
        <https://1145.am/db/1754242/Gsv_Ventures>,
        <https://1145.am/db/1754595/Global_Ventures>,
        <https://1145.am/db/1754595/Otg_Ventures>,
        <https://1145.am/db/1754751/Menlo_Ventures>,
        <https://1145.am/db/1754787/Letsventure>,
        <https://1145.am/db/1754997/Alkeon_Capital>,
        <https://1145.am/db/1755086/Kollective_Ventures>,
        <https://1145.am/db/1755278/Zeev_Ventures>,
        <https://1145.am/db/1755704/Promus_Ventures>,
        <https://1145.am/db/1755828/Future_Ventures>,
        <https://1145.am/db/1755860/Dg_Ventures>,
        <https://1145.am/db/1755860/Intudo_Ventures>,
        <https://1145.am/db/1756040/Altos_Ventures>,
        <https://1145.am/db/1756094/CRV>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756231/Kreos_Capital>,
        <https://1145.am/db/1756326/Neotribe_Ventures>,
        <https://1145.am/db/1756384/Abstract_Ventures>,
        <https://1145.am/db/1756384/Lightspeed_Ventures>,
        <https://1145.am/db/1756599/True_Ventures>,
        <https://1145.am/db/1757035/Vectr_Ventures>,
        <https://1145.am/db/1757365/Will_Ventures>,
        <https://1145.am/db/1757382/Gl_Ventures>,
        <https://1145.am/db/1757590/Kreos_Capital>,
        <https://1145.am/db/1757772/Lorimer_Ventures>,
        <https://1145.am/db/1758193/Tenoneten_Ventures>,
        <https://1145.am/db/1758193/Valia_Ventures>,
        <https://1145.am/db/1758313/Venture_Field>,
        <https://1145.am/db/1758622/Oca_Ventures>,
        <https://1145.am/db/1759048/Avid_Ventures>,
        <https://1145.am/db/1759048/Lightspeed_Ventures>,
        <https://1145.am/db/1759567/J_Ventures>,
        <https://1145.am/db/1759922/Verance_Capital>,
        <https://1145.am/db/1760383/True_Ventures>,
        <https://1145.am/db/1760520/Prologis_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1760984/Sequoia_Capital>,
        <https://1145.am/db/1760985/Frontier_Ventures>,
        <https://1145.am/db/1761126/Redpoint_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761607/Menlo_Ventures>,
        <https://1145.am/db/1761607/Sinewave_Ventures>,
        <https://1145.am/db/1761957/Alkeon_Capital>,
        <https://1145.am/db/1761999/Ggv_Capital>,
        <https://1145.am/db/1762031/Menlo_Ventures>,
        <https://1145.am/db/1762055/Altos_Ventures>,
        <https://1145.am/db/1762277/Ac_Ventures>,
        <https://1145.am/db/1762453/Line_Ventures>,
        <https://1145.am/db/1762561/Grotech_Ventures>,
        <https://1145.am/db/1762669/Creandum>,
        <https://1145.am/db/1762844/Signum_Capital>,
        <https://1145.am/db/1763356/Agla_Ventures>,
        <https://1145.am/db/1763371/Spacecadet_Ventures>,
        <https://1145.am/db/1763395/Idc_Ventures>,
        <https://1145.am/db/1763565/Felicis_Ventures>,
        <https://1145.am/db/1763774/Ggv_Capital>,
        <https://1145.am/db/1763795/Ventures_Platform>,
        <https://1145.am/db/1763795/Xyz_Ventures>,
        <https://1145.am/db/1763875/Golden_Gate_Ventures>,
        <https://1145.am/db/1764027/Menlo_Ventures>,
        <https://1145.am/db/1764255/Pathbreaker_Ventures>,
        <https://1145.am/db/1764255/Stageone_Ventures>,
        <https://1145.am/db/1764345/Talis_Capital>,
        <https://1145.am/db/1764527/Presidio_Ventures>,
        <https://1145.am/db/1764527/Yl_Ventures>,
        <https://1145.am/db/1765273/Adevinta_Ventures>,
        <https://1145.am/db/1765273/Venturefriends>,
        <https://1145.am/db/1765372/Irobot_Ventures>,
        <https://1145.am/db/1765377/Redpoint_Ventures>,
        <https://1145.am/db/1765550/Sequoia_Capital>,
        <https://1145.am/db/1765646/Amiti_Ventures>,
        <https://1145.am/db/1765673/Salesforce_Ventures>,
        <https://1145.am/db/1766091/Inreach_Ventures>,
        <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1766096/Northpond_Ventures>,
        <https://1145.am/db/1766253/Redpoint_Ventures>,
        <https://1145.am/db/1766253/True_Ventures>,
        <https://1145.am/db/1766540/Industry_Ventures>,
        <https://1145.am/db/1766978/Rga_Ventures>,
        <https://1145.am/db/1768099/Eventures>,
        <https://1145.am/db/1768363/Golden_Gate_Ventures>,
        <https://1145.am/db/1768841/Sequoia_Capital>,
        <https://1145.am/db/1769188/Felicis_Ventures>,
        <https://1145.am/db/1770095/Crosslink_Capital>,
        <https://1145.am/db/1770139/Victress_Capital>,
        <https://1145.am/db/1770265/Techstars_Ventures>,
        <https://1145.am/db/1770372/Avalon_Ventures>,
        <https://1145.am/db/1770372/Korelya_Capital>,
        <https://1145.am/db/1770802/Sequoia_Capital>,
        <https://1145.am/db/1770982/Gv>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771011/Ggv_Capital>,
        <https://1145.am/db/1771548/Seekdource_Capital>,
        <https://1145.am/db/1771613/Creandum>,
        <https://1145.am/db/1771642/Felicis_Ventures>,
        <https://1145.am/db/1772004/Raed_Ventures>,
        <https://1145.am/db/1772004/Seed_Equity_Venture_Partners>,
        <https://1145.am/db/1772381/Altos_Ventures>,
        <https://1145.am/db/1772452/Connect_Ventures>,
        <https://1145.am/db/1773130/Capnamic_Ventures>,
        <https://1145.am/db/1773143/Venturefriends>,
        <https://1145.am/db/1773323/Crosslink_Capital>,
        <https://1145.am/db/1774348/True_Ventures>,
        <https://1145.am/db/1774535/Felicis_Ventures>,
        <https://1145.am/db/1774535/Susa_Ventures>,
        <https://1145.am/db/1774658/Gv>,
        <https://1145.am/db/1775965/Felicis_Ventures>,
        <https://1145.am/db/1776340/Ggv_Capital>,
        <https://1145.am/db/1776340/Menlo_Ventures>,
        <https://1145.am/db/1776537/Origin_Ventures>,
        <https://1145.am/db/1776537/Tekton_Ventures>,
        <https://1145.am/db/1776621/Redpoint_Ventures>,
        <https://1145.am/db/1777289/Dn_Capital>,
        <https://1145.am/db/1777563/Evolv_Ventures>,
        <https://1145.am/db/1777563/Ggv_Capital>,
        <https://1145.am/db/1777848/Industry_Ventures>,
        <https://1145.am/db/1778935/Oryzn_Capital>,
        <https://1145.am/db/1780024/Partech_Ventures>,
        <https://1145.am/db/1782098/Addventure>,
        <https://1145.am/db/1782221/Point72_Ventures>,
        <https://1145.am/db/1783189/Citi_Ventures>,
        <https://1145.am/db/1784644/Creathor_Ventures>,
        <https://1145.am/db/1784964/Clear_Ventures>,
        <https://1145.am/db/1785361/M_Ventures>,
        <https://1145.am/db/1786249/Redpoint_Ventures>,
        <https://1145.am/db/1786249/Resolute_Ventures>,
        <https://1145.am/db/1786663/Edenred_Capital_Partners>,
        <https://1145.am/db/1786663/Eqt_Ventures>,
        <https://1145.am/db/1787249/Kpn_Ventures>,
        <https://1145.am/db/1787342/Korelya_Capital>,
        <https://1145.am/db/1787536/Point72_Ventures>,
        <https://1145.am/db/1787791/True_Ventures>,
        <https://1145.am/db/1787886/True_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1788570/Sequoia_Capital>,
        <https://1145.am/db/1788726/Redbeat_Capital>,
        <https://1145.am/db/1789460/Eventures>,
        <https://1145.am/db/1789754/Advancit_Capital>,
        <https://1145.am/db/1790280/Arthur_Ventures>,
        <https://1145.am/db/1790399/Capnamic_Ventures>,
        <https://1145.am/db/1790574/Crosslink_Capital>,
        <https://1145.am/db/1790574/Red_Swan_Ventures>,
        <https://1145.am/db/1790574/Sherpa_Ventures>,
        <https://1145.am/db/1790641/Dn_Capital>,
        <https://1145.am/db/1790771/Redpoint_Ventures>,
        <https://1145.am/db/1790777/Connect_Ventures>,
        <https://1145.am/db/1791216/True_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791628/Industry_Ventures>,
        <https://1145.am/db/1791838/Advancit_Capital>,
        <https://1145.am/db/1792186/Sequoia_Capital>,
        <https://1145.am/db/1792771/Softtechvc>,
        <https://1145.am/db/1792887/Kaedan_Capital>,
        <https://1145.am/db/1792887/Stageone_Ventures>,
        <https://1145.am/db/1794699/Ws_Ventures>,
        <https://1145.am/db/1794935/Intervest_Co_Ltd>,
        <https://1145.am/db/1795020/Redpoint_Ventures>,
        <https://1145.am/db/1795210/Sequoia_Capital>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1795538/Skystar_Capital>,
        <https://1145.am/db/1796109/Contour_Venture_Partners>,
        <https://1145.am/db/1796593/Tenoneten_Ventures>,
        <https://1145.am/db/1796901/Red_Swan_Ventures>,
        <https://1145.am/db/1796922/Cagni_Ventures>,
        <https://1145.am/db/1797209/Kdwc_Ventures>,
        <https://1145.am/db/1797518/Sequoia_Capital>,
        <https://1145.am/db/1797899/Brave_Ventures>,
        <https://1145.am/db/1797999/Redpoint_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1799099/Inovia_Capital>,
        <https://1145.am/db/1799184/Ggv_Capital>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800929/Ventureast>,
        <https://1145.am/db/1802086/High_Line_Ventures>,
        <https://1145.am/db/1802227/Advancit_Capital>,
        <https://1145.am/db/1802288/Sequoia_Capital>,
        <https://1145.am/db/1802336/Capnamic_Ventures>,
        <https://1145.am/db/1804102/True_Ventures>,
        <https://1145.am/db/1804247/Holtzbrinck_Ventures>,
        <https://1145.am/db/1804476/Felicis_Ventures>,
        <https://1145.am/db/1804476/True_Ventures>,
        <https://1145.am/db/1804992/Talis_Capital>,
        <https://1145.am/db/1805389/Industry_Ventures>,
        <https://1145.am/db/1805604/Connect_Ventures>,
        <https://1145.am/db/1805604/Inreach_Ventures>,
        <https://1145.am/db/1806644/Sequoia_Capital>,
        <https://1145.am/db/1806739/Golden_Gate_Ventures>,
        <https://1145.am/db/1808047/Salesforce_Ventures>,
        <https://1145.am/db/1808505/Helion_Ventures>,
        <https://1145.am/db/1808723/Mindworks_Ventures>,
        <https://1145.am/db/1808735/Commonangels_Ventures>,
        <https://1145.am/db/1809007/Sequoia_Capital>,
        <https://1145.am/db/1809844/Real_Ventures>,
        <https://1145.am/db/1809862/Acequia_Capital>,
        <https://1145.am/db/1810384/Starstrike_Ventures>,
        <https://1145.am/db/1810710/Ia_Ventures>,
        <https://1145.am/db/1810714/Catalus_Capital>,
        <https://1145.am/db/1810769/Eventures>,
        <https://1145.am/db/1810769/Sequoia_Capital>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812233/Sequoia_Capital>,
        <https://1145.am/db/1812856/Exfinity_Ventures>,
        <https://1145.am/db/1813375/Creandum>,
        <https://1145.am/db/1813575/Ggv_Capital>,
        <https://1145.am/db/1813944/Menlo_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1814643/Corigin_Ventures>,
        <https://1145.am/db/1814643/Launchcapital>,
        <https://1145.am/db/1815038/Plus_Ventures>,
        <https://1145.am/db/1815507/Globis_Capital_Partners>,
        <https://1145.am/db/1815697/Cherubic_Ventures>,
        <https://1145.am/db/1815701/True_Ventures>,
        <https://1145.am/db/1815886/Teneleven_Ventures>,
        <https://1145.am/db/1816491/Grotech_Ventures>,
        <https://1145.am/db/1818174/Advancit_Capital>,
        <https://1145.am/db/1818876/Kreos_Capital>,
        <https://1145.am/db/1818901/Sequoia_Capital>,
        <https://1145.am/db/1819374/Rothenberg_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1820882/Inven_Capital>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1821711/Winton_Ventures>,
        <https://1145.am/db/1821752/Sequoia_Capital>,
        <https://1145.am/db/1823162/True_Ventures>,
        <https://1145.am/db/1823217/Kdc_Ventures>,
        <https://1145.am/db/1823217/Nbm_Ventures>,
        <https://1145.am/db/1823684/Dcm_Ventures>,
        <https://1145.am/db/1823684/Idg_Ventures>,
        <https://1145.am/db/1824252/Allos_Ventures>,
        <https://1145.am/db/1824253/Trinity_Ventures>,
        <https://1145.am/db/1824944/True_Ventures>,
        <https://1145.am/db/1825465/Ben_Narasin>,
        <https://1145.am/db/1825713/Menlo_Ventures>,
        <https://1145.am/db/1825946/Lerer_Ventures>,
        <https://1145.am/db/1826265/Idg_Ventures>,
        <https://1145.am/db/1826648/True_Ventures>,
        <https://1145.am/db/1826922/Ggv_Capital>,
        <https://1145.am/db/1827021/Dag_Ventures>,
        <https://1145.am/db/1828036/Redpoint_Ventures>,
        <https://1145.am/db/1828092/Eden_Ventures>,
        <https://1145.am/db/1828251/Golden_Gate_Ventures>,
        <https://1145.am/db/1828455/Quotidien_Ventures>,
        <https://1145.am/db/1828658/Focus_Ventures>,
        <https://1145.am/db/1828663/Great_Oaks_Ventures>,
        <https://1145.am/db/1828663/Inovia_Capital>,
        <https://1145.am/db/1829257/Sequoia_Capital>,
        <https://1145.am/db/1829422/Felicis_Ventures>,
        <https://1145.am/db/1829422/Rothenberg_Ventures>,
        <https://1145.am/db/1829612/Lerer_Ventures>,
        <https://1145.am/db/1830502/Frontline_Ventures>,
        <https://1145.am/db/1830613/True_Ventures>,
        <https://1145.am/db/1830809/Numecent>,
        <https://1145.am/db/1830809/T-Ventures>,
        <https://1145.am/db/1830817/Charles_River_Ventures>,
        <https://1145.am/db/1831577/Artiman_Ventures>,
        <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1831764/Sequoia_Capital>,
        <https://1145.am/db/1832038/True_Ventures>,
        <https://1145.am/db/1832316/Partech_Ventures>,
        <https://1145.am/db/1832316/Scentan_Ventures>,
        <https://1145.am/db/1832316/Startcaps_Ventures>,
        <https://1145.am/db/1832856/Grotech_Ventures>,
        <https://1145.am/db/1834224/Avalon_Ventures>,
        <https://1145.am/db/1834224/Orix_Ventures>,
        <https://1145.am/db/1834305/Charles_River_Ventures>,
        <https://1145.am/db/1834334/Altos_Ventures>,
        <https://1145.am/db/1834334/Baseline_Ventures>,
        <https://1145.am/db/1834334/Firebolt_Ventures>,
        <https://1145.am/db/1834334/Lazerow_Ventures>,
        <https://1145.am/db/1834520/Ben_Horowitz>,
        <https://1145.am/db/1834541/Avalon_Ventures>,
        <https://1145.am/db/1834708/Sherpa_Ventures>,
        <https://1145.am/db/1834965/Lerer_Ventures>,
        <https://1145.am/db/1835229/Lerer_Ventures>,
        <https://1145.am/db/1835229/Trinity_Ventures>,
        <https://1145.am/db/1835229/Xg_Ventures>,
        <https://1145.am/db/1835740/Lerer_Ventures>,
        <https://1145.am/db/1835749/Gree_Ventures>,
        <https://1145.am/db/1835825/Focus_Ventures>,
        <https://1145.am/db/1836984/Siemer_Ventures>,
        <https://1145.am/db/1836984/Tekton_Ventures>,
        <https://1145.am/db/1837741/Menlo_Ventures>,
        <https://1145.am/db/1838026/Plus_Ventures>,
        <https://1145.am/db/1840775/Ggv_Capital>,
        <https://1145.am/db/1840881/Felicis_Ventures>,
        <https://1145.am/db/1840881/Trinity_Ventures>,
        <https://1145.am/db/1841176/Lerer_Ventures>,
        <https://1145.am/db/1841176/True_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1842402/Redpoint_Ventures>,
        <https://1145.am/db/1842898/Grotech_Ventures>,
        <https://1145.am/db/1843003/Eventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1843449/Redpoint_Ventures>,
        <https://1145.am/db/1843602/Nextview_Ventures>,
        <https://1145.am/db/1843659/Sequoia_Capital>,
        <https://1145.am/db/1844143/Inovia_Capital>,
        <https://1145.am/db/1844472/Sequoia_Capital>,
        <https://1145.am/db/1844737/True_Ventures>,
        <https://1145.am/db/1844931/Charles_River_Ventures>,
        <https://1145.am/db/1845308/Ia_Ventures>,
        <https://1145.am/db/1845960/Lerer_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846483/Inovia_Capital>,
        <https://1145.am/db/1847463/Prism_Ventureworks>,
        <https://1145.am/db/1847752/T-Venture>,
        <https://1145.am/db/1848523/Trinity_Ventures>,
        <https://1145.am/db/1849673/Inventure_Partners>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849949/Holtzbrinck_Ventures>,
        <https://1145.am/db/1850020/Sequoia_Capital>,
        <https://1145.am/db/1850668/True_Ventures>,
        <https://1145.am/db/1850989/Artiman_Ventures>,
        <https://1145.am/db/1850989/Sequoia_Capital>,
        <https://1145.am/db/1851035/Acequia_Capital>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851035/Redpoint_Ventures>,
        <https://1145.am/db/1851705/Promus_Ventures>,
        <https://1145.am/db/1851854/Partech_Ventures>,
        <https://1145.am/db/1851923/Dag_Ventures>,
        <https://1145.am/db/1852308/Plus_Ventures>,
        <https://1145.am/db/1852513/Quotidian_Ventures>,
        <https://1145.am/db/1852513/Trestle_Ventures>,
        <https://1145.am/db/1852556/Dave_Morin>,
        <https://1145.am/db/1852806/Redpoint_Ventures>,
        <https://1145.am/db/1852870/Golden_Gate_Ventures>,
        <https://1145.am/db/1852870/Siemer_Ventures>,
        <https://1145.am/db/1853417/Catamount_Ventures>,
        <https://1145.am/db/1853496/T-Ventures>,
        <https://1145.am/db/1854200/Ggv_Capital>,
        <https://1145.am/db/1854201/Charles_River_Ventures>,
        <https://1145.am/db/1854786/Eden_Ventures>,
        <https://1145.am/db/1854874/Crosslink_Capital>,
        <https://1145.am/db/1854874/Sherpa_Ventures>,
        <https://1145.am/db/1854874/Softtech>,
        <https://1145.am/db/1855353/Sequoia_Capital>,
        <https://1145.am/db/1855363/True_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1855780/Bds_Ventures>,
        <https://1145.am/db/1855780/Ggv_Capital>,
        <https://1145.am/db/1856191/Creandum>,
        <https://1145.am/db/1856380/Softtech>,
        <https://1145.am/db/1856402/Sequoia_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1856616/Redpoint_Ventures>,
        <https://1145.am/db/1856834/Sequoia_Capital>,
        <https://1145.am/db/1857635/Rikard_Steiber>,
        <https://1145.am/db/1857659/Revolution_Ventures>,
        <https://1145.am/db/1857930/Inovia_Capital>,
        <https://1145.am/db/1857930/Version_One_Ventures>,
        <https://1145.am/db/1858323/Avalon_Ventures>,
        <https://1145.am/db/1858545/Sequoia_Capital>,
        <https://1145.am/db/1858592/Apex_Venture_Partners>,
        <https://1145.am/db/1858592/Origin_Ventures>,
        <https://1145.am/db/1858991/Capnamic_Ventures>,
        <https://1145.am/db/1859199/True_Ventures>,
        <https://1145.am/db/1859314/Version_One_Ventures>,
        <https://1145.am/db/1860163/Inovia_Capital>,
        <https://1145.am/db/1860345/Commonangels>,
        <https://1145.am/db/1860345/Launchcapital>,
        <https://1145.am/db/1861054/Sequoia_Capital>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1862590/Felicis_Ventures>,
        <https://1145.am/db/1862878/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1863147/Apex_Venture_Partners>,
        <https://1145.am/db/1864601/Trinity_Ventures>,
        <https://1145.am/db/1864646/Inventus_Capital>,
        <https://1145.am/db/1865436/Sequoia_Capital>,
        <https://1145.am/db/1865480/Felicis_Ventures>,
        <https://1145.am/db/1865480/Sequoia_Capital>,
        <https://1145.am/db/1865480/Sherpalo_Ventures>,
        <https://1145.am/db/1866032/Launchcapital>,
        <https://1145.am/db/1866134/Embarcadero_Ventures>,
        <https://1145.am/db/1866134/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1866155/Presidio_Ventures>,
        <https://1145.am/db/1867543/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1867599/Cava_Capital>,
        <https://1145.am/db/1868107/Redpoint_Ventures>,
        <https://1145.am/db/1868109/Charles_River_Ventures>,
        <https://1145.am/db/1868178/True_Ventures>,
        <https://1145.am/db/1870015/Redpoint_Ventures>,
        <https://1145.am/db/1870465/Nextview_Ventures>,
        <https://1145.am/db/1871221/True_Ventures>,
        <https://1145.am/db/1871574/Redpoint_Ventures>,
        <https://1145.am/db/1871777/Charles_River_Ventures>,
        <https://1145.am/db/1871784/Charles_River_Ventures>,
        <https://1145.am/db/1871888/Charles_River_Ventures>,
        <https://1145.am/db/1873191/El_Dorado_Ventures>,
        <https://1145.am/db/1873680/Crosslink_Capital>,
        <https://1145.am/db/1873680/Lerer_Ventures>,
        <https://1145.am/db/1873680/Xg_Ventures>,
        <https://1145.am/db/1874749/True_Ventures>,
        <https://1145.am/db/1874937/Quotidian_Ventures>,
        <https://1145.am/db/1877243/Felicis_Ventures>,
        <https://1145.am/db/1877283/Northzone_Ventures>,
        <https://1145.am/db/1877473/True_Ventures>,
        <https://1145.am/db/1877642/Dag_Ventures>,
        <https://1145.am/db/1878620/Ggv_Capital>,
        <https://1145.am/db/1879279/High_Line_Ventures>,
        <https://1145.am/db/1879759/T-Venture>,
        <https://1145.am/db/1880679/Northzone_Ventures>,
        <https://1145.am/db/1881464/Ggv_Capital>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1882330/New_World_Ventures>,
        <https://1145.am/db/1882727/Charles_River_Ventures>,
        <https://1145.am/db/1882907/Starfish_Ventures>,
        <https://1145.am/db/1883568/Eden_Ventures>,
        <https://1145.am/db/1883572/Astutia_Ventures>,
        <https://1145.am/db/1886402/New_Atlantic_Ventures>,
        <https://1145.am/db/1886566/Sequoia_Capital>,
        <https://1145.am/db/1889394/Focus_Ventures>,
        <https://1145.am/db/1889629/Sequoia_Capital>,
        <https://1145.am/db/1890000/Lerer_Ventures>,
        <https://1145.am/db/1890122/East_Ventures>,
        <https://1145.am/db/1890133/Crosslink_Capital>,
        <https://1145.am/db/1890133/Dag_Ventures>,
        <https://1145.am/db/1890133/Focus_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/1890208/Menlo_Ventures>,
        <https://1145.am/db/1890619/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1890839/Inovia_Capital>,
        <https://1145.am/db/1890903/Miven_Ventures>,
        <https://1145.am/db/1891615/Holtzbrinck_Ventures>,
        <https://1145.am/db/1891777/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1891913/New_World_Ventures>,
        <https://1145.am/db/1891913/Oca_Ventures>,
        <https://1145.am/db/1891926/New_World_Ventures>,
        <https://1145.am/db/1892050/Charles_River_Ventures>,
        <https://1145.am/db/1892105/Crosscreek_Capital>,
        <https://1145.am/db/1892105/Industry_Ventures>,
        <https://1145.am/db/1892106/Altos_Ventures>,
        <https://1145.am/db/1892106/Illuminate_Ventures>,
        <https://1145.am/db/1892620/True_Ventures>,
        <https://1145.am/db/1892674/Appian_Ventures>,
        <https://1145.am/db/1892902/Crosslink_Capital>,
        <https://1145.am/db/1892955/Guy_Gamzu>,
        <https://1145.am/db/1895072/Nextview_Ventures>,
        <https://1145.am/db/1895951/Windward_Ventures>,
        <https://1145.am/db/1896159/Ia_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1896379/Redpoint_Ventures>,
        <https://1145.am/db/1896419/True_Ventures>,
        <https://1145.am/db/1902330/Baseline_Ventures>,
        <https://1145.am/db/1905483/Industry_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1907771/Dag_Ventures>,
        <https://1145.am/db/1909430/Menlo_Ventures>,
        <https://1145.am/db/1909651/Revolution_Ventures>,
        <https://1145.am/db/1910694/True_Ventures>,
        <https://1145.am/db/1910922/Charles_River_Ventures>,
        <https://1145.am/db/1912684/Charles_River_Ventures>,
        <https://1145.am/db/1913863/Tl_Ventures>,
        <https://1145.am/db/1913874/Redpoint_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915393/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1915862/Dag_Ventures>,
        <https://1145.am/db/1915862/Focus_Ventures>,
        <https://1145.am/db/1919724/Dag_Ventures>,
        <https://1145.am/db/1920478/Dawntreader_Ventures>,
        <https://1145.am/db/1920837/Onset_Ventures>,
        <https://1145.am/db/1927817/Trm_Ventures>,
        <https://1145.am/db/1939926/Cobalt_Ventures>,
        <https://1145.am/db/1945479/Crosslink_Capital>,
        <https://1145.am/db/1947303/Cavallo_Ventures>,
        <https://1145.am/db/1947312/Boldstart_Ventures>,
        <https://1145.am/db/1952989/Singularity_Ventures>,
        <https://1145.am/db/1954147/Accomplice_Ventures>,
        <https://1145.am/db/1957179/Sozo_Ventures>,
        <https://1145.am/db/1958963/Prosus_Ventures>,
        <https://1145.am/db/1959001/Capital_Technology_Ventures>,
        <https://1145.am/db/1959001/Glasswing_Ventures>,
        <https://1145.am/db/1962819/Connetic_Ventures>,
        <https://1145.am/db/1967592/Firebolt_Ventures>,
        <https://1145.am/db/1967683/Dig_Ventures_Vine_Ventures>,
        <https://1145.am/db/1975490/Northview_Ventures>,
        <https://1145.am/db/1975547/Nanban_Ventures>,
        <https://1145.am/db/1975547/Sinewave_Ventures>,
        <https://1145.am/db/1986122/Menlo_Ventures>,
        <https://1145.am/db/1995926/Neotribe_Ventures>,
        <https://1145.am/db/1998196/Gni_Group_Ltd>,
        <https://1145.am/db/1999771/Servicenow_Ventures>,
        <https://1145.am/db/2004427/Convivialit_Ventures>,
        <https://1145.am/db/2005131/Wwventures>,
        <https://1145.am/db/2007132/Nventures>,
        <https://1145.am/db/2020041/Inovia_Capital>,
        <https://1145.am/db/2020041/TCV>,
        <https://1145.am/db/2023596/Salesforce_Ventures>,
        <https://1145.am/db/2025081/True_Ventures>,
        <https://1145.am/db/2029648/Sequoia_Capital>,
        <https://1145.am/db/2035454/Gv>,
        <https://1145.am/db/2036021/Clear_Ventures>,
        <https://1145.am/db/2038783/Sequoia_Capital>,
        <https://1145.am/db/2039177/Stellantis_Ventures>,
        <https://1145.am/db/2041480/Brunnur_Ventures>,
        <https://1145.am/db/2042858/Gv>,
        <https://1145.am/db/2044380/20sales>,
        <https://1145.am/db/2045587/Veritec_Ventures>,
        <https://1145.am/db/2050229/Nventures>,
        <https://1145.am/db/2050359/At_One_Ventures>,
        <https://1145.am/db/2051164/Aviso_Ventures>,
        <https://1145.am/db/2053027/Glasswing_Ventures>,
        <https://1145.am/db/2055707/Globis_Capital_Partners>,
        <https://1145.am/db/2056931/We_Ventures>,
        <https://1145.am/db/2060003/Crit_Ventures_100___100_Ventures>,
        <https://1145.am/db/2061278/Incisive_Ventures>,
        <https://1145.am/db/2061278/Volo_Ventures>,
        <https://1145.am/db/2063642/Clear_Bridge_Ventures>,
        <https://1145.am/db/2063967/Vsquared_Ventures>,
        <https://1145.am/db/2069147/Boldstart_Ventures>,
        <https://1145.am/db/2069147/Pelion_Ventures>,
        <https://1145.am/db/2069147/Salesforce_Ventures>,
        <https://1145.am/db/2069495/Intermountain_Ventures>,
        <https://1145.am/db/2069495/Northpond_Ventures>,
        <https://1145.am/db/2073129/Abstract_Ventures>,
        <https://1145.am/db/2073132/Idc_Ventures>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2075625/Rocketship_Ventures>,
        <https://1145.am/db/2081180/S4s_Ventures>,
        <https://1145.am/db/2081674/Capital_One_Ventures>,
        <https://1145.am/db/2082068/Arctern_Ventures>,
        <https://1145.am/db/2082068/Prelude_Ventures>,
        <https://1145.am/db/2083987/Vanterra_Ventures>,
        <https://1145.am/db/2087289/Jven_Capital>,
        <https://1145.am/db/2087289/Northpond_Ventures>,
        <https://1145.am/db/2089206/Crescendo_Venture_Partners>,
        <https://1145.am/db/2093427/Yl_Ventures>,
        <https://1145.am/db/2093713/Yl_Ventures>,
        <https://1145.am/db/209861/Crosslink_Capital>,
        <https://1145.am/db/2100116/Epic_Ventures>,
        <https://1145.am/db/2107533/Globis_Capital_Partners>,
        <https://1145.am/db/2109529/Point72_Ventures>,
        <https://1145.am/db/2109799/Sofinnova_Partners>,
        <https://1145.am/db/2109932/Catalio_Capital_Management>,
        <https://1145.am/db/2109932/Epic_Ventures>,
        <https://1145.am/db/2109932/Intermountain_Ventures>,
        <https://1145.am/db/2109932/North_South_Ventures>,
        <https://1145.am/db/2116769/Celesta_Capital>,
        <https://1145.am/db/2116769/Chiratae_Ventures>,
        <https://1145.am/db/2123953/Amex_Ventures>,
        <https://1145.am/db/2123953/Industry_Ventures>,
        <https://1145.am/db/2123953/Infinity_Ventures>,
        <https://1145.am/db/2124766/P1_Ventures>,
        <https://1145.am/db/2125182/Nevcaut_Ventures>,
        <https://1145.am/db/2125182/Ulu_Ventures>,
        <https://1145.am/db/2125927/1984_Ventures>,
        <https://1145.am/db/2127882/Akkadian_Ventures>,
        <https://1145.am/db/2134989/Clear_Ventures>,
        <https://1145.am/db/2134989/Felicis_Ventures>,
        <https://1145.am/db/2141183/S_Ventures>,
        <https://1145.am/db/2141328/Connetic_Ventures>,
        <https://1145.am/db/2143438/Scorpio_Capital>,
        <https://1145.am/db/2147767/Catapult_Ventures>,
        <https://1145.am/db/2147767/Tenoneten_Ventures>,
        <https://1145.am/db/2151983/CRV>,
        <https://1145.am/db/2151983/Greatpoint_Ventures>,
        <https://1145.am/db/2155426/Brighteyes_Ventures>,
        <https://1145.am/db/2155625/Sofinnova_Partners>,
        <https://1145.am/db/2164121/Menlo_Ventures>,
        <https://1145.am/db/2169799/Nwise_Ventures>,
        <https://1145.am/db/217906/Sequoia_Capital>,
        <https://1145.am/db/2181016/Foresite_Capital>,
        <https://1145.am/db/2182443/Global_Ventures>,
        <https://1145.am/db/2183352/Optum_Ventures>,
        <https://1145.am/db/2186568/Frist_Cressey_Ventures>,
        <https://1145.am/db/2186568/Springrock_Ventures>,
        <https://1145.am/db/2186949/Greatpoint_Ventures_And_Cross_Creek>,
        <https://1145.am/db/2186949/Springrock_Ventures>,
        <https://1145.am/db/2190141/Link_Ventures>,
        <https://1145.am/db/2192636/TCV>,
        <https://1145.am/db/219311/Origin_Ventures>,
        <https://1145.am/db/2196875/Sequoia_Capital>,
        <https://1145.am/db/2208603/McKesson_Ventures>,
        <https://1145.am/db/2210557/True_Ventures>,
        <https://1145.am/db/221321/Ggv_Capital>,
        <https://1145.am/db/2214690/Idg_Ventures>,
        <https://1145.am/db/2254568/Felicis_Ventures>,
        <https://1145.am/db/2264763/True_Ventures>,
        <https://1145.am/db/2283006/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Northpond_Ventures>,
        <https://1145.am/db/2284412/Soleus_Capital>,
        <https://1145.am/db/2286665/Shanda_Group>,
        <https://1145.am/db/2288209/Echelon_Ventures>,
        <https://1145.am/db/2288596/Sanderling_Ventures>,
        <https://1145.am/db/2291277/Foresite_Capital>,
        <https://1145.am/db/2293172/Prospect_Ventures>,
        <https://1145.am/db/2294202/Trinitas_Capital>,
        <https://1145.am/db/2294815/Foresite_Capital>,
        <https://1145.am/db/2295253/Arkitekt_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2296249/Proxima_Ventures>,
        <https://1145.am/db/2296869/Dcm_Ventures>,
        <https://1145.am/db/2297406/Sequoia_Capital>,
        <https://1145.am/db/2298897/Eshelman_Ventures>,
        <https://1145.am/db/2300254/Sequoia_Capital>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2302750/Sofinnova_Partners>,
        <https://1145.am/db/2302897/Ventures_West_Capital>,
        <https://1145.am/db/2303098/Seaflower_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304606/Prism_Ventureworks>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2305745/Sanderling_Ventures>,
        <https://1145.am/db/2306281/Sanderling_Ventures>,
        <https://1145.am/db/2306568/Cmea_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2312792/Onset_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2314380/Puretech_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314515/Apjohnventures>,
        <https://1145.am/db/2315754/Arcturus_Capital>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2317779/Sofinnova_Partners>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2321856/Ventures_West_Capital_Ltd>,
        <https://1145.am/db/2323785/Eshelman_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2325015/True_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325257/Ventures_West>,
        <https://1145.am/db/2325337/Resolvyx>,
        <https://1145.am/db/2326080/Felicis_Ventures>,
        <https://1145.am/db/2326362/Nextech_Venture>,
        <https://1145.am/db/2326404/Intersouth_Partners>,
        <https://1145.am/db/2328585/Cmea_Ventures>,
        <https://1145.am/db/2329870/Sofinnova_Partners>,
        <https://1145.am/db/2330775/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335587/Sofinnova_Partners>,
        <https://1145.am/db/2338023/Cipla_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2338236/Sanderling_Ventures>,
        <https://1145.am/db/2338703/Wavepoint_Ventures>,
        <https://1145.am/db/2339206/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2340429/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341942/High-Tech_Grnderfonds>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2343184/Jven_Capital>,
        <https://1145.am/db/2345017/Venture_Investments>,
        <https://1145.am/db/2345268/Foresite_Capital>,
        <https://1145.am/db/2346300/High-Tech_Grnderfonds>,
        <https://1145.am/db/2346452/Aescap_Venture>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Partners>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2350044/Avalon_Ventures>,
        <https://1145.am/db/2352436/Forward_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2356384/Sofinnova_Partners>,
        <https://1145.am/db/2357487/Savitr_Capital>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358657/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2358747/Solon_Ventures>,
        <https://1145.am/db/2358812/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2359960/Sofinnova_Partners>,
        <https://1145.am/db/2362638/Launchpad_Venture_Group>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2363854/Chrysalis_Ventures>,
        <https://1145.am/db/2364820/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365103/Aescap_Venture>,
        <https://1145.am/db/2367675/Avalon_Ventures>,
        <https://1145.am/db/2369967/Foresite_Capital>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/238282/Carnrite_Ventures>,
        <https://1145.am/db/2400536/Capital_One_Ventures>,
        <https://1145.am/db/2423653/Venturewell>,
        <https://1145.am/db/253438/Esplanade_Ventures>,
        <https://1145.am/db/254357/Ulu_Ventures>,
        <https://1145.am/db/2549491/Ktb_Ventures>,
        <https://1145.am/db/2552636/Morningside_Ventures>,
        <https://1145.am/db/2569491/High-Tech_Grnderfonds>,
        <https://1145.am/db/2570138/Sherpa_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Partners>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2603254/Salesforce_Ventures>,
        <https://1145.am/db/2628424/Verana_Networks>,
        <https://1145.am/db/2628848/Neocarta_Ventures>,
        <https://1145.am/db/2635849/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2638432/Nissay_Capital>,
        <https://1145.am/db/2641337/Promus_Ventures>,
        <https://1145.am/db/2641337/True_Ventures>,
        <https://1145.am/db/2654391/Biggell_Finance>,
        <https://1145.am/db/265532/Ulu_Ventures>,
        <https://1145.am/db/2702871/Inovia_Capital>,
        <https://1145.am/db/274170/G1_Ventures>,
        <https://1145.am/db/2754677/Golden_Gate_Ventures>,
        <https://1145.am/db/2765022/Garuda_Ventures>,
        <https://1145.am/db/2765030/Daniel_Ventures>,
        <https://1145.am/db/2765418/Rw3_Ventures>,
        <https://1145.am/db/2786411/Allegion_Ventures>,
        <https://1145.am/db/2788052/Rx_Ventures>,
        <https://1145.am/db/2790064/Novastar_Ventures>,
        <https://1145.am/db/2794396/Snowpoint_Ventures>,
        <https://1145.am/db/2797562/Menlo_Ventures>,
        <https://1145.am/db/283272/Salesforce_Ventures>,
        <https://1145.am/db/283607/Salesforce_Ventures>,
        <https://1145.am/db/293715/Signum_Capital>,
        <https://1145.am/db/293849/Felicis_Ventures>,
        <https://1145.am/db/293891/Ggv_Capital>,
        <https://1145.am/db/299738/Steadfast_Capital_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/319155/Bgv_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/341984/Salesforce_Ventures>,
        <https://1145.am/db/341984/Sequoia_Capital>,
        <https://1145.am/db/341990/Salesforce_Ventures>,
        <https://1145.am/db/341990/Sequoia_Capital>,
        <https://1145.am/db/343459/F7_Ventures>,
        <https://1145.am/db/346598/Salesforce_Ventures>,
        <https://1145.am/db/348442/Triventures>,
        <https://1145.am/db/348659/Launchpad_Capital>,
        <https://1145.am/db/361303/Sequoia_Capital>,
        <https://1145.am/db/364168/Alerion_Ventures>,
        <https://1145.am/db/367592/Gv>,
        <https://1145.am/db/367592/Sequoia_Capital>,
        <https://1145.am/db/388551/Vestigo_Ventures>,
        <https://1145.am/db/396305/Real_Ventures>,
        <https://1145.am/db/402103/1776_Ventures>,
        <https://1145.am/db/402701/January_Ventures>,
        <https://1145.am/db/403810/Riverstone_Ventures>,
        <https://1145.am/db/410322/Gv>,
        <https://1145.am/db/410473/Celesta_Capital>,
        <https://1145.am/db/410473/Lytical_Ventures_And_Nepenthe_Capital>,
        <https://1145.am/db/410529/Goodyear_Ventures>,
        <https://1145.am/db/411539/Zeev_Ventures>,
        <https://1145.am/db/412020/Defi_Ventures_Inc>,
        <https://1145.am/db/415322/CRV>,
        <https://1145.am/db/416041/Akkadian_Ventures>,
        <https://1145.am/db/416041/Signia_Ventures>,
        <https://1145.am/db/416041/Zeev_Ventures>,
        <https://1145.am/db/419489/Point72_Ventures>,
        <https://1145.am/db/424877/North_First_Ventures>,
        <https://1145.am/db/425262/Yl_Ventures>,
        <https://1145.am/db/425423/True_Ventures>,
        <https://1145.am/db/425973/Will_Ventures>,
        <https://1145.am/db/426615/Sequoia_Capital>,
        <https://1145.am/db/429179/C5_Capital>,
        <https://1145.am/db/430986/Cortado_Ventures>,
        <https://1145.am/db/434334/1up_Ventures>,
        <https://1145.am/db/435691/Klick_Ventures>,
        <https://1145.am/db/439819/Cavu_Ventures>,
        <https://1145.am/db/441319/Celesta_Capital>,
        <https://1145.am/db/444105/Exfinity_Ventures>,
        <https://1145.am/db/445365/Revolution_Ventures>,
        <https://1145.am/db/446341/Sinewave_Ventures>,
        <https://1145.am/db/455558/Intudo_Ventures>,
        <https://1145.am/db/457435/Alerce>,
        <https://1145.am/db/457435/Clin>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/471253/Gv>,
        <https://1145.am/db/471436/Citi_Ventures>,
        <https://1145.am/db/471504/Canapi_Ventures>,
        <https://1145.am/db/473030/Highsage_Ventures>,
        <https://1145.am/db/474928/Susa_Ventures>,
        <https://1145.am/db/478049/Worldquant_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/479113/Menlo_Ventures>,
        <https://1145.am/db/485616/K3_Ventures>,
        <https://1145.am/db/486858/Gaingels>,
        <https://1145.am/db/486901/Gaingels>,
        <https://1145.am/db/488743/Salesforce_Ventures>,
        <https://1145.am/db/491130/Raiven_Capital>,
        <https://1145.am/db/491338/Raiven_Capital>,
        <https://1145.am/db/493560/Tyh_Ventures>,
        <https://1145.am/db/495912/Regah_Ventures>,
        <https://1145.am/db/506588/Trinity_Ventures>,
        <https://1145.am/db/508145/Sora_Finance>,
        <https://1145.am/db/508161/Sora_Finance>,
        <https://1145.am/db/510565/Epic_Ventures>,
        <https://1145.am/db/513305/Avid_Ventures>,
        <https://1145.am/db/513305/Canapi_Ventures>,
        <https://1145.am/db/513897/Rlc_Ventures>,
        <https://1145.am/db/514151/Rlc_Ventures>,
        <https://1145.am/db/516396/Acequia_Capital>,
        <https://1145.am/db/517213/Acequia_Capital>,
        <https://1145.am/db/523349/Osf_Ventures>,
        <https://1145.am/db/523776/Root_Ventures>,
        <https://1145.am/db/525285/Inventum_Ventures>,
        <https://1145.am/db/525285/Optima_Ventures>,
        <https://1145.am/db/526109/Ggv_Capital>,
        <https://1145.am/db/526175/Ridgeline_Ventures>,
        <https://1145.am/db/529812/Inventum_Ventures>,
        <https://1145.am/db/529812/Optima_Ventures>,
        <https://1145.am/db/532016/Id_Ventures>,
        <https://1145.am/db/539571/Origin_Ventures>,
        <https://1145.am/db/545843/Capital_One_Ventures>,
        <https://1145.am/db/545852/Boxone_Ventures>,
        <https://1145.am/db/545852/Panache_Ventures>,
        <https://1145.am/db/547770/BGV>,
        <https://1145.am/db/547944/BGV>,
        <https://1145.am/db/554552/Konvoy_Ventures>,
        <https://1145.am/db/555193/Illumina_Ventures>,
        <https://1145.am/db/555193/Technology_Venture_Partners>,
        <https://1145.am/db/556705/Congress_Ave_Ventures>,
        <https://1145.am/db/558005/Illumina_Ventures>,
        <https://1145.am/db/558005/Technology_Venture_Partners>,
        <https://1145.am/db/558877/Falabella_Ventures>,
        <https://1145.am/db/559220/Ulu_Ventures>,
        <https://1145.am/db/561662/Redpoint_Ventures>,
        <https://1145.am/db/561662/Vandelay_Ventures>,
        <https://1145.am/db/562745/Vinmar_Ventures>,
        <https://1145.am/db/563575/Celesta_Capital>,
        <https://1145.am/db/564008/D1_Ventures>,
        <https://1145.am/db/571769/Illumina_Ventures>,
        <https://1145.am/db/571769/M_Ventures>,
        <https://1145.am/db/572097/Menlo_Ventures>,
        <https://1145.am/db/572097/Teneleven_Ventures>,
        <https://1145.am/db/575249/TCV>,
        <https://1145.am/db/576186/Konvoy_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/586525/Tenoneten_Ventures>,
        <https://1145.am/db/587038/Coparion>,
        <https://1145.am/db/591566/Morningside_Ventures>,
        <https://1145.am/db/596145/Anorak_Ventures>,
        <https://1145.am/db/596564/Anorak_Ventures>,
        <https://1145.am/db/601455/Morningside_Ventures>,
        <https://1145.am/db/603725/Ignitexl_Ventures>,
        <https://1145.am/db/606074/Fiscus_Ventures>,
        <https://1145.am/db/606144/Ggv_Capital>,
        <https://1145.am/db/615337/Companyon_Ventures>,
        <https://1145.am/db/619284/Scf_Ventures>,
        <https://1145.am/db/619366/Capital_One_Ventures>,
        <https://1145.am/db/619736/Lightspeed_Ventures>,
        <https://1145.am/db/623178/Array_Ventures>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/626781/Dnx_Ventures>,
        <https://1145.am/db/627030/Launchpad_Capital>,
        <https://1145.am/db/628654/Prologis_Ventures>,
        <https://1145.am/db/633238/True_Ventures>,
        <https://1145.am/db/633869/Skywell_Capital_Partners>,
        <https://1145.am/db/633869/Stageone_Ventures>,
        <https://1145.am/db/640939/Ggv_Capital>,
        <https://1145.am/db/642123/Charles_River_Ventures>,
        <https://1145.am/db/642518/Network_Ventures>,
        <https://1145.am/db/643600/Vinco_Ventures>,
        <https://1145.am/db/648552/True_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/659675/Gv>,
        <https://1145.am/db/661747/Adit_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/665129/Ac_Ventures>,
        <https://1145.am/db/665776/Firstime_Ventures>,
        <https://1145.am/db/676217/Steelsky_Ventures>,
        <https://1145.am/db/676869/Ggv_Capital>,
        <https://1145.am/db/678140/Ggv_Capital>,
        <https://1145.am/db/678587/Lightshed_Ventures>,
        <https://1145.am/db/678593/Solana_Ventures>,
        <https://1145.am/db/687538/Kayyak_Ventures>,
        <https://1145.am/db/689460/True_Ventures>,
        <https://1145.am/db/694513/Authentic_Ventures>,
        <https://1145.am/db/694924/Avid_Ventures>,
        <https://1145.am/db/700171/Sequoia_Capital>,
        <https://1145.am/db/700327/Menlo_Ventures>,
        <https://1145.am/db/700877/Gaingels>,
        <https://1145.am/db/703983/Eqventure>,
        <https://1145.am/db/704489/Eqventure>,
        <https://1145.am/db/704753/Felicis_Ventures>,
        <https://1145.am/db/704753/Menlo_Ventures>,
        <https://1145.am/db/704793/Quidnet_Ventures>,
        <https://1145.am/db/704991/Gaingels>,
        <https://1145.am/db/709633/Connetic_Ventures>,
        <https://1145.am/db/726461/Contour_Ventures>,
        <https://1145.am/db/729628/Kyber_Ventures>,
        <https://1145.am/db/729628/Signum_Capital>,
        <https://1145.am/db/738920/Oca_Ventures>,
        <https://1145.am/db/738920/Susa_Ventures>,
        <https://1145.am/db/739538/Morpheus_Ventures>,
        <https://1145.am/db/739538/Oca_Ventures>,
        <https://1145.am/db/739538/Susa_Ventures>,
        <https://1145.am/db/747051/Tenoneten_Ventures>,
        <https://1145.am/db/747771/Ta_Ventures>,
        <https://1145.am/db/749147/1984_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/1984_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/750305/Yl_Ventures>,
        <https://1145.am/db/750725/Vestigo_Ventures>,
        <https://1145.am/db/751176/Maverick_Ventures>,
        <https://1145.am/db/751176/Susa_Ventures>,
        <https://1145.am/db/751387/Menlo_Ventures>,
        <https://1145.am/db/753120/Sequoia_Capital>,
        <https://1145.am/db/753251/Savantus_Ventures>,
        <https://1145.am/db/753913/Brunnur_Ventures>,
        <https://1145.am/db/755844/Sequoia_Capital>,
        <https://1145.am/db/758206/Great_North_Ventures>,
        <https://1145.am/db/758206/Grotech_Ventures>,
        <https://1145.am/db/759749/Cava_Capital>,
        <https://1145.am/db/763083/Gaingels>,
        <https://1145.am/db/764875/Rev1_Ventures>,
        <https://1145.am/db/764896/Rev1_Ventures>,
        <https://1145.am/db/765216/True_Ventures>,
        <https://1145.am/db/768172/Gaingels>,
        <https://1145.am/db/768172/Type_One_Ventures>,
        <https://1145.am/db/768349/Salesforce_Ventures>,
        <https://1145.am/db/768852/Felicis_Ventures>,
        <https://1145.am/db/769568/Axon_Ventures>,
        <https://1145.am/db/772099/Array_Ventures>,
        <https://1145.am/db/773235/Prelude_Ventures>,
        <https://1145.am/db/773684/Fulgur_Ventures>,
        <https://1145.am/db/773794/Array_Ventures>,
        <https://1145.am/db/778025/Felicis_Ventures>,
        <https://1145.am/db/778423/Sentiero_Ventures>,
        <https://1145.am/db/779637/Felicis_Ventures>,
        <https://1145.am/db/779867/Genesis_Block_Ventures>,
        <https://1145.am/db/780272/East_Ventures>,
        <https://1145.am/db/780289/East_Ventures>,
        <https://1145.am/db/783431/Cathay_Venture_Inc>,
        <https://1145.am/db/784093/Boldstart_Ventures>,
        <https://1145.am/db/787806/Boldstart_Ventures>,
        <https://1145.am/db/788016/Boldstart_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796250/Sp_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/797597/Lansdowne_Partners>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/798753/Sofinnova_Partners>,
        <https://1145.am/db/800093/Sequoia_Capital>,
        <https://1145.am/db/800101/Gaingels>,
        <https://1145.am/db/803541/Credo_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/803541/Sequoia_Capital>,
        <https://1145.am/db/8045/Greatpoint_Ventures>,
        <https://1145.am/db/806828/Promus_Ventures>,
        <https://1145.am/db/806994/Companyon_Ventures>,
        <https://1145.am/db/807080/K3_Ventures>,
        <https://1145.am/db/808020/Starlight_Ventures>,
        <https://1145.am/db/808020/Valo_Ventures>,
        <https://1145.am/db/8146/Rev1_Ventures>,
        <https://1145.am/db/817162/Orbia_Ventures>,
        <https://1145.am/db/818444/1984_Ventures>,
        <https://1145.am/db/821135/Se_Ventures>,
        <https://1145.am/db/823763/Infinity_Ventures>,
        <https://1145.am/db/828716/Idc_Ventures>,
        <https://1145.am/db/829118/Salesforce_Ventures>,
        <https://1145.am/db/830571/Company_Ventures>,
        <https://1145.am/db/830689/Soleus_Capital>,
        <https://1145.am/db/832264/Salesforce_Ventures>,
        <https://1145.am/db/832573/Solasta_Ventures>,
        <https://1145.am/db/834864/Ggv_Capital>,
        <https://1145.am/db/834864/K3_Ventures>,
        <https://1145.am/db/836848/Technexus_Venture_Collaborative>,
        <https://1145.am/db/836908/Frontier_Ventures>,
        <https://1145.am/db/837034/Redpoint_Ventures>,
        <https://1145.am/db/838138/Root_Ventures>,
        <https://1145.am/db/838181/Sequoia_Capital>,
        <https://1145.am/db/838691/Crosslink_Capital>,
        <https://1145.am/db/847157/Signum_Capital>,
        <https://1145.am/db/847862/Wise_Ventures>,
        <https://1145.am/db/854001/Gv>,
        <https://1145.am/db/854589/Verance_Capital>,
        <https://1145.am/db/854654/Mrtnz_Ventures>,
        <https://1145.am/db/854795/Menlo_Ventures>,
        <https://1145.am/db/867865/Applied_Ventures>,
        <https://1145.am/db/868093/Cobro_Ventures>,
        <https://1145.am/db/869652/Forever_Ventures>,
        <https://1145.am/db/874394/Nextview_Ventures>,
        <https://1145.am/db/874394/True_Ventures>,
        <https://1145.am/db/880050/Crosslink_Capital>,
        <https://1145.am/db/881298/At_One_Ventures>,
        <https://1145.am/db/882723/At_One_Ventures>,
        <https://1145.am/db/884787/Foresite_Capital>,
        <https://1145.am/db/884787/Gv>,
        <https://1145.am/db/884787/Northpond_Ventures>,
        <https://1145.am/db/886445/Gv>,
        <https://1145.am/db/887062/Panoramic_Ventures>,
        <https://1145.am/db/889246/At_One_Ventures>,
        <https://1145.am/db/890271/Panoramic_Ventures>,
        <https://1145.am/db/891162/Emergingvc>,
        <https://1145.am/db/891162/Launchpad_Venture_Group>,
        <https://1145.am/db/903689/Vectr_Ventures>,
        <https://1145.am/db/904276/Nextview_Ventures>,
        <https://1145.am/db/906393/East_Ventures>,
        <https://1145.am/db/907844/Argon_Ventures>,
        <https://1145.am/db/907844/Glasswing_Ventures>,
        <https://1145.am/db/913422/Sequoia_Capital>,
        <https://1145.am/db/913678/Sandbridge_Capital>,
        <https://1145.am/db/919636/Menlo_Ventures>,
        <https://1145.am/db/921704/Scop_Ventures>,
        <https://1145.am/db/92200/Knoll_Ventures>,
        <https://1145.am/db/922066/Irrvrnt_Vc>,
        <https://1145.am/db/922192/Gv>,
        <https://1145.am/db/922498/Sozo_Ventures>,
        <https://1145.am/db/923723/Scop_Ventures>,
        <https://1145.am/db/928711/Frontline_Ventures>,
        <https://1145.am/db/934946/Ggv_Capital>,
        <https://1145.am/db/935046/Origin_Ventures>,
        <https://1145.am/db/935249/Victress_Capital>,
        <https://1145.am/db/935322/Alpana_Ventures>,
        <https://1145.am/db/935322/M_Ventures>,
        <https://1145.am/db/935796/Salesforce_Ventures>,
        <https://1145.am/db/935962/Digitalbridge_Ventures>,
        <https://1145.am/db/936045/Lpc_Ventures>,
        <https://1145.am/db/936057/Noemis_Ventures>,
        <https://1145.am/db/936154/Salesforce_Ventures>,
        <https://1145.am/db/936448/Ggv_Capital>,
        <https://1145.am/db/936862/Lool_Ventures>,
        <https://1145.am/db/936906/Neotribe_Ventures>,
        <https://1145.am/db/937210/Citi_Ventures>,
        <https://1145.am/db/937210/Firebolt_Ventures>,
        <https://1145.am/db/937460/Sequoia_Capital>,
        <https://1145.am/db/938108/Conti_Ventures>,
        <https://1145.am/db/938555/Digitalbridge_Ventures>,
        <https://1145.am/db/938586/Venturesouth>,
        <https://1145.am/db/938921/Redpoint_Ventures>,
        <https://1145.am/db/938975/Ggv_Capital>,
        <https://1145.am/db/939163/Goodyear_Ventures>,
        <https://1145.am/db/940740/Agnc_Ventures>,
        <https://1145.am/db/940913/True_Ventures>,
        <https://1145.am/db/941816/Radical_Ventures>,
        <https://1145.am/db/942825/Argon_Ventures>,
        <https://1145.am/db/946710/Citi_Ventures>,
        <https://1145.am/db/947238/Kyros_Ventures>,
        <https://1145.am/db/952434/Verissimo_Ventures>,
        <https://1145.am/db/955201/Gv>,
        <https://1145.am/db/960022/Verance_Capital>,
        <https://1145.am/db/961837/Sequoia_Capital>,
        <https://1145.am/db/962622/Sequoia_Capital>,
        <https://1145.am/db/970950/Ulu_Ventures>,
        <https://1145.am/db/971415/Altai_Ventures>,
        <https://1145.am/db/971450/Allon_Ventures>,
        <https://1145.am/db/971939/Formic_Ventures>,
        <https://1145.am/db/975114/Formic_Ventures>,
        <https://1145.am/db/979753/Menlo_Ventures>,
        <https://1145.am/db/980678/Menlo_Ventures>,
        <https://1145.am/db/984645/Vinco_Ventures>,
        <https://1145.am/db/987688/Brightspark_Ventures>,
        <https://1145.am/db/987700/Infinityvc>,
        <https://1145.am/db/988084/Abstract_Ventures>,
        <https://1145.am/db/988084/Blank_Ventures>,
        <https://1145.am/db/988318/Arthur_Ventures>,
        <https://1145.am/db/988482/Brightspark_Ventures>,
        <https://1145.am/db/988979/Infinityvc>,
        <https://1145.am/db/989392/Arthur_Ventures>,
        <https://1145.am/db/990085/Radical_Ventures>,
        <https://1145.am/db/995593/Raiven_Capital>,
        <https://1145.am/db/995737/Nuoyan_Capital>,
        <https://1145.am/db/996563/Raiven_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2301824/Ventures_West_Capital>,
        <https://1145.am/db/2321851/Ventures_West_Capital>,
        <https://1145.am/db/2355936/Ventures_West_Capital>,
        <https://1145.am/db/2355938/Ventures_West_Capital>,
        <https://1145.am/db/2364457/Ventures_West_Capital>,
        <https://1145.am/db/2364458/Ventures_West_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346988/Flybridge_Capital_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "Flybridge Capital Partners" ;
    ns1:investor <https://1145.am/db/2346988/Investment_Flagship_Ventures_Flybridge_Capital_Partners_Polaris_Partners_Taris_Third_Rock_Ventures_Completed> ;
    ns1:name "Flybridge Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/166572/Flybridge>,
        <https://1145.am/db/1740945/Fly_Ventures>,
        <https://1145.am/db/1825300/Flybridge>,
        <https://1145.am/db/1840032/Flybridge_Capital_Partners>,
        <https://1145.am/db/1858690/Flybridge_Capital_Partners>,
        <https://1145.am/db/1860868/Flybridge_Capital_Partners>,
        <https://1145.am/db/1862549/Flybridge_Capital_Partners>,
        <https://1145.am/db/709163/Flyover_Capital>,
        <https://1145.am/db/710955/Flyover_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1072477/Flybridge_Capital_Partners>,
        <https://1145.am/db/1371739/Flybridge_Capital_Partners>,
        <https://1145.am/db/1747059/Flybridge_Capital_Partners>,
        <https://1145.am/db/1761511/Flybridge_Capital_Partners>,
        <https://1145.am/db/1802088/Flybridge_Capital_Partners>,
        <https://1145.am/db/1828416/Flybridge_Capital_Partners>,
        <https://1145.am/db/1828974/Flybridge_Capital_Partners>,
        <https://1145.am/db/1847883/Flybridge_Capital_Partners>,
        <https://1145.am/db/1850391/Flybridge_Capital_Partners>,
        <https://1145.am/db/1863185/Flybridge_Capital_Partners>,
        <https://1145.am/db/1866404/Flybridge_Capital_Partners>,
        <https://1145.am/db/1875909/Flybridge_Capital_Partners>,
        <https://1145.am/db/1885336/Flybridge_Capital_Partners>,
        <https://1145.am/db/2207324/Flybridge_Capital_Partners>,
        <https://1145.am/db/2239029/Flybridge_Capital_Partners>,
        <https://1145.am/db/2249658/Flybridge_Capital_Partners>,
        <https://1145.am/db/2291818/Flybridge_Capital_Partners>,
        <https://1145.am/db/2292800/Flybridge_Capital_Partners>,
        <https://1145.am/db/2300340/Flybridge_Capital_Partners>,
        <https://1145.am/db/2342084/Flybridge_Capital_Partners>,
        <https://1145.am/db/2358378/Flybridge_Capital_Partners>,
        <https://1145.am/db/2364422/Flybridge_Capital_Partners>,
        <https://1145.am/db/955858/Flybridge_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346988/Third_Rock_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2346988/Investment_Flagship_Ventures_Flybridge_Capital_Partners_Polaris_Partners_Taris_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/1782938/Third_Kind_Venture_Capital>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348030/French_Agency_For_Innovation> a org:Organization ;
    ns1:basedInLowRaw "French" ;
    ns1:description "granting financial support" ;
    ns1:documentDate "2013-04-09T11:46:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "THERADIAG granted 1.2 million euros by OSEOas part of the collaborative project CaReNA" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/theradiag-granted-1-2-million-euros-by-oseoas-part-of-collaborative-project-carena> ;
    ns1:foundName "Oso" ;
    ns1:investor <https://1145.am/db/2348030/Investment_French_Agency_For_Innovation_Theradiag_Theradiag_Completed> ;
    ns1:name "French Agency for Innovation" ;
    ns1:sameAsHigh <https://1145.am/db/2324335/French_Agency_For_Industrial_Innovation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348055/Bergamo_Acquisition_Corp> a org:Organization ;
    ns1:basedInLowRaw "European" ;
    ns1:description "investment banking fees",
        "investment holding company" ;
    ns1:documentDate "2013-04-10T15:17:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VistaGen Announces $36 Million Strategic Financing Agreement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vistagen-announces-36-million-strategic-financing-agreement> ;
    ns1:foundName "Bergamo",
        "Bergamo Acquisition Corp",
        "Bergamo'" ;
    ns1:investor <https://1145.am/db/2348055/Investment_Bergamo_Acquisition_Corp_Vistagen_Therapeutics_Has_Not_Happened> ;
    ns1:name "Bergamo",
        "Bergamo Acquisition Corp" ;
    ns1:participant <https://1145.am/db/2348055/Investment_Bergamo_Acquisition_Corp_Vistagen_Therapeutics_Has_Not_Happened> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348066/Alexandria_Real_Estate_Equities> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "real estate" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "Alexandria Real Estate Equities",
        "Alexandria Real Estate Equities, Inc" ;
    ns1:investor <https://1145.am/db/2348066/Investment_Alexandria_Real_Estate_Equities_Cydan_New_Enterprise_Associates_Pfizer_Venture_Investments_Completed> ;
    ns1:name "Alexandria Real Estate Equities" ;
    ns1:sameAsHigh <https://1145.am/db/2325257/Alexandria_Real_Estate>,
        <https://1145.am/db/2344926/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2347469/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2351302/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2360559/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/737053/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/737766/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/766800/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/805220/Alexandria_Real_Estate_Equities> ;
    ns1:sameAsMedium <https://1145.am/db/2152070/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2319822/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/2324289/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/2331763/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2331909/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2345223/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2345769/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/2368428/Alexandria_Real_Estate_Equities>,
        <https://1145.am/db/743238/Alexandria_Real_Estate_Equities_Inc>,
        <https://1145.am/db/931821/Alexandria_Real_Estate_Equities> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348066/Nea> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, Mass." ;
    ns1:description "investing" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "NEA" ;
    ns1:investor <https://1145.am/db/2348066/Investment_Alexandria_Real_Estate_Equities_Cydan_New_Enterprise_Associates_Pfizer_Venture_Investments_Completed> ;
    ns1:name "NEA" ;
    ns1:sameAsHigh <https://1145.am/db/1137051/Nea>,
        <https://1145.am/db/129908/Nea>,
        <https://1145.am/db/1445426/Nea>,
        <https://1145.am/db/1503651/Negma>,
        <https://1145.am/db/1699512/Nea>,
        <https://1145.am/db/1747054/Nea>,
        <https://1145.am/db/1773703/Nea>,
        <https://1145.am/db/1790986/Nea>,
        <https://1145.am/db/1817209/Nea>,
        <https://1145.am/db/1823612/Nea>,
        <https://1145.am/db/1830084/Nea>,
        <https://1145.am/db/1830819/Nea>,
        <https://1145.am/db/1848523/Nea>,
        <https://1145.am/db/1945485/Nea>,
        <https://1145.am/db/1960888/Nea>,
        <https://1145.am/db/2337972/Nea>,
        <https://1145.am/db/526175/Nea>,
        <https://1145.am/db/591538/Nea>,
        <https://1145.am/db/641613/Nea>,
        <https://1145.am/db/700388/Nea> ;
    ns1:sameAsMedium <https://1145.am/db/1131171/Nea>,
        <https://1145.am/db/1166550/Nea>,
        <https://1145.am/db/1169121/Nea>,
        <https://1145.am/db/1174277/Nea>,
        <https://1145.am/db/1174670/Nea>,
        <https://1145.am/db/1338464/Nea>,
        <https://1145.am/db/1362581/Nea>,
        <https://1145.am/db/1442931/Nea>,
        <https://1145.am/db/1533327/Nea>,
        <https://1145.am/db/1533685/Nea>,
        <https://1145.am/db/1578326/Nea>,
        <https://1145.am/db/1694450/Nea>,
        <https://1145.am/db/1696426/Nea>,
        <https://1145.am/db/1704817/Nea>,
        <https://1145.am/db/1708920/Nea>,
        <https://1145.am/db/1709685/Nea>,
        <https://1145.am/db/1716622/Nea>,
        <https://1145.am/db/1722914/Nea>,
        <https://1145.am/db/1734259/Nea>,
        <https://1145.am/db/1735722/Nea>,
        <https://1145.am/db/1737425/Nea>,
        <https://1145.am/db/1741791/Nea>,
        <https://1145.am/db/1741884/Nea>,
        <https://1145.am/db/1741929/Nea>,
        <https://1145.am/db/1742516/Nea>,
        <https://1145.am/db/1744029/Nea>,
        <https://1145.am/db/1744900/Nea>,
        <https://1145.am/db/1746577/Nea>,
        <https://1145.am/db/1751877/Nea>,
        <https://1145.am/db/1752390/Nea>,
        <https://1145.am/db/1756163/Nea>,
        <https://1145.am/db/1761276/Nea>,
        <https://1145.am/db/1761402/Nea>,
        <https://1145.am/db/1767301/Nea>,
        <https://1145.am/db/1770553/Nea>,
        <https://1145.am/db/1770931/Nea>,
        <https://1145.am/db/1774939/Nea>,
        <https://1145.am/db/1775434/Nea>,
        <https://1145.am/db/1776201/Nea>,
        <https://1145.am/db/1776613/Nea>,
        <https://1145.am/db/1776646/Nea>,
        <https://1145.am/db/1777232/Nea>,
        <https://1145.am/db/1778132/Nea>,
        <https://1145.am/db/1788267/Nea>,
        <https://1145.am/db/1791640/Nea>,
        <https://1145.am/db/1791780/Nea>,
        <https://1145.am/db/1792401/Nea>,
        <https://1145.am/db/1795013/Nea>,
        <https://1145.am/db/1799888/Nea>,
        <https://1145.am/db/1801287/Nea>,
        <https://1145.am/db/1801621/Nea>,
        <https://1145.am/db/1801792/Nea>,
        <https://1145.am/db/1803774/Nea>,
        <https://1145.am/db/1804152/Nea>,
        <https://1145.am/db/1805468/Nea>,
        <https://1145.am/db/1807968/Nea>,
        <https://1145.am/db/1808099/Nea>,
        <https://1145.am/db/1809161/Nea>,
        <https://1145.am/db/1809853/Nea>,
        <https://1145.am/db/1811740/Nea>,
        <https://1145.am/db/1816840/Nea>,
        <https://1145.am/db/1819956/Nea>,
        <https://1145.am/db/1824137/Nea>,
        <https://1145.am/db/1827025/Nea>,
        <https://1145.am/db/1828441/Nea>,
        <https://1145.am/db/1833265/Nea>,
        <https://1145.am/db/1833278/Nea>,
        <https://1145.am/db/1833814/Nea>,
        <https://1145.am/db/1835007/Nea>,
        <https://1145.am/db/1835740/Nea>,
        <https://1145.am/db/1836989/Nea>,
        <https://1145.am/db/1840478/Nea>,
        <https://1145.am/db/1843003/Nea>,
        <https://1145.am/db/1849606/Nea>,
        <https://1145.am/db/1849884/Nea>,
        <https://1145.am/db/1850271/Nea>,
        <https://1145.am/db/1850352/Nea>,
        <https://1145.am/db/1851595/Nea>,
        <https://1145.am/db/1854587/Nea>,
        <https://1145.am/db/1856900/Nea>,
        <https://1145.am/db/1867420/Nea>,
        <https://1145.am/db/1870426/Nea>,
        <https://1145.am/db/1875184/Nea>,
        <https://1145.am/db/1876063/Nea>,
        <https://1145.am/db/1877241/Nea>,
        <https://1145.am/db/1895232/Nea>,
        <https://1145.am/db/1896326/Nea>,
        <https://1145.am/db/2009539/Nea>,
        <https://1145.am/db/2062003/Nea>,
        <https://1145.am/db/2133555/Nea>,
        <https://1145.am/db/214119/Nea>,
        <https://1145.am/db/2196875/Nea>,
        <https://1145.am/db/2298510/Nea>,
        <https://1145.am/db/2303548/Nea>,
        <https://1145.am/db/2303560/Nea>,
        <https://1145.am/db/2323138/Nea>,
        <https://1145.am/db/2331700/Nea>,
        <https://1145.am/db/2336634/Nea>,
        <https://1145.am/db/2348967/Nea>,
        <https://1145.am/db/2687902/Nea>,
        <https://1145.am/db/396154/Nea>,
        <https://1145.am/db/415557/Nea>,
        <https://1145.am/db/417606/Nea>,
        <https://1145.am/db/474783/Nea>,
        <https://1145.am/db/488687/Nea>,
        <https://1145.am/db/606235/Nea>,
        <https://1145.am/db/644429/Nea>,
        <https://1145.am/db/765986/Nea>,
        <https://1145.am/db/887690/Nea>,
        <https://1145.am/db/909436/Nea>,
        <https://1145.am/db/947292/Nea>,
        <https://1145.am/db/960286/Nea>,
        <https://1145.am/db/971811/Nea>,
        <https://1145.am/db/973579/Nea>,
        <https://1145.am/db/993478/Nea> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348074/Arch_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "MA" ;
    ns1:documentDate "2013-04-11T15:17:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Syros Pharmaceuticals Launches with $30 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/syros-pharmaceuticals-launches-30-million-series-a-financing> ;
    ns1:foundName "ARCH Venture Partners" ;
    ns1:investor <https://1145.am/db/2348074/Series_A_Investment_Arch_Venture_Partners_Flagship_Ventures_Syros_Pharmaceuticals_Completed> ;
    ns1:name "ARCH Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1042080/Arch_Venture_Partners>,
        <https://1145.am/db/1105790/Arch_Venture_Partners>,
        <https://1145.am/db/1108240/Arch_Venture_Partners>,
        <https://1145.am/db/1320499/Arch_Venture_Partners>,
        <https://1145.am/db/1334395/Arch_Venture_Partners>,
        <https://1145.am/db/1376077/Arch_Venture_Partners>,
        <https://1145.am/db/1406211/Arch_Venture_Partners>,
        <https://1145.am/db/1476658/Arch_Venture_Partners>,
        <https://1145.am/db/1519613/Arch_Venture_Partners>,
        <https://1145.am/db/1519799/Arch_Venture_Partners>,
        <https://1145.am/db/1553175/Arch_Venture_Partners>,
        <https://1145.am/db/1553459/Arch_Venture_Partners>,
        <https://1145.am/db/1582111/Arch_Venture_Partners>,
        <https://1145.am/db/1619794/Arch_Venture_Partners>,
        <https://1145.am/db/1663313/Arch_Venture_Partners>,
        <https://1145.am/db/1750401/Arch_Venture_Partners>,
        <https://1145.am/db/1791220/Arch_Venture_Partners>,
        <https://1145.am/db/1799828/Arch_Venture_Partners>,
        <https://1145.am/db/1928208/Arch_Venture_Partners>,
        <https://1145.am/db/1984721/Arch_Venture_Partners>,
        <https://1145.am/db/2095032/Arch_Venture_Partners>,
        <https://1145.am/db/2151983/Arch_Venture_Partners>,
        <https://1145.am/db/2181184/Arch_Venture_Partners>,
        <https://1145.am/db/2280315/Arch_Venture_Partners>,
        <https://1145.am/db/2281905/Arch_Venture_Partners>,
        <https://1145.am/db/2282162/Arch_Venture_Partners>,
        <https://1145.am/db/2284585/Arch_Venture_Partners>,
        <https://1145.am/db/2292675/Arch_Venture_Partners>,
        <https://1145.am/db/2294815/Arch_Venture_Partners>,
        <https://1145.am/db/2296113/Arch_Venture_Partners>,
        <https://1145.am/db/2301122/Arch_Venture_Partners>,
        <https://1145.am/db/2302047/Arch_Venture_Partners>,
        <https://1145.am/db/2305524/Arch_Venture_Partners>,
        <https://1145.am/db/2306529/Arch_Venture_Partners>,
        <https://1145.am/db/2315446/Arch_Venture_Partners>,
        <https://1145.am/db/2328599/Arch_Venture_Partners>,
        <https://1145.am/db/2330075/Arch_Venture_Partners>,
        <https://1145.am/db/2330712/Arch_Venture_Partners>,
        <https://1145.am/db/2330852/Arch_Venture_Partners>,
        <https://1145.am/db/2331754/Arch_Venture_Partners>,
        <https://1145.am/db/2331868/Arch_Venture_Partners>,
        <https://1145.am/db/2335701/Arch_Venture_Partners>,
        <https://1145.am/db/2335714/Arch_Venture_Partners>,
        <https://1145.am/db/2335773/Arch_Venture_Partners>,
        <https://1145.am/db/2336126/Arch_Venture_Partners>,
        <https://1145.am/db/2337140/Arch_Venture_Partners>,
        <https://1145.am/db/2339413/Arch_Venture_Partners>,
        <https://1145.am/db/2340344/Arch_Venture_Partners>,
        <https://1145.am/db/2340345/Arch_Venture_Partners>,
        <https://1145.am/db/2340348/Arch_Venture_Partners>,
        <https://1145.am/db/2341599/Arch_Venture_Partners>,
        <https://1145.am/db/2345223/Arch_Venture_Partners>,
        <https://1145.am/db/2345769/Arch_Venture_Partners>,
        <https://1145.am/db/2347368/Arch_Venture_Partners>,
        <https://1145.am/db/2347469/Arch_Venture_Partners>,
        <https://1145.am/db/2356066/Arch_Venture_Partners>,
        <https://1145.am/db/2357253/Arch_Venture_Partners>,
        <https://1145.am/db/2357256/Arch_Venture_Partners>,
        <https://1145.am/db/2358725/Arch_Venture_Partners>,
        <https://1145.am/db/2359124/Arch_Venture_Partners>,
        <https://1145.am/db/2359447/Arch_Venture_Partners>,
        <https://1145.am/db/2359655/Arch_Venture_Partners>,
        <https://1145.am/db/2364332/Arch_Venture_Partners>,
        <https://1145.am/db/2364336/Arch_Venture_Partners>,
        <https://1145.am/db/2366536/Arch_Venture_Partners>,
        <https://1145.am/db/2366539/Arch_Venture_Partners>,
        <https://1145.am/db/2366654/Arch_Venture_Partners>,
        <https://1145.am/db/2368912/Arch_Venture_Partners>,
        <https://1145.am/db/2369000/Arch_Venture_Partners>,
        <https://1145.am/db/2369549/Arch_Venture_Partners>,
        <https://1145.am/db/2371167/Arch_Venture_Partners>,
        <https://1145.am/db/2592611/Arch_Venture_Partners>,
        <https://1145.am/db/430986/Arch_Venture_Partners>,
        <https://1145.am/db/531806/Arch_Venture_Partners>,
        <https://1145.am/db/769568/Arch_Venture_Partners>,
        <https://1145.am/db/847865/Arch_Venture_Partners>,
        <https://1145.am/db/900779/Arch_Venture_Partners>,
        <https://1145.am/db/900943/Arch_Venture_Partners>,
        <https://1145.am/db/922192/Arch_Venture_Partners>,
        <https://1145.am/db/944358/Arch_Venture_Partners>,
        <https://1145.am/db/979509/Arch_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350097/Cet_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "Seattle" ;
    ns1:documentDate "2013-04-17T15:49:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BEAT BioTherapeutics Corporation Closes $2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/beat-biotherapeutics-corporation-closes-2-5mm-seed-financing-to-develop-its-gene-therapy> ;
    ns1:foundName "CET Capital Partners" ;
    ns1:investor <https://1145.am/db/2350097/Seed_Stage_Investment_Beat_Biotherapeutics_Corporation_Cet_Capital_Partners_Seattle_W_Fund_Completed> ;
    ns1:name "CET Capital Partners" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350097/W_Fund> a org:Organization ;
    ns1:basedInLowRaw "Seattle" ;
    ns1:documentDate "2013-04-17T15:49:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BEAT BioTherapeutics Corporation Closes $2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/beat-biotherapeutics-corporation-closes-2-5mm-seed-financing-to-develop-its-gene-therapy> ;
    ns1:foundName "the W Fund" ;
    ns1:investor <https://1145.am/db/2350097/Seed_Stage_Investment_Beat_Biotherapeutics_Corporation_Cet_Capital_Partners_Seattle_W_Fund_Completed> ;
    ns1:name "W Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2287843/W_Fund>,
        <https://1145.am/db/538403/W_Fund>,
        <https://1145.am/db/542875/W_Fund>,
        <https://1145.am/db/543432/W_Fund>,
        <https://1145.am/db/674484/W_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351184/Opko_Health> a org:Organization ;
    ns1:basedInHighGeoName "Miami" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4164138/about.rdf> ;
    ns1:basedInHighRaw "MIAMI" ;
    ns1:buyer <https://1145.am/db/2351184/Prolor_Biotech_Acquisition> ;
    ns1:description "developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins" ;
    ns1:documentDate "2013-04-24T12:56:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OPKO Health To Acquire PROLOR Biotech" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opko-health-to-acquire-prolor-biotech> ;
    ns1:foundName "OPKO",
        "OPKO Health, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "OPKO Health" ;
    ns1:sameAsHigh <https://1145.am/db/1042168/Opko_Health>,
        <https://1145.am/db/1520070/Opna_Bio>,
        <https://1145.am/db/2300237/Opko_Health>,
        <https://1145.am/db/2303326/Opko_Health>,
        <https://1145.am/db/2308778/Opko>,
        <https://1145.am/db/2312501/Opko_Health>,
        <https://1145.am/db/2319365/Opko_Health>,
        <https://1145.am/db/2319368/Opko_Health>,
        <https://1145.am/db/2328509/Opko_Health>,
        <https://1145.am/db/2341100/Opko_Health>,
        <https://1145.am/db/2342385/Opko_Health>,
        <https://1145.am/db/2350564/Opko_Health>,
        <https://1145.am/db/2351183/Opko_Health>,
        <https://1145.am/db/2538211/Opko_Health>,
        <https://1145.am/db/2543138/Opko_Health>,
        <https://1145.am/db/2564042/Opko_Health>,
        <https://1145.am/db/2587996/Opko_Health> ;
    ns1:sameAsMedium <https://1145.am/db/1283748/Opko_Health>,
        <https://1145.am/db/2294238/Opko_Health>,
        <https://1145.am/db/2318305/Opko_Health>,
        <https://1145.am/db/2321707/Opko_Health>,
        <https://1145.am/db/2340036/Opko_Health>,
        <https://1145.am/db/2342345/Opko_Health>,
        <https://1145.am/db/2361481/Opko_Health>,
        <https://1145.am/db/2592678/Opko_Health>,
        <https://1145.am/db/611905/Opko_Health>,
        <https://1145.am/db/613011/Opko_Health>,
        <https://1145.am/db/613838/Opko_Health> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352162/Bvf_Partners_Lp> a org:Organization ;
    ns1:basedInLowRaw "USA" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2013-04-25T11:56:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/acumen-pharmaceuticals-inc-announces-first-close-of-series-a-financing> ;
    ns1:foundName "BVF Partners L.P." ;
    ns1:industry "life sciences" ;
    ns1:investor <https://1145.am/db/2352162/Series_A_Investment_Acumen_Pharmaceuticals_Inc_Bvf_Partners_Lp_Completed> ;
    ns1:name "BVF Partners L.P." ;
    ns1:sameAsHigh <https://1145.am/db/2075754/Bvf_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1293978/Bvf_Partners_Lp>,
        <https://1145.am/db/1294718/Bvf_Partners_Lp>,
        <https://1145.am/db/1334624/Bvf_Partners_Lp>,
        <https://1145.am/db/1352333/Bvf_Partners_Lp>,
        <https://1145.am/db/1387524/Bvf_Partners_Lp>,
        <https://1145.am/db/1581637/Bvf_Partners_Lp>,
        <https://1145.am/db/1623159/Bvf_Partners_Lp>,
        <https://1145.am/db/2153860/Bvf_Partners>,
        <https://1145.am/db/2280707/Bvf_Partners>,
        <https://1145.am/db/2291277/Bvf_Partners_Lp>,
        <https://1145.am/db/2368333/Bvf_Partners_Lp>,
        <https://1145.am/db/474852/Bvf_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Arboretum_Ventures> a org:Organization ;
    ns1:description "investing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Arboretum Ventures" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Arboretum Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1464210/Arboretum_Ventures>,
        <https://1145.am/db/2281033/Arboretum_Ventures>,
        <https://1145.am/db/2283394/Arboretum_Ventures>,
        <https://1145.am/db/2300316/Arboretum_Ventures>,
        <https://1145.am/db/2303767/Arboretum_Ventures>,
        <https://1145.am/db/475825/Arboretum_Ventures>,
        <https://1145.am/db/580008/Arboretum_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1465033/Arboretum_Ventures>,
        <https://1145.am/db/1580071/Arboretum_Ventures>,
        <https://1145.am/db/1618952/Arboretum_Ventures>,
        <https://1145.am/db/1619685/Arboretum_Ventures>,
        <https://1145.am/db/2286665/Arboretum_Ventures>,
        <https://1145.am/db/2297479/Arboretum_Ventures>,
        <https://1145.am/db/2306790/Arboretum_Ventures>,
        <https://1145.am/db/2317222/Arboretum_Ventures>,
        <https://1145.am/db/2323825/Arboretum_Ventures>,
        <https://1145.am/db/2352167/Arboretum_Ventures>,
        <https://1145.am/db/2367381/Arboretum_Ventures>,
        <https://1145.am/db/474783/Arboretum_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Asset_Management> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Asset Management" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Asset Management" ;
    ns1:sameAsHigh <https://1145.am/db/1028744/Sectoral_Asset_Management>,
        <https://1145.am/db/1029882/Sectoral_Asset_Management>,
        <https://1145.am/db/1086595/Focus_Asset_Management>,
        <https://1145.am/db/1086595/Welcome_Asset_Management>,
        <https://1145.am/db/1089254/Focus_Asset_Management>,
        <https://1145.am/db/1089254/Welcome_Asset_Management>,
        <https://1145.am/db/1133405/Fengate_Asset_Management>,
        <https://1145.am/db/1134471/Fengate_Asset_Management>,
        <https://1145.am/db/1579810/Concord_Asset_Management>,
        <https://1145.am/db/1613904/Sectoral_Asset_Management>,
        <https://1145.am/db/1615580/Sectoral_Asset_Management>,
        <https://1145.am/db/1665536/Sectoral_Asset_Management>,
        <https://1145.am/db/1673121/Crescendo_Asset_Management_Llc>,
        <https://1145.am/db/1928388/Sectoral_Asset_Management>,
        <https://1145.am/db/1960684/Assured_Investment_Management_Llc>,
        <https://1145.am/db/2011094/Sectoral_Asset_Management>,
        <https://1145.am/db/2304587/Asset_Management_Company>,
        <https://1145.am/db/2319433/Sectoral_Asset_Management>,
        <https://1145.am/db/2338236/Asset_Management_Company>,
        <https://1145.am/db/474864/Capital_Investment___Asset_Management_Group>,
        <https://1145.am/db/530828/Muus_Asset_Management>,
        <https://1145.am/db/556149/Ds_Asset_Management>,
        <https://1145.am/db/613133/Asset_Value_Investors>,
        <https://1145.am/db/648565/Futuregrowth_Asset_Management>,
        <https://1145.am/db/648707/Futuregrowth_Asset_Management>,
        <https://1145.am/db/683988/Infinitum_Asset_Management>,
        <https://1145.am/db/838323/Sectoral_Asset_Management> ;
    ns1:sameAsMedium <https://1145.am/db/2306281/Asset_Management_Company>,
        <https://1145.am/db/2327227/Asset_Management_Company>,
        <https://1145.am/db/2330920/Asset_Management>,
        <https://1145.am/db/2338237/Asset_Management_Company>,
        <https://1145.am/db/2352167/Asset_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Longitude_Capital> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Longitude Capital" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Longitude Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1503165/Longitude_Capital>,
        <https://1145.am/db/1519688/Longitude_Capital>,
        <https://1145.am/db/1520070/Longitude_Capital>,
        <https://1145.am/db/2288251/Longitude_Capital>,
        <https://1145.am/db/2305615/Longitude_Venture_Partners>,
        <https://1145.am/db/2305625/Longitude_Venture_Partners>,
        <https://1145.am/db/2323797/Longitude_Venture_Partners_Iii>,
        <https://1145.am/db/2339214/Longitude_Capital>,
        <https://1145.am/db/2339223/Longitude_Capital>,
        <https://1145.am/db/2351129/Longitude_Capital>,
        <https://1145.am/db/2365501/Longitude_Capital>,
        <https://1145.am/db/2583466/Longitude_Capital>,
        <https://1145.am/db/955355/Longitude_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1467975/Longitude_Capital>,
        <https://1145.am/db/1482048/Longitude_Capital>,
        <https://1145.am/db/2075754/Longitude_Capital>,
        <https://1145.am/db/2152399/Longitude_Capital>,
        <https://1145.am/db/2155668/Longitude_Capital>,
        <https://1145.am/db/2182698/Longitude_Capital>,
        <https://1145.am/db/2198647/Longitude_Capital>,
        <https://1145.am/db/2290453/Longitude_Capital>,
        <https://1145.am/db/2297930/Longitude_Capital>,
        <https://1145.am/db/2298634/Longitude_Capital>,
        <https://1145.am/db/2300708/Longitude_Capital>,
        <https://1145.am/db/2330799/Longitude_Capital>,
        <https://1145.am/db/2337591/Longitude_Capital>,
        <https://1145.am/db/2338428/Longitude_Capital>,
        <https://1145.am/db/2340204/Longitude_Capital>,
        <https://1145.am/db/2340207/Longitude_Capital>,
        <https://1145.am/db/2352167/Longitude_Capital>,
        <https://1145.am/db/2366753/Longitude_Capital>,
        <https://1145.am/db/2368232/Longitude_Capital>,
        <https://1145.am/db/2369359/Longitude_Capital>,
        <https://1145.am/db/2564563/Longitude_Capital>,
        <https://1145.am/db/958767/Longitude_Capital>,
        <https://1145.am/db/959519/Longitude_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/Biotech_Growth_Nv> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, MA" ;
    ns1:description "Biotech" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "Biotech Growth N.V." ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "Biotech Growth N.V." ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/F2_Biosciences_Iii_Lp> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, MA" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "F2 Biosciences III, L.P." ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "F2 Biosciences III, L.P." ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/Mpm_Bio_Iv_Nvs_Strategic_Fund> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "MPM Bio IV NVS Strategic Fund" ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "MPM Bio IV NVS Strategic Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2303833/Mpm_Bio_Iv_Nvs_Strategic_Fund_Lp>,
        <https://1145.am/db/2308887/Mpm_Bio_Iv_Nvs_Strategic_Fund>,
        <https://1145.am/db/2346204/Mpm_Bio_Iv_Nvs_Strategic_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/Mpm_Capital> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "MPM Capital" ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "MPM Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1325968/Mpm_Capital>,
        <https://1145.am/db/1752458/Mpm_Capital>,
        <https://1145.am/db/2285876/Mpm_Capital>,
        <https://1145.am/db/2287191/Mpm_Capital>,
        <https://1145.am/db/2292334/Mpm_Capital>,
        <https://1145.am/db/2292353/Mpm_Capital>,
        <https://1145.am/db/2300455/Mpm_Capital>,
        <https://1145.am/db/2301901/Mpm_Capital>,
        <https://1145.am/db/2303391/Mpm_Capital>,
        <https://1145.am/db/2303833/Mpm_Capital>,
        <https://1145.am/db/2303855/Mpm_Capital>,
        <https://1145.am/db/2304634/Mpm_Capital>,
        <https://1145.am/db/2305503/Mpm_Capital>,
        <https://1145.am/db/2305656/Mpm_Capital>,
        <https://1145.am/db/2306705/Mpm_Capital>,
        <https://1145.am/db/2308887/Mpm_Capital>,
        <https://1145.am/db/2309845/Mpm_Capital>,
        <https://1145.am/db/2311551/Mpm_Capital>,
        <https://1145.am/db/2312285/Mpm_Capital>,
        <https://1145.am/db/2312309/Mpm_Capital>,
        <https://1145.am/db/2316391/Mpm_Capital>,
        <https://1145.am/db/2323055/Mpm_Capital>,
        <https://1145.am/db/2323066/Mpm_Capital>,
        <https://1145.am/db/2323094/Mpm_Capital>,
        <https://1145.am/db/2323563/Mpm_Capital>,
        <https://1145.am/db/2323568/Mpm_Capital>,
        <https://1145.am/db/2324195/Mpm_Capital>,
        <https://1145.am/db/2324226/Mpm_Capital>,
        <https://1145.am/db/2328338/Mpm_Capital>,
        <https://1145.am/db/2333119/Mpm_Capital>,
        <https://1145.am/db/2333525/Mpm_Capital>,
        <https://1145.am/db/2335701/Mpm_Capital>,
        <https://1145.am/db/2335714/Mpm_Capital>,
        <https://1145.am/db/2337140/Mpm_Capital>,
        <https://1145.am/db/2340957/Mpm_Capital>,
        <https://1145.am/db/2345299/Mpm_Capital>,
        <https://1145.am/db/2345318/Mpm_Capital>,
        <https://1145.am/db/2346204/Mpm_Capital>,
        <https://1145.am/db/2347140/Mpm_Capital>,
        <https://1145.am/db/2347469/Mpm_Capital>,
        <https://1145.am/db/2347984/Mpm_Capital>,
        <https://1145.am/db/2348484/Mpm_Capital>,
        <https://1145.am/db/2350030/Mpm_Capital>,
        <https://1145.am/db/2352362/Mpm_Capital>,
        <https://1145.am/db/2352899/Mpm_Capital>,
        <https://1145.am/db/2353365/Mpm_Capital>,
        <https://1145.am/db/2353404/Mpm_Capital>,
        <https://1145.am/db/2353413/Mpm_Capital>,
        <https://1145.am/db/2353415/Mpm_Capital>,
        <https://1145.am/db/2356396/Mpm_Capital>,
        <https://1145.am/db/2358979/Mpm_Capital>,
        <https://1145.am/db/2359001/Mpm_Capital>,
        <https://1145.am/db/2359873/Mpm_Capital>,
        <https://1145.am/db/2359875/Mpm_Capital>,
        <https://1145.am/db/2360526/Mpm_Capital>,
        <https://1145.am/db/2362871/Mpm_Capital>,
        <https://1145.am/db/2364492/Mpm_Capital>,
        <https://1145.am/db/2365098/Mpm_Capital>,
        <https://1145.am/db/2366744/Mpm_Capital>,
        <https://1145.am/db/2367199/Mpm_Capital>,
        <https://1145.am/db/2369202/Mpm_Capital>,
        <https://1145.am/db/2370582/Mpm_Capital>,
        <https://1145.am/db/2541350/Mpm_Capital>,
        <https://1145.am/db/677075/Mpm_Capital>,
        <https://1145.am/db/678997/Mpm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352211/Blavatnik_Family> a org:Organization ;
    ns1:documentDate "2013-04-29T14:00:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Harvard Announces $50 Million Gift from the Blavatnik Family Foundation" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/harvard-announces-50-million-gift-from-blavatnik-family-foundation> ;
    ns1:foundName "Blavatnik (M.B.A. '89)",
        "Blavatnik Family" ;
    ns1:investor <https://1145.am/db/2352211/Investment_Blavatnik_Family_Harvard_University_The_Blavatnik_Family_Foundation_Completed> ;
    ns1:name "Blavatnik",
        "Blavatnik Family" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352211/The_Blavatnik_Family_Foundation> a org:Organization ;
    ns1:description "Support for early-stage research and new inventions" ;
    ns1:documentDate "2013-04-29T14:00:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Harvard Announces $50 Million Gift from the Blavatnik Family Foundation" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/harvard-announces-50-million-gift-from-blavatnik-family-foundation> ;
    ns1:foundName "Blavatnik",
        "The Blavatnik Family Foundation" ;
    ns1:investor <https://1145.am/db/2352211/Investment_Blavatnik_Family_Harvard_University_The_Blavatnik_Family_Foundation_Completed> ;
    ns1:name "Blavatnik Family Foundation",
        "The Blavatnik Family Foundation" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353209/Valence_Life_Sciences> a org:Organization ;
    ns1:documentDate "2013-05-01T13:19:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VCs provide $40M to finance Celator's pivotal PhIII AML study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/vcs-provide-40m-to-finance-celator-s-pivotal-phiii-aml-study> ;
    ns1:foundName "Valence Life Sciences" ;
    ns1:investor <https://1145.am/db/2353209/Investment_Celator_Pharmaceuticals_Valence_Life_Sciences_Has_Not_Happened> ;
    ns1:name "Valence Life Sciences" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353241/Danica_Pension> a org:Organization ;
    ns1:description "pension" ;
    ns1:documentDate "2013-05-02T12:25:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Symphogen Expands Previous Private Equity Round, Reaching a Total of EUR 141 million (USD 185 Million)" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/symphogen-expands-previous-private-equity-round-reaching-a-total-of-eur-141-million-usd-185> ;
    ns1:foundName "Danica Pension" ;
    ns1:investor <https://1145.am/db/2353241/Preferred_Stock_Investment_Danica_Pension_Novo_A_S_Pka_Symphogen_Completed> ;
    ns1:name "Danica Pension" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353241/Pka> a org:Organization ;
    ns1:basedInLowRaw "Danica Pension" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-05-02T12:25:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Symphogen Expands Previous Private Equity Round, Reaching a Total of EUR 141 million (USD 185 Million)" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/symphogen-expands-previous-private-equity-round-reaching-a-total-of-eur-141-million-usd-185> ;
    ns1:foundName "PKA" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2353241/Preferred_Stock_Investment_Danica_Pension_Novo_A_S_Pka_Symphogen_Completed> ;
    ns1:name "PKA" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354266/Investment_Neurophage_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEUROPHAGE, INC. RAISES $ 6.4 MILLION IN ADDITIONAL FINANCING." ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "RAISES" ;
    ns1:name "RAISES" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2354266/Neurophage_Inc> ;
    ns1:valueRaw "$ 6.4 MILLION" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2354266/Mrieux_Dveloppement> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "Mrieux Dveloppement" ;
    ns1:investor <https://1145.am/db/2354266/Investment_Mrieux_Dveloppement_Neurophage_Pharmaceuticals_Shire_Llc_Completed> ;
    ns1:name "Mrieux Dveloppement" ;
    ns1:sameAsMedium <https://1145.am/db/2288936/Mrieux_Dveloppement>,
        <https://1145.am/db/2337294/Mrieux_Dveloppement>,
        <https://1145.am/db/2337976/Mrieux_Dveloppement>,
        <https://1145.am/db/2344202/Merieux_Developpement>,
        <https://1145.am/db/2344205/Merieux_Developpement>,
        <https://1145.am/db/2348350/Merieux_Developpement>,
        <https://1145.am/db/2351734/Mrieux_Dveloppement>,
        <https://1145.am/db/2354277/Mrieux_Dveloppement>,
        <https://1145.am/db/2361809/Merieux_Developpement> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354266/Shire_Llc> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "Shire LLC" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2354266/Investment_Mrieux_Dveloppement_Neurophage_Pharmaceuticals_Shire_Llc_Completed> ;
    ns1:name "Shire LLC" ;
    ns1:sameAsHigh <https://1145.am/db/142937/Shire_Plc>,
        <https://1145.am/db/2155273/Shire>,
        <https://1145.am/db/2225348/Shire_Plc>,
        <https://1145.am/db/2225352/Shire_Plc>,
        <https://1145.am/db/2290932/Shire>,
        <https://1145.am/db/2291354/Shire>,
        <https://1145.am/db/2292991/Shire>,
        <https://1145.am/db/2296208/Shire>,
        <https://1145.am/db/2296243/Shire>,
        <https://1145.am/db/2298391/Shire>,
        <https://1145.am/db/2300483/Shire>,
        <https://1145.am/db/2302783/Shire_Limited>,
        <https://1145.am/db/2303789/Shire>,
        <https://1145.am/db/2305581/Shire_Plc>,
        <https://1145.am/db/2306762/Shire>,
        <https://1145.am/db/2310002/Shire>,
        <https://1145.am/db/2311383/Shire_Pharmaceuticals>,
        <https://1145.am/db/2311393/Shire_Pharmaceuticals_Group>,
        <https://1145.am/db/2314408/Shire_Limited>,
        <https://1145.am/db/2315296/Shire_Biochem>,
        <https://1145.am/db/2315308/Shire_Biochem_Inc>,
        <https://1145.am/db/2320137/Shire>,
        <https://1145.am/db/2320509/Shire>,
        <https://1145.am/db/2324621/Shire_Plc>,
        <https://1145.am/db/2326381/Shire_Plc>,
        <https://1145.am/db/2328189/Shire>,
        <https://1145.am/db/2328700/Shire_Laboratories>,
        <https://1145.am/db/2328788/Shire_Plc>,
        <https://1145.am/db/2331795/Shire_Plc>,
        <https://1145.am/db/2335641/Shire>,
        <https://1145.am/db/2336575/Shire>,
        <https://1145.am/db/2336581/Shire>,
        <https://1145.am/db/2336708/Shire>,
        <https://1145.am/db/2338009/Shire>,
        <https://1145.am/db/2338011/Shire>,
        <https://1145.am/db/2340575/Shire>,
        <https://1145.am/db/2341074/Shire>,
        <https://1145.am/db/2341522/Shire>,
        <https://1145.am/db/2341828/Shire_Plc>,
        <https://1145.am/db/2341829/Shire>,
        <https://1145.am/db/2341838/Shire>,
        <https://1145.am/db/2341902/Shire>,
        <https://1145.am/db/2342514/Shire>,
        <https://1145.am/db/2342570/Shire>,
        <https://1145.am/db/2344160/Shire>,
        <https://1145.am/db/2344202/Shire>,
        <https://1145.am/db/2344913/Shire>,
        <https://1145.am/db/2344914/Shire_Plc>,
        <https://1145.am/db/2344928/Shire_Plc>,
        <https://1145.am/db/2345238/Shire>,
        <https://1145.am/db/2345248/Shire_Plc>,
        <https://1145.am/db/2345825/Shire_Plc>,
        <https://1145.am/db/2345826/Shire_Plc>,
        <https://1145.am/db/2346202/Shire>,
        <https://1145.am/db/2346640/Shire>,
        <https://1145.am/db/2346644/Shire_Plc>,
        <https://1145.am/db/2346646/Shire_Plc>,
        <https://1145.am/db/2346752/Shire_Plc>,
        <https://1145.am/db/2346863/Shire_Plc>,
        <https://1145.am/db/2347646/Shire_Plc>,
        <https://1145.am/db/2348661/Shire>,
        <https://1145.am/db/2348742/Shire>,
        <https://1145.am/db/2348750/Shire>,
        <https://1145.am/db/2351482/Shire>,
        <https://1145.am/db/2351483/Shire>,
        <https://1145.am/db/2351754/Shire>,
        <https://1145.am/db/2352906/Shire>,
        <https://1145.am/db/2357032/Shire>,
        <https://1145.am/db/2357116/Shire>,
        <https://1145.am/db/2359634/Shire>,
        <https://1145.am/db/2360712/Shire_Board>,
        <https://1145.am/db/2361514/Shire_Plc>,
        <https://1145.am/db/2361641/Shire>,
        <https://1145.am/db/2364136/Shire_Plc>,
        <https://1145.am/db/2364149/Shire_Plc>,
        <https://1145.am/db/2364556/Shire>,
        <https://1145.am/db/2364813/Shire>,
        <https://1145.am/db/2365002/Shire_Plc>,
        <https://1145.am/db/2367132/Shire_Plc>,
        <https://1145.am/db/2367297/Shire>,
        <https://1145.am/db/2368862/Shire>,
        <https://1145.am/db/2369141/Shire>,
        <https://1145.am/db/2369949/Shire>,
        <https://1145.am/db/2370010/Shire>,
        <https://1145.am/db/2370189/Shire>,
        <https://1145.am/db/2370740/Shire>,
        <https://1145.am/db/2371519/Shire>,
        <https://1145.am/db/2537396/Shire>,
        <https://1145.am/db/2541146/Shire>,
        <https://1145.am/db/2544223/Shire>,
        <https://1145.am/db/2544459/Shire>,
        <https://1145.am/db/2544726/Shire>,
        <https://1145.am/db/2546262/Shire>,
        <https://1145.am/db/2546291/Shire>,
        <https://1145.am/db/2547036/Shire>,
        <https://1145.am/db/2547277/Shire>,
        <https://1145.am/db/2548051/Shire>,
        <https://1145.am/db/2548859/Shire>,
        <https://1145.am/db/2550985/Shire>,
        <https://1145.am/db/2552455/Shire>,
        <https://1145.am/db/2554294/Shire>,
        <https://1145.am/db/2556988/Shire>,
        <https://1145.am/db/2559769/Shire>,
        <https://1145.am/db/2561541/Shire>,
        <https://1145.am/db/2563175/Shire>,
        <https://1145.am/db/2564899/Shire>,
        <https://1145.am/db/2565613/Shire>,
        <https://1145.am/db/2569388/Shire>,
        <https://1145.am/db/2569952/Shire>,
        <https://1145.am/db/2570020/Shire>,
        <https://1145.am/db/2570036/Shire>,
        <https://1145.am/db/2570733/Shire_Plc>,
        <https://1145.am/db/2570807/Shire>,
        <https://1145.am/db/2571521/Shire>,
        <https://1145.am/db/2571526/Shire>,
        <https://1145.am/db/2572335/Shire>,
        <https://1145.am/db/2573463/Shire>,
        <https://1145.am/db/2573508/Shire>,
        <https://1145.am/db/2574443/Shire>,
        <https://1145.am/db/2574731/Shire>,
        <https://1145.am/db/2575259/Shire>,
        <https://1145.am/db/2576815/Shire>,
        <https://1145.am/db/2576959/Shire>,
        <https://1145.am/db/2577117/Shire>,
        <https://1145.am/db/2577652/Shire_Plc>,
        <https://1145.am/db/2578085/Shire_Plc>,
        <https://1145.am/db/2578086/So_Shire>,
        <https://1145.am/db/2578319/Shire>,
        <https://1145.am/db/2578503/Shire>,
        <https://1145.am/db/2578568/Shire>,
        <https://1145.am/db/2579035/Shire_Plc>,
        <https://1145.am/db/2580603/Shire>,
        <https://1145.am/db/2580620/Shire>,
        <https://1145.am/db/2580622/Shire>,
        <https://1145.am/db/2580747/Shire>,
        <https://1145.am/db/2581261/Shire>,
        <https://1145.am/db/2582265/Shire>,
        <https://1145.am/db/2583177/Shire>,
        <https://1145.am/db/2583662/Shire>,
        <https://1145.am/db/2584216/Shire>,
        <https://1145.am/db/2585066/Shire>,
        <https://1145.am/db/2586884/Shire>,
        <https://1145.am/db/2586889/Shire>,
        <https://1145.am/db/2587094/Shire>,
        <https://1145.am/db/2587511/Shire>,
        <https://1145.am/db/2588152/Shire>,
        <https://1145.am/db/2589981/Shire_Plc>,
        <https://1145.am/db/2591412/Shire>,
        <https://1145.am/db/2592333/Shire>,
        <https://1145.am/db/2592562/Shire>,
        <https://1145.am/db/2595190/Shire>,
        <https://1145.am/db/2595210/Shire>,
        <https://1145.am/db/2597158/Shire>,
        <https://1145.am/db/2598205/Shire>,
        <https://1145.am/db/2976/Shire> ;
    ns1:sameAsMedium <https://1145.am/db/2288537/Shire>,
        <https://1145.am/db/2293472/Shire>,
        <https://1145.am/db/2297066/Shire>,
        <https://1145.am/db/2332620/Shire>,
        <https://1145.am/db/2333419/Shire>,
        <https://1145.am/db/2336126/Shire_Plc>,
        <https://1145.am/db/2339117/Shire>,
        <https://1145.am/db/2339733/Shire_Plc>,
        <https://1145.am/db/2340560/Shire>,
        <https://1145.am/db/2340566/Shire_Plc>,
        <https://1145.am/db/2341068/Shire>,
        <https://1145.am/db/2344205/Shire>,
        <https://1145.am/db/2345096/Shire>,
        <https://1145.am/db/2346872/Shire_Plc>,
        <https://1145.am/db/2346879/Shire>,
        <https://1145.am/db/2347772/Shire>,
        <https://1145.am/db/2348523/Shire>,
        <https://1145.am/db/2348805/Shire>,
        <https://1145.am/db/2350265/Shire_Plc>,
        <https://1145.am/db/2351734/Shire_Llc>,
        <https://1145.am/db/2351737/Shire_Llc>,
        <https://1145.am/db/2353283/Shire_Plc>,
        <https://1145.am/db/2354277/Shire>,
        <https://1145.am/db/2356384/Shire>,
        <https://1145.am/db/2357487/Shire>,
        <https://1145.am/db/2359681/Shire>,
        <https://1145.am/db/2360712/Shire_Plc>,
        <https://1145.am/db/2361640/Shire_Plc>,
        <https://1145.am/db/2362744/Shire>,
        <https://1145.am/db/2365826/Shire_Plc>,
        <https://1145.am/db/2366303/Shire>,
        <https://1145.am/db/2368144/Shire>,
        <https://1145.am/db/2368885/Shire>,
        <https://1145.am/db/2368915/Shire>,
        <https://1145.am/db/2368936/Shire>,
        <https://1145.am/db/2369701/Shire>,
        <https://1145.am/db/2370358/Shire>,
        <https://1145.am/db/2370514/Shire>,
        <https://1145.am/db/2371522/Shire>,
        <https://1145.am/db/2539292/Shire>,
        <https://1145.am/db/2544434/Shire>,
        <https://1145.am/db/2547575/Shire_Plc>,
        <https://1145.am/db/2548805/Shire>,
        <https://1145.am/db/2548979/Shire>,
        <https://1145.am/db/2552180/Shire>,
        <https://1145.am/db/2554269/Shire>,
        <https://1145.am/db/2558927/Shire>,
        <https://1145.am/db/2566716/Shire>,
        <https://1145.am/db/2570363/Shire>,
        <https://1145.am/db/2572113/Shire_Plc>,
        <https://1145.am/db/2572559/Shire>,
        <https://1145.am/db/2575050/Shire>,
        <https://1145.am/db/2577114/Shire>,
        <https://1145.am/db/2577176/Shire_Plc>,
        <https://1145.am/db/2577793/Shire_Plc>,
        <https://1145.am/db/2579062/Shire_Plc>,
        <https://1145.am/db/2580279/Shire>,
        <https://1145.am/db/2583624/Shire_Plc>,
        <https://1145.am/db/2585132/Shire>,
        <https://1145.am/db/2586132/Shire>,
        <https://1145.am/db/2592336/Shire> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355274/Pappas_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-05-08T12:12:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "LUMENA PHARMACEUTICALS ANNOUNCES $23 MILLION SERIES A FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lumena-pharmaceuticals-announces-23-million-series-a-financing> ;
    ns1:foundName "Pappas Ventures" ;
    ns1:investor <https://1145.am/db/2355274/Series_A_Investment_Alta_Partners_Lumena_Pharmaceuticals_Pappas_Ventures_Rivervest_Venture_Partners_Completed> ;
    ns1:name "Pappas Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2289229/Pappas_Ventures>,
        <https://1145.am/db/2305706/Pappas_Ventures>,
        <https://1145.am/db/2305713/Pappas_Ventures>,
        <https://1145.am/db/2308329/Pappas_Ventures>,
        <https://1145.am/db/2312277/Pappas_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314492/Pappas_Ventures>,
        <https://1145.am/db/2319029/Pappas_Ventures>,
        <https://1145.am/db/2324289/Pappas_Ventures>,
        <https://1145.am/db/2328388/Pappas_Ventures>,
        <https://1145.am/db/2332753/Pappas_Ventures>,
        <https://1145.am/db/2341904/Pappas_Ventures>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346542/Pappas_Ventures>,
        <https://1145.am/db/2350779/Pappas_Ventures>,
        <https://1145.am/db/2350780/Pappas_Ventures>,
        <https://1145.am/db/2352805/Pappas_Ventures>,
        <https://1145.am/db/2352808/Pappas_Ventures>,
        <https://1145.am/db/2354537/Pappas_Ventures>,
        <https://1145.am/db/2354540/Pappas_Ventures>,
        <https://1145.am/db/2356216/Pappas_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2539913/Pappas_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Abingworth> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Abingworth" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "Abingworth" ;
    ns1:sameAsMedium <https://1145.am/db/1533327/Abingworth>,
        <https://1145.am/db/1533685/Abingworth>,
        <https://1145.am/db/1669813/Abingworth>,
        <https://1145.am/db/2198942/Abingworth>,
        <https://1145.am/db/2235767/Abingworth>,
        <https://1145.am/db/2281044/Abingworth>,
        <https://1145.am/db/2282263/Abingworth>,
        <https://1145.am/db/2284358/Abingworth>,
        <https://1145.am/db/2285674/Abingworth>,
        <https://1145.am/db/2286368/Abingworth>,
        <https://1145.am/db/2286541/Abingworth>,
        <https://1145.am/db/2288699/Abingworth>,
        <https://1145.am/db/2292721/Abingworth>,
        <https://1145.am/db/2293814/Abingworth>,
        <https://1145.am/db/2293845/Abingworth>,
        <https://1145.am/db/2294502/Abingworth>,
        <https://1145.am/db/2298306/Abingworth>,
        <https://1145.am/db/2299499/Abingworth>,
        <https://1145.am/db/2301901/Abingworth>,
        <https://1145.am/db/2303656/Abingworth>,
        <https://1145.am/db/2308925/Abingworth>,
        <https://1145.am/db/2308931/Abingworth>,
        <https://1145.am/db/2316391/Abingworth>,
        <https://1145.am/db/2316478/Abingworth>,
        <https://1145.am/db/2317934/Abingworth>,
        <https://1145.am/db/2318733/Abingworth>,
        <https://1145.am/db/2319412/Abingworth>,
        <https://1145.am/db/2319784/Abingworth>,
        <https://1145.am/db/2322012/Abingworth>,
        <https://1145.am/db/2324936/Abingworth_Llp>,
        <https://1145.am/db/2328502/Abingworth>,
        <https://1145.am/db/2328763/Abingworth>,
        <https://1145.am/db/2328769/Abingworth>,
        <https://1145.am/db/2331750/Abingworth>,
        <https://1145.am/db/2335701/Abingworth>,
        <https://1145.am/db/2335714/Abingworth>,
        <https://1145.am/db/2335928/Abingworth_Llp>,
        <https://1145.am/db/2337140/Abingworth>,
        <https://1145.am/db/2346293/Abingworth>,
        <https://1145.am/db/2348012/Abingworth_Llp>,
        <https://1145.am/db/2349233/Abingworth>,
        <https://1145.am/db/2349753/Abingworth>,
        <https://1145.am/db/2352357/Abingworth>,
        <https://1145.am/db/2352361/Abingworth>,
        <https://1145.am/db/2364517/Abingworth_Llp>,
        <https://1145.am/db/2368164/Abingworth>,
        <https://1145.am/db/2368251/Abingworth>,
        <https://1145.am/db/2370582/Abingworth>,
        <https://1145.am/db/2787528/Abingworth>,
        <https://1145.am/db/4142/Abingworth_Llp>,
        <https://1145.am/db/899382/Abingworth>,
        <https://1145.am/db/951050/Abingworth> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Astellas_Venture_Management> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Astellas Venture Management" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "Astellas Venture Management" ;
    ns1:sameAsMedium <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1156304/Astellas_Venture_Management>,
        <https://1145.am/db/1503058/Astellas_Venture_Management>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2318733/Astellas_Venture_Management>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2320476/Astellas_Venture_Management>,
        <https://1145.am/db/2329125/Astellas_Venture_Management>,
        <https://1145.am/db/2329131/Astellas_Venture_Management>,
        <https://1145.am/db/2357858/Astellas_Venture_Management>,
        <https://1145.am/db/2358657/Astellas_Venture_Management>,
        <https://1145.am/db/2362871/Astellas_Venture_Management>,
        <https://1145.am/db/2365138/Astellas_Venture_Management>,
        <https://1145.am/db/2365748/Astellas_Venture_Management>,
        <https://1145.am/db/2370582/Astellas_Venture_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Mission_Bay_Capital> a org:Organization ;
    ns1:basedInLowRaw "San Diego" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Mission Bay Capital" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "Mission Bay Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2342925/Mission_Bay_Capital>,
        <https://1145.am/db/2342937/Mission_Bay_Capital>,
        <https://1145.am/db/2344017/Mission_Bay_Capital>,
        <https://1145.am/db/2355051/Mission_Bay_Capital>,
        <https://1145.am/db/2367204/Mission_Bay_Capital>,
        <https://1145.am/db/2367621/Mission_Bay_Capital>,
        <https://1145.am/db/2370208/Mission_Bay_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Osage_University_Partners> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Osage University Partners" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "Osage University Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1441781/Osage_University_Partners>,
        <https://1145.am/db/1533327/Osage_University_Partners>,
        <https://1145.am/db/1533685/Osage_University_Partners>,
        <https://1145.am/db/1619110/Osage_University_Partners>,
        <https://1145.am/db/1696377/Osage_University_Partners>,
        <https://1145.am/db/1759759/Osage_University_Partners>,
        <https://1145.am/db/1774684/Osage_University_Partners>,
        <https://1145.am/db/1782234/Osage_University_Partners>,
        <https://1145.am/db/1802088/Osage_University_Partners>,
        <https://1145.am/db/1810714/Osage_University_Partners>,
        <https://1145.am/db/1823287/Osage_University_Partners>,
        <https://1145.am/db/1858399/Osage_University_Partners>,
        <https://1145.am/db/2153910/Osage_University_Partners>,
        <https://1145.am/db/2278799/Osage_University_Partners>,
        <https://1145.am/db/2292287/Osage_University_Partners>,
        <https://1145.am/db/2294753/Osage_University_Partners>,
        <https://1145.am/db/2301464/Osage_University_Partners>,
        <https://1145.am/db/2319360/Osage_University_Partners>,
        <https://1145.am/db/2336032/Osage_University_Partners>,
        <https://1145.am/db/2336221/Osage_University_Partners>,
        <https://1145.am/db/2340284/Osage_University_Partners>,
        <https://1145.am/db/2340888/Osage_University_Partners>,
        <https://1145.am/db/2341896/Osage_University_Partners>,
        <https://1145.am/db/2349691/Osage_University_Partners>,
        <https://1145.am/db/2349838/Osage_University_Partners>,
        <https://1145.am/db/2350044/Osage_University_Partners>,
        <https://1145.am/db/2350199/Osage_University_Partners>,
        <https://1145.am/db/2352349/Osage_University_Partners>,
        <https://1145.am/db/2352350/Osage_University_Partners>,
        <https://1145.am/db/2353771/Osage_University_Partners>,
        <https://1145.am/db/2353789/Osage_University_Partners>,
        <https://1145.am/db/2359404/Osage_University_Partners>,
        <https://1145.am/db/2360521/Osage_University_Partners>,
        <https://1145.am/db/2360526/Osage_University_Partners>,
        <https://1145.am/db/2368351/Osage_University_Partners>,
        <https://1145.am/db/2369165/Osage_University_Partners>,
        <https://1145.am/db/2369169/Osage_University_Partners>,
        <https://1145.am/db/2370626/Osage_University_Partners>,
        <https://1145.am/db/2569831/Osage_University_Partners>,
        <https://1145.am/db/425953/Osage_University_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Us_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "U.S. Venture Partners" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "U.S. Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1147854/Us_Venture_Partners>,
        <https://1145.am/db/1418766/Us_Venture_Partners>,
        <https://1145.am/db/1454909/Us_Venture_Partners>,
        <https://1145.am/db/1681426/Us_Venture_Partners>,
        <https://1145.am/db/1697656/Us_Venture_Partners>,
        <https://1145.am/db/1701580/Us_Venture_Partners>,
        <https://1145.am/db/1710567/Us_Venture_Partners>,
        <https://1145.am/db/1712506/Us_Venture_Partners>,
        <https://1145.am/db/1718048/Us_Venture_Partners>,
        <https://1145.am/db/1725165/Us_Venture_Partners>,
        <https://1145.am/db/1737882/Us_Venture_Partners>,
        <https://1145.am/db/1748970/Us_Venture_Partners>,
        <https://1145.am/db/1758985/Us_Venture_Partners>,
        <https://1145.am/db/1763964/Us_Venture_Partners>,
        <https://1145.am/db/1771750/Us_Venture_Partners>,
        <https://1145.am/db/1787502/Us_Venture_Partners>,
        <https://1145.am/db/1796259/Us_Venture_Partners>,
        <https://1145.am/db/1797905/Us_Venture_Partners>,
        <https://1145.am/db/1812267/Us_Venture_Partners>,
        <https://1145.am/db/1831222/Us_Venture_Partners>,
        <https://1145.am/db/1834392/Us_Venture_Partners>,
        <https://1145.am/db/1842350/Us_Venture_Partners>,
        <https://1145.am/db/1842466/Us_Venture_Partners>,
        <https://1145.am/db/1844571/Us_Venture_Partners>,
        <https://1145.am/db/1845308/Us_Venture_Partners>,
        <https://1145.am/db/1845321/Us_Venture_Partners>,
        <https://1145.am/db/1845924/Us_Venture_Partners>,
        <https://1145.am/db/1846470/Us_Venture_Partners>,
        <https://1145.am/db/1847323/Us_Venture_Partners>,
        <https://1145.am/db/1851689/Us_Venture_Partners>,
        <https://1145.am/db/1852806/Us_Venture_Partners>,
        <https://1145.am/db/1863147/Us_Venture_Partners>,
        <https://1145.am/db/1864900/Us_Venture_Partners>,
        <https://1145.am/db/1867951/Us_Venture_Partners>,
        <https://1145.am/db/1870790/Us_Venture_Partners>,
        <https://1145.am/db/1871784/Us_Venture_Partners>,
        <https://1145.am/db/1877830/Us_Venture_Partners>,
        <https://1145.am/db/1879026/Us_Venture_Partners>,
        <https://1145.am/db/1884155/Us_Venture_Partners>,
        <https://1145.am/db/1895986/Us_Venture_Partners>,
        <https://1145.am/db/1915640/Us_Venture_Partners>,
        <https://1145.am/db/2050254/Us_Venture_Partners>,
        <https://1145.am/db/2150562/Us_Venture_Partners>,
        <https://1145.am/db/2192716/Us_Venture_Partners>,
        <https://1145.am/db/2257512/Us_Venture_Partners>,
        <https://1145.am/db/2278799/Us_Venture_Partners>,
        <https://1145.am/db/2279124/Us_Venture_Partners>,
        <https://1145.am/db/2288251/Us_Venture_Partners>,
        <https://1145.am/db/2288899/Us_Venture_Partners>,
        <https://1145.am/db/2293765/Us_Venture_Partners>,
        <https://1145.am/db/2299776/Us_Venture_Partners>,
        <https://1145.am/db/2301809/Us_Venture_Partners>,
        <https://1145.am/db/2319658/Us_Venture_Partners>,
        <https://1145.am/db/2343206/Us_Venture_Partners>,
        <https://1145.am/db/2357858/Us_Venture_Partners>,
        <https://1145.am/db/2367204/Us_Venture_Partners>,
        <https://1145.am/db/2645160/Us_Venture_Partners>,
        <https://1145.am/db/425262/Us_Venture_Partners>,
        <https://1145.am/db/838691/Us_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Fox_Foundation_For_Parkinsons_Research> a org:Organization ;
    ns1:description "Research" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Fox Foundation for Parkinson's Research" ;
    ns1:investor <https://1145.am/db/2360562/Investment_Astrazeneca_Fox_Foundation_For_Parkinsons_Research_Completed> ;
    ns1:name "Fox Foundation for Parkinson's Research" ;
    ns1:sameAsHigh <https://1145.am/db/1121190/The_Parkinsons_Foundation>,
        <https://1145.am/db/1326957/Penn_Medicine>,
        <https://1145.am/db/1665917/Michael_J>,
        <https://1145.am/db/1665917/Soturi>,
        <https://1145.am/db/1665917/The_Michael_J_Fox_Foundation_For_Parkinsons_Research>,
        <https://1145.am/db/2211370/Fox_Foundation_For_Parkinsons_Research>,
        <https://1145.am/db/2296526/Neuroderm>,
        <https://1145.am/db/2302835/The_Michael_J>,
        <https://1145.am/db/2369380/Biotie>,
        <https://1145.am/db/2558110/Civitas> ;
    ns1:sameAsMedium <https://1145.am/db/1665917/Fox_Foundation_For_Parkinsons>,
        <https://1145.am/db/1975681/The_Michael_J_Fox_Foundation_For_Parkinson>,
        <https://1145.am/db/2302835/Fox_Foundation_For_Parkinsons_Research>,
        <https://1145.am/db/2328798/Fox_Foundation_For_Parkinsons_Research>,
        <https://1145.am/db/738087/The_Michael_J_Fox_Foundation_For_Parkinsons_Research> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Janssen> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Janssen" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2360562/Investment_Janssen_Johnson___Johnson_Innovation_Has_Not_Happened> ;
    ns1:name "Janssen" ;
    ns1:sameAsHigh <https://1145.am/db/1112385/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/1117296/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/1118214/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/1184327/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/1492157/Janssen>,
        <https://1145.am/db/1557072/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/2156018/Janssen>,
        <https://1145.am/db/2283907/Janssen>,
        <https://1145.am/db/2293696/Janssen>,
        <https://1145.am/db/2298414/Janssen>,
        <https://1145.am/db/2301619/Janssen>,
        <https://1145.am/db/2301833/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/2318965/Janssen>,
        <https://1145.am/db/2324079/Janssen_Pharmaceutica>,
        <https://1145.am/db/2339892/Janssen_Biotech>,
        <https://1145.am/db/2340074/Janssen_Pharmaceutical_Companies>,
        <https://1145.am/db/2340122/Janssen_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350116/Janssen_Pharmaceutical>,
        <https://1145.am/db/2357361/Janssen_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360254/Janssen_Pharmaceutical_Companies>,
        <https://1145.am/db/2362898/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2362969/Janssen-Cilag_Gmbh>,
        <https://1145.am/db/2362972/Janssen-Cilag>,
        <https://1145.am/db/2366562/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/2549545/Janssen_Pharmaceutical_Companies>,
        <https://1145.am/db/2550569/Janssen_Pharmaceutical_Companies>,
        <https://1145.am/db/2551625/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2551629/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2551645/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2552615/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2552633/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2557907/Janssen_Pharmaceutica>,
        <https://1145.am/db/2567517/Janssen>,
        <https://1145.am/db/2569231/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2569234/Janssen>,
        <https://1145.am/db/2569487/Janssen_Pharmaceutical_Companies>,
        <https://1145.am/db/2569516/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2570135/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2572329/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/2572612/Janssen>,
        <https://1145.am/db/2586420/Janssen_Pharmaceutica>,
        <https://1145.am/db/2587640/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2588178/Janssen_Uk>,
        <https://1145.am/db/2588718/Janssen_Biotech>,
        <https://1145.am/db/2589568/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2590997/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/2591001/Janssen_Pharmaceutica>,
        <https://1145.am/db/2595241/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2595242/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2595856/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2595857/Janssen_Pharmaceuticals>,
        <https://1145.am/db/2597433/Janssen_Pharmaceuticals>,
        <https://1145.am/db/364803/Janssen>,
        <https://1145.am/db/800219/Janssen_Pharmaceuticals_Inc>,
        <https://1145.am/db/955117/Janssen_Pharmaceutica_Nv>,
        <https://1145.am/db/955781/Janssen_Pharmaceutica_Nv> ;
    ns1:sameAsMedium <https://1145.am/db/2585710/Janssen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Johnson___Johnson_Innovation> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "research work on neurological diseases" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Johnson & Johnson Innovation" ;
    ns1:investor <https://1145.am/db/2360562/Investment_Janssen_Johnson___Johnson_Innovation_Has_Not_Happened> ;
    ns1:name "Johnson & Johnson Innovation" ;
    ns1:sameAsMedium <https://1145.am/db/1118732/Johnson___Johnson_Innovation>,
        <https://1145.am/db/1464782/Johnson___Johnson_Innovation>,
        <https://1145.am/db/1745868/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2095032/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2155668/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2196895/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2280368/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2283006/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2284205/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2293709/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2295278/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2297195/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2297644/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2298631/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2301381/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2333993/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2334956/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2339206/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2368322/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2369157/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2369951/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2586501/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2586502/Johnson___Johnson_Innovation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Canaan_Partners> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "Canaan Partners" ;
    ns1:investor <https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> ;
    ns1:name "Canaan Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1043342/Canaan_Partners>,
        <https://1145.am/db/146274/Canaan_Partners>,
        <https://1145.am/db/1695894/Canaan_Partners>,
        <https://1145.am/db/1696766/Canaan_Partners>,
        <https://1145.am/db/1697131/Canaan_Partners>,
        <https://1145.am/db/1702857/Canaan_Partners>,
        <https://1145.am/db/1711633/Canaan_Partners>,
        <https://1145.am/db/1724566/Canaan_Partners>,
        <https://1145.am/db/1734259/Canaan_Partners>,
        <https://1145.am/db/1741014/Canaan_Partners>,
        <https://1145.am/db/1741105/Canaan_Partners>,
        <https://1145.am/db/1741424/Canaan_Partners>,
        <https://1145.am/db/1749744/Canaan_Partners>,
        <https://1145.am/db/1754820/Canaan_Partners>,
        <https://1145.am/db/1768400/Canaan_Partners>,
        <https://1145.am/db/1770648/Canaan_Partners>,
        <https://1145.am/db/1791628/Canaan_Partners>,
        <https://1145.am/db/1792426/Canaan_Partners>,
        <https://1145.am/db/1793543/Canaan_Partners>,
        <https://1145.am/db/1796375/Canaan_Partners>,
        <https://1145.am/db/1814413/Canaan_Partners>,
        <https://1145.am/db/1819543/Canaan_Partners>,
        <https://1145.am/db/1827240/Canaan_Partners>,
        <https://1145.am/db/1829078/Canaan_Partners>,
        <https://1145.am/db/1829544/Canaan_Partners>,
        <https://1145.am/db/1836578/Canaan_Partners>,
        <https://1145.am/db/1842466/Canaan_Partners>,
        <https://1145.am/db/1845119/Canaan_Partners>,
        <https://1145.am/db/1852066/Canaan_Partners>,
        <https://1145.am/db/1858762/Canaan_Partners>,
        <https://1145.am/db/1863401/Canaan_Partners>,
        <https://1145.am/db/1866968/Canaan_Partners>,
        <https://1145.am/db/1894670/Canaan_Partners>,
        <https://1145.am/db/1897255/Canaan_Partners>,
        <https://1145.am/db/1900458/Canaan_Partners>,
        <https://1145.am/db/1906336/Canaan_Partners>,
        <https://1145.am/db/1907151/Canaan_Partners>,
        <https://1145.am/db/1907762/Canaan_Partners>,
        <https://1145.am/db/1910644/Canaan_Partners>,
        <https://1145.am/db/1919135/Canaan_Partners>,
        <https://1145.am/db/1920478/Canaan_Partners>,
        <https://1145.am/db/2164798/Canaan_Partners>,
        <https://1145.am/db/2164838/Canaan_Partners>,
        <https://1145.am/db/2210939/Canaan_Partners>,
        <https://1145.am/db/2238667/Canaan_Partners>,
        <https://1145.am/db/2287025/Canaan_Partners>,
        <https://1145.am/db/2287777/Canaan_Partners>,
        <https://1145.am/db/2297592/Canaan_Partners>,
        <https://1145.am/db/2298642/Canaan_Partners>,
        <https://1145.am/db/2301765/Canaan_Partners>,
        <https://1145.am/db/2304587/Canaan_Partners>,
        <https://1145.am/db/2304605/Canaan_Partners>,
        <https://1145.am/db/2306281/Canaan_Partners>,
        <https://1145.am/db/2308329/Canaan_Partners>,
        <https://1145.am/db/2309376/Canaan_Partners>,
        <https://1145.am/db/2309387/Canaan_Partners>,
        <https://1145.am/db/2313171/Canaan_Partners>,
        <https://1145.am/db/2320925/Canaan_Partners>,
        <https://1145.am/db/2322231/Canaan_Partners>,
        <https://1145.am/db/2329010/Canaan_Partners>,
        <https://1145.am/db/2329011/Canaan_Partners>,
        <https://1145.am/db/2329531/Canaan_Partners>,
        <https://1145.am/db/2332322/Canaan_Partners>,
        <https://1145.am/db/2337958/Canaan_Partners>,
        <https://1145.am/db/2337974/Canaan_Partners>,
        <https://1145.am/db/2346532/Canaan_Partners>,
        <https://1145.am/db/2347469/Canaan_Partners>,
        <https://1145.am/db/2351129/Canaan_Partners>,
        <https://1145.am/db/2351316/Canaan_Partners>,
        <https://1145.am/db/2351684/Canaan_Partners>,
        <https://1145.am/db/2353588/Canaan_Partners>,
        <https://1145.am/db/2353608/Canaan_Partners>,
        <https://1145.am/db/2355043/Canaan_Partners>,
        <https://1145.am/db/2355238/Canaan_Partners>,
        <https://1145.am/db/2355715/Canaan_Partners>,
        <https://1145.am/db/2358378/Canaan_Partners>,
        <https://1145.am/db/2359185/Canaan_Partners>,
        <https://1145.am/db/2360258/Canaan_Partners>,
        <https://1145.am/db/2360266/Canaan_Partners>,
        <https://1145.am/db/2363535/Canaan_Partners>,
        <https://1145.am/db/2365700/Canaan_Partners>,
        <https://1145.am/db/2366187/Canaan_Partners>,
        <https://1145.am/db/2366753/Canaan_Partners>,
        <https://1145.am/db/2368322/Canaan_Partners>,
        <https://1145.am/db/2368973/Canaan_Partners>,
        <https://1145.am/db/2368982/Canaan_Partners>,
        <https://1145.am/db/2370582/Canaan_Partners>,
        <https://1145.am/db/2370802/Canaan_Partners>,
        <https://1145.am/db/2370834/Canaan_Partners>,
        <https://1145.am/db/2572398/Canaan_Partners>,
        <https://1145.am/db/2583466/Canaan_Partners>,
        <https://1145.am/db/2635439/Canaan_Partners>,
        <https://1145.am/db/316299/Canaan_Partners>,
        <https://1145.am/db/319155/Canaan_Partners>,
        <https://1145.am/db/353476/Canaan_Partners>,
        <https://1145.am/db/411041/Canaan_Partners>,
        <https://1145.am/db/523179/Canaan_Partners>,
        <https://1145.am/db/564082/Canaan_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Interwest_Partners> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "InterWest Partners" ;
    ns1:investor <https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> ;
    ns1:name "InterWest Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1091554/Riverfront_Ventures>,
        <https://1145.am/db/1091576/Riverfront_Ventures>,
        <https://1145.am/db/1150154/Norwind_Capital>,
        <https://1145.am/db/1263825/Westbridge_Capital>,
        <https://1145.am/db/1334273/West_Hill_Capital>,
        <https://1145.am/db/1335021/West_Hill_Capital>,
        <https://1145.am/db/1339788/Northzone>,
        <https://1145.am/db/1343467/Stormbreaker_Ventures>,
        <https://1145.am/db/1355824/Shorewind_Capital>,
        <https://1145.am/db/1398917/Red_River_West>,
        <https://1145.am/db/1407496/Storm_Ventures>,
        <https://1145.am/db/1433429/North_Island_Ventures>,
        <https://1145.am/db/1508460/North_Island_Ventures>,
        <https://1145.am/db/168364/Riverfront_Ventures>,
        <https://1145.am/db/1695419/Northgate_Capital>,
        <https://1145.am/db/1696310/Northzone>,
        <https://1145.am/db/1706170/Storm_Ventures>,
        <https://1145.am/db/1708291/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1717023/North_Island_Ventures>,
        <https://1145.am/db/1722944/Wind_Ventures>,
        <https://1145.am/db/1735168/Northgate_Capital>,
        <https://1145.am/db/1738465/Northzone>,
        <https://1145.am/db/1749607/Northzone>,
        <https://1145.am/db/1751200/Storm_Ventures>,
        <https://1145.am/db/1751800/Northgate_Capital>,
        <https://1145.am/db/1753643/Westbridge_Capital>,
        <https://1145.am/db/1754080/Northzone>,
        <https://1145.am/db/1760985/Westbridge_Capital>,
        <https://1145.am/db/1762493/Westbridge>,
        <https://1145.am/db/1765673/Norwest>,
        <https://1145.am/db/1791628/Interwest_Partners>,
        <https://1145.am/db/1793458/Storm_Ventures>,
        <https://1145.am/db/1808484/Northgate_Capital>,
        <https://1145.am/db/1808735/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1818901/Northgate_Capital>,
        <https://1145.am/db/1824252/Northgate_Capital>,
        <https://1145.am/db/1830655/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1832969/Interwest_Partners>,
        <https://1145.am/db/1841022/Northgate_Capital>,
        <https://1145.am/db/1846718/Northwest_Venture_Partners>,
        <https://1145.am/db/1848921/Interwest_Partners>,
        <https://1145.am/db/1849310/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1854203/Storm_Ventures>,
        <https://1145.am/db/1854846/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1857632/Northgate_Capital>,
        <https://1145.am/db/1860345/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1862872/Interwest_Partners>,
        <https://1145.am/db/1863401/Interwest_Partners>,
        <https://1145.am/db/1870838/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1872490/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1881065/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1890261/Storm_Ventures>,
        <https://1145.am/db/1890619/Northgate_Capital>,
        <https://1145.am/db/1894848/Storm_Ventures>,
        <https://1145.am/db/1906336/North_Bridge_Venture_Partners>,
        <https://1145.am/db/1911080/Northbridge_Venture_Partners>,
        <https://1145.am/db/1991347/Loop_Ventures>,
        <https://1145.am/db/2294753/Interwest_Partners>,
        <https://1145.am/db/2304606/Interwest_Partners>,
        <https://1145.am/db/2305507/Interwest_Partners>,
        <https://1145.am/db/2309051/Warburg_Pincus>,
        <https://1145.am/db/2314380/Interwest_Partners>,
        <https://1145.am/db/2340284/Interwest_Partners>,
        <https://1145.am/db/2355531/Interwest_Partners>,
        <https://1145.am/db/2355543/Interwest_Partners>,
        <https://1145.am/db/2362453/Warburg_Pincus>,
        <https://1145.am/db/2370582/Interwest_Partners>,
        <https://1145.am/db/2606743/Pacificap>,
        <https://1145.am/db/2614160/North_Bridge_Venture_Partners>,
        <https://1145.am/db/474123/Northzone> ;
    ns1:sameAsMedium <https://1145.am/db/1697098/Interwest_Partners>,
        <https://1145.am/db/1711300/Interwest_Partners>,
        <https://1145.am/db/1717613/Interwest_Partners>,
        <https://1145.am/db/1792426/Interwest_Partners>,
        <https://1145.am/db/1831689/Interwest_Partners>,
        <https://1145.am/db/1840379/Interwest_Partners>,
        <https://1145.am/db/1842466/Interwest_Partners>,
        <https://1145.am/db/1842817/Interwest_Partners>,
        <https://1145.am/db/1847994/Interwest_Partners>,
        <https://1145.am/db/1853156/Interwest_Partners>,
        <https://1145.am/db/1853882/Interwest_Partners>,
        <https://1145.am/db/1860832/Interwest_Partners>,
        <https://1145.am/db/1864172/Interwest_Partners>,
        <https://1145.am/db/1866990/Interwest_Partners>,
        <https://1145.am/db/1881935/Interwest_Partners>,
        <https://1145.am/db/1882810/Interwest_Partners>,
        <https://1145.am/db/1883990/Interwest_Partners>,
        <https://1145.am/db/1886261/Interwest_Partners>,
        <https://1145.am/db/1891834/Interwest_Partners>,
        <https://1145.am/db/1906428/Interwest_Partners>,
        <https://1145.am/db/1911578/Interwest_Partners>,
        <https://1145.am/db/2155189/Interwest_Partners>,
        <https://1145.am/db/2218486/Interwest_Partners>,
        <https://1145.am/db/2242262/Interwest_Partners>,
        <https://1145.am/db/2242266/Interwest_Partners>,
        <https://1145.am/db/2296841/Interwest_Partners>,
        <https://1145.am/db/2301464/Interwest_Partners>,
        <https://1145.am/db/2301901/Interwest_Partners>,
        <https://1145.am/db/2302076/Interwest_Partners>,
        <https://1145.am/db/2302091/Interwest_Partners>,
        <https://1145.am/db/2302108/Interwest_Partners>,
        <https://1145.am/db/2302289/Interwest_Partners>,
        <https://1145.am/db/2304598/Interwest_Partners>,
        <https://1145.am/db/2305514/Interwest_Partners>,
        <https://1145.am/db/2310073/Interwest_Partners>,
        <https://1145.am/db/2313357/Interwest_Partners>,
        <https://1145.am/db/2314964/Interwest_Partners>,
        <https://1145.am/db/2315289/Interwest_Partners>,
        <https://1145.am/db/2317561/Interwest_Partners>,
        <https://1145.am/db/2317564/Interwest_Partners>,
        <https://1145.am/db/2317750/Interwest_Partners>,
        <https://1145.am/db/2317753/Interwest_Partners>,
        <https://1145.am/db/2319809/Interwest_Partners>,
        <https://1145.am/db/2325257/Interwest_Partners>,
        <https://1145.am/db/2326361/Interwest_Partners>,
        <https://1145.am/db/2326373/Interwest_Partners>,
        <https://1145.am/db/2332991/Interwest_Partners>,
        <https://1145.am/db/2339393/Interwest_Partners>,
        <https://1145.am/db/2340224/Interwest_Partners>,
        <https://1145.am/db/2348754/Interwest_Partners>,
        <https://1145.am/db/2349838/Interwest_Partners>,
        <https://1145.am/db/2358234/Interwest_Partners>,
        <https://1145.am/db/2447807/Interwest_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Series_A_Acquisition_Pfizer_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Labrys Biologics Secures $ 31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer." ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "Acquires" ;
    ns1:name "Acquires" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 31 Million" ;
    ns1:vendor <https://1145.am/db/2360647/Pfizer_Inc> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2360647/Sofinnova_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "Sofinnova Ventures" ;
    ns1:investor <https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> ;
    ns1:name "Sofinnova Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1876390/Sofinnova_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2301093/Sofinnova_Ventures>,
        <https://1145.am/db/2303548/Sofinnova_Ventures>,
        <https://1145.am/db/2303560/Sofinnova_Ventures>,
        <https://1145.am/db/2304598/Sofinnova_Ventures>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305328/Sofinnova_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2310073/Sofinnova_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2311075/Sofinnova_Ventures>,
        <https://1145.am/db/2312051/Sofinnova_Ventures>,
        <https://1145.am/db/2313171/Sofinnova_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314964/Sofinnova_Ventures>,
        <https://1145.am/db/2317750/Sofinnova_Ventures>,
        <https://1145.am/db/2317753/Sofinnova_Ventures>,
        <https://1145.am/db/2322231/Sofinnova_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2324223/Sofinnova_Ventures>,
        <https://1145.am/db/2325549/Sofinnova_Ventures>,
        <https://1145.am/db/2328338/Sofinnova_Ventures>,
        <https://1145.am/db/2330799/Sofinnova_Ventures>,
        <https://1145.am/db/2330914/Sofinnova_Ventures>,
        <https://1145.am/db/2330920/Sofinnova_Ventures>,
        <https://1145.am/db/2331700/Sofinnova_Ventures>,
        <https://1145.am/db/2336102/Sofinnova_Ventures>,
        <https://1145.am/db/2336109/Sofinnova_Ventures>,
        <https://1145.am/db/2337140/Sofinnova_Ventures>,
        <https://1145.am/db/2339666/Sofinnova_Ventures>,
        <https://1145.am/db/2340542/Sofinnova_Ventures>,
        <https://1145.am/db/2340888/Sofinnova_Ventures>,
        <https://1145.am/db/2340890/Sofinnova_Ventures>,
        <https://1145.am/db/2341869/Sofinnova_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341897/Sofinnova_Ventures>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2345047/Sofinnova_Ventures>,
        <https://1145.am/db/2345262/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2349013/Sofinnova_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2349834/Sofinnova_Ventures>,
        <https://1145.am/db/2350231/Sofinnova_Ventures>,
        <https://1145.am/db/2350855/Sofinnova_Ventures>,
        <https://1145.am/db/2352059/Sofinnova_Ventures>,
        <https://1145.am/db/2353771/Sofinnova_Ventures>,
        <https://1145.am/db/2353789/Sofinnova_Ventures>,
        <https://1145.am/db/2355183/Sofinnova_Ventures>,
        <https://1145.am/db/2357105/Sofinnova_Ventures>,
        <https://1145.am/db/2357356/Sofinnova_Ventures>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358234/Sofinnova_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2359124/Sofinnova_Ventures>,
        <https://1145.am/db/2360266/Sofinnova_Ventures>,
        <https://1145.am/db/2362902/Sofinnova_Ventures>,
        <https://1145.am/db/2362909/Sofinnova_Ventures>,
        <https://1145.am/db/2362910/Sofinnova_Ventures>,
        <https://1145.am/db/2366710/Sofinnova_Ventures>,
        <https://1145.am/db/2366712/Sofinnova_Ventures>,
        <https://1145.am/db/2367022/Sofinnova_Ventures>,
        <https://1145.am/db/2367023/Sofinnova_Ventures>,
        <https://1145.am/db/2368982/Sofinnova_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/2569522/Sofinnova_Ventures>,
        <https://1145.am/db/2570520/Sofinnova_Ventures>,
        <https://1145.am/db/2570523/Sofinnova_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2578627/Sofinnova_Ventures>,
        <https://1145.am/db/2588372/Sofinnova_Ventures>,
        <https://1145.am/db/2592611/Sofinnova_Ventures>,
        <https://1145.am/db/2630808/Sofinnova_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360667/Technology_Joint_Venture_Solstice_Biologics_Llc_Uc_San_Diego_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "joint venture" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Solstice Biologics Secures $ 18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego." ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "Licenses" ;
    ns1:name "Licenses" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:targetDetails "Technology" ;
    ns1:valueRaw "$ 18 Million" ;
    ns1:vendor <https://1145.am/db/2360667/Solstice_Biologics_Llc>,
        <https://1145.am/db/2360667/Uc_San_Diego> ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "San Diego" .

<https://1145.am/db/2361581/Starfish_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Melbourne" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2158177/about.rdf> ;
    ns1:basedInHighRaw "Melbourne, Australia" ;
    ns1:documentDate "2013-06-04T11:33:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagonist Therapeutics Raises $14 Million in Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/protagonist-therapeutics-raises-14-million-series-b-venture-financing> ;
    ns1:foundName "Starfish Ventures (Melbourne, Australia)" ;
    ns1:investor <https://1145.am/db/2361581/Venture_Investment_Johnson___Johnson_Development_Corporation_Lilly_Ventures_Protagonist_Therapeutics_Starfish_Ventures_Completed> ;
    ns1:name "Starfish Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1830016/Starfish_Ventures>,
        <https://1145.am/db/1882907/Starfish_Ventures>,
        <https://1145.am/db/1893938/Starfish_Ventures>,
        <https://1145.am/db/2368322/Starfish_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Biotie_Therapies> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Finland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/660013/about.rdf> ;
    ns1:basedInHighRaw "Finland" ;
    ns1:buyer <https://1145.am/db/2361595/Neurelis_Acquisition> ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "Biotie Therapies" ;
    ns1:name "Biotie Therapies" ;
    ns1:sameAsMedium <https://1145.am/db/2302655/Biotie_Therapies_Inc>,
        <https://1145.am/db/2318288/Biotie_Therapies_Corp>,
        <https://1145.am/db/2348178/Biotie_Therapies_Corp>,
        <https://1145.am/db/2353371/Biotie_Therapies>,
        <https://1145.am/db/2361597/Biotie_Therapies_Corp>,
        <https://1145.am/db/2367019/Biotie_Therapies_Corp>,
        <https://1145.am/db/2369308/Biotie_Therapies_Corp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Investment_Protagonist_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "@ RyanMFierce: J & J backs $ biotech startup Protagonist in $ 14M financing." ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2361595/Protagonist> ;
    ns1:valueRaw "$ 14M" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2361595/Lincoln_Park_Capital_Fund> a org:Organization ;
    ns1:basedInLowRaw "Newark, CA" ;
    ns1:buyer <https://1145.am/db/2361595/Ipo_Lincoln_Park_Capital_Fund_Stemcells_Has_Not_Happened>,
        <https://1145.am/db/2361595/Stemcells_Ipo> ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "Lincoln Park Capital Fund" ;
    ns1:name "Lincoln Park Capital Fund" ;
    ns1:sameAsMedium <https://1145.am/db/1222727/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/1511889/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/1511890/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2023831/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2241339/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2354950/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2355286/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2359973/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2360399/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/2361594/Lincoln_Park_Capital_Fund_Llc>,
        <https://1145.am/db/580584/Lincoln_Park_Capital_Fund_Llc>,
        <https://1145.am/db/654207/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/656129/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/670877/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/881704/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/883509/Lincoln_Park_Capital_Fund>,
        <https://1145.am/db/974716/Lincoln_Park_Capital_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Series_Investment_Edge_Therapeutics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Edge Therapeutics says it raised $ 18 million in a Series C. The biotech is developing hospital products for acute, fatal or debilitating conditions." ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2361595/Edge_Therapeutics> ;
    ns1:targetDetails "Series" ;
    ns1:targetName "Edge Therapeutics" ;
    ns1:valueRaw "$ 18 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2361625/Canaan_Partners_Sofinnova_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Conn",
        "U.S." ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "Canaan Partners",
        "Canaan Partners, Sofinnova Ventures",
        "Sofinnova Ventures" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2361625/Series_C_Investment_Canaan_Partners_Sofinnova_Ventures_Domain_Associates_Foundation_Medical_Partners_Marinus_Pharmaceuticals_Inc_Rusnanomedinvest_Has_Not_Happened> ;
    ns1:name "Canaan Partners",
        "Canaan Partners, Sofinnova Ventures",
        "Sofinnova Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1196618/Sofinnova_Partners>,
        <https://1145.am/db/1199155/Sofinnova_Partners>,
        <https://1145.am/db/1520914/Sanno_Capital>,
        <https://1145.am/db/1586510/Sopris_Capital>,
        <https://1145.am/db/1945485/Sozo_Ventures>,
        <https://1145.am/db/2079459/Sopris_Capital>,
        <https://1145.am/db/2102258/Shoni_Top_Ventures>,
        <https://1145.am/db/2144387/Okapi_Capital>,
        <https://1145.am/db/2152399/Sofinnova_Investments>,
        <https://1145.am/db/2153373/Sofinnova_Partners>,
        <https://1145.am/db/2156284/Avalon_Ventures>,
        <https://1145.am/db/2286182/Sofinnova_Partners>,
        <https://1145.am/db/2305713/Pappas_Ventures>,
        <https://1145.am/db/2311075/Sofinnova_Ventures>,
        <https://1145.am/db/2312051/Sofinnova_Ventures>,
        <https://1145.am/db/2319806/Interwest_Partners_Prospect_Venture_Partners_New_Enterprise_Associates_Puretech_Ventures>,
        <https://1145.am/db/2335675/Versant_Ventures>,
        <https://1145.am/db/2341897/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2355885/Sofinnova_Partners>,
        <https://1145.am/db/2356351/Plexus_Ventures>,
        <https://1145.am/db/2358269/Sofinnova_Partners>,
        <https://1145.am/db/2358657/Astellas_Venture_Management>,
        <https://1145.am/db/2363442/Eshelman_Ventures>,
        <https://1145.am/db/2363597/Sofinnova_Partners>,
        <https://1145.am/db/2630808/Sofinnova_Ventures>,
        <https://1145.am/db/779867/Mirana_Ventures>,
        <https://1145.am/db/955466/Sofinnova_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361625/Foundation_Medical_Partners> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "Foundation Medical Partners" ;
    ns1:investor <https://1145.am/db/2361625/Series_C_Investment_Canaan_Partners_Sofinnova_Ventures_Domain_Associates_Foundation_Medical_Partners_Marinus_Pharmaceuticals_Inc_Rusnanomedinvest_Has_Not_Happened> ;
    ns1:name "Foundation Medical Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2301824/Nexus_Medical_Partners>,
        <https://1145.am/db/2336109/Foundation_Medical_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2287777/Foundation_Medical_Partners>,
        <https://1145.am/db/2295207/Foundation_Medical_Partners>,
        <https://1145.am/db/2313171/Foundation_Medical_Partners>,
        <https://1145.am/db/2317467/Foundation_Medical_Partners>,
        <https://1145.am/db/2318779/Foundation_Medical_Partners>,
        <https://1145.am/db/2322231/Foundation_Medical_Partners>,
        <https://1145.am/db/2336102/Foundation_Medical_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361625/Rusnanomedinvest> a org:Organization ;
    ns1:basedInLowRaw "Russia" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "RusnanoMedInvest",
        "RusnanoMedInvest (RMI)" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2361625/Series_C_Investment_Canaan_Partners_Sofinnova_Ventures_Domain_Associates_Foundation_Medical_Partners_Marinus_Pharmaceuticals_Inc_Rusnanomedinvest_Has_Not_Happened> ;
    ns1:name "RusnanoMedInvest" ;
    ns1:sameAsHigh <https://1145.am/db/2336125/Rusnanomedinvest>,
        <https://1145.am/db/2339894/Rusnanomedinvest> ;
    ns1:sameAsMedium <https://1145.am/db/2297408/Rusnanomedinvest>,
        <https://1145.am/db/2347984/Rusnanomedinvest>,
        <https://1145.am/db/2356301/Rusnanomedinvest>,
        <https://1145.am/db/2357325/Rusnanomedinvest>,
        <https://1145.am/db/2358541/Rusnanomedinvest>,
        <https://1145.am/db/2360258/Rusnanomedinvest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362715/Apple_Tree_Partners> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Apple",
        "Apple Tree Partners" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "Apple Tree Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2073567/Apple_Tree_Partners>,
        <https://1145.am/db/2151802/Apple_Tree_Partners>,
        <https://1145.am/db/2297471/Apple_Tree_Partners>,
        <https://1145.am/db/2301527/Apple_Tree_Partners>,
        <https://1145.am/db/2309506/Apple_Tree_Partners>,
        <https://1145.am/db/2309507/Apple_Tree_Partners>,
        <https://1145.am/db/2323210/Apple_Tree_Partners>,
        <https://1145.am/db/2323228/Apple_Tree_Partners>,
        <https://1145.am/db/2326222/Apple_Tree_Partners>,
        <https://1145.am/db/2336328/Apple_Tree_Partners>,
        <https://1145.am/db/2352897/Apple_Tree_Partners>,
        <https://1145.am/db/2352899/Apple_Tree_Partners>,
        <https://1145.am/db/2359185/Apple_Tree_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362715/Excel_Venture_Management> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Excel Venture Management" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "Excel Venture Management" ;
    ns1:sameAsMedium <https://1145.am/db/1852302/Excel_Venture_Management>,
        <https://1145.am/db/1854385/Excel_Venture_Management>,
        <https://1145.am/db/2147446/Excel_Venture_Management>,
        <https://1145.am/db/2230624/Excel_Venture_Management>,
        <https://1145.am/db/2235852/Excel_Venture_Management>,
        <https://1145.am/db/2319506/Excel_Venture_Management>,
        <https://1145.am/db/2332698/Excel_Venture_Management>,
        <https://1145.am/db/2336328/Excel_Venture_Management>,
        <https://1145.am/db/2342269/Excel_Venture_Management>,
        <https://1145.am/db/2359287/Excel_Venture_Management> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/Advent_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Redwood City, CA" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "Advent Venture Partners" ;
    ns1:investor <https://1145.am/db/2362736/C_Investment_Advent_Venture_Partners_Aisling_Capital_Index_Ventures_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Advent Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1699773/Advent_Venture_Partners_Llp>,
        <https://1145.am/db/1828930/Advent_Venture_Partners>,
        <https://1145.am/db/1873136/Advent_Venture_Partners>,
        <https://1145.am/db/1875469/Advent_Venture_Partners>,
        <https://1145.am/db/1879760/Advent_Venture_Partners>,
        <https://1145.am/db/1895619/Advent_Venture_Partners>,
        <https://1145.am/db/1895903/Advent_Venture_Partners>,
        <https://1145.am/db/1910490/Advent_Venture_Partners>,
        <https://1145.am/db/1919816/Advent_Venture_Partners>,
        <https://1145.am/db/2303656/Advent_Venture_Partners>,
        <https://1145.am/db/2314546/Advent_Venture_Partners>,
        <https://1145.am/db/2322622/Advent_Venture_Partners>,
        <https://1145.am/db/2331935/Advent_Venture_Partners>,
        <https://1145.am/db/2331946/Advent_Venture_Partners>,
        <https://1145.am/db/2346534/Advent_Venture_Partners>,
        <https://1145.am/db/2352566/Advent_Venture_Partners>,
        <https://1145.am/db/2365819/Advent_Venture_Partners>,
        <https://1145.am/db/2638432/Advent_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2536483/Ajinomoto_Co_Inc> a org:Organization ;
    ns1:basedInLowRaw "Japan",
        "TYO" ;
    ns1:buyer <https://1145.am/db/2536483/Althea_Technologies_Acquisition> ;
    ns1:description "Biopharmaceutical development and manufacturing services",
        "biopharmaceutical development and manufacturing services" ;
    ns1:documentDate "2013-03-06T13:34:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/ajinomoto-co-inc-agrees-to-acquire-althea-technologies-inc> ;
    ns1:foundName "Ajinomoto Co.",
        "Ajinomoto Co., Inc." ;
    ns1:name "Ajinomoto Co.",
        "Ajinomoto Co., Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2340776/Ajinomoto_Co_Inc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2536882/Ajinomoto> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japan" ;
    ns1:buyer <https://1145.am/db/2536882/Althea_Plant_Acquisition> ;
    ns1:description "biotechnology" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "Ajinomoto" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2536882/Investment_Ajinomoto_Has_Not_Happened> ;
    ns1:name "Ajinomoto" ;
    ns1:sameAsHigh <https://1145.am/db/1483462/Plandai_Biotechnology_Inc>,
        <https://1145.am/db/1486466/Plandai_Biotechnologies>,
        <https://1145.am/db/2023900/Meiji_Seika_Pharma_Co_Ltd>,
        <https://1145.am/db/2319721/Teikoku_Pharma>,
        <https://1145.am/db/2327868/Karo_Bio>,
        <https://1145.am/db/2564030/Japan>,
        <https://1145.am/db/2564191/Teijin_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/2340775/Ajinomoto>,
        <https://1145.am/db/2548483/Ajinomoto>,
        <https://1145.am/db/2804244/Ajinomoto_Co> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2536882/Innovent_Biologics> a org:Organization ;
    ns1:basedInHighGeoName "Suzhou" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1886760/about.rdf> ;
    ns1:basedInHighRaw "Suzhou, China" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "Innovent Biologics" ;
    ns1:industry "biologics" ;
    ns1:investor <https://1145.am/db/2536882/Althea_Plant_Acquisition>,
        <https://1145.am/db/2536882/Plant_Investment_Innovent_Biologics_Novartis_Has_Not_Happened> ;
    ns1:name "Innovent Biologics" ;
    ns1:sameAsHigh <https://1145.am/db/2359240/Innovent_Biologics> ;
    ns1:sameAsMedium <https://1145.am/db/2301308/Innovent_Biologics>,
        <https://1145.am/db/2550996/Innovent_Biologics>,
        <https://1145.am/db/2560070/Innovent_Biologics>,
        <https://1145.am/db/2560075/Innovent_Biologics_Inc>,
        <https://1145.am/db/2758736/Innovent_Biologics>,
        <https://1145.am/db/694561/Innovent_Biologics> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2536882/Novartis> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "Novartis",
        "Novartis ($ NVS)" ;
    ns1:industry "biologics" ;
    ns1:investor <https://1145.am/db/2536882/Plant_Investment_Innovent_Biologics_Novartis_Has_Not_Happened> ;
    ns1:name "Novartis" ;
    ns1:sameAsHigh <https://1145.am/db/1048908/Johnson___Johnson>,
        <https://1145.am/db/1176158/Novartis>,
        <https://1145.am/db/1177562/Novartis>,
        <https://1145.am/db/1262552/Johnson___Johnson>,
        <https://1145.am/db/1270868/Johnson___Johnson>,
        <https://1145.am/db/131136/Novartis>,
        <https://1145.am/db/132002/Novartis>,
        <https://1145.am/db/1328753/Novartis>,
        <https://1145.am/db/1507918/Novartis_Ag>,
        <https://1145.am/db/156403/Novartis>,
        <https://1145.am/db/1567521/Novartis>,
        <https://1145.am/db/1578114/Novartis>,
        <https://1145.am/db/1628428/Novalgen_Ltd>,
        <https://1145.am/db/1629605/Novartis>,
        <https://1145.am/db/1629663/Novartis>,
        <https://1145.am/db/165056/Novartis>,
        <https://1145.am/db/1673527/Johnson___Johnson>,
        <https://1145.am/db/176334/Novartis>,
        <https://1145.am/db/177096/Novartis>,
        <https://1145.am/db/1822601/Johnson___Johnson>,
        <https://1145.am/db/1986468/Novabay_Pharmaceuticals_Inc>,
        <https://1145.am/db/2033677/Novartis>,
        <https://1145.am/db/2033933/Novartis>,
        <https://1145.am/db/2036487/Novartis_Ag>,
        <https://1145.am/db/2057335/Johnson___Johnson>,
        <https://1145.am/db/2062728/Novan>,
        <https://1145.am/db/2065993/Novartis_Ag>,
        <https://1145.am/db/2089281/Johnson___Johnson>,
        <https://1145.am/db/2103283/Johnson___Johnson>,
        <https://1145.am/db/2107835/Novartis>,
        <https://1145.am/db/2129754/Novartis>,
        <https://1145.am/db/2152605/Novartis>,
        <https://1145.am/db/2152618/Novartis>,
        <https://1145.am/db/2153059/Novartis>,
        <https://1145.am/db/2153410/Johnson___Johnson>,
        <https://1145.am/db/2154194/Johnson___Johnson>,
        <https://1145.am/db/2154521/Johnson___Johnson>,
        <https://1145.am/db/2154527/Novartis>,
        <https://1145.am/db/2155069/Novartis>,
        <https://1145.am/db/2155665/Novartis>,
        <https://1145.am/db/2190363/Novartis_Ag>,
        <https://1145.am/db/2193661/Johnson___Johnson>,
        <https://1145.am/db/2194161/Novartis>,
        <https://1145.am/db/2279108/Novartis>,
        <https://1145.am/db/2279232/Novartis>,
        <https://1145.am/db/2279829/Novartis>,
        <https://1145.am/db/2280153/Novartis>,
        <https://1145.am/db/2280350/Novartis>,
        <https://1145.am/db/2280422/Johnson___Johnson>,
        <https://1145.am/db/2282888/Johnson_And_Johnson>,
        <https://1145.am/db/2282888/Johnson___Johnson>,
        <https://1145.am/db/2283590/Novartis>,
        <https://1145.am/db/2283645/Novartis>,
        <https://1145.am/db/2285311/Novartis>,
        <https://1145.am/db/2285587/Johnson___Johnson>,
        <https://1145.am/db/2286603/Johnson___Johnson>,
        <https://1145.am/db/2286604/Novartis>,
        <https://1145.am/db/2287377/Johnson___Johnson>,
        <https://1145.am/db/2288851/Novartis>,
        <https://1145.am/db/2289846/Novartis>,
        <https://1145.am/db/2290022/Novartis>,
        <https://1145.am/db/2290342/Johnson___Johnson>,
        <https://1145.am/db/2290894/Johnson___Johnson>,
        <https://1145.am/db/2291777/Johnson___Johnson>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2293323/Novartis>,
        <https://1145.am/db/2293342/Novartis>,
        <https://1145.am/db/2293591/Novartis>,
        <https://1145.am/db/2294026/Novartis>,
        <https://1145.am/db/2294585/Novartis>,
        <https://1145.am/db/2296402/Johnson___Johnson>,
        <https://1145.am/db/2296504/Novartis>,
        <https://1145.am/db/2296552/Novartis>,
        <https://1145.am/db/2296598/Johnson___Johnson>,
        <https://1145.am/db/2298037/Johnson___Johnson>,
        <https://1145.am/db/2298501/Johnson___Johnson>,
        <https://1145.am/db/2298606/Novartis>,
        <https://1145.am/db/2301066/Novartis>,
        <https://1145.am/db/2301089/Novartis>,
        <https://1145.am/db/2301705/Novasep>,
        <https://1145.am/db/2301735/Novartis>,
        <https://1145.am/db/2301857/Novartis>,
        <https://1145.am/db/2302724/Novartis>,
        <https://1145.am/db/2302727/Novartis>,
        <https://1145.am/db/2303121/Novartis_Bioventures>,
        <https://1145.am/db/230344/Swiss_Drugmaker_Novartis>,
        <https://1145.am/db/2304113/Novartis>,
        <https://1145.am/db/2304373/Novartis>,
        <https://1145.am/db/2304374/Novartis>,
        <https://1145.am/db/2305192/Novartis>,
        <https://1145.am/db/2305244/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2307228/Novadel_Pharma_Inc>,
        <https://1145.am/db/2307347/Novartis>,
        <https://1145.am/db/2307847/Novartis>,
        <https://1145.am/db/2307851/Novartis>,
        <https://1145.am/db/2307863/Novartis>,
        <https://1145.am/db/2307998/Novartis>,
        <https://1145.am/db/2308010/Novartis>,
        <https://1145.am/db/2308298/Novartis>,
        <https://1145.am/db/2308765/Novartis>,
        <https://1145.am/db/2308812/Novartis>,
        <https://1145.am/db/2308946/Novartis_Ag>,
        <https://1145.am/db/2309065/Novartis_Intercell>,
        <https://1145.am/db/2309930/Johnson___Johnson>,
        <https://1145.am/db/2310118/Johnson___Johnson>,
        <https://1145.am/db/2310150/Novartis>,
        <https://1145.am/db/2312008/Novartis>,
        <https://1145.am/db/2312018/Novartis_International_Ag>,
        <https://1145.am/db/2312088/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2312436/Novartis>,
        <https://1145.am/db/2314331/Johnson___Johnson>,
        <https://1145.am/db/2315481/Johnson___Johnson>,
        <https://1145.am/db/2317181/Johnson___Johnson>,
        <https://1145.am/db/2317639/Johnson___Johnson>,
        <https://1145.am/db/2317845/Novadel>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2317951/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318685/Johnson___Johnson>,
        <https://1145.am/db/2318994/Novadel>,
        <https://1145.am/db/2319412/Novartis>,
        <https://1145.am/db/2319656/Johnson___Johnson>,
        <https://1145.am/db/2320828/Novartis>,
        <https://1145.am/db/2321067/Novartis>,
        <https://1145.am/db/2322024/Johnson___Johnson>,
        <https://1145.am/db/2322266/Novartis>,
        <https://1145.am/db/2323000/Johnson___Johnson>,
        <https://1145.am/db/2323188/Novartis>,
        <https://1145.am/db/2323692/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2325073/Novartis>,
        <https://1145.am/db/2325869/Novartis>,
        <https://1145.am/db/2326949/Novartis>,
        <https://1145.am/db/2327024/Johnson___Johnson>,
        <https://1145.am/db/2327560/Novartis>,
        <https://1145.am/db/2329413/Novadel_Pharma_Inc>,
        <https://1145.am/db/2329475/Novadel_Pharma>,
        <https://1145.am/db/2329487/Johnson___Johnson>,
        <https://1145.am/db/2329597/Novartis>,
        <https://1145.am/db/2330648/Novartis>,
        <https://1145.am/db/2330734/Johnson___Johnson>,
        <https://1145.am/db/2331875/Novadel>,
        <https://1145.am/db/2332005/Novartis>,
        <https://1145.am/db/2332788/Novartis_Ag>,
        <https://1145.am/db/2332796/Novadel_Pharma_Inc>,
        <https://1145.am/db/2332872/Novartis>,
        <https://1145.am/db/2334206/Novartis>,
        <https://1145.am/db/2334645/Novast>,
        <https://1145.am/db/2336028/Novartis>,
        <https://1145.am/db/2336704/Novartis>,
        <https://1145.am/db/2336790/Johnson___Johnson>,
        <https://1145.am/db/2336797/Johnson___Johnson>,
        <https://1145.am/db/2336990/Novartis>,
        <https://1145.am/db/2339656/Novartis>,
        <https://1145.am/db/2339669/Novartis>,
        <https://1145.am/db/2340071/Johnson___Johnson>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2340948/Novartis>,
        <https://1145.am/db/2341850/Johnson___Johnson>,
        <https://1145.am/db/2344017/Novartis>,
        <https://1145.am/db/2344434/Novartis>,
        <https://1145.am/db/2344683/Johnson___Johnson>,
        <https://1145.am/db/2346576/Novadel_Pharma_Inc>,
        <https://1145.am/db/2346629/Novartis>,
        <https://1145.am/db/2348176/Novartis>,
        <https://1145.am/db/2349068/Novartis>,
        <https://1145.am/db/2350116/Johnson___Johnson>,
        <https://1145.am/db/2350440/Johnson___Johnson_Inc>,
        <https://1145.am/db/2352045/Novartis>,
        <https://1145.am/db/2352046/Novartis>,
        <https://1145.am/db/2352178/Novartis>,
        <https://1145.am/db/2354148/Novartis>,
        <https://1145.am/db/2354402/Johnson___Johnson>,
        <https://1145.am/db/2358273/Novartis>,
        <https://1145.am/db/2358297/Novartis>,
        <https://1145.am/db/2358579/Novartis>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2359165/Novartis>,
        <https://1145.am/db/2359179/Novartis>,
        <https://1145.am/db/2359302/Johnson___Johnson>,
        <https://1145.am/db/2359915/Novadel_Pharma_Inc>,
        <https://1145.am/db/2360309/Novartis_Pharma_Ag>,
        <https://1145.am/db/2360526/Novartis>,
        <https://1145.am/db/2360633/Novartis>,
        <https://1145.am/db/2360754/Johnson___Johnson>,
        <https://1145.am/db/2362448/Novadel_Pharma_Inc>,
        <https://1145.am/db/2363618/Novartis_Uk>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364601/Johnson___Johnson>,
        <https://1145.am/db/2366653/Johnson___Johnson>,
        <https://1145.am/db/2367118/Novabay_Pharmaceuticals>,
        <https://1145.am/db/2367207/Novartis>,
        <https://1145.am/db/2367616/Johnson___Johnson>,
        <https://1145.am/db/2367617/Johnson___Johnson>,
        <https://1145.am/db/2367829/Novartis_International_Ag>,
        <https://1145.am/db/2367836/Novartis_International_Ag>,
        <https://1145.am/db/2367993/Novabay>,
        <https://1145.am/db/2368571/Novartis>,
        <https://1145.am/db/2368646/Novartis>,
        <https://1145.am/db/2368659/Novartis>,
        <https://1145.am/db/2369183/Novartis>,
        <https://1145.am/db/2369449/Novartis_Pharma_Ag>,
        <https://1145.am/db/2369450/Novartis>,
        <https://1145.am/db/2369451/Novartis>,
        <https://1145.am/db/2369555/Swiss_Pharma_Giant_Novartis>,
        <https://1145.am/db/2369718/Novartis>,
        <https://1145.am/db/2370010/Novartis>,
        <https://1145.am/db/2370013/Novartis>,
        <https://1145.am/db/2370259/Johnson___Johnson>,
        <https://1145.am/db/2370615/Novartis>,
        <https://1145.am/db/2370635/Novartis>,
        <https://1145.am/db/2371070/Novartis>,
        <https://1145.am/db/2371077/Novartis>,
        <https://1145.am/db/2371188/Novartis>,
        <https://1145.am/db/2371323/Novartis>,
        <https://1145.am/db/2371326/Novartis>,
        <https://1145.am/db/2434670/Novartis>,
        <https://1145.am/db/2536264/Johnson___Johnson>,
        <https://1145.am/db/2536325/Novartis>,
        <https://1145.am/db/2536914/Novartis>,
        <https://1145.am/db/2537064/Novartis>,
        <https://1145.am/db/2537477/Novartis>,
        <https://1145.am/db/2537482/Novacea>,
        <https://1145.am/db/2538344/Novartis>,
        <https://1145.am/db/2538791/Novartis>,
        <https://1145.am/db/2539541/Novasep>,
        <https://1145.am/db/2539787/Novartis>,
        <https://1145.am/db/2539925/Novartis>,
        <https://1145.am/db/2540187/Novartis>,
        <https://1145.am/db/2541511/Novartis>,
        <https://1145.am/db/2542938/Novartis>,
        <https://1145.am/db/2543689/Novartis>,
        <https://1145.am/db/2543863/Johnson___Johnson>,
        <https://1145.am/db/2544236/Novartis>,
        <https://1145.am/db/2544326/Novartis>,
        <https://1145.am/db/2545284/Novartis>,
        <https://1145.am/db/2545522/Johnson___Johnson>,
        <https://1145.am/db/2545651/Novartis>,
        <https://1145.am/db/2545966/Novartis>,
        <https://1145.am/db/2545986/Novartis>,
        <https://1145.am/db/2546157/Novartis>,
        <https://1145.am/db/2546170/Novartis>,
        <https://1145.am/db/2546172/Johnson___Johnson>,
        <https://1145.am/db/2546603/Novartis>,
        <https://1145.am/db/2547152/Johnson___Johnson>,
        <https://1145.am/db/2547397/Novartis>,
        <https://1145.am/db/2548223/Novartis>,
        <https://1145.am/db/2548224/Novartis_Group>,
        <https://1145.am/db/2549043/Novartis>,
        <https://1145.am/db/2549631/Novast>,
        <https://1145.am/db/2550855/Novartis>,
        <https://1145.am/db/2551143/Novartis>,
        <https://1145.am/db/2551693/Novartis>,
        <https://1145.am/db/2551694/Novartis>,
        <https://1145.am/db/2552165/Novartis>,
        <https://1145.am/db/2552258/Novartis>,
        <https://1145.am/db/2553024/Johnson___Johnson>,
        <https://1145.am/db/2553024/Novartis>,
        <https://1145.am/db/2553276/Novartis>,
        <https://1145.am/db/2553480/Novartis>,
        <https://1145.am/db/2553740/Novasep>,
        <https://1145.am/db/2553810/Novartis>,
        <https://1145.am/db/2553846/Novartis>,
        <https://1145.am/db/2553852/Johnson___Johnson>,
        <https://1145.am/db/2554060/Novartis>,
        <https://1145.am/db/2554669/Novasep>,
        <https://1145.am/db/2555555/Novartis>,
        <https://1145.am/db/2555561/Novartis>,
        <https://1145.am/db/2556030/Novartis>,
        <https://1145.am/db/2556543/Novartis>,
        <https://1145.am/db/2557204/Novartis>,
        <https://1145.am/db/2557588/Novartis>,
        <https://1145.am/db/2558316/Novartis>,
        <https://1145.am/db/2558415/Novartis>,
        <https://1145.am/db/2558779/Novartis>,
        <https://1145.am/db/2558927/Novartis>,
        <https://1145.am/db/2559306/Novartis>,
        <https://1145.am/db/2559655/Novartis>,
        <https://1145.am/db/2559797/Novartis>,
        <https://1145.am/db/2559802/Novartis>,
        <https://1145.am/db/2559810/Switzerlands_Novartis>,
        <https://1145.am/db/2560023/Novartis>,
        <https://1145.am/db/2560079/Novartis>,
        <https://1145.am/db/2560372/Johnson___Johnson>,
        <https://1145.am/db/2561162/Novasep>,
        <https://1145.am/db/2561268/Novartis>,
        <https://1145.am/db/2561541/Novartis>,
        <https://1145.am/db/2561955/Novartis>,
        <https://1145.am/db/2562202/Novartis>,
        <https://1145.am/db/2562695/Novartis>,
        <https://1145.am/db/2562951/Novartis>,
        <https://1145.am/db/2563497/Novartis>,
        <https://1145.am/db/2563987/Novartis>,
        <https://1145.am/db/2564032/Johnson___Johnson>,
        <https://1145.am/db/2564141/Novartis>,
        <https://1145.am/db/2564268/Novartis>,
        <https://1145.am/db/2564462/Johnson___Johnson_Novartis>,
        <https://1145.am/db/2564695/Novartis>,
        <https://1145.am/db/2565142/Novartis>,
        <https://1145.am/db/2565794/Novartis>,
        <https://1145.am/db/2565844/Novartis>,
        <https://1145.am/db/2566121/Novartis>,
        <https://1145.am/db/2566147/Johnson___Johnson>,
        <https://1145.am/db/2567283/Novartis>,
        <https://1145.am/db/2567300/Novartis>,
        <https://1145.am/db/2567942/Novartis>,
        <https://1145.am/db/2568308/Novartis>,
        <https://1145.am/db/2568734/Novartis>,
        <https://1145.am/db/2568932/Novartis>,
        <https://1145.am/db/2568968/Novartis>,
        <https://1145.am/db/2568973/Novartis>,
        <https://1145.am/db/2569724/Novartis>,
        <https://1145.am/db/2570214/Novartis>,
        <https://1145.am/db/2570721/Novartis>,
        <https://1145.am/db/2570791/Novartis>,
        <https://1145.am/db/2570932/Novartis>,
        <https://1145.am/db/2570937/Novartis_Uk>,
        <https://1145.am/db/2571513/Novartis>,
        <https://1145.am/db/2571519/Novartis>,
        <https://1145.am/db/2571527/Novartis>,
        <https://1145.am/db/2572466/Johnson___Johnson>,
        <https://1145.am/db/2572713/Novartis>,
        <https://1145.am/db/2572904/Novartis_Group>,
        <https://1145.am/db/2572985/Novartis>,
        <https://1145.am/db/2573002/Novartis>,
        <https://1145.am/db/2573373/Johnson___Johnson>,
        <https://1145.am/db/2573473/Novartis>,
        <https://1145.am/db/2573517/Novartis>,
        <https://1145.am/db/2573611/Novartis>,
        <https://1145.am/db/2574347/Johnson___Johnson>,
        <https://1145.am/db/2574584/Novartis>,
        <https://1145.am/db/2574958/Novartis>,
        <https://1145.am/db/2575047/Novartis>,
        <https://1145.am/db/2575310/Novartis>,
        <https://1145.am/db/2575313/Novartis>,
        <https://1145.am/db/2575488/Novartis>,
        <https://1145.am/db/2575492/Johnson___Johnson>,
        <https://1145.am/db/2575496/Johnson___Johnson>,
        <https://1145.am/db/2575545/Novartis>,
        <https://1145.am/db/2575625/Novartis>,
        <https://1145.am/db/2575702/Novartis>,
        <https://1145.am/db/2575712/Novartis>,
        <https://1145.am/db/2575810/Novartis_Ag>,
        <https://1145.am/db/2575810/Novartis_Pharma_Ag>,
        <https://1145.am/db/2575813/Novartis>,
        <https://1145.am/db/2576242/Novartis>,
        <https://1145.am/db/2576254/Novartis>,
        <https://1145.am/db/2576439/Johnson___Johnson>,
        <https://1145.am/db/2576547/Novartis>,
        <https://1145.am/db/2576933/Novartis>,
        <https://1145.am/db/2576962/Johnson___Johnson>,
        <https://1145.am/db/2577129/Novartis>,
        <https://1145.am/db/2577419/Novartis>,
        <https://1145.am/db/2577998/Novartis>,
        <https://1145.am/db/2579507/Novartis>,
        <https://1145.am/db/2579519/Novartis>,
        <https://1145.am/db/2580047/Novartis>,
        <https://1145.am/db/2580401/Novartis>,
        <https://1145.am/db/2580963/Novartis>,
        <https://1145.am/db/2581378/Novartis>,
        <https://1145.am/db/2581394/Novartis>,
        <https://1145.am/db/2581397/Novartis>,
        <https://1145.am/db/2581493/Novartis>,
        <https://1145.am/db/2581716/Novartis>,
        <https://1145.am/db/2582355/Novartis>,
        <https://1145.am/db/2582395/Novartis>,
        <https://1145.am/db/2582400/Novartis>,
        <https://1145.am/db/2582402/Novartis>,
        <https://1145.am/db/2582623/Novartis>,
        <https://1145.am/db/2582643/Novartis>,
        <https://1145.am/db/2583067/Novartis>,
        <https://1145.am/db/2583189/Johnson___Johnson>,
        <https://1145.am/db/2584383/Johnson___Johnson>,
        <https://1145.am/db/2584538/Novartis>,
        <https://1145.am/db/2585039/Novartis>,
        <https://1145.am/db/2585121/Novartis>,
        <https://1145.am/db/2585710/Johnson___Johnson>,
        <https://1145.am/db/2586661/Novatis>,
        <https://1145.am/db/2586670/Novartis>,
        <https://1145.am/db/2587047/Novartis>,
        <https://1145.am/db/2587143/Johnson___Johnson>,
        <https://1145.am/db/2587177/Johnson___Johnson>,
        <https://1145.am/db/2587805/Novartis>,
        <https://1145.am/db/2587857/Novartis>,
        <https://1145.am/db/2588074/Johnson___Johnson>,
        <https://1145.am/db/2588196/Novartis>,
        <https://1145.am/db/2589178/Novartis>,
        <https://1145.am/db/2589402/Johnson___Johnson>,
        <https://1145.am/db/2589535/Novartis>,
        <https://1145.am/db/2589799/Novartis>,
        <https://1145.am/db/2591073/Johnson___Johnson>,
        <https://1145.am/db/2591074/Johnson___Johnson>,
        <https://1145.am/db/2591076/Johnson___Johnson>,
        <https://1145.am/db/2591905/Novartis>,
        <https://1145.am/db/2592351/Novartis>,
        <https://1145.am/db/2592505/Novartis>,
        <https://1145.am/db/2592534/Johnson___Johnson>,
        <https://1145.am/db/2592895/Novartis>,
        <https://1145.am/db/2592987/Novartis>,
        <https://1145.am/db/2593443/Novartis>,
        <https://1145.am/db/2593889/Johnson___Johnson>,
        <https://1145.am/db/2594106/Johnson___Johnson>,
        <https://1145.am/db/2594494/Novartis>,
        <https://1145.am/db/2594935/Novartis>,
        <https://1145.am/db/2594940/Novartis>,
        <https://1145.am/db/2595048/Novartis>,
        <https://1145.am/db/2595150/Novartis>,
        <https://1145.am/db/2595688/Novartis>,
        <https://1145.am/db/2595924/Novartis_Ag>,
        <https://1145.am/db/2596344/Novartis>,
        <https://1145.am/db/2597135/Johnson___Johnson>,
        <https://1145.am/db/2597197/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2598439/Johnson___Johnson_Inc>,
        <https://1145.am/db/2598636/Novartis>,
        <https://1145.am/db/2787530/Novartis>,
        <https://1145.am/db/2787550/Johnson___Johnson>,
        <https://1145.am/db/282192/Novartis>,
        <https://1145.am/db/346162/Novartis>,
        <https://1145.am/db/488391/Novartis>,
        <https://1145.am/db/509708/Novabay_Pharmaceuticals_Inc>,
        <https://1145.am/db/595011/Novartis>,
        <https://1145.am/db/601300/Novabay_Pharmaceuticals_Inc>,
        <https://1145.am/db/637582/Novartis>,
        <https://1145.am/db/652831/Novartis>,
        <https://1145.am/db/661296/Novartis>,
        <https://1145.am/db/691279/Novartis>,
        <https://1145.am/db/699695/Johnson___Johnson>,
        <https://1145.am/db/712016/Novartis>,
        <https://1145.am/db/895235/Novan> ;
    ns1:sameAsMedium <https://1145.am/db/1151476/Novartis>,
        <https://1145.am/db/1629127/Novartis>,
        <https://1145.am/db/1630421/Novartis>,
        <https://1145.am/db/2076347/Novartis>,
        <https://1145.am/db/2155042/Novartis>,
        <https://1145.am/db/2186148/Novartis>,
        <https://1145.am/db/2290898/Novartis>,
        <https://1145.am/db/2291090/Novartis>,
        <https://1145.am/db/2291713/Novartis>,
        <https://1145.am/db/2293419/Novartis>,
        <https://1145.am/db/2294680/Novartis>,
        <https://1145.am/db/2299847/Novartis>,
        <https://1145.am/db/2309347/Novartis>,
        <https://1145.am/db/2321958/Novartis>,
        <https://1145.am/db/2325386/Novartis>,
        <https://1145.am/db/2332408/Novartis>,
        <https://1145.am/db/2333390/Novartis>,
        <https://1145.am/db/2337976/Novartis>,
        <https://1145.am/db/2342687/Novartis>,
        <https://1145.am/db/2343460/Novartis>,
        <https://1145.am/db/2358559/Novartis>,
        <https://1145.am/db/2361451/Novartis>,
        <https://1145.am/db/2369178/Novartis>,
        <https://1145.am/db/2371165/Novartis>,
        <https://1145.am/db/2371203/Novartis>,
        <https://1145.am/db/2536538/Novartis>,
        <https://1145.am/db/2537155/Novartis>,
        <https://1145.am/db/2544350/Novartis>,
        <https://1145.am/db/2544409/Novartis>,
        <https://1145.am/db/2550764/Novartis>,
        <https://1145.am/db/2551001/Novartis>,
        <https://1145.am/db/2551402/Novartis>,
        <https://1145.am/db/2552856/Novartis>,
        <https://1145.am/db/2553487/Novartis>,
        <https://1145.am/db/2560238/Novartis>,
        <https://1145.am/db/2562442/Novartis>,
        <https://1145.am/db/2565564/Novartis>,
        <https://1145.am/db/2570062/Novartis>,
        <https://1145.am/db/2571462/Novartis>,
        <https://1145.am/db/2573984/Novartis>,
        <https://1145.am/db/2574950/Novartis>,
        <https://1145.am/db/2575947/Novartis>,
        <https://1145.am/db/2576892/Novartis>,
        <https://1145.am/db/2578046/Novartis>,
        <https://1145.am/db/2579890/Novartis>,
        <https://1145.am/db/2581804/Novartis>,
        <https://1145.am/db/2582646/Novartis>,
        <https://1145.am/db/2583163/Novartis>,
        <https://1145.am/db/2584135/Novartis>,
        <https://1145.am/db/2584245/Novartis>,
        <https://1145.am/db/2587048/Novartis>,
        <https://1145.am/db/2588333/Novartis>,
        <https://1145.am/db/2588691/Novartis>,
        <https://1145.am/db/2590887/Novartis>,
        <https://1145.am/db/2593780/Novartis>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2537461/Baxter_International> a org:Organization ;
    ns1:basedInLowRaw "Danish" ;
    ns1:buyer <https://1145.am/db/2537461/Genmab_Antibody_Plant_Acquisition> ;
    ns1:documentDate "2013-04-17T14:27:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Baxter to put $300M into old Genmab plant" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/baxter-to-put-300m-into-old-genmab-plant> ;
    ns1:foundName "Baxter International" ;
    ns1:investor <https://1145.am/db/2537461/Genmab_Antibody_Plant_Acquisition> ;
    ns1:name "Baxter International" ;
    ns1:sameAsMedium <https://1145.am/db/1625722/Baxter_International_Inc>,
        <https://1145.am/db/166496/Baxter_International_Inc>,
        <https://1145.am/db/1943061/Baxter_International_Inc>,
        <https://1145.am/db/1997451/Baxter_International_Inc>,
        <https://1145.am/db/1997970/Baxter_International_Inc>,
        <https://1145.am/db/1998744/Baxter_International_Inc>,
        <https://1145.am/db/1999800/Baxter_International_Inc>,
        <https://1145.am/db/2000474/Baxter_International_Inc>,
        <https://1145.am/db/2001027/Baxter_International>,
        <https://1145.am/db/2053360/Baxter_International_Inc>,
        <https://1145.am/db/2068105/Baxter_International_Inc>,
        <https://1145.am/db/2092837/Baxter_International_Inc>,
        <https://1145.am/db/2132018/Baxter_International_Inc>,
        <https://1145.am/db/2133696/Baxter_International_Inc>,
        <https://1145.am/db/2187070/Baxter_International>,
        <https://1145.am/db/2232422/Baxter_International_Inc>,
        <https://1145.am/db/2234720/Baxter_International_Inc>,
        <https://1145.am/db/2290136/Baxter_International>,
        <https://1145.am/db/2295497/Baxter_International>,
        <https://1145.am/db/2295646/Baxter_International>,
        <https://1145.am/db/2296958/Baxter_International>,
        <https://1145.am/db/2303013/Baxter_International_Inc>,
        <https://1145.am/db/2305834/Baxter_International>,
        <https://1145.am/db/2317780/Baxter_International>,
        <https://1145.am/db/2318881/Baxter_International>,
        <https://1145.am/db/2319221/Baxter_International_Inc>,
        <https://1145.am/db/2319224/Baxter_International>,
        <https://1145.am/db/2319235/Baxter_International_Inc>,
        <https://1145.am/db/2325476/Baxter_International>,
        <https://1145.am/db/2327576/Baxter_International>,
        <https://1145.am/db/2333665/Baxter_International>,
        <https://1145.am/db/2336789/Baxter_International>,
        <https://1145.am/db/2337649/Baxter_International_Inc>,
        <https://1145.am/db/2341671/Baxter_International_Inc>,
        <https://1145.am/db/2343327/Baxter_International>,
        <https://1145.am/db/2346138/Baxter_International_Inc>,
        <https://1145.am/db/2346568/Baxter_International_Inc>,
        <https://1145.am/db/2350809/Baxter_International_Inc>,
        <https://1145.am/db/2352126/Baxter_International_Inc>,
        <https://1145.am/db/2354318/Baxter_International_Inc>,
        <https://1145.am/db/2354471/Baxter_International_Inc>,
        <https://1145.am/db/2359064/Baxter_International_Inc>,
        <https://1145.am/db/2361441/Baxter_International_Inc>,
        <https://1145.am/db/2361442/Baxter_International>,
        <https://1145.am/db/2364637/Baxter_International>,
        <https://1145.am/db/2366139/Baxter_International_Inc>,
        <https://1145.am/db/2366540/Baxter_International_Inc>,
        <https://1145.am/db/2536430/Baxter_International>,
        <https://1145.am/db/2537054/Baxter_International_Inc>,
        <https://1145.am/db/2537057/Baxter_International_Inc>,
        <https://1145.am/db/2540502/Baxter_International>,
        <https://1145.am/db/2551486/Baxter_International_Inc>,
        <https://1145.am/db/2551490/Baxter_International>,
        <https://1145.am/db/2551513/Baxter_International>,
        <https://1145.am/db/2552077/Baxter_International>,
        <https://1145.am/db/2555342/Baxter_International>,
        <https://1145.am/db/2556983/Baxter_International_Inc>,
        <https://1145.am/db/2560265/Baxter_International>,
        <https://1145.am/db/2562102/Baxter_International_Inc>,
        <https://1145.am/db/2563850/Baxter_International>,
        <https://1145.am/db/2568922/Baxter_International_Inc>,
        <https://1145.am/db/2572551/Baxter_International_Inc>,
        <https://1145.am/db/2572570/Baxter_International_Inc>,
        <https://1145.am/db/2572573/Baxter_International_Inc>,
        <https://1145.am/db/2573883/Baxter_International_Inc>,
        <https://1145.am/db/2574459/Baxter_International_Inc>,
        <https://1145.am/db/2574461/Baxter_International_Inc>,
        <https://1145.am/db/2576789/Baxter_International_Inc>,
        <https://1145.am/db/2579268/Baxter_International_Inc>,
        <https://1145.am/db/2585871/Baxter_International>,
        <https://1145.am/db/2586046/Baxter_International_Inc>,
        <https://1145.am/db/2588251/Baxter_International_Inc>,
        <https://1145.am/db/2592173/Baxter_International>,
        <https://1145.am/db/2594139/Baxter_International_Inc>,
        <https://1145.am/db/2594742/Baxter_International>,
        <https://1145.am/db/2597180/Baxter_International_Inc>,
        <https://1145.am/db/435880/Baxter_International_Inc>,
        <https://1145.am/db/438971/Baxter_International>,
        <https://1145.am/db/446169/Baxter_International_Inc>,
        <https://1145.am/db/446405/Baxter_International>,
        <https://1145.am/db/446720/Baxter_International_Inc>,
        <https://1145.am/db/447058/Baxter_International_Inc>,
        <https://1145.am/db/448129/Baxter_International_Inc>,
        <https://1145.am/db/450035/Baxter_International_Inc>,
        <https://1145.am/db/450185/Baxter_International_Inc>,
        <https://1145.am/db/451392/Baxter_International_Inc>,
        <https://1145.am/db/454668/Baxter_International_Inc>,
        <https://1145.am/db/461561/Baxter_International_Inc>,
        <https://1145.am/db/519147/Baxter_International_Inc>,
        <https://1145.am/db/590996/Baxter_International_Inc>,
        <https://1145.am/db/670267/Baxter_International_Inc>,
        <https://1145.am/db/693233/Baxter_International_Inc>,
        <https://1145.am/db/694622/Baxter_International_Inc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2562245/American_Capital> a org:Organization ;
    ns1:basedInLowRaw "American" ;
    ns1:buyer <https://1145.am/db/2562245/Cambridge_Major_Laboratories_Inc_Acquisition> ;
    ns1:description "Healthcare products and services companies" ;
    ns1:documentDate "2013-01-15T13:12:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "American Capital Commits $212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/american-capital-commits-212-million-one-stop-buyout%C2%AE-of-cambridge-major-laboratories> ;
    ns1:foundName "American Capital",
        "American Capital, Ltd" ;
    ns1:investor <https://1145.am/db/2562245/Cambridge_Major_Laboratories_Inc_Acquisition>,
        <https://1145.am/db/2562245/One_Stop_Buyout_Investment> ;
    ns1:name "American Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2307566/American_Capital>,
        <https://1145.am/db/2544488/American_Capital>,
        <https://1145.am/db/2547546/American_Capital>,
        <https://1145.am/db/2562248/American_Capital>,
        <https://1145.am/db/2577081/American_Capital> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580543/Seed_Investment_Arcturus_Therapeutics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-04T20:18:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ARCTURUS THERAPEUTICS RAISES $ 1.3 MILLION IN SERIES SEED FUNDING.",
        "SAN DIEGO, Calif., June 1, 2013 - Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $ 1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada." ;
    ns1:documentTitle "ARCTURUS THERAPEUTICS RAISES $1.3 MILLION IN SERIES SEED FUNDING" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/arcturus-therapeutics-raises-1-3-million-series-seed-funding> ;
    ns1:foundName "RAIS",
        "funding" ;
    ns1:name "RAIS",
        "funding" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2580543/Arcturus_Therapeutics> ;
    ns1:targetDetails "seed" ;
    ns1:valueRaw "$ 1.3 MILLION",
        "$ 1.3 million" ;
    ns1:when "2013-06-01T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 1, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2580564/North_West_Fund> a org:Organization ;
    ns1:documentDate "2013-06-12T13:23:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alchemy 400,000 Investment Boost" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/alchemy-%C2%A3400-000-investment-boost> ;
    ns1:foundName "North West Fund" ;
    ns1:name "North West Fund" ;
    ns1:participant <https://1145.am/db/2580564/Investment_Alchemy_Pharmatech_North_West_Fund_Has_Not_Happened> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2584818/Teva_Pharmaceutical> a org:Organization ;
    ns1:basedInLowRaw "Israel" ;
    ns1:buyer <https://1145.am/db/2584818/Microdose_Therapeutx_Acquisition> ;
    ns1:description "drug-delivery specialist" ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:foundName "Teva Pharmaceutical" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Teva Pharmaceutical" ;
    ns1:sameAsHigh <https://1145.am/db/1177474/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/1178087/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/1522618/Teva_Pharmaceutical>,
        <https://1145.am/db/2129381/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2201211/Teva>,
        <https://1145.am/db/2239056/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2243196/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2244234/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2259244/Teva>,
        <https://1145.am/db/2302310/Teva>,
        <https://1145.am/db/2302340/Teva>,
        <https://1145.am/db/2302799/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2303398/Teva>,
        <https://1145.am/db/2303404/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2304325/Teva_Pharmaceuticals>,
        <https://1145.am/db/2304451/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2305956/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2308917/Teva_Pharmaceuticals_Industries_Ltd>,
        <https://1145.am/db/2308946/Teva>,
        <https://1145.am/db/2308962/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2308964/Teva>,
        <https://1145.am/db/2309115/Teva>,
        <https://1145.am/db/2313246/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2313528/Teva>,
        <https://1145.am/db/2314439/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2316058/Teva>,
        <https://1145.am/db/2316537/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2317929/Teva_Pharmaceuticals>,
        <https://1145.am/db/2319919/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2319919/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2320510/Teva>,
        <https://1145.am/db/2322476/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2324654/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2325949/Teva_Pharmaceutical>,
        <https://1145.am/db/2326087/Teva_Pharmaceutical>,
        <https://1145.am/db/2326095/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2328509/Teva_Pharmaceuticals_Industries_Ltd>,
        <https://1145.am/db/2331853/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2333444/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2335886/Teva>,
        <https://1145.am/db/2335888/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2338474/Teva>,
        <https://1145.am/db/2338480/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2339602/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2339813/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2340427/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2341991/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342533/Teva_Pharmaceutical>,
        <https://1145.am/db/2342540/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342764/Teva>,
        <https://1145.am/db/2342966/Teva>,
        <https://1145.am/db/2342970/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342980/Teva>,
        <https://1145.am/db/2344775/Teva>,
        <https://1145.am/db/2345850/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2346033/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2347107/Teva_Americas_Generics>,
        <https://1145.am/db/2347630/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2349699/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2350564/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2350567/Teva_Pharmaceutical>,
        <https://1145.am/db/2351258/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2353121/Teva>,
        <https://1145.am/db/2356821/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2359165/Teva>,
        <https://1145.am/db/2360060/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2361881/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2362614/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2362877/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2364375/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2364393/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2364463/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2365818/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2367099/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2536415/Teva>,
        <https://1145.am/db/2536575/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2536576/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2537261/Teva_Pharmaceutical>,
        <https://1145.am/db/2537347/Teva>,
        <https://1145.am/db/2537383/Teva>,
        <https://1145.am/db/2537911/Teva>,
        <https://1145.am/db/2538861/Teva>,
        <https://1145.am/db/2538918/Teva>,
        <https://1145.am/db/2539357/Teva>,
        <https://1145.am/db/2541555/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2541838/Teva>,
        <https://1145.am/db/2541911/Teva>,
        <https://1145.am/db/2542380/Teva>,
        <https://1145.am/db/2542518/Teva_Pharmaceuticals>,
        <https://1145.am/db/2543548/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544354/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544399/Teva>,
        <https://1145.am/db/2544434/Teva>,
        <https://1145.am/db/2544552/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544588/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2546097/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2546317/Teva>,
        <https://1145.am/db/2546583/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2547068/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2547181/Teva_Pharmaceutical>,
        <https://1145.am/db/2548005/Teva>,
        <https://1145.am/db/2548022/Teva>,
        <https://1145.am/db/2550094/Teva>,
        <https://1145.am/db/2550387/Teva>,
        <https://1145.am/db/2550476/Teva>,
        <https://1145.am/db/2552222/Teva_Pharmaceutical>,
        <https://1145.am/db/2552465/Teva>,
        <https://1145.am/db/2552547/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2552799/Teva>,
        <https://1145.am/db/2553028/Teva_Pharmaceutical>,
        <https://1145.am/db/2553677/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2553841/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2554237/Teva>,
        <https://1145.am/db/2554286/Teva>,
        <https://1145.am/db/2554769/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2555705/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2555708/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2555873/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2556798/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2556903/Teva>,
        <https://1145.am/db/2557091/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2557469/Teva>,
        <https://1145.am/db/2557785/Teva>,
        <https://1145.am/db/2557821/Teva>,
        <https://1145.am/db/2559209/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2559637/Teva_Pharmaceutical>,
        <https://1145.am/db/2560610/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2560744/Teva>,
        <https://1145.am/db/2560844/Teva>,
        <https://1145.am/db/2561438/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2562902/Teva>,
        <https://1145.am/db/2562919/Teva>,
        <https://1145.am/db/2563815/Teva_Pharmaceutical>,
        <https://1145.am/db/2563858/Teva>,
        <https://1145.am/db/2564988/Teva>,
        <https://1145.am/db/2566019/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2568379/Teva>,
        <https://1145.am/db/2569371/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2569442/Teva>,
        <https://1145.am/db/2570095/Teva>,
        <https://1145.am/db/2570098/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570307/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570353/Teva>,
        <https://1145.am/db/2570574/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570841/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570949/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571326/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2571370/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571373/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571443/Teva>,
        <https://1145.am/db/2571706/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2571717/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571723/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572066/Teva>,
        <https://1145.am/db/2572137/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572213/Teva>,
        <https://1145.am/db/2572452/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572474/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572533/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572541/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572542/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572985/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2573173/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2573256/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2574106/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2574382/Teva_Pharmaceuticals>,
        <https://1145.am/db/2574807/Teva>,
        <https://1145.am/db/2574829/Teva>,
        <https://1145.am/db/2575004/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2575012/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2575028/Teva>,
        <https://1145.am/db/2575623/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2576122/Teva_Pharmaceuticals>,
        <https://1145.am/db/2577101/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577657/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577833/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577839/Teva>,
        <https://1145.am/db/2578103/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578166/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578176/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578393/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578420/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578466/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578482/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578490/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578503/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578908/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578932/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2579090/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579092/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579093/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579464/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579467/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580140/Teva>,
        <https://1145.am/db/2580401/Teva_Pharmaceutical>,
        <https://1145.am/db/2580491/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2580562/Teva_Pharmaceuticals>,
        <https://1145.am/db/2580570/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580872/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580875/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2581347/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582326/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582327/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582675/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582685/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582705/Teva>,
        <https://1145.am/db/2583627/Teva>,
        <https://1145.am/db/2586385/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2586692/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2586703/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2586716/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2587626/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2587948/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2587993/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588510/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588611/Teva_Pharmaceutical>,
        <https://1145.am/db/2588837/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588941/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588942/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2589459/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2590292/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590783/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590827/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2590891/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590954/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2591396/Teva>,
        <https://1145.am/db/2591596/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2592620/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2592950/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2594992/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595027/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595051/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595587/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2596015/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2596755/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2597184/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598026/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598250/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598261/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598266/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598391/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598400/Teva>,
        <https://1145.am/db/2598408/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598543/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/576418/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/584349/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/586645/Teva_Pharmaceutical_Industries_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2201221/Teva_Pharmaceuticals>,
        <https://1145.am/db/2339763/Teva_Pharmaceutical>,
        <https://1145.am/db/2567583/Teva_Pharmaceuticals> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2584818/Valeant_Pharmaceuticals> a org:Organization ;
    ns1:buyer <https://1145.am/db/2584818/Bausch_+_Lomb_Acquisition> ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:foundName "Valeant Pharmaceuticals" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Valeant Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2294967/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2295456/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302002/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302007/Valeant_Canada_Limited>,
        <https://1145.am/db/2302007/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2302826/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305757/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305758/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306724/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306813/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2308734/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312215/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312221/Valeant>,
        <https://1145.am/db/2313272/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313282/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2313320/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313365/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2315100/Valeant>,
        <https://1145.am/db/2318350/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2318405/Valeant>,
        <https://1145.am/db/2319331/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2319722/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2322159/Valeant>,
        <https://1145.am/db/2322776/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2323106/Valeant>,
        <https://1145.am/db/2323111/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2324422/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2325692/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2325895/Valeant>,
        <https://1145.am/db/2330074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2332074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2335641/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2336083/Valeant>,
        <https://1145.am/db/2336258/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2336278/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2337634/Valeant>,
        <https://1145.am/db/2341518/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2346832/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2346833/Valeant_Canada_Limited>,
        <https://1145.am/db/2346833/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2348864/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2349239/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2349461/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2350907/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2353646/Valeant>,
        <https://1145.am/db/2354801/Valeant>,
        <https://1145.am/db/2354804/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2356945/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2357416/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2360703/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2361172/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2361190/Valeant>,
        <https://1145.am/db/2362893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2363430/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2365199/Valeant>,
        <https://1145.am/db/2365200/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2366467/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2366468/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2369037/Valeant>,
        <https://1145.am/db/2369371/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2369374/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2369618/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2538017/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2539802/Valeant>,
        <https://1145.am/db/2540219/Valeant>,
        <https://1145.am/db/2540467/Valeant>,
        <https://1145.am/db/2543893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2543904/Valeant>,
        <https://1145.am/db/2544888/Valeant>,
        <https://1145.am/db/2545075/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2550867/Valeant>,
        <https://1145.am/db/2556458/Valeant>,
        <https://1145.am/db/2556718/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2556805/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2557472/Valeant>,
        <https://1145.am/db/2560716/Valeant>,
        <https://1145.am/db/2560770/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2566037/Valeant>,
        <https://1145.am/db/2568778/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2568799/Valeant_Canada>,
        <https://1145.am/db/2568808/Valeant_Canada>,
        <https://1145.am/db/2569148/Valeant>,
        <https://1145.am/db/2569149/Valeant>,
        <https://1145.am/db/2570033/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2570121/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2570390/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571019/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571068/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572086/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572449/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572450/Valeant>,
        <https://1145.am/db/2572552/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572553/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572568/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572605/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572612/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572932/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2573147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2573199/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2573880/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2574433/Valeant>,
        <https://1145.am/db/2575134/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2575289/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575552/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575615/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575800/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576039/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576047/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576205/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576478/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576482/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576956/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576962/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577145/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577419/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577770/Valeant>,
        <https://1145.am/db/2577771/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577775/Valeant>,
        <https://1145.am/db/2577846/Valeant>,
        <https://1145.am/db/2577958/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578188/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578333/Valeant_Canada>,
        <https://1145.am/db/2578700/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2579147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580042/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580047/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580122/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580140/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580775/Valeant>,
        <https://1145.am/db/2580831/Valeant>,
        <https://1145.am/db/2581225/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2582260/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2582935/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2583270/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2583732/Valeant>,
        <https://1145.am/db/2583843/Valeant_Pharmaceuticals_North_America>,
        <https://1145.am/db/2584209/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584216/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2584226/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584644/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584750/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2585746/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2586657/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2586658/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2587640/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2588178/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589040/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2589223/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589781/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2590589/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2591690/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2592575/And_Valeant>,
        <https://1145.am/db/2593443/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2593831/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594087/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594236/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594249/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594252/Valeant>,
        <https://1145.am/db/2594253/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2594281/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594413/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594414/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594557/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594858/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2595025/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595150/Valeant>,
        <https://1145.am/db/2595287/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595706/Valeant>,
        <https://1145.am/db/2595853/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2595929/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2596290/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2596891/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597119/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597158/Valeant>,
        <https://1145.am/db/2597223/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2597542/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597746/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597769/Valeant>,
        <https://1145.am/db/2598012/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2598032/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598205/Valeant>,
        <https://1145.am/db/2598266/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598558/Valeant_Pharmaceuticals_International> ;
    ns1:sameAsMedium <https://1145.am/db/2598261/Valeant_Pharmaceuticals> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2595684/Perrigo> a org:Organization ;
    ns1:buyer <https://1145.am/db/2595684/Cobrek_Pharmaceuticals_Stake_Acquisition> ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-12-28T15:28:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $45 Million" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/perrigo-company-acquires-remaining-stake-cobrek-pharmaceuticals-inc-for-approximately-45> ;
    ns1:foundName "Perrigo",
        "Perrigo Company" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Perrigo" ;
    ns1:sameAsHigh <https://1145.am/db/140347/Perrigo>,
        <https://1145.am/db/2301756/Pergamum_Ab>,
        <https://1145.am/db/2305515/Perrigo_Company>,
        <https://1145.am/db/2319220/Perrigo_Company>,
        <https://1145.am/db/2319399/Perrigo>,
        <https://1145.am/db/2319885/Perrigo_Company>,
        <https://1145.am/db/2322083/Perrigo>,
        <https://1145.am/db/2328536/Perrigo_Company>,
        <https://1145.am/db/2341767/Perrigo>,
        <https://1145.am/db/2349480/Perosphere_Inc>,
        <https://1145.am/db/2350515/Perosphere_Inc>,
        <https://1145.am/db/2355339/Perrigo_Pharmaceuticals>,
        <https://1145.am/db/2537398/Perrigo>,
        <https://1145.am/db/2538031/Perrigo>,
        <https://1145.am/db/2538653/Perrigo>,
        <https://1145.am/db/2540105/Perrigo>,
        <https://1145.am/db/2540521/Perrigo>,
        <https://1145.am/db/2541499/Perrigo>,
        <https://1145.am/db/2544762/Perrigo>,
        <https://1145.am/db/2546145/Perrigo>,
        <https://1145.am/db/2546149/Perrigo>,
        <https://1145.am/db/2546959/Perrigo>,
        <https://1145.am/db/2561423/Perrigo>,
        <https://1145.am/db/2562362/Perrigo>,
        <https://1145.am/db/2563325/Perrigo>,
        <https://1145.am/db/2563341/Perrigo>,
        <https://1145.am/db/2563450/Perrigo>,
        <https://1145.am/db/2569075/Perrigo>,
        <https://1145.am/db/2569076/Perrigo>,
        <https://1145.am/db/2570437/Perrigo>,
        <https://1145.am/db/2571324/Perrigo>,
        <https://1145.am/db/2571355/Perrigo>,
        <https://1145.am/db/2572093/Perrigo>,
        <https://1145.am/db/2572985/Perrigo>,
        <https://1145.am/db/2575861/Perrigo>,
        <https://1145.am/db/2575863/Perrigo>,
        <https://1145.am/db/2576144/Perrigo>,
        <https://1145.am/db/2577804/Perrigo>,
        <https://1145.am/db/2577810/Perrigo>,
        <https://1145.am/db/2578176/Perrigo>,
        <https://1145.am/db/2578808/Perrigo>,
        <https://1145.am/db/2578827/Perrigo>,
        <https://1145.am/db/2579630/Perrigo>,
        <https://1145.am/db/2581325/Perrigo>,
        <https://1145.am/db/2583414/Perrigo>,
        <https://1145.am/db/2583676/Perrigo>,
        <https://1145.am/db/2584589/Perrigo>,
        <https://1145.am/db/2584909/Perrigo>,
        <https://1145.am/db/2585327/Perrigo_Company>,
        <https://1145.am/db/2585605/Perrigo>,
        <https://1145.am/db/2587506/Perrigo>,
        <https://1145.am/db/2587539/Perrigo>,
        <https://1145.am/db/2588053/Perrigo>,
        <https://1145.am/db/2589750/Perrigo>,
        <https://1145.am/db/2594992/Perrigo>,
        <https://1145.am/db/2595051/Perrigo>,
        <https://1145.am/db/2595564/Perrigo>,
        <https://1145.am/db/2595688/Perrigo>,
        <https://1145.am/db/2598736/Perrigo> ;
    ns1:sameAsMedium <https://1145.am/db/1466026/Perrigo>,
        <https://1145.am/db/2306691/Perrigo_Company>,
        <https://1145.am/db/2311233/Perrigo>,
        <https://1145.am/db/2322064/Perrigo_Company>,
        <https://1145.am/db/2325736/Perrigo_Company>,
        <https://1145.am/db/2334551/Perrigo>,
        <https://1145.am/db/2339612/Perrigo>,
        <https://1145.am/db/2343835/Perrigo>,
        <https://1145.am/db/2354155/Perrigo>,
        <https://1145.am/db/252316/Perrigo>,
        <https://1145.am/db/2538226/Perrigo>,
        <https://1145.am/db/2539012/Perrigo>,
        <https://1145.am/db/2549203/Perrigo>,
        <https://1145.am/db/2553219/Perrigo>,
        <https://1145.am/db/2555939/Perrigo>,
        <https://1145.am/db/2562354/Perrigo>,
        <https://1145.am/db/2564219/Perrigo>,
        <https://1145.am/db/2568858/Perrigo>,
        <https://1145.am/db/2572018/Perrigo>,
        <https://1145.am/db/2572085/Perrigo>,
        <https://1145.am/db/2576104/Perrigo>,
        <https://1145.am/db/2577809/Perrigo>,
        <https://1145.am/db/2578160/Perrigo>,
        <https://1145.am/db/2581804/Perrigo>,
        <https://1145.am/db/2584598/Perrigo>,
        <https://1145.am/db/2584603/Perrigo>,
        <https://1145.am/db/2585584/Perrigo>,
        <https://1145.am/db/2585604/Perrigo>,
        <https://1145.am/db/2585606/Perrigo>,
        <https://1145.am/db/2586571/Perrigo>,
        <https://1145.am/db/2586572/Perrigo>,
        <https://1145.am/db/2587513/Perrigo>,
        <https://1145.am/db/2588051/Perrigo>,
        <https://1145.am/db/2590594/Perrigo>,
        <https://1145.am/db/2592352/Perrigo>,
        <https://1145.am/db/2593465/Perrigo>,
        <https://1145.am/db/2594877/Perrigo> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2596947/Nestle> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:buyer <https://1145.am/db/2596947/Zoetis_Business_Acquisition> ;
    ns1:description "food" ;
    ns1:documentDate "2013-01-22T16:58:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J CEO eyes sale of Ortho diagnostics unit" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/j-j-ceo-eyes-sale-of-ortho-diagnostics-unit> ;
    ns1:foundName "Nestle" ;
    ns1:name "Nestle" ;
    ns1:sameAsHigh <https://1145.am/db/102578/Nestle>,
        <https://1145.am/db/107688/Nestle>,
        <https://1145.am/db/107857/Nestle>,
        <https://1145.am/db/135716/Nestle>,
        <https://1145.am/db/156125/Nestle>,
        <https://1145.am/db/1961632/Nestl>,
        <https://1145.am/db/2106406/Nestle>,
        <https://1145.am/db/2108869/Nestle>,
        <https://1145.am/db/2109377/Nestle>,
        <https://1145.am/db/2292189/Nestl>,
        <https://1145.am/db/2327560/Nestle>,
        <https://1145.am/db/237583/Nestle>,
        <https://1145.am/db/2549982/Nestl>,
        <https://1145.am/db/2558316/Nestle>,
        <https://1145.am/db/2560477/Nestl>,
        <https://1145.am/db/2582400/Nestl>,
        <https://1145.am/db/2594249/Nestle>,
        <https://1145.am/db/2597078/Nestle>,
        <https://1145.am/db/320746/Nestle>,
        <https://1145.am/db/544750/Nestle>,
        <https://1145.am/db/681432/Nestle_Sa>,
        <https://1145.am/db/836550/Nestle> ;
    ns1:sameAsMedium <https://1145.am/db/1466026/Nestle_Sa>,
        <https://1145.am/db/1527177/Nestle>,
        <https://1145.am/db/1574226/Nestle>,
        <https://1145.am/db/1777197/Nestle>,
        <https://1145.am/db/190820/Nestl_Sa>,
        <https://1145.am/db/2022502/Nestle>,
        <https://1145.am/db/2069033/Nestle>,
        <https://1145.am/db/218697/Nestle_Sa>,
        <https://1145.am/db/2291397/Nestl>,
        <https://1145.am/db/2299847/Nestle>,
        <https://1145.am/db/2325386/Nestle>,
        <https://1145.am/db/2346208/Nestl>,
        <https://1145.am/db/2559797/Nestle>,
        <https://1145.am/db/2563194/Nestl>,
        <https://1145.am/db/2563348/Nestl_Sa>,
        <https://1145.am/db/2566415/Nestl>,
        <https://1145.am/db/2567953/Nestl>,
        <https://1145.am/db/2572568/Nestle_Sa>,
        <https://1145.am/db/2573611/Nestle>,
        <https://1145.am/db/2574332/Nestl>,
        <https://1145.am/db/2576962/Nestle>,
        <https://1145.am/db/2579519/Nestle>,
        <https://1145.am/db/2582395/Nestl>,
        <https://1145.am/db/2582402/Nestle>,
        <https://1145.am/db/2588438/Nestl>,
        <https://1145.am/db/2590095/Nestle>,
        <https://1145.am/db/2591520/Nestle>,
        <https://1145.am/db/2591733/Nestle>,
        <https://1145.am/db/315049/Nestle>,
        <https://1145.am/db/315797/Nestle>,
        <https://1145.am/db/319737/Nestl>,
        <https://1145.am/db/633223/Nestl>,
        <https://1145.am/db/680407/Nestle> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2616502/Marlin_Equity_Partners> a org:Organization ;
    ns1:documentDate "2013-03-11T12:01:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sycamore Networks ends its run" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/sycamore-networks-ends-its-run> ;
    ns1:foundName "Marlin",
        "Marlin Equity Partners" ;
    ns1:investor <https://1145.am/db/2616502/Sycamore_Networks_Unit_Acquisition>,
        <https://1145.am/db/2616502/Unit_Investment_Marlin_Equity_Partners_Nokia_Siemens_Networks_Completed> ;
    ns1:name "Marlin",
        "Marlin Equity Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1703088/Marlin_Equity_Partners>,
        <https://1145.am/db/1755583/Marlin_Equity_Partners>,
        <https://1145.am/db/1780201/Marlin_Equity_Partners>,
        <https://1145.am/db/1870517/Marlin_Equity_Partners>,
        <https://1145.am/db/1871597/Marlin_Equity_Partners>,
        <https://1145.am/db/2600044/Marlin_Equity_Partners>,
        <https://1145.am/db/2608843/Marlin_Equity_Partners>,
        <https://1145.am/db/2611268/Marlin_Equity_Partners>,
        <https://1145.am/db/2611280/Marlin_Equity_Partners>,
        <https://1145.am/db/2614245/Marlin_Equity_Partners>,
        <https://1145.am/db/2616541/Marlin_Equity_Partners>,
        <https://1145.am/db/2642458/Marlin_Equity_Partners>,
        <https://1145.am/db/2662032/Marlin_Equity_Partners>,
        <https://1145.am/db/2662041/Marlin_Equity_Partners>,
        <https://1145.am/db/2662048/Marlin_Equity_Partners>,
        <https://1145.am/db/2662865/Marlin_Equity_Partners>,
        <https://1145.am/db/2663081/Marlin_Equity_Partners>,
        <https://1145.am/db/646965/Marlin_Equity_Partners>,
        <https://1145.am/db/757514/Marlin_Equity_Partners> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2664167/Altimo> a org:Organization ;
    ns1:basedInLowRaw "Czech" ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:foundName "Altimo" ;
    ns1:industry "telecoms" ;
    ns1:investor <https://1145.am/db/2664167/Vimpelcom_Investment> ;
    ns1:name "Altimo" ;
    ns1:sameAsHigh <https://1145.am/db/174181/Altice_Europe>,
        <https://1145.am/db/2171023/Altice>,
        <https://1145.am/db/2604559/Alteva>,
        <https://1145.am/db/2663846/Altimo>,
        <https://1145.am/db/2673108/Altimo>,
        <https://1145.am/db/787696/Altice_Europe_Nv>,
        <https://1145.am/db/789202/Altice_Europe_Nv> ;
    ns1:sameAsMedium <https://1145.am/db/2607010/Altimo>,
        <https://1145.am/db/2650898/Altimo>,
        <https://1145.am/db/2673027/Altimo> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2664167/Research_In_Motion> a org:Organization ;
    ns1:basedInLowRaw "Canada" ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:foundName "Research In Motion" ;
    ns1:investor <https://1145.am/db/2664167/Investment_Nokia_Research_In_Motion_Completed> ;
    ns1:name "Research In Motion" ;
    ns1:sameAsMedium <https://1145.am/db/1698637/Research_In_Motion>,
        <https://1145.am/db/1860667/Research_In_Motion>,
        <https://1145.am/db/1862073/Research_In_Motion>,
        <https://1145.am/db/1870645/Research_In_Motion>,
        <https://1145.am/db/1874406/Research_In_Motion>,
        <https://1145.am/db/1877778/Research_In_Motion>,
        <https://1145.am/db/1913995/Research_In_Motion>,
        <https://1145.am/db/2622037/Research_In_Motion>,
        <https://1145.am/db/2622254/Research_In_Motion>,
        <https://1145.am/db/2623835/Research_In_Motion>,
        <https://1145.am/db/2625068/Research_In_Motion>,
        <https://1145.am/db/2639570/Research_In_Motion>,
        <https://1145.am/db/2639656/Research_In_Motion>,
        <https://1145.am/db/2643132/Research_In_Motion>,
        <https://1145.am/db/2643557/Research_In_Motion>,
        <https://1145.am/db/2647251/Research_In_Motion>,
        <https://1145.am/db/2663417/Research_In_Motion>,
        <https://1145.am/db/2665619/Research_In_Motion>,
        <https://1145.am/db/2665884/Research_In_Motion>,
        <https://1145.am/db/2668834/Research_In_Motion>,
        <https://1145.am/db/2670133/Research_In_Motion>,
        <https://1145.am/db/2672194/Research_In_Motion>,
        <https://1145.am/db/2672211/Research_In_Motion>,
        <https://1145.am/db/2673373/Research_In_Motion>,
        <https://1145.am/db/2673385/Research_In_Motion>,
        <https://1145.am/db/2674543/Research_In_Motion>,
        <https://1145.am/db/2674950/Research_In_Motion>,
        <https://1145.am/db/2675784/Research_In_Motion>,
        <https://1145.am/db/2683325/Research_In_Motion>,
        <https://1145.am/db/2683888/Research_In_Motion>,
        <https://1145.am/db/2683925/Research_In_Motion>,
        <https://1145.am/db/2684891/Research_In_Motion>,
        <https://1145.am/db/2684919/Research_In_Motion>,
        <https://1145.am/db/2685100/Research_In_Motion>,
        <https://1145.am/db/2685515/Research_In_Motion>,
        <https://1145.am/db/2685807/Research_In_Motion>,
        <https://1145.am/db/2686285/Research_In_Motion>,
        <https://1145.am/db/2686301/Research_In_Motion>,
        <https://1145.am/db/2686449/Research_In_Motion> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2667192/Alcatel-Lucent> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2013-02-07T16:08:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Nokia Siemens parents could use Alcatel-Lucent to exit JV" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-nokia-siemens-parents-could-use-alcatel-lucent-to-exit-jv> ;
    ns1:foundName "Alcatel-Lucent" ;
    ns1:investor <https://1145.am/db/2667192/Nokia_Siemens_Networks_Stake_Acquisition> ;
    ns1:name "Alcatel-Lucent" ;
    ns1:sameAsMedium <https://1145.am/db/1790667/Alcatel-Lucent>,
        <https://1145.am/db/1790669/Alcatel-Lucent>,
        <https://1145.am/db/1790693/Alcatel-Lucent>,
        <https://1145.am/db/1795878/Alcatel-Lucent>,
        <https://1145.am/db/1819651/Alcatel-Lucent>,
        <https://1145.am/db/1855135/Alcatel-Lucent>,
        <https://1145.am/db/1875987/Alcatel-Lucent>,
        <https://1145.am/db/1885641/Alcatel-Lucent>,
        <https://1145.am/db/2174456/Alcatel-Lucent>,
        <https://1145.am/db/2449514/Alcatel-Lucent>,
        <https://1145.am/db/2599088/Alcatel-Lucent>,
        <https://1145.am/db/2599392/Alcatel-Lucent>,
        <https://1145.am/db/2599632/Alcatel-Lucent>,
        <https://1145.am/db/2599798/Alcatel-Lucent>,
        <https://1145.am/db/2600870/Alcatel-Lucent>,
        <https://1145.am/db/2601072/Alcatel-Lucent>,
        <https://1145.am/db/2601349/Alcatel-Lucent>,
        <https://1145.am/db/2601506/Alcatel-Lucent>,
        <https://1145.am/db/2601537/Alcatel-Lucent>,
        <https://1145.am/db/2601910/Alcatel-Lucent>,
        <https://1145.am/db/2602219/Alcatel-Lucent>,
        <https://1145.am/db/2602933/Alcatel-Lucent>,
        <https://1145.am/db/2604986/Alcatel-Lucent>,
        <https://1145.am/db/2604991/Alcatel-Lucent>,
        <https://1145.am/db/2606223/Alcatel-Lucent>,
        <https://1145.am/db/2606495/Alcatel-Lucent>,
        <https://1145.am/db/2606731/Alcatel-Lucent>,
        <https://1145.am/db/2607244/Alcatel-Lucent>,
        <https://1145.am/db/2607408/Alcatel-Lucent>,
        <https://1145.am/db/2607614/Alcatel-Lucent>,
        <https://1145.am/db/2609611/Alcatel-Lucent>,
        <https://1145.am/db/2609629/Alcatel-Lucent>,
        <https://1145.am/db/2609645/Alcatel-Lucent>,
        <https://1145.am/db/2609817/Alcatel-Lucent>,
        <https://1145.am/db/2610550/Alcatel-Lucent>,
        <https://1145.am/db/2610915/Alcatel-Lucent>,
        <https://1145.am/db/2611850/Alcatel-Lucent>,
        <https://1145.am/db/2611855/Alcatel-Lucent>,
        <https://1145.am/db/2612045/Alcatel-Lucent>,
        <https://1145.am/db/2612072/Alcatel-Lucent>,
        <https://1145.am/db/2612273/Alcatel-Lucent>,
        <https://1145.am/db/2612583/Alcatel-Lucent>,
        <https://1145.am/db/2612780/Alcatel-Lucent>,
        <https://1145.am/db/2613443/Alcatel-Lucent>,
        <https://1145.am/db/2614261/Alcatel-Lucent>,
        <https://1145.am/db/2614782/Alcatel-Lucent>,
        <https://1145.am/db/2614789/Alcatel-Lucent>,
        <https://1145.am/db/2614792/Alcatel-Lucent>,
        <https://1145.am/db/2614999/Alcatel-Lucent>,
        <https://1145.am/db/2615500/Alcatel-Lucent>,
        <https://1145.am/db/2617770/Alcatel-Lucent>,
        <https://1145.am/db/2620115/Alcatel-Lucent>,
        <https://1145.am/db/2624637/Alcatel-Lucent>,
        <https://1145.am/db/2625358/Alcatel-Lucent>,
        <https://1145.am/db/2633937/Alcatel-Lucent>,
        <https://1145.am/db/2635749/Alcatel-Lucent>,
        <https://1145.am/db/2636765/Alcatel-Lucent>,
        <https://1145.am/db/2636778/Alcatel-Lucent>,
        <https://1145.am/db/2638547/Alcatel-Lucent>,
        <https://1145.am/db/2639975/Alcatel-Lucent>,
        <https://1145.am/db/2641663/Alcatel-Lucent>,
        <https://1145.am/db/2642991/Alcatel-Lucent>,
        <https://1145.am/db/2651008/Alcatel-Lucent>,
        <https://1145.am/db/2651521/Alcatel-Lucent>,
        <https://1145.am/db/2651685/Alcatel-Lucent>,
        <https://1145.am/db/2652551/Alcatel-Lucent>,
        <https://1145.am/db/2653427/Alcatel-Lucent>,
        <https://1145.am/db/2654012/Alcatel-Lucent>,
        <https://1145.am/db/2654017/Alcatel-Lucent>,
        <https://1145.am/db/2654155/Alcatel-Lucent>,
        <https://1145.am/db/2654238/Alcatel-Lucent>,
        <https://1145.am/db/2654528/Alcatel_Lucent>,
        <https://1145.am/db/2655001/Alcatel-Lucent>,
        <https://1145.am/db/2655372/Alcatel-Lucent>,
        <https://1145.am/db/2655622/Alcatel-Lucent>,
        <https://1145.am/db/2655768/Alcatel-Lucent>,
        <https://1145.am/db/2655792/Alcatel-Lucent>,
        <https://1145.am/db/2656166/Alcatel-Lucent>,
        <https://1145.am/db/2656737/Alcatel-Lucent>,
        <https://1145.am/db/2656749/Alcatel-Lucent>,
        <https://1145.am/db/2656808/Alcatel-Lucent>,
        <https://1145.am/db/2656920/Alcatel-Lucent>,
        <https://1145.am/db/2657196/Alcatel-Lucent>,
        <https://1145.am/db/2657268/Alcatel-Lucent>,
        <https://1145.am/db/2657902/Alcatel-Lucent>,
        <https://1145.am/db/2658200/Alcatel-Lucent>,
        <https://1145.am/db/2658774/Alcatel-Lucent>,
        <https://1145.am/db/2659374/Alcatel-Lucent>,
        <https://1145.am/db/2660932/Alcatel-Lucent>,
        <https://1145.am/db/2661927/Alcatel-Lucent>,
        <https://1145.am/db/2663033/Alcatel-Lucent>,
        <https://1145.am/db/2663052/Alcatel-Lucent>,
        <https://1145.am/db/2663073/Alcatel-Lucent>,
        <https://1145.am/db/2663106/Alcatel-Lucent>,
        <https://1145.am/db/2663114/Alcatel-Lucent>,
        <https://1145.am/db/2663834/Alcatel-Lucent>,
        <https://1145.am/db/2663941/Alcatel-Lucent>,
        <https://1145.am/db/2664215/Alcatel-Lucent>,
        <https://1145.am/db/2664225/Alcatel-Lucent>,
        <https://1145.am/db/2664922/Alcatel-Lucent>,
        <https://1145.am/db/2665201/Alcatel-Lucent>,
        <https://1145.am/db/2665703/Alcatel-Lucent>,
        <https://1145.am/db/2665720/Alcatel-Lucent>,
        <https://1145.am/db/2665866/Alcatel-Lucent>,
        <https://1145.am/db/2666163/Alcatel-Lucent>,
        <https://1145.am/db/2666280/Alcatel-Lucent>,
        <https://1145.am/db/2666307/Alcatel-Lucent>,
        <https://1145.am/db/2666346/Alcatel-Lucent>,
        <https://1145.am/db/2666366/Alcatel-Lucent>,
        <https://1145.am/db/2666375/Alcatel-Lucent>,
        <https://1145.am/db/2666563/Alcatel-Lucent>,
        <https://1145.am/db/2666729/Alcatel_Lucent>,
        <https://1145.am/db/2666818/Alcatel-Lucent>,
        <https://1145.am/db/2667186/Alcatel-Lucent>,
        <https://1145.am/db/2667452/Alcatel-Lucent>,
        <https://1145.am/db/2668257/Alcatel-Lucent>,
        <https://1145.am/db/2668422/Alcatel-Lucent>,
        <https://1145.am/db/2668973/Alcatel-Lucent>,
        <https://1145.am/db/2668986/Alcatel-Lucent>,
        <https://1145.am/db/2670204/Alcatel-Lucent>,
        <https://1145.am/db/2670501/Alcatel-Lucent>,
        <https://1145.am/db/2670547/Alcatel-Lucent>,
        <https://1145.am/db/2670735/Alcatel-Lucent>,
        <https://1145.am/db/2670748/Alcatel-Lucent>,
        <https://1145.am/db/2671140/Alcatel-Lucent>,
        <https://1145.am/db/2671336/Alcatel-Lucent>,
        <https://1145.am/db/2671922/Alcatel-Lucent>,
        <https://1145.am/db/2672328/Alcatel-Lucent>,
        <https://1145.am/db/2672337/Alcatel-Lucent>,
        <https://1145.am/db/2672864/Alcatel-Lucent>,
        <https://1145.am/db/2672932/Alcatel-Lucent>,
        <https://1145.am/db/2674110/Alcatel_Lucent>,
        <https://1145.am/db/2675256/Alcatel-Lucent>,
        <https://1145.am/db/2676711/Alcatel-Lucent>,
        <https://1145.am/db/2676997/Alcatel-Lucent>,
        <https://1145.am/db/2678826/Alcatel-Lucent>,
        <https://1145.am/db/2678859/Alcatel-Lucent>,
        <https://1145.am/db/2679013/Alcatel-Lucent>,
        <https://1145.am/db/2679049/Alcatel-Lucent>,
        <https://1145.am/db/2679386/Alcatel-Lucent>,
        <https://1145.am/db/2679680/Alcatel-Lucent>,
        <https://1145.am/db/2680847/Alcatel-Lucent>,
        <https://1145.am/db/2681373/Alcatel-Lucent>,
        <https://1145.am/db/2681782/Alcatel-Lucent>,
        <https://1145.am/db/2682873/Alcatel-Lucent>,
        <https://1145.am/db/2683040/Alcatel-Lucent>,
        <https://1145.am/db/2683818/Alcatel-Lucent>,
        <https://1145.am/db/2684278/Alcatel-Lucent> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2669324/Vodafone> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "London" ;
    ns1:documentDate "2013-03-05T18:07:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Verizon wants to resolve Vodafone relationship in 2013" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-verizon-wants-to-resolve-vodafone-relationship-2013> ;
    ns1:foundName "Vodafone" ;
    ns1:name "Vodafone" ;
    ns1:protagonist <https://1145.am/db/2669324/Verizon_Wireless_Stake_Investment> ;
    ns1:sameAsMedium <https://1145.am/db/102640/Vodafone>,
        <https://1145.am/db/1048791/Vodafone>,
        <https://1145.am/db/1058951/Vodafone>,
        <https://1145.am/db/1071658/Vodafone>,
        <https://1145.am/db/1293352/Vodafone>,
        <https://1145.am/db/1299724/Vodafone>,
        <https://1145.am/db/1358299/Vodafone>,
        <https://1145.am/db/1389347/Vodafone>,
        <https://1145.am/db/1389651/Vodafone>,
        <https://1145.am/db/1420625/Vodafone>,
        <https://1145.am/db/1421912/Vodafone>,
        <https://1145.am/db/1552870/Vodafone>,
        <https://1145.am/db/1627625/Vodafone>,
        <https://1145.am/db/1628420/Vodafone>,
        <https://1145.am/db/1687890/Vodafone>,
        <https://1145.am/db/1729077/Vodafone>,
        <https://1145.am/db/1805873/Vodafone>,
        <https://1145.am/db/181882/Vodafone>,
        <https://1145.am/db/1872318/Vodafone>,
        <https://1145.am/db/1896956/Vodafone>,
        <https://1145.am/db/1919221/Vodafone>,
        <https://1145.am/db/1969437/Vodafone>,
        <https://1145.am/db/1993312/Vodafone>,
        <https://1145.am/db/2005677/Vodafone>,
        <https://1145.am/db/2009302/Vodafone>,
        <https://1145.am/db/2029449/Vodafone>,
        <https://1145.am/db/2036731/Vodafone>,
        <https://1145.am/db/2037305/Vodafone_Uk>,
        <https://1145.am/db/2037901/Vodafone>,
        <https://1145.am/db/2044056/Vodafone>,
        <https://1145.am/db/2066713/Vodafone>,
        <https://1145.am/db/2140764/Vodafone>,
        <https://1145.am/db/2149846/Vodafone>,
        <https://1145.am/db/2162588/Vodafone>,
        <https://1145.am/db/2167342/Vodafone>,
        <https://1145.am/db/2172635/Vodafone>,
        <https://1145.am/db/2174251/Vodafone>,
        <https://1145.am/db/2174257/Vodafone>,
        <https://1145.am/db/2175059/Vodafone>,
        <https://1145.am/db/2175880/Vodafone>,
        <https://1145.am/db/2176686/Vodafone>,
        <https://1145.am/db/2177533/Vodafone>,
        <https://1145.am/db/219260/Vodafone>,
        <https://1145.am/db/219415/Vodafone>,
        <https://1145.am/db/243358/Vodafone>,
        <https://1145.am/db/245901/Vodafone>,
        <https://1145.am/db/2549313/Vodafone>,
        <https://1145.am/db/2601966/Vodafone>,
        <https://1145.am/db/2602132/Vodafone>,
        <https://1145.am/db/2602659/Vodafone>,
        <https://1145.am/db/2603641/Vodafone>,
        <https://1145.am/db/2604430/Vodafone>,
        <https://1145.am/db/2604744/Vodafone>,
        <https://1145.am/db/2607321/Vodafone>,
        <https://1145.am/db/2610786/Vodafone>,
        <https://1145.am/db/2611210/Vodafone>,
        <https://1145.am/db/2616043/Vodafone>,
        <https://1145.am/db/2618856/Vodafone>,
        <https://1145.am/db/2619168/Vodafone>,
        <https://1145.am/db/2619431/Vodafone>,
        <https://1145.am/db/2619973/Vodafone>,
        <https://1145.am/db/2619998/Vodafone>,
        <https://1145.am/db/2620945/Vodafone>,
        <https://1145.am/db/2621829/Vodafone>,
        <https://1145.am/db/2623767/Vodafone>,
        <https://1145.am/db/2625228/Vodafone>,
        <https://1145.am/db/2627269/Vodafone>,
        <https://1145.am/db/2627411/Vodafone>,
        <https://1145.am/db/2628118/Vodafone>,
        <https://1145.am/db/2629279/Vodafone>,
        <https://1145.am/db/2637785/Vodafone>,
        <https://1145.am/db/2638371/Vodafone>,
        <https://1145.am/db/2639390/Vodafone>,
        <https://1145.am/db/2640422/Vodafone>,
        <https://1145.am/db/2642043/Vodafone>,
        <https://1145.am/db/2642380/Vodafone>,
        <https://1145.am/db/2642427/Vodafone>,
        <https://1145.am/db/2643398/Vodafone>,
        <https://1145.am/db/2643528/Vodafone>,
        <https://1145.am/db/2646466/Vodafone>,
        <https://1145.am/db/2647254/Vodafone>,
        <https://1145.am/db/2648461/Vodafone>,
        <https://1145.am/db/2648535/Vodafone>,
        <https://1145.am/db/2650576/Vodafone>,
        <https://1145.am/db/2650894/Vodafone>,
        <https://1145.am/db/2651116/Vodafone>,
        <https://1145.am/db/2651393/Vodafone>,
        <https://1145.am/db/2651401/Vodafone>,
        <https://1145.am/db/2651472/Vodafone>,
        <https://1145.am/db/2651481/Vodafone>,
        <https://1145.am/db/2651531/Vodafone>,
        <https://1145.am/db/2651536/Vodafone>,
        <https://1145.am/db/2651657/Vodafone>,
        <https://1145.am/db/2651735/Vodafone_Uk>,
        <https://1145.am/db/2651863/Vodafone>,
        <https://1145.am/db/2652007/Vodafone>,
        <https://1145.am/db/2652011/Vodafone>,
        <https://1145.am/db/2652523/Vodafone>,
        <https://1145.am/db/2652568/Vodafone>,
        <https://1145.am/db/2652681/Vodafone>,
        <https://1145.am/db/2652980/Vodafone>,
        <https://1145.am/db/2653074/Vodafone>,
        <https://1145.am/db/2653078/Vodafone>,
        <https://1145.am/db/2653299/Vodafone>,
        <https://1145.am/db/2653355/Vodafone>,
        <https://1145.am/db/2653489/Vodafone>,
        <https://1145.am/db/2653502/Vodafone>,
        <https://1145.am/db/2654160/Vodafone>,
        <https://1145.am/db/2654684/Vodafone>,
        <https://1145.am/db/2654827/Vodafone>,
        <https://1145.am/db/2654966/Vodafone>,
        <https://1145.am/db/2655003/Vodafone>,
        <https://1145.am/db/2655513/Vodafone>,
        <https://1145.am/db/2655523/Vodafone>,
        <https://1145.am/db/2655569/Vodafone>,
        <https://1145.am/db/2655783/Vodafone>,
        <https://1145.am/db/2655927/Vodafone>,
        <https://1145.am/db/2656108/Vodafone>,
        <https://1145.am/db/2656193/Vodafone>,
        <https://1145.am/db/2656296/Vodafone>,
        <https://1145.am/db/2656675/Vodafone>,
        <https://1145.am/db/2656843/Vodafone>,
        <https://1145.am/db/2656915/Vodafone>,
        <https://1145.am/db/2657119/Vodafone>,
        <https://1145.am/db/2657380/Vodafone>,
        <https://1145.am/db/2658006/Vodafone>,
        <https://1145.am/db/2658765/Vodafone>,
        <https://1145.am/db/2658879/Vodafone>,
        <https://1145.am/db/2659254/Vodafone_Uk>,
        <https://1145.am/db/2659542/Vodafone>,
        <https://1145.am/db/2659966/Vodafone>,
        <https://1145.am/db/2660422/Vodafone>,
        <https://1145.am/db/2660581/Vodafone>,
        <https://1145.am/db/2660622/Vodafone>,
        <https://1145.am/db/2660995/Vodafone>,
        <https://1145.am/db/2661169/Vodafone>,
        <https://1145.am/db/2662074/Vodafone>,
        <https://1145.am/db/2662248/Vodafone>,
        <https://1145.am/db/2662640/Vodafone>,
        <https://1145.am/db/2662671/Vodafone>,
        <https://1145.am/db/2662741/Vodafone>,
        <https://1145.am/db/2662747/Vodafone>,
        <https://1145.am/db/2663184/Vodafone>,
        <https://1145.am/db/2663787/Vodafone>,
        <https://1145.am/db/2664232/Vodafone>,
        <https://1145.am/db/2664269/Vodafone>,
        <https://1145.am/db/2664436/Vodafone>,
        <https://1145.am/db/2664734/Vodafone>,
        <https://1145.am/db/2664887/Vodafone>,
        <https://1145.am/db/2665348/Vodafone>,
        <https://1145.am/db/2665363/Vodafone>,
        <https://1145.am/db/2665805/Vodafone>,
        <https://1145.am/db/2665849/Vodafone>,
        <https://1145.am/db/2666006/Vodafone>,
        <https://1145.am/db/2666397/Vodafone>,
        <https://1145.am/db/2666418/Vodafone>,
        <https://1145.am/db/2666740/Vodafone>,
        <https://1145.am/db/2666771/Vodafone>,
        <https://1145.am/db/2667394/Vodafone>,
        <https://1145.am/db/2667413/Vodafone>,
        <https://1145.am/db/2667420/Vodafone>,
        <https://1145.am/db/2667435/Vodafone>,
        <https://1145.am/db/2667439/Vodafone>,
        <https://1145.am/db/2667470/Vodafone>,
        <https://1145.am/db/2667525/Vodafone>,
        <https://1145.am/db/2667804/Vodafone>,
        <https://1145.am/db/2667843/Vodafone>,
        <https://1145.am/db/2668097/Vodafone>,
        <https://1145.am/db/2668504/Vodafone>,
        <https://1145.am/db/2668524/Vodafone>,
        <https://1145.am/db/2668781/Vodafone>,
        <https://1145.am/db/2668926/Vodafone>,
        <https://1145.am/db/2669483/Vodafone>,
        <https://1145.am/db/2669642/Vodafone>,
        <https://1145.am/db/2669661/Vodafone>,
        <https://1145.am/db/2670097/Vodafone>,
        <https://1145.am/db/2670157/Vodafone>,
        <https://1145.am/db/2670202/Vodafone>,
        <https://1145.am/db/2670747/Vodafone>,
        <https://1145.am/db/2671282/Vodafone>,
        <https://1145.am/db/2671912/Vodafone>,
        <https://1145.am/db/2671937/Vodafone>,
        <https://1145.am/db/2671975/Vodafone>,
        <https://1145.am/db/2672455/Vodafone>,
        <https://1145.am/db/2672595/Vodafone>,
        <https://1145.am/db/2673101/Vodafone>,
        <https://1145.am/db/2673796/Vodafone>,
        <https://1145.am/db/2673809/Vodafone>,
        <https://1145.am/db/2673830/Vodafone>,
        <https://1145.am/db/2673945/Vodafone>,
        <https://1145.am/db/2673958/Vodafone>,
        <https://1145.am/db/2674304/Vodafone>,
        <https://1145.am/db/2674316/Vodafone>,
        <https://1145.am/db/2674986/Vodafone>,
        <https://1145.am/db/2676263/Vodafone>,
        <https://1145.am/db/2676293/Vodafone>,
        <https://1145.am/db/2676572/Vodafone_Nl>,
        <https://1145.am/db/2676653/Vodafone>,
        <https://1145.am/db/2676679/Vodafone_Uk>,
        <https://1145.am/db/2677037/Vodafone>,
        <https://1145.am/db/2677134/Vodafone>,
        <https://1145.am/db/2677181/Vodafone>,
        <https://1145.am/db/2677247/Vodafone>,
        <https://1145.am/db/2677846/Vodafone>,
        <https://1145.am/db/2678352/Vodafone>,
        <https://1145.am/db/2678973/Vodafone>,
        <https://1145.am/db/2679009/Vodafone>,
        <https://1145.am/db/2679024/Vodafone>,
        <https://1145.am/db/2679037/Vodafone>,
        <https://1145.am/db/2679067/Vodafone>,
        <https://1145.am/db/2679163/Vodafone>,
        <https://1145.am/db/2679561/Vodafone>,
        <https://1145.am/db/2679756/Vodafone>,
        <https://1145.am/db/2679758/Vodafone>,
        <https://1145.am/db/2679807/Vodafone>,
        <https://1145.am/db/2679815/Vodafone>,
        <https://1145.am/db/2680056/Vodafone>,
        <https://1145.am/db/2680662/Vodafone>,
        <https://1145.am/db/2680795/Vodafone>,
        <https://1145.am/db/2681222/Vodafone>,
        <https://1145.am/db/2681332/Vodafone>,
        <https://1145.am/db/2681502/Vodafone>,
        <https://1145.am/db/2682215/Vodafone>,
        <https://1145.am/db/2682262/Vodafone>,
        <https://1145.am/db/2682269/Vodafone>,
        <https://1145.am/db/2682308/Vodafone>,
        <https://1145.am/db/2682869/Vodafone>,
        <https://1145.am/db/2683077/Vodafone>,
        <https://1145.am/db/2683432/Vodafone>,
        <https://1145.am/db/2683443/Vodafone>,
        <https://1145.am/db/2683648/Vodafone>,
        <https://1145.am/db/2683951/Vodafone>,
        <https://1145.am/db/2684208/Vodafone>,
        <https://1145.am/db/276165/Vodafone>,
        <https://1145.am/db/2787061/Vodafone>,
        <https://1145.am/db/2790448/Vodafone>,
        <https://1145.am/db/2792664/Vodafone>,
        <https://1145.am/db/76144/Vodafone>,
        <https://1145.am/db/77455/Vodafone>,
        <https://1145.am/db/776787/Vodafone>,
        <https://1145.am/db/782490/Vodafone>,
        <https://1145.am/db/799527/Vodafone>,
        <https://1145.am/db/821887/Vodafone>,
        <https://1145.am/db/849181/Vodafone>,
        <https://1145.am/db/849502/Vodafone> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2671617/Cisco> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:buyer <https://1145.am/db/2671617/Ubiquisys_Acquisition> ;
    ns1:description "small cell" ;
    ns1:documentDate "2013-04-03T16:36:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cisco buys Ubiquisys for $310M to add 'intelligence in the network'" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/cisco-buys-ubiquisys-for-310m-to-add-intelligence-network> ;
    ns1:foundName "Cisco Systems" ;
    ns1:name "Cisco" ;
    ns1:sameAsMedium <https://1145.am/db/1027690/Cisco>,
        <https://1145.am/db/1028774/Cisco>,
        <https://1145.am/db/1256453/Cisco>,
        <https://1145.am/db/1696201/Cisco>,
        <https://1145.am/db/1697078/Cisco>,
        <https://1145.am/db/1700191/Cisco>,
        <https://1145.am/db/1700963/Cisco>,
        <https://1145.am/db/1701907/Cisco>,
        <https://1145.am/db/1702017/Cisco>,
        <https://1145.am/db/1704548/Cisco>,
        <https://1145.am/db/1708036/Cisco>,
        <https://1145.am/db/1710590/Cisco>,
        <https://1145.am/db/1717967/Cisco>,
        <https://1145.am/db/1717977/Cisco>,
        <https://1145.am/db/1717993/Cisco>,
        <https://1145.am/db/1724559/Cisco>,
        <https://1145.am/db/1727419/Cisco>,
        <https://1145.am/db/1733739/Cisco>,
        <https://1145.am/db/1738152/Cisco>,
        <https://1145.am/db/1742704/Cisco>,
        <https://1145.am/db/1743362/Cisco>,
        <https://1145.am/db/1752792/Cisco>,
        <https://1145.am/db/1753887/Cisco>,
        <https://1145.am/db/1762081/Cisco>,
        <https://1145.am/db/1766185/Cisco>,
        <https://1145.am/db/1767815/Cisco>,
        <https://1145.am/db/1771378/Cisco>,
        <https://1145.am/db/1783231/Cisco>,
        <https://1145.am/db/1784917/Cisco>,
        <https://1145.am/db/1794453/Cisco>,
        <https://1145.am/db/1795721/Cisco>,
        <https://1145.am/db/1799582/Cisco>,
        <https://1145.am/db/1806956/Cisco>,
        <https://1145.am/db/1809700/Cisco>,
        <https://1145.am/db/1810827/Cisco>,
        <https://1145.am/db/1814119/Cisco>,
        <https://1145.am/db/1814224/Cisco>,
        <https://1145.am/db/1815435/Cisco>,
        <https://1145.am/db/1815500/Cisco>,
        <https://1145.am/db/1819033/Cisco>,
        <https://1145.am/db/1821893/Cisco>,
        <https://1145.am/db/1822505/Cisco>,
        <https://1145.am/db/1822639/Cisco>,
        <https://1145.am/db/1826832/Cisco>,
        <https://1145.am/db/1828458/Cisco>,
        <https://1145.am/db/1830084/Cisco>,
        <https://1145.am/db/1830952/Cisco>,
        <https://1145.am/db/1831852/Cisco>,
        <https://1145.am/db/1834671/Cisco>,
        <https://1145.am/db/1835330/Cisco>,
        <https://1145.am/db/1836417/Cisco>,
        <https://1145.am/db/1836953/Cisco>,
        <https://1145.am/db/1837563/Cisco>,
        <https://1145.am/db/1838070/Cisco>,
        <https://1145.am/db/1838216/Cisco>,
        <https://1145.am/db/1842440/Cisco>,
        <https://1145.am/db/1846654/Cisco>,
        <https://1145.am/db/1857825/Cisco>,
        <https://1145.am/db/1867943/Cisco>,
        <https://1145.am/db/1872388/Cisco>,
        <https://1145.am/db/1876483/Cisco>,
        <https://1145.am/db/1877473/Cisco>,
        <https://1145.am/db/1897659/Cisco>,
        <https://1145.am/db/1905954/Cisco>,
        <https://1145.am/db/1906341/Cisco>,
        <https://1145.am/db/1913543/Cisco>,
        <https://1145.am/db/2045709/Cisco>,
        <https://1145.am/db/2121547/Cisco>,
        <https://1145.am/db/2122478/Cisco>,
        <https://1145.am/db/2131916/Cisco>,
        <https://1145.am/db/2157044/Cisco>,
        <https://1145.am/db/2157150/Cisco>,
        <https://1145.am/db/2157342/Cisco>,
        <https://1145.am/db/2157512/Cisco>,
        <https://1145.am/db/2157628/Cisco>,
        <https://1145.am/db/2159181/Cisco>,
        <https://1145.am/db/2159845/Cisco>,
        <https://1145.am/db/2160873/Cisco>,
        <https://1145.am/db/2161318/Cisco>,
        <https://1145.am/db/2162767/Cisco>,
        <https://1145.am/db/2162792/Cisco>,
        <https://1145.am/db/2162802/Cisco>,
        <https://1145.am/db/2162803/Cisco>,
        <https://1145.am/db/2164203/Cisco>,
        <https://1145.am/db/2166974/Cisco>,
        <https://1145.am/db/2166984/Cisco>,
        <https://1145.am/db/2169483/Cisco>,
        <https://1145.am/db/2169876/Cisco>,
        <https://1145.am/db/2173942/Cisco>,
        <https://1145.am/db/2173994/Cisco>,
        <https://1145.am/db/2174781/Cisco>,
        <https://1145.am/db/2175327/Cisco>,
        <https://1145.am/db/2176378/Cisco>,
        <https://1145.am/db/2176546/Cisco>,
        <https://1145.am/db/2404118/Cisco>,
        <https://1145.am/db/2406325/Cisco>,
        <https://1145.am/db/2598857/Cisco>,
        <https://1145.am/db/2598885/Cisco>,
        <https://1145.am/db/2598895/Cisco>,
        <https://1145.am/db/2598977/Cisco>,
        <https://1145.am/db/2599080/Cisco>,
        <https://1145.am/db/2599960/Cisco>,
        <https://1145.am/db/2600159/Cisco>,
        <https://1145.am/db/2600308/Cisco>,
        <https://1145.am/db/2600954/Cisco>,
        <https://1145.am/db/2600989/Cisco>,
        <https://1145.am/db/2601836/Cisco>,
        <https://1145.am/db/2602447/Cisco>,
        <https://1145.am/db/2603184/Cisco>,
        <https://1145.am/db/2603247/Cisco>,
        <https://1145.am/db/2603577/Cisco>,
        <https://1145.am/db/2603662/Cisco>,
        <https://1145.am/db/2603672/Cisco>,
        <https://1145.am/db/2604434/Cisco>,
        <https://1145.am/db/2604771/Cisco>,
        <https://1145.am/db/2604935/Cisco>,
        <https://1145.am/db/2605255/Cisco>,
        <https://1145.am/db/2605659/Cisco>,
        <https://1145.am/db/2605983/Cisco>,
        <https://1145.am/db/2607197/Cisco>,
        <https://1145.am/db/2607581/Cisco>,
        <https://1145.am/db/2607645/Cisco>,
        <https://1145.am/db/2607648/Cisco>,
        <https://1145.am/db/2608260/Cisco>,
        <https://1145.am/db/2608818/Cisco>,
        <https://1145.am/db/2609061/Cisco>,
        <https://1145.am/db/2609364/Cisco>,
        <https://1145.am/db/2609629/Cisco>,
        <https://1145.am/db/2610101/Cisco>,
        <https://1145.am/db/2611248/Cisco>,
        <https://1145.am/db/2612021/Cisco>,
        <https://1145.am/db/2612342/Cisco>,
        <https://1145.am/db/2613058/Cisco>,
        <https://1145.am/db/2613511/Cisco>,
        <https://1145.am/db/2613523/Cisco>,
        <https://1145.am/db/2613706/Cisco>,
        <https://1145.am/db/2613721/Cisco>,
        <https://1145.am/db/2613863/Cisco>,
        <https://1145.am/db/2614353/Cisco>,
        <https://1145.am/db/2614409/Cisco>,
        <https://1145.am/db/2614456/Cisco>,
        <https://1145.am/db/2614569/Cisco>,
        <https://1145.am/db/2615174/Cisco>,
        <https://1145.am/db/2615295/Cisco>,
        <https://1145.am/db/2615806/Cisco>,
        <https://1145.am/db/2616219/Cisco>,
        <https://1145.am/db/2616303/Cisco>,
        <https://1145.am/db/2616548/Cisco>,
        <https://1145.am/db/2616680/Cisco>,
        <https://1145.am/db/2616748/Cisco>,
        <https://1145.am/db/2617245/Cisco>,
        <https://1145.am/db/2617604/Cisco>,
        <https://1145.am/db/2617779/Cisco>,
        <https://1145.am/db/2618170/Cisco>,
        <https://1145.am/db/2618416/Cisco>,
        <https://1145.am/db/2618625/Cisco>,
        <https://1145.am/db/2618833/Cisco>,
        <https://1145.am/db/2619519/Cisco>,
        <https://1145.am/db/2619621/Cisco>,
        <https://1145.am/db/2619945/Cisco>,
        <https://1145.am/db/2620707/Cisco>,
        <https://1145.am/db/2624098/Cisco>,
        <https://1145.am/db/2628002/Cisco>,
        <https://1145.am/db/2628475/Cisco>,
        <https://1145.am/db/2634430/Cisco>,
        <https://1145.am/db/2634790/Cisco>,
        <https://1145.am/db/2637729/Cisco>,
        <https://1145.am/db/2640046/Cisco>,
        <https://1145.am/db/2640659/Cisco>,
        <https://1145.am/db/2641810/Cisco>,
        <https://1145.am/db/2641999/Cisco>,
        <https://1145.am/db/2643723/Cisco>,
        <https://1145.am/db/2644389/Cisco>,
        <https://1145.am/db/2644576/Cisco>,
        <https://1145.am/db/2646055/Cisco>,
        <https://1145.am/db/2649253/Cisco>,
        <https://1145.am/db/2651712/Cisco>,
        <https://1145.am/db/2651992/Cisco>,
        <https://1145.am/db/2652389/Cisco>,
        <https://1145.am/db/2655699/Cisco>,
        <https://1145.am/db/2656110/Cisco>,
        <https://1145.am/db/2657684/Cisco>,
        <https://1145.am/db/2660246/Cisco>,
        <https://1145.am/db/2660927/Cisco>,
        <https://1145.am/db/2660938/Cisco>,
        <https://1145.am/db/2661491/Cisco>,
        <https://1145.am/db/2662802/Cisco>,
        <https://1145.am/db/2665662/Cisco>,
        <https://1145.am/db/2666737/Cisco>,
        <https://1145.am/db/2668413/Cisco>,
        <https://1145.am/db/2669154/Cisco>,
        <https://1145.am/db/2670616/Cisco>,
        <https://1145.am/db/2675037/Cisco>,
        <https://1145.am/db/2678680/Cisco>,
        <https://1145.am/db/2681174/Cisco>,
        <https://1145.am/db/2681760/Cisco>,
        <https://1145.am/db/2681771/Cisco>,
        <https://1145.am/db/2682553/Cisco>,
        <https://1145.am/db/2683016/Cisco>,
        <https://1145.am/db/2683019/Cisco>,
        <https://1145.am/db/2683584/Cisco>,
        <https://1145.am/db/2685036/Cisco>,
        <https://1145.am/db/731124/Cisco>,
        <https://1145.am/db/734617/Cisco>,
        <https://1145.am/db/833076/Cisco> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2674215/Deutsche_Telekom> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "business" ;
    ns1:documentDate "2013-05-01T09:56:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OTE sells Bulgarian unit to Telenor for 717M" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/ote-sells-bulgarian-unit-to-telenor-for-eu717m> ;
    ns1:foundName "Deutsche Telekom" ;
    ns1:investor <https://1145.am/db/2674215/Globul_Unit_Acquisition> ;
    ns1:name "Deutsche Telekom" ;
    ns1:sameAsHigh <https://1145.am/db/1177231/Deutsche_Telekom>,
        <https://1145.am/db/1204904/Deutsche_Telekom>,
        <https://1145.am/db/1205338/Deutsche_Telekom>,
        <https://1145.am/db/1339791/Deutsche_Telekom>,
        <https://1145.am/db/1754033/Deutsche_Telekom>,
        <https://1145.am/db/1841425/Deutsche_Telekom>,
        <https://1145.am/db/194838/Deutsche_Telekom>,
        <https://1145.am/db/194855/Deutsche_Telekom>,
        <https://1145.am/db/1961170/Deutsche>,
        <https://1145.am/db/202888/Deutsche_Telekom>,
        <https://1145.am/db/2606974/Deutsche_Telekom>,
        <https://1145.am/db/2614200/Deutsche_Telekom>,
        <https://1145.am/db/2624446/Deutsche_Telekom>,
        <https://1145.am/db/2628029/Deutsche_Telekom>,
        <https://1145.am/db/2629337/Deutsche_Telekom>,
        <https://1145.am/db/2631186/Deutsche_Telekom>,
        <https://1145.am/db/2640243/Deutsche_Telekom>,
        <https://1145.am/db/2643007/Deutsche_Telekom>,
        <https://1145.am/db/2651025/Telefnica_Deutschland>,
        <https://1145.am/db/2651118/Deutsche_Telekom>,
        <https://1145.am/db/2651511/Telefnica_Deutschland>,
        <https://1145.am/db/2651808/Deutsche_Telekom>,
        <https://1145.am/db/2652793/Deutsche_Telekom>,
        <https://1145.am/db/2653257/Deutsche_Telekom>,
        <https://1145.am/db/2653978/Deutsche_Telekom>,
        <https://1145.am/db/2655754/Telefnica_Deutschland>,
        <https://1145.am/db/2655776/Deutsche_Telekom>,
        <https://1145.am/db/2656752/Deutsche_Telekom>,
        <https://1145.am/db/2656845/Deutsche_Telekom>,
        <https://1145.am/db/2656851/Deutsche_Telekom>,
        <https://1145.am/db/2657928/Deutsche_Telekom>,
        <https://1145.am/db/2659597/Deutsche_Telekom>,
        <https://1145.am/db/2659631/Deutsche_Telekom>,
        <https://1145.am/db/2660467/Deutsche_Telekom>,
        <https://1145.am/db/2662264/Deutsche_Telekom>,
        <https://1145.am/db/2664232/Deutsche_Telekom>,
        <https://1145.am/db/2664873/Deutsche_Telekom>,
        <https://1145.am/db/2665038/Deutsche_Telekom>,
        <https://1145.am/db/2665382/Deutsche_Telekom>,
        <https://1145.am/db/2666440/Telefnica_Deutschland>,
        <https://1145.am/db/2666650/Deutsche_Telekom_Ag>,
        <https://1145.am/db/2666767/Deutsche_Telekom>,
        <https://1145.am/db/2666977/Deutsche_Telekom>,
        <https://1145.am/db/2667483/Deutsche_Telekom>,
        <https://1145.am/db/2668148/Deutsche_Telekom>,
        <https://1145.am/db/2668430/Deutsche_Telekom>,
        <https://1145.am/db/2669553/Deutsche_Telekom>,
        <https://1145.am/db/2669627/Telefnica_Deutschland>,
        <https://1145.am/db/2669661/Telefnica_Deutschland>,
        <https://1145.am/db/2669665/Deutsche_Telekom>,
        <https://1145.am/db/2669701/Deutsche_Telekom>,
        <https://1145.am/db/2669829/Deutsche_Telekom>,
        <https://1145.am/db/2669859/Deutsche_Telekom>,
        <https://1145.am/db/2670741/Deutsche_Telekom>,
        <https://1145.am/db/2670759/Telefnica_Deutschland>,
        <https://1145.am/db/2670930/Deutsche_Telekom>,
        <https://1145.am/db/2673920/Deutsche_Telekom>,
        <https://1145.am/db/2674057/Deutsche_Telekom>,
        <https://1145.am/db/2675183/Deutsche_Telekom>,
        <https://1145.am/db/2675329/Deutsche_Telekom>,
        <https://1145.am/db/2675380/Deutsche_Telekom>,
        <https://1145.am/db/2676572/Deutsche_Telekom>,
        <https://1145.am/db/2676632/Deutsche_Telekom>,
        <https://1145.am/db/2676662/Telefnica_Deutschland>,
        <https://1145.am/db/2677616/Deutsche_Telekom>,
        <https://1145.am/db/2677617/Deutsche_Telekom>,
        <https://1145.am/db/2678023/Deutsche_Telekom>,
        <https://1145.am/db/2680106/Telefnica_Deutschland>,
        <https://1145.am/db/2681082/Deutsche_Telekom>,
        <https://1145.am/db/2681489/Deutsche_Telekom>,
        <https://1145.am/db/338081/Deutsche_Telekom>,
        <https://1145.am/db/455601/Deutsche_Telekom>,
        <https://1145.am/db/599311/Deutsche_Telekom>,
        <https://1145.am/db/895888/Deutsche_Telekom>,
        <https://1145.am/db/976442/Deutsche_Telekom> ;
    ns1:sameAsMedium <https://1145.am/db/1200070/Deutsche_Telekom>,
        <https://1145.am/db/1204075/Deutsche_Telekom_Ag>,
        <https://1145.am/db/1204728/Deutsche_Telekom>,
        <https://1145.am/db/1205180/Deutsche_Telekom_Ag>,
        <https://1145.am/db/1432446/Deutsche_Telekom>,
        <https://1145.am/db/1703907/Deutsche_Telekom>,
        <https://1145.am/db/1755882/Deutsche_Telekom>,
        <https://1145.am/db/1798764/Deutsche_Telekom>,
        <https://1145.am/db/1847752/Deutsche_Telekom>,
        <https://1145.am/db/1849761/Deutsche_Telekom>,
        <https://1145.am/db/1857982/Deutsche_Telekom>,
        <https://1145.am/db/1868921/Deutsche_Telekom>,
        <https://1145.am/db/1874419/Deutsche_Telekom>,
        <https://1145.am/db/1906790/Deutsche_Telekom>,
        <https://1145.am/db/1945321/Deutsche_Telekom>,
        <https://1145.am/db/2156872/Deutsche_Telekom>,
        <https://1145.am/db/2222550/Deutsche_Telekom>,
        <https://1145.am/db/2599629/Deutsche_Telekom>,
        <https://1145.am/db/2606781/Deutsche_Telekom>,
        <https://1145.am/db/2608515/Deutsche_Telekom>,
        <https://1145.am/db/2609688/Deutsche_Telekom>,
        <https://1145.am/db/2610028/Deutsche_Telekom>,
        <https://1145.am/db/2611152/Deutsche_Telekom>,
        <https://1145.am/db/2615830/Deutsche_Telekom>,
        <https://1145.am/db/2622122/Deutsche_Telekom>,
        <https://1145.am/db/2622558/Deutsche_Telekom>,
        <https://1145.am/db/2630698/Deutsche_Telekom>,
        <https://1145.am/db/2631705/Deutsche_Telekom>,
        <https://1145.am/db/2631973/Deutsche_Telekom>,
        <https://1145.am/db/2632088/Deutsche_Telekom>,
        <https://1145.am/db/2632668/Deutsche_Telekom>,
        <https://1145.am/db/2634933/Deutsche_Telekom>,
        <https://1145.am/db/2644699/Deutsche_Telekom>,
        <https://1145.am/db/2649221/Deutsche_Telekom>,
        <https://1145.am/db/2650041/Deutsche_Telekom>,
        <https://1145.am/db/2651098/Deutsche_Telekom>,
        <https://1145.am/db/2651353/Deutsche_Telekom>,
        <https://1145.am/db/2652170/Deutsche_Telekom>,
        <https://1145.am/db/2652628/Deutsche_Telekom>,
        <https://1145.am/db/2654875/Deutsche_Telekom>,
        <https://1145.am/db/2655766/Deutsche_Telekom>,
        <https://1145.am/db/2655910/Deutsche_Telekom>,
        <https://1145.am/db/2657105/Deutsche_Telekom>,
        <https://1145.am/db/2658104/Deutsche_Telekom>,
        <https://1145.am/db/2658569/Deutsche_Telekom>,
        <https://1145.am/db/2658575/Deutsche_Telekom>,
        <https://1145.am/db/2658580/Deutsche_Telekom>,
        <https://1145.am/db/2658755/Deutsche_Telekom>,
        <https://1145.am/db/2659591/Deutsche_Telekom>,
        <https://1145.am/db/266035/Deutsche_Telekom>,
        <https://1145.am/db/2660472/Deutsche_Telekom>,
        <https://1145.am/db/2660499/Deutsche_Telekom>,
        <https://1145.am/db/2661225/Deutsche_Telekom>,
        <https://1145.am/db/2661660/Deutsche_Telekom>,
        <https://1145.am/db/2662456/Deutsche_Telekom>,
        <https://1145.am/db/2663041/Deutsche_Telekom>,
        <https://1145.am/db/2663133/Deutsche_Telekom>,
        <https://1145.am/db/2663146/Deutsche_Telekom>,
        <https://1145.am/db/2663873/Deutsche_Telekom>,
        <https://1145.am/db/2664134/Deutsche_Telekom>,
        <https://1145.am/db/2664255/Deutsche_Telekom>,
        <https://1145.am/db/2664887/Deutsche_Telekom>,
        <https://1145.am/db/2666759/Deutsche_Telekom>,
        <https://1145.am/db/2666968/Deutsche_Telekom>,
        <https://1145.am/db/2667499/Deutsche_Telekom>,
        <https://1145.am/db/2668196/Deutsche_Telekom>,
        <https://1145.am/db/2669110/Deutsche_Telekom>,
        <https://1145.am/db/2669512/Deutsche_Telekom>,
        <https://1145.am/db/2671188/Deutsche_Telekom>,
        <https://1145.am/db/2671623/Deutsche_Telekom>,
        <https://1145.am/db/2672660/Deutsche_Telekom>,
        <https://1145.am/db/2672903/Deutsche_Telekom>,
        <https://1145.am/db/2673296/Deutsche_Telekom>,
        <https://1145.am/db/2673336/Deutsche_Telekom>,
        <https://1145.am/db/2674444/Deutsche_Telekom>,
        <https://1145.am/db/2675377/Deutsche_Telekom>,
        <https://1145.am/db/2676653/Deutsche_Telekom>,
        <https://1145.am/db/2677655/Deutsche_Telekom>,
        <https://1145.am/db/2677854/Deutsche_Telekom>,
        <https://1145.am/db/2678018/Deutsche_Telekom>,
        <https://1145.am/db/2679698/Deutsche_Telekom>,
        <https://1145.am/db/2680746/Deutsche_Telekom>,
        <https://1145.am/db/2680760/Deutsche_Telekom>,
        <https://1145.am/db/2680879/Deutsche_Telekom>,
        <https://1145.am/db/2681407/Deutsche_Telekom>,
        <https://1145.am/db/2681486/Deutsche_Telekom>,
        <https://1145.am/db/2681971/Deutsche_Telekom>,
        <https://1145.am/db/2682116/Deutsche_Telekom>,
        <https://1145.am/db/2682125/Deutsche_Telekom>,
        <https://1145.am/db/2684592/Deutsche_Telekom>,
        <https://1145.am/db/2685113/Deutsche_Telekom>,
        <https://1145.am/db/2685202/Deutsche_Telekom>,
        <https://1145.am/db/310186/Deutsche_Telekom>,
        <https://1145.am/db/310814/Deutsche_Telekom>,
        <https://1145.am/db/461272/Deutsche_Telekom>,
        <https://1145.am/db/627492/Deutsche_Telekom>,
        <https://1145.am/db/673281/Deutsche_Telekom>,
        <https://1145.am/db/676008/Deutsche_Telekom>,
        <https://1145.am/db/699276/Deutsche_Telekom>,
        <https://1145.am/db/704303/Deutsche_Telekom>,
        <https://1145.am/db/97818/Deutsche_Telekom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2674215/Telenor> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Norway" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3144096/about.rdf> ;
    ns1:basedInHighRaw "Norway" ;
    ns1:buyer <https://1145.am/db/2674215/Globul_Unit_Acquisition> ;
    ns1:description "telecoms" ;
    ns1:documentDate "2013-05-01T09:56:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OTE sells Bulgarian unit to Telenor for 717M" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/ote-sells-bulgarian-unit-to-telenor-for-eu717m> ;
    ns1:foundName "Telenor" ;
    ns1:name "Telenor" ;
    ns1:sameAsHigh <https://1145.am/db/1170938/Telenor_Asa>,
        <https://1145.am/db/1436432/Telenor_Asa>,
        <https://1145.am/db/1438131/Telenor_Group>,
        <https://1145.am/db/1796174/Telenor>,
        <https://1145.am/db/1806742/Telenor>,
        <https://1145.am/db/2094378/Telenor>,
        <https://1145.am/db/2652368/Telenor>,
        <https://1145.am/db/2653225/Telenor>,
        <https://1145.am/db/2654657/Telenor>,
        <https://1145.am/db/2655477/Telenor>,
        <https://1145.am/db/2656915/Telenor>,
        <https://1145.am/db/2663848/Telenor>,
        <https://1145.am/db/2664153/Telenor>,
        <https://1145.am/db/2666421/Telenor>,
        <https://1145.am/db/2673173/Telenor>,
        <https://1145.am/db/2674820/Telenor>,
        <https://1145.am/db/2674846/Telenor>,
        <https://1145.am/db/2681794/Telenor>,
        <https://1145.am/db/354360/Telenor_Asa>,
        <https://1145.am/db/357674/Telenor_Asa>,
        <https://1145.am/db/367882/Telenor>,
        <https://1145.am/db/373562/Telenor>,
        <https://1145.am/db/476905/Telenor>,
        <https://1145.am/db/602860/Telenor>,
        <https://1145.am/db/643839/Telenor>,
        <https://1145.am/db/649246/Telenor_Asa>,
        <https://1145.am/db/650742/Telenor_Asa>,
        <https://1145.am/db/932342/Telenor> ;
    ns1:sameAsMedium <https://1145.am/db/1346263/Telenor_Asa>,
        <https://1145.am/db/1399415/Telenor>,
        <https://1145.am/db/1939108/Telenor>,
        <https://1145.am/db/2607010/Telenor>,
        <https://1145.am/db/2614152/Telenor>,
        <https://1145.am/db/2628991/Telenor>,
        <https://1145.am/db/2636581/Telenor>,
        <https://1145.am/db/2639340/Telenor>,
        <https://1145.am/db/2650869/Telenor>,
        <https://1145.am/db/2652904/Telenor>,
        <https://1145.am/db/2653163/Telenor>,
        <https://1145.am/db/2653239/Telenor>,
        <https://1145.am/db/2653265/Telenor>,
        <https://1145.am/db/2654892/Telenor>,
        <https://1145.am/db/2659180/Telenor>,
        <https://1145.am/db/2659514/Telenor>,
        <https://1145.am/db/2659801/Telenor>,
        <https://1145.am/db/2659847/Telenor>,
        <https://1145.am/db/2660884/Telenor>,
        <https://1145.am/db/2660899/Telenor>,
        <https://1145.am/db/2661979/Telenor>,
        <https://1145.am/db/2663652/Telenor>,
        <https://1145.am/db/2663852/Telenor>,
        <https://1145.am/db/2663973/Telenor>,
        <https://1145.am/db/2664724/Telenor>,
        <https://1145.am/db/2666299/Telenor>,
        <https://1145.am/db/2667068/Telenor>,
        <https://1145.am/db/2667384/Telenor>,
        <https://1145.am/db/2669581/Telenor>,
        <https://1145.am/db/2670746/Telenor>,
        <https://1145.am/db/2671481/Telenor>,
        <https://1145.am/db/2672659/Telenor>,
        <https://1145.am/db/2672667/Telenor>,
        <https://1145.am/db/2672936/Telenor>,
        <https://1145.am/db/2672959/Telenor>,
        <https://1145.am/db/2672967/Telenor>,
        <https://1145.am/db/2674119/Telenor>,
        <https://1145.am/db/2674464/Telenor>,
        <https://1145.am/db/2674480/Telenor>,
        <https://1145.am/db/2675034/Telenor>,
        <https://1145.am/db/2675322/Telenor>,
        <https://1145.am/db/2677894/Telenor>,
        <https://1145.am/db/2677980/Telenor>,
        <https://1145.am/db/2682600/Telenor>,
        <https://1145.am/db/2683657/Telenor>,
        <https://1145.am/db/302649/Telenor_Asa>,
        <https://1145.am/db/303526/Telenor_Asa>,
        <https://1145.am/db/367876/Telenor>,
        <https://1145.am/db/383545/Telenor>,
        <https://1145.am/db/638291/Telenor_Asa>,
        <https://1145.am/db/638417/Telenor>,
        <https://1145.am/db/773044/Telenor>,
        <https://1145.am/db/834341/Telenor>,
        <https://1145.am/db/912047/Telenor> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676599/Batelco> a org:Organization ;
    ns1:basedInLowRaw "Monaco" ;
    ns1:buyer <https://1145.am/db/2676599/Compagnie_Monegasque_De_Communication_Stake_Acquisition> ;
    ns1:description "telecom" ;
    ns1:documentDate "2013-05-22T14:42:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tiny Monaco thwarting CWC efforts to focus on pan-American strategy" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/tiny-monaco-thwarting-cwc-efforts-to-focus-pan-american-strategy> ;
    ns1:foundName "Batelco" ;
    ns1:investor <https://1145.am/db/2676599/Compagnie_Monegasque_De_Communication_Stake_Acquisition> ;
    ns1:name "Batelco" ;
    ns1:sameAsHigh <https://1145.am/db/2660604/Batelco_And_Kingdom_Holding>,
        <https://1145.am/db/2664834/Batelco> ;
    ns1:sameAsMedium <https://1145.am/db/2611272/Batelco>,
        <https://1145.am/db/2662077/Batelco>,
        <https://1145.am/db/2664273/Batelco>,
        <https://1145.am/db/2667523/Batelco>,
        <https://1145.am/db/2669617/Batelco>,
        <https://1145.am/db/2670351/Batelco>,
        <https://1145.am/db/2672997/Batelco>,
        <https://1145.am/db/2674136/Batelco>,
        <https://1145.am/db/2680805/Batelco>,
        <https://1145.am/db/357303/Batelco> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676643/Investment_Orascom_Telecom_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Zimbabwe will not renew the licence of a unit of Egypt's Orascom Telecom until it turns over a majority of its shares to local shareholders, according to state media reports." ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2676643/Orascom_Telecom> ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia" .

<https://1145.am/db/2676643/Rostelecom> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:description "mergers" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "Rostelecom" ;
    ns1:name "Rostelecom" ;
    ns1:protagonist <https://1145.am/db/2676643/Merger_Rostelecom_Tele2_Russia_Has_Not_Happened> ;
    ns1:sameAsMedium <https://1145.am/db/2658919/Rostelecom>,
        <https://1145.am/db/2662068/Rostelecom>,
        <https://1145.am/db/2662904/Rostelecom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676643/Syniverse_Technologies> a org:Organization ;
    ns1:basedInLowRaw "European Union" ;
    ns1:buyer <https://1145.am/db/2676643/Mach_Acquisition> ;
    ns1:description "business" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "Syniverse Technologies" ;
    ns1:name "Syniverse Technologies" ;
    ns1:sameAsHigh <https://1145.am/db/2624738/Syniverse_Technologies>,
        <https://1145.am/db/410015/Syniverse_Technologies_Corporation>,
        <https://1145.am/db/411578/Syniverse_Technologies_Corporation>,
        <https://1145.am/db/797400/Syniverse_Corporation>,
        <https://1145.am/db/800951/Syniverse_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/1748407/Syniverse_Technologies>,
        <https://1145.am/db/253141/Syniverse_Technologies>,
        <https://1145.am/db/2646149/Syniverse_Technologies>,
        <https://1145.am/db/2681611/Syniverse_Technologies>,
        <https://1145.am/db/334958/Syniverse_Technologies_Llc>,
        <https://1145.am/db/334966/Syniverse_Technologies_Llc>,
        <https://1145.am/db/817809/Syniverse_Technologies> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Dna_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment",
        "ipo" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Finnish operator DNA considers an IPO or a sale to a private-equity company in an effort to broaden its ownership." ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "IPO",
        "sale" ;
    ns1:name "IPO",
        "sale" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2678993/Dna> ;
    ns1:targetName "DNA" ;
    ns1:whereGeoName "Republic of Finland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/660013/about.rdf> ;
    ns1:whereRaw "Finland" .

<https://1145.am/db/2678993/Iliad> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:buyer <https://1145.am/db/2678993/Mobistar_Acquisition> ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "Iliad" ;
    ns1:name "Iliad" ;
    ns1:sameAsMedium <https://1145.am/db/121346/Iliad>,
        <https://1145.am/db/126144/Iliad>,
        <https://1145.am/db/2160856/Iliad>,
        <https://1145.am/db/2162594/Iliad>,
        <https://1145.am/db/2162996/Iliad>,
        <https://1145.am/db/2163998/Iliad>,
        <https://1145.am/db/2308069/Iliad>,
        <https://1145.am/db/2605979/Iliad>,
        <https://1145.am/db/2651397/Iliad>,
        <https://1145.am/db/2656802/Iliad>,
        <https://1145.am/db/2667491/Iliad>,
        <https://1145.am/db/2670731/Iliad>,
        <https://1145.am/db/2672035/Iliad>,
        <https://1145.am/db/2673142/Iliad>,
        <https://1145.am/db/2674415/Iliad>,
        <https://1145.am/db/2675647/Iliad>,
        <https://1145.am/db/2676518/Iliad>,
        <https://1145.am/db/2676846/Iliad>,
        <https://1145.am/db/2677884/Iliad>,
        <https://1145.am/db/2678018/Iliad>,
        <https://1145.am/db/2678023/Iliad>,
        <https://1145.am/db/301217/Iliad>,
        <https://1145.am/db/489558/Iliad_Sa>,
        <https://1145.am/db/776787/Iliad>,
        <https://1145.am/db/782490/Iliad>,
        <https://1145.am/db/821887/Iliad>,
        <https://1145.am/db/822050/Iliad>,
        <https://1145.am/db/945663/Iliad_Sa>,
        <https://1145.am/db/947184/Iliad_Sa>,
        <https://1145.am/db/977823/Iliad> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/VTB> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:buyer <https://1145.am/db/2678993/Tele2_Russia_Investment> ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "VTB" ;
    ns1:industry "bank" ;
    ns1:name "VTB" ;
    ns1:sameAsHigh <https://1145.am/db/1136812/VTB>,
        <https://1145.am/db/1206175/Vtb_Bank>,
        <https://1145.am/db/1247089/VTB>,
        <https://1145.am/db/1494339/VTB>,
        <https://1145.am/db/1560270/VTB>,
        <https://1145.am/db/1599449/VTB>,
        <https://1145.am/db/1610024/VTB>,
        <https://1145.am/db/1666606/VTB>,
        <https://1145.am/db/2011881/VTB>,
        <https://1145.am/db/2019419/VTB>,
        <https://1145.am/db/2029382/VTB>,
        <https://1145.am/db/2032755/VTB>,
        <https://1145.am/db/2032814/VTB>,
        <https://1145.am/db/214515/VTB>,
        <https://1145.am/db/2655942/VTB>,
        <https://1145.am/db/2670712/VTB>,
        <https://1145.am/db/2671855/Vtb_Group>,
        <https://1145.am/db/337256/VTB>,
        <https://1145.am/db/634400/VTB>,
        <https://1145.am/db/635015/VTB>,
        <https://1145.am/db/955209/VTB> ;
    ns1:sameAsMedium <https://1145.am/db/2655910/VTB>,
        <https://1145.am/db/336843/VTB>,
        <https://1145.am/db/347214/VTB>,
        <https://1145.am/db/453826/VTB> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2679862/Softbank> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japan" ;
    ns1:buyer <https://1145.am/db/2679862/Clearwire_Acquisition> ;
    ns1:description "Japanese operator" ;
    ns1:documentDate "2013-06-28T14:38:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: FCC won't force Sprint, Clearwire to give up spectrum as part of mergers" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-fcc-won-t-force-sprint-clearwire-to-give-up-spectrum-as-part-mergers> ;
    ns1:foundName "SoftBank" ;
    ns1:name "SoftBank" ;
    ns1:sameAsHigh <https://1145.am/db/2653485/Softbank>,
        <https://1145.am/db/2659591/Softbank>,
        <https://1145.am/db/2659594/Softbank>,
        <https://1145.am/db/2671590/Softbank>,
        <https://1145.am/db/2676370/Softbank>,
        <https://1145.am/db/2678777/Softbank> ;
    ns1:sameAsMedium <https://1145.am/db/103808/Softbank_Corp>,
        <https://1145.am/db/1129671/Softbank>,
        <https://1145.am/db/1130952/Softbank>,
        <https://1145.am/db/1140286/Softbank>,
        <https://1145.am/db/116996/Softbank>,
        <https://1145.am/db/1179523/Softbank>,
        <https://1145.am/db/1193504/Softbank>,
        <https://1145.am/db/1215073/Softbank>,
        <https://1145.am/db/1255221/Softbank>,
        <https://1145.am/db/1347499/Softbank>,
        <https://1145.am/db/1492141/Softbank>,
        <https://1145.am/db/1558864/Softbank>,
        <https://1145.am/db/1566837/Softbank>,
        <https://1145.am/db/1684127/Softbank>,
        <https://1145.am/db/1694388/Softbank>,
        <https://1145.am/db/1734925/Softbank>,
        <https://1145.am/db/1735554/Softbank>,
        <https://1145.am/db/1735679/Softbank>,
        <https://1145.am/db/1739469/Softbank>,
        <https://1145.am/db/1740946/Softbank>,
        <https://1145.am/db/1742129/Softbank>,
        <https://1145.am/db/1742163/Softbank>,
        <https://1145.am/db/1742280/Softbank>,
        <https://1145.am/db/1748253/Softbank_Corp>,
        <https://1145.am/db/1748731/Softbank>,
        <https://1145.am/db/1750206/Softbank>,
        <https://1145.am/db/1750248/Softbank>,
        <https://1145.am/db/1753451/Softbank>,
        <https://1145.am/db/1754897/Softbank>,
        <https://1145.am/db/1755776/Softbank>,
        <https://1145.am/db/1756852/Softbank>,
        <https://1145.am/db/1758188/Softbank>,
        <https://1145.am/db/1758916/Softbank>,
        <https://1145.am/db/1759748/Softbank>,
        <https://1145.am/db/1759802/Softbank>,
        <https://1145.am/db/1760606/Softbank>,
        <https://1145.am/db/1763417/Softbank>,
        <https://1145.am/db/1766871/Softbank>,
        <https://1145.am/db/1766892/Softbank>,
        <https://1145.am/db/1767668/Softbank>,
        <https://1145.am/db/1768278/Softbank>,
        <https://1145.am/db/1769212/Softbank>,
        <https://1145.am/db/1769550/Softbank>,
        <https://1145.am/db/1770897/Softbank>,
        <https://1145.am/db/1772843/Softbank>,
        <https://1145.am/db/1775977/Softbank>,
        <https://1145.am/db/1776410/Softbank>,
        <https://1145.am/db/1779650/Softbank>,
        <https://1145.am/db/1782128/Softbank>,
        <https://1145.am/db/1786903/Softbank>,
        <https://1145.am/db/1787663/Softbank>,
        <https://1145.am/db/1787801/Softbank>,
        <https://1145.am/db/1788297/Softbank>,
        <https://1145.am/db/1788831/Softbank>,
        <https://1145.am/db/1789602/Softbank>,
        <https://1145.am/db/1790374/Softbank>,
        <https://1145.am/db/1792881/Softbank>,
        <https://1145.am/db/1795875/Softbank>,
        <https://1145.am/db/1797477/Softbank>,
        <https://1145.am/db/1798154/Softbank>,
        <https://1145.am/db/1803340/Softbank>,
        <https://1145.am/db/1804251/Softbank>,
        <https://1145.am/db/1804413/Softbank>,
        <https://1145.am/db/1805577/Softbank>,
        <https://1145.am/db/1806191/Softbank>,
        <https://1145.am/db/1807737/Softbank>,
        <https://1145.am/db/1808504/Softbank>,
        <https://1145.am/db/1808604/Softbank>,
        <https://1145.am/db/1809360/Softbank>,
        <https://1145.am/db/1811437/Softbank>,
        <https://1145.am/db/1811458/Softbank>,
        <https://1145.am/db/1815886/Softbank>,
        <https://1145.am/db/1816406/Softbank>,
        <https://1145.am/db/1816990/Softbank>,
        <https://1145.am/db/1818582/Softbank>,
        <https://1145.am/db/1818992/Softbank>,
        <https://1145.am/db/1819190/Softbank>,
        <https://1145.am/db/1821102/Softbank>,
        <https://1145.am/db/1822498/Softbank>,
        <https://1145.am/db/1822884/Softbank>,
        <https://1145.am/db/1823172/Softbank>,
        <https://1145.am/db/1827733/Softbank>,
        <https://1145.am/db/1835740/Softbank>,
        <https://1145.am/db/1835811/Softbank_Corp>,
        <https://1145.am/db/1837864/Softbank>,
        <https://1145.am/db/1839534/Softbank_Corp>,
        <https://1145.am/db/1846380/Softbank>,
        <https://1145.am/db/1852090/Softbank>,
        <https://1145.am/db/1853730/Softbank>,
        <https://1145.am/db/1858650/Softbank>,
        <https://1145.am/db/1860196/Softbank>,
        <https://1145.am/db/1860815/Softbank>,
        <https://1145.am/db/1868572/Softbank>,
        <https://1145.am/db/1870857/Softbank>,
        <https://1145.am/db/1875218/Softbank>,
        <https://1145.am/db/1879401/Softbank>,
        <https://1145.am/db/1893839/Softbank>,
        <https://1145.am/db/1921528/Softbank>,
        <https://1145.am/db/1950339/Softbank>,
        <https://1145.am/db/1956539/Softbank_Corp>,
        <https://1145.am/db/2056248/Softbank>,
        <https://1145.am/db/2059616/Softbank>,
        <https://1145.am/db/2084597/Softbank>,
        <https://1145.am/db/2107274/Softbank>,
        <https://1145.am/db/210986/Softbank_Corp>,
        <https://1145.am/db/2119946/Softbank>,
        <https://1145.am/db/2159062/Softbank_Corp>,
        <https://1145.am/db/2164394/Softbank>,
        <https://1145.am/db/2164415/Softbank_Corp>,
        <https://1145.am/db/2185522/Softbank>,
        <https://1145.am/db/2287135/Softbank>,
        <https://1145.am/db/2295289/Softbank>,
        <https://1145.am/db/2407089/Softbank>,
        <https://1145.am/db/2410135/Softbank>,
        <https://1145.am/db/2410849/Softbank>,
        <https://1145.am/db/2412438/Softbank>,
        <https://1145.am/db/2412439/Softbank>,
        <https://1145.am/db/2425544/Softbank_Corp>,
        <https://1145.am/db/2430024/Softbank>,
        <https://1145.am/db/244985/Softbank>,
        <https://1145.am/db/2616385/Softbank_Corp>,
        <https://1145.am/db/2616774/Softbank>,
        <https://1145.am/db/2618577/Softbank_Corp>,
        <https://1145.am/db/2629357/Softbank>,
        <https://1145.am/db/2630698/Softbank>,
        <https://1145.am/db/2633199/Softbank>,
        <https://1145.am/db/2643948/Softbank>,
        <https://1145.am/db/2648388/Softbank>,
        <https://1145.am/db/2648461/Softbank>,
        <https://1145.am/db/2654774/Softbank>,
        <https://1145.am/db/2655150/Softbank>,
        <https://1145.am/db/2655930/Softbank>,
        <https://1145.am/db/2655974/Softbank>,
        <https://1145.am/db/2656904/Softbank>,
        <https://1145.am/db/2656997/Softbank>,
        <https://1145.am/db/2658979/Softbank>,
        <https://1145.am/db/2658990/Softbank>,
        <https://1145.am/db/2659014/Softbank>,
        <https://1145.am/db/2659276/Softbank>,
        <https://1145.am/db/2659492/Softbank>,
        <https://1145.am/db/2659586/Softbank>,
        <https://1145.am/db/2659587/Softbank>,
        <https://1145.am/db/2659601/Softbank>,
        <https://1145.am/db/2659612/Softbank>,
        <https://1145.am/db/2659619/Softbank>,
        <https://1145.am/db/2659620/Softbank>,
        <https://1145.am/db/2659633/Softbank>,
        <https://1145.am/db/2661725/Softbank>,
        <https://1145.am/db/2663254/Softbank>,
        <https://1145.am/db/2664293/Softbank>,
        <https://1145.am/db/2664422/Softbank>,
        <https://1145.am/db/2665296/Softbank>,
        <https://1145.am/db/2666063/Softbank>,
        <https://1145.am/db/2666088/Softbank>,
        <https://1145.am/db/2666839/Softbank>,
        <https://1145.am/db/2667152/Softbank>,
        <https://1145.am/db/2669621/Softbank>,
        <https://1145.am/db/2670440/Softbank>,
        <https://1145.am/db/2670872/Softbank>,
        <https://1145.am/db/2675650/Softbank>,
        <https://1145.am/db/2675856/Softbank>,
        <https://1145.am/db/2676358/Softbank>,
        <https://1145.am/db/2676565/Softbank>,
        <https://1145.am/db/2677542/Softbank>,
        <https://1145.am/db/2678734/Softbank>,
        <https://1145.am/db/2678752/Softbank>,
        <https://1145.am/db/2679897/Softbank>,
        <https://1145.am/db/2680061/Softbank>,
        <https://1145.am/db/2684180/Softbank>,
        <https://1145.am/db/2684436/Softbank>,
        <https://1145.am/db/2749329/Softbank>,
        <https://1145.am/db/277038/Softbank>,
        <https://1145.am/db/283626/Softbank>,
        <https://1145.am/db/302450/Softbank>,
        <https://1145.am/db/328776/Softbank_Corp>,
        <https://1145.am/db/328788/Softbank_Corp>,
        <https://1145.am/db/329019/Softbank>,
        <https://1145.am/db/329219/Softbank>,
        <https://1145.am/db/329220/Softbank>,
        <https://1145.am/db/331680/Softbank>,
        <https://1145.am/db/343587/Softbank>,
        <https://1145.am/db/344177/Softbank>,
        <https://1145.am/db/357570/Softbank>,
        <https://1145.am/db/359190/Softbank>,
        <https://1145.am/db/368673/Softbank>,
        <https://1145.am/db/368676/Softbank>,
        <https://1145.am/db/369042/Softbank>,
        <https://1145.am/db/370085/Softbank>,
        <https://1145.am/db/377807/Softbank>,
        <https://1145.am/db/387932/Softbank>,
        <https://1145.am/db/394986/Softbank>,
        <https://1145.am/db/395563/Softbank>,
        <https://1145.am/db/437556/Softbank>,
        <https://1145.am/db/438632/Softbank>,
        <https://1145.am/db/439819/Softbank>,
        <https://1145.am/db/477269/Softbank>,
        <https://1145.am/db/488382/Softbank>,
        <https://1145.am/db/531806/Softbank>,
        <https://1145.am/db/559220/Softbank>,
        <https://1145.am/db/592879/Softbank_Corp>,
        <https://1145.am/db/638401/Softbank>,
        <https://1145.am/db/653010/Softbank>,
        <https://1145.am/db/667957/Softbank>,
        <https://1145.am/db/668011/Softbank>,
        <https://1145.am/db/670806/Softbank>,
        <https://1145.am/db/685688/Softbank>,
        <https://1145.am/db/745714/Softbank>,
        <https://1145.am/db/747644/Softbank>,
        <https://1145.am/db/752217/Softbank>,
        <https://1145.am/db/753020/Softbank>,
        <https://1145.am/db/778652/Softbank>,
        <https://1145.am/db/799047/Softbank>,
        <https://1145.am/db/799292/Softbank>,
        <https://1145.am/db/8080/Softbank>,
        <https://1145.am/db/813667/Softbank>,
        <https://1145.am/db/857493/Softbank>,
        <https://1145.am/db/886532/Softbank>,
        <https://1145.am/db/915106/Softbank>,
        <https://1145.am/db/930512/Softbank>,
        <https://1145.am/db/976375/Softbank>,
        <https://1145.am/db/999577/Softbank> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2201859/Repaccess> a org:Organization ;
    ns1:description "appointment scheduling" ;
    ns1:documentDate "2013-06-06T12:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "RxVantage Continues Rapid Growth with Acquisition of Competitor RepAccess" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/rxvantage-continues-rapid-growth-acquisition-competitor-repaccess> ;
    ns1:foundName "RepAccess" ;
    ns1:name "RepAccess" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2201859/Repaccess_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-06-06T12:00:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract ", a cloud - based technology platform that enables physicians' practices to streamline and improve their relationships with pharmaceutical and other medical sales representatives, today announced the acquisition of regional industry competitor RepAccess.",
        "RxVantage Continues Rapid Growth with Acquisition of Competitor RepAccess." ;
    ns1:documentTitle "RxVantage Continues Rapid Growth with Acquisition of Competitor RepAccess" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/rxvantage-continues-rapid-growth-acquisition-competitor-repaccess> ;
    ns1:foundName "Acquisition",
        "acquisition" ;
    ns1:name "Acquisition",
        "acquisition" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2201859/Repaccess> ;
    ns1:targetName "RepAccess" ;
    ns1:whereGeoName "Regional" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6394381/about.rdf> ;
    ns1:whereRaw "regional" .

<https://1145.am/db/2205089/Lightspeed_Venture_Partners> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-06-26T13:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NuMedii Receives $3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/numedii-receives-3-5m-a-series-a-financing-from-claremont-creek-ventures-and-lightspeed-venture> ;
    ns1:foundName "Lightspeed Venture Partners" ;
    ns1:investor <https://1145.am/db/2205089/Series_A_Investment_Claremont_Creek_Ventures_Life_Science_Angels_Lightspeed_Venture_Partners_Numedii_Completed> ;
    ns1:name "Lightspeed Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1014186/Citylight_Vc>,
        <https://1145.am/db/1153338/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1272476/Cosmic_Venture_Partners>,
        <https://1145.am/db/1273257/Cosmic_Venture_Partners>,
        <https://1145.am/db/1327277/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1329603/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1386496/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1425749/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1488858/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1494028/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1575302/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1582024/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1704842/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1709168/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1714641/Brightpixel_Capital>,
        <https://1145.am/db/1717363/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1717968/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1719408/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1736514/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1738465/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1739484/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1742702/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1744313/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1744864/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1748678/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1751950/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1754997/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760367/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760696/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1767037/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1775434/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1778667/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1782325/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1784577/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1788570/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795210/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795863/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795934/Lightbank_Ventures>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1804458/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1809007/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1826922/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1827407/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1833389/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1835126/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1837800/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1841062/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1844140/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1845066/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1846040/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1854200/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1860644/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1862796/Rimlight_Capital>,
        <https://1145.am/db/1872837/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1881464/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1881748/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1883859/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1891664/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1918590/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1927859/Blossom_Street_Ventures>,
        <https://1145.am/db/2003542/Starlight_Ventures>,
        <https://1145.am/db/2043018/Shine_Capital>,
        <https://1145.am/db/2044325/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2044393/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2075137/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2154438/Biostar_Ventures>,
        <https://1145.am/db/2190702/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2297471/Biostar_Ventures>,
        <https://1145.am/db/2323746/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2352203/Sunstone_Capital>,
        <https://1145.am/db/2393775/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2608620/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2629526/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2791832/Lightspeed_Venture_Partners>,
        <https://1145.am/db/284996/Lightspeed_Venture_Partners>,
        <https://1145.am/db/402675/Lightspeed_Venture_Partners>,
        <https://1145.am/db/513305/Lightspeed_Venture_Partners>,
        <https://1145.am/db/531354/Lightspeed_Venture_Partners>,
        <https://1145.am/db/545196/Lightspeed_Venture_Partners>,
        <https://1145.am/db/576932/Lightspeed_Venture_Partners>,
        <https://1145.am/db/642123/Lightspeed_Venture_Partners>,
        <https://1145.am/db/676217/Lightship_Capital>,
        <https://1145.am/db/696051/Skyvision_Capital>,
        <https://1145.am/db/804799/Starlight_Ventures>,
        <https://1145.am/db/884806/Lightspeed_Venture_Partners>,
        <https://1145.am/db/922144/Lightspeed_Venture_Partners>,
        <https://1145.am/db/956106/Shine_Capital>,
        <https://1145.am/db/963185/Lightspeed_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1166471/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1298167/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1311917/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1338458/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1429421/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1694946/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1702551/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1710303/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1710361/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1713715/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1717313/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1719145/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1724798/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1727288/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1735394/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1738508/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1740000/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1741225/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1742799/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1742802/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1742964/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1743215/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1744228/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1745895/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1746835/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1747252/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1747689/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1747851/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1751205/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1752403/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1754614/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1756775/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1759040/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760254/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760381/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760517/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1762968/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1763214/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1770095/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1776566/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1779231/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1783600/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1783964/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1786090/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1786249/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1788131/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1796103/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1796702/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1798993/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1801502/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1806318/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1809610/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1811933/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1813855/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1815537/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1826725/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1827025/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1830084/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1830452/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1836989/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1837754/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1838745/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1839077/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1842500/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1853884/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1857074/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1870343/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1875271/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1884888/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1887447/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1906428/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2052812/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2074087/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2074106/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2194249/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2295700/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2303734/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2319634/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2333966/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2370240/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2602429/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2797562/Lightspeed_Venture_Partners>,
        <https://1145.am/db/410407/Lightspeed_Venture_Partners>,
        <https://1145.am/db/426615/Lightspeed_Venture_Partners>,
        <https://1145.am/db/433117/Lightspeed_Venture_Partners>,
        <https://1145.am/db/513673/Lightspeed_Venture_Partners>,
        <https://1145.am/db/532510/Lightspeed_Venture_Partners>,
        <https://1145.am/db/604574/Lightspeed_Venture_Partners>,
        <https://1145.am/db/668077/Lightspeed_Venture_Partners>,
        <https://1145.am/db/700308/Lightspeed_Venture_Partners>,
        <https://1145.am/db/768306/Lightspeed_Venture_Partners>,
        <https://1145.am/db/785709/Lightspeed_Venture_Partners>,
        <https://1145.am/db/848283/Lightspeed_Venture_Partners>,
        <https://1145.am/db/867907/Lightspeed_Venture_Partners>,
        <https://1145.am/db/887034/Lightspeed_Venture_Partners>,
        <https://1145.am/db/890257/Lightspeed_Venture_Partners>,
        <https://1145.am/db/922656/Lightspeed_Venture_Partners>,
        <https://1145.am/db/923779/Lightspeed_Venture_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2205089/Numedii> a org:Organization ;
    ns1:description "Business" ;
    ns1:documentDate "2013-06-26T13:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NuMedii Receives $3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/numedii-receives-3-5m-a-series-a-financing-from-claremont-creek-ventures-and-lightspeed-venture> ;
    ns1:foundName "NuMedii",
        "NuMedii, Inc." ;
    ns1:industry "Life Science" ;
    ns1:name "NuMedii" ;
    ns1:sameAsHigh <https://1145.am/db/2303734/Numedii> ;
    ns1:sameAsMedium <https://1145.am/db/2336954/Numedii> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2206103/Reach_Health> a org:Organization ;
    ns1:description "telemedicine" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "REACH Health",
        "REACH Health, Inc." ;
    ns1:industry "telemedicine" ;
    ns1:name "REACH Health" ;
    ns1:sameAsHigh <https://1145.am/db/1003683/Teladoc_Health>,
        <https://1145.am/db/1174890/SHL>,
        <https://1145.am/db/1229921/Teladoc_Health>,
        <https://1145.am/db/1444536/Teladoc_Health>,
        <https://1145.am/db/1710398/Index_Health>,
        <https://1145.am/db/1736878/Nue_Life_Health>,
        <https://1145.am/db/174200/Workit_Health>,
        <https://1145.am/db/1744474/Alpha_Medical>,
        <https://1145.am/db/1746574/Jd_Health>,
        <https://1145.am/db/1748711/Twentyeight_Health>,
        <https://1145.am/db/2181961/Teladoc_Health>,
        <https://1145.am/db/2183352/Brightside_Health>,
        <https://1145.am/db/2186610/Mdecindirect>,
        <https://1145.am/db/2186610/Teladoc>,
        <https://1145.am/db/2186976/Teladoc>,
        <https://1145.am/db/2187962/Teladoc>,
        <https://1145.am/db/2188085/Intouch_Health>,
        <https://1145.am/db/2188085/Teladoc_Health>,
        <https://1145.am/db/2190528/Teladoc>,
        <https://1145.am/db/2190552/Teladoc>,
        <https://1145.am/db/2191526/Teladoc>,
        <https://1145.am/db/2192610/Teladoc>,
        <https://1145.am/db/2192612/Teladoc>,
        <https://1145.am/db/2193606/Teladoc>,
        <https://1145.am/db/2194185/Teladoc>,
        <https://1145.am/db/2194209/Teladoc>,
        <https://1145.am/db/2215217/Teladoc_Medical_Services>,
        <https://1145.am/db/2215768/Teladoc>,
        <https://1145.am/db/2219406/Hca>,
        <https://1145.am/db/2223795/Telemedicine_Institute>,
        <https://1145.am/db/2230414/Teladoc>,
        <https://1145.am/db/2233078/Reach_Health>,
        <https://1145.am/db/2234150/Reach_Health>,
        <https://1145.am/db/2240575/Teladoc>,
        <https://1145.am/db/2287463/Teladoc>,
        <https://1145.am/db/2294927/Healthspot>,
        <https://1145.am/db/2363728/Compumed>,
        <https://1145.am/db/936559/Brightside_Health>,
        <https://1145.am/db/939279/Brightside_Health>,
        <https://1145.am/db/995703/Specialist_Telemed>,
        <https://1145.am/db/997007/Specialist_Telemed> ;
    ns1:sameAsMedium <https://1145.am/db/2243650/Reach_Health_Inc> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2223723/Iora_Health> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "health care" ;
    ns1:documentDate "2013-04-17T11:00:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iora Health Secures $14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/iora-health-secures-14-million-series-b-growth-financing-investor-group-includes-all> ;
    ns1:foundName "Iora Health" ;
    ns1:industry "healthcare" ;
    ns1:name "Iora Health" ;
    ns1:sameAsHigh <https://1145.am/db/1323276/Ior_Partners>,
        <https://1145.am/db/2187023/Iora_Health>,
        <https://1145.am/db/2187299/Iora_Health>,
        <https://1145.am/db/2191166/Iora_Health>,
        <https://1145.am/db/2195374/Iora_Health>,
        <https://1145.am/db/2196431/Iora_Health>,
        <https://1145.am/db/2196868/Iora_Health>,
        <https://1145.am/db/2249740/Ioa> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2223723/Polaris_Partners> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-17T11:00:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Iora Health Secures $14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/iora-health-secures-14-million-series-b-growth-financing-investor-group-includes-all> ;
    ns1:foundName "Polaris Partners" ;
    ns1:investor <https://1145.am/db/2223723/Growth_Investment_406_Ventures_Fidelity_Biosciences_Iora_Health_Polaris_Partners_Completed> ;
    ns1:name "Polaris Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1163164/Polaris_Partners>,
        <https://1145.am/db/1166225/Polaris_Partners>,
        <https://1145.am/db/127343/Polaris_Partners>,
        <https://1145.am/db/1340338/Polaris_Partners>,
        <https://1145.am/db/1406211/Polaris_Partners>,
        <https://1145.am/db/1412727/Polaris_Partners>,
        <https://1145.am/db/1545490/Polaris_Partners>,
        <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1796259/Polaris_Capital>,
        <https://1145.am/db/1803886/Polaris_Partners>,
        <https://1145.am/db/1845960/Polaris_Partners>,
        <https://1145.am/db/1854788/Polaris_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1885717/Polaris_Ventures>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/1947183/Polaris_Partners>,
        <https://1145.am/db/2140474/Polaris_Capital_Management>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2181016/Polaris_Partners>,
        <https://1145.am/db/2187023/Polaris_Partners>,
        <https://1145.am/db/2194844/Polaris_Partners>,
        <https://1145.am/db/2196895/Polaris_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2317918/Polaris_Ventures>,
        <https://1145.am/db/2318310/Polaris_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2335531/Flagship_Ventures_Polaris_Partners>,
        <https://1145.am/db/2335750/Polaris_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2341599/Polaris_Partners>,
        <https://1145.am/db/2343467/Polaris_Ventures>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2354955/Polaris_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2368913/Polaris_Partners>,
        <https://1145.am/db/2369304/Polaris_Partners>,
        <https://1145.am/db/2369305/Polaris_Partners>,
        <https://1145.am/db/250010/Polaris_Partners>,
        <https://1145.am/db/364226/Polaris_Partners>,
        <https://1145.am/db/572097/Polaris_Partners>,
        <https://1145.am/db/612707/Polaris_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1229314/Polaris_Partners>,
        <https://1145.am/db/1793129/Polaris_Partners>,
        <https://1145.am/db/1796910/Polaris_Partners>,
        <https://1145.am/db/1813337/Polaris_Partners>,
        <https://1145.am/db/1817112/Polaris_Partners>,
        <https://1145.am/db/1830311/Polaris_Partners>,
        <https://1145.am/db/1834199/Polaris_Partners>,
        <https://1145.am/db/1835107/Polaris_Partners>,
        <https://1145.am/db/1858995/Polaris_Partners>,
        <https://1145.am/db/2193661/Polaris_Partners>,
        <https://1145.am/db/2198647/Polaris_Partners>,
        <https://1145.am/db/2282077/Polaris_Partners>,
        <https://1145.am/db/2282162/Polaris_Partners>,
        <https://1145.am/db/2335755/Polaris_Partners>,
        <https://1145.am/db/2341595/Polaris_Partners>,
        <https://1145.am/db/2341764/Polaris_Partners>,
        <https://1145.am/db/2345675/Polaris_Partners>,
        <https://1145.am/db/2346988/Polaris_Partners>,
        <https://1145.am/db/2364332/Polaris_Partners>,
        <https://1145.am/db/2364336/Polaris_Partners>,
        <https://1145.am/db/2368912/Polaris_Partners>,
        <https://1145.am/db/2370208/Polaris_Partners>,
        <https://1145.am/db/2611628/Polaris_Partners>,
        <https://1145.am/db/2787561/Polaris_Partners> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235248/Investment_Craig_Hospital_Wells_Fargo_Securities_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-30T21:00:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Wells Fargo Securities, the investment banking and capital markets business of Wells Fargo (NYSE: WFC) , announced a $ 37.6 million bond transaction with Craig Hospital, a nationally recognized provider of traumatic brain and spinal cord rehabilitative services, as it undergoes an expansion and renovation to its Denver facilities." ;
    ns1:documentTitle "Craig Hospital Undergoes State-of-the-Art Renovations With Support from Wells Fargo Securities" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/craig-hospital-undergoes-state-art-renovations-support-from-wells-fargo-securities> ;
    ns1:foundName "bond transaction",
        "transaction" ;
    ns1:name "bond transaction",
        "transaction" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2235248/Wells_Fargo_Securities> ;
    ns1:valueRaw "$ 37.6 million" ;
    ns1:whereGeoName "Colorado" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5417618/about.rdf> ;
    ns1:whereRaw "Colorado" .

<https://1145.am/db/2235248/Wells_Fargo_Securities> a org:Organization ;
    ns1:basedInLowRaw "Denver" ;
    ns1:description "investment banking and capital markets" ;
    ns1:documentDate "2013-05-30T21:00:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Craig Hospital Undergoes State-of-the-Art Renovations With Support from Wells Fargo Securities" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/craig-hospital-undergoes-state-art-renovations-support-from-wells-fargo-securities> ;
    ns1:foundName "Wells Fargo Securities" ;
    ns1:industry "investment banking and capital markets" ;
    ns1:name "Wells Fargo Securities" ;
    ns1:sameAsHigh <https://1145.am/db/113141/Wells_Fargo>,
        <https://1145.am/db/1187545/Wells_Fargo___Company>,
        <https://1145.am/db/1199173/Wells_Fargo>,
        <https://1145.am/db/1222960/Wells_Fargo___Company>,
        <https://1145.am/db/123135/Wells_Fargo>,
        <https://1145.am/db/137824/Wells_Fargo>,
        <https://1145.am/db/1413780/Wells_Fargo_Advisors>,
        <https://1145.am/db/1754996/Wells_Fargo>,
        <https://1145.am/db/1780621/Wells_Fargo>,
        <https://1145.am/db/196197/Wells_Fargo>,
        <https://1145.am/db/1968579/Wells_Fargo>,
        <https://1145.am/db/2058119/Wells_Fargo>,
        <https://1145.am/db/2058716/Wells_Fargo>,
        <https://1145.am/db/2078968/Wells_Fargo>,
        <https://1145.am/db/2108106/Wells_Fargo>,
        <https://1145.am/db/2109886/Wells_Fargo>,
        <https://1145.am/db/2111403/Wells_Fargo>,
        <https://1145.am/db/2257483/Wells_Fargo>,
        <https://1145.am/db/245016/Wells_Fargo>,
        <https://1145.am/db/2609043/Wells_Fargo>,
        <https://1145.am/db/272400/Wells_Fargo>,
        <https://1145.am/db/2783023/Wells_Fargo>,
        <https://1145.am/db/284577/Wells_Fargo>,
        <https://1145.am/db/334964/Wells_Fargo>,
        <https://1145.am/db/340564/Wells_Fargo___Co>,
        <https://1145.am/db/374098/Wells_Fargo>,
        <https://1145.am/db/395031/Wells_Fargo>,
        <https://1145.am/db/412907/Wells_Fargo>,
        <https://1145.am/db/449555/Wells_Fargo___Company>,
        <https://1145.am/db/450194/Wells_Fargo___Company>,
        <https://1145.am/db/450576/Wells_Fargo___Co>,
        <https://1145.am/db/733471/Wells_Fargo>,
        <https://1145.am/db/765198/Wells_Fargo_Securities>,
        <https://1145.am/db/767743/Wells_Fargo>,
        <https://1145.am/db/867176/Wells_Fargo> ;
    ns1:sameAsMedium <https://1145.am/db/1481541/Wells_Fargo_Securities_Llc>,
        <https://1145.am/db/1482729/Wells_Fargo_Securities_Llc>,
        <https://1145.am/db/780547/Wells_Fargo_Securities> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235258/Esensa_Sas> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Colombia" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3686110/about.rdf> ;
    ns1:basedInHighRaw "Colombia" ;
    ns1:description "Health care" ;
    ns1:documentDate "2013-06-03T13:00:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "DaVita Expands Operations into Latin America" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/davita-expands-operations-into-latin-america> ;
    ns1:foundName "Esensa S.A.S",
        "Esensa S.A.S." ;
    ns1:industry "HealthCare" ;
    ns1:name "Esensa S.A.S",
        "Esensa S.A.S." ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2235258/Esensa_Sas_Interest_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-06-03T13:00:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "DaVita acquires majority interest in Colombia's Esensa S.A.S.",
        ", a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced it has taken majority ownership of Esensa S.A.S., the largest independent renal services provider in Colombia." ;
    ns1:documentTitle "DaVita Expands Operations into Latin America" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/davita-expands-operations-into-latin-america> ;
    ns1:foundName "acquires",
        "taken" ;
    ns1:name "acquires",
        "taken" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2235258/Esensa_Sas> ;
    ns1:targetDetails "interest",
        "ownership" ;
    ns1:targetName "Esensa S.A.S",
        "Esensa S.A.S." ;
    ns1:whereGeoName "Republic of Colombia" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3686110/about.rdf> ;
    ns1:whereRaw "Colombia" .

<https://1145.am/db/2247010/Saltzer_Medical_Group> a org:Organization ;
    ns1:basedInHighGeoName "Idaho" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5596512/about.rdf> ;
    ns1:basedInHighRaw "Idaho" ;
    ns1:description "family practice, internal medicine and pediatrics" ;
    ns1:documentDate "2013-03-14T17:01:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Despite increasing healthcare consolidation, FTC remains wary" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/despite-increasing-healthcare-consolidation-ftc-remains-wary> ;
    ns1:foundName "Saltzer Medical Group" ;
    ns1:industry "health care" ;
    ns1:name "Saltzer Medical Group" ;
    ns1:sameAsHigh <https://1145.am/db/2194492/Saltzer_Medical_Group>,
        <https://1145.am/db/2254888/Saltzer_Medical_Group>,
        <https://1145.am/db/2257072/Saltzer_Medical_Group>,
        <https://1145.am/db/2257111/Saltzer_Medical_Group>,
        <https://1145.am/db/2260588/Saltzer_Medical_Group_Of_Nampa>,
        <https://1145.am/db/2261433/Saltzer_Medical_Group_Of_Nampa>,
        <https://1145.am/db/2262350/Saltzer_Medical_Group>,
        <https://1145.am/db/2264918/Saltzer_Medical_Group>,
        <https://1145.am/db/2268178/Saltzer_Medical_Group>,
        <https://1145.am/db/2271176/Saltzer_Medical_Group>,
        <https://1145.am/db/2274631/Saltzer_Medical_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2239082/Saltzer_Medical_Group> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2247010/Saltzer_Medical_Group_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-03-14T17:01:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "On Tuesday, the commission sued to prevent Idaho's largest hospital group from acquiring the state's largest physician group, the latest hospital deal to be under the scrutiny of the FTC, according to Reuters.",
        "The antitrust complaint was filed in Idaho federal district court, aiming to block Boise - based St. Luke's Health System's acquisition of Saltzer Medical Group, which specializes in family practice, internal medicine and pediatrics." ;
    ns1:documentTitle "Despite increasing healthcare consolidation, FTC remains wary" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/despite-increasing-healthcare-consolidation-ftc-remains-wary> ;
    ns1:foundName "acquiring",
        "acquisition" ;
    ns1:name "acquiring",
        "acquisition" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2247010/Saltzer_Medical_Group> ;
    ns1:targetName "Saltzer Medical Group" ;
    ns1:whereGeoName "Idaho" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5596512/about.rdf> ;
    ns1:whereRaw "Idaho" .

<https://1145.am/db/2249121/Investment_Lancaster_Pollard_Wood_County_Hospital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-02T21:27:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BOWLING GREEN, OHIO (March 19, 2013) - Lancaster Pollard, a national financial services firm headquartered in Columbus, Ohio, that provides capital funding to health care, senior living and housing providers, recently closed on a $ 54 million refunding and financing for Wood County Hospital in Bowling Green, according to Kass Matt, senior vice president and regional manager." ;
    ns1:documentTitle "Lancaster Pollard Completes $54 Million Refunding-Financing for Ohio Hospital" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/lancaster-pollard-completes-54-million-refunding-financing-for-ohio-hospital> ;
    ns1:foundName "financing",
        "refunding" ;
    ns1:name "financing",
        "refunding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2249121/Wood_County_Hospital> ;
    ns1:targetName "Wood County Hospital" ;
    ns1:valueRaw "$ 54 million" ;
    ns1:when "2013-03-19T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 19, 2013" ;
    ns1:whereGeoName "Ohio" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5165418/about.rdf> ;
    ns1:whereRaw "Ohio" .

<https://1145.am/db/2249121/Wood_County_Hospital> a org:Organization ;
    ns1:basedInHighGeoName "Bowling Green" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4285268/about.rdf> ;
    ns1:basedInHighRaw "Bowling Green" ;
    ns1:description "health care" ;
    ns1:documentDate "2013-04-02T21:27:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Lancaster Pollard Completes $54 Million Refunding-Financing for Ohio Hospital" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/lancaster-pollard-completes-54-million-refunding-financing-for-ohio-hospital> ;
    ns1:foundName "Wood County Hospital",
        "Wood County Hospital in Bowling Green" ;
    ns1:industry "health care" ;
    ns1:name "Wood County Hospital" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2266902/Chartered_Health_Plan> a org:Organization ;
    ns1:basedInHighGeoName "Washington" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4140963/about.rdf> ;
    ns1:basedInHighRaw "Washington, D.C." ;
    ns1:description "Medicaid" ;
    ns1:documentDate "2013-02-27T18:04:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AmeriHealth to buy embattled Medicaid plan" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/amerihealth-to-buy-embattled-medicaid-plan> ;
    ns1:foundName "Chartered",
        "Chartered Health Plan" ;
    ns1:industry "health insurer" ;
    ns1:name "Chartered Health Plan" ;
    ns1:sameAsHigh <https://1145.am/db/2186777/Wellcare_Health_Plans>,
        <https://1145.am/db/2195953/Wellcare>,
        <https://1145.am/db/2260786/Medicaid_Insurer>,
        <https://1145.am/db/2262482/Unitedhealthcare>,
        <https://1145.am/db/2263448/Health_Net>,
        <https://1145.am/db/2266926/Health_Net> ;
    ns1:sameAsMedium <https://1145.am/db/2261617/Chartered_Health_Plan>,
        <https://1145.am/db/2266915/Chartered_Health_Plan> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2294872/Halt_Medical> a org:Organization ;
    ns1:documentDate "2013-01-04T13:17:37+00:00"^^xsd:dateTime ;
    ns1:documentTitle "UPDATED: Halt Medical snags $15M to launch uterine fibroid device" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/updated-halt-medical-snags-15m-to-launch-uterine-fibroid-device> ;
    ns1:foundName "Halt Medical" ;
    ns1:industry "medical" ;
    ns1:name "Halt Medical" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2294893/Rivervest_Venture_Partners> a org:Organization ;
    ns1:description "Venture Capital" ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "RiverVest",
        "RiverVest Venture Partners" ;
    ns1:investor <https://1145.am/db/2294893/Equity_Investment_3x5_Special_Opportunity_Fund_Ptv_Sciences_Rivervest_Venture_Partners_Spray_Venture_Partners_Tryton_Medical_Completed> ;
    ns1:name "RiverVest Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1065366/Riverstone_Holdings>,
        <https://1145.am/db/1153383/Bluestone_Venture_Partners>,
        <https://1145.am/db/1283038/Rivervest_Venture_Partners>,
        <https://1145.am/db/1735706/Waterman_Ventures>,
        <https://1145.am/db/1892105/River_Street_Management>,
        <https://1145.am/db/2151983/Waterman_Ventures>,
        <https://1145.am/db/2280492/Bluestone_Venture_Partners>,
        <https://1145.am/db/2329550/Rivervest_Venture_Partners>,
        <https://1145.am/db/2354899/Rivervest_Venture_Partners>,
        <https://1145.am/db/583798/Rivervest_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1669813/Rivervest_Venture_Partners>,
        <https://1145.am/db/2155730/Rivervest_Venture_Partners>,
        <https://1145.am/db/2286035/Rivervest_Venture_Partners>,
        <https://1145.am/db/2288553/Rivervest_Venture_Partners>,
        <https://1145.am/db/2294113/Rivervest_Venture_Partners>,
        <https://1145.am/db/2296631/Rivervest_Venture_Partners>,
        <https://1145.am/db/2299423/Rivervest_Venture_Partners>,
        <https://1145.am/db/2336221/Rivervest_Venture_Partners>,
        <https://1145.am/db/2337106/Rivervest_Venture_Partners>,
        <https://1145.am/db/2340887/Rivervest_Venture_Partners>,
        <https://1145.am/db/2350044/Rivervest_Venture_Partners>,
        <https://1145.am/db/2355274/Rivervest_Venture_Partners>,
        <https://1145.am/db/2356216/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358496/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358502/Rivervest_Venture_Partners>,
        <https://1145.am/db/2369916/Rivervest_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2294893/Tryton_Medical> a org:Organization ;
    ns1:description "a devicemaker" ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "Tryton Medical" ;
    ns1:industry "medical" ;
    ns1:name "Tryton Medical" ;
    ns1:sameAsHigh <https://1145.am/db/1635342/Tryten>,
        <https://1145.am/db/2288553/Tryton_Medical>,
        <https://1145.am/db/2294889/Tryton_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2295809/Direct_Flow_Medical> a org:Organization ;
    ns1:documentDate "2013-01-28T15:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J kicks off oral arguments in all-metal hip trial; Cook Medical launches ureteral access sheath;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/j-j-kicks-off-oral-arguments-all-metal-hip-trial-cook-medical-launches-ureteral> ;
    ns1:foundName "Direct Flow Medical" ;
    ns1:industry "Medical" ;
    ns1:name "Direct Flow Medical" ;
    ns1:sameAsHigh <https://1145.am/db/2236048/Direct_Flow_Medical>,
        <https://1145.am/db/2293561/Direct_Flow_Medical>,
        <https://1145.am/db/2295862/Direct_Flow_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2295809/Series_A_Investment_Direct_Flow_Medical_Founders_Fund_Tribogenics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-28T15:04:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Tribogenics closed its $ 6.2 million Series A financing in a round led by Founders Fund." ;
    ns1:documentTitle "J&J kicks off oral arguments in all-metal hip trial; Cook Medical launches ureteral access sheath;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/j-j-kicks-off-oral-arguments-all-metal-hip-trial-cook-medical-launches-ureteral> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2295809/Direct_Flow_Medical>,
        <https://1145.am/db/2295809/Tribogenics> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 6.2 million" .

<https://1145.am/db/2295809/Tribogenics> a org:Organization ;
    ns1:description "R & D" ;
    ns1:documentDate "2013-01-28T15:04:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J kicks off oral arguments in all-metal hip trial; Cook Medical launches ureteral access sheath;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/j-j-kicks-off-oral-arguments-all-metal-hip-trial-cook-medical-launches-ureteral> ;
    ns1:foundName "Tribogenics" ;
    ns1:name "Tribogenics" ;
    ns1:sameAsMedium <https://1145.am/db/2291004/Tribogenics>,
        <https://1145.am/db/2295226/Tribogenics>,
        <https://1145.am/db/2335353/Tribogenics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2296302/Gold_Standard_Diagnostics> a org:Organization ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:foundName "Gold Standard Diagnostics" ;
    ns1:name "Gold Standard Diagnostics" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2296302/Investment_Burrill___Company_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> India's Strand Life Sciences, a maker of microarray tools for diagnostics work, attracted a \"multi-million-dollar\" investment from Burrill & Company, which included a secondary buyout of the company's lead Series A investors." ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:valueRaw "multi-million-dollar" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2296302/Investment_Burrill___Company_Strand_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> India's Strand Life Sciences, a maker of microarray tools for diagnostics work, attracted a \"multi-million-dollar\" investment from Burrill & Company, which included a secondary buyout of the company's lead Series A investors." ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2296302/Strand_Life_Sciences> ;
    ns1:targetName "Strand Life Sciences" ;
    ns1:valueRaw "multi-million-dollar" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2296302/Strand_Life_Sciences> a org:Organization ;
    ns1:basedInHighGeoName "Republic of India" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:basedInHighRaw "India" ;
    ns1:description "microarray tools for diagnostics work" ;
    ns1:documentDate "2013-02-12T13:38:54+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Strand Life Sciences draws major Burrill & Co. investment; Varian teams with Russian agencies to spur radiotherapy R&D;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/strand-life-sciences-draws-major-burrill-co-investment-varian-teams-russian> ;
    ns1:foundName "Strand Life Sciences" ;
    ns1:industry "Life Sciences" ;
    ns1:name "Strand Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2155866/Strand_Life_Sciences>,
        <https://1145.am/db/2347118/Strand_Life_Sciences>,
        <https://1145.am/db/2367940/Strand_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297264/Life_Technologies> a org:Organization ;
    ns1:description "sequencing" ;
    ns1:documentDate "2013-03-05T23:31:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Life Tech may have found a buyer after all" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-life-tech-may-have-found-a-buyer-after-all> ;
    ns1:foundName "Life Technologies" ;
    ns1:name "Life Technologies" ;
    ns1:sameAsHigh <https://1145.am/db/2296261/Life_Technologies>,
        <https://1145.am/db/2298696/Life_Technologies>,
        <https://1145.am/db/2299139/Life_Technologies> ;
    ns1:sameAsMedium <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/2287839/Life_Technologies>,
        <https://1145.am/db/2288640/Life_Technologies>,
        <https://1145.am/db/2289479/Life_Technologies>,
        <https://1145.am/db/2291513/Life_Technologies>,
        <https://1145.am/db/2294528/Life_Technologies>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296417/Life_Technologies>,
        <https://1145.am/db/2296920/Life_Technologies>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298270/Life_Technologies>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298815/Life_Technologies>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299612/Life_Technologies>,
        <https://1145.am/db/2300265/Life_Technologies>,
        <https://1145.am/db/2306511/Life_Technologies>,
        <https://1145.am/db/2306535/Life_Technologies>,
        <https://1145.am/db/2309321/Life_Technologies>,
        <https://1145.am/db/2313983/Life_Technologies>,
        <https://1145.am/db/2316481/Life_Technologies>,
        <https://1145.am/db/2328026/Life_Technologies>,
        <https://1145.am/db/2328028/Life_Technologies_Corporation>,
        <https://1145.am/db/2332195/Life_Technologies>,
        <https://1145.am/db/2332200/Life_Technologies>,
        <https://1145.am/db/2332668/Life_Technologies_Corporation>,
        <https://1145.am/db/2337045/Life_Technologies>,
        <https://1145.am/db/2351845/Life_Technologies_Corporation>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2360368/Life_Technologies_Corporation>,
        <https://1145.am/db/2363019/Life_Technologies_Corporation>,
        <https://1145.am/db/2364025/Life_Technologies_Corporation>,
        <https://1145.am/db/2366638/Life_Technologies_Corporation>,
        <https://1145.am/db/2551499/Life_Technologies>,
        <https://1145.am/db/2574083/Life_Technologies>,
        <https://1145.am/db/2594467/Life_Technologies_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297756/Investment_Athyrium_Opportunities_Fund_Syncardia_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-20T14:19:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Arizona's SynCardia Systems has reeled in another $ 19 million, money the company will use to develop a next-generation Total Artificial Heart." ;
    ns1:documentTitle "SynCardia snags $19M for artificial heart" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/syncardia-snags-19m-for-artificial-heart> ;
    ns1:foundName "reeled" ;
    ns1:name "reeled" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2297756/Syncardia> ;
    ns1:valueRaw "$ 15 million",
        "$ 19 million" ;
    ns1:whereGeoName "Arizona" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5551752/about.rdf> ;
    ns1:whereRaw "Arizona" .

<https://1145.am/db/2297756/Syncardia> a org:Organization ;
    ns1:basedInHighGeoName "Arizona" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5551752/about.rdf> ;
    ns1:basedInHighRaw "Arizona" ;
    ns1:description "Artificial Heart" ;
    ns1:documentDate "2013-03-20T14:19:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "SynCardia snags $19M for artificial heart" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/syncardia-snags-19m-for-artificial-heart> ;
    ns1:foundName "SynCardia Systems" ;
    ns1:name "SynCardia" ;
    ns1:sameAsHigh <https://1145.am/db/2280652/Syncardia>,
        <https://1145.am/db/2324877/Syncardia_Systems> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2299629/Nasoform> a org:Organization ;
    ns1:basedInHighGeoName "Menlo Park" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5372223/about.rdf> ;
    ns1:basedInHighRaw "Menlo Park, CA" ;
    ns1:description "medical" ;
    ns1:documentDate "2013-04-29T12:53:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tough market for venture-backed Dx outfits; Medtronic launches spinal tech;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tough-market-for-venture-backed-dx-outfits-medtronic-launches-spinal-tech> ;
    ns1:foundName "Nasoform" ;
    ns1:industry "medical device" ;
    ns1:name "Nasoform" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2299645/Aerocrine> a org:Organization ;
    ns1:documentDate "2013-04-30T14:50:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Asthma devicemaker Aerocrine nabs $50M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asthma-devicemaker-aerocrine-nabs-50m> ;
    ns1:foundName "Aerocrine" ;
    ns1:name "Aerocrine" ;
    ns1:sameAsMedium <https://1145.am/db/2298277/Aerocrine>,
        <https://1145.am/db/2310707/Aerocrine>,
        <https://1145.am/db/2310711/Aerocrine>,
        <https://1145.am/db/2353373/Aerocrine>,
        <https://1145.am/db/2353375/Aerocrine> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300074/Good_Start_Genetics> a org:Organization ;
    ns1:basedInHighGeoName "Massachusetts" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6254926/about.rdf> ;
    ns1:basedInHighRaw "Massachusetts" ;
    ns1:description "IVF" ;
    ns1:documentDate "2013-05-08T10:45:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Good Start Genetics raises $28M for carrier Dx" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/good-start-genetics-raises-28m-for-carrier-dx> ;
    ns1:foundName "Massachusetts' Good Start Genetics" ;
    ns1:name "Good Start Genetics" ;
    ns1:sameAsMedium <https://1145.am/db/2296069/Good_Start_Genetics>,
        <https://1145.am/db/2297604/Good_Start_Genetics>,
        <https://1145.am/db/2359125/Good_Start_Genetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2300131/Daktari_Diagnostics> a org:Organization ;
    ns1:basedInHighGeoName "Scotland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2638360/about.rdf> ;
    ns1:basedInHighRaw "Scotland" ;
    ns1:documentDate "2013-05-15T14:43:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Daktari Diagnostics reels in $7M as it preps for Scotland expansion" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/daktari-diagnostics-reels-7m-as-it-preps-for-scotland-expansion> ;
    ns1:foundName "Daktari Diagnostics" ;
    ns1:name "Daktari Diagnostics" ;
    ns1:sameAsMedium <https://1145.am/db/2297846/Daktari_Diagnostics>,
        <https://1145.am/db/2299767/Daktari_Diagnostics>,
        <https://1145.am/db/2299784/Daktari_Diagnostics>,
        <https://1145.am/db/2367520/Daktari_Diagnostics>,
        <https://1145.am/db/2369059/Daktari_Diagnostics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307565/Gobalto> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "Clinical study startup" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "goBalto",
        "goBalto, Inc." ;
    ns1:industry "clinical research" ;
    ns1:name "goBalto" ;
    ns1:sameAsHigh <https://1145.am/db/2319644/Gobalto>,
        <https://1145.am/db/2332478/Gobalto> ;
    ns1:sameAsMedium <https://1145.am/db/1802098/Gobalto>,
        <https://1145.am/db/2307561/Gobalto>,
        <https://1145.am/db/2308682/Gobalto>,
        <https://1145.am/db/2319646/Gobalto>,
        <https://1145.am/db/2323531/Gobalto>,
        <https://1145.am/db/2332479/Gobalto>,
        <https://1145.am/db/2333129/Gobalto>,
        <https://1145.am/db/2338167/Gobalto>,
        <https://1145.am/db/2338176/Gobalto>,
        <https://1145.am/db/2362035/Gobalto> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2309242/Isotechnika_Pharma_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Alberta" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5883102/about.rdf> ;
    ns1:basedInHighRaw "Alberta" ;
    ns1:basedInLowRaw "Canada" ;
    ns1:description "Pharmaceutical",
        "Pharmaceuticals" ;
    ns1:documentDate "2013-06-20T18:20:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/isotechnika-pharma-receives-additional-funding-from-government-of-canada-for-preclinical> ;
    ns1:foundName "Government of Canada",
        "Isotechnika Pharma",
        "Isotechnika Pharma Inc" ;
    ns1:industry "Pharmaceutical" ;
    ns1:investor <https://1145.am/db/2309242/Investment_Isotechnika_Pharma_Inc_National_Research_Council_Industrial_Research_Assistance_Program_Has_Not_Happened> ;
    ns1:name "Isotechnika Pharma",
        "Isotechnika Pharma Inc" ;
    ns1:sameAsMedium <https://1145.am/db/2331731/Isotechnika_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335249/Helmsley_Center_For_Genomic_Medicine> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "NEW YORK" ;
    ns1:description "research" ;
    ns1:documentDate "2013-01-24T19:48:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Salk Institute Awarded Historic $42 Million Grant From the Helmsley Charitable Trust" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/salk-institute-awarded-historic-42-million-grant-from-helmsley-charitable-trust> ;
    ns1:foundName "the Helmsley Center for Genomic Medicine" ;
    ns1:name "Helmsley Center for Genomic Medicine" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335249/Salk_Institute_For_Biological_Studies> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "NEW YORK" ;
    ns1:description "interdisciplinary research" ;
    ns1:documentDate "2013-01-24T19:48:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Salk Institute Awarded Historic $42 Million Grant From the Helmsley Charitable Trust" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/salk-institute-awarded-historic-42-million-grant-from-helmsley-charitable-trust> ;
    ns1:foundName "The Salk Institute for Biological Studies" ;
    ns1:name "Salk Institute for Biological Studies" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335882/Activartis_Gmbh> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Austria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2782113/about.rdf> ;
    ns1:basedInHighRaw "Austria" ;
    ns1:description "Biotech" ;
    ns1:documentDate "2013-06-18T13:03:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aop-orphan-spins-off-its-stake-activartis-and-outlines-business-strategy> ;
    ns1:foundName "Activartis",
        "Activartis GmbH" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Activartis",
        "Activartis GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/2335887/Activartis> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335882/Aop_Orphan_Pharmaceuticals_Ag> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Austria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2782113/about.rdf> ;
    ns1:basedInHighRaw "Austria" ;
    ns1:documentDate "2013-06-18T13:03:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aop-orphan-spins-off-its-stake-activartis-and-outlines-business-strategy> ;
    ns1:foundName "AOP Orphan Pharmaceuticals AG" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "AOP Orphan Pharmaceuticals AG" ;
    ns1:sameAsHigh <https://1145.am/db/2335887/Aop_Orphan_Pharmaceuticals>,
        <https://1145.am/db/2364599/Aop_Orphan_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335936/Series_A_Investment_Baxter_Ventures_Zytoprotec_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-29T13:20:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Vienna, Austria, January 29, 2013 / B3C newswire / - Zytoprotec, a company developing novel peritoneal dialysis solutions and other treatments based on active cytoprotection, today announced that is has raised EUR 2 million in financing from new investor Baxter Ventures towards a EUR 4 million Series A financing.",
        "Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures." ;
    ns1:documentTitle "Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zytoprotec-raises-eur-2-million-financing-from-baxter-ventures> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2335936/Baxter_Ventures>,
        <https://1145.am/db/2335936/Zytoprotec> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "EUR 2 Million",
        "EUR 2 million",
        "EUR 4 million" ;
    ns1:when "2013-01-29T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "January 29, 2013" ;
    ns1:whereGeoName "Europe" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6255148/about.rdf> ;
    ns1:whereRaw "Europe" .

<https://1145.am/db/2335936/Zytoprotec> a org:Organization ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2013-01-29T13:20:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zytoprotec-raises-eur-2-million-financing-from-baxter-ventures> ;
    ns1:foundName "Zytoprotec" ;
    ns1:industry "Biotechnology" ;
    ns1:name "Zytoprotec" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336391/3-V_Biosciences> a org:Organization ;
    ns1:description "a biopharmaceutical company" ;
    ns1:documentDate "2013-06-21T15:24:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "3-V Biosciences Completes $20 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/3-v-biosciences-completes-20-million-series-c-financing> ;
    ns1:foundName "3-V Biosciences",
        "3-V Biosciences, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "3-V Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2305256/3-V_Biosciences>,
        <https://1145.am/db/2336066/3-V_Biosciences>,
        <https://1145.am/db/2336390/3-V> ;
    ns1:sameAsMedium <https://1145.am/db/2340358/3-V_Biosciences>,
        <https://1145.am/db/2342464/3-V_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336391/Kleiner_Perkins_Caufield___Byers> a org:Organization ;
    ns1:basedInLowRaw "MENLO PARK" ;
    ns1:documentDate "2013-06-21T15:24:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "3-V Biosciences Completes $20 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/3-v-biosciences-completes-20-million-series-c-financing> ;
    ns1:foundName "Kleiner Perkins Caufield & Byers" ;
    ns1:investor <https://1145.am/db/2336391/Series_C_Investment_3-V_Biosciences_Kleiner_Perkins_Caufield___Byers_New_Enterprise_Associates_Completed> ;
    ns1:name "Kleiner Perkins Caufield & Byers" ;
    ns1:sameAsMedium <https://1145.am/db/1697155/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1709036/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1714786/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1719362/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1792401/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1794049/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1794342/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1795003/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1796259/Kleiner_Perkins_Caufield_Byers>,
        <https://1145.am/db/1798154/Kleiner_Perkins_Caufield_Byers>,
        <https://1145.am/db/1802208/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1802525/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1805986/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1806158/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1808735/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1814186/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1816928/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1821378/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1824878/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1825866/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1826126/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1827381/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1830311/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1835647/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1838965/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1839326/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1840650/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1844931/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1845205/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1847021/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1849969/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850246/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850293/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850642/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1852048/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1852697/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1853217/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1853292/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/1854098/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1856424/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1858545/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1858646/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1859219/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1860406/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1860644/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1861870/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1864650/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1865436/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1868593/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1868958/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1870791/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1871768/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1872947/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/1872971/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1874419/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1876759/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1881582/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1883859/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1890121/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1891856/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1892105/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1892746/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1895292/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1906922/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1907771/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1915400/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2227037/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2230414/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2288899/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2289585/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2291836/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2293308/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2300306/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2300337/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2305254/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2305256/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2310485/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2311540/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2312700/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2313567/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2316038/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2317750/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2317753/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2321949/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2325726/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2326444/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2326926/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2331026/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2331047/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2332010/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2338251/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2338254/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2341484/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2341487/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2344782/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2349519/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2355531/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2355543/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2359987/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2362457/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2364035/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2367199/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2629526/Kleiner_Perkins_Caufield___Byers> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336391/New_Enterprise_Associates> a org:Organization ;
    ns1:basedInLowRaw "MENLO PARK" ;
    ns1:documentDate "2013-06-21T15:24:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "3-V Biosciences Completes $20 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/3-v-biosciences-completes-20-million-series-c-financing> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2336391/Series_C_Investment_3-V_Biosciences_Kleiner_Perkins_Caufield___Byers_New_Enterprise_Associates_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336410/Vasopharm_Gmbh> a org:Organization ;
    ns1:basedInHighRaw "Wuerzburg" ;
    ns1:basedInLowRaw "Austria" ;
    ns1:description "treating diseases" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "vasopharm",
        "vasopharm GmbH" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "vasopharm",
        "vasopharm GmbH" ;
    ns1:sameAsHigh <https://1145.am/db/2152188/Vasopharm>,
        <https://1145.am/db/2369428/Vasopharm_Gmbh> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Complix> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Complix" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Complix" ;
    ns1:sameAsHigh <https://1145.am/db/1042008/Jazz_Pharmaceuticals>,
        <https://1145.am/db/1203801/Theravance_Biopharma>,
        <https://1145.am/db/1205635/Theravance_Biopharma>,
        <https://1145.am/db/1205649/Theravance_Biopharma>,
        <https://1145.am/db/1282163/Pharmasimple>,
        <https://1145.am/db/1283229/Pharmasimple>,
        <https://1145.am/db/1443968/Pharmajet>,
        <https://1145.am/db/1445613/Pharmajet>,
        <https://1145.am/db/1497218/Opiant_Pharmaceuticals>,
        <https://1145.am/db/1500616/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1502096/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1537336/Pharmajet>,
        <https://1145.am/db/1538786/Pharmajet>,
        <https://1145.am/db/1624479/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1625532/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1629605/Biogen>,
        <https://1145.am/db/1629663/Biogen>,
        <https://1145.am/db/2035521/Civica>,
        <https://1145.am/db/2062728/Novan>,
        <https://1145.am/db/2280153/Pharming>,
        <https://1145.am/db/2296094/Biogen>,
        <https://1145.am/db/2298037/Ethicon>,
        <https://1145.am/db/2302587/Access_Pharmaceuticals>,
        <https://1145.am/db/2303008/Access_Pharmaceuticals>,
        <https://1145.am/db/2303352/Mgi_Pharma>,
        <https://1145.am/db/2303791/Inspire_Pharmaceuticals>,
        <https://1145.am/db/2303804/Access_Pharmaceuticals>,
        <https://1145.am/db/2303934/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2313320/Nycomed>,
        <https://1145.am/db/2313323/Nycomed_Us>,
        <https://1145.am/db/2313336/Sound_Pharmaceuticals>,
        <https://1145.am/db/2314680/Pharming>,
        <https://1145.am/db/2316658/Medidur__Fa>,
        <https://1145.am/db/2317917/Nycomed_Us_Inc>,
        <https://1145.am/db/2323783/Jazz_Pharmaceuticals>,
        <https://1145.am/db/2324017/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2327264/Inspire_Pharmaceuticals>,
        <https://1145.am/db/2333492/Access_Pharmaceuticals>,
        <https://1145.am/db/2333624/Pharmos>,
        <https://1145.am/db/2337986/Pharmagen_Inc>,
        <https://1145.am/db/2338735/Map_Pharmaceuticals>,
        <https://1145.am/db/2339816/Nuevolution_A_S>,
        <https://1145.am/db/2342100/Inspire_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344318/Theraclone_Sciences>,
        <https://1145.am/db/2344820/Jazz_Pharmaceuticals>,
        <https://1145.am/db/2347882/Medigene_Ag>,
        <https://1145.am/db/2347977/Pharmstandard>,
        <https://1145.am/db/2348785/Jazz_Pharmaceuticals_Plc>,
        <https://1145.am/db/2350440/Ethicon>,
        <https://1145.am/db/2350626/Epicept_Corporation>,
        <https://1145.am/db/2353565/Jazz_Pharmaceuticals>,
        <https://1145.am/db/2354582/Action_Pharma>,
        <https://1145.am/db/2355925/Inspire_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357823/Map_Pharmaceuticals>,
        <https://1145.am/db/2358405/Pharmagen_Inc>,
        <https://1145.am/db/2360489/Medac_Pharma>,
        <https://1145.am/db/2362453/Action_Pharma>,
        <https://1145.am/db/2362456/Action_Pharma_A_S>,
        <https://1145.am/db/2363387/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2364538/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2371015/M_Pharma>,
        <https://1145.am/db/2371016/M_Pharma>,
        <https://1145.am/db/2538908/Mission_Pharmacal_Company>,
        <https://1145.am/db/2539568/Zao>,
        <https://1145.am/db/2540578/Bever_Pharmaceutical_Pte_Ltd>,
        <https://1145.am/db/2543839/British_Pharma>,
        <https://1145.am/db/2544721/Imcopharma>,
        <https://1145.am/db/2548593/Jazz_Pharmaceuticals>,
        <https://1145.am/db/2550148/Organon_Biosciences>,
        <https://1145.am/db/2550758/Medley>,
        <https://1145.am/db/2558955/Amdipharm>,
        <https://1145.am/db/2567651/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2574077/Inspire_Pharmaceuticals_Inc>,
        <https://1145.am/db/2575222/Map_Pharmaceuticals>,
        <https://1145.am/db/2576103/Jazz_Pharmaceuticals>,
        <https://1145.am/db/2577958/Specifar>,
        <https://1145.am/db/2580479/Pharmaxis>,
        <https://1145.am/db/2586802/Pharma_Healthcare_Pte_Ltd>,
        <https://1145.am/db/2586804/Pharma_Healthcare>,
        <https://1145.am/db/2588884/Map_Pharmaceuticals>,
        <https://1145.am/db/2590195/Pro-Tect_Pharmaceuticals>,
        <https://1145.am/db/2596632/Nycomed>,
        <https://1145.am/db/426114/Novan>,
        <https://1145.am/db/934888/Jazz_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2336927/Complix> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Gemma_Frisius_Fund_Trustcapital_Vinnof> a org:Organization ;
    ns1:basedInLowRaw "Belgium",
        "France" ;
    ns1:description "Life Sciences",
        "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Gemma Frisius Fund, TrustCapital",
        "Gemma Frisius Fund, TrustCapital, Vinnof",
        "Vinnof" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Gemma Frisius Fund, TrustCapital",
        "Gemma Frisius Fund, TrustCapital, Vinnof",
        "Vinnof" ;
    ns1:sameAsHigh <https://1145.am/db/2336923/Vinnof_Baekeland_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/LRM> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "LRM" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "LRM" ;
    ns1:sameAsHigh <https://1145.am/db/2062003/Fidelity_Management___Research_Company_Llc>,
        <https://1145.am/db/2062003/Invus>,
        <https://1145.am/db/2062003/Platanus>,
        <https://1145.am/db/2062003/Point72>,
        <https://1145.am/db/2310922/Life_Sciences_Partners>,
        <https://1145.am/db/2322622/Kbc_Private_Equity>,
        <https://1145.am/db/2331946/Life_Science_Partners>,
        <https://1145.am/db/2331946/Life_Sciences_Partners>,
        <https://1145.am/db/2336923/Vesalius_Biocapital>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2346397/LRM>,
        <https://1145.am/db/2346397/Life_Sciences_Research_Partners>,
        <https://1145.am/db/2352059/Advent_Life_Sciences>,
        <https://1145.am/db/2352059/Sofinnova_Ventures>,
        <https://1145.am/db/923059/Catalio_Capital_Management> ;
    ns1:sameAsMedium <https://1145.am/db/1060208/LRM>,
        <https://1145.am/db/2293248/LRM>,
        <https://1145.am/db/2336927/LRM>,
        <https://1145.am/db/2350031/LRM>,
        <https://1145.am/db/2370680/LRM>,
        <https://1145.am/db/2370786/LRM> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Vesalius_Biocapital> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Vesalius Biocapital" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Vesalius Biocapital" ;
    ns1:sameAsHigh <https://1145.am/db/2062003/Fidelity_Management___Research_Company_Llc>,
        <https://1145.am/db/2062003/Invus>,
        <https://1145.am/db/2062003/Platanus>,
        <https://1145.am/db/2062003/Point72>,
        <https://1145.am/db/2310922/Life_Sciences_Partners>,
        <https://1145.am/db/2322622/Kbc_Private_Equity>,
        <https://1145.am/db/2331946/Life_Science_Partners>,
        <https://1145.am/db/2331946/Life_Sciences_Partners>,
        <https://1145.am/db/2336923/LRM>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2346397/LRM>,
        <https://1145.am/db/2346397/Life_Sciences_Research_Partners>,
        <https://1145.am/db/2352059/Advent_Life_Sciences>,
        <https://1145.am/db/2352059/Sofinnova_Ventures>,
        <https://1145.am/db/923059/Catalio_Capital_Management> ;
    ns1:sameAsMedium <https://1145.am/db/2152317/Vesalius_Biocapital>,
        <https://1145.am/db/2310041/Vesalius_Biocapital>,
        <https://1145.am/db/2336927/Vesalius_Biocapital>,
        <https://1145.am/db/2346397/Vesalius_Biocapital>,
        <https://1145.am/db/2370680/Vesalius_Biocapital>,
        <https://1145.am/db/2370786/Vesalius_Biocapital>,
        <https://1145.am/db/2790236/Vesalius_Biocapital>,
        <https://1145.am/db/831774/Vesalius_Biocapital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336923/Vinnof_Baekeland_Fund> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:description "Life Sciences",
        "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "Baekeland Fund",
        "Vinnof, Baekeland Fund" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Baekeland Fund",
        "Vinnof, Baekeland Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2336923/Gemma_Frisius_Fund_Trustcapital_Vinnof> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336944/Heptares_Therapeutics> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:description "Pharmaceuticals",
        "drug discovery and development" ;
    ns1:documentDate "2013-06-27T15:06:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/heptares-raises-us-21-million-to-advance-novel-gpcr-medicines-into-clinical-development> ;
    ns1:foundName "Heptares",
        "Heptares Therapeutics" ;
    ns1:industry "drug discovery and development" ;
    ns1:name "Heptares",
        "Heptares Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2289508/Heptares_Therapeutics>,
        <https://1145.am/db/2289522/Heptares_Therapeutics>,
        <https://1145.am/db/2302076/Heptares_Therapeutics>,
        <https://1145.am/db/2332748/Heptares_Therapeutics_Ltd>,
        <https://1145.am/db/2340059/Heptares_Therapeutics>,
        <https://1145.am/db/2370104/Heptares_Therapeutics>,
        <https://1145.am/db/2370775/Heptares_Therapeutics>,
        <https://1145.am/db/2370795/Heptares>,
        <https://1145.am/db/2538702/Heptares_Therapeutics>,
        <https://1145.am/db/2550556/Heptares> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336957/Ampliphi_Biosciences_Corp> a org:Organization ;
    ns1:basedInLowRaw "Australia",
        "United States" ;
    ns1:description "bacteriophage - based antibacterial therapies" ;
    ns1:documentDate "2013-06-27T16:09:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ampliphi Biosciences Corp : AmpliPhi Closes $7 Million Private Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ampliphi-biosciences-corp-ampliphi-closes-7-million-private-placement> ;
    ns1:foundName "AmpliPhi BioSciences Corp.",
        "Ampliphi Biosciences Corp: AmpliPhi" ;
    ns1:industry "life-sciences" ;
    ns1:name "AmpliPhi",
        "AmpliPhi BioSciences Corp." ;
    ns1:sameAsHigh <https://1145.am/db/2336292/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2338446/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2338446/Intrexon>,
        <https://1145.am/db/2339435/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2339860/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2351279/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2369442/Ampliphi_Biosciences_Corporation>,
        <https://1145.am/db/2369867/Ampliphi_Biosciences_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2336954/Ampliphi_Biosciences>,
        <https://1145.am/db/2338449/Ampliphi_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336957/Third_Security_Llc> a org:Organization ;
    ns1:description "life-sciences investors" ;
    ns1:documentDate "2013-06-27T16:09:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ampliphi Biosciences Corp : AmpliPhi Closes $7 Million Private Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ampliphi-biosciences-corp-ampliphi-closes-7-million-private-placement> ;
    ns1:foundName "Third Security, LLC" ;
    ns1:investor <https://1145.am/db/2336957/Investment_Ampliphi_Biosciences_Corp_Bioscience_Managers_Pty_Ltd_Ra_Capital_Management_Third_Security_Llc_Completed> ;
    ns1:name "Third Security, LLC" ;
    ns1:sameAsMedium <https://1145.am/db/2337071/Third_Security_Llc>,
        <https://1145.am/db/2348287/Third_Security_Llc>,
        <https://1145.am/db/2353230/Third_Security_Llc>,
        <https://1145.am/db/636070/Third_Security>,
        <https://1145.am/db/637012/Third_Security> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338254/Elcelyx_Therapeutics> a org:Organization ;
    ns1:documentDate "2013-02-14T15:40:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elcelyx-therapeutics-completes-20-million-series-c-financing-to-advance-newmet-and-lovidia> ;
    ns1:foundName "Elcelyx Therapeutics" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Elcelyx Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2213473/Arno_Therapeutics_Inc>,
        <https://1145.am/db/2320472/Aryx_Therapeutics_Inc>,
        <https://1145.am/db/2336844/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2337706/Arno_Therapeutics>,
        <https://1145.am/db/2342845/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2345831/Arno_Therapeutics_Inc>,
        <https://1145.am/db/2346087/Argos_Therapeutics>,
        <https://1145.am/db/2347977/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2350043/Elcelyx_Therapeutics>,
        <https://1145.am/db/2354125/Arno_Therapeutics>,
        <https://1145.am/db/2360213/Arno_Therapeutics>,
        <https://1145.am/db/2362563/Arno_Therapeutics>,
        <https://1145.am/db/2367611/Arog_Pharmaceuticals>,
        <https://1145.am/db/2370779/Elcelyx_Therapeutics>,
        <https://1145.am/db/2551380/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2559208/Argos_Therapeutics>,
        <https://1145.am/db/588256/Arrevus>,
        <https://1145.am/db/677973/Arrakis_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2338251/Elcelyx_Therapeutics>,
        <https://1145.am/db/2346480/Elcelyx_Therapeutics>,
        <https://1145.am/db/2346482/Elcelyx_Therapeutics>,
        <https://1145.am/db/2370778/Elcelyx_Therapeutics>,
        <https://1145.am/db/2541304/Elcelyx_Therapeutics>,
        <https://1145.am/db/2595068/Elcelyx_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338254/Kleiner_Perkins_Caufield___Byers> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-02-14T15:40:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elcelyx-therapeutics-completes-20-million-series-c-financing-to-advance-newmet-and-lovidia> ;
    ns1:foundName "Kleiner Perkins Caufield & Byers" ;
    ns1:investor <https://1145.am/db/2338254/Series_C_Investment_Elcelyx_Therapeutics_Kleiner_Perkins_Caufield___Byers_Morgenthaler_Ventures_Technology_Partners_Completed> ;
    ns1:name "Kleiner Perkins Caufield & Byers" ;
    ns1:sameAsMedium <https://1145.am/db/1697155/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1709036/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1714786/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1719362/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1792401/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1794049/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1794342/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1795003/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1796259/Kleiner_Perkins_Caufield_Byers>,
        <https://1145.am/db/1798154/Kleiner_Perkins_Caufield_Byers>,
        <https://1145.am/db/1802208/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1802525/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1805986/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1806158/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1808735/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1814186/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1816928/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1821378/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1824878/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1825866/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1826126/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1827381/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1830311/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1835647/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1838965/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1839326/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1840650/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1844931/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1845205/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1847021/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1849969/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850246/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850293/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1850642/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1852048/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1852697/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1853217/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1853292/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/1854098/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1856424/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1858545/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1858646/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1859219/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1860406/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1860644/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1861870/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1864650/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1865436/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1868593/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1868958/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1870791/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1871768/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1872947/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/1872971/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1874419/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1876759/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1881582/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1883859/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1890121/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1891856/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1892105/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1892746/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1895292/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1906922/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/1907771/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/1915400/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2227037/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2230414/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2288899/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2289585/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2291836/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2293308/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2300306/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2300337/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2305254/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2305256/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2310485/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2311540/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2312700/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2313567/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2316038/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2317750/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2317753/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2321949/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2325726/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2326444/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2326926/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2331026/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2331047/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2332010/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2336391/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2338251/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2341484/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2341487/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2344782/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2349519/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2355531/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2355543/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2359987/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2362457/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2364035/Kleiner_Perkins_Caufield_And_Byers>,
        <https://1145.am/db/2367199/Kleiner_Perkins_Caufield___Byers>,
        <https://1145.am/db/2629526/Kleiner_Perkins_Caufield___Byers> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338254/Morgenthaler_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-02-14T15:40:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elcelyx-therapeutics-completes-20-million-series-c-financing-to-advance-newmet-and-lovidia> ;
    ns1:foundName "Morgenthaler Ventures" ;
    ns1:investor <https://1145.am/db/2338254/Series_C_Investment_Elcelyx_Therapeutics_Kleiner_Perkins_Caufield___Byers_Morgenthaler_Ventures_Technology_Partners_Completed> ;
    ns1:name "Morgenthaler Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1695894/Morgenthaler_Ventures>,
        <https://1145.am/db/1699268/Morgenthaler_Ventures>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1724566/Morgenthaler_Ventures>,
        <https://1145.am/db/1826128/Morgenthaler_Ventures>,
        <https://1145.am/db/1829487/Morgenthaler_Ventures>,
        <https://1145.am/db/1830084/Morgenthaler_Ventures>,
        <https://1145.am/db/1836989/Morgenthaler_Ventures>,
        <https://1145.am/db/1837117/Morgenthaler_Ventures>,
        <https://1145.am/db/1839836/Morgenthaler_Ventures>,
        <https://1145.am/db/1846752/Morgenthaler_Ventures>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/2246579/Morgenthaler_Ventures>,
        <https://1145.am/db/2257512/Morgenthaler_Ventures>,
        <https://1145.am/db/2297408/Morgenthaler_Ventures>,
        <https://1145.am/db/2297592/Morgenthaler_Ventures>,
        <https://1145.am/db/2307644/Morgenthaler_Ventures>,
        <https://1145.am/db/2308142/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311075/Morgenthaler_Ventures>,
        <https://1145.am/db/2312192/Morgenthaler_Ventures>,
        <https://1145.am/db/2323586/Morgenthaler_Ventures>,
        <https://1145.am/db/2329524/Morgenthaler_Ventures>,
        <https://1145.am/db/2329531/Morgenthaler_Ventures>,
        <https://1145.am/db/2338251/Morgenthaler_Ventures>,
        <https://1145.am/db/2338373/Morgenthaler_Ventures>,
        <https://1145.am/db/2338703/Morgenthaler_Ventures>,
        <https://1145.am/db/2338704/Morgenthaler_Ventures>,
        <https://1145.am/db/2342925/Morgenthaler_Ventures>,
        <https://1145.am/db/2342937/Morgenthaler_Ventures>,
        <https://1145.am/db/2343202/Morgenthaler_Ventures>,
        <https://1145.am/db/2343210/Morgenthaler_Ventures>,
        <https://1145.am/db/2352207/Morgenthaler_Ventures>,
        <https://1145.am/db/2362553/Morgenthaler_Ventures>,
        <https://1145.am/db/2363510/Morgenthaler_Ventures>,
        <https://1145.am/db/2364939/Morgenthaler_Ventures>,
        <https://1145.am/db/2367204/Morgenthaler_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338254/Technology_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-02-14T15:40:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elcelyx-therapeutics-completes-20-million-series-c-financing-to-advance-newmet-and-lovidia> ;
    ns1:foundName "Technology Partners" ;
    ns1:investor <https://1145.am/db/2338254/Series_C_Investment_Elcelyx_Therapeutics_Kleiner_Perkins_Caufield___Byers_Morgenthaler_Ventures_Technology_Partners_Completed> ;
    ns1:name "Technology Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1223975/Technology_Partners_Llc>,
        <https://1145.am/db/2314492/Technology_Partners>,
        <https://1145.am/db/2324289/Technology_Partners>,
        <https://1145.am/db/2329531/Technology_Partners>,
        <https://1145.am/db/2338251/Technology_Partners>,
        <https://1145.am/db/2352207/Technology_Partners>,
        <https://1145.am/db/646965/Technology_Partners_Llc>,
        <https://1145.am/db/796589/Technology_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338289/Acquisition_Chiesi_Farmaceutici_Spa_Cornerstone_Therapeutics_Inc_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-02-20T17:03:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CARY, NC- (Marketwire - Feb 20, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the \"Company\") announced today that its Board of Directors has received a letter from Chiesi Farmaceutici SpA (\"Chiesi\") ." ;
    ns1:documentTitle "Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cornerstone-therapeutics-inc-announces-receipt-of-take-private-proposal-from-its-majority> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:vendor <https://1145.am/db/2338289/Cornerstone_Therapeutics_Inc> ;
    ns1:whereGeoName "Cary" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4459467/about.rdf> ;
    ns1:whereRaw "CARY, NC" .

<https://1145.am/db/2338289/Cornerstone_Therapeutics_Inc_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-02-20T17:03:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CARY, NC- (Marketwire - Feb 20, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the \"Company\") announced today that its Board of Directors has received a letter from Chiesi Farmaceutici SpA (\"Chiesi\") .",
        "Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder." ;
    ns1:documentTitle "Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cornerstone-therapeutics-inc-announces-receipt-of-take-private-proposal-from-its-majority> ;
    ns1:foundName "Private",
        "Take",
        "acquire" ;
    ns1:name "Private",
        "Take",
        "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2338289/Cornerstone_Therapeutics_Inc> ;
    ns1:targetName "Cornerstone Therapeutics Inc",
        "Cornerstone Therapeutics Inc." ;
    ns1:whereGeoName "Cary",
        "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4459467/about.rdf>,
        <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "CARY, NC",
        "United States" .

<https://1145.am/db/2339099/Brickell_Biotech> a org:Organization ;
    ns1:basedInHighGeoName "Miami" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4164138/about.rdf> ;
    ns1:basedInHighRaw "MIAMI" ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "Dermatology",
        "pharmaceutical company" ;
    ns1:documentDate "2013-02-26T14:13:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Brickell Biotech Announces $7M Series B Financing to Fund Development of Novel Dermatology Treatments" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/brickell-biotech-announces-7m-series-b-financing-to-fund-development-of-novel-dermatology> ;
    ns1:foundName "Brickell",
        "Brickell Biotech",
        "Brickell Biotech, Inc",
        "Brickell Biotech, Inc." ;
    ns1:industry "Biotech",
        "pharmaceutical" ;
    ns1:name "Brickell",
        "Brickell Biotech" ;
    ns1:sameAsHigh <https://1145.am/db/1028934/Brickell_Biotech>,
        <https://1145.am/db/1055588/Brickell_Biotech>,
        <https://1145.am/db/2154930/Brickell_Biotech>,
        <https://1145.am/db/2281415/Brickell_Biotech>,
        <https://1145.am/db/2339102/Brickell_Biotech>,
        <https://1145.am/db/577067/Brickell_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339108/Glide_Pharma> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "U.K." ;
    ns1:description "Pharmaceutical" ;
    ns1:documentDate "2013-02-26T16:41:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Glide gets $21M round for drug/device work; Vivus shares battered on weak sales results for Qsymia;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/glide-gets-21m-round-for-drug-device-work-vivus-shares-battered-on-weak-sales-results-for> ;
    ns1:foundName "Glide Pharma" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Glide Pharma" ;
    ns1:sameAsHigh <https://1145.am/db/2330756/Glide_Pharma>,
        <https://1145.am/db/2339111/Glide_Pharma>,
        <https://1145.am/db/2340814/Glide_Pharma>,
        <https://1145.am/db/2358408/Glide_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339108/Investment_Glide_Pharma_Invesco_Perpetual_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-26T16:41:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> The U.K.'s Glide Pharma has completed a 14.0 million ($ 21.4 million) investment round." ;
    ns1:documentTitle "Glide gets $21M round for drug/device work; Vivus shares battered on weak sales results for Qsymia;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/glide-gets-21m-round-for-drug-device-work-vivus-shares-battered-on-weak-sales-results-for> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2339108/Glide_Pharma> ;
    ns1:valueRaw "$ 21.4 million",
        "14.0 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "U.K." .

<https://1145.am/db/2339108/Vivus> a org:Organization ;
    ns1:documentDate "2013-02-26T16:41:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Glide gets $21M round for drug/device work; Vivus shares battered on weak sales results for Qsymia;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/glide-gets-21m-round-for-drug-device-work-vivus-shares-battered-on-weak-sales-results-for> ;
    ns1:foundName "Vivus" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Vivus" ;
    ns1:sameAsHigh <https://1145.am/db/1050596/Vifor_Pharma_Ag>,
        <https://1145.am/db/1051576/Vifor_Pharma_Ag>,
        <https://1145.am/db/1140646/Vivera_Pharmaceuticals>,
        <https://1145.am/db/1200976/Vifor_Pharma_Ag>,
        <https://1145.am/db/1201659/Vifor_Pharma_Ag>,
        <https://1145.am/db/1245775/Vifor_Pharma_Ag>,
        <https://1145.am/db/1246749/Vifor_Pharma_Ag>,
        <https://1145.am/db/1423926/Vifor>,
        <https://1145.am/db/1632206/Vivus>,
        <https://1145.am/db/2279472/Vifor_Pharma>,
        <https://1145.am/db/2303189/Virochem_Pharma_Inc>,
        <https://1145.am/db/2303194/Virochem_Pharma>,
        <https://1145.am/db/2309826/Vivus>,
        <https://1145.am/db/2309836/Vivus>,
        <https://1145.am/db/2311264/Vion_Pharmaceuticals>,
        <https://1145.am/db/2312397/Vioquest_Pharmaceuticals>,
        <https://1145.am/db/2318933/Vioquest_Pharmaceuticals>,
        <https://1145.am/db/2322298/Vioquest_Pharmaceuticals>,
        <https://1145.am/db/2323794/Vifor_Pharma>,
        <https://1145.am/db/2324793/Virdante_Pharmaceuticals>,
        <https://1145.am/db/2324806/Vifor>,
        <https://1145.am/db/2325372/Virium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2341762/Vivus>,
        <https://1145.am/db/2342311/Vivus>,
        <https://1145.am/db/2344934/Vivus>,
        <https://1145.am/db/2356093/Vifor_Pharma>,
        <https://1145.am/db/2357419/Vivus_Inc>,
        <https://1145.am/db/2542600/Vifor_Pharma>,
        <https://1145.am/db/2547918/Vibalogics>,
        <https://1145.am/db/2550810/Vifor>,
        <https://1145.am/db/2565140/Vifor_Pharma>,
        <https://1145.am/db/2565148/Vifor>,
        <https://1145.am/db/2565158/Vifor>,
        <https://1145.am/db/2565182/Vifor_Pharma>,
        <https://1145.am/db/2576933/Virbac>,
        <https://1145.am/db/2582799/Virbac_Corporation>,
        <https://1145.am/db/2583163/Vivimed_Labs>,
        <https://1145.am/db/538467/Vifor_Pharma_Group>,
        <https://1145.am/db/638175/Vifor_Pharma>,
        <https://1145.am/db/658165/Vifor_Pharma>,
        <https://1145.am/db/666407/Vivera_Pharmaceuticals>,
        <https://1145.am/db/668060/Vifor_Pharma>,
        <https://1145.am/db/668095/Vifor_Pharma>,
        <https://1145.am/db/686504/Vifor_Pharma_Group>,
        <https://1145.am/db/689235/Vifor_Pharma_Group>,
        <https://1145.am/db/692923/Vifor_Pharma_Ltd>,
        <https://1145.am/db/693925/Vifor_Pharma_Ag>,
        <https://1145.am/db/699811/Vifor_Pharma_Ag>,
        <https://1145.am/db/700933/Vifor_Pharma_Group>,
        <https://1145.am/db/749567/Vivera_Pharmaceuticals>,
        <https://1145.am/db/763120/Vifor_Pharma_Ltd>,
        <https://1145.am/db/799870/Vifor_Pharma_Group>,
        <https://1145.am/db/854202/Vibliome>,
        <https://1145.am/db/867739/Vifor_Pharma_Ltd>,
        <https://1145.am/db/871338/Vifor_Pharma_Ltd>,
        <https://1145.am/db/881825/Vifor_Pharma_Ltd>,
        <https://1145.am/db/883404/Vifor_Pharma_Ltd>,
        <https://1145.am/db/921912/Vifor_Pharma_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2324301/Vivus>,
        <https://1145.am/db/2324401/Vivus>,
        <https://1145.am/db/2325870/Vivus>,
        <https://1145.am/db/2344939/Vivus>,
        <https://1145.am/db/2349295/Vivus>,
        <https://1145.am/db/2349910/Vivus_Inc>,
        <https://1145.am/db/2350051/Vivus>,
        <https://1145.am/db/2356370/Vivus>,
        <https://1145.am/db/2357335/Vivus>,
        <https://1145.am/db/2586586/Vivus> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339932/Acquisition_Centric_Research_Institute_Innovus_Pharmaceuticals_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Innovus Pharmaceuticals says it has signed a deal with Centric Research Institute for over $ 7.5 US million in upfront, milestones and sales royalty payments in order to acquire global ex- U.S. rights to the marketed skin cream, CIRCUMserum." ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:valueRaw "over $ 7.5 US million" ;
    ns1:vendor <https://1145.am/db/2339932/Centric_Research_Institute> ;
    ns1:whereGeoName "Kingdom of the Netherlands" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:whereRaw "Netherlands" .

<https://1145.am/db/2339932/Biogeneration_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dutch" ;
    ns1:description "Investing in biotech" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "BioGeneration Ventures" ;
    ns1:investor <https://1145.am/db/2339932/Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_New_Science_Ventures_Completed> ;
    ns1:name "BioGeneration Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1283038/Arkin_Bio_Ventures>,
        <https://1145.am/db/1657080/Alpha_Wave_Ventures>,
        <https://1145.am/db/2301824/Sagamore_Bioventures>,
        <https://1145.am/db/2302897/Sagamore_Bioventures>,
        <https://1145.am/db/2325348/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2331988/Bioventures_Investors>,
        <https://1145.am/db/2342557/Tpg_Biotech>,
        <https://1145.am/db/2353607/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2361588/Agechem_Venture>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/527072/Biobrit_Llc>,
        <https://1145.am/db/545842/Hx_Bio_Ventures>,
        <https://1145.am/db/674484/Trinity_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Biogeneration_Ventures>,
        <https://1145.am/db/2019705/Biogeneration_Ventures>,
        <https://1145.am/db/2154018/Biogeneration_Ventures>,
        <https://1145.am/db/2154415/Biogeneration_Ventures>,
        <https://1145.am/db/2285342/Biogeneration_Ventures>,
        <https://1145.am/db/2295805/Biogeneration_Ventures>,
        <https://1145.am/db/2301966/Biogeneration_Ventures>,
        <https://1145.am/db/2339933/Biogeneration_Ventures>,
        <https://1145.am/db/2343244/Biogeneration_Ventures>,
        <https://1145.am/db/2343250/Biogeneration_Ventures>,
        <https://1145.am/db/2353355/Biogeneration_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339932/Centric_Research_Institute> a org:Organization ;
    ns1:basedInLowRaw "U.S" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "Centric Research Institute" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Centric Research Institute" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339932/Forbion_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "Dutch" ;
    ns1:description "investing" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "Forbion Capital Partners" ;
    ns1:investor <https://1145.am/db/2339932/Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_New_Science_Ventures_Completed> ;
    ns1:name "Forbion Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2301966/Forbion_Capital_Partners>,
        <https://1145.am/db/2309865/Forbion_Capital_Partners>,
        <https://1145.am/db/2320503/Forbion_Capital_Partners>,
        <https://1145.am/db/2329919/Forbion_Capital_Partners>,
        <https://1145.am/db/2336126/Forbion_Capital_Partners>,
        <https://1145.am/db/2355511/Forbion_Capital_Partners>,
        <https://1145.am/db/2357941/Forbion_Capital_Partners>,
        <https://1145.am/db/2361390/Forbion_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Forbion_Capital_Partners>,
        <https://1145.am/db/2288529/Forbion_Capital_Partners>,
        <https://1145.am/db/2295207/Forbion_Capital_Partners>,
        <https://1145.am/db/2296065/Forbion_Capital_Partners>,
        <https://1145.am/db/2309872/Forbion_Capital_Partners>,
        <https://1145.am/db/2313401/Forbion_Capital_Partners>,
        <https://1145.am/db/2313410/Forbion_Capital_Partners>,
        <https://1145.am/db/2313915/Forbion_Capital_Partners>,
        <https://1145.am/db/2318829/Forbion_Capital_Partners>,
        <https://1145.am/db/2323586/Forbion_Capital_Partners>,
        <https://1145.am/db/2327009/Forbion_Capital_Partners>,
        <https://1145.am/db/2328040/Forbion_Capital_Partners>,
        <https://1145.am/db/2328763/Forbion_Capital_Partners>,
        <https://1145.am/db/2328769/Forbion_Capital_Partners>,
        <https://1145.am/db/2338373/Forbion_Capital_Partners>,
        <https://1145.am/db/2338987/Forbion_Capital_Partners>,
        <https://1145.am/db/2339427/Forbion_Capital_Partners>,
        <https://1145.am/db/2339428/Forbion_Capital_Partners>,
        <https://1145.am/db/2339933/Forbion_Capital_Partners>,
        <https://1145.am/db/2341942/Forbion_Capital_Partners>,
        <https://1145.am/db/2343202/Forbion_Capital_Partners>,
        <https://1145.am/db/2343210/Forbion_Capital_Partners>,
        <https://1145.am/db/2343244/Forbion_Capital_Partners>,
        <https://1145.am/db/2346397/Forbion_Capital_Partners>,
        <https://1145.am/db/2348506/Forbion_Capital_Partners>,
        <https://1145.am/db/2348523/Forbion_Capital_Partners>,
        <https://1145.am/db/2350101/Forbion_Capital_Partners>,
        <https://1145.am/db/2352566/Forbion_Capital_Partners>,
        <https://1145.am/db/2355512/Forbion_Capital_Partners>,
        <https://1145.am/db/2356989/Forbion_Capital_Partners>,
        <https://1145.am/db/2357956/Forbion_Capital_Partners>,
        <https://1145.am/db/2359960/Forbion_Capital_Partners>,
        <https://1145.am/db/2360313/Forbion_Capital_Partners>,
        <https://1145.am/db/2360317/Forbion_Capital_Partners>,
        <https://1145.am/db/2363593/Forbion_Capital_Partners>,
        <https://1145.am/db/2363597/Forbion_Capital_Partners>,
        <https://1145.am/db/2366539/Forbion_Capital_Partners>,
        <https://1145.am/db/2369872/Forbion_Capital_Partners>,
        <https://1145.am/db/2370054/Forbion_Capital_Partners>,
        <https://1145.am/db/2370056/Forbion_Capital_Partners>,
        <https://1145.am/db/2538923/Forbion_Capital_Partners>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339932/New_Science_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dutch" ;
    ns1:description "investing" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "New Science Ventures" ;
    ns1:investor <https://1145.am/db/2339932/Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_New_Science_Ventures_Completed> ;
    ns1:name "New Science Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2154415/New_Science_Ventures>,
        <https://1145.am/db/2309865/New_Science_Ventures>,
        <https://1145.am/db/2326139/New_Science_Ventures>,
        <https://1145.am/db/2339427/New_Science_Ventures>,
        <https://1145.am/db/2339933/New_Science_Ventures>,
        <https://1145.am/db/2343140/New_Science_Ventures>,
        <https://1145.am/db/2343989/New_Science_Ventures>,
        <https://1145.am/db/2344978/New_Science_Ventures>,
        <https://1145.am/db/2364827/New_Science_Ventures>,
        <https://1145.am/db/2370056/New_Science_Ventures>,
        <https://1145.am/db/704198/New_Science_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2304650/New_Science_Ventures>,
        <https://1145.am/db/2309872/New_Science_Ventures>,
        <https://1145.am/db/2314677/New_Science_Ventures>,
        <https://1145.am/db/2320692/New_Science_Ventures>,
        <https://1145.am/db/2322312/New_Science_Ventures>,
        <https://1145.am/db/2326130/New_Science_Ventures>,
        <https://1145.am/db/2331639/New_Science_Ventures>,
        <https://1145.am/db/2333573/New_Science_Ventures>,
        <https://1145.am/db/2333577/New_Science_Ventures>,
        <https://1145.am/db/2338987/New_Science_Ventures>,
        <https://1145.am/db/2339428/New_Science_Ventures>,
        <https://1145.am/db/2342717/New_Science_Ventures>,
        <https://1145.am/db/2363484/New_Science_Ventures>,
        <https://1145.am/db/2363485/New_Science_Ventures>,
        <https://1145.am/db/2364820/New_Science_Ventures>,
        <https://1145.am/db/2365444/New_Science_Ventures>,
        <https://1145.am/db/2370054/New_Science_Ventures>,
        <https://1145.am/db/2447981/New_Science_Ventures_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339933/Biogeneration_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of the Netherlands" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:basedInHighRaw "Netherlands" ;
    ns1:description "BioGeneration Ventures" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "BioGeneration Ventures (NL)" ;
    ns1:investor <https://1145.am/db/2339933/Series_A_Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_Completed> ;
    ns1:name "BioGeneration Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2301966/Biogeneration_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Biogeneration_Ventures>,
        <https://1145.am/db/2019705/Biogeneration_Ventures>,
        <https://1145.am/db/2154018/Biogeneration_Ventures>,
        <https://1145.am/db/2154415/Biogeneration_Ventures>,
        <https://1145.am/db/2285342/Biogeneration_Ventures>,
        <https://1145.am/db/2295805/Biogeneration_Ventures>,
        <https://1145.am/db/2339932/Biogeneration_Ventures>,
        <https://1145.am/db/2343244/Biogeneration_Ventures>,
        <https://1145.am/db/2343250/Biogeneration_Ventures>,
        <https://1145.am/db/2353355/Biogeneration_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339933/Forbion_Capital_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of the Netherlands" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:basedInHighRaw "Netherlands" ;
    ns1:description "Series A funding round" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "Forbion Capital Partners (NL)" ;
    ns1:investor <https://1145.am/db/2339933/Series_A_Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_Completed> ;
    ns1:name "Forbion Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2347983/Forbion_Capital>,
        <https://1145.am/db/2352566/Forbion_Capital_Partners>,
        <https://1145.am/db/2363593/Forbion_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Forbion_Capital_Partners>,
        <https://1145.am/db/2288529/Forbion_Capital_Partners>,
        <https://1145.am/db/2295207/Forbion_Capital_Partners>,
        <https://1145.am/db/2296065/Forbion_Capital_Partners>,
        <https://1145.am/db/2301966/Forbion_Capital_Partners>,
        <https://1145.am/db/2309865/Forbion_Capital_Partners>,
        <https://1145.am/db/2309872/Forbion_Capital_Partners>,
        <https://1145.am/db/2313401/Forbion_Capital_Partners>,
        <https://1145.am/db/2313410/Forbion_Capital_Partners>,
        <https://1145.am/db/2313915/Forbion_Capital_Partners>,
        <https://1145.am/db/2318829/Forbion_Capital_Partners>,
        <https://1145.am/db/2320503/Forbion_Capital_Partners>,
        <https://1145.am/db/2323586/Forbion_Capital_Partners>,
        <https://1145.am/db/2327009/Forbion_Capital_Partners>,
        <https://1145.am/db/2328040/Forbion_Capital_Partners>,
        <https://1145.am/db/2328763/Forbion_Capital_Partners>,
        <https://1145.am/db/2328769/Forbion_Capital_Partners>,
        <https://1145.am/db/2329919/Forbion_Capital_Partners>,
        <https://1145.am/db/2336126/Forbion_Capital_Partners>,
        <https://1145.am/db/2338373/Forbion_Capital_Partners>,
        <https://1145.am/db/2338987/Forbion_Capital_Partners>,
        <https://1145.am/db/2339427/Forbion_Capital_Partners>,
        <https://1145.am/db/2339428/Forbion_Capital_Partners>,
        <https://1145.am/db/2339932/Forbion_Capital_Partners>,
        <https://1145.am/db/2341942/Forbion_Capital_Partners>,
        <https://1145.am/db/2343202/Forbion_Capital_Partners>,
        <https://1145.am/db/2343210/Forbion_Capital_Partners>,
        <https://1145.am/db/2343244/Forbion_Capital_Partners>,
        <https://1145.am/db/2346397/Forbion_Capital_Partners>,
        <https://1145.am/db/2348506/Forbion_Capital_Partners>,
        <https://1145.am/db/2348523/Forbion_Capital_Partners>,
        <https://1145.am/db/2350101/Forbion_Capital_Partners>,
        <https://1145.am/db/2355511/Forbion_Capital_Partners>,
        <https://1145.am/db/2355512/Forbion_Capital_Partners>,
        <https://1145.am/db/2356989/Forbion_Capital_Partners>,
        <https://1145.am/db/2357941/Forbion_Capital_Partners>,
        <https://1145.am/db/2357956/Forbion_Capital_Partners>,
        <https://1145.am/db/2359960/Forbion_Capital_Partners>,
        <https://1145.am/db/2360313/Forbion_Capital_Partners>,
        <https://1145.am/db/2360317/Forbion_Capital_Partners>,
        <https://1145.am/db/2361390/Forbion_Capital_Partners>,
        <https://1145.am/db/2363597/Forbion_Capital_Partners>,
        <https://1145.am/db/2366539/Forbion_Capital_Partners>,
        <https://1145.am/db/2369872/Forbion_Capital_Partners>,
        <https://1145.am/db/2370054/Forbion_Capital_Partners>,
        <https://1145.am/db/2370056/Forbion_Capital_Partners>,
        <https://1145.am/db/2538923/Forbion_Capital_Partners>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339933/New_Science_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "United States" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:basedInHighRaw "USA" ;
    ns1:description "funding" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "New Science Ventures (USA)" ;
    ns1:investor <https://1145.am/db/2339933/Series_A_Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_Completed> ;
    ns1:name "New Science Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2154415/New_Science_Ventures>,
        <https://1145.am/db/2309865/New_Science_Ventures>,
        <https://1145.am/db/2326139/New_Science_Ventures>,
        <https://1145.am/db/2339427/New_Science_Ventures>,
        <https://1145.am/db/2339932/New_Science_Ventures>,
        <https://1145.am/db/2343140/New_Science_Ventures>,
        <https://1145.am/db/2343989/New_Science_Ventures>,
        <https://1145.am/db/2344978/New_Science_Ventures>,
        <https://1145.am/db/2364827/New_Science_Ventures>,
        <https://1145.am/db/2370056/New_Science_Ventures>,
        <https://1145.am/db/704198/New_Science_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2304650/New_Science_Ventures>,
        <https://1145.am/db/2309872/New_Science_Ventures>,
        <https://1145.am/db/2314677/New_Science_Ventures>,
        <https://1145.am/db/2320692/New_Science_Ventures>,
        <https://1145.am/db/2322312/New_Science_Ventures>,
        <https://1145.am/db/2326130/New_Science_Ventures>,
        <https://1145.am/db/2331639/New_Science_Ventures>,
        <https://1145.am/db/2333573/New_Science_Ventures>,
        <https://1145.am/db/2333577/New_Science_Ventures>,
        <https://1145.am/db/2338987/New_Science_Ventures>,
        <https://1145.am/db/2339428/New_Science_Ventures>,
        <https://1145.am/db/2342717/New_Science_Ventures>,
        <https://1145.am/db/2363484/New_Science_Ventures>,
        <https://1145.am/db/2363485/New_Science_Ventures>,
        <https://1145.am/db/2364820/New_Science_Ventures>,
        <https://1145.am/db/2365444/New_Science_Ventures>,
        <https://1145.am/db/2370054/New_Science_Ventures>,
        <https://1145.am/db/2447981/New_Science_Ventures_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2340819/Brookside_Capital_Partners_Fund> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "Brookside Capital Partners Fund, L.P." ;
    ns1:investor <https://1145.am/db/2340819/Investment_Adage_Capital_Management_Brookside_Capital_Partners_Fund_Jennison_Associates_Llc_Longwood_Fund_Ptc_Therapeutics_Inc_Completed> ;
    ns1:name "Brookside Capital Partners Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2327685/Brookside_Capital>,
        <https://1145.am/db/2352172/Brookside_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2325398/Brookside_Capital_Partners_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2340819/Ptc_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "South Plainfield" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5104844/about.rdf> ;
    ns1:basedInHighRaw "SOUTH PLAINFIELD, N.J." ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "PTC Therapeutics",
        "PTC Therapeutics, Inc",
        "PTC Therapeutics, Inc." ;
    ns1:name "PTC Therapeutics",
        "PTC Therapeutics, Inc",
        "PTC Therapeutics, Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2293338/Ptc_Therapeutics>,
        <https://1145.am/db/2304335/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2304340/Ptc_Therapeutics>,
        <https://1145.am/db/2305030/Ptc_Therapeutics>,
        <https://1145.am/db/2306291/Ptc_Therapeutics>,
        <https://1145.am/db/2331623/Ptc_Therapeutics>,
        <https://1145.am/db/2335700/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2335913/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2345070/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2346028/Ptc_Therapeutics>,
        <https://1145.am/db/2346877/Ptc_Therapeutics>,
        <https://1145.am/db/2347783/Ptc_Therapeutics>,
        <https://1145.am/db/2357307/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2362643/Ptc_Therapeutics>,
        <https://1145.am/db/2546781/Ptc_Therapeutics>,
        <https://1145.am/db/2584056/Ptc_Therapeutics_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342842/Bioclinica> a org:Organization ;
    ns1:basedInHighGeoName "Newtown" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5203354/about.rdf> ;
    ns1:basedInHighRaw "NEWTOWN, Pa." ;
    ns1:description "Clinical trial management" ;
    ns1:documentDate "2013-03-14T16:17:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BioClinica and CoreLab Partners Are One" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bioclinica-and-corelab-partners-are-one> ;
    ns1:foundName "BioClinica",
        "BioClinica, Inc." ;
    ns1:industry "pharmaceutical outsourcing" ;
    ns1:name "BioClinica" ;
    ns1:participant <https://1145.am/db/2342842/Bioclinica_Investment> ;
    ns1:sameAsHigh <https://1145.am/db/2308650/Bioclinica_Inc>,
        <https://1145.am/db/2309719/Bioclinica>,
        <https://1145.am/db/2312783/Bioclinica>,
        <https://1145.am/db/2328240/Bioclinica>,
        <https://1145.am/db/2333395/Bioclinica>,
        <https://1145.am/db/2334330/Bioclinica>,
        <https://1145.am/db/2336429/Bioclinica_Inc>,
        <https://1145.am/db/2348196/Bioclinica>,
        <https://1145.am/db/2354124/Biotec_Services_International>,
        <https://1145.am/db/2366217/Bioclinica> ;
    ns1:sameAsMedium <https://1145.am/db/2156283/Bioclinica>,
        <https://1145.am/db/2286632/Bioclinica>,
        <https://1145.am/db/2291327/Bioclinica>,
        <https://1145.am/db/2296000/Bioclinica>,
        <https://1145.am/db/2297919/Bioclinica>,
        <https://1145.am/db/2303747/Bioclinica>,
        <https://1145.am/db/2304163/Bioclinica>,
        <https://1145.am/db/2304165/Bioclinica>,
        <https://1145.am/db/2308646/Bioclinica>,
        <https://1145.am/db/2309721/Bioclinica>,
        <https://1145.am/db/2309736/Bioclinica>,
        <https://1145.am/db/2310425/Bioclinica>,
        <https://1145.am/db/2311476/Bioclinica>,
        <https://1145.am/db/2313742/Bioclinica>,
        <https://1145.am/db/2319587/Bioclinica>,
        <https://1145.am/db/2319589/Bioclinica>,
        <https://1145.am/db/2320646/Bioclinica>,
        <https://1145.am/db/2320648/Bioclinica>,
        <https://1145.am/db/2321368/Bioclinica>,
        <https://1145.am/db/2322670/Bioclinica>,
        <https://1145.am/db/2326031/Bioclinica>,
        <https://1145.am/db/2326032/Bioclinica>,
        <https://1145.am/db/2330506/Bioclinica>,
        <https://1145.am/db/2331511/Bioclinica>,
        <https://1145.am/db/2333773/Bioclinica>,
        <https://1145.am/db/2334589/Bioclinica>,
        <https://1145.am/db/2335029/Bioclinica>,
        <https://1145.am/db/2335031/Bioclinica>,
        <https://1145.am/db/2349891/Bioclinica>,
        <https://1145.am/db/2358612/Bioclinica>,
        <https://1145.am/db/2359141/Bioclinica> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Orbimed_Advisors> a org:Organization ;
    ns1:description "Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "OrbiMed Advisors" ;
    ns1:investor <https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "OrbiMed Advisors" ;
    ns1:sameAsHigh <https://1145.am/db/2342862/Avitide_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2297604/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2352807/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359125/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/2359864/Orbimed_Advisors>,
        <https://1145.am/db/2360174/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344916/Novira_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-03-25T13:58:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Novira Therapeutics Completes $25 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/novira-therapeutics-completes-25-million-series-a-financing-0> ;
    ns1:foundName "Novira Therapeutics",
        "Novira Therapeutics, Inc." ;
    ns1:name "Novira Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2347776/Novira_Therapeutics>,
        <https://1145.am/db/2359355/Novira_Therapeutics>,
        <https://1145.am/db/2361614/Novira_Therapeutics_Inc>,
        <https://1145.am/db/2365344/Novira_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2332322/Novira_Therapeutics_Inc>,
        <https://1145.am/db/2344915/Novira_Therapeutics>,
        <https://1145.am/db/2344922/Novira_Therapeutics>,
        <https://1145.am/db/2351683/Novira_Therapeutics>,
        <https://1145.am/db/2351684/Novira_Therapeutics_Inc>,
        <https://1145.am/db/2362653/Novira_Therapeutics_Inc>,
        <https://1145.am/db/2367617/Novira_Therapeutics>,
        <https://1145.am/db/2572398/Novira_Therapeutics_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344916/Series_A_Investment_Novira_Therapeutics_Versant_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-25T13:58:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "DOYLESTOWN, Pa., March 25, 2013 - Novira Therapeutics, Inc. today announced the completion of its Series A financing after securing $ 7.5 million from new investor Versant Ventures.",
        "Novira Therapeutics Completes $ 25 Million Series A Financing." ;
    ns1:documentTitle "Novira Therapeutics Completes $25 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/novira-therapeutics-completes-25-million-series-a-financing-0> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2344916/Novira_Therapeutics> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 25 Million",
        "$ 25 million",
        "$ 7.5 million" ;
    ns1:when "2013-03-25T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 25, 2013" ;
    ns1:whereGeoName "Doylestown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5187247/about.rdf> ;
    ns1:whereRaw "DOYLESTOWN, Pa" .

<https://1145.am/db/2346978/Aquinox_Pharmaceuticals_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Vancouver" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6173331/about.rdf> ;
    ns1:basedInHighRaw "VANCOUVER, BRITISH COLUMBIA" ;
    ns1:basedInLowRaw "US" ;
    ns1:description "pharmaceutical company" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Aquinox Pharmaceuticals",
        "Aquinox Pharmaceuticals Inc." ;
    ns1:industry "Pharmaceuticals",
        "pharmaceutical" ;
    ns1:name "Aquinox Pharmaceuticals",
        "Aquinox Pharmaceuticals Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2321851/Aquinox_Pharmaceuticals>,
        <https://1145.am/db/2321856/Aquinox_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346979/Aquinox_Pharmaceuticals>,
        <https://1145.am/db/2351924/Aquinox_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364457/Aquinox_Pharmaceuticals>,
        <https://1145.am/db/2364458/Aquinox_Pharmaceuticals_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346978/Johnson___Johnson_Development_Corporation> a org:Organization ;
    ns1:basedInLowRaw "BRITISH COLUMBIA" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Johnson & Johnson Development Corporation" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> ;
    ns1:name "Johnson & Johnson Development Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1048908/Johnson___Johnson>,
        <https://1145.am/db/1262552/Johnson___Johnson>,
        <https://1145.am/db/1270868/Johnson___Johnson>,
        <https://1145.am/db/1551329/Johnson___Johnson>,
        <https://1145.am/db/1673527/Johnson___Johnson>,
        <https://1145.am/db/1673809/Johnson___Johnson>,
        <https://1145.am/db/2096209/Johnson___Johnson>,
        <https://1145.am/db/2103283/Johnson___Johnson>,
        <https://1145.am/db/2153410/Johnson___Johnson>,
        <https://1145.am/db/2154521/Johnson___Johnson>,
        <https://1145.am/db/2193661/Johnson___Johnson>,
        <https://1145.am/db/2279434/Johnson___Johnson>,
        <https://1145.am/db/2282888/Johnson___Johnson>,
        <https://1145.am/db/2284930/Johnson___Johnson>,
        <https://1145.am/db/2287377/Johnson___Johnson>,
        <https://1145.am/db/2290342/Johnson___Johnson>,
        <https://1145.am/db/2291777/Johnson___Johnson>,
        <https://1145.am/db/2294862/Johnson___Johnson>,
        <https://1145.am/db/2295495/Johnson___Johnson>,
        <https://1145.am/db/2297186/Johnson___Johnson>,
        <https://1145.am/db/2297962/Johnson___Johnson>,
        <https://1145.am/db/2298037/Johnson___Johnson>,
        <https://1145.am/db/2298501/Johnson___Johnson>,
        <https://1145.am/db/2301819/Johnson___Johnson>,
        <https://1145.am/db/2302021/Johnson___Johnson>,
        <https://1145.am/db/2306163/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2309930/Johnson___Johnson>,
        <https://1145.am/db/2309931/Johnson___Johnson>,
        <https://1145.am/db/2310118/Johnson___Johnson>,
        <https://1145.am/db/2314331/Johnson___Johnson>,
        <https://1145.am/db/2315481/Johnson___Johnson>,
        <https://1145.am/db/2317181/Johnson___Johnson>,
        <https://1145.am/db/2317639/Johnson___Johnson>,
        <https://1145.am/db/2318685/Johnson___Johnson>,
        <https://1145.am/db/2319656/Johnson___Johnson>,
        <https://1145.am/db/2322998/Johnson___Johnson>,
        <https://1145.am/db/2323000/Johnson___Johnson>,
        <https://1145.am/db/2329487/Johnson___Johnson>,
        <https://1145.am/db/2330734/Johnson___Johnson>,
        <https://1145.am/db/2331745/Johnson___Johnson>,
        <https://1145.am/db/2331746/Johnson___Johnson>,
        <https://1145.am/db/2336790/Johnson___Johnson>,
        <https://1145.am/db/2336797/Johnson___Johnson>,
        <https://1145.am/db/2339892/Johnson___Johnson>,
        <https://1145.am/db/2340071/Johnson___Johnson>,
        <https://1145.am/db/2341850/Johnson___Johnson>,
        <https://1145.am/db/2344683/Johnson___Johnson>,
        <https://1145.am/db/2350115/Johnson___Johnson>,
        <https://1145.am/db/2350116/Johnson___Johnson>,
        <https://1145.am/db/2350440/Johnson___Johnson_Inc>,
        <https://1145.am/db/2354402/Johnson___Johnson>,
        <https://1145.am/db/2354835/Johnson___Johnson>,
        <https://1145.am/db/2355411/Johnson___Johnson>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358981/Johnson___Johnson>,
        <https://1145.am/db/2359302/Johnson___Johnson>,
        <https://1145.am/db/2359467/Johnson___Johnson>,
        <https://1145.am/db/2360256/Johnson___Johnson>,
        <https://1145.am/db/2362893/Johnson___Johnson>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364593/Johnson___Johnson>,
        <https://1145.am/db/2364601/Johnson___Johnson>,
        <https://1145.am/db/2366653/Johnson___Johnson>,
        <https://1145.am/db/2367617/Johnson___Johnson>,
        <https://1145.am/db/2536264/Johnson___Johnson>,
        <https://1145.am/db/2541548/Johnson___Johnson>,
        <https://1145.am/db/2543863/Johnson___Johnson>,
        <https://1145.am/db/2544755/Johnson___Johnson>,
        <https://1145.am/db/2545522/Johnson___Johnson>,
        <https://1145.am/db/2546172/Johnson___Johnson>,
        <https://1145.am/db/2548042/Johnson___Johnson>,
        <https://1145.am/db/2553852/Johnson___Johnson>,
        <https://1145.am/db/2557603/Johnson___Johnson>,
        <https://1145.am/db/2557900/Johnson___Johnson>,
        <https://1145.am/db/2560372/Johnson___Johnson>,
        <https://1145.am/db/2566147/Johnson___Johnson>,
        <https://1145.am/db/2572466/Johnson___Johnson>,
        <https://1145.am/db/2572655/Johnson___Johnson>,
        <https://1145.am/db/2573373/Johnson___Johnson>,
        <https://1145.am/db/2574907/Johnson___Johnson>,
        <https://1145.am/db/2575492/Johnson___Johnson>,
        <https://1145.am/db/2575496/Johnson___Johnson>,
        <https://1145.am/db/2576439/Johnson___Johnson>,
        <https://1145.am/db/2576962/Johnson___Johnson>,
        <https://1145.am/db/2577059/Johnson___Johnson>,
        <https://1145.am/db/2581480/Johnson___Johnson>,
        <https://1145.am/db/2583189/Johnson___Johnson>,
        <https://1145.am/db/2584814/Johnson___Johnson>,
        <https://1145.am/db/2585600/Johnson___Johnson>,
        <https://1145.am/db/2585710/Johnson___Johnson>,
        <https://1145.am/db/2587143/Johnson___Johnson>,
        <https://1145.am/db/2587177/Johnson___Johnson>,
        <https://1145.am/db/2587626/Johnson___Johnson>,
        <https://1145.am/db/2588074/Johnson___Johnson>,
        <https://1145.am/db/2588718/Johnson___Johnson>,
        <https://1145.am/db/2591073/Johnson___Johnson>,
        <https://1145.am/db/2591074/Johnson___Johnson>,
        <https://1145.am/db/2591076/Johnson___Johnson>,
        <https://1145.am/db/2592534/Johnson___Johnson>,
        <https://1145.am/db/2593889/Johnson___Johnson>,
        <https://1145.am/db/2594106/Johnson___Johnson>,
        <https://1145.am/db/2597086/Johnson___Johnson>,
        <https://1145.am/db/2597135/Johnson___Johnson>,
        <https://1145.am/db/2598439/Johnson___Johnson_Inc>,
        <https://1145.am/db/2598455/Johnson___Johnson_Merck_Consumer_Pharmaceuticals_Co>,
        <https://1145.am/db/2598458/Johnson___Johnson_Merck_Consumer_Pharmaceuticals_Co>,
        <https://1145.am/db/543155/Johnson___Johnson>,
        <https://1145.am/db/699695/Johnson___Johnson>,
        <https://1145.am/db/766907/Johnson___Johnson> ;
    ns1:sameAsMedium <https://1145.am/db/1883008/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2291836/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292334/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292353/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292975/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2299864/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2300306/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2300455/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2303009/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308781/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308791/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311069/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311075/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316619/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316624/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2317934/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2321856/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327212/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327227/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336890/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336943/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337571/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337577/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338236/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338237/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338527/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2341478/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344597/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344605/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2350327/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352357/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352361/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2356290/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358640/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358658/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358812/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2361581/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2363907/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364458/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2365296/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2546216/Johnson___Johnson_Development_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346978/Pfizer_Venture_Investments> a org:Organization ;
    ns1:basedInLowRaw "BRITISH COLUMBIA" ;
    ns1:description "venture-backed, pharmaceutical company" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Pfizer Venture Investments" ;
    ns1:investor <https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> ;
    ns1:name "Pfizer Venture Investments" ;
    ns1:sameAsHigh <https://1145.am/db/2299328/Pfizers> ;
    ns1:sameAsMedium <https://1145.am/db/2299758/Pfizer_Venture_Investments>,
        <https://1145.am/db/2306549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2318310/Pfizer_Venture_Investments>,
        <https://1145.am/db/2319442/Pfizer_Venture_Investments>,
        <https://1145.am/db/2322984/Pfizer_Venture_Investments>,
        <https://1145.am/db/2323003/Pfizer_Venture_Investments>,
        <https://1145.am/db/2336335/Pfizer_Venture_Investments>,
        <https://1145.am/db/2337971/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338527/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338528/Pfizer_Venture_Investments>,
        <https://1145.am/db/2340096/Pfizer_Venture_Investments>,
        <https://1145.am/db/2348066/Pfizer_Venture_Investments>,
        <https://1145.am/db/2349143/Pfizer_Venture_Investments>,
        <https://1145.am/db/2352226/Pfizer_Venture_Investments>,
        <https://1145.am/db/2354296/Pfizer_Venture_Investments>,
        <https://1145.am/db/2355043/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356287/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356290/Pfizer_Venture_Investments>,
        <https://1145.am/db/2359321/Pfizer_Venture_Investments>,
        <https://1145.am/db/2362862/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364457/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364458/Pfizer_Venture_Investments>,
        <https://1145.am/db/2367549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2369000/Pfizer_Venture_Investments>,
        <https://1145.am/db/2587938/Pfizer_Venture_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346988/Flagship_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "Flagship Ventures" ;
    ns1:investor <https://1145.am/db/2346988/Investment_Flagship_Ventures_Flybridge_Capital_Partners_Polaris_Partners_Taris_Third_Rock_Ventures_Completed> ;
    ns1:name "Flagship Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2306790/Flagship_Ventures>,
        <https://1145.am/db/2317918/Flagship_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2288209/Flagship_Ventures>,
        <https://1145.am/db/2292800/Flagship_Ventures>,
        <https://1145.am/db/2298439/Flagship_Ventures>,
        <https://1145.am/db/2302116/Flagship_Ventures>,
        <https://1145.am/db/2304650/Flagship_Ventures>,
        <https://1145.am/db/2308952/Flagship_Ventures>,
        <https://1145.am/db/2308959/Flagship_Ventures>,
        <https://1145.am/db/2313305/Flagship_Ventures>,
        <https://1145.am/db/2314964/Flagship_Ventures>,
        <https://1145.am/db/2315931/Flagship_Ventures>,
        <https://1145.am/db/2315933/Flagship_Ventures>,
        <https://1145.am/db/2321150/Flagship_Ventures>,
        <https://1145.am/db/2324431/Flagship_Ventures>,
        <https://1145.am/db/2334847/Flagship_Ventures>,
        <https://1145.am/db/2339413/Flagship_Ventures>,
        <https://1145.am/db/2341599/Flagship_Ventures>,
        <https://1145.am/db/2343592/Flagship_Ventures>,
        <https://1145.am/db/2343595/Flagship_Ventures>,
        <https://1145.am/db/2347102/Flagship_Ventures>,
        <https://1145.am/db/2348074/Flagship_Ventures>,
        <https://1145.am/db/2354351/Flagship_Ventures>,
        <https://1145.am/db/2354608/Flagship_Ventures>,
        <https://1145.am/db/2354613/Flagship_Ventures>,
        <https://1145.am/db/2354806/Flagship_Ventures>,
        <https://1145.am/db/2356730/Flagship_Ventures>,
        <https://1145.am/db/2356732/Flagship_Ventures>,
        <https://1145.am/db/2358234/Flagship_Ventures>,
        <https://1145.am/db/2358487/Flagship_Ventures>,
        <https://1145.am/db/2358506/Flagship_Ventures>,
        <https://1145.am/db/2358529/Flagship_Ventures>,
        <https://1145.am/db/2359287/Flagship_Ventures>,
        <https://1145.am/db/2366654/Flagship_Ventures>,
        <https://1145.am/db/2367381/Flagship_Ventures>,
        <https://1145.am/db/2367588/Flagship_Ventures>,
        <https://1145.am/db/2368493/Flagship_Ventures>,
        <https://1145.am/db/2369549/Flagship_Ventures>,
        <https://1145.am/db/2634324/Flagship_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346988/Polaris_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "Polaris Partners" ;
    ns1:investor <https://1145.am/db/2346988/Investment_Flagship_Ventures_Flybridge_Capital_Partners_Polaris_Partners_Taris_Third_Rock_Ventures_Completed> ;
    ns1:name "Polaris Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1163164/Polaris_Partners>,
        <https://1145.am/db/1166225/Polaris_Partners>,
        <https://1145.am/db/1229314/Polaris_Partners>,
        <https://1145.am/db/127343/Polaris_Partners>,
        <https://1145.am/db/1340338/Polaris_Partners>,
        <https://1145.am/db/1406211/Polaris_Partners>,
        <https://1145.am/db/1412727/Polaris_Partners>,
        <https://1145.am/db/1545490/Polaris_Partners>,
        <https://1145.am/db/1793129/Polaris_Partners>,
        <https://1145.am/db/1796910/Polaris_Partners>,
        <https://1145.am/db/1803886/Polaris_Partners>,
        <https://1145.am/db/1813337/Polaris_Partners>,
        <https://1145.am/db/1817112/Polaris_Partners>,
        <https://1145.am/db/1830311/Polaris_Partners>,
        <https://1145.am/db/1834199/Polaris_Partners>,
        <https://1145.am/db/1835107/Polaris_Partners>,
        <https://1145.am/db/1845960/Polaris_Partners>,
        <https://1145.am/db/1854788/Polaris_Partners>,
        <https://1145.am/db/1858995/Polaris_Partners>,
        <https://1145.am/db/1947183/Polaris_Partners>,
        <https://1145.am/db/2181016/Polaris_Partners>,
        <https://1145.am/db/2187023/Polaris_Partners>,
        <https://1145.am/db/2193661/Polaris_Partners>,
        <https://1145.am/db/2194844/Polaris_Partners>,
        <https://1145.am/db/2196895/Polaris_Partners>,
        <https://1145.am/db/2198647/Polaris_Partners>,
        <https://1145.am/db/2223723/Polaris_Partners>,
        <https://1145.am/db/2282077/Polaris_Partners>,
        <https://1145.am/db/2282162/Polaris_Partners>,
        <https://1145.am/db/2318310/Polaris_Partners>,
        <https://1145.am/db/2335750/Polaris_Partners>,
        <https://1145.am/db/2335755/Polaris_Partners>,
        <https://1145.am/db/2341595/Polaris_Partners>,
        <https://1145.am/db/2341599/Polaris_Partners>,
        <https://1145.am/db/2341764/Polaris_Partners>,
        <https://1145.am/db/2345675/Polaris_Partners>,
        <https://1145.am/db/2354955/Polaris_Partners>,
        <https://1145.am/db/2364332/Polaris_Partners>,
        <https://1145.am/db/2364336/Polaris_Partners>,
        <https://1145.am/db/2368912/Polaris_Partners>,
        <https://1145.am/db/2368913/Polaris_Partners>,
        <https://1145.am/db/2369304/Polaris_Partners>,
        <https://1145.am/db/2369305/Polaris_Partners>,
        <https://1145.am/db/2370208/Polaris_Partners>,
        <https://1145.am/db/250010/Polaris_Partners>,
        <https://1145.am/db/2611628/Polaris_Partners>,
        <https://1145.am/db/2787561/Polaris_Partners>,
        <https://1145.am/db/364226/Polaris_Partners>,
        <https://1145.am/db/572097/Polaris_Partners>,
        <https://1145.am/db/612707/Polaris_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346988/Taris> a org:Organization ;
    ns1:basedInHighGeoName "Lexington" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4941935/about.rdf> ;
    ns1:basedInHighRaw "LEXINGTON, Mass." ;
    ns1:description "pharmaceutical company",
        "pharmaceuticals" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "TARIS Biomedical",
        "TARIS" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "TARIS",
        "TARIS" ;
    ns1:sameAsHigh <https://1145.am/db/2303879/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2304127/Taro_Pharmaceutical>,
        <https://1145.am/db/2307738/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2307859/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2316028/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2316529/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2317682/Taro>,
        <https://1145.am/db/2319800/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2321137/Taro_Pharmaceutical_Industries>,
        <https://1145.am/db/2324243/Taro_Pharmaceutical_Industries>,
        <https://1145.am/db/2325227/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2328501/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2328513/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2330617/Taris_Biomedical>,
        <https://1145.am/db/2332824/Taro_Pharmaceutical_Industries>,
        <https://1145.am/db/2338620/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2341453/Taris_Biomedical>,
        <https://1145.am/db/2365109/Taris_Biomedical>,
        <https://1145.am/db/2365111/Taris_Biomedical>,
        <https://1145.am/db/2538647/Taro_Pharmaceuticals>,
        <https://1145.am/db/2539462/Taro_Pharmaceutical>,
        <https://1145.am/db/2549705/Taro_Pharmaceutical>,
        <https://1145.am/db/2563423/Taro_Pharma>,
        <https://1145.am/db/2571648/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2573447/Taro_Pharmaceutical>,
        <https://1145.am/db/2578262/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579495/Taro_Pharmaceutical_Industries>,
        <https://1145.am/db/2583089/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2585238/Taro_Pharmaceutical_Industries>,
        <https://1145.am/db/2586229/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2586399/Taris_Biomedical>,
        <https://1145.am/db/2595055/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2595688/Taro>,
        <https://1145.am/db/2597197/Taro_Pharmaceuticals>,
        <https://1145.am/db/2597320/Taro_Pharmaceuticals>,
        <https://1145.am/db/376971/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/665392/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/667006/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/849790/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/865475/Taro_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/870656/Taro_Pharmaceutical_Industries_Ltd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348030/Carena> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:description "RNA-targeting therapeutic and diagnostic solutions in the treatment of HIV/AIDS and obesity" ;
    ns1:documentDate "2013-04-09T11:46:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "THERADIAG granted 1.2 million euros by OSEOas part of the collaborative project CaReNA" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/theradiag-granted-1-2-million-euros-by-oseoas-part-of-collaborative-project-carena> ;
    ns1:foundName "CaReNA" ;
    ns1:name "CaReNA" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348030/Investment_French_Agency_For_Innovation_Theradiag_Theradiag_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-09T11:46:48+00:00"^^xsd:dateTime ;
    ns1:documentExtract "As part of the project, Theradiag will receive 1.2 million for developing and implementing 4 new diagnostic kits.",
        "Croissy-Beaubourg, April 9 2013 - Theradiag (ISIN: FR0004197747, Ticker: ALTER) , a company specializing in theranostic and in vitro diagnostics, today announced it has been granted financial support by Oso, the French Agency for Innovation, for its participation in CaReNA.",
        "THERADIAG granted 1.2 million euros by OSEOas part of the collaborative project CaReNA." ;
    ns1:documentTitle "THERADIAG granted 1.2 million euros by OSEOas part of the collaborative project CaReNA" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/theradiag-granted-1-2-million-euros-by-oseoas-part-of-collaborative-project-carena> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348030/Carena>,
        <https://1145.am/db/2348030/Theradiag> ;
    ns1:targetName "CaReNA" ;
    ns1:valueRaw "1.2 million euros",
        "18 M" ;
    ns1:whereGeoName "N",
        "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2357237/about.rdf>,
        <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "French",
        "no" .

<https://1145.am/db/2348030/Theradiag> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:basedInLowRaw "Austria" ;
    ns1:description "Research",
        "Theranostic and in vitro diagnostics" ;
    ns1:documentDate "2013-04-09T11:46:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "THERADIAG granted 1.2 million euros by OSEOas part of the collaborative project CaReNA" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/theradiag-granted-1-2-million-euros-by-oseoas-part-of-collaborative-project-carena> ;
    ns1:foundName "THERADIAG",
        "Theradiag" ;
    ns1:name "THERADIAG",
        "Theradiag" ;
    ns1:sameAsHigh <https://1145.am/db/1366213/Theradiag>,
        <https://1145.am/db/1382085/Theradiag>,
        <https://1145.am/db/658172/Theradiag>,
        <https://1145.am/db/938234/Theradiag> ;
    ns1:sameAsMedium <https://1145.am/db/2353189/Theradiag> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348055/Vistagen_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "South San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5397765/about.rdf> ;
    ns1:basedInHighRaw "SOUTH SAN FRANCISCO" ;
    ns1:description "Stem Cell Technology",
        "stem cell technology" ;
    ns1:documentDate "2013-04-10T15:17:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VistaGen Announces $36 Million Strategic Financing Agreement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vistagen-announces-36-million-strategic-financing-agreement> ;
    ns1:foundName "VistaGen",
        "VistaGen Therapeutics, Inc" ;
    ns1:industry "biotechnology" ;
    ns1:name "VistaGen",
        "VistaGen Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1081365/Odyssey_Therapeutics>,
        <https://1145.am/db/2008790/Horizon_Therapeutics>,
        <https://1145.am/db/2009117/Horizon_Therapeutics>,
        <https://1145.am/db/2012933/Horizon_Therapeutics>,
        <https://1145.am/db/2016970/Horizon_Therapeutics>,
        <https://1145.am/db/2043001/Horizon_Therapeutics>,
        <https://1145.am/db/2098829/Horizon_Therapeutics>,
        <https://1145.am/db/2106270/Horizon_Therapeutics>,
        <https://1145.am/db/2107919/Horizon_Therapeutics>,
        <https://1145.am/db/2135232/Odyssey_Therapeutics>,
        <https://1145.am/db/2328993/Horizon_Therapeutics>,
        <https://1145.am/db/2334131/Arrow_Therapeutics_Ltd>,
        <https://1145.am/db/2337337/Boston_Therapeutics_Inc>,
        <https://1145.am/db/2354110/Horizon_Discovery_Group>,
        <https://1145.am/db/2354147/Boston_Therapeutics>,
        <https://1145.am/db/2555175/Horizon_Therapeutics>,
        <https://1145.am/db/2557364/Horizon_Therapeutics>,
        <https://1145.am/db/2561650/Horizon_Therapeutics>,
        <https://1145.am/db/2564899/Horizon_Therapeutics>,
        <https://1145.am/db/2566348/Horizon_Therapeutics>,
        <https://1145.am/db/2567468/Horizon_Therapeutics>,
        <https://1145.am/db/2567517/Horizon_Therapeutics>,
        <https://1145.am/db/2567960/Horizon_Therapeutics>,
        <https://1145.am/db/2567981/Horizon_Therapeutics>,
        <https://1145.am/db/2802001/Horizon_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2131891/Vistagen_Therapeutics>,
        <https://1145.am/db/2310568/Vistagen_Therapeutics>,
        <https://1145.am/db/2364379/Vistagen_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348066/Cydan> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, Mass." ;
    ns1:description "Orphan Drug Accelerator" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "Cydan",
        "Cydan, LLC" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Cydan" ;
    ns1:sameAsHigh <https://1145.am/db/1646576/Cytovance_Biologics>,
        <https://1145.am/db/2282205/Cymabay>,
        <https://1145.am/db/2292690/Cydan>,
        <https://1145.am/db/2303514/Cytovance_Biologics>,
        <https://1145.am/db/2303519/Cytovance_Biologics_Inc>,
        <https://1145.am/db/2311724/Cytovance_Biologics>,
        <https://1145.am/db/2356903/Cytovance_Biologics>,
        <https://1145.am/db/2537372/Cytovance_Biologics>,
        <https://1145.am/db/2539062/Cytovance_Biologics>,
        <https://1145.am/db/541763/Cytovia> ;
    ns1:sameAsMedium <https://1145.am/db/2153416/Cydan>,
        <https://1145.am/db/2356262/Cydan> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348066/New_Enterprise_Associates> a org:Organization ;
    ns1:basedInLowRaw "LLC" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2348066/Investment_Alexandria_Real_Estate_Equities_Cydan_New_Enterprise_Associates_Pfizer_Venture_Investments_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348066/Pfizer_Venture_Investments> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "Pfizer Venture Investments" ;
    ns1:investor <https://1145.am/db/2348066/Investment_Alexandria_Real_Estate_Equities_Cydan_New_Enterprise_Associates_Pfizer_Venture_Investments_Completed> ;
    ns1:name "Pfizer Venture Investments" ;
    ns1:sameAsHigh <https://1145.am/db/1334624/Pfizer_Ventures>,
        <https://1145.am/db/2154844/Pfizer_Ventures>,
        <https://1145.am/db/2306549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2318310/Pfizer_Venture_Investments>,
        <https://1145.am/db/2318333/Pfizer>,
        <https://1145.am/db/2319442/Pfizer_Venture_Investments>,
        <https://1145.am/db/2322984/Pfizer_Venture_Investments>,
        <https://1145.am/db/2323003/Pfizer_Venture_Investments>,
        <https://1145.am/db/2325726/Pfizer_Ventures>,
        <https://1145.am/db/2341896/Pfizer_Ventures>,
        <https://1145.am/db/2354296/Pfizer_Venture_Investments>,
        <https://1145.am/db/2355043/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356290/Pfizer_Venture_Investments>,
        <https://1145.am/db/2359321/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364458/Pfizer_Venture_Investments>,
        <https://1145.am/db/2369000/Pfizer_Venture_Investments>,
        <https://1145.am/db/587045/Pfizer_Ventures>,
        <https://1145.am/db/591613/Pfizer_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2299758/Pfizer_Venture_Investments>,
        <https://1145.am/db/2336335/Pfizer_Venture_Investments>,
        <https://1145.am/db/2337971/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338527/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338528/Pfizer_Venture_Investments>,
        <https://1145.am/db/2340096/Pfizer_Venture_Investments>,
        <https://1145.am/db/2346978/Pfizer_Venture_Investments>,
        <https://1145.am/db/2349143/Pfizer_Venture_Investments>,
        <https://1145.am/db/2352226/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356287/Pfizer_Venture_Investments>,
        <https://1145.am/db/2362862/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364457/Pfizer_Venture_Investments>,
        <https://1145.am/db/2367549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2587938/Pfizer_Venture_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348074/Flagship_Ventures> a org:Organization ;
    ns1:basedInLowRaw "MA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-04-11T15:17:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Syros Pharmaceuticals Launches with $30 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/syros-pharmaceuticals-launches-30-million-series-a-financing> ;
    ns1:foundName "Flagship Ventures" ;
    ns1:investor <https://1145.am/db/2348074/Series_A_Investment_Arch_Venture_Partners_Flagship_Ventures_Syros_Pharmaceuticals_Completed> ;
    ns1:name "Flagship Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1010101/Vertical_Venture_Partners>,
        <https://1145.am/db/1038108/Vertical_Venture_Partners>,
        <https://1145.am/db/1048957/Kleiner_Perkins>,
        <https://1145.am/db/1049509/Lets_Venture>,
        <https://1145.am/db/1060146/Unshackled_Ventures>,
        <https://1145.am/db/1061911/Unshackled_Ventures>,
        <https://1145.am/db/1066120/Xfund>,
        <https://1145.am/db/1066435/Ycombinator>,
        <https://1145.am/db/1081175/Invesco_Private_Capital>,
        <https://1145.am/db/1082613/Invesco_Private_Capital>,
        <https://1145.am/db/1140226/Xyz_Venture_Capital>,
        <https://1145.am/db/1140692/Xyz_Venture_Capital>,
        <https://1145.am/db/1153338/Precursor_Ventures>,
        <https://1145.am/db/1196841/Story_Ventures>,
        <https://1145.am/db/1200328/Story_Ventures>,
        <https://1145.am/db/1232192/Capital_Factory>,
        <https://1145.am/db/1233314/Fine_Structure_Ventures>,
        <https://1145.am/db/1233642/Capital_Factory>,
        <https://1145.am/db/1297417/Kleiner_Perkins>,
        <https://1145.am/db/1334193/Equal_Ventures>,
        <https://1145.am/db/1341597/Congruent_Ventures>,
        <https://1145.am/db/1346694/Recurrent_Ventures>,
        <https://1145.am/db/1355550/Kleiner_Perkins>,
        <https://1145.am/db/1356166/Kleiner_Perkins>,
        <https://1145.am/db/1374842/Xyz_Venture_Capital>,
        <https://1145.am/db/1396753/Value_Creation_Capital>,
        <https://1145.am/db/1406168/Initialized_Capital>,
        <https://1145.am/db/1408996/Backed_Vc>,
        <https://1145.am/db/1419073/Capital_Factory>,
        <https://1145.am/db/1451849/Yummy_Ventures>,
        <https://1145.am/db/1467932/Congruent_Ventures>,
        <https://1145.am/db/1499630/Primary_Venture_Partners>,
        <https://1145.am/db/1505899/Company_Ventures>,
        <https://1145.am/db/1523231/Standup_Ventures>,
        <https://1145.am/db/1600581/Strategy_Capital>,
        <https://1145.am/db/1691364/Very_Early_Ventures>,
        <https://1145.am/db/1694038/Byfounders_Vc>,
        <https://1145.am/db/1709473/Exor>,
        <https://1145.am/db/1715565/Primary_Venture_Partners>,
        <https://1145.am/db/1715983/Good_Capital>,
        <https://1145.am/db/1734522/Precursor_Ventures>,
        <https://1145.am/db/1735706/Streamlined_Ventures>,
        <https://1145.am/db/1735774/10x_Capital>,
        <https://1145.am/db/1737609/Kleiner_Perkins>,
        <https://1145.am/db/1737617/Company_Ventures>,
        <https://1145.am/db/1742507/Debut_Capital>,
        <https://1145.am/db/1744229/Primary_Venture_Partners>,
        <https://1145.am/db/1744554/One_Capital>,
        <https://1145.am/db/1745062/Capital_Point>,
        <https://1145.am/db/1750968/New_Market_Venture_Partners>,
        <https://1145.am/db/1751051/Kleiner_Perkins>,
        <https://1145.am/db/1751079/Primary_Venture_Partners>,
        <https://1145.am/db/1751506/Primary_Venture_Partners>,
        <https://1145.am/db/1753099/Venture_Lab_Investment>,
        <https://1145.am/db/1761111/Kleiner_Perkins>,
        <https://1145.am/db/1761256/Kleiner_Perkins>,
        <https://1145.am/db/1761999/Anatole_Investment>,
        <https://1145.am/db/1764022/Archetype_Ventures>,
        <https://1145.am/db/1768585/Initialized_Capital>,
        <https://1145.am/db/1773024/Commerzventures>,
        <https://1145.am/db/1776250/Partech>,
        <https://1145.am/db/1778844/Kleiner_Perkins>,
        <https://1145.am/db/1780705/Congruent_Ventures>,
        <https://1145.am/db/1782474/Backed_Vc>,
        <https://1145.am/db/1783154/Commerzventures>,
        <https://1145.am/db/1785486/Equal_Ventures>,
        <https://1145.am/db/1786389/Kleiner_Perkins>,
        <https://1145.am/db/1788333/Precursor_Ventures>,
        <https://1145.am/db/1794548/Industry_Ventures>,
        <https://1145.am/db/1798154/Kleiner_Perkins_Caufield_Byers>,
        <https://1145.am/db/1799895/Kleiner_Perkins>,
        <https://1145.am/db/1801325/B-to-V_Partners>,
        <https://1145.am/db/1801874/Vast_Ventures>,
        <https://1145.am/db/1802991/Primary_Venture_Partners>,
        <https://1145.am/db/180673/Venture_Capital_Firm>,
        <https://1145.am/db/1809007/Formation_8>,
        <https://1145.am/db/1814239/Formation_8>,
        <https://1145.am/db/1826314/High_Peaks_Ventures>,
        <https://1145.am/db/1834965/Vast_Ventures>,
        <https://1145.am/db/1843514/DCM>,
        <https://1145.am/db/1853292/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/1870252/Perkins_Caufield___Byers>,
        <https://1145.am/db/1870810/Initial_Capital>,
        <https://1145.am/db/1879759/Dot_Corp>,
        <https://1145.am/db/1885090/Industry_Ventures>,
        <https://1145.am/db/1892530/Kleiner_Perkins>,
        <https://1145.am/db/1978877/Congruent_Ventures>,
        <https://1145.am/db/2000764/Possible_Ventures>,
        <https://1145.am/db/2043146/Xyz_Venture_Capital>,
        <https://1145.am/db/2075625/Possible_Ventures>,
        <https://1145.am/db/2135690/Possible_Ventures>,
        <https://1145.am/db/2138013/Construct_Capital>,
        <https://1145.am/db/2147446/Excel_Venture_Management>,
        <https://1145.am/db/2281481/M-Capital>,
        <https://1145.am/db/2292949/Proseed_Vc_Fund>,
        <https://1145.am/db/2303802/Fund_Creation_Co_Ltd>,
        <https://1145.am/db/2305254/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2312051/Inventages_Venture_Capital>,
        <https://1145.am/db/2313124/Future_Capital>,
        <https://1145.am/db/2319506/Excel_Venture_Management>,
        <https://1145.am/db/2321713/Venture_Investors>,
        <https://1145.am/db/2324431/Flagship_Ventures>,
        <https://1145.am/db/2325726/Kleiner_Perkins_Caulfield___Byers>,
        <https://1145.am/db/2326486/Investor_Growth_Capital>,
        <https://1145.am/db/2330775/Blue_Chip_Venture_Co>,
        <https://1145.am/db/2330775/Early_Stage_Partners>,
        <https://1145.am/db/2335035/Venture_Fund_Ab>,
        <https://1145.am/db/2340103/Vast_Ventures>,
        <https://1145.am/db/2352362/Investor_Growth_Capital>,
        <https://1145.am/db/2359287/Flagship_Ventures>,
        <https://1145.am/db/2364820/Early_Stage_Partners>,
        <https://1145.am/db/2367275/Investor_Growth_Capital>,
        <https://1145.am/db/2430644/Primary_Venture_Partners>,
        <https://1145.am/db/2606743/New_Venture_Partners>,
        <https://1145.am/db/2718832/First_In_Ventures>,
        <https://1145.am/db/2765030/Possible_Ventures>,
        <https://1145.am/db/2800533/Unconventional_Ventures>,
        <https://1145.am/db/402701/Company_Ventures>,
        <https://1145.am/db/425349/Mutual_Capital_Partners>,
        <https://1145.am/db/426317/Mutual_Capital_Partners>,
        <https://1145.am/db/441502/Primary_Venture_Partners>,
        <https://1145.am/db/444575/Xfund>,
        <https://1145.am/db/457229/Venture_Capital>,
        <https://1145.am/db/459986/Cofounders_Capital>,
        <https://1145.am/db/479113/A_Capital>,
        <https://1145.am/db/513673/Kleiner_Perkins>,
        <https://1145.am/db/528532/Congruent_Ventures>,
        <https://1145.am/db/532205/Background_Capital>,
        <https://1145.am/db/547663/Goal_Venture_Partners>,
        <https://1145.am/db/559318/Primary_Venture_Partners>,
        <https://1145.am/db/561662/Xyz_Venture_Capital>,
        <https://1145.am/db/606333/Equal_Ventures>,
        <https://1145.am/db/679825/First_In_Ventures>,
        <https://1145.am/db/694325/Story_Ventures>,
        <https://1145.am/db/694513/Level_Up_Ventures>,
        <https://1145.am/db/714765/Man_Capital>,
        <https://1145.am/db/739125/Vast_Ventures>,
        <https://1145.am/db/740541/Ince_Capital>,
        <https://1145.am/db/751137/Kleiner_Perkins>,
        <https://1145.am/db/751387/Initialized_Capital>,
        <https://1145.am/db/768172/Exor>,
        <https://1145.am/db/768172/Fine_Structure_Ventures>,
        <https://1145.am/db/768643/Initialized_Capital>,
        <https://1145.am/db/769427/Kleiner_Perkins>,
        <https://1145.am/db/782995/Section_32>,
        <https://1145.am/db/783060/Construct_Capital>,
        <https://1145.am/db/803541/Kleiner_Perkins>,
        <https://1145.am/db/847522/Kleiner_Perkins>,
        <https://1145.am/db/867116/Kleiner_Perkins>,
        <https://1145.am/db/869652/Kleiner_Perkins>,
        <https://1145.am/db/878305/Kleiner_Perkins>,
        <https://1145.am/db/892831/Unknown_Ventures>,
        <https://1145.am/db/918880/Information_Venture_Partners>,
        <https://1145.am/db/925588/Recurrent_Ventures>,
        <https://1145.am/db/971126/Limited_Partner>,
        <https://1145.am/db/972995/Limited_Partner>,
        <https://1145.am/db/993146/Nota> ;
    ns1:sameAsMedium <https://1145.am/db/2288209/Flagship_Ventures>,
        <https://1145.am/db/2292800/Flagship_Ventures>,
        <https://1145.am/db/2298439/Flagship_Ventures>,
        <https://1145.am/db/2302116/Flagship_Ventures>,
        <https://1145.am/db/2304650/Flagship_Ventures>,
        <https://1145.am/db/2306790/Flagship_Ventures>,
        <https://1145.am/db/2308952/Flagship_Ventures>,
        <https://1145.am/db/2308959/Flagship_Ventures>,
        <https://1145.am/db/2313305/Flagship_Ventures>,
        <https://1145.am/db/2314964/Flagship_Ventures>,
        <https://1145.am/db/2315931/Flagship_Ventures>,
        <https://1145.am/db/2315933/Flagship_Ventures>,
        <https://1145.am/db/2317918/Flagship_Ventures>,
        <https://1145.am/db/2321150/Flagship_Ventures>,
        <https://1145.am/db/2334847/Flagship_Ventures>,
        <https://1145.am/db/2339413/Flagship_Ventures>,
        <https://1145.am/db/2341599/Flagship_Ventures>,
        <https://1145.am/db/2343592/Flagship_Ventures>,
        <https://1145.am/db/2343595/Flagship_Ventures>,
        <https://1145.am/db/2346988/Flagship_Ventures>,
        <https://1145.am/db/2347102/Flagship_Ventures>,
        <https://1145.am/db/2354351/Flagship_Ventures>,
        <https://1145.am/db/2354608/Flagship_Ventures>,
        <https://1145.am/db/2354613/Flagship_Ventures>,
        <https://1145.am/db/2354806/Flagship_Ventures>,
        <https://1145.am/db/2356730/Flagship_Ventures>,
        <https://1145.am/db/2356732/Flagship_Ventures>,
        <https://1145.am/db/2358234/Flagship_Ventures>,
        <https://1145.am/db/2358487/Flagship_Ventures>,
        <https://1145.am/db/2358506/Flagship_Ventures>,
        <https://1145.am/db/2358529/Flagship_Ventures>,
        <https://1145.am/db/2366654/Flagship_Ventures>,
        <https://1145.am/db/2367381/Flagship_Ventures>,
        <https://1145.am/db/2367588/Flagship_Ventures>,
        <https://1145.am/db/2368493/Flagship_Ventures>,
        <https://1145.am/db/2369549/Flagship_Ventures>,
        <https://1145.am/db/2634324/Flagship_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349078/Echo_Pharma_Acquisition_Limited> a org:Organization ;
    ns1:basedInLowRaw "Irish" ;
    ns1:buyer <https://1145.am/db/2349078/Elan_Corporation_Acquisition> ;
    ns1:description "acquiring" ;
    ns1:documentDate "2013-04-15T13:21:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "Echo Pharma Acquisition Limited" ;
    ns1:name "Echo Pharma Acquisition Limited" ;
    ns1:sameAsHigh <https://1145.am/db/2351145/Echo_Pharma_Acquisition_Limited>,
        <https://1145.am/db/2363656/Echo_Pharma_Acquisition_Limited>,
        <https://1145.am/db/2577010/Echo_Pharma_Acquisition_Limited> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349078/Elan_Corporation_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-04-15T13:21:56+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK, April 15, 2013 /PRNewswire/ - Echo Pharma Acquisition Limited (\"Royalty Pharma\") today announced, pursuant to Rule 2.5 of the Irish take over Rules (the \"Announcement\") , the terms of a firm, all cash offer (the \"Offer\") for the entire issued and to be issued share capital of Elan Corporation, plc (\"Elan\") (NYSE: ELN) ." ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "offer" ;
    ns1:name "offer" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2349078/Elan_Corporation> ;
    ns1:targetName "Elan Corporation" ;
    ns1:whereGeoName "Irish" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5983801/about.rdf> ;
    ns1:whereRaw "Irish" .

<https://1145.am/db/2350097/Beat_Biotherapeutics_Corporation> a org:Organization ;
    ns1:basedInHighGeoName "Seattle" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5809844/about.rdf> ;
    ns1:basedInHighRaw "Seattle" ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "developing a novel gene therapy",
        "developing gene therapy treatment for heart failure" ;
    ns1:documentDate "2013-04-17T15:49:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BEAT BioTherapeutics Corporation Closes $2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/beat-biotherapeutics-corporation-closes-2-5mm-seed-financing-to-develop-its-gene-therapy> ;
    ns1:foundName "BEAT BioTherapeutics Corporation",
        "BEATBio" ;
    ns1:industry "biotechnology" ;
    ns1:name "BEAT BioTherapeutics Corporation",
        "BEATBio" ;
    ns1:sameAsHigh <https://1145.am/db/1129653/Asher_Biotherapeutics_Inc>,
        <https://1145.am/db/1130835/Asher_Biotherapeutics_Inc>,
        <https://1145.am/db/1185334/Asher_Biotherapeutics_Inc>,
        <https://1145.am/db/1186761/Asher_Biotherapeutics_Inc>,
        <https://1145.am/db/1619789/Asher_Biotherapeutics_Inc>,
        <https://1145.am/db/1624707/Perceive_Biotherapeutics>,
        <https://1145.am/db/2338074/Northwest_Biotherapeutics>,
        <https://1145.am/db/2344032/Northwest_Biotherapeutics>,
        <https://1145.am/db/2344857/Northwest_Biotherapeutics>,
        <https://1145.am/db/2346675/Oxford_Biotherapeutics>,
        <https://1145.am/db/2346758/Northwest_Biotherapeutics>,
        <https://1145.am/db/2351656/Eleven_Biotherapeutics>,
        <https://1145.am/db/2353939/Juventas_Therapeutics>,
        <https://1145.am/db/2354613/Eleven_Biotherapeutics>,
        <https://1145.am/db/2363528/Northwest_Biotherapeutics>,
        <https://1145.am/db/2558852/Northwest_Biotherapeutics>,
        <https://1145.am/db/441151/Asher_Biotherapeutics>,
        <https://1145.am/db/659619/Northwest_Biotherapeutics>,
        <https://1145.am/db/750044/Aro_Biotherapeutics>,
        <https://1145.am/db/777994/Asher_Biotherapeutics>,
        <https://1145.am/db/779563/Asher_Biotherapeutics>,
        <https://1145.am/db/830218/Asher_Biotherapeutics>,
        <https://1145.am/db/928346/Integrated_Biotherapeutics_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2360442/Beat_Biotherapeutics_Corp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350097/Seattle> a org:Organization ;
    ns1:basedInHighGeoName "Washington" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5815135/about.rdf> ;
    ns1:basedInHighRaw "Wash" ;
    ns1:documentDate "2013-04-17T15:49:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "BEAT BioTherapeutics Corporation Closes $2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/beat-biotherapeutics-corporation-closes-2-5mm-seed-financing-to-develop-its-gene-therapy> ;
    ns1:foundName "SEATTLE" ;
    ns1:industry "biotechnology" ;
    ns1:name "Seattle" ;
    ns1:sameAsHigh <https://1145.am/db/2311007/Seattle_Genetics>,
        <https://1145.am/db/2347467/Seattle>,
        <https://1145.am/db/2357584/Seattle_Genetics>,
        <https://1145.am/db/2357604/Seattle_Genetics>,
        <https://1145.am/db/2359683/Seattle_Genetics_Inc>,
        <https://1145.am/db/2572632/Seattle_Genetics> ;
    ns1:sameAsMedium <https://1145.am/db/1076272/Seattle>,
        <https://1145.am/db/1723067/Seattle>,
        <https://1145.am/db/376078/Seattle>,
        <https://1145.am/db/376099/Seattle> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351184/Prolor_Biotech> a org:Organization ;
    ns1:basedInHighGeoName "Miami",
        "Ness Ziona" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/294074/about.rdf>,
        <https://sws.geonames.org/4164138/about.rdf> ;
    ns1:basedInHighRaw "MIAMI and NES-ZIONA, Israel" ;
    ns1:description "developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins" ;
    ns1:documentDate "2013-04-24T12:56:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OPKO Health To Acquire PROLOR Biotech" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opko-health-to-acquire-prolor-biotech> ;
    ns1:foundName "PROLOR" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "PROLOR Biotech" ;
    ns1:sameAsHigh <https://1145.am/db/2310907/Protemix_Corporation_Limited>,
        <https://1145.am/db/2351183/Prolor_Biotech> ;
    ns1:sameAsMedium <https://1145.am/db/2355625/Prolor_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351184/Prolor_Biotech_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-04-24T12:56:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MIAMI and NES-ZIONA, Israel, April 24, 2013 /PRNewswire/ - OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction." ;
    ns1:documentTitle "OPKO Health To Acquire PROLOR Biotech" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opko-health-to-acquire-prolor-biotech> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2351184/Prolor_Biotech> ;
    ns1:targetName "PROLOR Biotech" ;
    ns1:valueRaw "approximately $ 480 million" ;
    ns1:whereGeoName "State of Israel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:whereRaw "Israel" .

<https://1145.am/db/2351191/Amundi_Private_Equity_Funds> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Private Equity" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "Amundi Private Equity Funds" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Amundi Private Equity Funds" ;
    ns1:sameAsHigh <https://1145.am/db/2538903/Amundi_Private_Equity_Funds>,
        <https://1145.am/db/2637499/Mitsui_Private_Equity> ;
    ns1:sameAsMedium <https://1145.am/db/2351192/Amundi_Private_Equity_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351191/Idinvest_Partners> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "IDInvest Partners" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "IDInvest Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1736066/Idinvest_Partners>,
        <https://1145.am/db/1738123/Idinvest_Partners>,
        <https://1145.am/db/1740498/Idinvest_Partners>,
        <https://1145.am/db/1750172/Idinvest_Partners>,
        <https://1145.am/db/1755422/Idinvest_Partners>,
        <https://1145.am/db/1757815/Idinvest_Partners>,
        <https://1145.am/db/1769445/Idinvest_Partners>,
        <https://1145.am/db/1772963/Idinvest_Partners>,
        <https://1145.am/db/1773328/Idinvest_Partners>,
        <https://1145.am/db/1776250/Idinvest_Partners>,
        <https://1145.am/db/1787342/Idinvest_Partners>,
        <https://1145.am/db/1790627/Idinvest_Partners>,
        <https://1145.am/db/1793731/Idinvest_Partners>,
        <https://1145.am/db/1793936/Idinvest_Partners>,
        <https://1145.am/db/1811087/Idinvest_Partners>,
        <https://1145.am/db/1813827/Idinvest_Partners>,
        <https://1145.am/db/1819930/Idinvest_Partners>,
        <https://1145.am/db/1828275/Idinvest_Partners>,
        <https://1145.am/db/1832549/Idinvest_Partners>,
        <https://1145.am/db/1833939/Idinvest_Partners>,
        <https://1145.am/db/1851854/Idinvest_Partners>,
        <https://1145.am/db/1869732/Idinvest_Partners>,
        <https://1145.am/db/1913303/Idinvest_Partners>,
        <https://1145.am/db/2154431/Idinvest_Partners>,
        <https://1145.am/db/2154909/Idinvest_Partners>,
        <https://1145.am/db/2293867/Idinvest_Partners>,
        <https://1145.am/db/2348506/Idinvest_Partners>,
        <https://1145.am/db/2348523/Idinvest_Partners>,
        <https://1145.am/db/2351192/Idinvest_Partners>,
        <https://1145.am/db/2371169/Idinvest_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351191/Innobio_Fund> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Biopharmaceutical" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "InnoBio fund *" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "InnoBio fund" ;
    ns1:sameAsMedium <https://1145.am/db/2351192/Innobio_Fund>,
        <https://1145.am/db/2365826/Innobio_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351191/Irdi> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "IRDI" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "IRDI" ;
    ns1:sameAsMedium <https://1145.am/db/2351192/Irdi> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351191/Wellington_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Munich" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2867714/about.rdf> ;
    ns1:basedInHighRaw "Munich, Germany" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "Wellington Partners" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Wellington Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1680280/Wellington_Partners>,
        <https://1145.am/db/1742188/Wellington_Partners>,
        <https://1145.am/db/1742782/Wellington_Partners>,
        <https://1145.am/db/1764682/Wellington_Partners>,
        <https://1145.am/db/1769525/Wellington_Partners>,
        <https://1145.am/db/1793936/Wellington_Partners>,
        <https://1145.am/db/1817949/Wellington_Partners>,
        <https://1145.am/db/1821883/Wellington_Partners>,
        <https://1145.am/db/1828037/Wellington_Partners>,
        <https://1145.am/db/1829991/Wellington_Partners>,
        <https://1145.am/db/1833958/Wellington_Partners>,
        <https://1145.am/db/1834220/Wellington_Partners>,
        <https://1145.am/db/1846466/Wellington_Partners>,
        <https://1145.am/db/1848420/Wellington_Partners>,
        <https://1145.am/db/1854186/Wellington_Partners>,
        <https://1145.am/db/1856207/Wellington_Partners>,
        <https://1145.am/db/1864259/Wellington_Partners>,
        <https://1145.am/db/1868569/Wellington_Partners>,
        <https://1145.am/db/1875469/Wellington_Partners>,
        <https://1145.am/db/1879760/Wellington_Partners>,
        <https://1145.am/db/1881652/Wellington_Partners>,
        <https://1145.am/db/1883959/Wellington_Partners>,
        <https://1145.am/db/1887703/Wellington_Partners>,
        <https://1145.am/db/1893512/Wellington_Partners>,
        <https://1145.am/db/1901284/Wellington_Partners>,
        <https://1145.am/db/1905277/Wellington_Partners>,
        <https://1145.am/db/2151950/Wellington_Partners>,
        <https://1145.am/db/2288440/Wellington_Partners>,
        <https://1145.am/db/2289349/Wellington_Partners>,
        <https://1145.am/db/2295712/Wellington_Partners>,
        <https://1145.am/db/2296842/Wellington_Partners>,
        <https://1145.am/db/2298846/Wellington_Partners>,
        <https://1145.am/db/2323700/Wellington_Partners>,
        <https://1145.am/db/2323705/Wellington_Partners>,
        <https://1145.am/db/2331736/Wellington_Partners>,
        <https://1145.am/db/2332658/Wellington_Partners>,
        <https://1145.am/db/2332659/Wellington_Partners>,
        <https://1145.am/db/2338929/Wellington_Partners>,
        <https://1145.am/db/2341942/Wellington_Partners>,
        <https://1145.am/db/2342582/Wellington_Partners>,
        <https://1145.am/db/2348331/Wellington_Partners>,
        <https://1145.am/db/2349301/Wellington_Partners>,
        <https://1145.am/db/2351192/Wellington_Partners>,
        <https://1145.am/db/2351312/Wellington_Partners>,
        <https://1145.am/db/2351879/Wellington_Partners>,
        <https://1145.am/db/2351883/Wellington_Partners>,
        <https://1145.am/db/2359443/Wellington_Partners>,
        <https://1145.am/db/2361113/Wellington_Partners>,
        <https://1145.am/db/2363262/Wellington_Partners>,
        <https://1145.am/db/2363274/Wellington_Partners>,
        <https://1145.am/db/2363275/Wellington_Partners>,
        <https://1145.am/db/2536547/Wellington_Partners>,
        <https://1145.am/db/2562086/Wellington_Partners>,
        <https://1145.am/db/2569491/Wellington_Partners>,
        <https://1145.am/db/2580665/Wellington_Partners>,
        <https://1145.am/db/530060/Wellington_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Amundi_Private_Equity_Funds> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "Amundi Private Equity Funds" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Amundi Private Equity Funds" ;
    ns1:sameAsMedium <https://1145.am/db/2351191/Amundi_Private_Equity_Funds>,
        <https://1145.am/db/2538903/Amundi_Private_Equity_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Idinvest_Partners> a org:Organization ;
    ns1:basedInLowRaw "Europe" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "IDInvest Partners" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "IDInvest Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1736066/Idinvest_Partners>,
        <https://1145.am/db/1738123/Idinvest_Partners>,
        <https://1145.am/db/1740498/Idinvest_Partners>,
        <https://1145.am/db/1750172/Idinvest_Partners>,
        <https://1145.am/db/1755422/Idinvest_Partners>,
        <https://1145.am/db/1757815/Idinvest_Partners>,
        <https://1145.am/db/1769445/Idinvest_Partners>,
        <https://1145.am/db/1772963/Idinvest_Partners>,
        <https://1145.am/db/1773328/Idinvest_Partners>,
        <https://1145.am/db/1776250/Idinvest_Partners>,
        <https://1145.am/db/1787342/Idinvest_Partners>,
        <https://1145.am/db/1790627/Idinvest_Partners>,
        <https://1145.am/db/1793731/Idinvest_Partners>,
        <https://1145.am/db/1793936/Idinvest_Partners>,
        <https://1145.am/db/1811087/Idinvest_Partners>,
        <https://1145.am/db/1813827/Idinvest_Partners>,
        <https://1145.am/db/1819930/Idinvest_Partners>,
        <https://1145.am/db/1828275/Idinvest_Partners>,
        <https://1145.am/db/1832549/Idinvest_Partners>,
        <https://1145.am/db/1833939/Idinvest_Partners>,
        <https://1145.am/db/1851854/Idinvest_Partners>,
        <https://1145.am/db/1869732/Idinvest_Partners>,
        <https://1145.am/db/1913303/Idinvest_Partners>,
        <https://1145.am/db/2154431/Idinvest_Partners>,
        <https://1145.am/db/2154909/Idinvest_Partners>,
        <https://1145.am/db/2293867/Idinvest_Partners>,
        <https://1145.am/db/2348506/Idinvest_Partners>,
        <https://1145.am/db/2348523/Idinvest_Partners>,
        <https://1145.am/db/2351191/Idinvest_Partners>,
        <https://1145.am/db/2371169/Idinvest_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Innobio_Fund> a org:Organization ;
    ns1:basedInLowRaw "Europe" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "InnoBio fund" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "InnoBio fund" ;
    ns1:sameAsMedium <https://1145.am/db/2351191/Innobio_Fund>,
        <https://1145.am/db/2365826/Innobio_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Irdi> a org:Organization ;
    ns1:basedInLowRaw "Europe" ;
    ns1:description "life science investors" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "IRDI" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "IRDI" ;
    ns1:sameAsMedium <https://1145.am/db/2351191/Irdi> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Wellington_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Munich" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2867714/about.rdf> ;
    ns1:basedInHighRaw "Munich" ;
    ns1:description "life science investors" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "Wellington Partners" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Wellington Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2152146/Wellington_Management_Company> ;
    ns1:sameAsMedium <https://1145.am/db/1680280/Wellington_Partners>,
        <https://1145.am/db/1742188/Wellington_Partners>,
        <https://1145.am/db/1742782/Wellington_Partners>,
        <https://1145.am/db/1764682/Wellington_Partners>,
        <https://1145.am/db/1769525/Wellington_Partners>,
        <https://1145.am/db/1793936/Wellington_Partners>,
        <https://1145.am/db/1817949/Wellington_Partners>,
        <https://1145.am/db/1821883/Wellington_Partners>,
        <https://1145.am/db/1828037/Wellington_Partners>,
        <https://1145.am/db/1829991/Wellington_Partners>,
        <https://1145.am/db/1833958/Wellington_Partners>,
        <https://1145.am/db/1834220/Wellington_Partners>,
        <https://1145.am/db/1846466/Wellington_Partners>,
        <https://1145.am/db/1848420/Wellington_Partners>,
        <https://1145.am/db/1854186/Wellington_Partners>,
        <https://1145.am/db/1856207/Wellington_Partners>,
        <https://1145.am/db/1864259/Wellington_Partners>,
        <https://1145.am/db/1868569/Wellington_Partners>,
        <https://1145.am/db/1875469/Wellington_Partners>,
        <https://1145.am/db/1879760/Wellington_Partners>,
        <https://1145.am/db/1881652/Wellington_Partners>,
        <https://1145.am/db/1883959/Wellington_Partners>,
        <https://1145.am/db/1887703/Wellington_Partners>,
        <https://1145.am/db/1893512/Wellington_Partners>,
        <https://1145.am/db/1901284/Wellington_Partners>,
        <https://1145.am/db/1905277/Wellington_Partners>,
        <https://1145.am/db/2151950/Wellington_Partners>,
        <https://1145.am/db/2288440/Wellington_Partners>,
        <https://1145.am/db/2289349/Wellington_Partners>,
        <https://1145.am/db/2295712/Wellington_Partners>,
        <https://1145.am/db/2296842/Wellington_Partners>,
        <https://1145.am/db/2298846/Wellington_Partners>,
        <https://1145.am/db/2323700/Wellington_Partners>,
        <https://1145.am/db/2323705/Wellington_Partners>,
        <https://1145.am/db/2331736/Wellington_Partners>,
        <https://1145.am/db/2332658/Wellington_Partners>,
        <https://1145.am/db/2332659/Wellington_Partners>,
        <https://1145.am/db/2338929/Wellington_Partners>,
        <https://1145.am/db/2341942/Wellington_Partners>,
        <https://1145.am/db/2342582/Wellington_Partners>,
        <https://1145.am/db/2348331/Wellington_Partners>,
        <https://1145.am/db/2349301/Wellington_Partners>,
        <https://1145.am/db/2351191/Wellington_Partners>,
        <https://1145.am/db/2351312/Wellington_Partners>,
        <https://1145.am/db/2351879/Wellington_Partners>,
        <https://1145.am/db/2351883/Wellington_Partners>,
        <https://1145.am/db/2359443/Wellington_Partners>,
        <https://1145.am/db/2361113/Wellington_Partners>,
        <https://1145.am/db/2363262/Wellington_Partners>,
        <https://1145.am/db/2363274/Wellington_Partners>,
        <https://1145.am/db/2363275/Wellington_Partners>,
        <https://1145.am/db/2536547/Wellington_Partners>,
        <https://1145.am/db/2562086/Wellington_Partners>,
        <https://1145.am/db/2569491/Wellington_Partners>,
        <https://1145.am/db/2580665/Wellington_Partners>,
        <https://1145.am/db/530060/Wellington_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352162/Acumen_Pharmaceuticals_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Livermore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5367440/about.rdf> ;
    ns1:basedInHighRaw "Livermore, CA, USA" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2013-04-25T11:56:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/acumen-pharmaceuticals-inc-announces-first-close-of-series-a-financing> ;
    ns1:foundName "Acumen Pharmaceuticals Inc.",
        "Acumen Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals",
        "pharmaceuticals" ;
    ns1:name "Acumen Pharmaceuticals",
        "Acumen Pharmaceuticals Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1541259/Advanced_Clinical>,
        <https://1145.am/db/1616851/Acumen_Pharmaceuticals>,
        <https://1145.am/db/2283693/Acumen_Pharmaceuticals>,
        <https://1145.am/db/2352166/Acumen_Pharmaceuticals>,
        <https://1145.am/db/2359700/Advanced_Clinical>,
        <https://1145.am/db/885614/Advanced_Clinical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352162/Series_A_Investment_Acumen_Pharmaceuticals_Inc_Bvf_Partners_Lp_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-25T11:56:03+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing.",
        "Livermore, CA, USA, April 25, 2013 - Acumen Pharmaceuticals, Inc., today announced it has completed a first closing of a $ 20 million Series A financing led by BVF Partners L.P. (BVF) , a leading life sciences investment firm which manages the Biotechnology Value Fund, L.P. NeuroVentures Fund, L.P., Praxis Technologies, Glynn Ventures and private investors also participated in the closing." ;
    ns1:documentTitle "Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/acumen-pharmaceuticals-inc-announces-first-close-of-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352162/Acumen_Pharmaceuticals_Inc> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 20 million" ;
    ns1:when "2013-04-25T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 25, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2352170/Alta_Partners> a org:Organization ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Alta Partners" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Alta Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1387471/Altamont_Capital_Partners>,
        <https://1145.am/db/2303814/Alta_Partners>,
        <https://1145.am/db/2318577/Alta_Partners>,
        <https://1145.am/db/2326176/Alta_Partners>,
        <https://1145.am/db/2327677/Alta_Partners>,
        <https://1145.am/db/2353771/Alta_Partners>,
        <https://1145.am/db/2353789/Alta_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1156304/Alta_Partners>,
        <https://1145.am/db/1230022/Alta_Partners>,
        <https://1145.am/db/1333948/Altas_Partners>,
        <https://1145.am/db/1334727/Altas_Partners>,
        <https://1145.am/db/2303810/Alta_Partners>,
        <https://1145.am/db/2304769/Alta_Partners>,
        <https://1145.am/db/2304870/Alta_Partners>,
        <https://1145.am/db/2305729/Alta_Partners>,
        <https://1145.am/db/2305745/Alta_Partners>,
        <https://1145.am/db/2306281/Alta_Partners>,
        <https://1145.am/db/2306568/Alta_Partners>,
        <https://1145.am/db/2307682/Alta_Partners>,
        <https://1145.am/db/2307691/Alta_Partners>,
        <https://1145.am/db/2307824/Alta_Partners>,
        <https://1145.am/db/2307829/Alta_Partners>,
        <https://1145.am/db/2308855/Alta_Partners>,
        <https://1145.am/db/2311011/Alta_Partners>,
        <https://1145.am/db/2313143/Alta_Partners>,
        <https://1145.am/db/2313405/Alta_Partners>,
        <https://1145.am/db/2316391/Alta_Partners>,
        <https://1145.am/db/2318635/Alta_Partners>,
        <https://1145.am/db/2322984/Alta_Partners>,
        <https://1145.am/db/2323003/Alta_Partners>,
        <https://1145.am/db/2323243/Alta_Partners>,
        <https://1145.am/db/2324012/Alta_Partners>,
        <https://1145.am/db/2324015/Alta_Partners>,
        <https://1145.am/db/2326903/Alta_Partners>,
        <https://1145.am/db/2327441/Alta_Partners>,
        <https://1145.am/db/2327442/Alta_Partners>,
        <https://1145.am/db/2328815/Alta_Partners>,
        <https://1145.am/db/2330075/Alta_Partners>,
        <https://1145.am/db/2330079/Alta_Partners>,
        <https://1145.am/db/2338126/Alta_Partners>,
        <https://1145.am/db/2338127/Alta_Partners>,
        <https://1145.am/db/2340887/Alta_Partners>,
        <https://1145.am/db/2341764/Alta_Partners>,
        <https://1145.am/db/2343547/Alta_Partners>,
        <https://1145.am/db/2344092/Alta_Partners>,
        <https://1145.am/db/2344100/Alta_Partners>,
        <https://1145.am/db/2346542/Alta_Partners>,
        <https://1145.am/db/2351224/Alta_Partners>,
        <https://1145.am/db/2351897/Alta_Partners>,
        <https://1145.am/db/2352167/Alta_Partners>,
        <https://1145.am/db/2352362/Alta_Partners>,
        <https://1145.am/db/2352831/Alta_Partners>,
        <https://1145.am/db/2353439/Alta_Partners>,
        <https://1145.am/db/2354299/Alta_Partners>,
        <https://1145.am/db/2354307/Alta_Partners>,
        <https://1145.am/db/2354314/Alta_Partners>,
        <https://1145.am/db/2355183/Alta_Partners>,
        <https://1145.am/db/2355274/Alta_Partners>,
        <https://1145.am/db/2355586/Alta_Partners>,
        <https://1145.am/db/2356216/Alta_Partners>,
        <https://1145.am/db/2358496/Alta_Partners>,
        <https://1145.am/db/2358502/Alta_Partners>,
        <https://1145.am/db/2362565/Alta_Partners>,
        <https://1145.am/db/2362566/Alta_Partners>,
        <https://1145.am/db/2362902/Alta_Partners>,
        <https://1145.am/db/2362909/Alta_Partners>,
        <https://1145.am/db/2362910/Alta_Partners>,
        <https://1145.am/db/2363364/Alta_Partners>,
        <https://1145.am/db/2363510/Alta_Partners>,
        <https://1145.am/db/2365748/Alta_Partners>,
        <https://1145.am/db/2366693/Alta_Partners>,
        <https://1145.am/db/2366700/Alta_Partners>,
        <https://1145.am/db/2367497/Alta_Partners>,
        <https://1145.am/db/328387/Altas_Partners>,
        <https://1145.am/db/443962/Altas_Partners>,
        <https://1145.am/db/750997/Alta_Partners>,
        <https://1145.am/db/979509/Alta_Partners>,
        <https://1145.am/db/987929/Alta_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Domain_Associates> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Domain Associates" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsHigh <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Esperion_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Esperion Therapeutics",
        "Esperion Therapeutics, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Esperion Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1137091/Avilar_Therapeutics>,
        <https://1145.am/db/2309847/Egalet>,
        <https://1145.am/db/2327511/Esperion_Therapeutics>,
        <https://1145.am/db/2336926/Esperion_Therapeutics_Inc>,
        <https://1145.am/db/2340106/Esperion_Therapeutics>,
        <https://1145.am/db/2341297/Elusys_Therapeutics>,
        <https://1145.am/db/2347668/Elusys_Therapeutics_Inc>,
        <https://1145.am/db/2352167/Esperion_Therapeutics>,
        <https://1145.am/db/2360051/Elusys_Therapeutics>,
        <https://1145.am/db/2360052/Elusys_Therapeutics_Inc>,
        <https://1145.am/db/2361669/Esperion_Therapeutics>,
        <https://1145.am/db/2591761/Elusys_Therapeutics>,
        <https://1145.am/db/505996/Elevar>,
        <https://1145.am/db/633100/Avilar_Therapeutics>,
        <https://1145.am/db/734840/Elevar>,
        <https://1145.am/db/991384/Elusys_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/Brookside_Capital> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE, MA" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "Brookside Capital" ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "Brookside Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2327685/Brookside_Capital>,
        <https://1145.am/db/2340819/Brookside_Capital_Partners_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2303098/Brookside_Capital>,
        <https://1145.am/db/2316391/Brookside_Capital>,
        <https://1145.am/db/2338126/Brookside_Capital>,
        <https://1145.am/db/2338127/Brookside_Capital>,
        <https://1145.am/db/2346063/Brookside_Capital>,
        <https://1145.am/db/2346204/Brookside_Capital>,
        <https://1145.am/db/2657684/Brookside_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352172/Radius_Health> a org:Organization ;
    ns1:description "developing new therapeutics for the treatment of osteoporosis and other women's health" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "Radius Health",
        "Radius Health, Inc",
        "Radius Health, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Radius Health" ;
    ns1:sameAsHigh <https://1145.am/db/1278945/Radius_Health>,
        <https://1145.am/db/2083899/Radius_Pharmaceuticals>,
        <https://1145.am/db/2336183/Radius_Health>,
        <https://1145.am/db/2337687/Radius_Health>,
        <https://1145.am/db/2341186/Radius_Health>,
        <https://1145.am/db/2349449/Radius_Health>,
        <https://1145.am/db/2370073/Radius_Health> ;
    ns1:sameAsMedium <https://1145.am/db/1076059/Radius_Health_Inc>,
        <https://1145.am/db/1156145/Radius_Health>,
        <https://1145.am/db/1157508/Radius_Health>,
        <https://1145.am/db/1157615/Radius_Health>,
        <https://1145.am/db/1158644/Radius_Health>,
        <https://1145.am/db/1159902/Radius_Health>,
        <https://1145.am/db/1160656/Radius_Health>,
        <https://1145.am/db/1161401/Radius_Health>,
        <https://1145.am/db/1166101/Radius_Health>,
        <https://1145.am/db/1186635/Radius_Health>,
        <https://1145.am/db/1203594/Radius_Health>,
        <https://1145.am/db/1204941/Radius_Health>,
        <https://1145.am/db/1204986/Radius_Health>,
        <https://1145.am/db/2152927/Radius_Health>,
        <https://1145.am/db/2279738/Radius_Health>,
        <https://1145.am/db/2291409/Radius_Health>,
        <https://1145.am/db/2308887/Radius_Health>,
        <https://1145.am/db/2321020/Radius_Health>,
        <https://1145.am/db/2340685/Radius_Health>,
        <https://1145.am/db/2341182/Radius_Health>,
        <https://1145.am/db/2346204/Radius_Health_Inc>,
        <https://1145.am/db/2346205/Radius_Health>,
        <https://1145.am/db/2349447/Radius_Health> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352207/Morgenthaler_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:29:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Scioderm Closes $16 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/scioderm-closes-16-million-series-a-financing> ;
    ns1:foundName "Morgenthaler Ventures" ;
    ns1:investor <https://1145.am/db/2352207/Series_A_Investment_Morgenthaler_Ventures_Scioderm_Technology_Partners_Completed> ;
    ns1:name "Morgenthaler Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1826128/Morgenthaler_Ventures>,
        <https://1145.am/db/1846752/Morgenthaler_Ventures>,
        <https://1145.am/db/2303124/Morgenthaler_Partners_Vii_Lp>,
        <https://1145.am/db/2362553/Morgenthaler_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1695894/Morgenthaler_Ventures>,
        <https://1145.am/db/1699268/Morgenthaler_Ventures>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1724566/Morgenthaler_Ventures>,
        <https://1145.am/db/1829487/Morgenthaler_Ventures>,
        <https://1145.am/db/1830084/Morgenthaler_Ventures>,
        <https://1145.am/db/1836989/Morgenthaler_Ventures>,
        <https://1145.am/db/1837117/Morgenthaler_Ventures>,
        <https://1145.am/db/1839836/Morgenthaler_Ventures>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/2246579/Morgenthaler_Ventures>,
        <https://1145.am/db/2257512/Morgenthaler_Ventures>,
        <https://1145.am/db/2297408/Morgenthaler_Ventures>,
        <https://1145.am/db/2297592/Morgenthaler_Ventures>,
        <https://1145.am/db/2307644/Morgenthaler_Ventures>,
        <https://1145.am/db/2308142/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311075/Morgenthaler_Ventures>,
        <https://1145.am/db/2312192/Morgenthaler_Ventures>,
        <https://1145.am/db/2323586/Morgenthaler_Ventures>,
        <https://1145.am/db/2329524/Morgenthaler_Ventures>,
        <https://1145.am/db/2329531/Morgenthaler_Ventures>,
        <https://1145.am/db/2338251/Morgenthaler_Ventures>,
        <https://1145.am/db/2338254/Morgenthaler_Ventures>,
        <https://1145.am/db/2338373/Morgenthaler_Ventures>,
        <https://1145.am/db/2338703/Morgenthaler_Ventures>,
        <https://1145.am/db/2338704/Morgenthaler_Ventures>,
        <https://1145.am/db/2342925/Morgenthaler_Ventures>,
        <https://1145.am/db/2342937/Morgenthaler_Ventures>,
        <https://1145.am/db/2343202/Morgenthaler_Ventures>,
        <https://1145.am/db/2343210/Morgenthaler_Ventures>,
        <https://1145.am/db/2363510/Morgenthaler_Ventures>,
        <https://1145.am/db/2364939/Morgenthaler_Ventures>,
        <https://1145.am/db/2367204/Morgenthaler_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352207/Scioderm> a org:Organization ;
    ns1:description "dermatology therapeutics" ;
    ns1:documentDate "2013-04-29T11:29:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Scioderm Closes $16 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/scioderm-closes-16-million-series-a-financing> ;
    ns1:foundName "Scioderm" ;
    ns1:industry "dermatology therapeutics" ;
    ns1:name "Scioderm" ;
    ns1:sameAsMedium <https://1145.am/db/2344627/Scioderm_Inc>,
        <https://1145.am/db/2356083/Scioderm>,
        <https://1145.am/db/2369705/Scioderm> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352207/Technology_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:29:17+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Scioderm Closes $16 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/scioderm-closes-16-million-series-a-financing> ;
    ns1:foundName "Technology Partners" ;
    ns1:investor <https://1145.am/db/2352207/Series_A_Investment_Morgenthaler_Ventures_Scioderm_Technology_Partners_Completed> ;
    ns1:name "Technology Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1223975/Technology_Partners_Llc>,
        <https://1145.am/db/2314492/Technology_Partners>,
        <https://1145.am/db/2324289/Technology_Partners>,
        <https://1145.am/db/2329531/Technology_Partners>,
        <https://1145.am/db/2338251/Technology_Partners>,
        <https://1145.am/db/2338254/Technology_Partners>,
        <https://1145.am/db/646965/Technology_Partners_Llc>,
        <https://1145.am/db/796589/Technology_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352211/Harvard_University> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "life sciences" ;
    ns1:documentDate "2013-04-29T14:00:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Harvard Announces $50 Million Gift from the Blavatnik Family Foundation" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/harvard-announces-50-million-gift-from-blavatnik-family-foundation> ;
    ns1:foundName "Harvard",
        "Harvard University" ;
    ns1:name "Harvard",
        "Harvard University" ;
    ns1:sameAsHigh <https://1145.am/db/1572160/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2348007/Harvard_Bioscience>,
        <https://1145.am/db/2357284/Harvard_Bioscience> ;
    ns1:sameAsMedium <https://1145.am/db/1583210/Harvard_University>,
        <https://1145.am/db/1588580/Harvard_University>,
        <https://1145.am/db/2307936/Harvard_University>,
        <https://1145.am/db/2329653/Harvard_University> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353209/Celator_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Princeton" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5102922/about.rdf> ;
    ns1:basedInHighRaw "Princeton, NJ" ;
    ns1:documentDate "2013-05-01T13:19:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VCs provide $40M to finance Celator's pivotal PhIII AML study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/vcs-provide-40m-to-finance-celator-s-pivotal-phiii-aml-study> ;
    ns1:foundName "Celator",
        "Celator Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Celator",
        "Celator Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1081367/Casi_Pharmaceuticals_Inc>,
        <https://1145.am/db/1192310/Casi_Pharmaceuticals_Inc>,
        <https://1145.am/db/1366554/Casi_Pharmaceuticals_Inc>,
        <https://1145.am/db/1396752/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2153295/Curzion_Pharmaceuticals>,
        <https://1145.am/db/2156297/Cerevel>,
        <https://1145.am/db/2285587/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2287377/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2301933/Ecr_Pharmaceuticals>,
        <https://1145.am/db/2301947/Ecr_Pharmaceuticals>,
        <https://1145.am/db/2302649/Ecr_Pharmaceuticals>,
        <https://1145.am/db/2309970/Eurand_Pharmaceuticals>,
        <https://1145.am/db/2311099/Celator_Pharmaceuticals>,
        <https://1145.am/db/2313397/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2313471/Celator_Pharmaceuticals>,
        <https://1145.am/db/2314551/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2314554/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2320852/Cempra_Pharmaceuticals>,
        <https://1145.am/db/2320853/Cempra_Pharmaceuticals>,
        <https://1145.am/db/2322242/Cerimon_Pharmaceuticals>,
        <https://1145.am/db/2326327/Provectus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2328825/Cempra_Pharmaceuticals>,
        <https://1145.am/db/2330539/Celator_Pharmaceuticals>,
        <https://1145.am/db/2338173/Celator_Pharmaceuticals>,
        <https://1145.am/db/2339182/Provectus_Pharmaceuticals>,
        <https://1145.am/db/2344274/Momenta_Pharmaceuticals_Inc>,
        <https://1145.am/db/2355936/Celator_Pharmaceuticals>,
        <https://1145.am/db/2355938/Celator_Pharmaceuticals>,
        <https://1145.am/db/2361666/Celator_Pharmaceuticals>,
        <https://1145.am/db/2364675/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2364774/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2364776/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2365376/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2365795/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2366302/Cempra_Pharmaceuticals>,
        <https://1145.am/db/2367072/Provectus_Pharmaceuticals>,
        <https://1145.am/db/2367292/Cempra_Pharmaceuticals>,
        <https://1145.am/db/2368333/Celator_Pharmaceuticals>,
        <https://1145.am/db/2537737/Cevec_Pharmaceuticals>,
        <https://1145.am/db/2553248/Cenes_Pharmaceutical>,
        <https://1145.am/db/2574942/Celator_Pharmaceuticals>,
        <https://1145.am/db/958376/Cardior_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2330549/Celator_Pharmaceuticals>,
        <https://1145.am/db/2353210/Celator_Pharmaceuticals>,
        <https://1145.am/db/2358532/Celator_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353209/Investment_Celator_Pharmaceuticals_Valence_Life_Sciences_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-01T13:19:31+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Princeton, NJ - based Celator Pharmaceuticals has raised close to $ 40 million, enough to get its lead cancer drug-a reformulation of standard drugs infused in nano-sized delivery vehicles-through a pivotal late-stage study that is now enrolling patients with secondary cases of acute myeloid leukemia.",
        "Valence Life Sciences led this latest fundraising for Celator, which includes $ 32.5 million in a final closing and an additional $ 6.8 million from an initial buy-in." ;
    ns1:documentTitle "VCs provide $40M to finance Celator's pivotal PhIII AML study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/vcs-provide-40m-to-finance-celator-s-pivotal-phiii-aml-study> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2353209/Celator_Pharmaceuticals> ;
    ns1:valueRaw "$ 32.5 million",
        "$ 6.8 million",
        "close to $ 40 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2353230/Intrexon_Corporation> a org:Organization ;
    ns1:description "Research and development" ;
    ns1:documentDate "2013-05-01T20:56:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/intrexon-corporation-raises-150-million-for-synthetic-biology-initiatives> ;
    ns1:foundName "Intrexon Corporation" ;
    ns1:industry "synthetic biology" ;
    ns1:name "Intrexon Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2307365/Intrexon_Corporation>,
        <https://1145.am/db/2318279/Intrexon_Corporation>,
        <https://1145.am/db/2340489/Intrexon_Corporation>,
        <https://1145.am/db/2341688/Intrexon_Corporation>,
        <https://1145.am/db/2348287/Intrexon_Corporation>,
        <https://1145.am/db/2349873/Intrexon_Corporation>,
        <https://1145.am/db/2357278/Intrexon_Corporation>,
        <https://1145.am/db/2367297/Intrexon>,
        <https://1145.am/db/2367300/Intrexon_Corporation>,
        <https://1145.am/db/2369101/Intrexon>,
        <https://1145.am/db/2369501/Intrexon_Corporation>,
        <https://1145.am/db/2370849/Intrexon>,
        <https://1145.am/db/2370855/Intrexon>,
        <https://1145.am/db/2550653/Intrexon_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2287906/Intrexon>,
        <https://1145.am/db/2311701/Intrexon>,
        <https://1145.am/db/2317501/Intrexon>,
        <https://1145.am/db/2317505/Intrexon_Corporation>,
        <https://1145.am/db/2317680/Intrexon>,
        <https://1145.am/db/2318272/Intrexon_Corporation>,
        <https://1145.am/db/2335640/Intrexon>,
        <https://1145.am/db/2335645/Intrexon_Corporation>,
        <https://1145.am/db/2338446/Intrexon>,
        <https://1145.am/db/2338449/Intrexon>,
        <https://1145.am/db/2348279/Intrexon>,
        <https://1145.am/db/2353234/Intrexon>,
        <https://1145.am/db/2355386/Intrexon>,
        <https://1145.am/db/2550647/Intrexon_Corporation>,
        <https://1145.am/db/2550649/Intrexon_Corporation>,
        <https://1145.am/db/2568997/Intrexon> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353230/Preferred_Investment_Intrexon_Corporation_Third_Security_Llc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-01T20:56:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "GERMANTOWN, Md., May 1, 2013 /PRNewswire/ - Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series F preferred investment round of $ 150 million, bringing the company's total capital raised to $ 509 million.",
        "Intrexon Corporation Raises $ 150 Million for Synthetic Biology Initiatives." ;
    ns1:documentTitle "Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/intrexon-corporation-raises-150-million-for-synthetic-biology-initiatives> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2353230/Intrexon_Corporation> ;
    ns1:targetDetails "preferred" ;
    ns1:valueRaw "$ 150 Million",
        "$ 150 million",
        "$ 509 million" ;
    ns1:when "2013-05-01T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 1, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2353230/Third_Security_Llc> a org:Organization ;
    ns1:basedInLowRaw "Md" ;
    ns1:documentDate "2013-05-01T20:56:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/intrexon-corporation-raises-150-million-for-synthetic-biology-initiatives> ;
    ns1:foundName "Third Security, LLC" ;
    ns1:investor <https://1145.am/db/2353230/Preferred_Investment_Intrexon_Corporation_Third_Security_Llc_Completed> ;
    ns1:name "Third Security, LLC" ;
    ns1:sameAsMedium <https://1145.am/db/2336957/Third_Security_Llc>,
        <https://1145.am/db/2337071/Third_Security_Llc>,
        <https://1145.am/db/2348287/Third_Security_Llc>,
        <https://1145.am/db/636070/Third_Security>,
        <https://1145.am/db/637012/Third_Security> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354266/Neurophage_Inc> a org:Organization ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "NEUROPHAGE, INC." ;
    ns1:name "Neurophage, Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2307114/Neurophage>,
        <https://1145.am/db/2354277/Neurophage> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354266/Neurophage_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, MA" ;
    ns1:description "developing breakthrough therapies for neurodegenerative diseases" ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "NeuroPhage Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "NeuroPhage Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1377016/Neurocrine_Biosciences>,
        <https://1145.am/db/1631951/Neurotech_Pharmaceuticals_Inc>,
        <https://1145.am/db/2296526/Neuroderm>,
        <https://1145.am/db/2303308/Neuro-Hitech_Inc>,
        <https://1145.am/db/2303464/Neuromed_Pharmaceuticals>,
        <https://1145.am/db/2305157/Neuromed_Pharmaceuticals>,
        <https://1145.am/db/2305956/Neurogen>,
        <https://1145.am/db/2306726/Neurogen_Corporation>,
        <https://1145.am/db/2307114/Neurophage>,
        <https://1145.am/db/2309521/Neurogen>,
        <https://1145.am/db/2314313/Neuroscience_Pharmaceuticals>,
        <https://1145.am/db/2314563/Neurosearch>,
        <https://1145.am/db/2314820/Neurocrine_Biosciences_Inc>,
        <https://1145.am/db/2315317/Neuroscience_Pharmaceuticals_Inc>,
        <https://1145.am/db/2321184/Neurotech>,
        <https://1145.am/db/2322276/Neurocrine_Biosciences>,
        <https://1145.am/db/2322492/Neuropharm_Group_Plc>,
        <https://1145.am/db/2322639/Neurosearch>,
        <https://1145.am/db/2326209/Proximagen_Neuroscience_Plc>,
        <https://1145.am/db/2328039/Neurotherapeutics_Pharma>,
        <https://1145.am/db/2329093/Neurotherapeutics_Pharma>,
        <https://1145.am/db/2329848/Neurologix>,
        <https://1145.am/db/2331732/Neuromed_Pharmaceuticals>,
        <https://1145.am/db/2332947/Neuromed_Pharmaceuticals>,
        <https://1145.am/db/2333525/Neuromed_Pharmaceuticals>,
        <https://1145.am/db/2337344/Neurocrine_Biosciences_Inc>,
        <https://1145.am/db/2340127/Knopp_Neurosciences>,
        <https://1145.am/db/2340630/Nautilus_Neurosciences>,
        <https://1145.am/db/2340631/Nautilus_Neurosciences>,
        <https://1145.am/db/2340922/Neurotech_Pharmaceuticals>,
        <https://1145.am/db/2344202/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2344205/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2344651/Neurotrope_Bioscience>,
        <https://1145.am/db/2344651/Neurotrope_Inc>,
        <https://1145.am/db/2344664/Neurocrine_Biosciences>,
        <https://1145.am/db/2344667/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2344837/Neurotech_Pharmaceuticals>,
        <https://1145.am/db/2345731/Neuroderm_Ltd>,
        <https://1145.am/db/2347890/Neurotrope_Inc>,
        <https://1145.am/db/2348917/Neurotrope_Inc>,
        <https://1145.am/db/2349036/Neurotrope_Bioscience>,
        <https://1145.am/db/2349039/Neurotrope_Bioscience>,
        <https://1145.am/db/2349039/Neurotrope_Inc>,
        <https://1145.am/db/2351734/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2351737/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2351754/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2352320/Neuralstem_Inc>,
        <https://1145.am/db/2356122/Neurotherapeutics_Pharma>,
        <https://1145.am/db/2356124/Neurotherapeutics_Pharma>,
        <https://1145.am/db/2357163/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2358144/Neurop_Inc>,
        <https://1145.am/db/2358606/Neurocrine_Biosciences>,
        <https://1145.am/db/2359388/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2359398/Neurophage_Pharmaceuticals>,
        <https://1145.am/db/2360218/Neuroderm_Ltd>,
        <https://1145.am/db/2363142/Cns_Therapeutics>,
        <https://1145.am/db/2363145/Cns_Therapeutics>,
        <https://1145.am/db/2365319/Neurop>,
        <https://1145.am/db/2370127/Neuralstem>,
        <https://1145.am/db/2370135/Neuralstem>,
        <https://1145.am/db/2568701/Neurocrine_Biosciences>,
        <https://1145.am/db/2581057/Cns_Therapeutics>,
        <https://1145.am/db/569563/Alto_Neuroscience>,
        <https://1145.am/db/663779/Neurocrine_Biosciences>,
        <https://1145.am/db/972366/Alto_Neuroscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355274/Alta_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-05-08T12:12:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "LUMENA PHARMACEUTICALS ANNOUNCES $23 MILLION SERIES A FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lumena-pharmaceuticals-announces-23-million-series-a-financing> ;
    ns1:foundName "Alta Partners" ;
    ns1:investor <https://1145.am/db/2355274/Series_A_Investment_Alta_Partners_Lumena_Pharmaceuticals_Pappas_Ventures_Rivervest_Venture_Partners_Completed> ;
    ns1:name "Alta Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1156304/Alta_Partners>,
        <https://1145.am/db/1230022/Alta_Partners>,
        <https://1145.am/db/1333948/Altas_Partners>,
        <https://1145.am/db/1334727/Altas_Partners>,
        <https://1145.am/db/2303810/Alta_Partners>,
        <https://1145.am/db/2303814/Alta_Partners>,
        <https://1145.am/db/2304769/Alta_Partners>,
        <https://1145.am/db/2304870/Alta_Partners>,
        <https://1145.am/db/2305729/Alta_Partners>,
        <https://1145.am/db/2305745/Alta_Partners>,
        <https://1145.am/db/2306281/Alta_Partners>,
        <https://1145.am/db/2306568/Alta_Partners>,
        <https://1145.am/db/2307682/Alta_Partners>,
        <https://1145.am/db/2307691/Alta_Partners>,
        <https://1145.am/db/2307824/Alta_Partners>,
        <https://1145.am/db/2307829/Alta_Partners>,
        <https://1145.am/db/2308855/Alta_Partners>,
        <https://1145.am/db/2311011/Alta_Partners>,
        <https://1145.am/db/2313143/Alta_Partners>,
        <https://1145.am/db/2313405/Alta_Partners>,
        <https://1145.am/db/2316391/Alta_Partners>,
        <https://1145.am/db/2318577/Alta_Partners>,
        <https://1145.am/db/2318635/Alta_Partners>,
        <https://1145.am/db/2322984/Alta_Partners>,
        <https://1145.am/db/2323003/Alta_Partners>,
        <https://1145.am/db/2323243/Alta_Partners>,
        <https://1145.am/db/2324012/Alta_Partners>,
        <https://1145.am/db/2324015/Alta_Partners>,
        <https://1145.am/db/2326176/Alta_Partners>,
        <https://1145.am/db/2326903/Alta_Partners>,
        <https://1145.am/db/2327441/Alta_Partners>,
        <https://1145.am/db/2327442/Alta_Partners>,
        <https://1145.am/db/2327677/Alta_Partners>,
        <https://1145.am/db/2328815/Alta_Partners>,
        <https://1145.am/db/2330075/Alta_Partners>,
        <https://1145.am/db/2330079/Alta_Partners>,
        <https://1145.am/db/2338126/Alta_Partners>,
        <https://1145.am/db/2338127/Alta_Partners>,
        <https://1145.am/db/2340887/Alta_Partners>,
        <https://1145.am/db/2341764/Alta_Partners>,
        <https://1145.am/db/2343547/Alta_Partners>,
        <https://1145.am/db/2344092/Alta_Partners>,
        <https://1145.am/db/2344100/Alta_Partners>,
        <https://1145.am/db/2346542/Alta_Partners>,
        <https://1145.am/db/2351224/Alta_Partners>,
        <https://1145.am/db/2351897/Alta_Partners>,
        <https://1145.am/db/2352167/Alta_Partners>,
        <https://1145.am/db/2352170/Alta_Partners>,
        <https://1145.am/db/2352362/Alta_Partners>,
        <https://1145.am/db/2352831/Alta_Partners>,
        <https://1145.am/db/2353439/Alta_Partners>,
        <https://1145.am/db/2353771/Alta_Partners>,
        <https://1145.am/db/2353789/Alta_Partners>,
        <https://1145.am/db/2354299/Alta_Partners>,
        <https://1145.am/db/2354307/Alta_Partners>,
        <https://1145.am/db/2354314/Alta_Partners>,
        <https://1145.am/db/2355183/Alta_Partners>,
        <https://1145.am/db/2355586/Alta_Partners>,
        <https://1145.am/db/2356216/Alta_Partners>,
        <https://1145.am/db/2358496/Alta_Partners>,
        <https://1145.am/db/2358502/Alta_Partners>,
        <https://1145.am/db/2362565/Alta_Partners>,
        <https://1145.am/db/2362566/Alta_Partners>,
        <https://1145.am/db/2362902/Alta_Partners>,
        <https://1145.am/db/2362909/Alta_Partners>,
        <https://1145.am/db/2362910/Alta_Partners>,
        <https://1145.am/db/2363364/Alta_Partners>,
        <https://1145.am/db/2363510/Alta_Partners>,
        <https://1145.am/db/2365748/Alta_Partners>,
        <https://1145.am/db/2366693/Alta_Partners>,
        <https://1145.am/db/2366700/Alta_Partners>,
        <https://1145.am/db/2367497/Alta_Partners>,
        <https://1145.am/db/328387/Altas_Partners>,
        <https://1145.am/db/443962/Altas_Partners>,
        <https://1145.am/db/750997/Alta_Partners>,
        <https://1145.am/db/979509/Alta_Partners>,
        <https://1145.am/db/987929/Alta_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355274/Lumena_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "SAN DIEGO" ;
    ns1:description "developing oral therapeutics for rare liver diseases" ;
    ns1:documentDate "2013-05-08T12:12:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "LUMENA PHARMACEUTICALS ANNOUNCES $23 MILLION SERIES A FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lumena-pharmaceuticals-announces-23-million-series-a-financing> ;
    ns1:foundName "LUMENA PHARMACEUTICALS",
        "Lumena Pharmaceuticals" ;
    ns1:industry "Pharmaceutical",
        "Pharmaceuticals" ;
    ns1:name "LUMENA PHARMACEUTICALS",
        "Lumena Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2338009/Lumena_Pharmaceuticals>,
        <https://1145.am/db/2342570/Lumena_Pharmaceuticals>,
        <https://1145.am/db/2356216/Lumena_Pharmaceuticals>,
        <https://1145.am/db/2356221/Lumena_Pharmaceuticals>,
        <https://1145.am/db/2592562/Lumena_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2361448/Lumena_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355274/Rivervest_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2013-05-08T12:12:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "LUMENA PHARMACEUTICALS ANNOUNCES $23 MILLION SERIES A FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lumena-pharmaceuticals-announces-23-million-series-a-financing> ;
    ns1:foundName "RiverVest Venture Partners" ;
    ns1:investor <https://1145.am/db/2355274/Series_A_Investment_Alta_Partners_Lumena_Pharmaceuticals_Pappas_Ventures_Rivervest_Venture_Partners_Completed> ;
    ns1:name "RiverVest Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1283038/Rivervest_Venture_Partners>,
        <https://1145.am/db/1669813/Rivervest_Venture_Partners>,
        <https://1145.am/db/2155730/Rivervest_Venture_Partners>,
        <https://1145.am/db/2286035/Rivervest_Venture_Partners>,
        <https://1145.am/db/2288553/Rivervest_Venture_Partners>,
        <https://1145.am/db/2294113/Rivervest_Venture_Partners>,
        <https://1145.am/db/2294893/Rivervest_Venture_Partners>,
        <https://1145.am/db/2296631/Rivervest_Venture_Partners>,
        <https://1145.am/db/2299423/Rivervest_Venture_Partners>,
        <https://1145.am/db/2329550/Rivervest_Venture_Partners>,
        <https://1145.am/db/2336221/Rivervest_Venture_Partners>,
        <https://1145.am/db/2337106/Rivervest_Venture_Partners>,
        <https://1145.am/db/2340887/Rivervest_Venture_Partners>,
        <https://1145.am/db/2350044/Rivervest_Venture_Partners>,
        <https://1145.am/db/2354899/Rivervest_Venture_Partners>,
        <https://1145.am/db/2356216/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358496/Rivervest_Venture_Partners>,
        <https://1145.am/db/2358502/Rivervest_Venture_Partners>,
        <https://1145.am/db/2369916/Rivervest_Venture_Partners>,
        <https://1145.am/db/583798/Rivervest_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Effector_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "eFFECTOR Therapeutics" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "eFFECTOR Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1140590/Allarity_Therapeutics_Inc>,
        <https://1145.am/db/1195836/Allarity_Therapeutics_Inc>,
        <https://1145.am/db/1370127/Allarity_Therapeutics>,
        <https://1145.am/db/1370618/Effector_Therapeutics>,
        <https://1145.am/db/1463656/Sage_Therapeutics>,
        <https://1145.am/db/1574498/Allay_Therapeutics>,
        <https://1145.am/db/158742/Sage_Therapeutics>,
        <https://1145.am/db/2251159/Novelos_Therapeutics>,
        <https://1145.am/db/2286730/Sage_Therapeutics>,
        <https://1145.am/db/2304792/Cv_Therapeutics>,
        <https://1145.am/db/2305544/Cv_Therapeutics>,
        <https://1145.am/db/2305547/Cv_Therapeutics>,
        <https://1145.am/db/2324241/Cv_Therapeutics>,
        <https://1145.am/db/2324249/Cv_Therapeutics>,
        <https://1145.am/db/2335865/Novelos_Therapeutics>,
        <https://1145.am/db/2340106/Esperion_Therapeutics>,
        <https://1145.am/db/2345880/Sage_Therapeutics>,
        <https://1145.am/db/2352037/Alexion_Pharma>,
        <https://1145.am/db/2365068/Novelos_Therapeutics>,
        <https://1145.am/db/2368773/Effector_Therapeutics>,
        <https://1145.am/db/2370145/Effector_Therapeutics>,
        <https://1145.am/db/2545610/Cv_Therapeutics>,
        <https://1145.am/db/2548693/Cv_Therapeutics>,
        <https://1145.am/db/2559469/Alexion_Pharma>,
        <https://1145.am/db/556200/Aegis_Therapeutics_Llc>,
        <https://1145.am/db/590159/Effector_Therapeutics>,
        <https://1145.am/db/952248/Effector_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/1262283/Effector_Therapeutics>,
        <https://1145.am/db/1264213/Effector_Therapeutics>,
        <https://1145.am/db/2358429/Effector_Therapeutics>,
        <https://1145.am/db/2368874/Effector_Therapeutics>,
        <https://1145.am/db/432117/Effector_Therapeutics_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Sr_One> a org:Organization ;
    ns1:basedInLowRaw "San Diego" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "SR One" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "SR One" ;
    ns1:sameAsMedium <https://1145.am/db/1169952/Sr_One>,
        <https://1145.am/db/1334624/Sr_One>,
        <https://1145.am/db/1949427/Sr_One>,
        <https://1145.am/db/2095130/Sr_One>,
        <https://1145.am/db/2110113/Sr_One>,
        <https://1145.am/db/2280707/Sr_One>,
        <https://1145.am/db/2305791/Sr_One>,
        <https://1145.am/db/2317934/Sr_One>,
        <https://1145.am/db/2317951/Sr_One>,
        <https://1145.am/db/2318310/Sr_One>,
        <https://1145.am/db/2326222/Sr_One_Ltd>,
        <https://1145.am/db/2327305/Sr_One>,
        <https://1145.am/db/2327488/Sr_One_Ltd>,
        <https://1145.am/db/2331763/Sr_One>,
        <https://1145.am/db/2336328/Sr_One>,
        <https://1145.am/db/2337571/Sr_One>,
        <https://1145.am/db/2337577/Sr_One>,
        <https://1145.am/db/2340096/Sr_One>,
        <https://1145.am/db/2341904/Sr_One>,
        <https://1145.am/db/2342084/Sr_One>,
        <https://1145.am/db/2342983/Sr_One>,
        <https://1145.am/db/2343301/Sr_One>,
        <https://1145.am/db/2345675/Sr_One>,
        <https://1145.am/db/2347482/Sr_One>,
        <https://1145.am/db/2347594/Sr_One>,
        <https://1145.am/db/2349233/Sr_One>,
        <https://1145.am/db/2350030/Sr_One>,
        <https://1145.am/db/2350364/Sr_One>,
        <https://1145.am/db/2353917/Sr_One>,
        <https://1145.am/db/2356402/Sr_One>,
        <https://1145.am/db/2356411/Sr_One>,
        <https://1145.am/db/2357676/Sr_One>,
        <https://1145.am/db/2357679/Sr_One>,
        <https://1145.am/db/2357682/Sr_One>,
        <https://1145.am/db/2358860/Sr_One>,
        <https://1145.am/db/2359334/Sr_One>,
        <https://1145.am/db/2362533/Sr_One>,
        <https://1145.am/db/2362715/Sr_One>,
        <https://1145.am/db/2363947/Sr_One>,
        <https://1145.am/db/2363950/Sr_One>,
        <https://1145.am/db/2365103/Sr_One>,
        <https://1145.am/db/2365104/Sr_One>,
        <https://1145.am/db/2365105/Sr_One>,
        <https://1145.am/db/2365296/Sr_One>,
        <https://1145.am/db/2365300/Sr_One>,
        <https://1145.am/db/2367549/Sr_One>,
        <https://1145.am/db/2368501/Sr_One>,
        <https://1145.am/db/2371191/Sr_One>,
        <https://1145.am/db/2371304/Sr_One>,
        <https://1145.am/db/2544138/Sr_One>,
        <https://1145.am/db/2544140/Sr_One>,
        <https://1145.am/db/2546216/Sr_One>,
        <https://1145.am/db/2573068/Sr_One>,
        <https://1145.am/db/2595958/Sr_One> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359547/Equity_Capital_Investment_Jennerex_Inc_Transgene_Sa_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-28T16:00:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Transgene Announces a Follow-on Investment in Jennerex, Inc.",
        "Transgene SA (Paris: TNG) , a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announces an additional $ 2.5 million investment in the equity capital of Jennerex, Inc." ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Investment",
        "investment" ;
    ns1:name "Investment",
        "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359547/Jennerex_Inc> ;
    ns1:targetDetails "equity capital" ;
    ns1:targetName "Jennerex, Inc." ;
    ns1:valueRaw "$ 2.5 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2359547/Transgene_Sa> a org:Organization ;
    ns1:basedInHighGeoName "Paris" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2988507/about.rdf> ;
    ns1:basedInHighRaw "Paris" ;
    ns1:description "Biotechnology",
        "immunotherapy products" ;
    ns1:documentDate "2013-05-28T16:00:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Transgene",
        "Transgene SA" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2359547/Equity_Capital_Investment_Jennerex_Inc_Transgene_Sa_Has_Not_Happened> ;
    ns1:name "Transgene",
        "Transgene SA" ;
    ns1:sameAsHigh <https://1145.am/db/2293817/Transgene>,
        <https://1145.am/db/2306960/Transgene_Sa>,
        <https://1145.am/db/2336281/Transgene>,
        <https://1145.am/db/2336864/Transgenomic_Inc>,
        <https://1145.am/db/2357306/Transgenomic_Inc>,
        <https://1145.am/db/2581948/Transgene_Sa>,
        <https://1145.am/db/2593472/Transgenomic_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1932925/Transgene>,
        <https://1145.am/db/1967508/Transgene>,
        <https://1145.am/db/2062962/Transgene>,
        <https://1145.am/db/2153367/Transgene>,
        <https://1145.am/db/2306961/Transgene>,
        <https://1145.am/db/2312344/Transgene>,
        <https://1145.am/db/2324335/Transgene_Sa>,
        <https://1145.am/db/2336284/Transgene>,
        <https://1145.am/db/2336704/Transgene>,
        <https://1145.am/db/2344918/Transgene>,
        <https://1145.am/db/819348/Transgene>,
        <https://1145.am/db/944644/Transgene>,
        <https://1145.am/db/946928/Transgene> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Astrazeneca> a org:Organization ;
    ns1:description "Research" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "AstraZeneca" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "AstraZeneca" ;
    ns1:sameAsHigh <https://1145.am/db/1392122/Astrazeneca>,
        <https://1145.am/db/1539672/Astrazeneca>,
        <https://1145.am/db/1627652/Astrazeneca>,
        <https://1145.am/db/1633177/Astrazeneca>,
        <https://1145.am/db/171176/Astrazeneca>,
        <https://1145.am/db/172070/Astrazeneca>,
        <https://1145.am/db/173169/Astrazeneca>,
        <https://1145.am/db/1988637/Astellas_Pharma_Inc>,
        <https://1145.am/db/2010010/Astellas_Pharma_Inc>,
        <https://1145.am/db/2038202/Astellas_Pharma_Inc>,
        <https://1145.am/db/2041475/Astrazeneca>,
        <https://1145.am/db/2071435/Astrazeneca>,
        <https://1145.am/db/2151794/Astrazeneca>,
        <https://1145.am/db/2154218/Astrazeneca>,
        <https://1145.am/db/2154845/Astellas_Pharma>,
        <https://1145.am/db/2201236/Astrazeneca>,
        <https://1145.am/db/2278880/Astrazeneca>,
        <https://1145.am/db/2279647/Astrazeneca>,
        <https://1145.am/db/2280668/Astrazeneca>,
        <https://1145.am/db/2282580/Astrazeneca>,
        <https://1145.am/db/2282957/Astrazeneca>,
        <https://1145.am/db/2283156/Astrazeneca>,
        <https://1145.am/db/2283309/Astrazeneca>,
        <https://1145.am/db/2284338/Astrazeneca>,
        <https://1145.am/db/2285828/Astrazeneca>,
        <https://1145.am/db/2287488/Astrazeneca>,
        <https://1145.am/db/2290060/Astrazeneca>,
        <https://1145.am/db/2291200/Astellas_Pharma>,
        <https://1145.am/db/2292385/Astellas_Pharma>,
        <https://1145.am/db/2293132/Astrazeneca>,
        <https://1145.am/db/2296196/Astrazeneca>,
        <https://1145.am/db/2299349/Astrazeneca>,
        <https://1145.am/db/2302618/Astellas_Pharma_Inc>,
        <https://1145.am/db/2303415/Astellas_Pharma>,
        <https://1145.am/db/2303920/Astrazeneca>,
        <https://1145.am/db/2304902/Astellas_Pharma>,
        <https://1145.am/db/2305152/Astrazeneca>,
        <https://1145.am/db/2305155/Astrazeneca>,
        <https://1145.am/db/2305826/Astrazeneca>,
        <https://1145.am/db/2305866/Astrazeneca>,
        <https://1145.am/db/2306464/Asterand>,
        <https://1145.am/db/2306905/Astrazeneca>,
        <https://1145.am/db/2307059/Astrazeneca>,
        <https://1145.am/db/2307068/Astrazeneca>,
        <https://1145.am/db/2307834/Astrazeneca>,
        <https://1145.am/db/2307913/Astrazeneca>,
        <https://1145.am/db/2310968/Astellas_Pharma_Inc>,
        <https://1145.am/db/2312088/Astellas_Pharma>,
        <https://1145.am/db/2312476/Astrazeneca>,
        <https://1145.am/db/2318484/Astrazeneca>,
        <https://1145.am/db/2318485/Astrazeneca>,
        <https://1145.am/db/2318609/Astrazeneca>,
        <https://1145.am/db/2319111/Astellas_Pharma>,
        <https://1145.am/db/2319208/Astellas_Pharma>,
        <https://1145.am/db/2319211/Astellas_Pharma_Inc>,
        <https://1145.am/db/2319675/Astrazeneca>,
        <https://1145.am/db/2325196/Astellas_Pharma_Inc>,
        <https://1145.am/db/2327304/Astellas_Pharma_Inc>,
        <https://1145.am/db/2328825/Ascendis_Pharma>,
        <https://1145.am/db/2331796/Astellas_Pharma_Inc>,
        <https://1145.am/db/2334131/Astrazeneca>,
        <https://1145.am/db/2335286/Astrazeneca>,
        <https://1145.am/db/2335717/Astrazeneca>,
        <https://1145.am/db/2339206/Astrazeneca>,
        <https://1145.am/db/2342367/Astellas_Pharma>,
        <https://1145.am/db/2342722/Astrazeneca>,
        <https://1145.am/db/2343632/Astrazeneca>,
        <https://1145.am/db/2343892/Astrazeneca>,
        <https://1145.am/db/2343913/Astrazeneca>,
        <https://1145.am/db/2343920/Astrazeneca>,
        <https://1145.am/db/2344057/Astrazeneca>,
        <https://1145.am/db/2345187/Astrazeneca>,
        <https://1145.am/db/2345375/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345426/Astrazeneca>,
        <https://1145.am/db/2345983/Astrazeneca>,
        <https://1145.am/db/2345996/Astrazeneca>,
        <https://1145.am/db/2347800/Astrazeneca>,
        <https://1145.am/db/2347971/Astrazeneca>,
        <https://1145.am/db/2350134/Astellas_Pharma_Inc>,
        <https://1145.am/db/2352067/Astrazeneca>,
        <https://1145.am/db/2352525/Astrazeneca>,
        <https://1145.am/db/2352532/Astrazeneca>,
        <https://1145.am/db/2353153/Astrazeneca>,
        <https://1145.am/db/2353550/Astrazeneca>,
        <https://1145.am/db/2353551/Astrazeneca>,
        <https://1145.am/db/2354064/Astellas_Pharma_Inc>,
        <https://1145.am/db/2354086/Astellas_Pharma_Inc>,
        <https://1145.am/db/2354112/Astrazeneca>,
        <https://1145.am/db/2354774/Astrazeneca>,
        <https://1145.am/db/2354978/Astrazeneca>,
        <https://1145.am/db/2354998/Astrazeneca>,
        <https://1145.am/db/2355029/Astrazeneca>,
        <https://1145.am/db/2356098/Astrazeneca>,
        <https://1145.am/db/2356384/Astrazeneca>,
        <https://1145.am/db/2356965/Astellas_Pharma_Inc>,
        <https://1145.am/db/2357230/Astrazeneca>,
        <https://1145.am/db/2357962/Astellas_Pharma>,
        <https://1145.am/db/2358193/Astellas_Pharma_Inc>,
        <https://1145.am/db/2358228/Astrazeneca>,
        <https://1145.am/db/2358734/Astellas_Pharma_Inc>,
        <https://1145.am/db/2358768/Astrazeneca>,
        <https://1145.am/db/2359439/Astrazeneca>,
        <https://1145.am/db/2359539/Astrazeneca>,
        <https://1145.am/db/2359745/Astellas_Pharma>,
        <https://1145.am/db/2360237/Astrazeneca>,
        <https://1145.am/db/2360371/Astellas_Pharma>,
        <https://1145.am/db/2360683/Astrazeneca>,
        <https://1145.am/db/2362425/Astellas_Pharma_Inc>,
        <https://1145.am/db/2362667/Astrazeneca>,
        <https://1145.am/db/2362670/Astrazeneca>,
        <https://1145.am/db/2362966/Astrazeneca>,
        <https://1145.am/db/2363405/Astrazeneca>,
        <https://1145.am/db/2364184/Astex_Pharmaceuticals>,
        <https://1145.am/db/2364191/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364805/Astrazeneca>,
        <https://1145.am/db/2365403/Astrazeneca>,
        <https://1145.am/db/2366678/Astellas_Pharma_Inc>,
        <https://1145.am/db/2367645/Astrazeneca>,
        <https://1145.am/db/2367646/Astrazeneca>,
        <https://1145.am/db/2367730/Astellas_Pharma_Inc>,
        <https://1145.am/db/2367731/Astellas_Pharma>,
        <https://1145.am/db/2368632/Astrazeneca>,
        <https://1145.am/db/2368654/Astellas_Pharma>,
        <https://1145.am/db/2368742/Astrazeneca>,
        <https://1145.am/db/2368900/Astrazeneca>,
        <https://1145.am/db/2369491/Astrazeneca>,
        <https://1145.am/db/2369493/Astrazeneca>,
        <https://1145.am/db/2369520/Astellas_Pharma_Inc>,
        <https://1145.am/db/2369607/Astrazeneca>,
        <https://1145.am/db/2370174/Astrazeneca>,
        <https://1145.am/db/2370175/Astrazeneca>,
        <https://1145.am/db/2370409/Astellas_Pharma>,
        <https://1145.am/db/2371094/Astrazeneca>,
        <https://1145.am/db/252780/Astrazeneca>,
        <https://1145.am/db/2537410/Astrazeneca>,
        <https://1145.am/db/2538238/Astrazeneca>,
        <https://1145.am/db/2538239/Astrazeneca>,
        <https://1145.am/db/2538821/Astrazeneca>,
        <https://1145.am/db/2539508/Astrazeneca>,
        <https://1145.am/db/2539509/Astrazeneca>,
        <https://1145.am/db/2539517/Astrazeneca>,
        <https://1145.am/db/2540845/Astrazeneca>,
        <https://1145.am/db/2543372/Astellas_Pharma>,
        <https://1145.am/db/2543375/Astellas_Pharma_Inc>,
        <https://1145.am/db/2543378/Astellas_Pharma>,
        <https://1145.am/db/2544077/Astrazeneca>,
        <https://1145.am/db/2544536/Astrazeneca>,
        <https://1145.am/db/2544701/Astrazeneca>,
        <https://1145.am/db/2545023/Astrazeneca>,
        <https://1145.am/db/2545426/Astrazeneca>,
        <https://1145.am/db/2545610/Astellas_Pharma>,
        <https://1145.am/db/2546143/Astrazeneca>,
        <https://1145.am/db/2546314/Astrazeneca>,
        <https://1145.am/db/2547386/Astrazeneca>,
        <https://1145.am/db/2547785/Astrazeneca>,
        <https://1145.am/db/2548384/Astrazeneca>,
        <https://1145.am/db/2549670/Astellas_Pharma>,
        <https://1145.am/db/2549890/Astrazeneca>,
        <https://1145.am/db/2550962/Astrazeneca>,
        <https://1145.am/db/2551557/Aslan_Pharmaceuticals>,
        <https://1145.am/db/2553162/Astrazeneca>,
        <https://1145.am/db/2553168/Astrazeneca>,
        <https://1145.am/db/2553619/Astellas_Pharma>,
        <https://1145.am/db/2554064/Astrazeneca>,
        <https://1145.am/db/2554571/Astrazeneca>,
        <https://1145.am/db/2554933/Astrazeneca>,
        <https://1145.am/db/2555142/Astrazeneca>,
        <https://1145.am/db/2556522/Astrazeneca>,
        <https://1145.am/db/2556536/Astrazeneca>,
        <https://1145.am/db/2556928/Astrazeneca>,
        <https://1145.am/db/2557406/Astrazeneca>,
        <https://1145.am/db/2558118/Astrazeneca>,
        <https://1145.am/db/2558133/Astellas_Pharma>,
        <https://1145.am/db/2559469/Astrazeneca>,
        <https://1145.am/db/2560865/Astellas_Pharma>,
        <https://1145.am/db/2561319/Astrazeneca>,
        <https://1145.am/db/2562249/Astrazeneca>,
        <https://1145.am/db/2562728/Astrazeneca>,
        <https://1145.am/db/2563422/Astellas_Pharma>,
        <https://1145.am/db/2564897/Astrazeneca>,
        <https://1145.am/db/2565399/Astrazeneca>,
        <https://1145.am/db/2565951/Astrazeneca>,
        <https://1145.am/db/2566037/Astrazeneca>,
        <https://1145.am/db/2566038/Astellas_Pharma>,
        <https://1145.am/db/2566415/Astrazeneca>,
        <https://1145.am/db/2566926/Astrazeneca>,
        <https://1145.am/db/2566929/Astrazeneca>,
        <https://1145.am/db/2567518/Astrazeneca>,
        <https://1145.am/db/2568895/Astrazeneca>,
        <https://1145.am/db/2569075/Astrazeneca_Plc>,
        <https://1145.am/db/2569709/Astrazeneca>,
        <https://1145.am/db/2570586/Astrazeneca>,
        <https://1145.am/db/2570592/Astrazeneca>,
        <https://1145.am/db/257192/Astrazeneca_Plc>,
        <https://1145.am/db/2572938/Astrazeneca>,
        <https://1145.am/db/2573339/Astellas_Pharma>,
        <https://1145.am/db/2573463/Astrazeneca>,
        <https://1145.am/db/2573978/Astrazeneca>,
        <https://1145.am/db/2573984/Astrazeneca>,
        <https://1145.am/db/2574096/Astrazeneca>,
        <https://1145.am/db/2575176/Astrazeneca>,
        <https://1145.am/db/2575183/Astrazeneca>,
        <https://1145.am/db/2575270/Astrazeneca>,
        <https://1145.am/db/257625/Astrazeneca_Plc>,
        <https://1145.am/db/2577419/Astellas_Pharma>,
        <https://1145.am/db/2577797/Astrazeneca>,
        <https://1145.am/db/2578213/Astrazeneca>,
        <https://1145.am/db/2578454/Astrazeneca>,
        <https://1145.am/db/2579507/Astrazeneca>,
        <https://1145.am/db/2579630/Astrazeneca>,
        <https://1145.am/db/2580038/Astrazeneca>,
        <https://1145.am/db/2580053/Astrazeneca>,
        <https://1145.am/db/2580491/Astrazeneca>,
        <https://1145.am/db/2580556/Astrazeneca>,
        <https://1145.am/db/2580632/Astrazeneca>,
        <https://1145.am/db/2580642/Astrazeneca>,
        <https://1145.am/db/2582242/Astrazeneca>,
        <https://1145.am/db/2583124/Astrazeneca>,
        <https://1145.am/db/2583402/Astellas_Pharma>,
        <https://1145.am/db/2585866/Astrazeneca_Kk>,
        <https://1145.am/db/2586257/Astrazeneca>,
        <https://1145.am/db/2587500/Astrazeneca>,
        <https://1145.am/db/2588049/Astrazeneca>,
        <https://1145.am/db/2590009/Astrazeneca>,
        <https://1145.am/db/2590159/Astellas_Pharma_Inc>,
        <https://1145.am/db/2591384/Astrazeneca>,
        <https://1145.am/db/2591652/Astrazeneca>,
        <https://1145.am/db/2591691/Astrazeneca>,
        <https://1145.am/db/2592696/Astrazeneca>,
        <https://1145.am/db/2593265/Astrazeneca>,
        <https://1145.am/db/2594107/Astrazeneca>,
        <https://1145.am/db/2594183/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594184/Astex_Pharmaceuticals>,
        <https://1145.am/db/2594365/Astrazeneca>,
        <https://1145.am/db/2594602/Astellas_Pharma>,
        <https://1145.am/db/2595368/Astellas_Pharma>,
        <https://1145.am/db/2595413/Astellas_Pharma_Inc>,
        <https://1145.am/db/2595981/Astrazeneca>,
        <https://1145.am/db/2596046/Astrazeneca>,
        <https://1145.am/db/2596053/Astrazeneca>,
        <https://1145.am/db/2596838/Astex_Pharmaceuticals>,
        <https://1145.am/db/2597175/Astrazeneca>,
        <https://1145.am/db/2597935/Astellas_Pharma>,
        <https://1145.am/db/2789987/Astrazeneca>,
        <https://1145.am/db/340451/Astrazeneca>,
        <https://1145.am/db/340474/Astrazeneca>,
        <https://1145.am/db/381681/Astrazeneca_Plc>,
        <https://1145.am/db/488413/Astrazeneca>,
        <https://1145.am/db/510316/Astrazeneca>,
        <https://1145.am/db/624169/Astrazeneca> ;
    ns1:sameAsMedium <https://1145.am/db/1180597/Astrazeneca>,
        <https://1145.am/db/1241325/Astrazeneca>,
        <https://1145.am/db/1536697/Astrazeneca>,
        <https://1145.am/db/2280289/Astrazeneca>,
        <https://1145.am/db/2282916/Astrazeneca>,
        <https://1145.am/db/2290860/Astrazeneca>,
        <https://1145.am/db/2291860/Astrazeneca>,
        <https://1145.am/db/2294263/Astrazeneca>,
        <https://1145.am/db/2309183/Astrazeneca>,
        <https://1145.am/db/2315716/Astrazeneca>,
        <https://1145.am/db/2316364/Astrazeneca>,
        <https://1145.am/db/2329585/Astrazeneca>,
        <https://1145.am/db/2331622/Astrazeneca>,
        <https://1145.am/db/2336050/Astrazeneca>,
        <https://1145.am/db/2340097/Astrazeneca>,
        <https://1145.am/db/2342213/Astrazeneca>,
        <https://1145.am/db/2347970/Astrazeneca>,
        <https://1145.am/db/2352716/Astrazeneca>,
        <https://1145.am/db/2353753/Astrazeneca>,
        <https://1145.am/db/2359437/Astrazeneca>,
        <https://1145.am/db/2539787/Astrazeneca>,
        <https://1145.am/db/2545184/Astrazeneca>,
        <https://1145.am/db/2545769/Astrazeneca>,
        <https://1145.am/db/2555141/Astrazeneca>,
        <https://1145.am/db/2559649/Astrazeneca>,
        <https://1145.am/db/2565682/Astrazeneca>,
        <https://1145.am/db/2575269/Astrazeneca>,
        <https://1145.am/db/2582823/Astrazeneca>,
        <https://1145.am/db/2582826/Astrazeneca>,
        <https://1145.am/db/2585819/Astrazeneca>,
        <https://1145.am/db/2588089/Astrazeneca>,
        <https://1145.am/db/2588660/Astrazeneca>,
        <https://1145.am/db/2598202/Astrazeneca>,
        <https://1145.am/db/347044/Astrazeneca>,
        <https://1145.am/db/376382/Astrazeneca> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Investment_Astrazeneca_Fox_Foundation_For_Parkinsons_Research_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Fox Foundation for Parkinson's Research awarded AstraZeneca a $ 465,000 grant to support research on levodopa-induced dyskinesias, a complication of therapies commonly used to reduce Parkinson's disease symptoms." ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "grant" ;
    ns1:name "grant" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360562/Astrazeneca> ;
    ns1:valueRaw "$ 465,000" ;
    ns1:whereGeoName "Kingdom of Belgium" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:whereRaw "Belgium" .

<https://1145.am/db/2360562/Investment_Ophthotech_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "@ FierceBiotech: GSK buys Okairos (Fierce 15 profile) for $ 325M, strengthens vaccines biz.",
        "@ JohnCFierce: Novo spearheads $ 175M financing to back Ophthotech's PhIII AMD study." ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360562/Okairos>,
        <https://1145.am/db/2360562/Ophthotech> ;
    ns1:targetName "Okairos" ;
    ns1:valueRaw "$ 175M" ;
    ns1:whereRaw "no other information" .

<https://1145.am/db/2360562/Okairos_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "@ FierceBiotech: GSK buys Okairos (Fierce 15 profile) for $ 325M, strengthens vaccines biz." ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "buys" ;
    ns1:name "buys" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360562/Okairos> ;
    ns1:targetName "Okairos" ;
    ns1:valueRaw "$ 325M" ;
    ns1:vendor <https://1145.am/db/2360562/Ophthotech> ;
    ns1:whereRaw "no other information" .

<https://1145.am/db/2360647/Labrys_Biologics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:buyer <https://1145.am/db/2360647/Series_A_Acquisition_Labrys_Biologics_Inc_Pfizer_Inc_Completed> ;
    ns1:description "pharmaceutical",
        "pharmaceuticals" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "Labrys",
        "Labrys Biologics Inc." ;
    ns1:investor <https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> ;
    ns1:name "Labrys Biologics",
        "Labrys Biologics Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2339763/Labrys_Biologics> ;
    ns1:sameAsMedium <https://1145.am/db/2342533/Labrys_Biologics>,
        <https://1145.am/db/2342540/Labrys_Biologics>,
        <https://1145.am/db/2343910/Labrys_Biologics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Series_A_Acquisition_Labrys_Biologics_Inc_Pfizer_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ - Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $ 31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures." ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "acquired" ;
    ns1:name "acquired" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 31 Million" ;
    ns1:vendor <https://1145.am/db/2360647/Pfizer_Inc> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2360667/Aeris_Capital_Ag> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "Aeris Capital AG" ;
    ns1:investor <https://1145.am/db/2360667/License_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> ;
    ns1:name "Aeris Capital AG" ;
    ns1:sameAsMedium <https://1145.am/db/1697327/Aeris_Capital>,
        <https://1145.am/db/1730217/Aeris_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1860817/Aeris_Capital>,
        <https://1145.am/db/2293308/Aeris_Capital_Ag>,
        <https://1145.am/db/2308420/Aeris_Capital>,
        <https://1145.am/db/2308423/Aeris_Capital_Ag>,
        <https://1145.am/db/2308429/Aeris_Capital_Ag>,
        <https://1145.am/db/2326926/Aeris_Capital>,
        <https://1145.am/db/2326935/Aeris_Capital>,
        <https://1145.am/db/2337043/Aeris_Capital>,
        <https://1145.am/db/2349519/Aeris_Capital_Ag>,
        <https://1145.am/db/2575687/Aeris_Capital_Ag> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361581/Johnson___Johnson_Development_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Menlo Park, Calif" ;
    ns1:description "Venture Investments" ;
    ns1:documentDate "2013-06-04T11:33:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagonist Therapeutics Raises $14 Million in Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/protagonist-therapeutics-raises-14-million-series-b-venture-financing> ;
    ns1:foundName "Johnson & Johnson Development Corporation" ;
    ns1:investor <https://1145.am/db/2361581/Venture_Investment_Johnson___Johnson_Development_Corporation_Lilly_Ventures_Protagonist_Therapeutics_Starfish_Ventures_Completed> ;
    ns1:name "Johnson & Johnson Development Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1118732/Johnson___Johnson_Innovation>,
        <https://1145.am/db/1553175/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/1553459/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/1620209/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/2095032/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2196895/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2284205/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2300306/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308791/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311069/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311075/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336890/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337577/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344597/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352361/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358640/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358658/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358812/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2363907/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2546216/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/768105/Johnson_And_Johnson_Innovation-Jjdc_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1883008/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2291836/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292334/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292353/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292975/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2299864/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2300455/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2303009/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2306163/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308781/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316619/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316624/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2317934/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2321856/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327212/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327227/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336943/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337571/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338236/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338237/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338527/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2341478/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344605/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2346978/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2350327/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352357/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2356290/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364458/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2365296/Johnson___Johnson_Development_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361581/Lilly_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Menlo Park, Calif" ;
    ns1:documentDate "2013-06-04T11:33:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagonist Therapeutics Raises $14 Million in Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/protagonist-therapeutics-raises-14-million-series-b-venture-financing> ;
    ns1:foundName "Lilly Ventures" ;
    ns1:investor <https://1145.am/db/2361581/Venture_Investment_Johnson___Johnson_Development_Corporation_Lilly_Ventures_Protagonist_Therapeutics_Starfish_Ventures_Completed> ;
    ns1:name "Lilly Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301739/Lilly_Ventures>,
        <https://1145.am/db/2317455/Lilly_Ventures>,
        <https://1145.am/db/2318733/Lilly_Ventures>,
        <https://1145.am/db/2319777/Lilly_Ventures>,
        <https://1145.am/db/2320082/Lilly_Ventures>,
        <https://1145.am/db/2322022/Lilly_Ventures>,
        <https://1145.am/db/2322984/Lilly_Ventures>,
        <https://1145.am/db/2323003/Lilly_Ventures>,
        <https://1145.am/db/2324042/Lilly_Ventures>,
        <https://1145.am/db/2326222/Lilly_Ventures>,
        <https://1145.am/db/2327441/Lilly_Ventures>,
        <https://1145.am/db/2327442/Lilly_Ventures>,
        <https://1145.am/db/2332864/Lilly_Ventures>,
        <https://1145.am/db/2332868/Lilly_Ventures>,
        <https://1145.am/db/2336328/Lilly_Ventures>,
        <https://1145.am/db/2339666/Lilly_Ventures>,
        <https://1145.am/db/2340096/Lilly_Ventures>,
        <https://1145.am/db/2340942/Lilly_Ventures>,
        <https://1145.am/db/2343723/Lilly_Ventures>,
        <https://1145.am/db/2343724/Lilly_Ventures>,
        <https://1145.am/db/2347682/Lilly_Ventures>,
        <https://1145.am/db/2348448/Lilly_Ventures>,
        <https://1145.am/db/2352414/Lilly_Ventures>,
        <https://1145.am/db/2353439/Lilly_Ventures>,
        <https://1145.am/db/2355586/Lilly_Ventures>,
        <https://1145.am/db/2356048/Lilly_Ventures>,
        <https://1145.am/db/2357676/Lilly_Ventures>,
        <https://1145.am/db/2357679/Lilly_Ventures>,
        <https://1145.am/db/2357682/Lilly_Ventures>,
        <https://1145.am/db/2362715/Lilly_Ventures>,
        <https://1145.am/db/2363396/Lilly_Ventures>,
        <https://1145.am/db/2368240/Lilly_Ventures>,
        <https://1145.am/db/2368322/Lilly_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361581/Protagonist_Therapeutics> a org:Organization ;
    ns1:description "Discovery and development of oral di-sulfide rich peptide (DRP)" ;
    ns1:documentDate "2013-06-04T11:33:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Protagonist Therapeutics Raises $14 Million in Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/protagonist-therapeutics-raises-14-million-series-b-venture-financing> ;
    ns1:foundName "Protagonist Therapeutics",
        "Protagonist Therapeutics, Inc." ;
    ns1:name "Protagonist Therapeutics" ;
    ns1:sameAsMedium <https://1145.am/db/1471957/Protagonist_Therapeutics>,
        <https://1145.am/db/2298501/Protagonist_Therapeutics>,
        <https://1145.am/db/2298906/Protagonist_Therapeutics>,
        <https://1145.am/db/2354196/Protagonist_Therapeutics>,
        <https://1145.am/db/2360582/Protagonist_Therapeutics>,
        <https://1145.am/db/2368322/Protagonist_Therapeutics>,
        <https://1145.am/db/2370074/Protagonist_Therapeutics>,
        <https://1145.am/db/2370139/Protagonist_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Edge_Therapeutics> a org:Organization ;
    ns1:description "developing hospital products for acute, fatal or debilitating conditions" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "Edge Therapeutics" ;
    ns1:industry "biotech" ;
    ns1:name "Edge Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1592216/Edgewise_Therapeutics>,
        <https://1145.am/db/1594546/Edgewise_Therapeutics>,
        <https://1145.am/db/1926501/Edgewise_Therapeutics_Inc>,
        <https://1145.am/db/2345037/Edge_Therapeutics>,
        <https://1145.am/db/2345047/Edge_Therapeutics>,
        <https://1145.am/db/2352119/Edge_Therapeutics>,
        <https://1145.am/db/2354749/Edge_Therapeutics>,
        <https://1145.am/db/2356063/Edge_Therapeutics>,
        <https://1145.am/db/2363327/Edge_Therapeutics>,
        <https://1145.am/db/2363565/Edge_Therapeutics>,
        <https://1145.am/db/2364625/Edge_Therapeutics_Inc>,
        <https://1145.am/db/2364648/Edge_Therapeutics>,
        <https://1145.am/db/2367657/Edge_Therapeutics>,
        <https://1145.am/db/2569522/Edge_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2356099/Edge_Therapeutics>,
        <https://1145.am/db/2370794/Edge_Therapeutics>,
        <https://1145.am/db/2569520/Edge_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Ipo_Lincoln_Park_Capital_Fund_Stemcells_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Newark, CA - based StemCells ($ STEM) forged a deal to sell up to $ 30 million in shares to Lincoln Park Capital Fund." ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "sell" ;
    ns1:name "sell" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:valueRaw "$ 30 million" ;
    ns1:vendor <https://1145.am/db/2361595/Stemcells> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2361595/Neurelis> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "San Diego" ;
    ns1:description "developing treatments for epilepsy and other CNS disorders" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "Neurelis" ;
    ns1:name "Neurelis" ;
    ns1:sameAsHigh <https://1145.am/db/2361597/Neurelis> ;
    ns1:sameAsMedium <https://1145.am/db/1398056/Neurelis>,
        <https://1145.am/db/402604/Neurelis>,
        <https://1145.am/db/556200/Neurelis> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Neurelis_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Finland's Biotie Therapies has snagged an option to acquire San Diego - based Neurelis, which is developing treatments for epilepsy and other CNS disorders." ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2361595/Neurelis> ;
    ns1:targetName "Neurelis" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "San Diego" .

<https://1145.am/db/2361595/Protagonist> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "Protagonist" ;
    ns1:industry "biotech" ;
    ns1:name "Protagonist" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Stemcells_Ipo> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Newark, CA - based StemCells ($ STEM) forged a deal to sell up to $ 30 million in shares to Lincoln Park Capital Fund." ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "sell" ;
    ns1:name "sell" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2361595/Stemcells> ;
    ns1:targetName "StemCells" ;
    ns1:valueRaw "$ 30 million" ;
    ns1:whereGeoName "Newark" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5376803/about.rdf> ;
    ns1:whereRaw "Newark, CA" .

<https://1145.am/db/2361625/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "Conn" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "Domain Associates",
        "Domain Associates, LLC" ;
    ns1:industry "venture capital" ;
    ns1:investor <https://1145.am/db/2361625/Series_C_Investment_Canaan_Partners_Sofinnova_Ventures_Domain_Associates_Foundation_Medical_Partners_Marinus_Pharmaceuticals_Inc_Rusnanomedinvest_Has_Not_Happened> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsHigh <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates> ;
    ns1:sameAsMedium <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2343206/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361625/Marinus_Pharmaceuticals_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Branford" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5283054/about.rdf> ;
    ns1:basedInHighRaw "Branford, Conn." ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "Marinus Pharmaceuticals",
        "Marinus Pharmaceuticals Inc.",
        "Marinus Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals",
        "pharmaceuticals" ;
    ns1:name "Marinus Pharmaceuticals",
        "Marinus Pharmaceuticals Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1204338/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1205672/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1299981/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1306144/Marinus_Pharmaceuticals_Inc>,
        <https://1145.am/db/1459836/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1459919/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1481404/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1481598/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1482300/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1482813/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1657520/Marinus_Pharmaceuticals>,
        <https://1145.am/db/1972628/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2010962/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2303707/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2313171/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2313183/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2356096/Marinus_Pharmaceuticals>,
        <https://1145.am/db/2368367/Marinus_Pharmaceuticals>,
        <https://1145.am/db/944325/Marinus_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2322231/Marinus_Pharmaceutical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362715/Aileron_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Aileron Therapeutics",
        "Aileron Therapeutics, Inc." ;
    ns1:name "Aileron Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2317929/Aileron_Therapeutics>,
        <https://1145.am/db/2320769/Aileron_Therapeutics>,
        <https://1145.am/db/2320778/Aileron>,
        <https://1145.am/db/2323228/Aileron_Therapeutics>,
        <https://1145.am/db/2326222/Aileron_Therapeutics>,
        <https://1145.am/db/2326231/Aileron>,
        <https://1145.am/db/2336328/Aileron_Therapeutics>,
        <https://1145.am/db/2336330/Aileron_Therapeutics>,
        <https://1145.am/db/2356882/Aileron_Therapeutics>,
        <https://1145.am/db/2365078/Aileron_Therapeutics>,
        <https://1145.am/db/709602/Aileron_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/1057188/Aileron_Therapeutics>,
        <https://1145.am/db/2323692/Aileron_Therapeutics>,
        <https://1145.am/db/2342638/Aileron_Therapeutics>,
        <https://1145.am/db/2356071/Aileron_Therapeutics>,
        <https://1145.am/db/2356099/Aileron_Therapeutics>,
        <https://1145.am/db/2356862/Aileron_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362715/Lilly_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Lilly Ventures" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "Lilly Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301739/Lilly_Ventures>,
        <https://1145.am/db/2317455/Lilly_Ventures>,
        <https://1145.am/db/2318733/Lilly_Ventures>,
        <https://1145.am/db/2319777/Lilly_Ventures>,
        <https://1145.am/db/2320082/Lilly_Ventures>,
        <https://1145.am/db/2322022/Lilly_Ventures>,
        <https://1145.am/db/2322984/Lilly_Ventures>,
        <https://1145.am/db/2323003/Lilly_Ventures>,
        <https://1145.am/db/2324042/Lilly_Ventures>,
        <https://1145.am/db/2326222/Lilly_Ventures>,
        <https://1145.am/db/2327441/Lilly_Ventures>,
        <https://1145.am/db/2327442/Lilly_Ventures>,
        <https://1145.am/db/2332864/Lilly_Ventures>,
        <https://1145.am/db/2332868/Lilly_Ventures>,
        <https://1145.am/db/2336328/Lilly_Ventures>,
        <https://1145.am/db/2339666/Lilly_Ventures>,
        <https://1145.am/db/2340096/Lilly_Ventures>,
        <https://1145.am/db/2340942/Lilly_Ventures>,
        <https://1145.am/db/2343723/Lilly_Ventures>,
        <https://1145.am/db/2343724/Lilly_Ventures>,
        <https://1145.am/db/2347682/Lilly_Ventures>,
        <https://1145.am/db/2348448/Lilly_Ventures>,
        <https://1145.am/db/2352414/Lilly_Ventures>,
        <https://1145.am/db/2353439/Lilly_Ventures>,
        <https://1145.am/db/2355586/Lilly_Ventures>,
        <https://1145.am/db/2356048/Lilly_Ventures>,
        <https://1145.am/db/2357676/Lilly_Ventures>,
        <https://1145.am/db/2357679/Lilly_Ventures>,
        <https://1145.am/db/2357682/Lilly_Ventures>,
        <https://1145.am/db/2361581/Lilly_Ventures>,
        <https://1145.am/db/2363396/Lilly_Ventures>,
        <https://1145.am/db/2368240/Lilly_Ventures>,
        <https://1145.am/db/2368322/Lilly_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362715/Sr_One> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "SR",
        "SR One" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "SR One" ;
    ns1:sameAsMedium <https://1145.am/db/1169952/Sr_One>,
        <https://1145.am/db/1334624/Sr_One>,
        <https://1145.am/db/1949427/Sr_One>,
        <https://1145.am/db/2095130/Sr_One>,
        <https://1145.am/db/2110113/Sr_One>,
        <https://1145.am/db/2280707/Sr_One>,
        <https://1145.am/db/2305791/Sr_One>,
        <https://1145.am/db/2317934/Sr_One>,
        <https://1145.am/db/2317951/Sr_One>,
        <https://1145.am/db/2318310/Sr_One>,
        <https://1145.am/db/2326222/Sr_One_Ltd>,
        <https://1145.am/db/2327305/Sr_One>,
        <https://1145.am/db/2327488/Sr_One_Ltd>,
        <https://1145.am/db/2331763/Sr_One>,
        <https://1145.am/db/2336328/Sr_One>,
        <https://1145.am/db/2337571/Sr_One>,
        <https://1145.am/db/2337577/Sr_One>,
        <https://1145.am/db/2340096/Sr_One>,
        <https://1145.am/db/2341904/Sr_One>,
        <https://1145.am/db/2342084/Sr_One>,
        <https://1145.am/db/2342983/Sr_One>,
        <https://1145.am/db/2343301/Sr_One>,
        <https://1145.am/db/2345675/Sr_One>,
        <https://1145.am/db/2347482/Sr_One>,
        <https://1145.am/db/2347594/Sr_One>,
        <https://1145.am/db/2349233/Sr_One>,
        <https://1145.am/db/2350030/Sr_One>,
        <https://1145.am/db/2350364/Sr_One>,
        <https://1145.am/db/2353917/Sr_One>,
        <https://1145.am/db/2356402/Sr_One>,
        <https://1145.am/db/2356411/Sr_One>,
        <https://1145.am/db/2357676/Sr_One>,
        <https://1145.am/db/2357679/Sr_One>,
        <https://1145.am/db/2357682/Sr_One>,
        <https://1145.am/db/2358430/Sr_One>,
        <https://1145.am/db/2358860/Sr_One>,
        <https://1145.am/db/2359334/Sr_One>,
        <https://1145.am/db/2362533/Sr_One>,
        <https://1145.am/db/2363947/Sr_One>,
        <https://1145.am/db/2363950/Sr_One>,
        <https://1145.am/db/2365103/Sr_One>,
        <https://1145.am/db/2365104/Sr_One>,
        <https://1145.am/db/2365105/Sr_One>,
        <https://1145.am/db/2365296/Sr_One>,
        <https://1145.am/db/2365300/Sr_One>,
        <https://1145.am/db/2367549/Sr_One>,
        <https://1145.am/db/2368501/Sr_One>,
        <https://1145.am/db/2371191/Sr_One>,
        <https://1145.am/db/2371304/Sr_One>,
        <https://1145.am/db/2544138/Sr_One>,
        <https://1145.am/db/2544140/Sr_One>,
        <https://1145.am/db/2546216/Sr_One>,
        <https://1145.am/db/2573068/Sr_One>,
        <https://1145.am/db/2595958/Sr_One> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/New_Leaf_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Redwood City, CA" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "New Leaf Venture Partners" ;
    ns1:investor <https://1145.am/db/2362736/C_Investment_Advent_Venture_Partners_Aisling_Capital_Index_Ventures_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "New Leaf Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1287338/New_Leaf_Venture_Partners>,
        <https://1145.am/db/1749104/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2151983/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2155668/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2208603/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2289585/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2293765/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2298642/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2300322/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301824/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301828/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305507/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305514/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2307682/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2311595/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2312792/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315071/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315932/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315934/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2316674/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2317919/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318656/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318657/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325326/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325398/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334479/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334797/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2341003/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342925/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342937/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2343298/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345037/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345047/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346532/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346542/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347043/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347571/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347876/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347878/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348149/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348618/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2349120/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350164/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350167/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350491/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2352059/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2357356/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2359683/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2360174/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2361416/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362737/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2366860/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2569522/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2594141/New_Leaf_Venture_Partners>,
        <https://1145.am/db/425953/New_Leaf_Venture_Partners>,
        <https://1145.am/db/583528/New_Leaf_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362737/New_Leaf_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "REDWOOD CITY, CA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "New Leaf Venture Partners" ;
    ns1:investor <https://1145.am/db/2362737/Series_C_Investment_Aisling_Capital_Index_Ventures_Life_Sciences_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "New Leaf Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1749104/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2151983/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2182517/New_Mountain_Capital>,
        <https://1145.am/db/2301824/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305507/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2312792/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325326/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2325398/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334797/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342925/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2342937/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2343298/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347043/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347571/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347876/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348618/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2359683/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2360174/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2361416/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2594141/New_Leaf_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1287338/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2155668/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2208603/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2289585/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2293765/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2298642/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2300322/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2301828/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2305514/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2307682/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2311595/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315071/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315932/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2315934/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2316674/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2317919/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318656/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2318657/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2334479/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2341003/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345037/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2345047/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346532/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2346542/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2347878/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2348149/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2349120/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350164/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350167/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2350491/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2352059/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2357356/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2362736/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2366860/New_Leaf_Venture_Partners>,
        <https://1145.am/db/2569522/New_Leaf_Venture_Partners>,
        <https://1145.am/db/425953/New_Leaf_Venture_Partners>,
        <https://1145.am/db/583528/New_Leaf_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364600/Investment_Index_Ventures_Xo1_Ltd_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-17T04:00:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cambridge, U.K., Monday, June 17, 2013: A newly-formed biotechnology company, XO1 Ltd, announced today that it has raised $ 11million to develop a novel anticoagulant drug that has the potential to prevent heart attack and stroke without causing bleeding - thereby saving millions of lives.",
        "XO1 Ltd raises $ 11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs." ;
    ns1:documentTitle "XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xo1-ltd-raises-11-million-from-index-ventures-to-develop-holy-grail-of-anticoagulant-drugs> ;
    ns1:foundName "raised",
        "raises" ;
    ns1:name "raised",
        "raises" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2364600/Xo1_Ltd> ;
    ns1:valueRaw "$ 11 million",
        "$ 11million" ;
    ns1:when "2013-06-17T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 17, 2013" ;
    ns1:whereGeoName "Commonwealth of Australia" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2077456/about.rdf> ;
    ns1:whereRaw "Australia" .

<https://1145.am/db/2364600/Xo1_Ltd> a org:Organization ;
    ns1:description "life science companies" ;
    ns1:documentDate "2013-06-17T04:00:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xo1-ltd-raises-11-million-from-index-ventures-to-develop-holy-grail-of-anticoagulant-drugs> ;
    ns1:foundName "XO1 Ltd" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "XO1 Ltd" ;
    ns1:sameAsMedium <https://1145.am/db/2340122/Xo1>,
        <https://1145.am/db/2354178/Xo1_Ltd>,
        <https://1145.am/db/2364597/Xo1> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2536483/Althea_Technologies> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:description "biopharmaceutical development and manufacturing services" ;
    ns1:documentDate "2013-03-06T13:34:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/ajinomoto-co-inc-agrees-to-acquire-althea-technologies-inc> ;
    ns1:foundName "Althea Technologies",
        "Althea Technologies, Inc." ;
    ns1:industry "biopharmaceutical development and manufacturing services" ;
    ns1:name "Althea Technologies" ;
    ns1:sameAsHigh <https://1145.am/db/1180905/Tyme_Technologies>,
        <https://1145.am/db/1181453/Tyme_Technologies>,
        <https://1145.am/db/1348218/Tyme_Technologies>,
        <https://1145.am/db/1349294/Tyme_Technologies>,
        <https://1145.am/db/2340775/Althea>,
        <https://1145.am/db/2349915/Althea_Technologies> ;
    ns1:sameAsMedium <https://1145.am/db/2302151/Althea_Technologies>,
        <https://1145.am/db/2340776/Althea_Technologies>,
        <https://1145.am/db/2584510/Althea_Technologies> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2536483/Althea_Technologies_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-03-06T13:34:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.",
        "SAN DIEGO, March 6, 2013 - Ajinomoto Co., Inc. (\"Ajinomoto Co.\"; TYO: 2802) and Althea Technologies, Inc. (\"Althea Technologies\") , announced today that they have entered into a definitive agreement by which Ajinomoto Co. will acquire Althea Technologies, a leading provider of biopharmaceutical development and manufacturing services, subject to the terms of the definitive agreement (including the satisfaction of customary closing conditions) ." ;
    ns1:documentTitle "Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/ajinomoto-co-inc-agrees-to-acquire-althea-technologies-inc> ;
    ns1:foundName "Acquire",
        "acquire" ;
    ns1:name "Acquire",
        "acquire" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2536483/Althea_Technologies> ;
    ns1:targetName "Althea Technologies" ;
    ns1:whereGeoName "San Diego County",
        "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf>,
        <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "SAN DIEGO",
        "United States" .

<https://1145.am/db/2536882/Althea> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "San Diego" ;
    ns1:description "production of microbial-derived recombinant proteins and plasmid DNA" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "Althea Technologies" ;
    ns1:industry "biotechnology" ;
    ns1:name "Althea" ;
    ns1:sameAsMedium <https://1145.am/db/1048903/Althea>,
        <https://1145.am/db/2340775/Althea> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2536882/Investment_Ajinomoto_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Japan's conglomerate Ajinomoto is giving its pharmaceutical operations a double boost of investment." ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Peoples Republic of China" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:whereRaw "China" .

<https://1145.am/db/2537461/Genmab_Antibody_Plant> a org:Organization ;
    ns1:basedInHighGeoName "Brooklyn Park" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5019335/about.rdf> ;
    ns1:basedInHighRaw "Brooklyn Park, MN" ;
    ns1:documentDate "2013-04-17T14:27:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Baxter to put $300M into old Genmab plant" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/baxter-to-put-300m-into-old-genmab-plant> ;
    ns1:foundName "Genmab antibody plant" ;
    ns1:name "Genmab antibody plant" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2562245/Cambridge_Major_Laboratories_Inc> a org:Organization ;
    ns1:basedInLowRaw "BETHESDA, Md." ;
    ns1:description "complex chemistry - based outsourcing services to the pharmaceutical and biotechnology industries" ;
    ns1:documentDate "2013-01-15T13:12:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "American Capital Commits $212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/american-capital-commits-212-million-one-stop-buyout%C2%AE-of-cambridge-major-laboratories> ;
    ns1:foundName "Cambridge Major Laboratories, Inc",
        "Cambridge Major Laboratories, Inc." ;
    ns1:industry "pharmaceutical and biotechnology" ;
    ns1:name "Cambridge Major Laboratories",
        "Cambridge Major Laboratories, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2303690/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2323097/Cambridge_Biotechnology>,
        <https://1145.am/db/2362605/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2543464/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2543471/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2544488/Cambridge_Major_Laboratories> ;
    ns1:sameAsMedium <https://1145.am/db/2307566/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2547546/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2562248/Cambridge_Major_Laboratories>,
        <https://1145.am/db/2562410/Cambridge_Major_Laboratories> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2562245/One_Stop_Buyout> a org:Organization ;
    ns1:basedInLowRaw "BETHESDA" ;
    ns1:description "Buying out a company" ;
    ns1:documentDate "2013-01-15T13:12:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "American Capital Commits $212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/american-capital-commits-212-million-one-stop-buyout%C2%AE-of-cambridge-major-laboratories> ;
    ns1:foundName "One Stop" ;
    ns1:name "One Stop Buyout" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2562245/One_Stop_Buyout_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-15T13:12:31+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BETHESDA, Md., Dec. 27,2012- American Capital, Ltd. (Nasdaq: ACAS) (\"American Capital\") announced today that it has committed $ 212 million in the One Stop Buyout of Cambridge Major Laboratories, Inc. (\"CML\" or the \"Company\") , a leading global provider of complex chemistry - based outsourcing services to the pharmaceutical and biotechnology industries." ;
    ns1:documentTitle "American Capital Commits $212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/american-capital-commits-212-million-one-stop-buyout%C2%AE-of-cambridge-major-laboratories> ;
    ns1:foundName "Buyout",
        "committed" ;
    ns1:name "Buyout",
        "committed" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2562245/One_Stop_Buyout> ;
    ns1:targetName "One Stop Buyout" ;
    ns1:valueRaw "$ 212 million" ;
    ns1:whenRaw "2012" .

<https://1145.am/db/2575687/Aeris_Capital_Ag> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "Aeris Capital AG" ;
    ns1:investor <https://1145.am/db/2575687/License_Investment_Aeris_Capital_Ag_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened>,
        <https://1145.am/db/2575687/Series_A_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_Venbio_Completed> ;
    ns1:name "Aeris Capital AG" ;
    ns1:sameAsMedium <https://1145.am/db/1697327/Aeris_Capital>,
        <https://1145.am/db/1730217/Aeris_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1860817/Aeris_Capital>,
        <https://1145.am/db/2293308/Aeris_Capital_Ag>,
        <https://1145.am/db/2308420/Aeris_Capital>,
        <https://1145.am/db/2308423/Aeris_Capital_Ag>,
        <https://1145.am/db/2308429/Aeris_Capital_Ag>,
        <https://1145.am/db/2326926/Aeris_Capital>,
        <https://1145.am/db/2326935/Aeris_Capital>,
        <https://1145.am/db/2337043/Aeris_Capital>,
        <https://1145.am/db/2349519/Aeris_Capital_Ag>,
        <https://1145.am/db/2360667/Aeris_Capital_Ag> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2577010/Echo_Pharma_Acquisition_Limited> a org:Organization ;
    ns1:basedInLowRaw "Irish" ;
    ns1:buyer <https://1145.am/db/2577010/Elan_Corporation_Acquisition> ;
    ns1:description "acquiring" ;
    ns1:documentDate "2013-04-15T13:54:27+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "Echo Pharma Acquisition Limited" ;
    ns1:name "Echo Pharma Acquisition Limited" ;
    ns1:sameAsHigh <https://1145.am/db/2349078/Echo_Pharma_Acquisition_Limited>,
        <https://1145.am/db/2351145/Echo_Pharma_Acquisition_Limited>,
        <https://1145.am/db/2363656/Echo_Pharma_Acquisition_Limited> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2577010/Elan_Corporation_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-04-15T13:54:27+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW YORK, April 15, 2013 /PRNewswire/ - Echo Pharma Acquisition Limited (\"Royalty Pharma\") today announced, pursuant to Rule 2.5 of the Irish take over Rules (the \"Announcement\") , the terms of a firm, all cash offer (the \"Offer\") for the entire issued and to be issued share capital of Elan Corporation, plc (\"Elan\") (NYSE: ELN) ." ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "offer" ;
    ns1:name "offer" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2577010/Elan_Corporation> ;
    ns1:targetName "Elan Corporation" ;
    ns1:whereGeoName "Irish" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5983801/about.rdf> ;
    ns1:whereRaw "Irish" .

<https://1145.am/db/2580543/Arcturus_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "San Diego" ;
    ns1:description "RNAi Delivery Technologies",
        "RNAi technologies for the treatment of disease" ;
    ns1:documentDate "2013-06-04T20:18:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ARCTURUS THERAPEUTICS RAISES $1.3 MILLION IN SERIES SEED FUNDING" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/arcturus-therapeutics-raises-1-3-million-series-seed-funding> ;
    ns1:foundName "ARCTURUS THERAPEUTICS",
        "Arcturus Therapeutics, Inc." ;
    ns1:name "ARCTURUS",
        "Arcturus Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1334444/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/1334495/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/1622317/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/1622994/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2300987/Arcturus_Therapeutics>,
        <https://1145.am/db/2319925/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2325198/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2335806/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2337777/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2338548/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2342632/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2344792/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2345890/Arcturus_Therapeutics>,
        <https://1145.am/db/2358229/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359414/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360527/Arcturus_Therapeutics>,
        <https://1145.am/db/2361757/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363724/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2366477/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2584442/Arcturus_Therapeutics>,
        <https://1145.am/db/2584442/Marina_Biotech>,
        <https://1145.am/db/2584443/Arcturus_Therapeutics>,
        <https://1145.am/db/2590264/Alnylam_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2125290/Arcturus_Therapeutics>,
        <https://1145.am/db/2345894/Arcturus_Therapeutics>,
        <https://1145.am/db/2351922/Arcturus_Therapeutics_Inc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580564/Alchemy_Pharmatech> a org:Organization ;
    ns1:basedInHighRaw "Daresbury Science and Innovation Park" ;
    ns1:description "pharmaceutical products" ;
    ns1:documentDate "2013-06-12T13:23:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alchemy 400,000 Investment Boost" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/alchemy-%C2%A3400-000-investment-boost> ;
    ns1:foundName "Alchemy Pharmatech" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Alchemy Pharmatech" ;
    ns1:sameAsHigh <https://1145.am/db/849790/Alchemee>,
        <https://1145.am/db/865475/Alchemee>,
        <https://1145.am/db/870656/Alchemee> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580564/Investment_Alchemy_Pharmatech_North_West_Fund_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-12T13:23:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alchemy Pharmatech (APT) , which has developed an intranasal drug delivery system has landed a 400,000 investment fron the North West Fund." ;
    ns1:documentTitle "Alchemy 400,000 Investment Boost" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/alchemy-%C2%A3400-000-investment-boost> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2580564/Alchemy_Pharmatech> ;
    ns1:valueRaw "400,000" ;
    ns1:whereGeoName "North West" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1085598/about.rdf> ;
    ns1:whereRaw "North West" .

<https://1145.am/db/2581948/Equity_Capital_Investment_Jennerex_Inc_Transgene_Sa_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-28T16:00:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Transgene Announces a Follow-on Investment in Jennerex, Inc.",
        "Transgene SA (Paris: TNG) , a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announces an additional $ 2.5 million investment in the equity capital of Jennerex, Inc." ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Investment",
        "investment" ;
    ns1:name "Investment",
        "investment" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2581948/Jennerex_Inc> ;
    ns1:targetDetails "equity capital" ;
    ns1:targetName "Jennerex, Inc." ;
    ns1:valueRaw "$ 2.5 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2581948/Transgene_Sa> a org:Organization ;
    ns1:basedInHighGeoName "Paris" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2988507/about.rdf> ;
    ns1:basedInHighRaw "Paris" ;
    ns1:description "Biotechnology",
        "immunotherapy products" ;
    ns1:documentDate "2013-05-28T16:00:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Transgene",
        "Transgene SA" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2581948/Equity_Capital_Investment_Jennerex_Inc_Transgene_Sa_Has_Not_Happened> ;
    ns1:name "Transgene",
        "Transgene SA" ;
    ns1:sameAsHigh <https://1145.am/db/2293817/Transgene>,
        <https://1145.am/db/2306960/Transgene_Sa>,
        <https://1145.am/db/2336281/Transgene>,
        <https://1145.am/db/2336864/Transgenomic_Inc>,
        <https://1145.am/db/2357306/Transgenomic_Inc>,
        <https://1145.am/db/2359547/Transgene_Sa>,
        <https://1145.am/db/2593472/Transgenomic_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1932925/Transgene>,
        <https://1145.am/db/1967508/Transgene>,
        <https://1145.am/db/2062962/Transgene>,
        <https://1145.am/db/2153367/Transgene>,
        <https://1145.am/db/2306961/Transgene>,
        <https://1145.am/db/2312344/Transgene>,
        <https://1145.am/db/2324335/Transgene_Sa>,
        <https://1145.am/db/2336284/Transgene>,
        <https://1145.am/db/2336704/Transgene>,
        <https://1145.am/db/2344918/Transgene>,
        <https://1145.am/db/819348/Transgene>,
        <https://1145.am/db/944644/Transgene>,
        <https://1145.am/db/946928/Transgene> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2584818/Bausch_+_Lomb> a org:Organization ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:foundName "Bausch + Lomb" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Bausch + Lomb" ;
    ns1:sameAsHigh <https://1145.am/db/1675233/Bausch_+_Lomb>,
        <https://1145.am/db/2156312/Bausch>,
        <https://1145.am/db/2282195/Bausch_Health>,
        <https://1145.am/db/2300600/Bausch>,
        <https://1145.am/db/246071/Bausch_Health_Companies_Inc>,
        <https://1145.am/db/2544253/Bausch>,
        <https://1145.am/db/2550471/Bausch_+_Lomb>,
        <https://1145.am/db/2569877/Bausch___Lomb>,
        <https://1145.am/db/2572460/Bausch_+_Lomb>,
        <https://1145.am/db/2572466/Bausch___Lomb>,
        <https://1145.am/db/2582935/Bausch___Lomb>,
        <https://1145.am/db/2583843/Bausch_+_Lomb>,
        <https://1145.am/db/2590589/Bausch_+_Lomb>,
        <https://1145.am/db/268201/Bausch_Health_Companies_Inc>,
        <https://1145.am/db/295206/Bausch_+_Lomb>,
        <https://1145.am/db/295206/Bausch_Health_Companies_Inc>,
        <https://1145.am/db/319279/Bausch_Health_Companies_Inc>,
        <https://1145.am/db/389616/Bausch_Health_Cos_Inc>,
        <https://1145.am/db/389983/Bausch_Health_Cos_Inc>,
        <https://1145.am/db/392352/Baumann> ;
    ns1:sameAsMedium <https://1145.am/db/1014989/Bausch_+_Lomb>,
        <https://1145.am/db/1014991/Bausch_+_Lomb>,
        <https://1145.am/db/1035674/Bausch_+_Lomb>,
        <https://1145.am/db/1046609/Bausch_+_Lomb>,
        <https://1145.am/db/1158677/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/1219613/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/1600136/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/1649635/Bausch_+_Lomb>,
        <https://1145.am/db/1650588/Bausch_+_Lomb>,
        <https://1145.am/db/2057335/Bausch_+_Lomb>,
        <https://1145.am/db/2076347/Bausch_+_Lomb>,
        <https://1145.am/db/2096476/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/2109653/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/2113007/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/2129754/Bausch_+_Lomb_Corporation>,
        <https://1145.am/db/2283046/Bausch_+_Lomb>,
        <https://1145.am/db/2288428/Bausch_+_Lomb>,
        <https://1145.am/db/2288758/Bausch_+_Lomb>,
        <https://1145.am/db/2292925/Bausch_+_Lomb>,
        <https://1145.am/db/2295812/Bausch_+_Lomb>,
        <https://1145.am/db/2323579/Bausch_+_Lomb>,
        <https://1145.am/db/2328143/Bausch_+_Lomb>,
        <https://1145.am/db/2347171/Bausch_+_Lomb>,
        <https://1145.am/db/2347227/Bausch_+_Lomb>,
        <https://1145.am/db/2347350/Bausch_+_Lomb>,
        <https://1145.am/db/2357607/Bausch_+_Lomb>,
        <https://1145.am/db/2553024/Bausch_+_Lomb>,
        <https://1145.am/db/2554060/Bausch_+_Lomb>,
        <https://1145.am/db/2582894/Bausch_+_Lomb>,
        <https://1145.am/db/2592575/Bausch_+_Lomb>,
        <https://1145.am/db/2593443/Bausch_+_Lomb>,
        <https://1145.am/db/2595708/Bausch_+_Lomb>,
        <https://1145.am/db/757517/Bausch_+_Lomb> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2584818/Bausch_+_Lomb_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> A prospectus says Valeant Pharmaceuticals ($ VRX) intends to sell about $ 2 billion worth of shares to help finance its $ 8.7 billion acquisition of Bausch + Lomb." ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:foundName "acquisition",
        "sell" ;
    ns1:name "acquisition",
        "sell" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2584818/Bausch_+_Lomb> ;
    ns1:targetName "Bausch + Lomb" ;
    ns1:valueRaw "$ 8.7 billion" .

<https://1145.am/db/2584818/Microdose_Therapeutx> a org:Organization ;
    ns1:description "drug-delivery" ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:foundName "MicroDose Therapeutx" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "MicroDose Therapeutx" ;
    ns1:sameAsHigh <https://1145.am/db/2580570/Microdose_Therapeutx> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2584818/Microdose_Therapeutx_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-06-18T15:37:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Teva Pharmaceutical ($ TEVA) will pay $ 40 million in upfront cash and up to $ 125 in contingent payments to get drug-delivery specialist MicroDose Therapeutx to expand its respiratory business." ;
    ns1:documentTitle "Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/teva-snags-microdose-valeant-selling-2-billion-shares-mylan-sued-by-pfizer-merck-abbvie> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2584818/Microdose_Therapeutx> ;
    ns1:targetName "MicroDose Therapeutx" ;
    ns1:valueRaw "$ 40 million",
        "up to $ 125" .

<https://1145.am/db/2595684/Cobrek_Pharmaceuticals> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-12-28T15:28:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $45 Million" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/perrigo-company-acquires-remaining-stake-cobrek-pharmaceuticals-inc-for-approximately-45> ;
    ns1:foundName "Cobrek Pharmaceuticals, Inc",
        "Cobrek Pharmaceuticals, Inc." ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Cobrek Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2299388/Cormorant_Pharmaceuticals>,
        <https://1145.am/db/2337348/Cosmo_Technologies_Limited>,
        <https://1145.am/db/2345913/Covis_Holdings>,
        <https://1145.am/db/2360739/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2569192/Covis_Pharma_Commercial_Assets>,
        <https://1145.am/db/2569192/Covis_Pharma_Srl>,
        <https://1145.am/db/2576043/Covis_Pharma>,
        <https://1145.am/db/2576044/Covis_Pharma>,
        <https://1145.am/db/2582149/Cosme_Pharma>,
        <https://1145.am/db/2588918/Covis_Pharma>,
        <https://1145.am/db/2595688/Cobrek>,
        <https://1145.am/db/796298/Covis_Pharma_Group> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2595684/Cobrek_Pharmaceuticals_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-12-28T15:28:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ALLEGAN, Mich., Dec. 28, 2012 - Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek) , a privately-held, Chicago, Illinois - based drug development company, for approximately $ 45 million on a cash free and debt free basis.",
        "Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $ 45 Million." ;
    ns1:documentTitle "Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $45 Million" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/perrigo-company-acquires-remaining-stake-cobrek-pharmaceuticals-inc-for-approximately-45> ;
    ns1:foundName "Acquires",
        "acquisition" ;
    ns1:name "Acquires",
        "acquisition" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2595684/Cobrek_Pharmaceuticals> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Cobrek Pharmaceuticals" ;
    ns1:valueRaw "Approximately $ 45 Million",
        "approximately $ 45 million" ;
    ns1:when "2012-12-28T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Dec. 28, 2012" ;
    ns1:whereGeoName "Chicago" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4887398/about.rdf> ;
    ns1:whereRaw "Chicago, Illinois" .

<https://1145.am/db/2596947/Zoetis> a org:Organization ;
    ns1:description "animal health" ;
    ns1:documentDate "2013-01-22T16:58:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J CEO eyes sale of Ortho diagnostics unit" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/j-j-ceo-eyes-sale-of-ortho-diagnostics-unit> ;
    ns1:foundName "Zoetis" ;
    ns1:industry "animal health" ;
    ns1:name "Zoetis" ;
    ns1:sameAsHigh <https://1145.am/db/1115215/Zoetis_Inc>,
        <https://1145.am/db/1119265/Zoetis_Inc>,
        <https://1145.am/db/1135981/Inovet>,
        <https://1145.am/db/1150558/Zoetis_Inc>,
        <https://1145.am/db/1152461/Zoetis_Inc>,
        <https://1145.am/db/1282864/Ceva_Animal_Health>,
        <https://1145.am/db/1370926/Covetrus>,
        <https://1145.am/db/1381791/Zoetis_Inc>,
        <https://1145.am/db/1382690/Zoetis_Inc>,
        <https://1145.am/db/1690821/Zoetis>,
        <https://1145.am/db/194881/Elanco_Animal_Health>,
        <https://1145.am/db/227172/Elanco_Animal_Health>,
        <https://1145.am/db/2336174/Zoetis_Inc>,
        <https://1145.am/db/2367825/Zoetis>,
        <https://1145.am/db/2546156/Zoetis>,
        <https://1145.am/db/2547130/Zoetis>,
        <https://1145.am/db/2553245/Zoetis>,
        <https://1145.am/db/2559940/Vgx_Animal_Health>,
        <https://1145.am/db/2569196/Zoetis>,
        <https://1145.am/db/2570042/Zoetis>,
        <https://1145.am/db/2572277/Zoetis>,
        <https://1145.am/db/2575575/Wyeth>,
        <https://1145.am/db/2575912/Zoetis>,
        <https://1145.am/db/2579823/Zoetis>,
        <https://1145.am/db/2579859/Zoetis_Inc>,
        <https://1145.am/db/2580831/Zoetis>,
        <https://1145.am/db/2583700/Zoetis>,
        <https://1145.am/db/2583732/Zoetis>,
        <https://1145.am/db/2583746/Zoetis>,
        <https://1145.am/db/2584676/Zoetis>,
        <https://1145.am/db/2584705/Zoetis_Inc>,
        <https://1145.am/db/2587611/Zoetis>,
        <https://1145.am/db/2588540/Zoetis>,
        <https://1145.am/db/2588547/Zoetis_Inc>,
        <https://1145.am/db/2588580/Animalytix>,
        <https://1145.am/db/2588584/Animalytix>,
        <https://1145.am/db/2589008/Zoetis>,
        <https://1145.am/db/2589014/Zoetis>,
        <https://1145.am/db/2589536/Zoetis>,
        <https://1145.am/db/2589960/Zoetis_Inc>,
        <https://1145.am/db/2589962/Zoetis>,
        <https://1145.am/db/2589969/Zoetis>,
        <https://1145.am/db/2589971/Zoetis>,
        <https://1145.am/db/2592350/Zoetis_Inc>,
        <https://1145.am/db/2596312/Zoetis>,
        <https://1145.am/db/498856/Ceva_Animal_Health>,
        <https://1145.am/db/499888/Ceva_Animal_Health>,
        <https://1145.am/db/555317/Zoetis_Inc>,
        <https://1145.am/db/558179/Zoetis_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1229982/Zoetis_Inc>,
        <https://1145.am/db/1230856/Zoetis_Inc>,
        <https://1145.am/db/1485067/Zoetis_Inc>,
        <https://1145.am/db/1487751/Zoetis_Inc>,
        <https://1145.am/db/2058007/Zoetis_Inc>,
        <https://1145.am/db/2295408/Zoetis>,
        <https://1145.am/db/2315100/Zoetis>,
        <https://1145.am/db/2347139/Zoetis_Inc>,
        <https://1145.am/db/2547156/Zoetis>,
        <https://1145.am/db/2564954/Zoetis>,
        <https://1145.am/db/2570023/Zoetis>,
        <https://1145.am/db/2575913/Zoetis_Inc>,
        <https://1145.am/db/2577873/Zoetis_Inc>,
        <https://1145.am/db/2581809/Zoetis_Inc>,
        <https://1145.am/db/2585642/Zoetis>,
        <https://1145.am/db/2587616/Zoetis>,
        <https://1145.am/db/2588550/Zoetis_Inc>,
        <https://1145.am/db/328258/Zoetis_Inc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2596947/Zoetis_Business_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2013-01-22T16:58:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Pfizer ($ PFE) just priced an IPO for its animal health unit, Zoetis, and is in the middle of selling its nutrition business to Nestle." ;
    ns1:documentTitle "J&J CEO eyes sale of Ortho diagnostics unit" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/j-j-ceo-eyes-sale-of-ortho-diagnostics-unit> ;
    ns1:foundName "IPO",
        "selling" ;
    ns1:name "IPO",
        "selling" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2596947/Zoetis> ;
    ns1:targetDetails "business" ;
    ns1:targetName "Zoetis" ;
    ns1:vendor <https://1145.am/db/2596947/Pfizer> .

<https://1145.am/db/2597558/GSK> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:buyer <https://1145.am/db/2597558/Glaxosmithkline_Pte_Stake_Ipo> ;
    ns1:description "Business" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "GSK" ;
    ns1:industry "Healthcare" ;
    ns1:investor <https://1145.am/db/2597558/Glaxosmithkline_Consumer_Healthcare_Ltd_Stake_Investment>,
        <https://1145.am/db/2597558/Stake_Investment_Gsk_Completed> ;
    ns1:name "GSK" ;
    ns1:sameAsHigh <https://1145.am/db/1019111/SGB>,
        <https://1145.am/db/1151879/Gs>,
        <https://1145.am/db/1752832/GSK>,
        <https://1145.am/db/2040517/GSK>,
        <https://1145.am/db/2133451/Gms_Inc>,
        <https://1145.am/db/2586802/GSK>,
        <https://1145.am/db/2594208/GSK>,
        <https://1145.am/db/392403/GFG>,
        <https://1145.am/db/401251/Gms_Inc>,
        <https://1145.am/db/588157/Gms_Inc>,
        <https://1145.am/db/592352/Gms_Inc>,
        <https://1145.am/db/665287/Gms_Inc>,
        <https://1145.am/db/666824/Gms_Inc>,
        <https://1145.am/db/989768/Gc_Corp> ;
    ns1:sameAsMedium <https://1145.am/db/1035942/GSK>,
        <https://1145.am/db/1037557/GSK>,
        <https://1145.am/db/1097779/GSK>,
        <https://1145.am/db/1097915/GSK>,
        <https://1145.am/db/1098950/GSK>,
        <https://1145.am/db/118488/GSK>,
        <https://1145.am/db/118625/GSK>,
        <https://1145.am/db/1361734/GSK>,
        <https://1145.am/db/1368193/GSK>,
        <https://1145.am/db/1369714/GSK>,
        <https://1145.am/db/1972441/GSK>,
        <https://1145.am/db/1983958/Gsk_Plc>,
        <https://1145.am/db/2137303/GSK>,
        <https://1145.am/db/2138577/GSK>,
        <https://1145.am/db/2183506/GSK>,
        <https://1145.am/db/2278803/GSK>,
        <https://1145.am/db/2281080/GSK>,
        <https://1145.am/db/2283867/GSK>,
        <https://1145.am/db/230344/GSK>,
        <https://1145.am/db/2314286/GSK>,
        <https://1145.am/db/2328681/GSK>,
        <https://1145.am/db/2335573/GSK>,
        <https://1145.am/db/2336704/GSK>,
        <https://1145.am/db/2340072/GSK>,
        <https://1145.am/db/2345251/GSK>,
        <https://1145.am/db/2348686/GSK>,
        <https://1145.am/db/2349724/GSK>,
        <https://1145.am/db/2355641/GSK>,
        <https://1145.am/db/2356811/GSK>,
        <https://1145.am/db/2359727/GSK>,
        <https://1145.am/db/2359858/GSK>,
        <https://1145.am/db/2360562/GSK>,
        <https://1145.am/db/2361700/GSK>,
        <https://1145.am/db/2361705/GSK>,
        <https://1145.am/db/2369755/GSK>,
        <https://1145.am/db/2370635/GSK>,
        <https://1145.am/db/238329/GSK>,
        <https://1145.am/db/2539695/GSK>,
        <https://1145.am/db/2541091/GSK>,
        <https://1145.am/db/2541721/GSK>,
        <https://1145.am/db/2542064/GSK>,
        <https://1145.am/db/2542065/GSK>,
        <https://1145.am/db/2542192/GSK>,
        <https://1145.am/db/2545847/GSK>,
        <https://1145.am/db/2548752/GSK>,
        <https://1145.am/db/2550460/GSK>,
        <https://1145.am/db/2553168/GSK>,
        <https://1145.am/db/2558862/GSK>,
        <https://1145.am/db/2561353/GSK>,
        <https://1145.am/db/2561650/GSK>,
        <https://1145.am/db/2562773/GSK>,
        <https://1145.am/db/2564884/GSK>,
        <https://1145.am/db/2566186/GSK>,
        <https://1145.am/db/2567104/GSK>,
        <https://1145.am/db/2575712/GSK>,
        <https://1145.am/db/2576267/GSK>,
        <https://1145.am/db/2578528/GSK>,
        <https://1145.am/db/2578705/GSK>,
        <https://1145.am/db/2579180/GSK>,
        <https://1145.am/db/2581659/GSK>,
        <https://1145.am/db/2586804/GSK>,
        <https://1145.am/db/2587747/GSK>,
        <https://1145.am/db/2587967/GSK>,
        <https://1145.am/db/2587968/GSK>,
        <https://1145.am/db/2589701/GSK>,
        <https://1145.am/db/2597004/GSK>,
        <https://1145.am/db/2797157/GSK>,
        <https://1145.am/db/338190/GSK>,
        <https://1145.am/db/385094/GSK>,
        <https://1145.am/db/385100/GSK>,
        <https://1145.am/db/494811/GSK>,
        <https://1145.am/db/582690/GSK>,
        <https://1145.am/db/661291/GSK>,
        <https://1145.am/db/766907/GSK>,
        <https://1145.am/db/977067/GSK> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2597558/Glaxosmithkline_Consumer_Healthcare_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "Republic of India" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:basedInHighRaw "India" ;
    ns1:description "Consumer Healthcare" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "GlaxoSmithKline Consumer Healthcare Ltd" ;
    ns1:industry "Healthcare" ;
    ns1:name "GlaxoSmithKline Consumer Healthcare Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/2367621/Glaxosmithkline>,
        <https://1145.am/db/2546781/Glaxosmithkline_Api>,
        <https://1145.am/db/2548518/Glaxosmithkline>,
        <https://1145.am/db/2575861/Glaxosmithkline_Consumer_Healthcare> ;
    ns1:sameAsMedium <https://1145.am/db/2320047/Glaxosmithkline_Consumer_Healthcare> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2597558/Glaxosmithkline_Consumer_Healthcare_Ltd_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment",
        "ipo" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte." ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "increased" ;
    ns1:name "increased" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2597558/Glaxosmithkline_Consumer_Healthcare_Ltd> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "GlaxoSmithKline Consumer Healthcare Ltd" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2597558/Glaxosmithkline_Pte_Stake_Ipo> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte." ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "open" ;
    ns1:name "open" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2597558/Glaxosmithkline_Pte> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "GlaxoSmithKline Pte" ;
    ns1:whereGeoName "Republic of Singapore" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:whereRaw "Singapore" .

<https://1145.am/db/2597558/Stake_Investment_Gsk_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "GSK increases stake in its publicly - listed Consumer Healthcare subsidiary in India to 72.5 per cent." ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "increases" ;
    ns1:name "increases" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:targetDetails "stake" ;
    ns1:when "2013-02-05T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "5 February 2013" ;
    ns1:whereGeoName "Republic of India" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1269750/about.rdf> ;
    ns1:whereRaw "India" .

<https://1145.am/db/2616502/Sycamore_Networks> a org:Organization ;
    ns1:basedInHighGeoName "Chelmsford" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4932869/about.rdf> ;
    ns1:basedInHighRaw "Chelmsford, Mass." ;
    ns1:description "the optical switch market" ;
    ns1:documentDate "2013-03-11T12:01:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sycamore Networks ends its run" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/sycamore-networks-ends-its-run> ;
    ns1:foundName "Sycamore",
        "Sycamore Networks" ;
    ns1:name "Sycamore",
        "Sycamore Networks" ;
    ns1:sameAsMedium <https://1145.am/db/2614245/Sycamore_Networks> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2616502/Sycamore_Networks_Unit_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "bankruptcy",
        "investment" ;
    ns1:documentDate "2013-03-11T12:01:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Marlin Equity Partners bought the last piece of Sycamore last month.",
        "Sycamore Networks, at one time a major contender in the optical switch market, confirmed late last week that it had filed its certificate of dissolution with the State of Delaware to complete the process of liquidating the company." ;
    ns1:documentTitle "Sycamore Networks ends its run" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/sycamore-networks-ends-its-run> ;
    ns1:foundName "bought",
        "dissolution",
        "liquidating",
        "sold" ;
    ns1:name "bought",
        "dissolution",
        "liquidating",
        "sold" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2616502/Sycamore_Networks> ;
    ns1:targetDetails "unit" ;
    ns1:targetName "Sycamore",
        "Sycamore Networks" ;
    ns1:when "2023-09-21T06:20:59.785394"^^xsd:dateTime ;
    ns1:whenRaw "last month" ;
    ns1:whereGeoName "Chelmsford" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4932869/about.rdf> ;
    ns1:whereRaw "Chelmsford, Mass." .

<https://1145.am/db/2616502/Unit_Investment_Marlin_Equity_Partners_Nokia_Siemens_Networks_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-11T12:01:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Marlin also bought the optical unit of Nokia Siemens Networks." ;
    ns1:documentTitle "Sycamore Networks ends its run" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/sycamore-networks-ends-its-run> ;
    ns1:foundName "bought" ;
    ns1:name "bought" ;
    ns1:sourceName "Fierce Telecom" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2616502/Nokia_Siemens_Networks> ;
    ns1:targetDetails "unit" .

<https://1145.am/db/2664167/Investment_Nokia_Research_In_Motion_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Research In Motion made its first patent licensing payment of around 49.3 million to Nokia." ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2664167/Nokia> ;
    ns1:valueRaw "around 49.3 million" ;
    ns1:whereGeoName "Republic of Finland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/660013/about.rdf> ;
    ns1:whereRaw "Finland" .

<https://1145.am/db/2664167/Nokia> a org:Organization ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:foundName "Nokia" ;
    ns1:name "Nokia" ;
    ns1:sameAsMedium <https://1145.am/db/1037186/Nokia>,
        <https://1145.am/db/1359660/Nokia>,
        <https://1145.am/db/1376231/Nokia>,
        <https://1145.am/db/1396756/Nokia>,
        <https://1145.am/db/1619378/Nokia>,
        <https://1145.am/db/165554/Nokia>,
        <https://1145.am/db/1695286/Nokia>,
        <https://1145.am/db/1696015/Nokia>,
        <https://1145.am/db/1696105/Nokia>,
        <https://1145.am/db/1698635/Nokia>,
        <https://1145.am/db/1703449/Nokia>,
        <https://1145.am/db/1712040/Nokia>,
        <https://1145.am/db/1712862/Nokia>,
        <https://1145.am/db/1714727/Nokia_Corp>,
        <https://1145.am/db/1717500/Nokia>,
        <https://1145.am/db/1738836/Nokia>,
        <https://1145.am/db/176372/Nokia>,
        <https://1145.am/db/1783319/Nokia>,
        <https://1145.am/db/1784898/Nokia>,
        <https://1145.am/db/1790667/Nokia>,
        <https://1145.am/db/1790669/Nokia>,
        <https://1145.am/db/1790693/Nokia>,
        <https://1145.am/db/1793899/Nokia>,
        <https://1145.am/db/1795878/Nokia>,
        <https://1145.am/db/1801551/Nokia>,
        <https://1145.am/db/1807573/Nokia>,
        <https://1145.am/db/1814938/Nokia>,
        <https://1145.am/db/1825996/Nokia>,
        <https://1145.am/db/1827015/Nokia>,
        <https://1145.am/db/1828575/Nokia>,
        <https://1145.am/db/1830298/Nokia>,
        <https://1145.am/db/1831301/Nokia>,
        <https://1145.am/db/1833187/Nokia>,
        <https://1145.am/db/1835448/Nokia>,
        <https://1145.am/db/1835609/Nokia>,
        <https://1145.am/db/1838210/Nokia>,
        <https://1145.am/db/1839894/Nokia>,
        <https://1145.am/db/1843539/Nokia>,
        <https://1145.am/db/1845326/Nokia>,
        <https://1145.am/db/1846111/Nokia>,
        <https://1145.am/db/1846882/Nokia>,
        <https://1145.am/db/1853227/Nokia>,
        <https://1145.am/db/1858692/Nokia>,
        <https://1145.am/db/1865499/Nokia>,
        <https://1145.am/db/1865872/Nokia>,
        <https://1145.am/db/1870230/Nokia>,
        <https://1145.am/db/1871174/Nokia>,
        <https://1145.am/db/1875661/Nokia_Inc>,
        <https://1145.am/db/1879750/Nokia>,
        <https://1145.am/db/1882299/Nokia>,
        <https://1145.am/db/1890614/Nokia>,
        <https://1145.am/db/1890976/Nokia>,
        <https://1145.am/db/1895447/Nokia>,
        <https://1145.am/db/1896374/Nokia>,
        <https://1145.am/db/1904425/Nokia>,
        <https://1145.am/db/1906036/Nokia>,
        <https://1145.am/db/1916486/Nokia>,
        <https://1145.am/db/1917471/Nokia>,
        <https://1145.am/db/1924700/Nokia>,
        <https://1145.am/db/1927944/Nokia>,
        <https://1145.am/db/2170316/Nokia>,
        <https://1145.am/db/2174288/Nokia>,
        <https://1145.am/db/2174456/Nokia>,
        <https://1145.am/db/2599088/Nokia>,
        <https://1145.am/db/2599918/Nokia>,
        <https://1145.am/db/2600870/Nokia>,
        <https://1145.am/db/2601537/Nokia>,
        <https://1145.am/db/2603904/Nokia>,
        <https://1145.am/db/2607614/Nokia>,
        <https://1145.am/db/2609511/Nokia>,
        <https://1145.am/db/2609716/Nokia>,
        <https://1145.am/db/2614782/Nokia>,
        <https://1145.am/db/2614789/Nokia>,
        <https://1145.am/db/2614792/Nokia>,
        <https://1145.am/db/2615500/Nokia>,
        <https://1145.am/db/2617770/Nokia>,
        <https://1145.am/db/2618495/Nokia>,
        <https://1145.am/db/2621187/Nokia>,
        <https://1145.am/db/2621962/Nokia>,
        <https://1145.am/db/2623767/Nokia>,
        <https://1145.am/db/2624147/Nokia>,
        <https://1145.am/db/2624535/Nokia>,
        <https://1145.am/db/2624696/Nokia>,
        <https://1145.am/db/2624733/Nokia>,
        <https://1145.am/db/2626031/Nokia>,
        <https://1145.am/db/2627160/Nokia>,
        <https://1145.am/db/2627372/Nokia>,
        <https://1145.am/db/2627414/Nokia>,
        <https://1145.am/db/2628699/Nokia>,
        <https://1145.am/db/2629266/Nokia>,
        <https://1145.am/db/2629267/Nokia>,
        <https://1145.am/db/2630737/Nokia>,
        <https://1145.am/db/2631028/Nokia>,
        <https://1145.am/db/2631707/Nokia>,
        <https://1145.am/db/2631993/Nokia>,
        <https://1145.am/db/2633794/Nokia>,
        <https://1145.am/db/2634501/Nokia>,
        <https://1145.am/db/2634920/Nokia>,
        <https://1145.am/db/2635003/Nokia>,
        <https://1145.am/db/2635759/Nokia>,
        <https://1145.am/db/2636183/Nokia>,
        <https://1145.am/db/2636760/Nokia>,
        <https://1145.am/db/2636765/Nokia>,
        <https://1145.am/db/2636778/Nokia>,
        <https://1145.am/db/2637157/Nokia>,
        <https://1145.am/db/2640215/Nokia>,
        <https://1145.am/db/2640228/Nokia>,
        <https://1145.am/db/2640373/Nokia>,
        <https://1145.am/db/2640910/Nokia>,
        <https://1145.am/db/2641276/Nokia>,
        <https://1145.am/db/2641414/Nokia>,
        <https://1145.am/db/2642217/Nokia>,
        <https://1145.am/db/2642235/Nokia>,
        <https://1145.am/db/2642646/Nokia>,
        <https://1145.am/db/2643193/Nokia>,
        <https://1145.am/db/2643195/Nokia>,
        <https://1145.am/db/2645829/Nokia>,
        <https://1145.am/db/2648546/Nokia>,
        <https://1145.am/db/2648701/Nokia>,
        <https://1145.am/db/2648885/Nokia>,
        <https://1145.am/db/2648954/Nokia>,
        <https://1145.am/db/2649144/Nokia>,
        <https://1145.am/db/2649563/Nokia>,
        <https://1145.am/db/2651127/Nokia>,
        <https://1145.am/db/2651231/Nokia>,
        <https://1145.am/db/2652286/Nokia>,
        <https://1145.am/db/2652949/Nokia>,
        <https://1145.am/db/2653255/Nokia>,
        <https://1145.am/db/2653265/Nokia>,
        <https://1145.am/db/2653297/Nokia>,
        <https://1145.am/db/2653300/Nokia>,
        <https://1145.am/db/2653310/Nokia>,
        <https://1145.am/db/2654000/Nokia>,
        <https://1145.am/db/2654017/Nokia>,
        <https://1145.am/db/2654138/Nokia>,
        <https://1145.am/db/2654146/Nokia>,
        <https://1145.am/db/2654241/Nokia>,
        <https://1145.am/db/2654294/Nokia>,
        <https://1145.am/db/2654800/Nokia>,
        <https://1145.am/db/2654830/Nokia>,
        <https://1145.am/db/2654869/Nokia>,
        <https://1145.am/db/2654873/Nokia>,
        <https://1145.am/db/2655001/Nokia>,
        <https://1145.am/db/2655146/Nokia>,
        <https://1145.am/db/2655779/Nokia>,
        <https://1145.am/db/2656076/Nokia>,
        <https://1145.am/db/2656279/Nokia>,
        <https://1145.am/db/2656749/Nokia>,
        <https://1145.am/db/2656794/Nokia>,
        <https://1145.am/db/2656808/Nokia>,
        <https://1145.am/db/2656858/Nokia>,
        <https://1145.am/db/2656866/Nokia>,
        <https://1145.am/db/2656920/Nokia>,
        <https://1145.am/db/2657048/Nokia>,
        <https://1145.am/db/2657106/Nokia>,
        <https://1145.am/db/2657253/Nokia>,
        <https://1145.am/db/2657268/Nokia>,
        <https://1145.am/db/2658174/Nokia>,
        <https://1145.am/db/2658419/Nokia>,
        <https://1145.am/db/2658434/Nokia>,
        <https://1145.am/db/2658583/Nokia>,
        <https://1145.am/db/2658760/Nokia>,
        <https://1145.am/db/2658770/Nokia>,
        <https://1145.am/db/2658774/Nokia>,
        <https://1145.am/db/2658799/Nokia>,
        <https://1145.am/db/2658913/Nokia>,
        <https://1145.am/db/2659333/Nokia>,
        <https://1145.am/db/2659924/Nokia>,
        <https://1145.am/db/2660647/Nokia>,
        <https://1145.am/db/2661009/Nokia>,
        <https://1145.am/db/2661124/Nokia>,
        <https://1145.am/db/2661125/Nokia>,
        <https://1145.am/db/2661307/Nokia>,
        <https://1145.am/db/2661570/Nokia>,
        <https://1145.am/db/2662029/Nokia>,
        <https://1145.am/db/2662211/Nokia>,
        <https://1145.am/db/2662505/Nokia>,
        <https://1145.am/db/2662711/Nokia>,
        <https://1145.am/db/2663033/Nokia>,
        <https://1145.am/db/2663052/Nokia>,
        <https://1145.am/db/2663295/Nokia>,
        <https://1145.am/db/2664139/Nokia>,
        <https://1145.am/db/2665201/Nokia>,
        <https://1145.am/db/2665211/Nokia>,
        <https://1145.am/db/2665218/Nokia>,
        <https://1145.am/db/2665697/Nokia>,
        <https://1145.am/db/2666307/Nokia>,
        <https://1145.am/db/2666818/Nokia>,
        <https://1145.am/db/2667146/Nokia>,
        <https://1145.am/db/2667474/Nokia>,
        <https://1145.am/db/2667526/Nokia>,
        <https://1145.am/db/2667660/Nokia>,
        <https://1145.am/db/2667808/Nokia>,
        <https://1145.am/db/2668422/Nokia>,
        <https://1145.am/db/2668600/Nokia>,
        <https://1145.am/db/2668973/Nokia>,
        <https://1145.am/db/2669356/Nokia>,
        <https://1145.am/db/2669831/Nokia>,
        <https://1145.am/db/2670472/Nokia>,
        <https://1145.am/db/2670745/Nokia>,
        <https://1145.am/db/2670934/Nokia>,
        <https://1145.am/db/2670935/Nokia>,
        <https://1145.am/db/2671116/Nokia>,
        <https://1145.am/db/2671140/Nokia>,
        <https://1145.am/db/2671171/Nokia>,
        <https://1145.am/db/2671363/Nokia>,
        <https://1145.am/db/2671571/Nokia>,
        <https://1145.am/db/2671749/Nokia>,
        <https://1145.am/db/2671764/Nokia>,
        <https://1145.am/db/2671825/Nokia>,
        <https://1145.am/db/2671931/Nokia>,
        <https://1145.am/db/2672194/Nokia>,
        <https://1145.am/db/2672328/Nokia>,
        <https://1145.am/db/2672515/Nokia>,
        <https://1145.am/db/2673284/Nokia>,
        <https://1145.am/db/2673373/Nokia>,
        <https://1145.am/db/2673385/Nokia>,
        <https://1145.am/db/2673516/Nokia>,
        <https://1145.am/db/2673525/Nokia>,
        <https://1145.am/db/2673653/Nokia>,
        <https://1145.am/db/2674160/Nokia>,
        <https://1145.am/db/2674307/Nokia>,
        <https://1145.am/db/2674340/Nokia>,
        <https://1145.am/db/2674487/Nokia>,
        <https://1145.am/db/2674670/Nokia>,
        <https://1145.am/db/2675030/Nokia>,
        <https://1145.am/db/2675387/Nokia>,
        <https://1145.am/db/2675874/Nokia>,
        <https://1145.am/db/2676121/Nokia>,
        <https://1145.am/db/2676774/Nokia>,
        <https://1145.am/db/2676911/Nokia>,
        <https://1145.am/db/2677134/Nokia>,
        <https://1145.am/db/2677206/Nokia>,
        <https://1145.am/db/2677229/Nokia>,
        <https://1145.am/db/2677310/Nokia>,
        <https://1145.am/db/2679410/Nokia>,
        <https://1145.am/db/2679418/Nokia>,
        <https://1145.am/db/2679533/Nokia_Corporation>,
        <https://1145.am/db/2679971/Nokia>,
        <https://1145.am/db/2680041/Nokia>,
        <https://1145.am/db/2680066/Nokia>,
        <https://1145.am/db/2680459/Nokia>,
        <https://1145.am/db/2680747/Nokia>,
        <https://1145.am/db/2680827/Nokia>,
        <https://1145.am/db/2681000/Nokia>,
        <https://1145.am/db/2681206/Nokia>,
        <https://1145.am/db/2682053/Nokia>,
        <https://1145.am/db/2682100/Nokia>,
        <https://1145.am/db/2682469/Nokia>,
        <https://1145.am/db/2683061/Nokia>,
        <https://1145.am/db/2683066/Nokia>,
        <https://1145.am/db/2683067/Nokia>,
        <https://1145.am/db/2683074/Nokia>,
        <https://1145.am/db/2683077/Nokia>,
        <https://1145.am/db/2683079/Nokia>,
        <https://1145.am/db/2683232/Nokia>,
        <https://1145.am/db/2683444/Nokia>,
        <https://1145.am/db/2683445/Nokia>,
        <https://1145.am/db/2683465/Nokia>,
        <https://1145.am/db/2683670/Nokia>,
        <https://1145.am/db/2685818/Nokia>,
        <https://1145.am/db/2685958/Nokia> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2664167/Vimpelcom> a org:Organization ;
    ns1:basedInLowRaw "Czech" ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:foundName "VimpelCom" ;
    ns1:industry "telecoms" ;
    ns1:name "VimpelCom" ;
    ns1:sameAsHigh <https://1145.am/db/1530772/Vimpelcom>,
        <https://1145.am/db/1659276/Vimpelcom>,
        <https://1145.am/db/2141019/Vimpelcom>,
        <https://1145.am/db/2602370/Vimpelcom>,
        <https://1145.am/db/2626593/Vimpelcom>,
        <https://1145.am/db/2652974/Vimpelcom>,
        <https://1145.am/db/2653311/Vimpelcom>,
        <https://1145.am/db/2654657/Vimpelcom>,
        <https://1145.am/db/2659847/Vimpelcom>,
        <https://1145.am/db/2662999/Vimpelcom>,
        <https://1145.am/db/2664571/Vimpelcom>,
        <https://1145.am/db/2665211/Vimpelcom>,
        <https://1145.am/db/2666405/Vimpelcom>,
        <https://1145.am/db/2666410/Vimpelcom>,
        <https://1145.am/db/2667105/Vimpelcom>,
        <https://1145.am/db/2671088/Vimpelcom>,
        <https://1145.am/db/2671104/Vimpelcom>,
        <https://1145.am/db/2671481/Vimpelcom>,
        <https://1145.am/db/2672659/Vimpelcom>,
        <https://1145.am/db/2672667/Vimpelcom>,
        <https://1145.am/db/2674298/Vimpelcom>,
        <https://1145.am/db/2679855/Vimpelcom>,
        <https://1145.am/db/2680662/Vimpelcom>,
        <https://1145.am/db/2723235/Vimpelcom> ;
    ns1:sameAsMedium <https://1145.am/db/1529511/Vimpelcom>,
        <https://1145.am/db/1656234/Vimpelcom>,
        <https://1145.am/db/1668852/Vimpelcom>,
        <https://1145.am/db/2600327/Vimpelcom>,
        <https://1145.am/db/2602398/Vimpelcom>,
        <https://1145.am/db/2607010/Vimpelcom>,
        <https://1145.am/db/2611520/Vimpelcom>,
        <https://1145.am/db/2625867/Vimpelcom>,
        <https://1145.am/db/2628046/Vimpelcom>,
        <https://1145.am/db/2646871/Vimpelcom>,
        <https://1145.am/db/2646907/Vimpelcom>,
        <https://1145.am/db/2651270/Vimpelcom>,
        <https://1145.am/db/2652389/Vimpelcom>,
        <https://1145.am/db/2652985/Vimpelcom>,
        <https://1145.am/db/2653167/Vimpelcom>,
        <https://1145.am/db/2653171/Vimpelcom>,
        <https://1145.am/db/2653186/Vimpelcom>,
        <https://1145.am/db/2653225/Vimpelcom>,
        <https://1145.am/db/2654675/Vimpelcom>,
        <https://1145.am/db/2655477/Vimpelcom>,
        <https://1145.am/db/2655754/Vimpelcom>,
        <https://1145.am/db/2658492/Vimpelcom>,
        <https://1145.am/db/2659767/Vimpelcom>,
        <https://1145.am/db/2659780/Vimpelcom>,
        <https://1145.am/db/2660593/Vimpelcom>,
        <https://1145.am/db/2661700/Vimpelcom>,
        <https://1145.am/db/2661979/Vimpelcom>,
        <https://1145.am/db/2663844/Vimpelcom>,
        <https://1145.am/db/2663852/Vimpelcom>,
        <https://1145.am/db/2664956/Vimpelcom>,
        <https://1145.am/db/2665182/Vimpelcom>,
        <https://1145.am/db/2665345/Vimpelcom>,
        <https://1145.am/db/2665678/Vimpelcom>,
        <https://1145.am/db/2666025/Vimpelcom>,
        <https://1145.am/db/2666299/Vimpelcom>,
        <https://1145.am/db/2667506/Vimpelcom>,
        <https://1145.am/db/2668411/Vimpelcom>,
        <https://1145.am/db/2668429/Vimpelcom>,
        <https://1145.am/db/2669505/Vimpelcom>,
        <https://1145.am/db/2669683/Vimpelcom>,
        <https://1145.am/db/2670639/Vimpelcom>,
        <https://1145.am/db/2670685/Vimpelcom>,
        <https://1145.am/db/2670712/Vimpelcom>,
        <https://1145.am/db/2671812/Vimpelcom>,
        <https://1145.am/db/2671929/Vimpelcom>,
        <https://1145.am/db/2671975/Vimpelcom>,
        <https://1145.am/db/2672959/Vimpelcom>,
        <https://1145.am/db/2673845/Vimpelcom>,
        <https://1145.am/db/2676518/Vimpelcom>,
        <https://1145.am/db/2676527/Vimpelcom>,
        <https://1145.am/db/2676659/Vimpelcom>,
        <https://1145.am/db/2678839/Vimpelcom>,
        <https://1145.am/db/2678849/Vimpelcom>,
        <https://1145.am/db/2683657/Vimpelcom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2664167/Vimpelcom_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-02T16:25:05+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> VimpelCom will net around 1 billion now that Altimo has increased its stake in the company." ;
    ns1:documentTitle "Nokia gets patent payment from RIM; VimpelCom to net 1B" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-gets-patent-payment-from-rim-vimpelcom-to-net-eu1b> ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2664167/Vimpelcom> ;
    ns1:targetName "VimpelCom" ;
    ns1:valueRaw "around 1 billion" ;
    ns1:whereGeoName "Czechia" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3077311/about.rdf> ;
    ns1:whereRaw "Czech" .

<https://1145.am/db/2664200/Shin_Corp> a org:Organization ;
    ns1:basedInLowRaw "Thai" ;
    ns1:documentDate "2013-01-11T00:02:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: Temasek pares Shin stake; Apple rejects cheap iPhone rumor?" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-temasek-pares-shin-stake-apple-rejects-cheap-iphone-rumor> ;
    ns1:foundName "Shin Corp" ;
    ns1:name "Shin Corp" ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2664200/Shin_Corp_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-01-11T00:02:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Singapore state investment company Temasek Holdings has sold a nearly 10 % stake in Shin Corp, owner of 40 % of Thai mobile operator AIS and 41 % of Thaicom, for 20.9 billion baht ($ 689.8 million) .",
        "Temasek's stake in Shin Corp has now been reduced to 13.3 %." ;
    ns1:documentTitle "Webwire: Temasek pares Shin stake; Apple rejects cheap iPhone rumor?" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-temasek-pares-shin-stake-apple-rejects-cheap-iphone-rumor> ;
    ns1:foundName "sold" ;
    ns1:name "sold" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "stopped" ;
    ns1:target <https://1145.am/db/2664200/Shin_Corp> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Shin Corp" ;
    ns1:valueRaw "$ 689.8 million",
        "20.9 billion baht" ;
    ns1:vendor <https://1145.am/db/2664200/Temasek_Holdings> ;
    ns1:whereGeoName "Republic of Singapore" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:whereRaw "Singapore" .

<https://1145.am/db/2664200/Temasek_Holdings> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Singapore" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:basedInHighRaw "Singapore" ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:documentDate "2013-01-11T00:02:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: Temasek pares Shin stake; Apple rejects cheap iPhone rumor?" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-temasek-pares-shin-stake-apple-rejects-cheap-iphone-rumor> ;
    ns1:foundName "Temasek",
        "Temasek Holdings" ;
    ns1:industry "investment" ;
    ns1:investor <https://1145.am/db/2664200/Shin_Corp_Stake_Acquisition> ;
    ns1:name "Temasek",
        "Temasek Holdings" ;
    ns1:sameAsHigh <https://1145.am/db/1066315/Temasek>,
        <https://1145.am/db/1066322/Temasek>,
        <https://1145.am/db/1066323/Temasek>,
        <https://1145.am/db/1066333/Temasek>,
        <https://1145.am/db/1067524/Temasek>,
        <https://1145.am/db/1067526/Temasek>,
        <https://1145.am/db/1067529/Temasek>,
        <https://1145.am/db/1067530/Temasek>,
        <https://1145.am/db/1068016/Temasek>,
        <https://1145.am/db/1403851/Temasek>,
        <https://1145.am/db/1403897/Temasek>,
        <https://1145.am/db/1648491/Temasek>,
        <https://1145.am/db/1821833/Temasek>,
        <https://1145.am/db/2111428/Temasek>,
        <https://1145.am/db/2299918/Temasek>,
        <https://1145.am/db/2550544/Limited_Partners_Temasek>,
        <https://1145.am/db/263686/Temasek_Holdings>,
        <https://1145.am/db/684583/Temasek>,
        <https://1145.am/db/782551/Temasek> ;
    ns1:sameAsMedium <https://1145.am/db/1095671/Temasek_Holdings>,
        <https://1145.am/db/1113195/Temasek_Holdings>,
        <https://1145.am/db/1263680/Temasek_Holdings>,
        <https://1145.am/db/1447378/Temasek_Holdings>,
        <https://1145.am/db/1473068/Temasek_Holdings>,
        <https://1145.am/db/1502825/Temasek_Holdings>,
        <https://1145.am/db/1772843/Temasek_Holdings>,
        <https://1145.am/db/1777816/Temasek_Holdings>,
        <https://1145.am/db/1785172/Temasek_Holdings>,
        <https://1145.am/db/1997182/Temasek_Holdings>,
        <https://1145.am/db/2028459/Temasek_Holdings>,
        <https://1145.am/db/228001/Temasek_Holdings>,
        <https://1145.am/db/2284769/Temasek_Holdings>,
        <https://1145.am/db/2599246/Temasek_Holdings>,
        <https://1145.am/db/2662465/Temasek_Holdings>,
        <https://1145.am/db/2721743/Temasek_Holdings>,
        <https://1145.am/db/274611/Temasek_Holdings>,
        <https://1145.am/db/2757495/Temasek_Holdings>,
        <https://1145.am/db/342617/Temasek_Holdings>,
        <https://1145.am/db/342626/Temasek_Holdings>,
        <https://1145.am/db/386715/Temasek_Holdings>,
        <https://1145.am/db/386742/Temasek_Holdings>,
        <https://1145.am/db/386758/Temasek_Holdings>,
        <https://1145.am/db/575352/Temasek_Holdings>,
        <https://1145.am/db/603078/Temasek_Holdings>,
        <https://1145.am/db/701062/Temasek_Holdings>,
        <https://1145.am/db/778583/Temasek_Holdings>,
        <https://1145.am/db/785709/Temasek_Holdings>,
        <https://1145.am/db/799292/Temasek_Holdings> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2667192/Siemens> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2013-02-07T16:08:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Nokia Siemens parents could use Alcatel-Lucent to exit JV" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-nokia-siemens-parents-could-use-alcatel-lucent-to-exit-jv> ;
    ns1:foundName "Siemens" ;
    ns1:name "Siemens" ;
    ns1:protagonist <https://1145.am/db/2667192/Nokia_Siemens_Networks_Stake_Acquisition> ;
    ns1:sameAsMedium <https://1145.am/db/1075888/Siemens>,
        <https://1145.am/db/1165094/Siemens>,
        <https://1145.am/db/1166647/Siemens>,
        <https://1145.am/db/1166933/Siemens_Ag>,
        <https://1145.am/db/132708/Siemens>,
        <https://1145.am/db/1467416/Siemens>,
        <https://1145.am/db/1681794/Siemens>,
        <https://1145.am/db/1689000/Siemens_Ag>,
        <https://1145.am/db/1703564/Siemens>,
        <https://1145.am/db/1715713/Siemens>,
        <https://1145.am/db/1738976/Siemens>,
        <https://1145.am/db/1752181/Siemens>,
        <https://1145.am/db/1771078/Siemens>,
        <https://1145.am/db/1771396/Siemens>,
        <https://1145.am/db/1776036/Siemens>,
        <https://1145.am/db/1857982/Siemens>,
        <https://1145.am/db/1872498/Siemens>,
        <https://1145.am/db/1928635/Siemens_Ag>,
        <https://1145.am/db/1930723/Siemens_Ag>,
        <https://1145.am/db/2036828/Siemens>,
        <https://1145.am/db/2210167/Siemens>,
        <https://1145.am/db/2213344/Siemens>,
        <https://1145.am/db/2220921/Siemens>,
        <https://1145.am/db/2222399/Siemens>,
        <https://1145.am/db/2226763/Siemens>,
        <https://1145.am/db/2247513/Siemens>,
        <https://1145.am/db/2287784/Siemens>,
        <https://1145.am/db/228811/Siemens>,
        <https://1145.am/db/2289427/Siemens>,
        <https://1145.am/db/2290671/Siemens>,
        <https://1145.am/db/2293219/Siemens>,
        <https://1145.am/db/2293973/Siemens>,
        <https://1145.am/db/2294479/Siemens>,
        <https://1145.am/db/2296530/Siemens>,
        <https://1145.am/db/2297769/Siemens>,
        <https://1145.am/db/2298756/Siemens>,
        <https://1145.am/db/2298848/Siemens>,
        <https://1145.am/db/2301652/Siemens>,
        <https://1145.am/db/2310148/Siemens>,
        <https://1145.am/db/2310168/Siemens>,
        <https://1145.am/db/2343808/Siemens>,
        <https://1145.am/db/2454110/Siemens>,
        <https://1145.am/db/2602219/Siemens>,
        <https://1145.am/db/2604506/Siemens>,
        <https://1145.am/db/2612583/Siemens>,
        <https://1145.am/db/2623455/Siemens>,
        <https://1145.am/db/2624733/Siemens>,
        <https://1145.am/db/2627938/Siemens>,
        <https://1145.am/db/2637775/Siemens>,
        <https://1145.am/db/2647326/Siemens>,
        <https://1145.am/db/2651127/Siemens>,
        <https://1145.am/db/2651897/Siemens>,
        <https://1145.am/db/2657363/Siemens>,
        <https://1145.am/db/2676115/Siemens>,
        <https://1145.am/db/2677518/Siemens>,
        <https://1145.am/db/2679119/Siemens>,
        <https://1145.am/db/2679877/Siemens>,
        <https://1145.am/db/2680041/Siemens>,
        <https://1145.am/db/2680048/Siemens>,
        <https://1145.am/db/2680066/Siemens>,
        <https://1145.am/db/2681746/Siemens>,
        <https://1145.am/db/2682593/Siemens>,
        <https://1145.am/db/2683272/Siemens>,
        <https://1145.am/db/2683690/Siemens>,
        <https://1145.am/db/2685508/Siemens>,
        <https://1145.am/db/2686194/Siemens>,
        <https://1145.am/db/2786046/Siemens_Ag>,
        <https://1145.am/db/2786046/Siemens_Ltd>,
        <https://1145.am/db/2792945/Siemens>,
        <https://1145.am/db/2793288/Siemens>,
        <https://1145.am/db/2796865/Siemens_Ag>,
        <https://1145.am/db/2796865/Siemens_Ltd>,
        <https://1145.am/db/334937/Siemens>,
        <https://1145.am/db/336095/Siemens_Ag>,
        <https://1145.am/db/553007/Siemens>,
        <https://1145.am/db/767649/Siemens>,
        <https://1145.am/db/817821/Siemens>,
        <https://1145.am/db/820046/Siemens>,
        <https://1145.am/db/820051/Siemens> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2669324/Verizon_Communications> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York City" ;
    ns1:description "rumors and speculation" ;
    ns1:documentDate "2013-03-05T18:07:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Verizon wants to resolve Vodafone relationship in 2013" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-verizon-wants-to-resolve-vodafone-relationship-2013> ;
    ns1:foundName "Verizon Communications" ;
    ns1:name "Verizon Communications" ;
    ns1:protagonist <https://1145.am/db/2669324/Verizon_Wireless_Stake_Investment> ;
    ns1:sameAsHigh <https://1145.am/db/2669324/Verizon_Wireless> ;
    ns1:sameAsMedium <https://1145.am/db/1481423/Verizon_Communications_Inc>,
        <https://1145.am/db/1692553/Verizon_Communications_Inc>,
        <https://1145.am/db/1778788/Verizon_Communications>,
        <https://1145.am/db/2168361/Verizon_Communications>,
        <https://1145.am/db/2208364/Verizon_Communications>,
        <https://1145.am/db/225795/Verizon_Communications_Inc>,
        <https://1145.am/db/2599911/Verizon_Communications>,
        <https://1145.am/db/2601627/Verizon_Communications>,
        <https://1145.am/db/2601628/Verizon_Communications>,
        <https://1145.am/db/2601661/Verizon_Communications>,
        <https://1145.am/db/2601763/Verizon_Communications>,
        <https://1145.am/db/2603198/Verizon_Communications>,
        <https://1145.am/db/2604998/Verizon_Communications>,
        <https://1145.am/db/2605480/Verizon_Communications>,
        <https://1145.am/db/2607119/Verizon_Communications>,
        <https://1145.am/db/2607321/Verizon_Communications>,
        <https://1145.am/db/2609080/Verizon_Communications>,
        <https://1145.am/db/2611992/Verizon_Communications>,
        <https://1145.am/db/2612682/Verizon_Communications>,
        <https://1145.am/db/2614891/Verizon_Communications>,
        <https://1145.am/db/2617079/Verizon_Communications>,
        <https://1145.am/db/2617789/Verizon_Communications>,
        <https://1145.am/db/2619759/Verizon_Communications>,
        <https://1145.am/db/2623357/Verizon_Communications>,
        <https://1145.am/db/2625937/Verizon_Communications>,
        <https://1145.am/db/2629002/Verizon_Communications>,
        <https://1145.am/db/2643559/Verizon_Communications>,
        <https://1145.am/db/2648450/Verizon_Communications>,
        <https://1145.am/db/2648546/Verizon_Communications>,
        <https://1145.am/db/2653299/Verizon_Communications>,
        <https://1145.am/db/2654246/Verizon_Communications>,
        <https://1145.am/db/2654888/Verizon_Communications>,
        <https://1145.am/db/2658006/Verizon_Communications>,
        <https://1145.am/db/2658665/Verizon_Communications>,
        <https://1145.am/db/2659280/Verizon_Communications>,
        <https://1145.am/db/2659282/Verizon_Communications>,
        <https://1145.am/db/2659283/Verizon_Communications>,
        <https://1145.am/db/2659290/Verizon_Communications>,
        <https://1145.am/db/2662471/Verizon_Communications>,
        <https://1145.am/db/2665564/Verizon_Communications>,
        <https://1145.am/db/2668987/Verizon_Communications>,
        <https://1145.am/db/2671605/Verizon_Communications>,
        <https://1145.am/db/2673958/Verizon_Communications>,
        <https://1145.am/db/2675634/Verizon_Communications>,
        <https://1145.am/db/2676254/Verizon_Communications>,
        <https://1145.am/db/2676804/Verizon_Communications>,
        <https://1145.am/db/2678495/Verizon_Communications>,
        <https://1145.am/db/2678725/Verizon_Communications>,
        <https://1145.am/db/2678739/Verizon_Communications>,
        <https://1145.am/db/2678778/Verizon_Communications>,
        <https://1145.am/db/2679163/Verizon_Communications>,
        <https://1145.am/db/2679183/Verizon_Communications>,
        <https://1145.am/db/2679270/Verizon_Communications>,
        <https://1145.am/db/2682579/Verizon_Communications>,
        <https://1145.am/db/2683077/Verizon_Communications>,
        <https://1145.am/db/2683349/Verizon_Communications>,
        <https://1145.am/db/2683443/Verizon_Communications>,
        <https://1145.am/db/2684545/Verizon_Communications>,
        <https://1145.am/db/2685978/Verizon_Communications>,
        <https://1145.am/db/2729585/Verizon_Communications>,
        <https://1145.am/db/2789493/Verizon_Communications>,
        <https://1145.am/db/322211/Verizon_Communications_Inc>,
        <https://1145.am/db/322866/Verizon_Communications>,
        <https://1145.am/db/362469/Verizon_Communications_Inc>,
        <https://1145.am/db/405781/Verizon_Communications_Inc>,
        <https://1145.am/db/464462/Verizon_Communications_Inc>,
        <https://1145.am/db/633390/Verizon_Communications>,
        <https://1145.am/db/637723/Verizon_Communications>,
        <https://1145.am/db/644214/Verizon_Communications_Inc>,
        <https://1145.am/db/644342/Verizon_Communications_Inc>,
        <https://1145.am/db/646163/Verizon_Communications>,
        <https://1145.am/db/839179/Verizon_Communications_Inc>,
        <https://1145.am/db/857905/Verizon_Communications_Inc>,
        <https://1145.am/db/883060/Verizon_Communications_Inc> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2671617/Ubiquisys> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "United Kingdom" ;
    ns1:description "small cell" ;
    ns1:documentDate "2013-04-03T16:36:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cisco buys Ubiquisys for $310M to add 'intelligence in the network'" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/cisco-buys-ubiquisys-for-310m-to-add-intelligence-network> ;
    ns1:foundName "Ubiquisys" ;
    ns1:industry "small cell" ;
    ns1:name "Ubiquisys" ;
    ns1:sameAsMedium <https://1145.am/db/1836953/Ubiquisys>,
        <https://1145.am/db/1890089/Ubiquisys>,
        <https://1145.am/db/1895903/Ubiquisys>,
        <https://1145.am/db/2599795/Ubiquisys>,
        <https://1145.am/db/2638432/Ubiquisys>,
        <https://1145.am/db/2639964/Ubiquisys>,
        <https://1145.am/db/2641504/Ubiquisys>,
        <https://1145.am/db/2646055/Ubiquisys>,
        <https://1145.am/db/2671842/Ubiquisys>,
        <https://1145.am/db/2672852/Ubiquisys> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2671617/Ubiquisys_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-04-03T16:36:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Continuing its mobile acquisition streak, Cisco Systems announced it will purchase United Kingdom - based small cell firm Ubiquisys in a deal valued at $ 310 million.",
        "The Ubiquisys acquisition is the latest in a string of mobile-related purchases Cisco has made in the past several months to strengthen its portfolio." ;
    ns1:documentTitle "Cisco buys Ubiquisys for $310M to add 'intelligence in the network'" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/cisco-buys-ubiquisys-for-310m-to-add-intelligence-network> ;
    ns1:foundName "acquisition",
        "purchase" ;
    ns1:name "acquisition",
        "purchase" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2671617/Ubiquisys> ;
    ns1:targetName "Ubiquisys" ;
    ns1:valueRaw "$ 310 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "United Kingdom" .

<https://1145.am/db/2674215/Globul> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Bulgaria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/732800/about.rdf> ;
    ns1:basedInHighRaw "Bulgaria" ;
    ns1:description "Bulgarian mobile operator" ;
    ns1:documentDate "2013-05-01T09:56:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OTE sells Bulgarian unit to Telenor for 717M" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/ote-sells-bulgarian-unit-to-telenor-for-eu717m> ;
    ns1:foundName "Globul" ;
    ns1:industry "mobile operator" ;
    ns1:name "Globul" ;
    ns1:sameAsHigh <https://1145.am/db/1813088/Ee>,
        <https://1145.am/db/1959743/Cellnex>,
        <https://1145.am/db/2653257/Globul>,
        <https://1145.am/db/2654808/In___Phone>,
        <https://1145.am/db/2661986/P4>,
        <https://1145.am/db/2662758/Iusacell>,
        <https://1145.am/db/2664123/Cell_C>,
        <https://1145.am/db/2666440/O2>,
        <https://1145.am/db/2666968/Debitel>,
        <https://1145.am/db/2670775/H3g>,
        <https://1145.am/db/2672620/Mobinil>,
        <https://1145.am/db/2673008/U:_Fon>,
        <https://1145.am/db/2674070/Mobinil>,
        <https://1145.am/db/2675258/Mobinil>,
        <https://1145.am/db/2677796/MTS>,
        <https://1145.am/db/2680662/Mobifone>,
        <https://1145.am/db/2680826/Base>,
        <https://1145.am/db/694224/MTS> ;
    ns1:sameAsMedium <https://1145.am/db/2670667/Globul>,
        <https://1145.am/db/2673046/Globul> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2674215/Ote> a org:Organization ;
    ns1:basedInHighGeoName "Hellenic Republic" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/390903/about.rdf> ;
    ns1:basedInHighRaw "Greece" ;
    ns1:description "Greek operator" ;
    ns1:documentDate "2013-05-01T09:56:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OTE sells Bulgarian unit to Telenor for 717M" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/ote-sells-bulgarian-unit-to-telenor-for-eu717m> ;
    ns1:foundName "OTE" ;
    ns1:industry "telecoms" ;
    ns1:name "OTE" ;
    ns1:sameAsHigh <https://1145.am/db/145211/Ote>,
        <https://1145.am/db/2653257/Ote> ;
    ns1:sameAsMedium <https://1145.am/db/2615058/Ote>,
        <https://1145.am/db/2615826/Ote>,
        <https://1145.am/db/2656761/Ote>,
        <https://1145.am/db/2657419/Ote>,
        <https://1145.am/db/2659467/Ote>,
        <https://1145.am/db/2659496/Ote>,
        <https://1145.am/db/2661621/Ote>,
        <https://1145.am/db/2663196/Ote>,
        <https://1145.am/db/2669237/Ote>,
        <https://1145.am/db/2670667/Ote>,
        <https://1145.am/db/2670786/Ote>,
        <https://1145.am/db/2673046/Ote>,
        <https://1145.am/db/2675558/Ote>,
        <https://1145.am/db/304860/Ote>,
        <https://1145.am/db/367624/Ote> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676599/Compagnie_Monegasque_De_Communication> a org:Organization ;
    ns1:basedInHighGeoName "Principality of Monaco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2993457/about.rdf> ;
    ns1:basedInHighRaw "Monaco" ;
    ns1:description "business" ;
    ns1:documentDate "2013-05-22T14:42:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tiny Monaco thwarting CWC efforts to focus on pan-American strategy" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/tiny-monaco-thwarting-cwc-efforts-to-focus-pan-american-strategy> ;
    ns1:foundName "Compagnie Monegasque de Communication" ;
    ns1:name "Compagnie Monegasque de Communication" ;
    ns1:sameAsHigh <https://1145.am/db/2618598/Compagnie_Monegasque_De_Communication> ;
    ns1:sameAsMedium <https://1145.am/db/2667523/Compagnie_Mongasque_De_Communication> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676643/Mach> a org:Organization ;
    ns1:basedInLowRaw "European Union" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "Mach" ;
    ns1:name "Mach" ;
    ns1:sameAsMedium <https://1145.am/db/2675439/Mach>,
        <https://1145.am/db/2680056/Mach> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676643/Mach_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "divestment" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Syniverse Technologies won conditional approval from European Union antitrust regulators for its 550 million take over of Mach after agreeing to divest a large part of its rival's operations." ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "divest",
        "take over" ;
    ns1:name "divest",
        "take over" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2676643/Mach> ;
    ns1:targetName "Mach" ;
    ns1:valueRaw "550 million" ;
    ns1:whereGeoName "European Union" ;
    ns1:whereRaw "European Union" .

<https://1145.am/db/2676643/Tele2_Russia> a org:Organization ;
    ns1:basedInLowRaw "Russia" ;
    ns1:description "business" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "Tele2 Russia" ;
    ns1:name "Tele2 Russia" ;
    ns1:protagonist <https://1145.am/db/2676643/Merger_Rostelecom_Tele2_Russia_Has_Not_Happened> ;
    ns1:sameAsHigh <https://1145.am/db/2671855/Tele2_Russia> ;
    ns1:sameAsMedium <https://1145.am/db/2655910/Tele2_Russia>,
        <https://1145.am/db/2655942/Tele2_Russia>,
        <https://1145.am/db/2656799/Tele2_Russia>,
        <https://1145.am/db/2658919/Tele2_Russia>,
        <https://1145.am/db/2662068/Tele2_Russia>,
        <https://1145.am/db/2678993/Tele2_Russia> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Dna> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Finland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/660013/about.rdf> ;
    ns1:basedInHighRaw "Finland" ;
    ns1:description "business" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "DNA" ;
    ns1:name "DNA" ;
    ns1:sameAsMedium <https://1145.am/db/2651118/Dna>,
        <https://1145.am/db/2659924/Dna>,
        <https://1145.am/db/2668550/Dna>,
        <https://1145.am/db/2676595/Dna> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Investment_Orascom_Telecom_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> VimpelCom unit Orascom Telecom dropped its bid to control Canada's Wind Mobile, even as Verizon has expressed interest." ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:whereGeoName "Canada" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6251999/about.rdf> ;
    ns1:whereRaw "Canada" .

<https://1145.am/db/2678993/Mobistar> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Belgium" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:basedInHighRaw "Belgium" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "Mobistar" ;
    ns1:name "Mobistar" ;
    ns1:sameAsMedium <https://1145.am/db/2663040/Mobistar> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Mobistar_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Iliad said it would also consider bidding for Belgian operators Mobistar or BASE, if the company is put up for sale." ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "bidding" ;
    ns1:name "bidding" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2678993/Mobistar> ;
    ns1:targetName "Mobistar" ;
    ns1:whereGeoName "Kingdom of Belgium" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:whereRaw "Belgium" .

<https://1145.am/db/2678993/Orascom_Telecom> a org:Organization ;
    ns1:basedInLowRaw "Egypt" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "Orascom Telecom" ;
    ns1:investor <https://1145.am/db/2678993/Investment_Orascom_Telecom_Stopped> ;
    ns1:name "Orascom Telecom" ;
    ns1:sameAsMedium <https://1145.am/db/2654421/Orascom_Telecom>,
        <https://1145.am/db/2655203/Orascom_Telecom>,
        <https://1145.am/db/2656676/Orascom_Telecom>,
        <https://1145.am/db/2657740/Orascom_Telecom>,
        <https://1145.am/db/2660593/Orascom_Telecom>,
        <https://1145.am/db/2668326/Orascom_Telecom>,
        <https://1145.am/db/2671104/Orascom_Telecom>,
        <https://1145.am/db/2673027/Orascom_Telecom>,
        <https://1145.am/db/2675258/Orascom_Telecom>,
        <https://1145.am/db/2676643/Orascom_Telecom>,
        <https://1145.am/db/2676888/Orascom_Telecom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Tele2_Russia_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment",
        "merger" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Russian bank VTB said it is seeking a partner for Tele2 Russia, but ruled out Rostelecom." ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "off",
        "partner" ;
    ns1:name "off",
        "partner" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened",
        "stopped" ;
    ns1:target <https://1145.am/db/2678993/Tele2_Russia> ;
    ns1:targetName "Tele2 Russia" ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia" .

<https://1145.am/db/2679862/Clearwire> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "a high-speed wireless network" ;
    ns1:documentDate "2013-06-28T14:38:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: FCC won't force Sprint, Clearwire to give up spectrum as part of mergers" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-fcc-won-t-force-sprint-clearwire-to-give-up-spectrum-as-part-mergers> ;
    ns1:foundName "Clearwire" ;
    ns1:name "Clearwire" ;
    ns1:sameAsHigh <https://1145.am/db/2674457/Clearwire> ;
    ns1:sameAsMedium <https://1145.am/db/1867892/Clearwire>,
        <https://1145.am/db/2159451/Clearwire>,
        <https://1145.am/db/2168120/Clearwire>,
        <https://1145.am/db/2169703/Clearwire>,
        <https://1145.am/db/2171240/Clearwire>,
        <https://1145.am/db/2171262/Clearwire>,
        <https://1145.am/db/2621796/Clearwire>,
        <https://1145.am/db/2625093/Clearwire>,
        <https://1145.am/db/2625177/Clearwire>,
        <https://1145.am/db/2625440/Clearwire>,
        <https://1145.am/db/2627955/Clearwire>,
        <https://1145.am/db/2630836/Clearwire>,
        <https://1145.am/db/2630855/Clearwire>,
        <https://1145.am/db/2630872/Clearwire>,
        <https://1145.am/db/2636624/Clearwire>,
        <https://1145.am/db/2637003/Clearwire>,
        <https://1145.am/db/2640962/Clearwire>,
        <https://1145.am/db/2642478/Clearwire>,
        <https://1145.am/db/2643597/Clearwire>,
        <https://1145.am/db/2646795/Clearwire>,
        <https://1145.am/db/2649592/Clearwire>,
        <https://1145.am/db/2649957/Clearwire>,
        <https://1145.am/db/2650501/Clearwire>,
        <https://1145.am/db/2652311/Clearwire>,
        <https://1145.am/db/2653485/Clearwire>,
        <https://1145.am/db/2655150/Clearwire>,
        <https://1145.am/db/2657564/Clearwire>,
        <https://1145.am/db/2659616/Clearwire>,
        <https://1145.am/db/2659619/Clearwire>,
        <https://1145.am/db/2659620/Clearwire>,
        <https://1145.am/db/2659633/Clearwire>,
        <https://1145.am/db/2660278/Clearwire>,
        <https://1145.am/db/2661265/Clearwire>,
        <https://1145.am/db/2661271/Clearwire>,
        <https://1145.am/db/2661308/Clearwire>,
        <https://1145.am/db/2661312/Clearwire>,
        <https://1145.am/db/2663091/Clearwire>,
        <https://1145.am/db/2663923/Clearwire>,
        <https://1145.am/db/2663931/Clearwire>,
        <https://1145.am/db/2663933/Clearwire>,
        <https://1145.am/db/2663948/Clearwire>,
        <https://1145.am/db/2664520/Clearwire>,
        <https://1145.am/db/2665968/Clearwire>,
        <https://1145.am/db/2667137/Clearwire>,
        <https://1145.am/db/2668249/Clearwire>,
        <https://1145.am/db/2668825/Clearwire>,
        <https://1145.am/db/2669292/Clearwire>,
        <https://1145.am/db/2669341/Clearwire>,
        <https://1145.am/db/2669741/Clearwire>,
        <https://1145.am/db/2670229/Clearwire>,
        <https://1145.am/db/2670429/Clearwire>,
        <https://1145.am/db/2671023/Clearwire>,
        <https://1145.am/db/2671053/Clearwire>,
        <https://1145.am/db/2671074/Clearwire>,
        <https://1145.am/db/2671624/Clearwire>,
        <https://1145.am/db/2672759/Clearwire>,
        <https://1145.am/db/2672778/Clearwire>,
        <https://1145.am/db/2672784/Clearwire>,
        <https://1145.am/db/2672787/Clearwire>,
        <https://1145.am/db/2673403/Clearwire>,
        <https://1145.am/db/2674903/Clearwire>,
        <https://1145.am/db/2675127/Clearwire>,
        <https://1145.am/db/2676361/Clearwire>,
        <https://1145.am/db/2676378/Clearwire>,
        <https://1145.am/db/2677262/Clearwire>,
        <https://1145.am/db/2678748/Clearwire>,
        <https://1145.am/db/2678781/Clearwire>,
        <https://1145.am/db/2679627/Clearwire>,
        <https://1145.am/db/2679897/Clearwire>,
        <https://1145.am/db/2680700/Clearwire>,
        <https://1145.am/db/2680710/Clearwire>,
        <https://1145.am/db/2680723/Clearwire>,
        <https://1145.am/db/2681306/Clearwire>,
        <https://1145.am/db/2682450/Clearwire>,
        <https://1145.am/db/2683321/Clearwire>,
        <https://1145.am/db/2683336/Clearwire>,
        <https://1145.am/db/2683681/Clearwire>,
        <https://1145.am/db/2683999/Clearwire>,
        <https://1145.am/db/2684106/Clearwire>,
        <https://1145.am/db/2684592/Clearwire>,
        <https://1145.am/db/2685131/Clearwire>,
        <https://1145.am/db/2686032/Clearwire> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2679862/Clearwire_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-06-28T14:38:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Regulators at the FCC will not push Sprint Nextel (NYSE: S) or Clearwire (NASDAQ: CLWR) to divest spectrum as they review Japanese operator SoftBank's proposed acquisition of Sprint and Sprint's proposed purchase of Clearwire, according to a Reuters report." ;
    ns1:documentTitle "Report: FCC won't force Sprint, Clearwire to give up spectrum as part of mergers" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-fcc-won-t-force-sprint-clearwire-to-give-up-spectrum-as-part-mergers> ;
    ns1:foundName "acquisition",
        "divest",
        "purchase" ;
    ns1:name "acquisition",
        "divest",
        "purchase" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened",
        "stopped" ;
    ns1:target <https://1145.am/db/2679862/Clearwire> ;
    ns1:targetName "Clearwire" .

<https://1145.am/db/2266902/Chartered_Health_Plan_Assets_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-02-27T18:04:22+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AmeriHealth Mercy wants to buy Medicaid provider Chartered Health Plan, paying $ 5 million for certain assets of the embattled Washington, D.C. - based health insurer.",
        "AmeriHealth also said it would invest $ 30 million into Chartered, according to a Washington Examiner article." ;
    ns1:documentTitle "AmeriHealth to buy embattled Medicaid plan" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/amerihealth-to-buy-embattled-medicaid-plan> ;
    ns1:foundName "buy",
        "invest" ;
    ns1:name "buy",
        "invest" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2266902/Chartered_Health_Plan> ;
    ns1:targetDetails "assets" ;
    ns1:targetName "Chartered Health Plan" ;
    ns1:valueRaw "$ 30 million",
        "$ 5 million" ;
    ns1:whereGeoName "Washington" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4140963/about.rdf> ;
    ns1:whereRaw "Washington, D.C.",
        "Washington, D.C. area" .

<https://1145.am/db/2299645/Investment_Aerocrine_Novo_Orbimed_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-30T14:50:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Aerocrine secured $ 50 million in financing to market the Niox Mino.-Courtesy of Aerocrine.",
        "Sweden's Aerocrine has secured $ 50 million in combined debt and equity financing, money the company will use to market its devices for asthma diagnostics." ;
    ns1:documentTitle "Asthma devicemaker Aerocrine nabs $50M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asthma-devicemaker-aerocrine-nabs-50m> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2299645/Aerocrine> ;
    ns1:valueRaw "$ 35 million",
        "$ 50 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2299645/Novo> a org:Organization ;
    ns1:basedInLowRaw "Sweden" ;
    ns1:documentDate "2013-04-30T14:50:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Asthma devicemaker Aerocrine nabs $50M" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asthma-devicemaker-aerocrine-nabs-50m> ;
    ns1:foundName "Novo" ;
    ns1:investor <https://1145.am/db/2299645/Investment_Aerocrine_Novo_Orbimed_Has_Not_Happened> ;
    ns1:name "Novo" ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307564/Shangpharma_Holdings_Limited> a org:Organization ;
    ns1:basedInHighGeoName "Peoples Republic of China" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:basedInHighRaw "China" ;
    ns1:description "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:documentDate "2013-01-01T23:20:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ShangPharma Corporation Enters into Definitive Merger Agreement for Going Private Transaction" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/shangpharma-corporation-enters-into-definitive-merger-agreement-for-going-private-transaction> ;
    ns1:foundName "ShangPharma Holdings Limited" ;
    ns1:industry "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:name "ShangPharma Holdings Limited" ;
    ns1:protagonist <https://1145.am/db/2307564/Shangpharma_Corporation_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/2307564/Shangpharma_Corporation>,
        <https://1145.am/db/2307564/Shangpharma_Parent_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Corporation>,
        <https://1145.am/db/2310766/Shangpharma_Holdings_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Parent_Limited>,
        <https://1145.am/db/2322854/Wuxi_Pharmatech>,
        <https://1145.am/db/2332973/Wuxi_Pharmatech>,
        <https://1145.am/db/2332977/Wuxi_Pharmatech>,
        <https://1145.am/db/2332992/Wuxi_Pharmatech>,
        <https://1145.am/db/2345752/Wuxi_Pharmatech>,
        <https://1145.am/db/2351337/Shangpharma_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2307564/Shangpharma_Parent_Limited> a org:Organization ;
    ns1:basedInLowRaw "China" ;
    ns1:buyer <https://1145.am/db/2307564/Shangpharma_Corporation_Acquisition> ;
    ns1:description "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:documentDate "2013-01-01T23:20:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ShangPharma Corporation Enters into Definitive Merger Agreement for Going Private Transaction" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/shangpharma-corporation-enters-into-definitive-merger-agreement-for-going-private-transaction> ;
    ns1:foundName "Parent",
        "ShangPharma Parent Limited" ;
    ns1:industry "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:name "ShangPharma Parent Limited" ;
    ns1:protagonist <https://1145.am/db/2307564/Shangpharma_Corporation_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/2307564/Shangpharma_Corporation>,
        <https://1145.am/db/2307564/Shangpharma_Holdings_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Corporation>,
        <https://1145.am/db/2310766/Shangpharma_Holdings_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Parent_Limited>,
        <https://1145.am/db/2345752/Wuxi_Pharmatech>,
        <https://1145.am/db/2351337/Shangpharma_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2309242/Investment_Isotechnika_Pharma_Inc_National_Research_Council_Industrial_Research_Assistance_Program_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-20T18:20:19+00:00"^^xsd:dateTime ;
    ns1:documentExtract "EDMONTON, Alberta, June 18, 2013 (GLOBE NEWSWIRE) - Isotechnika Pharma Inc. (TSX: ISA) (\"Isotechnika\" or the \"Company\") today announced that it has received additional funding from the National Research Council Industrial Research Assistance Program (\"NRC-IRAP\") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules (\"NICAMs\") program.",
        "Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent." ;
    ns1:documentTitle "Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent" ;
    ns1:documentURL <https://www.fiercebiotech.com/research/isotechnika-pharma-receives-additional-funding-from-government-of-canada-for-preclinical> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2309242/Isotechnika_Pharma_Inc> ;
    ns1:whereGeoName "Canada" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6251999/about.rdf> ;
    ns1:whereRaw "Canada" .

<https://1145.am/db/2336391/Series_C_Investment_3-V_Biosciences_Kleiner_Perkins_Caufield___Byers_New_Enterprise_Associates_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-21T15:24:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "3-V Biosciences Completes $ 20 Million Series C Financing.",
        "MENLO PARK, Calif., June 21, 2013 /PRNewswire via COMTEX/ - 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $ 20 million." ;
    ns1:documentTitle "3-V Biosciences Completes $20 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/3-v-biosciences-completes-20-million-series-c-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336391/3-V_Biosciences> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 20 Million",
        "$ 20 million" ;
    ns1:when "2013-06-21T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 21, 2013" ;
    ns1:whereGeoName "Menlo Park" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5372223/about.rdf> ;
    ns1:whereRaw "MENLO PARK" .

<https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:description "life sciences investors" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "investorsEdmond de Rothschild Investment Partners (France)" ;
    ns1:investor <https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2336927/Edmond_De_Rothschild_Investment_Partners_Gimv_And_Biotech_Fund_Flanders> ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2338289/Cornerstone_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Cary" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4459467/about.rdf> ;
    ns1:basedInHighRaw "CARY, NC" ;
    ns1:documentDate "2013-02-20T17:03:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cornerstone-therapeutics-inc-announces-receipt-of-take-private-proposal-from-its-majority> ;
    ns1:foundName "Cornerstone Therapeutics Inc",
        "Cornerstone Therapeutics Inc." ;
    ns1:name "Cornerstone Therapeutics Inc",
        "Cornerstone Therapeutics Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2303902/Cornerstone_Therapeutics_Inc>,
        <https://1145.am/db/2304396/Cornerstone_Therapeutics>,
        <https://1145.am/db/2313227/Cornerstone_Therapeutics>,
        <https://1145.am/db/2319710/Cornerstone_Therapeutics>,
        <https://1145.am/db/2329144/Cornerstone_Therapeutics_Inc>,
        <https://1145.am/db/2343987/Cornerstone_Therapeutics>,
        <https://1145.am/db/2347050/Cornerstone_Therapeutics>,
        <https://1145.am/db/2353122/Cornerstone_Therapeutics_Inc>,
        <https://1145.am/db/2353129/Cornerstone_Therapeutics>,
        <https://1145.am/db/2366689/Cornerstone_Therapeutics_Inc>,
        <https://1145.am/db/2366972/Cornerstone_Therapeutics_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339932/Dezima_Pharma> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of the Netherlands" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:basedInHighRaw "Netherlands" ;
    ns1:description "developing new drugs" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "Dezima Pharma" ;
    ns1:industry "biotech" ;
    ns1:name "Dezima Pharma" ;
    ns1:sameAsHigh <https://1145.am/db/2339933/Dezima_Pharma>,
        <https://1145.am/db/2363712/Dezima_Pharma>,
        <https://1145.am/db/2370215/Dezima>,
        <https://1145.am/db/2370217/Dezima_Pharma_Bv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339933/Dezima_Pharma> a org:Organization ;
    ns1:description "developing innovative drugs" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "Dezima",
        "Dezima Pharma" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Dezima Pharma" ;
    ns1:sameAsHigh <https://1145.am/db/2339932/Dezima_Pharma>,
        <https://1145.am/db/2363712/Dezima_Pharma>,
        <https://1145.am/db/2370215/Dezima>,
        <https://1145.am/db/2370217/Dezima_Pharma_Bv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Avitide_Inc> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "Avitide, Inc." ;
    ns1:industry "biotech" ;
    ns1:name "Avitide, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1229239/Aviceda_Therapeutics>,
        <https://1145.am/db/1229589/Aviceda_Therapeutics>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/677845/Avistone_Pharmaceuticals>,
        <https://1145.am/db/681970/Avistone_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2368966/Avitide> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342862/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInHighGeoName "Lebanon" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5088597/about.rdf> ;
    ns1:basedInHighRaw "LEBANON, N.H." ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1009450/Biocompare>,
        <https://1145.am/db/1023985/Orgenesis_Inc>,
        <https://1145.am/db/1051761/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1066819/Biocentriq_Inc>,
        <https://1145.am/db/1088717/Biosynth>,
        <https://1145.am/db/1089921/Biosynth>,
        <https://1145.am/db/1116501/Alvotech_Sa>,
        <https://1145.am/db/1117630/Alvotech_Sa>,
        <https://1145.am/db/1124798/Accustem_Sciences>,
        <https://1145.am/db/1130652/Cogent_Biosciences>,
        <https://1145.am/db/1132106/Cogent_Biosciences>,
        <https://1145.am/db/1140693/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1142391/Cogent_Biosciences_Inc>,
        <https://1145.am/db/1143081/Bioinvent_International_Ab>,
        <https://1145.am/db/1154042/Applied_Biology>,
        <https://1145.am/db/1167874/Ensysce_Biosciences>,
        <https://1145.am/db/1174373/Biosynth>,
        <https://1145.am/db/1175242/Biosynth>,
        <https://1145.am/db/1179100/Ensysce_Biosciences>,
        <https://1145.am/db/1216524/Forbion>,
        <https://1145.am/db/1216997/180_Life_Sciences>,
        <https://1145.am/db/1222768/180_Life_Sciences_Corp>,
        <https://1145.am/db/1229517/Enveric_Biosciences>,
        <https://1145.am/db/1236975/Enveric_Biosciences>,
        <https://1145.am/db/1252190/Forbion>,
        <https://1145.am/db/1271538/Ensysce_Biosciences>,
        <https://1145.am/db/1278078/Monod_Bio>,
        <https://1145.am/db/1278479/Monod_Bio>,
        <https://1145.am/db/1293677/Biosion>,
        <https://1145.am/db/1295884/Brii_Biosciences_Limited>,
        <https://1145.am/db/1320133/Hc_Bioscience>,
        <https://1145.am/db/1336573/Hc_Bioscience>,
        <https://1145.am/db/1354619/Biogen>,
        <https://1145.am/db/1382711/Solid_Biosciences_Inc>,
        <https://1145.am/db/1386738/Vergent_Bioscience>,
        <https://1145.am/db/1387057/Vergent_Bioscience>,
        <https://1145.am/db/1408611/Alvotech>,
        <https://1145.am/db/1490000/Enavate_Sciences>,
        <https://1145.am/db/1506505/Biodesix>,
        <https://1145.am/db/1509205/Biodesix>,
        <https://1145.am/db/1522275/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1534347/Enveric_Biosciences>,
        <https://1145.am/db/1536048/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/1537082/Vergent_Bioscience>,
        <https://1145.am/db/1537788/Vergent_Bioscience>,
        <https://1145.am/db/1547927/Solid_Biosciences_Inc>,
        <https://1145.am/db/1548092/Innoforce>,
        <https://1145.am/db/1548093/Alvotech>,
        <https://1145.am/db/1553518/Solid_Biosciences_Inc>,
        <https://1145.am/db/1562950/Ensysce_Biosciences>,
        <https://1145.am/db/1577542/Bioasis>,
        <https://1145.am/db/1585988/Alvotech>,
        <https://1145.am/db/1585992/Alvotech>,
        <https://1145.am/db/1586236/Alvotech>,
        <https://1145.am/db/1586786/Bioasis>,
        <https://1145.am/db/1619665/Bioversys_Ag>,
        <https://1145.am/db/1630753/Solid_Biosciences_Inc>,
        <https://1145.am/db/1639462/Forte_Biosciences>,
        <https://1145.am/db/1640582/Forte_Biosciences>,
        <https://1145.am/db/1664988/Upstream_Bio>,
        <https://1145.am/db/1668597/Verily>,
        <https://1145.am/db/1685433/Enveric_Biosciences>,
        <https://1145.am/db/1696213/Genentech>,
        <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/1787025/Verily>,
        <https://1145.am/db/1821833/Verily>,
        <https://1145.am/db/1945850/Puretech>,
        <https://1145.am/db/2000772/Biosynth>,
        <https://1145.am/db/2010010/Iveric_Bio_Inc>,
        <https://1145.am/db/2019705/Eqt_Life_Sciences>,
        <https://1145.am/db/2023773/Genentech>,
        <https://1145.am/db/2032047/Enavate_Sciences>,
        <https://1145.am/db/2032047/Upstream_Bio>,
        <https://1145.am/db/2053399/Univercells_Technologies>,
        <https://1145.am/db/2061027/Roivant_Sciences>,
        <https://1145.am/db/2073555/Puretech_Scientific>,
        <https://1145.am/db/209111/Bioage>,
        <https://1145.am/db/2113176/Genentech>,
        <https://1145.am/db/2115362/2seventy_Bio>,
        <https://1145.am/db/2123899/Biosynth>,
        <https://1145.am/db/2152786/Aruvant_Sciences>,
        <https://1145.am/db/2152862/Therachon>,
        <https://1145.am/db/2152961/Arcus_Biosciences>,
        <https://1145.am/db/2153083/Arcus_Biosciences>,
        <https://1145.am/db/2153509/Or>,
        <https://1145.am/db/2154521/Baergic_Bio>,
        <https://1145.am/db/2154848/Brii_Biosciences>,
        <https://1145.am/db/2155108/Roivant_Sciences>,
        <https://1145.am/db/2155252/Bioagilytix>,
        <https://1145.am/db/2156304/Puretech>,
        <https://1145.am/db/2181432/Verily>,
        <https://1145.am/db/2188567/Verily_Life_Sciences>,
        <https://1145.am/db/2189613/Genapsys>,
        <https://1145.am/db/2198949/Cellectricon>,
        <https://1145.am/db/222920/Genapsys_Inc>,
        <https://1145.am/db/2230848/Bioohio>,
        <https://1145.am/db/2280215/Concentra_Biosciences>,
        <https://1145.am/db/2280734/Forte_Biosciences>,
        <https://1145.am/db/2281285/Locus_Biosciences>,
        <https://1145.am/db/2281875/Solid_Biosciences>,
        <https://1145.am/db/2282549/Coave>,
        <https://1145.am/db/2282760/Bioreliance>,
        <https://1145.am/db/2282760/Inotiv>,
        <https://1145.am/db/2283398/Sab>,
        <https://1145.am/db/2283480/Hcbioscience>,
        <https://1145.am/db/2285390/Cellarity>,
        <https://1145.am/db/2285399/Solid_Biosciences>,
        <https://1145.am/db/2285897/Hologic>,
        <https://1145.am/db/2285963/Iveric_Bio>,
        <https://1145.am/db/2286634/Therachon>,
        <https://1145.am/db/2286677/Roivant_Sciences>,
        <https://1145.am/db/2287185/Brii_Biosciences>,
        <https://1145.am/db/2290342/Biotech_Sector>,
        <https://1145.am/db/2290381/Life_Sciences>,
        <https://1145.am/db/2292237/Bioinvent>,
        <https://1145.am/db/2293367/Ascentage>,
        <https://1145.am/db/2293654/Eleven_Bio>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2295596/Roivant_Sciences>,
        <https://1145.am/db/2295654/Sv>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296584/Enterin>,
        <https://1145.am/db/2296692/Tp>,
        <https://1145.am/db/2297083/Biogen_Idec>,
        <https://1145.am/db/2297978/Ocugen>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298404/Bioz>,
        <https://1145.am/db/2298499/Inthera_Bioscience>,
        <https://1145.am/db/2298505/Inventisbio>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298866/Biosafe_Group>,
        <https://1145.am/db/2298948/Bioverativ>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299472/Aadi_Bioscience>,
        <https://1145.am/db/2300786/Axovant_Sciences>,
        <https://1145.am/db/2300790/Axovant_Sciences>,
        <https://1145.am/db/2301003/Roivant_Sciences>,
        <https://1145.am/db/2301684/Biogen_Idec_Inc>,
        <https://1145.am/db/2301979/Biogen_Idec_Inc>,
        <https://1145.am/db/2301983/Biogen_Idec>,
        <https://1145.am/db/2302002/Biogen_Idec>,
        <https://1145.am/db/2303130/Bioreliance_Corporation>,
        <https://1145.am/db/2303317/Applied_Biosystems>,
        <https://1145.am/db/2303604/Biogen_Idec>,
        <https://1145.am/db/2304650/Bioprocessors_Corp>,
        <https://1145.am/db/2304650/Life>,
        <https://1145.am/db/2305210/Biogen_Idec>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2306259/Bioanalab>,
        <https://1145.am/db/2306288/Bioanalab>,
        <https://1145.am/db/2308142/Biogen_Idec>,
        <https://1145.am/db/2310216/Biogen_Idec>,
        <https://1145.am/db/2310216/Genentech>,
        <https://1145.am/db/2310979/Cogenics>,
        <https://1145.am/db/2311995/Biovitrum>,
        <https://1145.am/db/2312238/Prometic_Life_Sciences>,
        <https://1145.am/db/2313533/Biosource_International>,
        <https://1145.am/db/2313760/Sistemic_Ltd>,
        <https://1145.am/db/2313762/Sistemic_Ltd>,
        <https://1145.am/db/2313763/Biomarin>,
        <https://1145.am/db/2314526/Bio-Rad>,
        <https://1145.am/db/2315615/Anormed>,
        <https://1145.am/db/2316066/Biogen_Idec>,
        <https://1145.am/db/2317136/Biogen_Idec_Inc>,
        <https://1145.am/db/2318537/Genomics>,
        <https://1145.am/db/2319551/Medevol>,
        <https://1145.am/db/2319959/Progentech>,
        <https://1145.am/db/2320138/Biogen_Idec>,
        <https://1145.am/db/2320164/Anaptys_Biosciences>,
        <https://1145.am/db/2320435/Ym_Biosciences_Inc>,
        <https://1145.am/db/2322209/Genentech>,
        <https://1145.am/db/2322417/Bio-Quant>,
        <https://1145.am/db/2322417/Biotox_Sciences>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2325377/Celmed_Biosciences>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2326063/Biooutsource>,
        <https://1145.am/db/2327677/Fundamental_Applied_Biology>,
        <https://1145.am/db/2327982/Biovex_Inc>,
        <https://1145.am/db/2328028/Biotrove>,
        <https://1145.am/db/2328815/Fundamental_Applied_Biology>,
        <https://1145.am/db/2329870/Complex_Biosystems_Gmbh>,
        <https://1145.am/db/2330058/Bio-Quant>,
        <https://1145.am/db/2330348/Blaze_Bioscience>,
        <https://1145.am/db/2332771/S_*_Bio>,
        <https://1145.am/db/2333005/Genizon_Biosciences>,
        <https://1145.am/db/2334156/Genizon>,
        <https://1145.am/db/2335943/Genentech>,
        <https://1145.am/db/2336178/Biocon_Limited>,
        <https://1145.am/db/2336178/Biocon_Ltd>,
        <https://1145.am/db/2336383/Biocrates_Life_Sciences_Ag>,
        <https://1145.am/db/2336736/Coherus_Biosciences>,
        <https://1145.am/db/2336983/Biogen_Idec>,
        <https://1145.am/db/2337110/Bioutah>,
        <https://1145.am/db/2337412/Blaze_Bioscience>,
        <https://1145.am/db/2337664/Advent_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338837/Coherus_Biosciences>,
        <https://1145.am/db/2340502/Massbio>,
        <https://1145.am/db/2340513/Massbio>,
        <https://1145.am/db/2340560/Puretech>,
        <https://1145.am/db/2341443/Biosystems_International>,
        <https://1145.am/db/2341509/Epic_Sciences>,
        <https://1145.am/db/2341676/Bioforward>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2343761/Ovascience>,
        <https://1145.am/db/2343777/Ovascience>,
        <https://1145.am/db/2343791/Bioniche_Life_Sciences_Inc>,
        <https://1145.am/db/2344638/Coherus_Biosciences>,
        <https://1145.am/db/2345112/Med_Biogene_Inc>,
        <https://1145.am/db/2345132/Biocon>,
        <https://1145.am/db/2345999/Biogen_Idec>,
        <https://1145.am/db/2346485/Pracinostat>,
        <https://1145.am/db/2347467/Theraclone_Sciences>,
        <https://1145.am/db/2347950/Epic_Sciences>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2349436/Ovascience>,
        <https://1145.am/db/2350267/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2350471/Biovex>,
        <https://1145.am/db/2350645/Biochrom_Ag>,
        <https://1145.am/db/2351192/Genticel>,
        <https://1145.am/db/2351312/Themis_Bioscience>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2351472/Mymetics>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2351921/Ovascience>,
        <https://1145.am/db/2352069/Biogen_Idec>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2354835/Biovex>,
        <https://1145.am/db/2355219/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355236/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2356064/Frontline_Bioventures>,
        <https://1145.am/db/2356509/Inq_Biosciences_Corporation>,
        <https://1145.am/db/2357079/Techne_Corporation>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358296/Biogen_Idec>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2360075/Bionomics>,
        <https://1145.am/db/2360313/Engene>,
        <https://1145.am/db/2361502/Ovascience>,
        <https://1145.am/db/2362647/Bioqual>,
        <https://1145.am/db/2362737/Life_Sciences>,
        <https://1145.am/db/2363484/Bioscale>,
        <https://1145.am/db/2363485/Bioscale_Inc>,
        <https://1145.am/db/2363668/Ovasciencesm>,
        <https://1145.am/db/2364681/Biogen_Idec>,
        <https://1145.am/db/2366915/Biogen_Idec>,
        <https://1145.am/db/2368752/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/2369498/Genentech>,
        <https://1145.am/db/2370383/Prometic_Life_Sciences>,
        <https://1145.am/db/2370548/Bionovion>,
        <https://1145.am/db/2370549/Bionovion>,
        <https://1145.am/db/2370806/Alvotech>,
        <https://1145.am/db/2538197/Orgenesis>,
        <https://1145.am/db/2542617/Core_Biogenesis>,
        <https://1145.am/db/2542993/Biogen_Idec>,
        <https://1145.am/db/2550495/Bioatla>,
        <https://1145.am/db/2552636/Ark_Biosciences>,
        <https://1145.am/db/2553773/Mabxience>,
        <https://1145.am/db/2563996/Biocnd>,
        <https://1145.am/db/256464/Atai_Life_Sciences>,
        <https://1145.am/db/2566932/Exosomics>,
        <https://1145.am/db/2567231/Genentech>,
        <https://1145.am/db/2568479/Subintro>,
        <https://1145.am/db/2571023/Biochrom_Ag>,
        <https://1145.am/db/2577183/Biogen_Idec>,
        <https://1145.am/db/2577644/Presage_Biosciences>,
        <https://1145.am/db/2578308/Intermune>,
        <https://1145.am/db/2578528/Biogen_Idec>,
        <https://1145.am/db/2580665/Themis_Bioscience>,
        <https://1145.am/db/2580671/Themis_Bioscience>,
        <https://1145.am/db/2584538/Bionovion>,
        <https://1145.am/db/2594353/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2797140/Biotheus>,
        <https://1145.am/db/322594/Roivant_Sciences>,
        <https://1145.am/db/356493/Atai_Life_Sciences_Bv>,
        <https://1145.am/db/396787/Biotheryx>,
        <https://1145.am/db/417096/Solid_Biosciences_Inc>,
        <https://1145.am/db/417543/180_Life_Sciences_Corp>,
        <https://1145.am/db/417568/Ultivue>,
        <https://1145.am/db/425981/180_Life_Sciences_Corp>,
        <https://1145.am/db/436937/Triad_Life_Sciences>,
        <https://1145.am/db/471380/Insidescientific>,
        <https://1145.am/db/481671/Biolegend>,
        <https://1145.am/db/482988/Biolegend>,
        <https://1145.am/db/486391/Biolife_Solutions>,
        <https://1145.am/db/505292/Ensysce_Biosciences>,
        <https://1145.am/db/520363/Biohive>,
        <https://1145.am/db/521860/Tosoh_Bioscience_Llc>,
        <https://1145.am/db/523221/Biohive>,
        <https://1145.am/db/540091/Curative_Biotechnology_Inc>,
        <https://1145.am/db/540784/Coherus_Biosciences_Inc>,
        <https://1145.am/db/544370/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/591563/180_Life_Sciences>,
        <https://1145.am/db/624546/Ensysce_Biosciences>,
        <https://1145.am/db/730321/Biosion>,
        <https://1145.am/db/739185/Sqz_Biotechnologies>,
        <https://1145.am/db/767994/Biotech_Prokidney_Lp>,
        <https://1145.am/db/818850/Ensysce_Biosciences>,
        <https://1145.am/db/877317/Accustem_Sciences>,
        <https://1145.am/db/922807/Biolabs>,
        <https://1145.am/db/941576/Orgenesis_Inc>,
        <https://1145.am/db/948136/Ensysce_Biosciences_Inc>,
        <https://1145.am/db/958575/Biocompare>,
        <https://1145.am/db/958575/Scilan>,
        <https://1145.am/db/968301/Ansa_Biotechnologies>,
        <https://1145.am/db/972968/Ansa_Biotechnologies>,
        <https://1145.am/db/979663/Biostrand>,
        <https://1145.am/db/979842/Biostrand_Bv>,
        <https://1145.am/db/986828/Ensysce_Biosciences>,
        <https://1145.am/db/991347/Genovac> ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348055/Investment_Bergamo_Acquisition_Corp_Vistagen_Therapeutics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-10T15:17:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SOUTH SAN FRANCISCO, CA- (Apr 10, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA) , a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO) , a global diversified investment holding company.",
        "Under the terms of the agreement, Bergamo's European subsidiary will invest $ 36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $ 0.50 per share.",
        "VistaGen Announces $ 36 Million Strategic Financing Agreement." ;
    ns1:documentTitle "VistaGen Announces $36 Million Strategic Financing Agreement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vistagen-announces-36-million-strategic-financing-agreement> ;
    ns1:foundName "Financing",
        "financing",
        "invest",
        "strategic financing" ;
    ns1:name "Financing",
        "financing",
        "invest",
        "strategic financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2348055/Vistagen_Therapeutics> ;
    ns1:valueRaw "$ 36 Million",
        "$ 36 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2348074/Series_A_Investment_Arch_Venture_Partners_Flagship_Ventures_Syros_Pharmaceuticals_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-11T15:17:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Syros Pharmaceuticals Launches with $ 30 Million Series A Financing.",
        "WATERTOWN, MA, April 11, 2013 - Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced that it has completed a $ 30 million Series A financing led by company Co-founders ARCH Venture Partners and Flagship Ventures." ;
    ns1:documentTitle "Syros Pharmaceuticals Launches with $30 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/syros-pharmaceuticals-launches-30-million-series-a-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348074/Syros_Pharmaceuticals> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 30 Million",
        "$ 30 million" ;
    ns1:when "2013-04-11T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 11, 2013" ;
    ns1:whereGeoName "Watertown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4954611/about.rdf> ;
    ns1:whereRaw "WATERTOWN, MA" .

<https://1145.am/db/2348074/Syros_Pharmaceuticals> a org:Organization ;
    ns1:description "the treatment of cancer and other diseases" ;
    ns1:documentDate "2013-04-11T15:17:15+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Syros Pharmaceuticals Launches with $30 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/syros-pharmaceuticals-launches-30-million-series-a-financing> ;
    ns1:foundName "Syros Pharmaceuticals" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Syros Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1180905/Syros_Pharmaceuticals>,
        <https://1145.am/db/1181453/Syros_Pharmaceuticals>,
        <https://1145.am/db/1183641/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1184316/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1265967/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1266692/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1348218/Syros_Pharmaceuticals>,
        <https://1145.am/db/1349294/Syros_Pharmaceuticals>,
        <https://1145.am/db/2131988/Syros>,
        <https://1145.am/db/2281887/Symeres>,
        <https://1145.am/db/2285044/Symeres>,
        <https://1145.am/db/2317635/Symmetrix_Pharmaceuticals>,
        <https://1145.am/db/2325241/Symphogen_A_S>,
        <https://1145.am/db/2333086/Systech_International>,
        <https://1145.am/db/2333089/Systech_International>,
        <https://1145.am/db/2340496/Symphogen>,
        <https://1145.am/db/2341595/Syros_Pharmaceuticals>,
        <https://1145.am/db/2341599/Syros_Pharmaceuticals>,
        <https://1145.am/db/2353241/Symphogen>,
        <https://1145.am/db/2358489/Syros_Pharmaceuticals>,
        <https://1145.am/db/2359527/Syros_Pharmaceuticals>,
        <https://1145.am/db/2366114/Symphogen>,
        <https://1145.am/db/2366334/Symphogen>,
        <https://1145.am/db/2368617/Syros_Pharmaceuticals>,
        <https://1145.am/db/2369304/Syros_Pharmaceuticals>,
        <https://1145.am/db/2369305/Syros_Pharmaceuticals>,
        <https://1145.am/db/2370574/Syros_Pharmaceuticals>,
        <https://1145.am/db/464043/Syros_Pharmaceuticals>,
        <https://1145.am/db/464628/Syros_Pharmaceuticals>,
        <https://1145.am/db/502636/Syros_Pharmaceuticals>,
        <https://1145.am/db/539655/Syros_Pharmaceuticals>,
        <https://1145.am/db/641899/Sylphar_International> ;
    ns1:sameAsMedium <https://1145.am/db/2549482/Syros_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349078/Elan_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Irish" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-04-15T13:21:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "Elan Corporation, plc" ;
    ns1:name "Elan Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1591152/Eisai>,
        <https://1145.am/db/2303352/Eisai>,
        <https://1145.am/db/2303645/Eisai>,
        <https://1145.am/db/2303806/Eisai>,
        <https://1145.am/db/2305617/Eisai_Company>,
        <https://1145.am/db/2305969/Esprit_Pharma>,
        <https://1145.am/db/2308890/Elan_Corporation>,
        <https://1145.am/db/2320025/Esprit_Pharma>,
        <https://1145.am/db/2325490/Eisai>,
        <https://1145.am/db/2325525/Eisai>,
        <https://1145.am/db/2327327/Elan>,
        <https://1145.am/db/2332005/Eisai>,
        <https://1145.am/db/2332596/Esprit_Pharma>,
        <https://1145.am/db/2339096/Elan_Corporation>,
        <https://1145.am/db/2345264/clat_Pharmaceuticals>,
        <https://1145.am/db/2356207/Eisai_Inc>,
        <https://1145.am/db/2360786/Elan_Corporation>,
        <https://1145.am/db/2363656/Elan_Corporation>,
        <https://1145.am/db/2364580/Elan_Corporation>,
        <https://1145.am/db/2364612/Elan_Corporation>,
        <https://1145.am/db/2366961/Elan_Corporation>,
        <https://1145.am/db/2367151/Elan_Corporation>,
        <https://1145.am/db/2543572/Eisai>,
        <https://1145.am/db/2576144/Elan>,
        <https://1145.am/db/2577010/Elan_Corporation>,
        <https://1145.am/db/2578667/Eisai>,
        <https://1145.am/db/2579483/Eisai>,
        <https://1145.am/db/2580779/Eisai_Inc>,
        <https://1145.am/db/2582116/Eisai> ;
    ns1:sameAsMedium <https://1145.am/db/2249118/Elan_Corporation>,
        <https://1145.am/db/2268635/Elan_Corporation>,
        <https://1145.am/db/2308845/Elan>,
        <https://1145.am/db/2308886/Elan>,
        <https://1145.am/db/2309137/Elan>,
        <https://1145.am/db/2309970/Elan>,
        <https://1145.am/db/2319399/Elan>,
        <https://1145.am/db/2331746/Elan_Corporation>,
        <https://1145.am/db/2332005/Elan_Corporation>,
        <https://1145.am/db/2335881/Elan>,
        <https://1145.am/db/2335887/Elan>,
        <https://1145.am/db/2336358/Elan>,
        <https://1145.am/db/2336983/Elan>,
        <https://1145.am/db/2339086/Elan_Corporation>,
        <https://1145.am/db/2339950/Elan_Corporation>,
        <https://1145.am/db/2340188/Elan>,
        <https://1145.am/db/2340189/Elan_Corporation>,
        <https://1145.am/db/2341772/Elan_Corporation>,
        <https://1145.am/db/2342686/Elan_Corporation>,
        <https://1145.am/db/2343835/Elan>,
        <https://1145.am/db/2345479/Elan_Corporation>,
        <https://1145.am/db/2345992/Elan_Corporation>,
        <https://1145.am/db/2345999/Elan>,
        <https://1145.am/db/2346467/Elan_Corporation>,
        <https://1145.am/db/2346795/Elan_Corporation>,
        <https://1145.am/db/2346976/Elan_Corporation>,
        <https://1145.am/db/2347453/Elan_Corporation>,
        <https://1145.am/db/2348227/Elan_Corporation>,
        <https://1145.am/db/2350115/Elan>,
        <https://1145.am/db/2350116/Elan_Corporation>,
        <https://1145.am/db/2350550/Elan_Corporation>,
        <https://1145.am/db/2351144/Elan>,
        <https://1145.am/db/2351145/Elan_Corporation>,
        <https://1145.am/db/2358431/Elan>,
        <https://1145.am/db/2359529/Elan>,
        <https://1145.am/db/2359600/Elan_Corporation>,
        <https://1145.am/db/2359604/Elan_Corporation>,
        <https://1145.am/db/2364583/Elan>,
        <https://1145.am/db/2537542/Elan>,
        <https://1145.am/db/2554897/Elan>,
        <https://1145.am/db/2560865/Elan>,
        <https://1145.am/db/2573572/Elan>,
        <https://1145.am/db/2575100/Elan_Corporation>,
        <https://1145.am/db/2576104/Elan>,
        <https://1145.am/db/2577059/Elan_Corporation>,
        <https://1145.am/db/2580122/Elan>,
        <https://1145.am/db/2583839/Elan>,
        <https://1145.am/db/2584383/Elan>,
        <https://1145.am/db/2584834/Elan>,
        <https://1145.am/db/2584909/Elan>,
        <https://1145.am/db/2585770/Elan>,
        <https://1145.am/db/2586703/Elan>,
        <https://1145.am/db/2589750/Elan>,
        <https://1145.am/db/2590594/Elan>,
        <https://1145.am/db/2590596/Elan_Corporation>,
        <https://1145.am/db/2592543/Elan>,
        <https://1145.am/db/2593465/Elan>,
        <https://1145.am/db/2595063/Elan_Corporation>,
        <https://1145.am/db/2597331/Elan_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350097/Seed_Stage_Investment_Beat_Biotherapeutics_Corporation_Cet_Capital_Partners_Seattle_W_Fund_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-17T15:49:56+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BEAT BioTherapeutics Corporation Closes $ 2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure.",
        "SEATTLE- (BUSINESS WIRE) -BEATBio, a Seattle, Wash. - based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $ 2.5 million seed stage investment with funding provided by CET Capital Partners." ;
    ns1:documentTitle "BEAT BioTherapeutics Corporation Closes $2.5MM Seed Financing to Develop Its Gene Therapy Treatment for Heart Failure" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/beat-biotherapeutics-corporation-closes-2-5mm-seed-financing-to-develop-its-gene-therapy> ;
    ns1:foundName "Financing",
        "investment" ;
    ns1:name "Financing",
        "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2350097/Beat_Biotherapeutics_Corporation>,
        <https://1145.am/db/2350097/Seattle> ;
    ns1:targetDetails "Seed",
        "seed stage" ;
    ns1:valueRaw "$ 2.5 million",
        "$ 2.5MM" ;
    ns1:whereGeoName "Washington" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4140963/about.rdf> ;
    ns1:whereRaw "Washington" .

<https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInLowRaw "France" ;
    ns1:description "Private Equity Funds" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "Edmond de Rothschild Investment Partners (EdRIP)" ;
    ns1:investor <https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351191/Genticel> a org:Organization ;
    ns1:description "developing innovative vaccines for patients infected with human papillomavirus" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "Genticel" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Genticel" ;
    ns1:sameAsHigh <https://1145.am/db/1331709/Gensight_Biologics>,
        <https://1145.am/db/1378979/Genfit>,
        <https://1145.am/db/1472276/Gensight_Biologics>,
        <https://1145.am/db/1599800/Gensight_Biologics>,
        <https://1145.am/db/1663819/Gensight_Biologics>,
        <https://1145.am/db/2310091/Genmab>,
        <https://1145.am/db/2344595/Genhelix>,
        <https://1145.am/db/2347393/Genvec>,
        <https://1145.am/db/2348012/Gensight_Biologics>,
        <https://1145.am/db/2350770/Human_Genome_Sciences>,
        <https://1145.am/db/2350774/Human_Genome_Sciences_Inc>,
        <https://1145.am/db/2351544/Genvec_Inc>,
        <https://1145.am/db/2351907/Genfit>,
        <https://1145.am/db/2353970/Genocea_Biosciences>,
        <https://1145.am/db/2361021/Genfit>,
        <https://1145.am/db/2362804/Human_Genome_Sciences>,
        <https://1145.am/db/2363551/Genocea_Biosciences>,
        <https://1145.am/db/2367963/Genisphere>,
        <https://1145.am/db/2370473/Genfit>,
        <https://1145.am/db/2536128/Genocea_Biosciences_Inc>,
        <https://1145.am/db/2553761/Genhelix>,
        <https://1145.am/db/2580443/Human_Genome_Sciences>,
        <https://1145.am/db/470251/Genocea_Biosciences>,
        <https://1145.am/db/703837/Genfit>,
        <https://1145.am/db/795939/Gensight_Biologics>,
        <https://1145.am/db/883613/Genocea_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2351192/Genticel>,
        <https://1145.am/db/2364536/Genticel> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInLowRaw "Europe" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "Edmond de Rothschild Investment Partners" ;
    ns1:investor <https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352170/Aisling_Capital> a org:Organization ;
    ns1:basedInLowRaw "Ireland" ;
    ns1:description "Investing" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Aisling Capital" ;
    ns1:investor <https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> ;
    ns1:name "Aisling Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1334160/Aisling_Capital>,
        <https://1145.am/db/1334934/Aisling_Capital>,
        <https://1145.am/db/1665536/Aisling_Capital>,
        <https://1145.am/db/2328388/Aisling_Capital>,
        <https://1145.am/db/2332753/Aisling_Capital>,
        <https://1145.am/db/2339223/Aisling_Capital>,
        <https://1145.am/db/802321/Aisling_Capital>,
        <https://1145.am/db/803398/Aisling_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2280707/Aisling_Capital>,
        <https://1145.am/db/2291277/Aisling_Capital>,
        <https://1145.am/db/2292103/Aisling_Capital>,
        <https://1145.am/db/2292800/Aisling_Capital>,
        <https://1145.am/db/2294156/Aisling_Capital>,
        <https://1145.am/db/2297408/Aisling_Capital>,
        <https://1145.am/db/2307476/Aisling_Capital>,
        <https://1145.am/db/2310940/Aisling_Capital>,
        <https://1145.am/db/2317775/Aisling_Capital>,
        <https://1145.am/db/2319433/Aisling_Capital>,
        <https://1145.am/db/2320852/Aisling_Capital>,
        <https://1145.am/db/2320853/Aisling_Capital>,
        <https://1145.am/db/2324244/Aisling_Capital>,
        <https://1145.am/db/2324255/Aisling_Capital>,
        <https://1145.am/db/2325553/Aisling_Capital>,
        <https://1145.am/db/2326576/Aisling_Capital>,
        <https://1145.am/db/2336503/Aisling_Capital>,
        <https://1145.am/db/2336505/Aisling_Capital>,
        <https://1145.am/db/2336524/Aisling_Capital>,
        <https://1145.am/db/2337250/Aisling_Capital>,
        <https://1145.am/db/2337254/Aisling_Capital>,
        <https://1145.am/db/2339214/Aisling_Capital>,
        <https://1145.am/db/2341595/Aisling_Capital>,
        <https://1145.am/db/2341599/Aisling_Capital>,
        <https://1145.am/db/2344735/Aisling_Capital>,
        <https://1145.am/db/2344739/Aisling_Capital>,
        <https://1145.am/db/2344874/Aisling_Capital>,
        <https://1145.am/db/2346030/Aisling_Capital>,
        <https://1145.am/db/2346293/Aisling_Capital>,
        <https://1145.am/db/2348754/Aisling_Capital>,
        <https://1145.am/db/2352059/Aisling_Capital>,
        <https://1145.am/db/2352167/Aisling_Capital>,
        <https://1145.am/db/2356297/Aisling_Capital>,
        <https://1145.am/db/2357356/Aisling_Capital>,
        <https://1145.am/db/2359185/Aisling_Capital>,
        <https://1145.am/db/2359468/Aisling_Capital>,
        <https://1145.am/db/2362736/Aisling_Capital>,
        <https://1145.am/db/2362737/Aisling_Capital>,
        <https://1145.am/db/2367022/Aisling_Capital>,
        <https://1145.am/db/2367023/Aisling_Capital>,
        <https://1145.am/db/2369304/Aisling_Capital>,
        <https://1145.am/db/2369305/Aisling_Capital>,
        <https://1145.am/db/2539913/Aisling_Capital>,
        <https://1145.am/db/2583013/Aisling_Capital>,
        <https://1145.am/db/2588372/Aisling_Capital>,
        <https://1145.am/db/2591606/Aisling_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Amgen_Ventures> a org:Organization ;
    ns1:description "investors" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Embl_Ventures> a org:Organization ;
    ns1:description "The new investors joining the consortium are BB Biotech Ventures, Sunstone Capital, Ba" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "EMBL Ventures" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "EMBL Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301728/Embl_Ventures>,
        <https://1145.am/db/2305628/Embl_Ventures>,
        <https://1145.am/db/2320503/Embl_Ventures>,
        <https://1145.am/db/2350101/Embl_Ventures>,
        <https://1145.am/db/2352204/Embl_Ventures>,
        <https://1145.am/db/2352216/Embl_Ventures>,
        <https://1145.am/db/2361457/Embl_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Fountain_Healthcare_Partners> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Fountain Healthcare Partners" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Fountain Healthcare Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1061564/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219334/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219771/Fountain_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1173939/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2152706/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2228342/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2288332/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2288529/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2291023/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2294585/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2296850/Fountain_Healthcare>,
        <https://1145.am/db/2298125/Fountain_Healthcare>,
        <https://1145.am/db/2299803/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2327485/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2327490/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2330711/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2330799/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2331750/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2351129/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352204/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352216/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2358172/Fountain_Healthcare_Partners_Ii>,
        <https://1145.am/db/2360266/Fountain_Healthcare_Partners>,
        <https://1145.am/db/236357/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2569220/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2583466/Fountain_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Seroba_Kernel_Life_Sciences> a org:Organization ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Seroba Kernel Life Sciences" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Seroba Kernel Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1386529/Seroba_Life_Sciences>,
        <https://1145.am/db/2301096/Seroba_Life_Sciences>,
        <https://1145.am/db/2301620/Seroba_Life_Sciences>,
        <https://1145.am/db/2331751/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352204/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2355511/Seroba-Kernel_Life_Sciences_Ltd>,
        <https://1145.am/db/2356567/Seroba_Kernel_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2291361/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2330711/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331750/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2338987/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352216/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364510/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364514/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364518/Seroba_Kernel_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Amgen_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Embl_Ventures> a org:Organization ;
    ns1:description "investing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "EMBL Ventures" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "EMBL Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2053027/Amity_Ventures>,
        <https://1145.am/db/922278/Alter_Venture_Partners>,
        <https://1145.am/db/925630/Alter_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2301728/Embl_Ventures>,
        <https://1145.am/db/2305628/Embl_Ventures>,
        <https://1145.am/db/2320503/Embl_Ventures>,
        <https://1145.am/db/2350101/Embl_Ventures>,
        <https://1145.am/db/2352203/Embl_Ventures>,
        <https://1145.am/db/2352216/Embl_Ventures>,
        <https://1145.am/db/2361457/Embl_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Fountain_Healthcare_Partners> a org:Organization ;
    ns1:description "healthcare" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Fountain Healthcare Partners" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Fountain Healthcare Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2288529/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2298125/Fountain_Healthcare>,
        <https://1145.am/db/2299803/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2330711/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2330799/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2351129/Fountain_Healthcare_Partners>,
        <https://1145.am/db/236357/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2583466/Fountain_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1061564/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1173939/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219334/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219771/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2152706/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2228342/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2288332/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2291023/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2294585/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2296850/Fountain_Healthcare>,
        <https://1145.am/db/2327485/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2327490/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2331750/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352203/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352216/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2358172/Fountain_Healthcare_Partners_Ii>,
        <https://1145.am/db/2360266/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2569220/Fountain_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Seroba_Kernel_Life_Sciences> a org:Organization ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Seroba Kernel Life Sciences" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Seroba Kernel Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1386529/Seroba_Life_Sciences>,
        <https://1145.am/db/2301096/Seroba_Life_Sciences>,
        <https://1145.am/db/2301620/Seroba_Life_Sciences>,
        <https://1145.am/db/2331751/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352203/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2355511/Seroba-Kernel_Life_Sciences_Ltd>,
        <https://1145.am/db/2356567/Seroba_Kernel_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2291361/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2330711/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331750/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2338987/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352216/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364510/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364514/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364518/Seroba_Kernel_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Sunstone_Capital> a org:Organization ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Sunstone Capital" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Sunstone Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1388463/Schroders_Capital>,
        <https://1145.am/db/1503058/Schroders_Capital>,
        <https://1145.am/db/1648777/Hm_Capital>,
        <https://1145.am/db/2352361/Srone>,
        <https://1145.am/db/2790236/Schroders_Capital>,
        <https://1145.am/db/866508/Schroders_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1717714/Sunstone_Capital>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1791743/Sunstone_Capital>,
        <https://1145.am/db/1797413/Sunstone_Capital>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1803787/Sunstone_Capital>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1832434/Sunstone_Capital>,
        <https://1145.am/db/1833000/Sunstone_Capital>,
        <https://1145.am/db/1833646/Sunstone_Capital>,
        <https://1145.am/db/1850593/Sunstone_Capital>,
        <https://1145.am/db/1850760/Sunstone_Capital>,
        <https://1145.am/db/1854996/Sunstone_Capital>,
        <https://1145.am/db/1858818/Sunstone_Capital>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1868935/Sunstone_Capital>,
        <https://1145.am/db/1869517/Sunstone_Capital>,
        <https://1145.am/db/1870079/Sunstone_Capital>,
        <https://1145.am/db/1877786/Sunstone_Capital>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1885147/Sunstone_Capital>,
        <https://1145.am/db/1888954/Sunstone_Capital>,
        <https://1145.am/db/2323700/Sunstone_Capital>,
        <https://1145.am/db/2329919/Sunstone_Capital>,
        <https://1145.am/db/2336622/Sunstone_Capital>,
        <https://1145.am/db/2341942/Sunstone_Capital>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2347980/Sunstone_Capital>,
        <https://1145.am/db/2348003/Sunstone_Capital>,
        <https://1145.am/db/2352203/Sunstone_Capital>,
        <https://1145.am/db/2352216/Sunstone_Capital>,
        <https://1145.am/db/2355609/Sunstone_Capital>,
        <https://1145.am/db/2355841/Sunstone_Capital>,
        <https://1145.am/db/2360127/Sunstone_Capital>,
        <https://1145.am/db/2360922/Sunstone_Capital>,
        <https://1145.am/db/2367218/Sunstone_Capital>,
        <https://1145.am/db/2569491/Sunstone_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352207/Series_A_Investment_Morgenthaler_Ventures_Scioderm_Technology_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T11:29:17+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Scioderm Closes $ 16 Million in Series A Financing.",
        "Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $ 16 million." ;
    ns1:documentTitle "Scioderm Closes $16 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/scioderm-closes-16-million-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352207/Scioderm> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 16 Million",
        "$ 16 million" .

<https://1145.am/db/2352211/Investment_Blavatnik_Family_Harvard_University_The_Blavatnik_Family_Foundation_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T14:00:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Harvard Announces $ 50 Million Gift from the Blavatnik Family Foundation.",
        "The Blavatnik Family Foundation, headed by Len Blavatnik (M.B.A. '89) , has donated $ 50 million to Harvard University." ;
    ns1:documentTitle "Harvard Announces $50 Million Gift from the Blavatnik Family Foundation" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/harvard-announces-50-million-gift-from-blavatnik-family-foundation> ;
    ns1:foundName "Gift",
        "donated" ;
    ns1:name "Gift",
        "donated" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352211/Harvard_University> ;
    ns1:valueRaw "$ 50 Million",
        "$ 50 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2352216/Amgen_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Embl_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "EMBL Ventures" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "EMBL Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301728/Embl_Ventures>,
        <https://1145.am/db/2305628/Embl_Ventures>,
        <https://1145.am/db/2320503/Embl_Ventures>,
        <https://1145.am/db/2350101/Embl_Ventures>,
        <https://1145.am/db/2352203/Embl_Ventures>,
        <https://1145.am/db/2352204/Embl_Ventures>,
        <https://1145.am/db/2361457/Embl_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Fountain_Healthcare_Partners> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Fountain Healthcare Partners" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Fountain Healthcare Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1061564/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1173939/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219334/Fountain_Healthcare_Partners>,
        <https://1145.am/db/1219771/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2152706/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2228342/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2288332/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2288529/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2291023/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2294585/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2296850/Fountain_Healthcare>,
        <https://1145.am/db/2298125/Fountain_Healthcare>,
        <https://1145.am/db/2299803/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2327485/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2327490/Fountain_Healthcare_Partners_I>,
        <https://1145.am/db/2330711/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2330799/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2331750/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2351129/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352203/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2352204/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2358172/Fountain_Healthcare_Partners_Ii>,
        <https://1145.am/db/2360266/Fountain_Healthcare_Partners>,
        <https://1145.am/db/236357/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2569220/Fountain_Healthcare_Partners>,
        <https://1145.am/db/2583466/Fountain_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Seroba_Kernel_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Seroba Kernel Life Sciences" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Seroba Kernel Life Sciences" ;
    ns1:sameAsMedium <https://1145.am/db/2291361/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2330711/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331750/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2331751/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2338987/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352203/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2352204/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2356567/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364510/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364514/Seroba_Kernel_Life_Sciences>,
        <https://1145.am/db/2364518/Seroba_Kernel_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Sunstone_Capital> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Sunstone Capital" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Sunstone Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1717714/Sunstone_Capital>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1791743/Sunstone_Capital>,
        <https://1145.am/db/1797413/Sunstone_Capital>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1803787/Sunstone_Capital>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1832434/Sunstone_Capital>,
        <https://1145.am/db/1833000/Sunstone_Capital>,
        <https://1145.am/db/1833646/Sunstone_Capital>,
        <https://1145.am/db/1850593/Sunstone_Capital>,
        <https://1145.am/db/1850760/Sunstone_Capital>,
        <https://1145.am/db/1854996/Sunstone_Capital>,
        <https://1145.am/db/1858818/Sunstone_Capital>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1868935/Sunstone_Capital>,
        <https://1145.am/db/1869517/Sunstone_Capital>,
        <https://1145.am/db/1870079/Sunstone_Capital>,
        <https://1145.am/db/1877786/Sunstone_Capital>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1885147/Sunstone_Capital>,
        <https://1145.am/db/1888954/Sunstone_Capital>,
        <https://1145.am/db/2323700/Sunstone_Capital>,
        <https://1145.am/db/2329919/Sunstone_Capital>,
        <https://1145.am/db/2336622/Sunstone_Capital>,
        <https://1145.am/db/2341942/Sunstone_Capital>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2347980/Sunstone_Capital>,
        <https://1145.am/db/2348003/Sunstone_Capital>,
        <https://1145.am/db/2352203/Sunstone_Capital>,
        <https://1145.am/db/2352204/Sunstone_Capital>,
        <https://1145.am/db/2355609/Sunstone_Capital>,
        <https://1145.am/db/2355841/Sunstone_Capital>,
        <https://1145.am/db/2360127/Sunstone_Capital>,
        <https://1145.am/db/2360922/Sunstone_Capital>,
        <https://1145.am/db/2367218/Sunstone_Capital>,
        <https://1145.am/db/2569491/Sunstone_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353241/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:description "biopharmaceutical company" ;
    ns1:documentDate "2013-05-02T12:25:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Symphogen Expands Previous Private Equity Round, Reaching a Total of EUR 141 million (USD 185 Million)" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/symphogen-expands-previous-private-equity-round-reaching-a-total-of-eur-141-million-usd-185> ;
    ns1:foundName "Novo A/S" ;
    ns1:industry "biopharmaceutical" ;
    ns1:investor <https://1145.am/db/2353241/Preferred_Stock_Investment_Danica_Pension_Novo_A_S_Pka_Symphogen_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsHigh <https://1145.am/db/2117423/Novo_Holdings>,
        <https://1145.am/db/2121791/Novo_Holdings>,
        <https://1145.am/db/2296065/Novo_Holdings_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2343966/Novo_Ventures>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358601/Novogen_Limited>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2368537/Novogen_Limited>,
        <https://1145.am/db/2368599/Novogen_Limited>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2546388/Novogen_Limited>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2570463/Novo_Nordisk>,
        <https://1145.am/db/2587996/Novocol_Pharmaceutical>,
        <https://1145.am/db/803398/Novo_Holdings_A_S>,
        <https://1145.am/db/842953/Novo_Nordisk> ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353241/Symphogen> a org:Organization ;
    ns1:basedInLowRaw "Danica Pension" ;
    ns1:description "developing recombinant antibody mixtures" ;
    ns1:documentDate "2013-05-02T12:25:48+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Symphogen Expands Previous Private Equity Round, Reaching a Total of EUR 141 million (USD 185 Million)" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/symphogen-expands-previous-private-equity-round-reaching-a-total-of-eur-141-million-usd-185> ;
    ns1:foundName "Symphogen" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Symphogen" ;
    ns1:sameAsHigh <https://1145.am/db/1180905/Syros_Pharmaceuticals>,
        <https://1145.am/db/1181453/Syros_Pharmaceuticals>,
        <https://1145.am/db/1183641/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1184316/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1265967/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1266692/Syros_Pharmaceuticals_Inc>,
        <https://1145.am/db/1348218/Syros_Pharmaceuticals>,
        <https://1145.am/db/1349294/Syros_Pharmaceuticals>,
        <https://1145.am/db/2131988/Syros>,
        <https://1145.am/db/2281887/Symeres>,
        <https://1145.am/db/2285044/Symeres>,
        <https://1145.am/db/2317635/Symmetrix_Pharmaceuticals>,
        <https://1145.am/db/2325241/Symphogen_A_S>,
        <https://1145.am/db/2333086/Systech_International>,
        <https://1145.am/db/2333089/Systech_International>,
        <https://1145.am/db/2340496/Symphogen>,
        <https://1145.am/db/2341595/Syros_Pharmaceuticals>,
        <https://1145.am/db/2341599/Syros_Pharmaceuticals>,
        <https://1145.am/db/2348074/Syros_Pharmaceuticals>,
        <https://1145.am/db/2358489/Syros_Pharmaceuticals>,
        <https://1145.am/db/2359527/Syros_Pharmaceuticals>,
        <https://1145.am/db/2366114/Symphogen>,
        <https://1145.am/db/2366334/Symphogen>,
        <https://1145.am/db/2368617/Syros_Pharmaceuticals>,
        <https://1145.am/db/2369304/Syros_Pharmaceuticals>,
        <https://1145.am/db/2369305/Syros_Pharmaceuticals>,
        <https://1145.am/db/2370574/Syros_Pharmaceuticals>,
        <https://1145.am/db/464043/Syros_Pharmaceuticals>,
        <https://1145.am/db/464628/Syros_Pharmaceuticals>,
        <https://1145.am/db/502636/Syros_Pharmaceuticals>,
        <https://1145.am/db/539655/Syros_Pharmaceuticals>,
        <https://1145.am/db/641899/Sylphar_International> ;
    ns1:sameAsMedium <https://1145.am/db/2153288/Symphogen>,
        <https://1145.am/db/2323692/Symphogen_A_S>,
        <https://1145.am/db/2327350/Symphogen_A_S>,
        <https://1145.am/db/2327381/Symphogen_A_S>,
        <https://1145.am/db/2557634/Symphogen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354266/Investment_Mrieux_Dveloppement_Neurophage_Pharmaceuticals_Shire_Llc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-06T11:58:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cambridge, MA, May 6, 2013 - NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $ 6.4 million in a private equity financing round." ;
    ns1:documentTitle "NEUROPHAGE, INC. RAISES $6.4 MILLION IN ADDITIONAL FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/neurophage-inc-raises-6-4-million-additional-financing> ;
    ns1:foundName "financing",
        "private",
        "private equity",
        "raised" ;
    ns1:name "financing",
        "private",
        "private equity",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2354266/Neurophage_Pharmaceuticals> ;
    ns1:valueRaw "$ 6.4 million" ;
    ns1:when "2013-05-06T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 6, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2359547/Jennerex_Inc> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "immunotherapy products" ;
    ns1:documentDate "2013-05-28T16:00:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Jennerex, Inc",
        "Jennerex, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Jennerex, Inc",
        "Jennerex, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2320981/Jennerex>,
        <https://1145.am/db/2351856/Jennerex>,
        <https://1145.am/db/2353431/Jennerex>,
        <https://1145.am/db/2353849/Jennerex>,
        <https://1145.am/db/2581948/Jennerex_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2307230/Jennerex_Inc>,
        <https://1145.am/db/2319536/Jennerex>,
        <https://1145.am/db/2319537/Jennerex>,
        <https://1145.am/db/2337384/Jennerex>,
        <https://1145.am/db/2347602/Jennerex>,
        <https://1145.am/db/2365742/Jennerex> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Investment_Janssen_Johnson___Johnson_Innovation_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Janssen and Johnson & Johnson Innovation are committing up to 5 million over a 5-year period to sponsor research work on neurological diseases at VIB, KU Leuven and UZ Leuven." ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "committing" ;
    ns1:name "committing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:valueRaw "up to 5 million" ;
    ns1:whereGeoName "Kingdom of Belgium" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:whereRaw "Belgium" .

<https://1145.am/db/2360562/Novo> a org:Organization ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Nov" ;
    ns1:industry "Biotech" ;
    ns1:investor <https://1145.am/db/2360562/Investment_Ophthotech_Completed> ;
    ns1:name "Novo" ;
    ns1:sameAsHigh <https://1145.am/db/2117423/Novo_Holdings>,
        <https://1145.am/db/2121791/Novo_Holdings>,
        <https://1145.am/db/2296065/Novo_Holdings_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2343966/Novo_Ventures>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358601/Novogen_Limited>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2368537/Novogen_Limited>,
        <https://1145.am/db/2368599/Novogen_Limited>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2546388/Novogen_Limited>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2570463/Novo_Nordisk>,
        <https://1145.am/db/2587996/Novocol_Pharmaceutical>,
        <https://1145.am/db/842953/Novo_Nordisk> ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Okairos> a org:Organization ;
    ns1:basedInLowRaw "Greece" ;
    ns1:description "vaccines" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Okairos" ;
    ns1:industry "Biotech" ;
    ns1:name "Okairos" ;
    ns1:sameAsHigh <https://1145.am/db/1061765/Okyo>,
        <https://1145.am/db/2307682/Okairos>,
        <https://1145.am/db/2360552/Okairos> ;
    ns1:sameAsMedium <https://1145.am/db/2348505/Okairos>,
        <https://1145.am/db/2359553/Okairos_Ag>,
        <https://1145.am/db/2360189/Okairos>,
        <https://1145.am/db/2360191/Okairos> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360562/Ophthotech> a org:Organization ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "Ophthotech" ;
    ns1:industry "Biotech" ;
    ns1:name "Ophthotech" ;
    ns1:sameAsHigh <https://1145.am/db/2155325/Ophthotech>,
        <https://1145.am/db/2302994/Ophthotech>,
        <https://1145.am/db/2339669/Ophthotech>,
        <https://1145.am/db/2360554/Ophthotech> ;
    ns1:sameAsMedium <https://1145.am/db/2302995/Ophthotech_Corp>,
        <https://1145.am/db/2336272/Ophthotech_Corporation>,
        <https://1145.am/db/2355197/Ophthotech>,
        <https://1145.am/db/2360550/Ophthotech_Corporation>,
        <https://1145.am/db/2369057/Ophthotech_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Venbio> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "venBio" ;
    ns1:investor <https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> ;
    ns1:name "venBio" ;
    ns1:sameAsMedium <https://1145.am/db/2336503/Venbio>,
        <https://1145.am/db/2336505/Venbio>,
        <https://1145.am/db/2336524/Venbio>,
        <https://1145.am/db/2346293/Venbio>,
        <https://1145.am/db/2352349/Venbio>,
        <https://1145.am/db/2352350/Venbio>,
        <https://1145.am/db/2359468/Venbio>,
        <https://1145.am/db/2360667/Venbio>,
        <https://1145.am/db/2364514/Venbio>,
        <https://1145.am/db/2364518/Venbio>,
        <https://1145.am/db/2570520/Venbio>,
        <https://1145.am/db/2570523/Venbio>,
        <https://1145.am/db/2575687/Venbio>,
        <https://1145.am/db/2583013/Venbio>,
        <https://1145.am/db/428737/Venbio>,
        <https://1145.am/db/560096/Venbio>,
        <https://1145.am/db/704198/Venbio> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360667/Uc_San_Diego> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "research" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "UC San Diego" ;
    ns1:name "UC San Diego" ;
    ns1:sameAsHigh <https://1145.am/db/2575687/Uc_San_Diego> ;
    ns1:sameAsMedium <https://1145.am/db/2560987/Uc_San_Diego> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360667/University_Of_California_San_Diego_Intellectual_Property_Covering> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO",
        "San Diego" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "University of California, San Diego",
        "University of California, San Diego intellectual property covering" ;
    ns1:name "University of California, San Diego",
        "University of California, San Diego intellectual property covering" ;
    ns1:sameAsMedium <https://1145.am/db/2575687/University_Of_California_San_Diego_Intellectual_Property_Covering> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360667/Venbio> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "venBio" ;
    ns1:investor <https://1145.am/db/2360667/License_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> ;
    ns1:name "venBio" ;
    ns1:sameAsMedium <https://1145.am/db/2336503/Venbio>,
        <https://1145.am/db/2336505/Venbio>,
        <https://1145.am/db/2336524/Venbio>,
        <https://1145.am/db/2346293/Venbio>,
        <https://1145.am/db/2352349/Venbio>,
        <https://1145.am/db/2352350/Venbio>,
        <https://1145.am/db/2359468/Venbio>,
        <https://1145.am/db/2360647/Venbio>,
        <https://1145.am/db/2364514/Venbio>,
        <https://1145.am/db/2364518/Venbio>,
        <https://1145.am/db/2570520/Venbio>,
        <https://1145.am/db/2570523/Venbio>,
        <https://1145.am/db/2575687/Venbio>,
        <https://1145.am/db/2583013/Venbio>,
        <https://1145.am/db/428737/Venbio>,
        <https://1145.am/db/560096/Venbio>,
        <https://1145.am/db/704198/Venbio> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361595/Stemcells> a org:Organization ;
    ns1:basedInHighGeoName "Newark" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5376803/about.rdf> ;
    ns1:basedInHighRaw "Newark, CA" ;
    ns1:documentDate "2013-06-04T15:29:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "StemCells lines up $30M in financing; Biotie grabs option to buy San Diego biotech; Edge Therapeutics executes $18M Series C;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemcells-lines-up-30m-financing-biotie-grabs-option-to-buy-san-diego-biotech-edge> ;
    ns1:foundName "StemCells" ;
    ns1:name "StemCells" ;
    ns1:sameAsMedium <https://1145.am/db/2296007/Stemcells>,
        <https://1145.am/db/2307790/Stemcells_Inc>,
        <https://1145.am/db/2313373/Stemcells>,
        <https://1145.am/db/2313392/Stemcells_Inc>,
        <https://1145.am/db/2326453/Stemcells>,
        <https://1145.am/db/2333160/Stemcells>,
        <https://1145.am/db/2336320/Stemcells_Inc>,
        <https://1145.am/db/2341976/Stemcells_Inc>,
        <https://1145.am/db/2352908/Stemcells_Inc>,
        <https://1145.am/db/2361594/Stemcells>,
        <https://1145.am/db/2362442/Stemcells_Inc>,
        <https://1145.am/db/2363708/Stemcells_Inc>,
        <https://1145.am/db/2367002/Stemcells_Inc>,
        <https://1145.am/db/2369298/Stemcells_Inc>,
        <https://1145.am/db/2571560/Stemcells_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/Aisling_Capital> a org:Organization ;
    ns1:basedInLowRaw "Ireland" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "Aisling Capital" ;
    ns1:investor <https://1145.am/db/2362736/C_Investment_Advent_Venture_Partners_Aisling_Capital_Index_Ventures_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Aisling Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1334160/Aisling_Capital>,
        <https://1145.am/db/1334934/Aisling_Capital>,
        <https://1145.am/db/1665536/Aisling_Capital>,
        <https://1145.am/db/2280707/Aisling_Capital>,
        <https://1145.am/db/2291277/Aisling_Capital>,
        <https://1145.am/db/2292103/Aisling_Capital>,
        <https://1145.am/db/2292800/Aisling_Capital>,
        <https://1145.am/db/2294156/Aisling_Capital>,
        <https://1145.am/db/2297408/Aisling_Capital>,
        <https://1145.am/db/2307476/Aisling_Capital>,
        <https://1145.am/db/2310940/Aisling_Capital>,
        <https://1145.am/db/2317775/Aisling_Capital>,
        <https://1145.am/db/2319433/Aisling_Capital>,
        <https://1145.am/db/2320852/Aisling_Capital>,
        <https://1145.am/db/2320853/Aisling_Capital>,
        <https://1145.am/db/2324244/Aisling_Capital>,
        <https://1145.am/db/2324255/Aisling_Capital>,
        <https://1145.am/db/2325553/Aisling_Capital>,
        <https://1145.am/db/2326576/Aisling_Capital>,
        <https://1145.am/db/2328388/Aisling_Capital>,
        <https://1145.am/db/2332753/Aisling_Capital>,
        <https://1145.am/db/2336503/Aisling_Capital>,
        <https://1145.am/db/2336505/Aisling_Capital>,
        <https://1145.am/db/2336524/Aisling_Capital>,
        <https://1145.am/db/2337250/Aisling_Capital>,
        <https://1145.am/db/2337254/Aisling_Capital>,
        <https://1145.am/db/2339214/Aisling_Capital>,
        <https://1145.am/db/2339223/Aisling_Capital>,
        <https://1145.am/db/2341595/Aisling_Capital>,
        <https://1145.am/db/2341599/Aisling_Capital>,
        <https://1145.am/db/2344735/Aisling_Capital>,
        <https://1145.am/db/2344739/Aisling_Capital>,
        <https://1145.am/db/2344874/Aisling_Capital>,
        <https://1145.am/db/2346030/Aisling_Capital>,
        <https://1145.am/db/2346293/Aisling_Capital>,
        <https://1145.am/db/2348754/Aisling_Capital>,
        <https://1145.am/db/2352059/Aisling_Capital>,
        <https://1145.am/db/2352167/Aisling_Capital>,
        <https://1145.am/db/2352170/Aisling_Capital>,
        <https://1145.am/db/2356297/Aisling_Capital>,
        <https://1145.am/db/2357356/Aisling_Capital>,
        <https://1145.am/db/2359185/Aisling_Capital>,
        <https://1145.am/db/2359468/Aisling_Capital>,
        <https://1145.am/db/2362737/Aisling_Capital>,
        <https://1145.am/db/2367022/Aisling_Capital>,
        <https://1145.am/db/2367023/Aisling_Capital>,
        <https://1145.am/db/2369304/Aisling_Capital>,
        <https://1145.am/db/2369305/Aisling_Capital>,
        <https://1145.am/db/2539913/Aisling_Capital>,
        <https://1145.am/db/2583013/Aisling_Capital>,
        <https://1145.am/db/2588372/Aisling_Capital>,
        <https://1145.am/db/2591606/Aisling_Capital>,
        <https://1145.am/db/802321/Aisling_Capital>,
        <https://1145.am/db/803398/Aisling_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/Index_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Redwood City, CA" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "Index Ventures" ;
    ns1:investor <https://1145.am/db/2362736/C_Investment_Advent_Venture_Partners_Aisling_Capital_Index_Ventures_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Index Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1247967/Index_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1358814/Index_Ventures>,
        <https://1145.am/db/1490485/Index_Ventures>,
        <https://1145.am/db/1493654/Index_Ventures>,
        <https://1145.am/db/1553352/Index_Ventures>,
        <https://1145.am/db/1693951/Index_Ventures>,
        <https://1145.am/db/1694279/Index_Ventures>,
        <https://1145.am/db/1699089/Index_Ventures>,
        <https://1145.am/db/1704793/Index_Ventures>,
        <https://1145.am/db/1711587/Index_Ventures>,
        <https://1145.am/db/1711731/Index_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1712506/Index_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1717574/Index_Ventures>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1733028/Index_Ventures>,
        <https://1145.am/db/1735596/Index_Ventures>,
        <https://1145.am/db/1736117/Index_Ventures>,
        <https://1145.am/db/1737079/Index_Ventures>,
        <https://1145.am/db/1737527/Index_Ventures>,
        <https://1145.am/db/1737696/Index_Ventures>,
        <https://1145.am/db/1738402/Index_Ventures>,
        <https://1145.am/db/1738465/Index_Ventures>,
        <https://1145.am/db/1740781/Index_Ventures>,
        <https://1145.am/db/1742878/Index_Ventures>,
        <https://1145.am/db/1744753/Index_Ventures>,
        <https://1145.am/db/1745368/Index_Ventures>,
        <https://1145.am/db/1745702/Index_Ventures>,
        <https://1145.am/db/1746192/Index_Ventures>,
        <https://1145.am/db/1746800/Index_Ventures>,
        <https://1145.am/db/1746845/Index_Ventures>,
        <https://1145.am/db/1746947/Index_Ventures>,
        <https://1145.am/db/1747153/Index_Ventures>,
        <https://1145.am/db/1747208/Index_Ventures>,
        <https://1145.am/db/1748172/Index_Ventures>,
        <https://1145.am/db/1748621/Index_Ventures>,
        <https://1145.am/db/1750406/Index_Ventures>,
        <https://1145.am/db/1750420/Index_Ventures>,
        <https://1145.am/db/1750828/Index_Ventures>,
        <https://1145.am/db/1752154/Index_Ventures>,
        <https://1145.am/db/1755398/Index_Ventures>,
        <https://1145.am/db/1755899/Index_Ventures>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756768/Index_Ventures>,
        <https://1145.am/db/1756873/Index_Ventures>,
        <https://1145.am/db/1758069/Index_Ventures>,
        <https://1145.am/db/1758834/Index_Ventures>,
        <https://1145.am/db/1759939/Index_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760954/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761664/Index_Ventures>,
        <https://1145.am/db/1762988/Index_Ventures>,
        <https://1145.am/db/1763352/Index_Ventures>,
        <https://1145.am/db/1765809/Index_Ventures>,
        <https://1145.am/db/1765870/Index_Ventures>,
        <https://1145.am/db/1766059/Index_Ventures>,
        <https://1145.am/db/1766253/Index_Ventures>,
        <https://1145.am/db/1769654/Index_Ventures>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771672/Index_Ventures>,
        <https://1145.am/db/1771734/Index_Ventures>,
        <https://1145.am/db/1771773/Index_Ventures>,
        <https://1145.am/db/1775903/Index_Ventures>,
        <https://1145.am/db/1776139/Index_Ventures>,
        <https://1145.am/db/1776626/Index_Ventures>,
        <https://1145.am/db/1777546/Index_Ventures>,
        <https://1145.am/db/1778195/Index_Ventures>,
        <https://1145.am/db/1780507/Index_Ventures>,
        <https://1145.am/db/1780733/Index_Ventures>,
        <https://1145.am/db/1783754/Index_Ventures>,
        <https://1145.am/db/1787471/Index_Ventures>,
        <https://1145.am/db/1787621/Index_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1790777/Index_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791667/Index_Ventures>,
        <https://1145.am/db/1791743/Index_Ventures>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1796201/Index_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1798836/Index_Ventures>,
        <https://1145.am/db/1799293/Index_Ventures>,
        <https://1145.am/db/1800172/Index_Ventures>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800998/Index_Ventures>,
        <https://1145.am/db/1805201/Index_Ventures>,
        <https://1145.am/db/1805473/Index_Ventures>,
        <https://1145.am/db/1807173/Index_Ventures>,
        <https://1145.am/db/1808484/Index_Ventures>,
        <https://1145.am/db/1809821/Index_Ventures>,
        <https://1145.am/db/1810000/Index_Ventures>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812038/Index_Ventures>,
        <https://1145.am/db/1812890/Index_Ventures>,
        <https://1145.am/db/1813037/Index_Ventures>,
        <https://1145.am/db/1813404/Index_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1819133/Index_Ventures>,
        <https://1145.am/db/1819302/Index_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1823078/Index_Ventures>,
        <https://1145.am/db/1823141/Index_Ventures>,
        <https://1145.am/db/1824561/Index_Ventures>,
        <https://1145.am/db/1828638/Index_Ventures>,
        <https://1145.am/db/1829991/Index_Ventures>,
        <https://1145.am/db/1830023/Index_Ventures>,
        <https://1145.am/db/1831440/Index_Ventures>,
        <https://1145.am/db/1832655/Index_Ventures>,
        <https://1145.am/db/1832808/Index_Ventures>,
        <https://1145.am/db/1832926/Index_Ventures>,
        <https://1145.am/db/1835321/Index_Ventures>,
        <https://1145.am/db/1835516/Index_Ventures>,
        <https://1145.am/db/1836455/Index_Ventures>,
        <https://1145.am/db/1836572/Index_Ventures>,
        <https://1145.am/db/1837081/Index_Ventures>,
        <https://1145.am/db/1837143/Index_Ventures>,
        <https://1145.am/db/1839663/Index_Ventures>,
        <https://1145.am/db/1840137/Index_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1845548/Index_Ventures>,
        <https://1145.am/db/1845841/Index_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846794/Index_Ventures>,
        <https://1145.am/db/1847483/Index_Ventures>,
        <https://1145.am/db/1848631/Index_Ventures>,
        <https://1145.am/db/1849844/Index_Ventures>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849912/Index_Ventures>,
        <https://1145.am/db/1850428/Index_Ventures>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851744/Index_Ventures>,
        <https://1145.am/db/1853547/Index_Ventures>,
        <https://1145.am/db/1854191/Index_Ventures>,
        <https://1145.am/db/1856171/Index_Ventures>,
        <https://1145.am/db/1856191/Index_Ventures>,
        <https://1145.am/db/1856802/Index_Ventures>,
        <https://1145.am/db/1856967/Index_Ventures>,
        <https://1145.am/db/1857638/Index_Ventures>,
        <https://1145.am/db/1858520/Index_Ventures>,
        <https://1145.am/db/1858521/Index_Ventures>,
        <https://1145.am/db/1862594/Index_Ventures>,
        <https://1145.am/db/1863500/Index_Ventures>,
        <https://1145.am/db/1865106/Index_Ventures>,
        <https://1145.am/db/1865524/Index_Ventures>,
        <https://1145.am/db/1866804/Index_Ventures>,
        <https://1145.am/db/1868923/Index_Ventures>,
        <https://1145.am/db/1868935/Index_Ventures>,
        <https://1145.am/db/1870074/Index_Ventures>,
        <https://1145.am/db/1870079/Index_Ventures>,
        <https://1145.am/db/1870810/Index_Ventures>,
        <https://1145.am/db/1871091/Index_Ventures>,
        <https://1145.am/db/1876014/Index_Ventures>,
        <https://1145.am/db/1876914/Index_Ventures>,
        <https://1145.am/db/1878630/Index_Ventures>,
        <https://1145.am/db/1880386/Index_Ventures>,
        <https://1145.am/db/1881391/Index_Ventures>,
        <https://1145.am/db/1881430/Index_Ventures>,
        <https://1145.am/db/1882301/Index_Ventures>,
        <https://1145.am/db/1882686/Index_Ventures>,
        <https://1145.am/db/1884077/Index_Ventures>,
        <https://1145.am/db/1885147/Index_Ventures>,
        <https://1145.am/db/1890254/Index_Ventures>,
        <https://1145.am/db/1893255/Index_Ventures>,
        <https://1145.am/db/1894621/Index_Ventures>,
        <https://1145.am/db/1894627/Index_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1899697/Index_Ventures>,
        <https://1145.am/db/1900904/Index_Ventures>,
        <https://1145.am/db/1902032/Index_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1910957/Index_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915168/Index_Ventures>,
        <https://1145.am/db/1916258/Index_Ventures>,
        <https://1145.am/db/1916868/Index_Ventures>,
        <https://1145.am/db/1919238/Index_Ventures>,
        <https://1145.am/db/1967520/Index_Ventures>,
        <https://1145.am/db/1967683/Index_Ventures>,
        <https://1145.am/db/199212/Index_Ventures>,
        <https://1145.am/db/2028609/Index_Ventures>,
        <https://1145.am/db/2060465/Index_Ventures>,
        <https://1145.am/db/2062814/Index_Ventures>,
        <https://1145.am/db/2127786/Index_Ventures>,
        <https://1145.am/db/217906/Index_Ventures>,
        <https://1145.am/db/2198066/Index_Ventures>,
        <https://1145.am/db/2234558/Index_Ventures>,
        <https://1145.am/db/2290088/Index_Ventures>,
        <https://1145.am/db/2290200/Index_Ventures>,
        <https://1145.am/db/2297905/Index_Ventures>,
        <https://1145.am/db/2303009/Index_Ventures>,
        <https://1145.am/db/2303849/Index_Ventures>,
        <https://1145.am/db/2309490/Index_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2309847/Index_Ventures>,
        <https://1145.am/db/2313410/Index_Ventures>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325147/Index_Ventures>,
        <https://1145.am/db/2327222/Index_Ventures>,
        <https://1145.am/db/2333601/Index_Ventures>,
        <https://1145.am/db/2338079/Index_Ventures>,
        <https://1145.am/db/2338193/Index_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2344127/Index_Ventures>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2348012/Index_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2348620/Index_Ventures>,
        <https://1145.am/db/2350031/Index_Ventures>,
        <https://1145.am/db/2352142/Index_Ventures>,
        <https://1145.am/db/2352145/Index_Ventures>,
        <https://1145.am/db/2355609/Index_Ventures>,
        <https://1145.am/db/2355952/Index_Ventures>,
        <https://1145.am/db/2357169/Index_Ventures>,
        <https://1145.am/db/2357356/Index_Ventures>,
        <https://1145.am/db/2358233/Index_Ventures>,
        <https://1145.am/db/2358246/Index_Ventures>,
        <https://1145.am/db/2362737/Index_Ventures>,
        <https://1145.am/db/2364597/Index_Ventures>,
        <https://1145.am/db/2364600/Index_Ventures>,
        <https://1145.am/db/2507691/Index_Ventures>,
        <https://1145.am/db/2555540/Index_Ventures>,
        <https://1145.am/db/2589317/Index_Ventures>,
        <https://1145.am/db/2643797/Index_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/317470/Index_Ventures>,
        <https://1145.am/db/318142/Index_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/337401/Index_Ventures>,
        <https://1145.am/db/348633/Index_Ventures>,
        <https://1145.am/db/366983/Index_Ventures>,
        <https://1145.am/db/367008/Index_Ventures>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/475105/Index_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/539919/Index_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/578277/Index_Ventures>,
        <https://1145.am/db/633695/Index_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/707126/Index_Ventures>,
        <https://1145.am/db/709798/Index_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/768008/Index_Ventures>,
        <https://1145.am/db/789218/Index_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/854512/Index_Ventures>,
        <https://1145.am/db/868352/Index_Ventures>,
        <https://1145.am/db/893076/Index_Ventures>,
        <https://1145.am/db/893316/Index_Ventures>,
        <https://1145.am/db/909344/Index_Ventures>,
        <https://1145.am/db/957097/Index_Ventures>,
        <https://1145.am/db/980375/Index_Ventures>,
        <https://1145.am/db/981840/Index_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/Versartis> a org:Organization ;
    ns1:basedInHighGeoName "Redwood City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5386834/about.rdf> ;
    ns1:basedInHighRaw "Redwood City" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "Versartis" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Versartis" ;
    ns1:sameAsHigh <https://1145.am/db/1378979/Versantis>,
        <https://1145.am/db/2285189/Versanis>,
        <https://1145.am/db/2343678/Versartis_Inc>,
        <https://1145.am/db/2357360/Versartis>,
        <https://1145.am/db/2592555/Versapharm>,
        <https://1145.am/db/2592575/Versapharm>,
        <https://1145.am/db/701424/Versantis> ;
    ns1:sameAsMedium <https://1145.am/db/2325140/Versartis_Inc>,
        <https://1145.am/db/2325147/Versartis_Inc>,
        <https://1145.am/db/2340691/Versartis_Inc>,
        <https://1145.am/db/2347568/Versartis>,
        <https://1145.am/db/2347571/Versartis>,
        <https://1145.am/db/2347739/Versartis>,
        <https://1145.am/db/2348618/Versartis>,
        <https://1145.am/db/2348620/Versartis_Inc>,
        <https://1145.am/db/2352059/Versartis>,
        <https://1145.am/db/2352331/Versartis>,
        <https://1145.am/db/2357241/Versartis>,
        <https://1145.am/db/2357356/Versartis>,
        <https://1145.am/db/2359361/Versartis>,
        <https://1145.am/db/2359375/Versartis>,
        <https://1145.am/db/2362737/Versartis>,
        <https://1145.am/db/2370072/Versartis_Inc>,
        <https://1145.am/db/2589317/Versartis> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362737/Aisling_Capital> a org:Organization ;
    ns1:basedInLowRaw "CA" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "Aisling Capital" ;
    ns1:investor <https://1145.am/db/2362737/Series_C_Investment_Aisling_Capital_Index_Ventures_Life_Sciences_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Aisling Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1334160/Aisling_Capital>,
        <https://1145.am/db/1334934/Aisling_Capital>,
        <https://1145.am/db/1665536/Aisling_Capital>,
        <https://1145.am/db/2280707/Aisling_Capital>,
        <https://1145.am/db/2291277/Aisling_Capital>,
        <https://1145.am/db/2292103/Aisling_Capital>,
        <https://1145.am/db/2292800/Aisling_Capital>,
        <https://1145.am/db/2294156/Aisling_Capital>,
        <https://1145.am/db/2297408/Aisling_Capital>,
        <https://1145.am/db/2307476/Aisling_Capital>,
        <https://1145.am/db/2310940/Aisling_Capital>,
        <https://1145.am/db/2317775/Aisling_Capital>,
        <https://1145.am/db/2319433/Aisling_Capital>,
        <https://1145.am/db/2320852/Aisling_Capital>,
        <https://1145.am/db/2320853/Aisling_Capital>,
        <https://1145.am/db/2324244/Aisling_Capital>,
        <https://1145.am/db/2324255/Aisling_Capital>,
        <https://1145.am/db/2325553/Aisling_Capital>,
        <https://1145.am/db/2326576/Aisling_Capital>,
        <https://1145.am/db/2328388/Aisling_Capital>,
        <https://1145.am/db/2332753/Aisling_Capital>,
        <https://1145.am/db/2336503/Aisling_Capital>,
        <https://1145.am/db/2336505/Aisling_Capital>,
        <https://1145.am/db/2336524/Aisling_Capital>,
        <https://1145.am/db/2337250/Aisling_Capital>,
        <https://1145.am/db/2337254/Aisling_Capital>,
        <https://1145.am/db/2339214/Aisling_Capital>,
        <https://1145.am/db/2339223/Aisling_Capital>,
        <https://1145.am/db/2341595/Aisling_Capital>,
        <https://1145.am/db/2341599/Aisling_Capital>,
        <https://1145.am/db/2344735/Aisling_Capital>,
        <https://1145.am/db/2344739/Aisling_Capital>,
        <https://1145.am/db/2344874/Aisling_Capital>,
        <https://1145.am/db/2346030/Aisling_Capital>,
        <https://1145.am/db/2346293/Aisling_Capital>,
        <https://1145.am/db/2348754/Aisling_Capital>,
        <https://1145.am/db/2352059/Aisling_Capital>,
        <https://1145.am/db/2352167/Aisling_Capital>,
        <https://1145.am/db/2352170/Aisling_Capital>,
        <https://1145.am/db/2356297/Aisling_Capital>,
        <https://1145.am/db/2357356/Aisling_Capital>,
        <https://1145.am/db/2359185/Aisling_Capital>,
        <https://1145.am/db/2359468/Aisling_Capital>,
        <https://1145.am/db/2362736/Aisling_Capital>,
        <https://1145.am/db/2367022/Aisling_Capital>,
        <https://1145.am/db/2367023/Aisling_Capital>,
        <https://1145.am/db/2369304/Aisling_Capital>,
        <https://1145.am/db/2369305/Aisling_Capital>,
        <https://1145.am/db/2539913/Aisling_Capital>,
        <https://1145.am/db/2583013/Aisling_Capital>,
        <https://1145.am/db/2588372/Aisling_Capital>,
        <https://1145.am/db/2591606/Aisling_Capital>,
        <https://1145.am/db/802321/Aisling_Capital>,
        <https://1145.am/db/803398/Aisling_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362737/Index_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CA" ;
    ns1:description "investing" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "Index Ventures" ;
    ns1:investor <https://1145.am/db/2362737/Series_C_Investment_Aisling_Capital_Index_Ventures_Life_Sciences_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Index Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1247967/Index_Ventures>,
        <https://1145.am/db/1490485/Index_Ventures>,
        <https://1145.am/db/1704793/Index_Ventures>,
        <https://1145.am/db/1742878/Index_Ventures>,
        <https://1145.am/db/1746192/Index_Ventures>,
        <https://1145.am/db/1748621/Index_Ventures>,
        <https://1145.am/db/1766059/Index_Ventures>,
        <https://1145.am/db/1780507/Index_Ventures>,
        <https://1145.am/db/1799293/Index_Ventures>,
        <https://1145.am/db/1800172/Index_Ventures>,
        <https://1145.am/db/1849912/Index_Ventures>,
        <https://1145.am/db/1853547/Index_Ventures>,
        <https://1145.am/db/1856171/Index_Ventures>,
        <https://1145.am/db/1876014/Index_Ventures>,
        <https://1145.am/db/1876914/Index_Ventures>,
        <https://1145.am/db/1882301/Index_Ventures>,
        <https://1145.am/db/1893255/Index_Ventures>,
        <https://1145.am/db/1916868/Index_Ventures>,
        <https://1145.am/db/2028609/Index_Ventures>,
        <https://1145.am/db/2060465/Index_Ventures>,
        <https://1145.am/db/217906/Index_Ventures>,
        <https://1145.am/db/2234558/Index_Ventures>,
        <https://1145.am/db/2290200/Index_Ventures>,
        <https://1145.am/db/2309847/Index_Ventures>,
        <https://1145.am/db/2327222/Index_Ventures>,
        <https://1145.am/db/2357169/Index_Ventures>,
        <https://1145.am/db/2589317/Index_Ventures>,
        <https://1145.am/db/317470/Index_Ventures>,
        <https://1145.am/db/318142/Index_Ventures>,
        <https://1145.am/db/348633/Index_Ventures>,
        <https://1145.am/db/475105/Index_Ventures>,
        <https://1145.am/db/539919/Index_Ventures>,
        <https://1145.am/db/578277/Index_Ventures>,
        <https://1145.am/db/633695/Index_Ventures>,
        <https://1145.am/db/709798/Index_Ventures>,
        <https://1145.am/db/854512/Index_Ventures>,
        <https://1145.am/db/893076/Index_Ventures>,
        <https://1145.am/db/893316/Index_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1358814/Index_Ventures>,
        <https://1145.am/db/1493654/Index_Ventures>,
        <https://1145.am/db/1553352/Index_Ventures>,
        <https://1145.am/db/1693951/Index_Ventures>,
        <https://1145.am/db/1694279/Index_Ventures>,
        <https://1145.am/db/1699089/Index_Ventures>,
        <https://1145.am/db/1711587/Index_Ventures>,
        <https://1145.am/db/1711731/Index_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1712506/Index_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1717574/Index_Ventures>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1733028/Index_Ventures>,
        <https://1145.am/db/1735596/Index_Ventures>,
        <https://1145.am/db/1736117/Index_Ventures>,
        <https://1145.am/db/1737079/Index_Ventures>,
        <https://1145.am/db/1737527/Index_Ventures>,
        <https://1145.am/db/1737696/Index_Ventures>,
        <https://1145.am/db/1738402/Index_Ventures>,
        <https://1145.am/db/1738465/Index_Ventures>,
        <https://1145.am/db/1740781/Index_Ventures>,
        <https://1145.am/db/1744753/Index_Ventures>,
        <https://1145.am/db/1745368/Index_Ventures>,
        <https://1145.am/db/1745702/Index_Ventures>,
        <https://1145.am/db/1746800/Index_Ventures>,
        <https://1145.am/db/1746845/Index_Ventures>,
        <https://1145.am/db/1746947/Index_Ventures>,
        <https://1145.am/db/1747153/Index_Ventures>,
        <https://1145.am/db/1747208/Index_Ventures>,
        <https://1145.am/db/1748172/Index_Ventures>,
        <https://1145.am/db/1750406/Index_Ventures>,
        <https://1145.am/db/1750420/Index_Ventures>,
        <https://1145.am/db/1750828/Index_Ventures>,
        <https://1145.am/db/1752154/Index_Ventures>,
        <https://1145.am/db/1755398/Index_Ventures>,
        <https://1145.am/db/1755899/Index_Ventures>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756768/Index_Ventures>,
        <https://1145.am/db/1756873/Index_Ventures>,
        <https://1145.am/db/1758069/Index_Ventures>,
        <https://1145.am/db/1758834/Index_Ventures>,
        <https://1145.am/db/1759939/Index_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760954/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761664/Index_Ventures>,
        <https://1145.am/db/1762988/Index_Ventures>,
        <https://1145.am/db/1763352/Index_Ventures>,
        <https://1145.am/db/1765809/Index_Ventures>,
        <https://1145.am/db/1765870/Index_Ventures>,
        <https://1145.am/db/1766253/Index_Ventures>,
        <https://1145.am/db/1769654/Index_Ventures>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771672/Index_Ventures>,
        <https://1145.am/db/1771734/Index_Ventures>,
        <https://1145.am/db/1771773/Index_Ventures>,
        <https://1145.am/db/1775903/Index_Ventures>,
        <https://1145.am/db/1776139/Index_Ventures>,
        <https://1145.am/db/1776626/Index_Ventures>,
        <https://1145.am/db/1777546/Index_Ventures>,
        <https://1145.am/db/1778195/Index_Ventures>,
        <https://1145.am/db/1780733/Index_Ventures>,
        <https://1145.am/db/1783754/Index_Ventures>,
        <https://1145.am/db/1787471/Index_Ventures>,
        <https://1145.am/db/1787621/Index_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1790777/Index_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791667/Index_Ventures>,
        <https://1145.am/db/1791743/Index_Ventures>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1796201/Index_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1798836/Index_Ventures>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800998/Index_Ventures>,
        <https://1145.am/db/1805201/Index_Ventures>,
        <https://1145.am/db/1805473/Index_Ventures>,
        <https://1145.am/db/1807173/Index_Ventures>,
        <https://1145.am/db/1808484/Index_Ventures>,
        <https://1145.am/db/1809821/Index_Ventures>,
        <https://1145.am/db/1810000/Index_Ventures>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812038/Index_Ventures>,
        <https://1145.am/db/1812890/Index_Ventures>,
        <https://1145.am/db/1813037/Index_Ventures>,
        <https://1145.am/db/1813404/Index_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1819133/Index_Ventures>,
        <https://1145.am/db/1819302/Index_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1823078/Index_Ventures>,
        <https://1145.am/db/1823141/Index_Ventures>,
        <https://1145.am/db/1824561/Index_Ventures>,
        <https://1145.am/db/1828638/Index_Ventures>,
        <https://1145.am/db/1829991/Index_Ventures>,
        <https://1145.am/db/1830023/Index_Ventures>,
        <https://1145.am/db/1831440/Index_Ventures>,
        <https://1145.am/db/1832655/Index_Ventures>,
        <https://1145.am/db/1832808/Index_Ventures>,
        <https://1145.am/db/1832926/Index_Ventures>,
        <https://1145.am/db/1835321/Index_Ventures>,
        <https://1145.am/db/1835516/Index_Ventures>,
        <https://1145.am/db/1836455/Index_Ventures>,
        <https://1145.am/db/1836572/Index_Ventures>,
        <https://1145.am/db/1837081/Index_Ventures>,
        <https://1145.am/db/1837143/Index_Ventures>,
        <https://1145.am/db/1839663/Index_Ventures>,
        <https://1145.am/db/1840137/Index_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1845548/Index_Ventures>,
        <https://1145.am/db/1845841/Index_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846794/Index_Ventures>,
        <https://1145.am/db/1847483/Index_Ventures>,
        <https://1145.am/db/1848631/Index_Ventures>,
        <https://1145.am/db/1849844/Index_Ventures>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1850428/Index_Ventures>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851744/Index_Ventures>,
        <https://1145.am/db/1854191/Index_Ventures>,
        <https://1145.am/db/1856191/Index_Ventures>,
        <https://1145.am/db/1856802/Index_Ventures>,
        <https://1145.am/db/1856967/Index_Ventures>,
        <https://1145.am/db/1857638/Index_Ventures>,
        <https://1145.am/db/1858520/Index_Ventures>,
        <https://1145.am/db/1858521/Index_Ventures>,
        <https://1145.am/db/1862594/Index_Ventures>,
        <https://1145.am/db/1863500/Index_Ventures>,
        <https://1145.am/db/1865106/Index_Ventures>,
        <https://1145.am/db/1865524/Index_Ventures>,
        <https://1145.am/db/1866804/Index_Ventures>,
        <https://1145.am/db/1868923/Index_Ventures>,
        <https://1145.am/db/1868935/Index_Ventures>,
        <https://1145.am/db/1870074/Index_Ventures>,
        <https://1145.am/db/1870079/Index_Ventures>,
        <https://1145.am/db/1870810/Index_Ventures>,
        <https://1145.am/db/1871091/Index_Ventures>,
        <https://1145.am/db/1878630/Index_Ventures>,
        <https://1145.am/db/1880386/Index_Ventures>,
        <https://1145.am/db/1881391/Index_Ventures>,
        <https://1145.am/db/1881430/Index_Ventures>,
        <https://1145.am/db/1882686/Index_Ventures>,
        <https://1145.am/db/1884077/Index_Ventures>,
        <https://1145.am/db/1885147/Index_Ventures>,
        <https://1145.am/db/1890254/Index_Ventures>,
        <https://1145.am/db/1894621/Index_Ventures>,
        <https://1145.am/db/1894627/Index_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1899697/Index_Ventures>,
        <https://1145.am/db/1900904/Index_Ventures>,
        <https://1145.am/db/1902032/Index_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1910957/Index_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915168/Index_Ventures>,
        <https://1145.am/db/1916258/Index_Ventures>,
        <https://1145.am/db/1919238/Index_Ventures>,
        <https://1145.am/db/1967520/Index_Ventures>,
        <https://1145.am/db/1967683/Index_Ventures>,
        <https://1145.am/db/199212/Index_Ventures>,
        <https://1145.am/db/2062814/Index_Ventures>,
        <https://1145.am/db/2127786/Index_Ventures>,
        <https://1145.am/db/2198066/Index_Ventures>,
        <https://1145.am/db/2290088/Index_Ventures>,
        <https://1145.am/db/2297905/Index_Ventures>,
        <https://1145.am/db/2303009/Index_Ventures>,
        <https://1145.am/db/2303849/Index_Ventures>,
        <https://1145.am/db/2309490/Index_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2313410/Index_Ventures>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325147/Index_Ventures>,
        <https://1145.am/db/2333601/Index_Ventures>,
        <https://1145.am/db/2338079/Index_Ventures>,
        <https://1145.am/db/2338193/Index_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2344127/Index_Ventures>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2348012/Index_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2348620/Index_Ventures>,
        <https://1145.am/db/2350031/Index_Ventures>,
        <https://1145.am/db/2352142/Index_Ventures>,
        <https://1145.am/db/2352145/Index_Ventures>,
        <https://1145.am/db/2355609/Index_Ventures>,
        <https://1145.am/db/2355952/Index_Ventures>,
        <https://1145.am/db/2357356/Index_Ventures>,
        <https://1145.am/db/2358233/Index_Ventures>,
        <https://1145.am/db/2358246/Index_Ventures>,
        <https://1145.am/db/2362736/Index_Ventures>,
        <https://1145.am/db/2364597/Index_Ventures>,
        <https://1145.am/db/2364600/Index_Ventures>,
        <https://1145.am/db/2507691/Index_Ventures>,
        <https://1145.am/db/2555540/Index_Ventures>,
        <https://1145.am/db/2643797/Index_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/337401/Index_Ventures>,
        <https://1145.am/db/366983/Index_Ventures>,
        <https://1145.am/db/367008/Index_Ventures>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/707126/Index_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/768008/Index_Ventures>,
        <https://1145.am/db/789218/Index_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/868352/Index_Ventures>,
        <https://1145.am/db/909344/Index_Ventures>,
        <https://1145.am/db/957097/Index_Ventures>,
        <https://1145.am/db/980375/Index_Ventures>,
        <https://1145.am/db/981840/Index_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362737/Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "CA" ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "Life Sciences" ;
    ns1:industry "biotechnology" ;
    ns1:investor <https://1145.am/db/2362737/Series_C_Investment_Aisling_Capital_Index_Ventures_Life_Sciences_New_Leaf_Venture_Partners_Versartis_Completed> ;
    ns1:name "Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1009450/Biocompare>,
        <https://1145.am/db/1023985/Orgenesis_Inc>,
        <https://1145.am/db/1051761/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1066819/Biocentriq_Inc>,
        <https://1145.am/db/1088717/Biosynth>,
        <https://1145.am/db/1089921/Biosynth>,
        <https://1145.am/db/1116501/Alvotech_Sa>,
        <https://1145.am/db/1117630/Alvotech_Sa>,
        <https://1145.am/db/1124798/Accustem_Sciences>,
        <https://1145.am/db/1130652/Cogent_Biosciences>,
        <https://1145.am/db/1132106/Cogent_Biosciences>,
        <https://1145.am/db/1140693/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1142391/Cogent_Biosciences_Inc>,
        <https://1145.am/db/1143081/Bioinvent_International_Ab>,
        <https://1145.am/db/1154042/Applied_Biology>,
        <https://1145.am/db/1167874/Ensysce_Biosciences>,
        <https://1145.am/db/1174373/Biosynth>,
        <https://1145.am/db/1175242/Biosynth>,
        <https://1145.am/db/1179100/Ensysce_Biosciences>,
        <https://1145.am/db/1202633/Eqt_Life_Sciences>,
        <https://1145.am/db/1203099/Eqt_Life_Sciences>,
        <https://1145.am/db/1216524/Forbion>,
        <https://1145.am/db/1216997/180_Life_Sciences>,
        <https://1145.am/db/1222768/180_Life_Sciences_Corp>,
        <https://1145.am/db/1229517/Enveric_Biosciences>,
        <https://1145.am/db/1236975/Enveric_Biosciences>,
        <https://1145.am/db/1252190/Forbion>,
        <https://1145.am/db/1271538/Ensysce_Biosciences>,
        <https://1145.am/db/1278078/Monod_Bio>,
        <https://1145.am/db/1278479/Monod_Bio>,
        <https://1145.am/db/1293677/Biosion>,
        <https://1145.am/db/1295884/Brii_Biosciences_Limited>,
        <https://1145.am/db/1298251/Discovery_Life_Sciences>,
        <https://1145.am/db/1320133/Hc_Bioscience>,
        <https://1145.am/db/1336573/Hc_Bioscience>,
        <https://1145.am/db/1354619/Biogen>,
        <https://1145.am/db/1382711/Solid_Biosciences_Inc>,
        <https://1145.am/db/1386738/Vergent_Bioscience>,
        <https://1145.am/db/1387057/Vergent_Bioscience>,
        <https://1145.am/db/1408611/Alvotech>,
        <https://1145.am/db/1418969/Form_Bio>,
        <https://1145.am/db/1490000/Enavate_Sciences>,
        <https://1145.am/db/1506505/Biodesix>,
        <https://1145.am/db/1509205/Biodesix>,
        <https://1145.am/db/1522275/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1534347/Enveric_Biosciences>,
        <https://1145.am/db/1536048/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/1537082/Vergent_Bioscience>,
        <https://1145.am/db/1537788/Vergent_Bioscience>,
        <https://1145.am/db/1547927/Solid_Biosciences_Inc>,
        <https://1145.am/db/1548092/Innoforce>,
        <https://1145.am/db/1548093/Alvotech>,
        <https://1145.am/db/1553518/Solid_Biosciences_Inc>,
        <https://1145.am/db/1562950/Ensysce_Biosciences>,
        <https://1145.am/db/1577542/Bioasis>,
        <https://1145.am/db/1585988/Alvotech>,
        <https://1145.am/db/1585992/Alvotech>,
        <https://1145.am/db/1586236/Alvotech>,
        <https://1145.am/db/1586786/Bioasis>,
        <https://1145.am/db/1619665/Bioversys_Ag>,
        <https://1145.am/db/1630753/Solid_Biosciences_Inc>,
        <https://1145.am/db/1639462/Forte_Biosciences>,
        <https://1145.am/db/1640582/Forte_Biosciences>,
        <https://1145.am/db/1664988/Upstream_Bio>,
        <https://1145.am/db/1668597/Verily>,
        <https://1145.am/db/1685433/Enveric_Biosciences>,
        <https://1145.am/db/1696213/Genentech>,
        <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/1787025/Verily>,
        <https://1145.am/db/1821833/Verily>,
        <https://1145.am/db/1931929/Eqt_Life_Sciences>,
        <https://1145.am/db/1945850/Puretech>,
        <https://1145.am/db/2000772/Biosynth>,
        <https://1145.am/db/2010010/Iveric_Bio_Inc>,
        <https://1145.am/db/2019705/Eqt_Life_Sciences>,
        <https://1145.am/db/2023773/Genentech>,
        <https://1145.am/db/2032047/Enavate_Sciences>,
        <https://1145.am/db/2032047/Upstream_Bio>,
        <https://1145.am/db/2053399/Univercells_Technologies>,
        <https://1145.am/db/2061027/Roivant_Sciences>,
        <https://1145.am/db/2073555/Puretech_Scientific>,
        <https://1145.am/db/209111/Bioage>,
        <https://1145.am/db/2113176/Genentech>,
        <https://1145.am/db/2115362/2seventy_Bio>,
        <https://1145.am/db/2123899/Biosynth>,
        <https://1145.am/db/2152786/Aruvant_Sciences>,
        <https://1145.am/db/2152862/Therachon>,
        <https://1145.am/db/2152961/Arcus_Biosciences>,
        <https://1145.am/db/2153083/Arcus_Biosciences>,
        <https://1145.am/db/2153509/Or>,
        <https://1145.am/db/2154009/Valiance_Life_Sciences>,
        <https://1145.am/db/2154521/Baergic_Bio>,
        <https://1145.am/db/2154848/Brii_Biosciences>,
        <https://1145.am/db/2155108/Roivant_Sciences>,
        <https://1145.am/db/2155252/Bioagilytix>,
        <https://1145.am/db/2156304/Puretech>,
        <https://1145.am/db/2181432/Verily>,
        <https://1145.am/db/2188567/Verily_Life_Sciences>,
        <https://1145.am/db/2189613/Genapsys>,
        <https://1145.am/db/2198949/Cellectricon>,
        <https://1145.am/db/222920/Genapsys_Inc>,
        <https://1145.am/db/2230848/Bioohio>,
        <https://1145.am/db/2280215/Concentra_Biosciences>,
        <https://1145.am/db/2280734/Forte_Biosciences>,
        <https://1145.am/db/2281285/Locus_Biosciences>,
        <https://1145.am/db/2281875/Solid_Biosciences>,
        <https://1145.am/db/2282549/Coave>,
        <https://1145.am/db/2282760/Bioreliance>,
        <https://1145.am/db/2282760/Inotiv>,
        <https://1145.am/db/2283398/Sab>,
        <https://1145.am/db/2283480/Hcbioscience>,
        <https://1145.am/db/2285390/Cellarity>,
        <https://1145.am/db/2285399/Solid_Biosciences>,
        <https://1145.am/db/2285897/Hologic>,
        <https://1145.am/db/2285963/Iveric_Bio>,
        <https://1145.am/db/2286052/Insightful_Science>,
        <https://1145.am/db/2286634/Therachon>,
        <https://1145.am/db/2286677/Roivant_Sciences>,
        <https://1145.am/db/2287185/Brii_Biosciences>,
        <https://1145.am/db/2287839/Life_Technologies>,
        <https://1145.am/db/2289479/Life_Technologies>,
        <https://1145.am/db/2290342/Biotech_Sector>,
        <https://1145.am/db/2290381/Life_Sciences>,
        <https://1145.am/db/2292237/Bioinvent>,
        <https://1145.am/db/2293367/Ascentage>,
        <https://1145.am/db/2293654/Eleven_Bio>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2295596/Roivant_Sciences>,
        <https://1145.am/db/2295654/Sv>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296584/Enterin>,
        <https://1145.am/db/2296692/Tp>,
        <https://1145.am/db/2297083/Biogen_Idec>,
        <https://1145.am/db/2297978/Ocugen>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298404/Bioz>,
        <https://1145.am/db/2298499/Inthera_Bioscience>,
        <https://1145.am/db/2298505/Inventisbio>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298866/Biosafe_Group>,
        <https://1145.am/db/2298948/Bioverativ>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299472/Aadi_Bioscience>,
        <https://1145.am/db/2300265/Life_Technologies>,
        <https://1145.am/db/2300786/Axovant_Sciences>,
        <https://1145.am/db/2300790/Axovant_Sciences>,
        <https://1145.am/db/2301003/Roivant_Sciences>,
        <https://1145.am/db/2301684/Biogen_Idec_Inc>,
        <https://1145.am/db/2301979/Biogen_Idec_Inc>,
        <https://1145.am/db/2301983/Biogen_Idec>,
        <https://1145.am/db/2302002/Biogen_Idec>,
        <https://1145.am/db/2303130/Bioreliance_Corporation>,
        <https://1145.am/db/2303317/Applied_Biosystems>,
        <https://1145.am/db/2303604/Biogen_Idec>,
        <https://1145.am/db/2304650/Bioprocessors_Corp>,
        <https://1145.am/db/2304650/Life>,
        <https://1145.am/db/2305210/Biogen_Idec>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2306259/Bioanalab>,
        <https://1145.am/db/2306288/Bioanalab>,
        <https://1145.am/db/2308142/Biogen_Idec>,
        <https://1145.am/db/2309321/Life_Technologies>,
        <https://1145.am/db/2310216/Biogen_Idec>,
        <https://1145.am/db/2310216/Genentech>,
        <https://1145.am/db/2310979/Cogenics>,
        <https://1145.am/db/2311995/Biovitrum>,
        <https://1145.am/db/2312238/Prometic_Life_Sciences>,
        <https://1145.am/db/2313533/Biosource_International>,
        <https://1145.am/db/2313760/Sistemic_Ltd>,
        <https://1145.am/db/2313762/Sistemic_Ltd>,
        <https://1145.am/db/2313763/Biomarin>,
        <https://1145.am/db/2314526/Bio-Rad>,
        <https://1145.am/db/2315615/Anormed>,
        <https://1145.am/db/2316066/Biogen_Idec>,
        <https://1145.am/db/2317136/Biogen_Idec_Inc>,
        <https://1145.am/db/2318537/Genomics>,
        <https://1145.am/db/2319551/Medevol>,
        <https://1145.am/db/2319959/Progentech>,
        <https://1145.am/db/2320138/Biogen_Idec>,
        <https://1145.am/db/2320164/Anaptys_Biosciences>,
        <https://1145.am/db/2320435/Ym_Biosciences_Inc>,
        <https://1145.am/db/2322209/Genentech>,
        <https://1145.am/db/2322417/Bio-Quant>,
        <https://1145.am/db/2322417/Biotox_Sciences>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2325377/Celmed_Biosciences>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2326063/Biooutsource>,
        <https://1145.am/db/2327677/Fundamental_Applied_Biology>,
        <https://1145.am/db/2327982/Biovex_Inc>,
        <https://1145.am/db/2328028/Biotrove>,
        <https://1145.am/db/2328815/Fundamental_Applied_Biology>,
        <https://1145.am/db/2329870/Complex_Biosystems_Gmbh>,
        <https://1145.am/db/2330058/Bio-Quant>,
        <https://1145.am/db/2330348/Blaze_Bioscience>,
        <https://1145.am/db/2332771/S_*_Bio>,
        <https://1145.am/db/2333005/Genizon_Biosciences>,
        <https://1145.am/db/2334156/Genizon>,
        <https://1145.am/db/2335395/Incential>,
        <https://1145.am/db/2335943/Genentech>,
        <https://1145.am/db/2336178/Biocon_Limited>,
        <https://1145.am/db/2336178/Biocon_Ltd>,
        <https://1145.am/db/2336383/Biocrates_Life_Sciences_Ag>,
        <https://1145.am/db/2336736/Coherus_Biosciences>,
        <https://1145.am/db/2336983/Biogen_Idec>,
        <https://1145.am/db/2337110/Bioutah>,
        <https://1145.am/db/2337412/Blaze_Bioscience>,
        <https://1145.am/db/2337664/Advent_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338837/Coherus_Biosciences>,
        <https://1145.am/db/2340502/Massbio>,
        <https://1145.am/db/2340513/Massbio>,
        <https://1145.am/db/2340560/Puretech>,
        <https://1145.am/db/2341443/Biosystems_International>,
        <https://1145.am/db/2341509/Epic_Sciences>,
        <https://1145.am/db/2341676/Bioforward>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343761/Ovascience>,
        <https://1145.am/db/2343777/Ovascience>,
        <https://1145.am/db/2343791/Bioniche_Life_Sciences_Inc>,
        <https://1145.am/db/2344638/Coherus_Biosciences>,
        <https://1145.am/db/2345112/Med_Biogene_Inc>,
        <https://1145.am/db/2345132/Biocon>,
        <https://1145.am/db/2345999/Biogen_Idec>,
        <https://1145.am/db/2346485/Pracinostat>,
        <https://1145.am/db/2347467/Theraclone_Sciences>,
        <https://1145.am/db/2347950/Epic_Sciences>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2349436/Ovascience>,
        <https://1145.am/db/2350267/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2350471/Biovex>,
        <https://1145.am/db/2350645/Biochrom_Ag>,
        <https://1145.am/db/2351192/Genticel>,
        <https://1145.am/db/2351312/Themis_Bioscience>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2351472/Mymetics>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2351921/Ovascience>,
        <https://1145.am/db/2352069/Biogen_Idec>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2354835/Biovex>,
        <https://1145.am/db/2355219/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355236/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2356064/Frontline_Bioventures>,
        <https://1145.am/db/2356509/Inq_Biosciences_Corporation>,
        <https://1145.am/db/2357079/Techne_Corporation>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358296/Biogen_Idec>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2360075/Bionomics>,
        <https://1145.am/db/2360313/Engene>,
        <https://1145.am/db/2361502/Ovascience>,
        <https://1145.am/db/2362647/Bioqual>,
        <https://1145.am/db/2363484/Bioscale>,
        <https://1145.am/db/2363485/Bioscale_Inc>,
        <https://1145.am/db/2363668/Ovasciencesm>,
        <https://1145.am/db/2364681/Biogen_Idec>,
        <https://1145.am/db/2366915/Biogen_Idec>,
        <https://1145.am/db/2368752/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/2369498/Genentech>,
        <https://1145.am/db/2370383/Prometic_Life_Sciences>,
        <https://1145.am/db/2370548/Bionovion>,
        <https://1145.am/db/2370549/Bionovion>,
        <https://1145.am/db/2370806/Alvotech>,
        <https://1145.am/db/2538197/Orgenesis>,
        <https://1145.am/db/2542617/Core_Biogenesis>,
        <https://1145.am/db/2542993/Biogen_Idec>,
        <https://1145.am/db/2550495/Bioatla>,
        <https://1145.am/db/2552636/Ark_Biosciences>,
        <https://1145.am/db/2553773/Mabxience>,
        <https://1145.am/db/2563996/Biocnd>,
        <https://1145.am/db/256464/Atai_Life_Sciences>,
        <https://1145.am/db/2566932/Exosomics>,
        <https://1145.am/db/2567231/Genentech>,
        <https://1145.am/db/2568479/Subintro>,
        <https://1145.am/db/2571023/Biochrom_Ag>,
        <https://1145.am/db/2577183/Biogen_Idec>,
        <https://1145.am/db/2577644/Presage_Biosciences>,
        <https://1145.am/db/2578308/Intermune>,
        <https://1145.am/db/2578528/Biogen_Idec>,
        <https://1145.am/db/2580665/Themis_Bioscience>,
        <https://1145.am/db/2580671/Themis_Bioscience>,
        <https://1145.am/db/2584538/Bionovion>,
        <https://1145.am/db/2594353/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2797140/Biotheus>,
        <https://1145.am/db/317345/Realta_Life_Sciences>,
        <https://1145.am/db/322594/Roivant_Sciences>,
        <https://1145.am/db/356493/Atai_Life_Sciences_Bv>,
        <https://1145.am/db/396787/Biotheryx>,
        <https://1145.am/db/417096/Solid_Biosciences_Inc>,
        <https://1145.am/db/417543/180_Life_Sciences_Corp>,
        <https://1145.am/db/417568/Ultivue>,
        <https://1145.am/db/425981/180_Life_Sciences_Corp>,
        <https://1145.am/db/436937/Triad_Life_Sciences>,
        <https://1145.am/db/471380/Insidescientific>,
        <https://1145.am/db/481671/Biolegend>,
        <https://1145.am/db/482988/Biolegend>,
        <https://1145.am/db/486391/Biolife_Solutions>,
        <https://1145.am/db/505292/Ensysce_Biosciences>,
        <https://1145.am/db/520363/Biohive>,
        <https://1145.am/db/521860/Tosoh_Bioscience_Llc>,
        <https://1145.am/db/523221/Biohive>,
        <https://1145.am/db/540091/Curative_Biotechnology_Inc>,
        <https://1145.am/db/540784/Coherus_Biosciences_Inc>,
        <https://1145.am/db/544370/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/548356/Verily_Life_Sciences>,
        <https://1145.am/db/591563/180_Life_Sciences>,
        <https://1145.am/db/624546/Ensysce_Biosciences>,
        <https://1145.am/db/730321/Biosion>,
        <https://1145.am/db/739185/Sqz_Biotechnologies>,
        <https://1145.am/db/767994/Biotech_Prokidney_Lp>,
        <https://1145.am/db/818850/Ensysce_Biosciences>,
        <https://1145.am/db/877317/Accustem_Sciences>,
        <https://1145.am/db/922807/Biolabs>,
        <https://1145.am/db/941576/Orgenesis_Inc>,
        <https://1145.am/db/948136/Ensysce_Biosciences_Inc>,
        <https://1145.am/db/958575/Biocompare>,
        <https://1145.am/db/958575/Scilan>,
        <https://1145.am/db/968301/Ansa_Biotechnologies>,
        <https://1145.am/db/972968/Ansa_Biotechnologies>,
        <https://1145.am/db/979663/Biostrand>,
        <https://1145.am/db/979842/Biostrand_Bv>,
        <https://1145.am/db/986828/Ensysce_Biosciences>,
        <https://1145.am/db/991347/Genovac> ;
    ns1:sameAsMedium <https://1145.am/db/2295654/Life_Sciences>,
        <https://1145.am/db/2342574/Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362737/Versartis> a org:Organization ;
    ns1:description "pharmaceutical" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "Versartis",
        "Versartis, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "Versartis" ;
    ns1:sameAsHigh <https://1145.am/db/1219612/Versanis_Bio>,
        <https://1145.am/db/2284615/Versanis_Bio>,
        <https://1145.am/db/2325147/Versartis_Inc>,
        <https://1145.am/db/2343678/Versartis_Inc>,
        <https://1145.am/db/2347571/Versartis>,
        <https://1145.am/db/2347739/Versartis>,
        <https://1145.am/db/2348618/Versartis>,
        <https://1145.am/db/2348620/Versartis_Inc>,
        <https://1145.am/db/2352059/Versartis>,
        <https://1145.am/db/2352331/Versartis>,
        <https://1145.am/db/2357241/Versartis>,
        <https://1145.am/db/2357356/Versartis>,
        <https://1145.am/db/2359361/Versartis>,
        <https://1145.am/db/2359375/Versartis>,
        <https://1145.am/db/2370072/Versartis_Inc>,
        <https://1145.am/db/2589317/Versartis>,
        <https://1145.am/db/2592575/Versapharm> ;
    ns1:sameAsMedium <https://1145.am/db/2325140/Versartis_Inc>,
        <https://1145.am/db/2340691/Versartis_Inc>,
        <https://1145.am/db/2347568/Versartis>,
        <https://1145.am/db/2357360/Versartis>,
        <https://1145.am/db/2362736/Versartis> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364600/Index_Ventures> a org:Organization ;
    ns1:documentDate "2013-06-17T04:00:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/xo1-ltd-raises-11-million-from-index-ventures-to-develop-holy-grail-of-anticoagulant-drugs> ;
    ns1:foundName "Index Ventures" ;
    ns1:investor <https://1145.am/db/2364600/Investment_Index_Ventures_Xo1_Ltd_Completed> ;
    ns1:name "Index Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1247967/Index_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1358814/Index_Ventures>,
        <https://1145.am/db/1490485/Index_Ventures>,
        <https://1145.am/db/1493654/Index_Ventures>,
        <https://1145.am/db/1553352/Index_Ventures>,
        <https://1145.am/db/1693951/Index_Ventures>,
        <https://1145.am/db/1694279/Index_Ventures>,
        <https://1145.am/db/1699089/Index_Ventures>,
        <https://1145.am/db/1704793/Index_Ventures>,
        <https://1145.am/db/1711587/Index_Ventures>,
        <https://1145.am/db/1711731/Index_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1712506/Index_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1717574/Index_Ventures>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1733028/Index_Ventures>,
        <https://1145.am/db/1735596/Index_Ventures>,
        <https://1145.am/db/1736117/Index_Ventures>,
        <https://1145.am/db/1737079/Index_Ventures>,
        <https://1145.am/db/1737527/Index_Ventures>,
        <https://1145.am/db/1737696/Index_Ventures>,
        <https://1145.am/db/1738402/Index_Ventures>,
        <https://1145.am/db/1738465/Index_Ventures>,
        <https://1145.am/db/1740781/Index_Ventures>,
        <https://1145.am/db/1742878/Index_Ventures>,
        <https://1145.am/db/1744753/Index_Ventures>,
        <https://1145.am/db/1745368/Index_Ventures>,
        <https://1145.am/db/1745702/Index_Ventures>,
        <https://1145.am/db/1746192/Index_Ventures>,
        <https://1145.am/db/1746800/Index_Ventures>,
        <https://1145.am/db/1746845/Index_Ventures>,
        <https://1145.am/db/1746947/Index_Ventures>,
        <https://1145.am/db/1747153/Index_Ventures>,
        <https://1145.am/db/1747208/Index_Ventures>,
        <https://1145.am/db/1748172/Index_Ventures>,
        <https://1145.am/db/1748621/Index_Ventures>,
        <https://1145.am/db/1750406/Index_Ventures>,
        <https://1145.am/db/1750420/Index_Ventures>,
        <https://1145.am/db/1750828/Index_Ventures>,
        <https://1145.am/db/1752154/Index_Ventures>,
        <https://1145.am/db/1755398/Index_Ventures>,
        <https://1145.am/db/1755899/Index_Ventures>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756768/Index_Ventures>,
        <https://1145.am/db/1756873/Index_Ventures>,
        <https://1145.am/db/1758069/Index_Ventures>,
        <https://1145.am/db/1758834/Index_Ventures>,
        <https://1145.am/db/1759939/Index_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760954/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761664/Index_Ventures>,
        <https://1145.am/db/1762988/Index_Ventures>,
        <https://1145.am/db/1763352/Index_Ventures>,
        <https://1145.am/db/1765809/Index_Ventures>,
        <https://1145.am/db/1765870/Index_Ventures>,
        <https://1145.am/db/1766059/Index_Ventures>,
        <https://1145.am/db/1766253/Index_Ventures>,
        <https://1145.am/db/1769654/Index_Ventures>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771672/Index_Ventures>,
        <https://1145.am/db/1771734/Index_Ventures>,
        <https://1145.am/db/1771773/Index_Ventures>,
        <https://1145.am/db/1775903/Index_Ventures>,
        <https://1145.am/db/1776139/Index_Ventures>,
        <https://1145.am/db/1776626/Index_Ventures>,
        <https://1145.am/db/1777546/Index_Ventures>,
        <https://1145.am/db/1778195/Index_Ventures>,
        <https://1145.am/db/1780507/Index_Ventures>,
        <https://1145.am/db/1780733/Index_Ventures>,
        <https://1145.am/db/1783754/Index_Ventures>,
        <https://1145.am/db/1787471/Index_Ventures>,
        <https://1145.am/db/1787621/Index_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1790777/Index_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791667/Index_Ventures>,
        <https://1145.am/db/1791743/Index_Ventures>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1796201/Index_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1798836/Index_Ventures>,
        <https://1145.am/db/1799293/Index_Ventures>,
        <https://1145.am/db/1800172/Index_Ventures>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800998/Index_Ventures>,
        <https://1145.am/db/1805201/Index_Ventures>,
        <https://1145.am/db/1805473/Index_Ventures>,
        <https://1145.am/db/1807173/Index_Ventures>,
        <https://1145.am/db/1808484/Index_Ventures>,
        <https://1145.am/db/1809821/Index_Ventures>,
        <https://1145.am/db/1810000/Index_Ventures>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812038/Index_Ventures>,
        <https://1145.am/db/1812890/Index_Ventures>,
        <https://1145.am/db/1813037/Index_Ventures>,
        <https://1145.am/db/1813404/Index_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1819133/Index_Ventures>,
        <https://1145.am/db/1819302/Index_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1823078/Index_Ventures>,
        <https://1145.am/db/1823141/Index_Ventures>,
        <https://1145.am/db/1824561/Index_Ventures>,
        <https://1145.am/db/1828638/Index_Ventures>,
        <https://1145.am/db/1829991/Index_Ventures>,
        <https://1145.am/db/1830023/Index_Ventures>,
        <https://1145.am/db/1831440/Index_Ventures>,
        <https://1145.am/db/1832655/Index_Ventures>,
        <https://1145.am/db/1832808/Index_Ventures>,
        <https://1145.am/db/1832926/Index_Ventures>,
        <https://1145.am/db/1835321/Index_Ventures>,
        <https://1145.am/db/1835516/Index_Ventures>,
        <https://1145.am/db/1836455/Index_Ventures>,
        <https://1145.am/db/1836572/Index_Ventures>,
        <https://1145.am/db/1837081/Index_Ventures>,
        <https://1145.am/db/1837143/Index_Ventures>,
        <https://1145.am/db/1839663/Index_Ventures>,
        <https://1145.am/db/1840137/Index_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1845548/Index_Ventures>,
        <https://1145.am/db/1845841/Index_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846794/Index_Ventures>,
        <https://1145.am/db/1847483/Index_Ventures>,
        <https://1145.am/db/1848631/Index_Ventures>,
        <https://1145.am/db/1849844/Index_Ventures>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849912/Index_Ventures>,
        <https://1145.am/db/1850428/Index_Ventures>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851744/Index_Ventures>,
        <https://1145.am/db/1853547/Index_Ventures>,
        <https://1145.am/db/1854191/Index_Ventures>,
        <https://1145.am/db/1856171/Index_Ventures>,
        <https://1145.am/db/1856191/Index_Ventures>,
        <https://1145.am/db/1856802/Index_Ventures>,
        <https://1145.am/db/1856967/Index_Ventures>,
        <https://1145.am/db/1857638/Index_Ventures>,
        <https://1145.am/db/1858520/Index_Ventures>,
        <https://1145.am/db/1858521/Index_Ventures>,
        <https://1145.am/db/1862594/Index_Ventures>,
        <https://1145.am/db/1863500/Index_Ventures>,
        <https://1145.am/db/1865106/Index_Ventures>,
        <https://1145.am/db/1865524/Index_Ventures>,
        <https://1145.am/db/1866804/Index_Ventures>,
        <https://1145.am/db/1868923/Index_Ventures>,
        <https://1145.am/db/1868935/Index_Ventures>,
        <https://1145.am/db/1870074/Index_Ventures>,
        <https://1145.am/db/1870079/Index_Ventures>,
        <https://1145.am/db/1870810/Index_Ventures>,
        <https://1145.am/db/1871091/Index_Ventures>,
        <https://1145.am/db/1876014/Index_Ventures>,
        <https://1145.am/db/1876914/Index_Ventures>,
        <https://1145.am/db/1878630/Index_Ventures>,
        <https://1145.am/db/1880386/Index_Ventures>,
        <https://1145.am/db/1881391/Index_Ventures>,
        <https://1145.am/db/1881430/Index_Ventures>,
        <https://1145.am/db/1882301/Index_Ventures>,
        <https://1145.am/db/1882686/Index_Ventures>,
        <https://1145.am/db/1884077/Index_Ventures>,
        <https://1145.am/db/1885147/Index_Ventures>,
        <https://1145.am/db/1890254/Index_Ventures>,
        <https://1145.am/db/1893255/Index_Ventures>,
        <https://1145.am/db/1894621/Index_Ventures>,
        <https://1145.am/db/1894627/Index_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1899697/Index_Ventures>,
        <https://1145.am/db/1900904/Index_Ventures>,
        <https://1145.am/db/1902032/Index_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1910957/Index_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915168/Index_Ventures>,
        <https://1145.am/db/1916258/Index_Ventures>,
        <https://1145.am/db/1916868/Index_Ventures>,
        <https://1145.am/db/1919238/Index_Ventures>,
        <https://1145.am/db/1967520/Index_Ventures>,
        <https://1145.am/db/1967683/Index_Ventures>,
        <https://1145.am/db/199212/Index_Ventures>,
        <https://1145.am/db/2028609/Index_Ventures>,
        <https://1145.am/db/2060465/Index_Ventures>,
        <https://1145.am/db/2062814/Index_Ventures>,
        <https://1145.am/db/2127786/Index_Ventures>,
        <https://1145.am/db/217906/Index_Ventures>,
        <https://1145.am/db/2198066/Index_Ventures>,
        <https://1145.am/db/2234558/Index_Ventures>,
        <https://1145.am/db/2290088/Index_Ventures>,
        <https://1145.am/db/2290200/Index_Ventures>,
        <https://1145.am/db/2297905/Index_Ventures>,
        <https://1145.am/db/2303009/Index_Ventures>,
        <https://1145.am/db/2303849/Index_Ventures>,
        <https://1145.am/db/2309490/Index_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2309847/Index_Ventures>,
        <https://1145.am/db/2313410/Index_Ventures>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325147/Index_Ventures>,
        <https://1145.am/db/2327222/Index_Ventures>,
        <https://1145.am/db/2333601/Index_Ventures>,
        <https://1145.am/db/2338079/Index_Ventures>,
        <https://1145.am/db/2338193/Index_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2344127/Index_Ventures>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2348012/Index_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2348620/Index_Ventures>,
        <https://1145.am/db/2350031/Index_Ventures>,
        <https://1145.am/db/2352142/Index_Ventures>,
        <https://1145.am/db/2352145/Index_Ventures>,
        <https://1145.am/db/2355609/Index_Ventures>,
        <https://1145.am/db/2355952/Index_Ventures>,
        <https://1145.am/db/2357169/Index_Ventures>,
        <https://1145.am/db/2357356/Index_Ventures>,
        <https://1145.am/db/2358233/Index_Ventures>,
        <https://1145.am/db/2358246/Index_Ventures>,
        <https://1145.am/db/2362736/Index_Ventures>,
        <https://1145.am/db/2362737/Index_Ventures>,
        <https://1145.am/db/2364597/Index_Ventures>,
        <https://1145.am/db/2507691/Index_Ventures>,
        <https://1145.am/db/2555540/Index_Ventures>,
        <https://1145.am/db/2589317/Index_Ventures>,
        <https://1145.am/db/2643797/Index_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/317470/Index_Ventures>,
        <https://1145.am/db/318142/Index_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/337401/Index_Ventures>,
        <https://1145.am/db/348633/Index_Ventures>,
        <https://1145.am/db/366983/Index_Ventures>,
        <https://1145.am/db/367008/Index_Ventures>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/475105/Index_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/539919/Index_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/578277/Index_Ventures>,
        <https://1145.am/db/633695/Index_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/707126/Index_Ventures>,
        <https://1145.am/db/709798/Index_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/768008/Index_Ventures>,
        <https://1145.am/db/789218/Index_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/854512/Index_Ventures>,
        <https://1145.am/db/868352/Index_Ventures>,
        <https://1145.am/db/893076/Index_Ventures>,
        <https://1145.am/db/893316/Index_Ventures>,
        <https://1145.am/db/909344/Index_Ventures>,
        <https://1145.am/db/957097/Index_Ventures>,
        <https://1145.am/db/980375/Index_Ventures>,
        <https://1145.am/db/981840/Index_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2536882/Althea_Plant_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Ajinomoto said it has a deal to buy Althea Technologies, a San Diego - based contract development and manufacturing organization that provides everything from production of microbial-derived recombinant proteins and plasmid DNA, vial and syringe filling and product manufacturing." ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "buy",
        "erect",
        "invest" ;
    ns1:name "buy",
        "erect",
        "invest" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2536882/Althea> ;
    ns1:targetDetails "plant" ;
    ns1:targetName "Althea" ;
    ns1:valueRaw "$ 25 million",
        "$ 500 million" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "San Diego" .

<https://1145.am/db/2536882/Plant_Investment_Innovent_Biologics_Novartis_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-06T17:38:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Novartis ($ NVS) , for example, has a $ 500 million biologics manufacturing plant on tap for its campus in Singapore, while startup Innovent Biologics said it would invest $ 25 million to erect a biologics plant in Suzhou, China." ;
    ns1:documentTitle "Ajinomoto buying biologics CMO Althea" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/ajinomoto-buying-biologics-cmo-althea> ;
    ns1:foundName "erect",
        "invest" ;
    ns1:name "erect",
        "invest" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:targetDetails "plant" ;
    ns1:valueRaw "$ 13.9 million",
        "$ 25 million",
        "$ 500 million",
        "1.3 billion JPY" ;
    ns1:whereGeoName "Peoples Republic of China" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:whereRaw "China" .

<https://1145.am/db/2537461/Genmab_Antibody_Plant_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-04-17T14:27:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Baxter International ($ BAX) has picked up the former Genmab antibody plant near Minneapolis for a small sum and will now invest about $ 300 million to get it ready for its own use." ;
    ns1:documentTitle "Baxter to put $300M into old Genmab plant" ;
    ns1:documentURL <https://www.fiercepharma.com/supply-chain/baxter-to-put-300m-into-old-genmab-plant> ;
    ns1:foundName "invest",
        "picked up" ;
    ns1:name "invest",
        "picked up" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2537461/Genmab_Antibody_Plant> ;
    ns1:targetName "Genmab antibody plant" ;
    ns1:valueRaw "about $ 300 million" ;
    ns1:whenRaw "January" ;
    ns1:whereGeoName "Brooklyn Park" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5019335/about.rdf> ;
    ns1:whereRaw "Brooklyn Park, MN" .

<https://1145.am/db/2562245/Cambridge_Major_Laboratories_Inc_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-01-15T13:12:31+00:00"^^xsd:dateTime ;
    ns1:documentExtract "American Capital Commits $ 212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc.",
        "BETHESDA, Md., Dec. 27,2012- American Capital, Ltd. (Nasdaq: ACAS) (\"American Capital\") announced today that it has committed $ 212 million in the One Stop Buyout of Cambridge Major Laboratories, Inc. (\"CML\" or the \"Company\") , a leading global provider of complex chemistry - based outsourcing services to the pharmaceutical and biotechnology industries." ;
    ns1:documentTitle "American Capital Commits $212 Million In The One Stop Buyout Of Cambridge Major Laboratories, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/american-capital-commits-212-million-one-stop-buyout%C2%AE-of-cambridge-major-laboratories> ;
    ns1:foundName "Buyout" ;
    ns1:name "Buyout" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2562245/Cambridge_Major_Laboratories_Inc> ;
    ns1:targetName "Cambridge Major Laboratories",
        "Cambridge Major Laboratories, Inc." ;
    ns1:valueRaw "$ 212 Million",
        "$ 212 million" ;
    ns1:whenRaw "2012" ;
    ns1:whereGeoName "Bethesda",
        "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4348599/about.rdf>,
        <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "BETHESDA, Md",
        "United States" .

<https://1145.am/db/2575687/License_Investment_Aeris_Capital_Ag_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "In addition, Solstice has acquired an exclusive license to University of California, San Diego intellectual property covering technology that enables RNA molecules to cross membranes of multiple cell types, a perplexing problem that has been a bottleneck in delivering on the therapeutic potential of RNA interference (RNAi) and microRNA.",
        "SAN FRANCISCO, Jan. 4, 2013 - Solstice Biologics LLC, a company focused on solving the problem of targeting and delivery of nucleic acid therapeutics, today announced the completion of a $ 18 million Series A financing led by venBio and joined by Aeris Capital AG." ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "acquired" ;
    ns1:name "acquired" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2575687/University_Of_California_San_Diego_Intellectual_Property_Covering> ;
    ns1:targetDetails "license" ;
    ns1:targetName "University of California, San Diego intellectual property covering" ;
    ns1:valueRaw "$ 18 million" ;
    ns1:whereGeoName "California",
        "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5332921/about.rdf>,
        <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "California",
        "San Diego" .

<https://1145.am/db/2575687/Series_A_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_Venbio_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO, Jan. 4, 2013 - Solstice Biologics LLC, a company focused on solving the problem of targeting and delivery of nucleic acid therapeutics, today announced the completion of a $ 18 million Series A financing led by venBio and joined by Aeris Capital AG.",
        "Solstice Biologics Secures $ 18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego." ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2575687/Solstice_Biologics_Llc>,
        <https://1145.am/db/2575687/Uc_San_Diego> ;
    ns1:targetDetails "Series A",
        "Technology" ;
    ns1:valueRaw "$ 18 Million",
        "$ 18 million" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "San Diego" .

<https://1145.am/db/2575687/Solstice_Biologics_Llc> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:basedInLowRaw "California",
        "San Diego" ;
    ns1:description "Biotechnology",
        "a company focused on solving the problem of targeting and delivery of nucleic acid therapeutics" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "Solstice",
        "Solstice Biologics",
        "Solstice Biologics LLC" ;
    ns1:investor <https://1145.am/db/2575687/License_Investment_Aeris_Capital_Ag_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> ;
    ns1:name "Solstice",
        "Solstice Biologics",
        "Solstice Biologics LLC" ;
    ns1:sameAsHigh <https://1145.am/db/2360667/Solstice_Biologics_Llc> ;
    ns1:sameAsMedium <https://1145.am/db/2343608/Solstice_Biologics>,
        <https://1145.am/db/2343610/Solstice_Biologics_Llc>,
        <https://1145.am/db/2344628/Solstice_Biologics_Llc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2575687/Uc_San_Diego> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "research" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "UC San Diego" ;
    ns1:name "UC San Diego" ;
    ns1:sameAsHigh <https://1145.am/db/2360667/Uc_San_Diego> ;
    ns1:sameAsMedium <https://1145.am/db/2560987/Uc_San_Diego> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2575687/University_Of_California_San_Diego_Intellectual_Property_Covering> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO",
        "San Diego" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "University of California, San",
        "University of California, San Diego intellectual property covering" ;
    ns1:name "University of California, San",
        "University of California, San Diego intellectual property covering" ;
    ns1:sameAsMedium <https://1145.am/db/2360667/University_Of_California_San_Diego_Intellectual_Property_Covering> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2575687/Venbio> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:documentDate "2013-01-08T21:14:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercepharma.com/drug-delivery/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from> ;
    ns1:foundName "venBio" ;
    ns1:investor <https://1145.am/db/2575687/Series_A_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_Venbio_Completed> ;
    ns1:name "venBio" ;
    ns1:sameAsMedium <https://1145.am/db/2336503/Venbio>,
        <https://1145.am/db/2336505/Venbio>,
        <https://1145.am/db/2336524/Venbio>,
        <https://1145.am/db/2346293/Venbio>,
        <https://1145.am/db/2352349/Venbio>,
        <https://1145.am/db/2352350/Venbio>,
        <https://1145.am/db/2359468/Venbio>,
        <https://1145.am/db/2360647/Venbio>,
        <https://1145.am/db/2360667/Venbio>,
        <https://1145.am/db/2364514/Venbio>,
        <https://1145.am/db/2364518/Venbio>,
        <https://1145.am/db/2570520/Venbio>,
        <https://1145.am/db/2570523/Venbio>,
        <https://1145.am/db/2583013/Venbio>,
        <https://1145.am/db/428737/Venbio>,
        <https://1145.am/db/560096/Venbio>,
        <https://1145.am/db/704198/Venbio> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2577010/Elan_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Irish" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-04-15T13:54:27+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Royalty Pharma Announces Firm Offer to Acquire Elan" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/royalty-pharma-announces-firm-offer-to-acquire-elan> ;
    ns1:foundName "Elan Corporation, plc" ;
    ns1:name "Elan Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1591152/Eisai>,
        <https://1145.am/db/2303352/Eisai>,
        <https://1145.am/db/2303645/Eisai>,
        <https://1145.am/db/2303806/Eisai>,
        <https://1145.am/db/2305617/Eisai_Company>,
        <https://1145.am/db/2305969/Esprit_Pharma>,
        <https://1145.am/db/2308890/Elan_Corporation>,
        <https://1145.am/db/2320025/Esprit_Pharma>,
        <https://1145.am/db/2325490/Eisai>,
        <https://1145.am/db/2325525/Eisai>,
        <https://1145.am/db/2327327/Elan>,
        <https://1145.am/db/2332005/Eisai>,
        <https://1145.am/db/2332596/Esprit_Pharma>,
        <https://1145.am/db/2339096/Elan_Corporation>,
        <https://1145.am/db/2345264/clat_Pharmaceuticals>,
        <https://1145.am/db/2349078/Elan_Corporation>,
        <https://1145.am/db/2356207/Eisai_Inc>,
        <https://1145.am/db/2360786/Elan_Corporation>,
        <https://1145.am/db/2363656/Elan_Corporation>,
        <https://1145.am/db/2364580/Elan_Corporation>,
        <https://1145.am/db/2364612/Elan_Corporation>,
        <https://1145.am/db/2366961/Elan_Corporation>,
        <https://1145.am/db/2367151/Elan_Corporation>,
        <https://1145.am/db/2543572/Eisai>,
        <https://1145.am/db/2576144/Elan>,
        <https://1145.am/db/2578667/Eisai>,
        <https://1145.am/db/2579483/Eisai>,
        <https://1145.am/db/2580779/Eisai_Inc>,
        <https://1145.am/db/2582116/Eisai> ;
    ns1:sameAsMedium <https://1145.am/db/2249118/Elan_Corporation>,
        <https://1145.am/db/2268635/Elan_Corporation>,
        <https://1145.am/db/2308845/Elan>,
        <https://1145.am/db/2308886/Elan>,
        <https://1145.am/db/2309137/Elan>,
        <https://1145.am/db/2309970/Elan>,
        <https://1145.am/db/2319399/Elan>,
        <https://1145.am/db/2331746/Elan_Corporation>,
        <https://1145.am/db/2332005/Elan_Corporation>,
        <https://1145.am/db/2335881/Elan>,
        <https://1145.am/db/2335887/Elan>,
        <https://1145.am/db/2336358/Elan>,
        <https://1145.am/db/2336983/Elan>,
        <https://1145.am/db/2339086/Elan_Corporation>,
        <https://1145.am/db/2339950/Elan_Corporation>,
        <https://1145.am/db/2340188/Elan>,
        <https://1145.am/db/2340189/Elan_Corporation>,
        <https://1145.am/db/2341772/Elan_Corporation>,
        <https://1145.am/db/2342686/Elan_Corporation>,
        <https://1145.am/db/2343835/Elan>,
        <https://1145.am/db/2345479/Elan_Corporation>,
        <https://1145.am/db/2345992/Elan_Corporation>,
        <https://1145.am/db/2345999/Elan>,
        <https://1145.am/db/2346467/Elan_Corporation>,
        <https://1145.am/db/2346795/Elan_Corporation>,
        <https://1145.am/db/2346976/Elan_Corporation>,
        <https://1145.am/db/2347453/Elan_Corporation>,
        <https://1145.am/db/2348227/Elan_Corporation>,
        <https://1145.am/db/2350115/Elan>,
        <https://1145.am/db/2350116/Elan_Corporation>,
        <https://1145.am/db/2350550/Elan_Corporation>,
        <https://1145.am/db/2351144/Elan>,
        <https://1145.am/db/2351145/Elan_Corporation>,
        <https://1145.am/db/2358431/Elan>,
        <https://1145.am/db/2359529/Elan>,
        <https://1145.am/db/2359600/Elan_Corporation>,
        <https://1145.am/db/2359604/Elan_Corporation>,
        <https://1145.am/db/2364583/Elan>,
        <https://1145.am/db/2537542/Elan>,
        <https://1145.am/db/2554897/Elan>,
        <https://1145.am/db/2560865/Elan>,
        <https://1145.am/db/2573572/Elan>,
        <https://1145.am/db/2575100/Elan_Corporation>,
        <https://1145.am/db/2576104/Elan>,
        <https://1145.am/db/2577059/Elan_Corporation>,
        <https://1145.am/db/2580122/Elan>,
        <https://1145.am/db/2583839/Elan>,
        <https://1145.am/db/2584383/Elan>,
        <https://1145.am/db/2584834/Elan>,
        <https://1145.am/db/2584909/Elan>,
        <https://1145.am/db/2585770/Elan>,
        <https://1145.am/db/2586703/Elan>,
        <https://1145.am/db/2589750/Elan>,
        <https://1145.am/db/2590594/Elan>,
        <https://1145.am/db/2590596/Elan_Corporation>,
        <https://1145.am/db/2592543/Elan>,
        <https://1145.am/db/2593465/Elan>,
        <https://1145.am/db/2595063/Elan_Corporation>,
        <https://1145.am/db/2597331/Elan_Corporation> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2581948/Jennerex_Inc> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "immunotherapy products" ;
    ns1:documentDate "2013-05-28T16:00:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Transgene Announces a Follow-on Investment in Jennerex, Inc." ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/transgene-announces-a-follow-on-investment-jennerex-inc> ;
    ns1:foundName "Jennerex, Inc",
        "Jennerex, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Jennerex, Inc",
        "Jennerex, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2320981/Jennerex>,
        <https://1145.am/db/2351856/Jennerex>,
        <https://1145.am/db/2353431/Jennerex>,
        <https://1145.am/db/2353849/Jennerex>,
        <https://1145.am/db/2359547/Jennerex_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2307230/Jennerex_Inc>,
        <https://1145.am/db/2319536/Jennerex>,
        <https://1145.am/db/2319537/Jennerex>,
        <https://1145.am/db/2337384/Jennerex>,
        <https://1145.am/db/2347602/Jennerex>,
        <https://1145.am/db/2365742/Jennerex> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2596947/Pfizer> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-01-22T16:58:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J CEO eyes sale of Ortho diagnostics unit" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/j-j-ceo-eyes-sale-of-ortho-diagnostics-unit> ;
    ns1:foundName "Pfizer" ;
    ns1:name "Pfizer" ;
    ns1:sameAsHigh <https://1145.am/db/1018723/Pfizer_Inc>,
        <https://1145.am/db/1042002/Pfizer_Inc>,
        <https://1145.am/db/1045477/Pfizer_Inc>,
        <https://1145.am/db/1053698/Pfizer>,
        <https://1145.am/db/1065617/Pfizer_Inc>,
        <https://1145.am/db/1066444/Pfizer_Inc>,
        <https://1145.am/db/1097915/Pfizer>,
        <https://1145.am/db/1123210/Pfizer_Inc>,
        <https://1145.am/db/1124362/Pfizer_Inc>,
        <https://1145.am/db/1138594/Pfizer_Inc>,
        <https://1145.am/db/1146707/Pfizer>,
        <https://1145.am/db/1258904/Pfizer_Inc>,
        <https://1145.am/db/1260932/Pfizer_Inc>,
        <https://1145.am/db/1261278/Pfizer_Inc>,
        <https://1145.am/db/1262347/Pfizer_Inc>,
        <https://1145.am/db/1262354/Pfizer_Inc>,
        <https://1145.am/db/1262545/Pfizer_Inc>,
        <https://1145.am/db/1264461/Pfizer_Inc>,
        <https://1145.am/db/1264475/Pfizer_Inc>,
        <https://1145.am/db/1270781/Pfizer_Inc>,
        <https://1145.am/db/1271008/Pfizer>,
        <https://1145.am/db/1308148/Pfizer_Inc>,
        <https://1145.am/db/1308675/Pfizer_Inc>,
        <https://1145.am/db/1385939/Pfizer_Inc>,
        <https://1145.am/db/1390822/Pfizer_Inc>,
        <https://1145.am/db/1394279/Pfizer_Inc>,
        <https://1145.am/db/1395353/Pfizer_Inc>,
        <https://1145.am/db/1549114/Pfizer_Inc>,
        <https://1145.am/db/1550950/Pfizer_Inc>,
        <https://1145.am/db/1936001/Pfizer_Inc>,
        <https://1145.am/db/1936167/Pfizer_Inc>,
        <https://1145.am/db/2007025/Pfizer_Inc>,
        <https://1145.am/db/2009165/Pfizer_Inc>,
        <https://1145.am/db/2009856/Pfizer>,
        <https://1145.am/db/2057315/Pfizer>,
        <https://1145.am/db/2088776/Pfizer>,
        <https://1145.am/db/2119099/Pfizer>,
        <https://1145.am/db/2152862/Pfizer>,
        <https://1145.am/db/2221589/Pfizer>,
        <https://1145.am/db/2280707/Pfizer>,
        <https://1145.am/db/2280933/Pfizer>,
        <https://1145.am/db/2281629/Pfizer>,
        <https://1145.am/db/2284235/Pfizer>,
        <https://1145.am/db/2285463/Pfizer>,
        <https://1145.am/db/2285764/Pfizer>,
        <https://1145.am/db/2289503/Pfizer>,
        <https://1145.am/db/2293980/Pfizer>,
        <https://1145.am/db/2295427/Pfizer>,
        <https://1145.am/db/2296000/Pfizer>,
        <https://1145.am/db/2297455/Pfizer>,
        <https://1145.am/db/2297477/Pfizer>,
        <https://1145.am/db/2298256/Pfizer>,
        <https://1145.am/db/2304647/Pfizer>,
        <https://1145.am/db/2308656/Pfizer>,
        <https://1145.am/db/2308807/Pfizer>,
        <https://1145.am/db/2309065/Pfizer>,
        <https://1145.am/db/2310071/Pfizer_Inc>,
        <https://1145.am/db/2310072/Pfizer>,
        <https://1145.am/db/2310168/Pfizer>,
        <https://1145.am/db/2310241/Pfizer>,
        <https://1145.am/db/2311347/Pfizer>,
        <https://1145.am/db/2312314/Pfizer>,
        <https://1145.am/db/2312321/Pfizer_Inc>,
        <https://1145.am/db/2312995/Pfizer_Inc>,
        <https://1145.am/db/2313383/Pfizer_Inc>,
        <https://1145.am/db/2316517/Pfizer>,
        <https://1145.am/db/2316538/Pfizer_Inc>,
        <https://1145.am/db/2316843/Pfizer>,
        <https://1145.am/db/2317915/Pfizer>,
        <https://1145.am/db/2318922/Pfizer>,
        <https://1145.am/db/2322307/Pfizer>,
        <https://1145.am/db/2322620/Pfizer>,
        <https://1145.am/db/2322633/Pfizer_Inc>,
        <https://1145.am/db/2322733/Pfizer>,
        <https://1145.am/db/2322786/Pfizer>,
        <https://1145.am/db/2324155/Pfizer>,
        <https://1145.am/db/2325165/Pfizer_Inc>,
        <https://1145.am/db/2327511/Pfizer_Inc>,
        <https://1145.am/db/2328712/Pfizer>,
        <https://1145.am/db/2329920/Pfizer_Inc>,
        <https://1145.am/db/2330817/Pfizer_Inc>,
        <https://1145.am/db/2330955/Pfizer>,
        <https://1145.am/db/2332552/Pfizer>,
        <https://1145.am/db/2332767/Pfizer_Ltd>,
        <https://1145.am/db/2334133/Pfizer_Inc>,
        <https://1145.am/db/2334165/Pfizer_Inc>,
        <https://1145.am/db/2335634/Pfizer>,
        <https://1145.am/db/2335717/Pfizer>,
        <https://1145.am/db/2336333/Pfizer>,
        <https://1145.am/db/2337788/Pfizer>,
        <https://1145.am/db/2339633/Pfizer_Inc>,
        <https://1145.am/db/2340055/Pfizer>,
        <https://1145.am/db/2340321/Pfizer_Inc>,
        <https://1145.am/db/2340324/Pfizer_Inc>,
        <https://1145.am/db/2340325/Pfizer_Inc>,
        <https://1145.am/db/2340331/Pfizer_Inc>,
        <https://1145.am/db/2342559/Pfizer_Inc>,
        <https://1145.am/db/2343237/Pfizer_Inc>,
        <https://1145.am/db/2343273/Pfizer_Inc>,
        <https://1145.am/db/2343344/Pfizer>,
        <https://1145.am/db/2343454/Pfizer_Inc>,
        <https://1145.am/db/2346602/Pfizer_Inc>,
        <https://1145.am/db/2347383/Pfizer_Inc>,
        <https://1145.am/db/2348510/Pfizer_Inc>,
        <https://1145.am/db/2351730/Pfizer_Inc>,
        <https://1145.am/db/2353039/Pfizer_Inc>,
        <https://1145.am/db/2353364/Pfizer>,
        <https://1145.am/db/2355021/Pfizer>,
        <https://1145.am/db/2355025/Pfizer_Inc>,
        <https://1145.am/db/2355472/Pfizer_Inc>,
        <https://1145.am/db/2357232/Pfizer>,
        <https://1145.am/db/2357308/Pfizer_Inc>,
        <https://1145.am/db/2358128/Pfizer>,
        <https://1145.am/db/2359697/Pfizer>,
        <https://1145.am/db/2360633/Pfizer>,
        <https://1145.am/db/2360647/Pfizer_Inc>,
        <https://1145.am/db/2362439/Pfizer_Inc>,
        <https://1145.am/db/2362851/Pfizer_Inc>,
        <https://1145.am/db/2363446/Pfizer_Inc>,
        <https://1145.am/db/2363896/Pfizer>,
        <https://1145.am/db/2364087/Pfizer_Inc>,
        <https://1145.am/db/2365171/Pfizer_Ventures>,
        <https://1145.am/db/2369876/Pfizer>,
        <https://1145.am/db/2369909/Pfizer_Inc>,
        <https://1145.am/db/2370016/Pfizer>,
        <https://1145.am/db/2371512/Pfizer>,
        <https://1145.am/db/2507041/Pfizer>,
        <https://1145.am/db/2536358/Pfizer_Inc>,
        <https://1145.am/db/2536361/Pfizer_Inc>,
        <https://1145.am/db/2536362/Pfizer_Inc>,
        <https://1145.am/db/2536365/Pfizer_Inc>,
        <https://1145.am/db/2537054/Pfizer_Inc>,
        <https://1145.am/db/2537057/Pfizer_Inc>,
        <https://1145.am/db/2538568/Pfizer_Inc>,
        <https://1145.am/db/2538915/Pfizer_Inc>,
        <https://1145.am/db/2538924/Pfizer>,
        <https://1145.am/db/2539516/Pfizer>,
        <https://1145.am/db/2541139/Pfizer_Inc>,
        <https://1145.am/db/2541721/Pfizer>,
        <https://1145.am/db/2542067/Pfizer_Inc>,
        <https://1145.am/db/2543533/Pfizer>,
        <https://1145.am/db/2543826/Pfizer>,
        <https://1145.am/db/2544074/Pfizer>,
        <https://1145.am/db/2545058/Pfizer>,
        <https://1145.am/db/2545634/Pfizer>,
        <https://1145.am/db/2546596/Pfizer>,
        <https://1145.am/db/2547000/Pfizer>,
        <https://1145.am/db/2548752/Pfizer>,
        <https://1145.am/db/2548986/Pfizer>,
        <https://1145.am/db/2549719/Pfizer>,
        <https://1145.am/db/2550445/Pfizer>,
        <https://1145.am/db/2550685/Pfizer>,
        <https://1145.am/db/2553974/Pfizer>,
        <https://1145.am/db/2554937/Pfizer>,
        <https://1145.am/db/2554938/Pfizer>,
        <https://1145.am/db/2555896/Pfizer>,
        <https://1145.am/db/2558970/Pfizer>,
        <https://1145.am/db/2558971/Pfizer>,
        <https://1145.am/db/2559649/Pfizer>,
        <https://1145.am/db/2560282/Pfizer>,
        <https://1145.am/db/2560720/Pfizer>,
        <https://1145.am/db/2562102/Pfizer_Inc>,
        <https://1145.am/db/2562701/Pfizer>,
        <https://1145.am/db/2564032/Pfizer>,
        <https://1145.am/db/2568121/Pfizer>,
        <https://1145.am/db/2569378/Pfizer>,
        <https://1145.am/db/2570369/Pfizer_Inc>,
        <https://1145.am/db/2571798/Pfizer_Inc>,
        <https://1145.am/db/2572036/Pfizer>,
        <https://1145.am/db/2573245/Pfizer_Inc>,
        <https://1145.am/db/2573465/Pfizer_Inc>,
        <https://1145.am/db/2573466/Pfizer>,
        <https://1145.am/db/2573562/Pfizer>,
        <https://1145.am/db/2573707/Pfizer>,
        <https://1145.am/db/2574461/Pfizer_Inc>,
        <https://1145.am/db/2574687/Pfizer>,
        <https://1145.am/db/2574691/Pfizer_Inc>,
        <https://1145.am/db/2575139/Pfizer_Inc>,
        <https://1145.am/db/2575145/Pfizer_Inc>,
        <https://1145.am/db/2575320/Pfizer>,
        <https://1145.am/db/2575471/Pfizer>,
        <https://1145.am/db/2575505/Pfizer_Inc>,
        <https://1145.am/db/2575575/Pfizer>,
        <https://1145.am/db/2576330/Pfizer_Inc>,
        <https://1145.am/db/2577077/Pfizer>,
        <https://1145.am/db/2577258/Pfizer_Inc>,
        <https://1145.am/db/2579709/Pfizer_Inc>,
        <https://1145.am/db/2581331/Pfizer_Inc>,
        <https://1145.am/db/2581334/Pfizer_Inc>,
        <https://1145.am/db/2581339/Pfizer>,
        <https://1145.am/db/2581394/Pfizer>,
        <https://1145.am/db/2581661/Pfizer_Inc>,
        <https://1145.am/db/2582158/Pfizer_Inc>,
        <https://1145.am/db/2582160/Pfizer_Inc>,
        <https://1145.am/db/2582343/Pfizer_Inc>,
        <https://1145.am/db/2582879/Pfizer_Inc>,
        <https://1145.am/db/2583155/Pfizer_Inc>,
        <https://1145.am/db/2583163/Pfizer>,
        <https://1145.am/db/2583165/Pfizer_Inc>,
        <https://1145.am/db/2583172/Pfizer>,
        <https://1145.am/db/2583242/Pfizer_Inc>,
        <https://1145.am/db/2583783/Pfizer>,
        <https://1145.am/db/2584085/Pfizer_Inc>,
        <https://1145.am/db/2584258/Pfizer_Inc>,
        <https://1145.am/db/2584601/Pfizer_Inc>,
        <https://1145.am/db/2585700/Pfizer>,
        <https://1145.am/db/2585908/New_York-Pfizer_Inc>,
        <https://1145.am/db/2585908/Pfizer>,
        <https://1145.am/db/2585912/Pfizer>,
        <https://1145.am/db/2586034/Pfizer_Inc>,
        <https://1145.am/db/2586047/Pfizer_Inc>,
        <https://1145.am/db/2587673/Pfizer>,
        <https://1145.am/db/2588134/Pfizer_Inc>,
        <https://1145.am/db/2590549/Pfizer_Inc>,
        <https://1145.am/db/2590887/Pfizer>,
        <https://1145.am/db/2591081/Pfizer_Inc>,
        <https://1145.am/db/2591092/Pfizer_Inc>,
        <https://1145.am/db/2592980/Pfizer>,
        <https://1145.am/db/2592990/Pfizer_Inc>,
        <https://1145.am/db/2592992/Pfizer_Inc>,
        <https://1145.am/db/2593150/Pfizer>,
        <https://1145.am/db/2593886/Pfizer>,
        <https://1145.am/db/2593961/Pfizer_Inc>,
        <https://1145.am/db/2594268/Pfizer_Inc>,
        <https://1145.am/db/2594422/Pfizer>,
        <https://1145.am/db/2594489/Pfizer_Inc>,
        <https://1145.am/db/2594992/Pfizer>,
        <https://1145.am/db/2595320/Pfizer_Inc>,
        <https://1145.am/db/2595472/Pfizer>,
        <https://1145.am/db/2595499/Pfizer>,
        <https://1145.am/db/2596344/Pfizer>,
        <https://1145.am/db/2596754/Pfizer_Inc>,
        <https://1145.am/db/2596778/Pfizer>,
        <https://1145.am/db/2596874/Pfizer>,
        <https://1145.am/db/2597173/Pfizer>,
        <https://1145.am/db/2597183/Pfizer_Inc>,
        <https://1145.am/db/2597643/Pfizer_Inc>,
        <https://1145.am/db/2597650/Pfizer>,
        <https://1145.am/db/2597712/Pfizer>,
        <https://1145.am/db/274660/Pfizer_Inc>,
        <https://1145.am/db/274739/Pfizer_Inc>,
        <https://1145.am/db/318295/Pfizer_Inc>,
        <https://1145.am/db/422378/Pfizer_Inc>,
        <https://1145.am/db/424190/Pfizer_Inc>,
        <https://1145.am/db/426841/Pfizer_Inc>,
        <https://1145.am/db/428975/Pfizer_Inc>,
        <https://1145.am/db/626832/Pfizer_Inc>,
        <https://1145.am/db/627349/Pfizer_Inc>,
        <https://1145.am/db/631317/Pfizer_Inc>,
        <https://1145.am/db/635031/Pfizer>,
        <https://1145.am/db/692994/Pfizer_Inc>,
        <https://1145.am/db/694224/Pfizer_Inc>,
        <https://1145.am/db/699199/Pfizer>,
        <https://1145.am/db/76007/Pfizer>,
        <https://1145.am/db/761748/Pfizer>,
        <https://1145.am/db/764460/Pfizer>,
        <https://1145.am/db/797138/Pfizer_Inc>,
        <https://1145.am/db/800318/Pfizer_Inc>,
        <https://1145.am/db/896566/Pfizer_Inc>,
        <https://1145.am/db/897457/Pfizer_Inc>,
        <https://1145.am/db/962899/Pfizer_Inc>,
        <https://1145.am/db/965490/Pfizer_Inc>,
        <https://1145.am/db/968220/Pfizer_Inc>,
        <https://1145.am/db/971984/Pfizer_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1046923/Pfizer>,
        <https://1145.am/db/1054558/Pfizer_Inc>,
        <https://1145.am/db/1684001/Pfizer_Inc>,
        <https://1145.am/db/1936264/Pfizer_Inc>,
        <https://1145.am/db/1952785/Pfizer_Inc>,
        <https://1145.am/db/1983382/Pfizer_Inc>,
        <https://1145.am/db/2013022/Pfizer_Inc>,
        <https://1145.am/db/2070468/Pfizer>,
        <https://1145.am/db/2152849/Pfizer>,
        <https://1145.am/db/2207119/Pfizer_Inc>,
        <https://1145.am/db/2279140/Pfizer>,
        <https://1145.am/db/2280718/Pfizer>,
        <https://1145.am/db/2281622/Pfizer>,
        <https://1145.am/db/2281879/Pfizer>,
        <https://1145.am/db/2294613/Pfizer>,
        <https://1145.am/db/2301922/Pfizer>,
        <https://1145.am/db/2303447/Pfizer>,
        <https://1145.am/db/2311570/Pfizer_Inc>,
        <https://1145.am/db/2312865/Pfizer>,
        <https://1145.am/db/2312994/Pfizer>,
        <https://1145.am/db/2313175/Pfizer_Limited>,
        <https://1145.am/db/2314928/Pfizer>,
        <https://1145.am/db/2315552/Pfizer>,
        <https://1145.am/db/2318333/Pfizer>,
        <https://1145.am/db/2320509/Pfizer>,
        <https://1145.am/db/2322306/Pfizer>,
        <https://1145.am/db/2324128/Pfizer>,
        <https://1145.am/db/2327506/Pfizer>,
        <https://1145.am/db/2329902/Pfizer>,
        <https://1145.am/db/2332830/Pfizer>,
        <https://1145.am/db/2340890/Pfizer>,
        <https://1145.am/db/2341325/Pfizer>,
        <https://1145.am/db/2341516/Pfizer>,
        <https://1145.am/db/2343298/Pfizer_Inc>,
        <https://1145.am/db/2345065/Pfizer>,
        <https://1145.am/db/2350231/Pfizer>,
        <https://1145.am/db/2353325/Pfizer>,
        <https://1145.am/db/2353326/Pfizer>,
        <https://1145.am/db/2353337/Pfizer>,
        <https://1145.am/db/2353376/Pfizer>,
        <https://1145.am/db/2354370/Pfizer_Inc>,
        <https://1145.am/db/2354567/Pfizer>,
        <https://1145.am/db/2355916/Pfizer_Inc>,
        <https://1145.am/db/2356124/Pfizer_Inc>,
        <https://1145.am/db/2356597/Pfizer>,
        <https://1145.am/db/2356599/Pfizer>,
        <https://1145.am/db/2366395/Pfizer_Inc>,
        <https://1145.am/db/2367283/Pfizer_Inc>,
        <https://1145.am/db/2367982/Pfizer>,
        <https://1145.am/db/2368146/Pfizer>,
        <https://1145.am/db/2536475/Pfizer>,
        <https://1145.am/db/2536856/Pfizer>,
        <https://1145.am/db/2537171/Pfizer>,
        <https://1145.am/db/2537597/Pfizer>,
        <https://1145.am/db/2538861/Pfizer>,
        <https://1145.am/db/2539787/Pfizer>,
        <https://1145.am/db/2540356/Pfizer>,
        <https://1145.am/db/2541146/Pfizer>,
        <https://1145.am/db/2542072/Pfizer>,
        <https://1145.am/db/2542499/Pfizer>,
        <https://1145.am/db/2543278/Pfizer>,
        <https://1145.am/db/2543957/Pfizer>,
        <https://1145.am/db/2545122/Pfizer>,
        <https://1145.am/db/2545618/Pfizer>,
        <https://1145.am/db/2545818/Pfizer>,
        <https://1145.am/db/2546583/Pfizer>,
        <https://1145.am/db/2547653/Pfizer>,
        <https://1145.am/db/2548137/Pfizer>,
        <https://1145.am/db/2548244/Pfizer_Inc>,
        <https://1145.am/db/2548674/Pfizer>,
        <https://1145.am/db/2549151/Pfizer>,
        <https://1145.am/db/2549673/Pfizer>,
        <https://1145.am/db/2550761/Pfizer>,
        <https://1145.am/db/2552684/Pfizer>,
        <https://1145.am/db/2555992/Pfizer>,
        <https://1145.am/db/2557064/Pfizer>,
        <https://1145.am/db/2557083/Pfizer>,
        <https://1145.am/db/2557221/Pfizer>,
        <https://1145.am/db/2558268/Pfizer>,
        <https://1145.am/db/2558417/Pfizer>,
        <https://1145.am/db/2558464/Pfizer>,
        <https://1145.am/db/2561231/Pfizer>,
        <https://1145.am/db/2561650/Pfizer>,
        <https://1145.am/db/2563857/Pfizer>,
        <https://1145.am/db/2563889/Pfizer>,
        <https://1145.am/db/2568519/Pfizer>,
        <https://1145.am/db/2568899/Pfizer>,
        <https://1145.am/db/2572927/Pfizer>,
        <https://1145.am/db/2573173/Pfizer>,
        <https://1145.am/db/2573463/Pfizer>,
        <https://1145.am/db/2573551/Pfizer_Inc>,
        <https://1145.am/db/2573558/Pfizer_Inc>,
        <https://1145.am/db/2574332/Pfizer>,
        <https://1145.am/db/2574459/Pfizer_Inc>,
        <https://1145.am/db/2575723/Pfizer>,
        <https://1145.am/db/2576064/Pfizer>,
        <https://1145.am/db/2576526/Pfizer>,
        <https://1145.am/db/2576759/Pfizer>,
        <https://1145.am/db/2576762/Pfizer>,
        <https://1145.am/db/2577655/Pfizer>,
        <https://1145.am/db/2579252/Pfizer>,
        <https://1145.am/db/2579716/Pfizer>,
        <https://1145.am/db/2580940/Pfizer>,
        <https://1145.am/db/2581659/Pfizer>,
        <https://1145.am/db/2583245/Pfizer_Inc>,
        <https://1145.am/db/2583337/Pfizer_Inc>,
        <https://1145.am/db/2584968/Pfizer>,
        <https://1145.am/db/2587387/Pfizer>,
        <https://1145.am/db/2589365/Pfizer>,
        <https://1145.am/db/2590988/Pfizer>,
        <https://1145.am/db/2590989/Pfizer>,
        <https://1145.am/db/2591091/Pfizer>,
        <https://1145.am/db/2591281/Pfizer>,
        <https://1145.am/db/2591652/Pfizer>,
        <https://1145.am/db/2591691/Pfizer>,
        <https://1145.am/db/2591733/Pfizer>,
        <https://1145.am/db/2592975/Pfizer_Inc>,
        <https://1145.am/db/2592977/Pfizer_Inc>,
        <https://1145.am/db/2594141/Pfizer_Inc>,
        <https://1145.am/db/2594574/Pfizer>,
        <https://1145.am/db/2594581/Pfizer>,
        <https://1145.am/db/2595930/Pfizer>,
        <https://1145.am/db/2597185/Pfizer_Inc>,
        <https://1145.am/db/2597651/Pfizer_Inc>,
        <https://1145.am/db/2792911/Pfizer>,
        <https://1145.am/db/422377/Pfizer_Inc>,
        <https://1145.am/db/423571/Pfizer_Inc>,
        <https://1145.am/db/424896/Pfizer_Inc>,
        <https://1145.am/db/425689/Pfizer_Inc>,
        <https://1145.am/db/694218/Pfizer_Inc>,
        <https://1145.am/db/696927/Pfizer_Inc>,
        <https://1145.am/db/962850/Pfizer_Inc>,
        <https://1145.am/db/962851/Pfizer_Inc> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2597558/Glaxosmithkline_Pte> a org:Organization ;
    ns1:basedInLowRaw "India" ;
    ns1:description "business" ;
    ns1:documentDate "2013-02-05T12:43:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/gsk-increases-stake-its-publicly-listed-consumer-healthcare-subsidiary-india-to-72-5-per> ;
    ns1:foundName "GlaxoSmithKline Pte" ;
    ns1:industry "Healthcare" ;
    ns1:name "GlaxoSmithKline Pte" ;
    ns1:sameAsHigh <https://1145.am/db/1002406/Glaxosmithkline_Plc>,
        <https://1145.am/db/1003861/Glaxosmithkline_Plc>,
        <https://1145.am/db/1034874/Glaxosmithkline_Plc>,
        <https://1145.am/db/1035942/GSK>,
        <https://1145.am/db/1036772/Glaxosmithkline_Plc>,
        <https://1145.am/db/1037557/GSK>,
        <https://1145.am/db/118625/GSK>,
        <https://1145.am/db/1368193/GSK>,
        <https://1145.am/db/1369714/GSK>,
        <https://1145.am/db/1972441/GSK>,
        <https://1145.am/db/1983958/Gsk_Plc>,
        <https://1145.am/db/2153110/Glaxosmithkline>,
        <https://1145.am/db/2156284/Glaxosmithkline>,
        <https://1145.am/db/2190363/Glaxosmithkline>,
        <https://1145.am/db/2192331/Glaxosmithkline>,
        <https://1145.am/db/2200884/Glaxosmithkline>,
        <https://1145.am/db/2204941/Glaxosmithkline>,
        <https://1145.am/db/2224597/Glaxosmithkline>,
        <https://1145.am/db/2278803/GSK>,
        <https://1145.am/db/2279371/Glaxosmithkline>,
        <https://1145.am/db/2282253/Glaxosmithkline>,
        <https://1145.am/db/2282592/Glaxosmithkline>,
        <https://1145.am/db/2283644/Glaxosmithkline>,
        <https://1145.am/db/2286031/Glaxosmithkline>,
        <https://1145.am/db/2287351/Glaxosmithkline>,
        <https://1145.am/db/2289482/Glaxosmithkline>,
        <https://1145.am/db/2290507/Glaxosmithkline>,
        <https://1145.am/db/2290596/Glaxosmithkline>,
        <https://1145.am/db/2291302/Glaxosmithkline>,
        <https://1145.am/db/2291743/Glaxosmithkline>,
        <https://1145.am/db/2292884/Glaxosmithkline>,
        <https://1145.am/db/2293175/Glaxosmithkline>,
        <https://1145.am/db/2297702/Glaxosmithkline>,
        <https://1145.am/db/2302462/Glaxosmithkline>,
        <https://1145.am/db/2303242/Glaxosmithkline>,
        <https://1145.am/db/2303245/Glaxosmithkline>,
        <https://1145.am/db/230344/Glaxosmithkline>,
        <https://1145.am/db/2305277/Glaxosmithkline>,
        <https://1145.am/db/2305279/Glaxosmithkline>,
        <https://1145.am/db/2306213/Glaxosmithkline>,
        <https://1145.am/db/2306799/Glaxosmithkline>,
        <https://1145.am/db/2307723/Glaxosmithkline>,
        <https://1145.am/db/2308007/Glaxosmithkline>,
        <https://1145.am/db/2309511/Glaxo>,
        <https://1145.am/db/2310192/Glaxosmithkline>,
        <https://1145.am/db/2311402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2312131/Glaxosmithkline>,
        <https://1145.am/db/2312187/Glaxosmithkline>,
        <https://1145.am/db/2312416/Glaxosmithkline>,
        <https://1145.am/db/2312656/Glaxosmithkline>,
        <https://1145.am/db/2313289/Glaxosmithkline>,
        <https://1145.am/db/2314290/Glaxosmithkline>,
        <https://1145.am/db/2314853/Glaxosmithkline>,
        <https://1145.am/db/2315422/Glaxosmithkline>,
        <https://1145.am/db/2316364/Glaxosmithkline>,
        <https://1145.am/db/2316660/Glaxosmithkline>,
        <https://1145.am/db/2316797/Glaxosmithkline>,
        <https://1145.am/db/2317846/Glaxosmithkline>,
        <https://1145.am/db/2318310/Glaxosmithkline>,
        <https://1145.am/db/2318589/Glaxosmithkline>,
        <https://1145.am/db/2318644/Glaxosmithkline>,
        <https://1145.am/db/2318658/Glaxosmithkline_Plc>,
        <https://1145.am/db/2318681/Glaxosmithkline>,
        <https://1145.am/db/2318708/Glaxosmithkline>,
        <https://1145.am/db/2318919/Glaxosmithkline>,
        <https://1145.am/db/2319445/Glaxosmithkline>,
        <https://1145.am/db/2319763/Glaxosmithkline>,
        <https://1145.am/db/2319782/Glaxosmithkline>,
        <https://1145.am/db/2319892/Glaxosmithkline>,
        <https://1145.am/db/2320824/Glaxosmithkline>,
        <https://1145.am/db/2320992/Glaxosmithkline>,
        <https://1145.am/db/2321971/Glaxosmithkline>,
        <https://1145.am/db/2324095/Glaxosmithkline>,
        <https://1145.am/db/2324141/Glaxosmithkline>,
        <https://1145.am/db/2325359/Glaxosmithkline>,
        <https://1145.am/db/2325364/Glaxosmithkline>,
        <https://1145.am/db/2325490/Glaxosmithkline>,
        <https://1145.am/db/2325729/Glaxosmithkline_Plc>,
        <https://1145.am/db/2326266/Glaxosmithkline_(gsk)>,
        <https://1145.am/db/2326590/Glaxosmithkline>,
        <https://1145.am/db/2327305/Glaxosmithkline>,
        <https://1145.am/db/2327507/Glaxosmithkline>,
        <https://1145.am/db/2327529/Glaxosmithkline>,
        <https://1145.am/db/2327656/Glaxosmithkline>,
        <https://1145.am/db/2328471/Glaxosmithkline>,
        <https://1145.am/db/2328637/Glaxosmithkline>,
        <https://1145.am/db/2328666/Glaxosmithkline>,
        <https://1145.am/db/2328681/Glaxosmithkline>,
        <https://1145.am/db/2328981/Glaxosmithkline>,
        <https://1145.am/db/2330949/Glaxosmithkline>,
        <https://1145.am/db/2330955/Glaxosmithkline>,
        <https://1145.am/db/2330986/Glaxosmithkline>,
        <https://1145.am/db/2331010/Glaxosmithkline>,
        <https://1145.am/db/2331763/Glaxosmithkline>,
        <https://1145.am/db/2331819/Glaxosmithkline>,
        <https://1145.am/db/2331823/Glaxosmithkline>,
        <https://1145.am/db/2332005/Glaxosmithkline_Pliva>,
        <https://1145.am/db/2332660/Glaxosmithkline>,
        <https://1145.am/db/2332695/Glaxosmithkline>,
        <https://1145.am/db/2333658/Glaxosmithkline>,
        <https://1145.am/db/2335573/GSK>,
        <https://1145.am/db/2335582/Glaxosmithkline>,
        <https://1145.am/db/2335587/Glaxosmithkline>,
        <https://1145.am/db/2336060/Glaxosmithkline>,
        <https://1145.am/db/2336704/GSK>,
        <https://1145.am/db/2336990/Glaxosmithkline>,
        <https://1145.am/db/2337186/Glaxosmithkline>,
        <https://1145.am/db/2338296/Glaxosmithkline>,
        <https://1145.am/db/2339979/Glaxosmithkline>,
        <https://1145.am/db/2340071/Glaxosmithkline>,
        <https://1145.am/db/2340591/Glaxosmithkline>,
        <https://1145.am/db/2342074/Glaxosmithkline>,
        <https://1145.am/db/2342876/Glaxosmithkline>,
        <https://1145.am/db/2343855/Glaxosmithkline>,
        <https://1145.am/db/2343861/Glaxosmithkline>,
        <https://1145.am/db/2344023/Glaxosmithkline>,
        <https://1145.am/db/2344939/Glaxosmithkline>,
        <https://1145.am/db/2345251/GSK>,
        <https://1145.am/db/2345410/Glaxosmithkline>,
        <https://1145.am/db/2345604/Glaxosmithkline>,
        <https://1145.am/db/2348686/Glaxosmithkline>,
        <https://1145.am/db/2348693/Glaxosmithkline>,
        <https://1145.am/db/2349724/GSK>,
        <https://1145.am/db/2349724/Glaxosmithkline_Biologicals>,
        <https://1145.am/db/2352499/Glaxosmithkline>,
        <https://1145.am/db/2352506/Glaxosmithkline_Plc>,
        <https://1145.am/db/2353506/Glaxosmithkline>,
        <https://1145.am/db/2353547/Glaxosmithkline>,
        <https://1145.am/db/2354253/Glaxosmithkline>,
        <https://1145.am/db/2354577/Glaxosmithkline>,
        <https://1145.am/db/2355587/Glaxosmithkline>,
        <https://1145.am/db/2355595/Glaxosmithkline>,
        <https://1145.am/db/2355640/Cellzome>,
        <https://1145.am/db/2356391/Glaxosmithkline>,
        <https://1145.am/db/2356559/Glaxosmithkline>,
        <https://1145.am/db/2356560/Glaxosmithkline>,
        <https://1145.am/db/2356639/Glaxosmithkline>,
        <https://1145.am/db/2356654/Glaxosmithkline>,
        <https://1145.am/db/2357361/Glaxosmithkline_Plc>,
        <https://1145.am/db/2359072/Glaxosmithkline>,
        <https://1145.am/db/2359553/Glaxosmithkline>,
        <https://1145.am/db/2359727/GSK>,
        <https://1145.am/db/2359727/Glaxosmithkline>,
        <https://1145.am/db/2359836/Glaxosmithkline>,
        <https://1145.am/db/2359838/Glaxosmithkline>,
        <https://1145.am/db/2359858/Glaxosmithkline>,
        <https://1145.am/db/2360093/Glaxosmithkline>,
        <https://1145.am/db/2360094/Glaxosmithkline>,
        <https://1145.am/db/2360371/Glaxosmithkline>,
        <https://1145.am/db/2360552/Glaxosmithkline>,
        <https://1145.am/db/2360562/GSK>,
        <https://1145.am/db/2361700/GSK>,
        <https://1145.am/db/2364819/Glaxosmithkline>,
        <https://1145.am/db/2364846/Glaxosmithkline>,
        <https://1145.am/db/2367620/Glaxosmithkline>,
        <https://1145.am/db/2367621/Glaxosmithkline>,
        <https://1145.am/db/2368765/Glaxosmithkline>,
        <https://1145.am/db/2368770/Glaxosmithkline_Plc>,
        <https://1145.am/db/2369276/Glaxosmithkline>,
        <https://1145.am/db/2369449/Glaxosmithkline>,
        <https://1145.am/db/2369451/Glaxosmithkline>,
        <https://1145.am/db/2369755/GSK>,
        <https://1145.am/db/2369761/Glaxosmithkline>,
        <https://1145.am/db/2370635/GSK>,
        <https://1145.am/db/238329/Glaxosmithkline>,
        <https://1145.am/db/2536540/Glaxosmithkline>,
        <https://1145.am/db/2536585/Glaxosmithkline>,
        <https://1145.am/db/2536945/Glaxosmithkline>,
        <https://1145.am/db/2537064/Glaxosmithkline>,
        <https://1145.am/db/2537699/Glaxosmithkline>,
        <https://1145.am/db/2539219/Glaxosmithkline>,
        <https://1145.am/db/2539221/Glaxosmithkline>,
        <https://1145.am/db/2539308/Glaxosmithkline>,
        <https://1145.am/db/2539972/Glaxosmithkline>,
        <https://1145.am/db/2540020/Glaxosmithkline>,
        <https://1145.am/db/2540027/Glaxosmithkline>,
        <https://1145.am/db/2540091/Glaxosmithkline>,
        <https://1145.am/db/2540172/Glaxosmithkline>,
        <https://1145.am/db/2540527/Glaxosmithkline>,
        <https://1145.am/db/2541499/Glaxosmithkline>,
        <https://1145.am/db/2542064/GSK>,
        <https://1145.am/db/2542065/Glaxosmithkline>,
        <https://1145.am/db/2542090/Glaxosmithkline>,
        <https://1145.am/db/2542192/GSK>,
        <https://1145.am/db/2542499/Glaxosmithkline>,
        <https://1145.am/db/2542503/Glaxosmithkline>,
        <https://1145.am/db/2542506/Glaxosmithkline>,
        <https://1145.am/db/2543552/Glaxosmithkline>,
        <https://1145.am/db/2544274/Glaxosmithkline>,
        <https://1145.am/db/2544350/Glaxosmithkline>,
        <https://1145.am/db/2545023/Glaxosmithkline>,
        <https://1145.am/db/2545242/Glaxosmithkline>,
        <https://1145.am/db/2545284/Glaxosmithkline>,
        <https://1145.am/db/2545518/Glaxosmithkline>,
        <https://1145.am/db/2545537/Glaxosmithkline>,
        <https://1145.am/db/2546260/Glaxosmithkline>,
        <https://1145.am/db/2546574/Glaxosmithkline>,
        <https://1145.am/db/2546577/Glaxosmithkline>,
        <https://1145.am/db/2546616/Glaxosmithkline>,
        <https://1145.am/db/2546929/Glaxosmithkline>,
        <https://1145.am/db/2547142/Glaxosmithkline>,
        <https://1145.am/db/2547143/Glaxosmithkline>,
        <https://1145.am/db/2547835/Glaxosmithkline>,
        <https://1145.am/db/2547954/Glaxosmithkline>,
        <https://1145.am/db/2547976/Glaxosmithkline>,
        <https://1145.am/db/2548034/Glaxosmithkline>,
        <https://1145.am/db/2548208/Glaxosmithkline>,
        <https://1145.am/db/2548518/Glaxosmithkline>,
        <https://1145.am/db/2548523/Glaxosmithkline>,
        <https://1145.am/db/2549082/Glaxosmithkline>,
        <https://1145.am/db/2549876/Glaxosmithkline>,
        <https://1145.am/db/2550054/Glaxosmithkline>,
        <https://1145.am/db/2550318/Glaxosmithkline>,
        <https://1145.am/db/2550460/GSK>,
        <https://1145.am/db/2550460/Glaxosmithkline>,
        <https://1145.am/db/2550543/Glaxosmithkline>,
        <https://1145.am/db/2550662/Glaxosmithkline>,
        <https://1145.am/db/2551402/Glaxosmithkline>,
        <https://1145.am/db/2551695/Glaxosmithkline>,
        <https://1145.am/db/2552794/Glaxosmithkline>,
        <https://1145.am/db/2553168/GSK>,
        <https://1145.am/db/2553206/Glaxosmithkline>,
        <https://1145.am/db/2553462/Glaxosmithkline>,
        <https://1145.am/db/2554044/Glaxosmithkline>,
        <https://1145.am/db/2554324/Glaxosmithkline>,
        <https://1145.am/db/2554578/Glaxosmithkline>,
        <https://1145.am/db/2554641/Glaxosmithkline>,
        <https://1145.am/db/2554937/Glaxosmithkline>,
        <https://1145.am/db/2555012/Glaxosmithkline>,
        <https://1145.am/db/2556628/Glaxosmithkline>,
        <https://1145.am/db/2556820/Glaxosmithkline>,
        <https://1145.am/db/2556995/Glaxosmithkline>,
        <https://1145.am/db/2557515/Glaxosmithkline>,
        <https://1145.am/db/2558165/Glaxosmithkline>,
        <https://1145.am/db/2558862/GSK>,
        <https://1145.am/db/2558862/Glaxosmithkline>,
        <https://1145.am/db/2558927/Glaxosmithkline>,
        <https://1145.am/db/2558940/Glaxosmithkline>,
        <https://1145.am/db/2560234/Glaxosmithkline>,
        <https://1145.am/db/2560260/Glaxosmithkline>,
        <https://1145.am/db/2560633/Glaxosmithkline>,
        <https://1145.am/db/2560853/Glaxosmithkline>,
        <https://1145.am/db/2560873/Glaxosmithkline>,
        <https://1145.am/db/2561334/Glaxo>,
        <https://1145.am/db/2561353/Glaxosmithkline>,
        <https://1145.am/db/2561599/Glaxosmithkline>,
        <https://1145.am/db/2561650/GSK>,
        <https://1145.am/db/2561960/Glaxosmithkline>,
        <https://1145.am/db/2562951/Glaxosmithkline>,
        <https://1145.am/db/2563194/Glaxosmithkline>,
        <https://1145.am/db/2563381/Glaxosmithkline>,
        <https://1145.am/db/2564238/Glaxosmithkline>,
        <https://1145.am/db/2564695/Glaxosmithkline>,
        <https://1145.am/db/2564786/Glaxosmithkline>,
        <https://1145.am/db/2566186/GSK>,
        <https://1145.am/db/2566825/Glaxosmithkline>,
        <https://1145.am/db/2567009/Glaxosmithkline>,
        <https://1145.am/db/2567104/GSK>,
        <https://1145.am/db/2568932/Glaxosmithkline>,
        <https://1145.am/db/2568968/Glaxosmithkline>,
        <https://1145.am/db/2569734/Glaxosmithkline_Plc>,
        <https://1145.am/db/2569735/Glaxosmithkline_Plc>,
        <https://1145.am/db/2572429/Glaxosmithkline>,
        <https://1145.am/db/2572963/Glaxosmithkline>,
        <https://1145.am/db/2573002/Glaxosmithkline>,
        <https://1145.am/db/2573201/Glaxosmithkline>,
        <https://1145.am/db/2573585/Glaxosmithkline>,
        <https://1145.am/db/2574333/Glaxosmithkline>,
        <https://1145.am/db/2575289/Glaxosmithkline>,
        <https://1145.am/db/2575462/First_Glaxosmithkline>,
        <https://1145.am/db/2576042/Glaxosmithkline>,
        <https://1145.am/db/2576046/Glaxosmithkline>,
        <https://1145.am/db/2576156/Glaxosmithkline>,
        <https://1145.am/db/2576230/Glaxosmithkline_Plc>,
        <https://1145.am/db/2576242/Glaxosmithkline>,
        <https://1145.am/db/2576256/Glaxo>,
        <https://1145.am/db/2576263/Glaxosmithkline>,
        <https://1145.am/db/2576267/GSK>,
        <https://1145.am/db/2576267/Glaxosmithkline>,
        <https://1145.am/db/2576516/Glaxosmithkline>,
        <https://1145.am/db/2577566/First_Glaxosmithkline>,
        <https://1145.am/db/2577566/Glaxo>,
        <https://1145.am/db/2577747/Glaxosmithkline>,
        <https://1145.am/db/2577778/Glaxosmithkline>,
        <https://1145.am/db/2578161/Glaxosmithkline>,
        <https://1145.am/db/2578420/Glaxosmithkline>,
        <https://1145.am/db/2578528/GSK>,
        <https://1145.am/db/2578536/Glaxosmithkline>,
        <https://1145.am/db/2579172/Glaxosmithkline>,
        <https://1145.am/db/2579177/Glaxosmithkline>,
        <https://1145.am/db/2579180/GSK>,
        <https://1145.am/db/2579205/Glaxosmithkline>,
        <https://1145.am/db/2580047/Glaxosmithkline>,
        <https://1145.am/db/2580053/Glaxosmithkline>,
        <https://1145.am/db/2580140/Glaxosmithkline>,
        <https://1145.am/db/2580509/Glaxosmithkline>,
        <https://1145.am/db/2580916/Glaxosmithkline>,
        <https://1145.am/db/2581141/Glaxosmithkline_Plc>,
        <https://1145.am/db/2581145/Glaxosmithkline>,
        <https://1145.am/db/2581176/Glaxosmithkline>,
        <https://1145.am/db/2581659/GSK>,
        <https://1145.am/db/2581661/Glaxosmithkline>,
        <https://1145.am/db/2582227/Glaxosmithkline>,
        <https://1145.am/db/2582344/Glaxosmithkline>,
        <https://1145.am/db/2582416/Glaxosmithkline>,
        <https://1145.am/db/2583228/Glaxosmithkline_Plc>,
        <https://1145.am/db/2583281/Glaxosmithkline>,
        <https://1145.am/db/2583584/Glaxosmithkline>,
        <https://1145.am/db/2584216/Glaxosmithkline>,
        <https://1145.am/db/2584538/Glaxosmithkline>,
        <https://1145.am/db/2585246/Glaxosmithkline_Plc>,
        <https://1145.am/db/2585251/Glaxosmithkline>,
        <https://1145.am/db/2586067/Glaxosmithkline>,
        <https://1145.am/db/2586099/Glaxosmithkline>,
        <https://1145.am/db/2586139/Glaxosmithkline>,
        <https://1145.am/db/2586802/GSK>,
        <https://1145.am/db/2586802/Glaxosmithkline>,
        <https://1145.am/db/2587282/Glaxosmithkline>,
        <https://1145.am/db/2587657/Glaxosmithkline>,
        <https://1145.am/db/2587770/Glaxosmithkline>,
        <https://1145.am/db/2587966/Glaxosmithkline>,
        <https://1145.am/db/2587967/GSK>,
        <https://1145.am/db/2587968/GSK>,
        <https://1145.am/db/2588258/Glaxosmithkline>,
        <https://1145.am/db/2588918/Glaxosmithkline>,
        <https://1145.am/db/2589035/Glaxosmithkline>,
        <https://1145.am/db/2589642/Glaxosmithkline>,
        <https://1145.am/db/2589701/GSK>,
        <https://1145.am/db/2589701/Glaxosmithkline>,
        <https://1145.am/db/2590051/Glaxosmithkline>,
        <https://1145.am/db/2590712/Glaxosmithkline>,
        <https://1145.am/db/2592987/Glaxosmithkline>,
        <https://1145.am/db/2593710/Glaxosmithkline>,
        <https://1145.am/db/2594208/Glaxosmithkline>,
        <https://1145.am/db/2594422/Glaxosmithkline>,
        <https://1145.am/db/2595001/Glaxosmithkline>,
        <https://1145.am/db/2595150/Glaxosmithkline>,
        <https://1145.am/db/2596213/Glaxosmithkline>,
        <https://1145.am/db/2596402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2596577/Glaxosmithkline>,
        <https://1145.am/db/2596835/Glaxosmithkline>,
        <https://1145.am/db/2597004/GSK>,
        <https://1145.am/db/2597220/Glaxosmithkline>,
        <https://1145.am/db/2597554/Glaxosmithkline>,
        <https://1145.am/db/2597960/Glaxosmithkline>,
        <https://1145.am/db/286227/Glaxosmithkline>,
        <https://1145.am/db/338242/Glaxosmithkline>,
        <https://1145.am/db/377761/Glaxosmithkline>,
        <https://1145.am/db/377769/Glaxosmithkline>,
        <https://1145.am/db/446194/Glaxosmithkline>,
        <https://1145.am/db/494811/Glaxosmithkline>,
        <https://1145.am/db/538122/Glaxosmithkline>,
        <https://1145.am/db/576236/Glaxosmithkline>,
        <https://1145.am/db/582690/GSK>,
        <https://1145.am/db/702938/Glaxosmithkline>,
        <https://1145.am/db/761748/Glaxosmithkline>,
        <https://1145.am/db/761841/Glaxosmithkline_Plc>,
        <https://1145.am/db/763207/Glaxosmithkline>,
        <https://1145.am/db/771701/Glaxosmithkline>,
        <https://1145.am/db/85758/Glaxosmithkline>,
        <https://1145.am/db/922192/Glaxosmithkline>,
        <https://1145.am/db/970746/Glaxosmithkline>,
        <https://1145.am/db/973116/Glaxosmithkline>,
        <https://1145.am/db/975768/Glaxosmithkline>,
        <https://1145.am/db/977067/Glaxosmithkline> ;
    ns1:sameAsMedium <https://1145.am/db/1022812/Glaxosmithkline_Plc>,
        <https://1145.am/db/1026879/Glaxosmithkline>,
        <https://1145.am/db/1209318/Glaxosmithkline>,
        <https://1145.am/db/2293631/Glaxosmithkline>,
        <https://1145.am/db/2295635/Glaxosmithkline>,
        <https://1145.am/db/2329533/Glaxosmithkline>,
        <https://1145.am/db/2335568/Glaxosmithkline>,
        <https://1145.am/db/2340260/Glaxosmithkline>,
        <https://1145.am/db/2364813/Glaxosmithkline>,
        <https://1145.am/db/2365103/Glaxosmithkline>,
        <https://1145.am/db/2370843/Glaxosmithkline>,
        <https://1145.am/db/2536493/Glaxosmithkline>,
        <https://1145.am/db/2540170/Glaxosmithkline>,
        <https://1145.am/db/2541733/Glaxosmithkline>,
        <https://1145.am/db/2544062/Glaxosmithkline>,
        <https://1145.am/db/2546136/Glaxosmithkline>,
        <https://1145.am/db/2549598/Glaxosmithkline>,
        <https://1145.am/db/2549694/Glaxosmithkline>,
        <https://1145.am/db/2552165/Glaxosmithkline>,
        <https://1145.am/db/2554902/Glaxosmithkline>,
        <https://1145.am/db/2556407/Glaxosmithkline>,
        <https://1145.am/db/2557221/Glaxosmithkline>,
        <https://1145.am/db/2560668/Glaxosmithkline>,
        <https://1145.am/db/2568973/Glaxosmithkline>,
        <https://1145.am/db/2570721/Glaxosmithkline>,
        <https://1145.am/db/2570791/Glaxosmithkline>,
        <https://1145.am/db/2577226/Glaxosmithkline>,
        <https://1145.am/db/2582233/Glaxosmithkline>,
        <https://1145.am/db/2594187/Glaxosmithkline>,
        <https://1145.am/db/2598461/Glaxosmithkline>,
        <https://1145.am/db/582690/Glaxosmithkline>,
        <https://1145.am/db/704642/Glaxosmithkline_Plc>,
        <https://1145.am/db/87287/Glaxosmithkline> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2616502/Nokia_Siemens_Networks> a org:Organization ;
    ns1:documentDate "2013-03-11T12:01:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sycamore Networks ends its run" ;
    ns1:documentURL <https://www.fiercetelecom.com/telecom/sycamore-networks-ends-its-run> ;
    ns1:foundName "Nokia Siemens Networks" ;
    ns1:name "Nokia Siemens Networks" ;
    ns1:sameAsMedium <https://1145.am/db/1865517/Nokia_Siemens_Networks>,
        <https://1145.am/db/1866965/Nokia_Siemens_Networks>,
        <https://1145.am/db/1867044/Nokia_Siemens_Networks>,
        <https://1145.am/db/1893323/Nokia_Siemens_Networks>,
        <https://1145.am/db/2600044/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604319/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604506/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604853/Nokia_Siemens_Networks>,
        <https://1145.am/db/2606778/Nokia_Siemens_Networks>,
        <https://1145.am/db/2607155/Nokia_Siemens_Networks>,
        <https://1145.am/db/2607408/Nokia_Siemens_Networks>,
        <https://1145.am/db/2608234/Nokia_Siemens_Networks>,
        <https://1145.am/db/2608675/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611268/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611280/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611289/Nokia_Siemens_Networks>,
        <https://1145.am/db/2612831/Nokia_Siemens_Networks>,
        <https://1145.am/db/2613146/Nokia_Siemens_Networks>,
        <https://1145.am/db/2613169/Nokia_Siemens_Networks>,
        <https://1145.am/db/2614294/Nokia_Siemens_Networks>,
        <https://1145.am/db/2615021/Nokia_Siemens_Networks>,
        <https://1145.am/db/2616957/Nokia_Siemens_Networks>,
        <https://1145.am/db/2616995/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617005/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617493/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617657/Nokia_Siemens_Networks>,
        <https://1145.am/db/2618843/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619160/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619460/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619788/Nokia_Siemens_Networks>,
        <https://1145.am/db/2622268/Nokia_Siemens_Networks>,
        <https://1145.am/db/2625103/Nokia_Siemens_Networks>,
        <https://1145.am/db/2625106/Nokia_Siemens_Networks>,
        <https://1145.am/db/2629903/Nokia_Siemens_Networks>,
        <https://1145.am/db/2630841/Nokia_Siemens_Networks>,
        <https://1145.am/db/2631730/Nokia_Siemens_Networks>,
        <https://1145.am/db/2635511/Nokia_Siemens_Networks>,
        <https://1145.am/db/2635545/Nokia_Siemens_Networks>,
        <https://1145.am/db/2636044/Nokia_Siemens_Networks>,
        <https://1145.am/db/2636463/Nokia_Siemens_Networks>,
        <https://1145.am/db/2637962/Nokia_Siemens_Networks>,
        <https://1145.am/db/2638937/Nokia_Siemens_Networks>,
        <https://1145.am/db/2638938/Nokia_Siemens_Networks>,
        <https://1145.am/db/2639419/Nokia_Siemens_Networks>,
        <https://1145.am/db/2639425/Nokia_Siemens_Networks>,
        <https://1145.am/db/2640432/Nokia_Siemens_Networks>,
        <https://1145.am/db/2642116/Nokia_Siemens_Networks>,
        <https://1145.am/db/2643132/Nokia_Siemens_Networks>,
        <https://1145.am/db/2643438/Nokia_Siemens_Networks>,
        <https://1145.am/db/2647326/Nokia_Siemens_Networks>,
        <https://1145.am/db/2648177/Nokia_Siemens_Networks>,
        <https://1145.am/db/2648187/Nokia_Siemens_Networks>,
        <https://1145.am/db/2650490/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651649/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651664/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651668/Nokia_Siemens_Networks>,
        <https://1145.am/db/2652178/Nokia_Siemens_Networks>,
        <https://1145.am/db/2652962/Nokia_Siemens_Networks>,
        <https://1145.am/db/2653862/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654614/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654893/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654922/Nokia_Siemens_Networks>,
        <https://1145.am/db/2656598/Nokia_Siemens_Networks>,
        <https://1145.am/db/2656673/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657431/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657486/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657523/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659204/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659506/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659682/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660228/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660248/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660256/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660261/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662032/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662041/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662048/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662059/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662406/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662625/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662689/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662865/Nokia_Siemens_Networks>,
        <https://1145.am/db/2663834/Nokia_Siemens_Networks>,
        <https://1145.am/db/2664171/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665073/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665681/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665701/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665980/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666063/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666090/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666165/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666167/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666782/Nokia_Siemens_Networks>,
        <https://1145.am/db/2667192/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668320/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668329/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668820/Nokia_Siemens_Networks>,
        <https://1145.am/db/2669368/Nokia_Siemens_Networks>,
        <https://1145.am/db/2670327/Nokia_Siemens_Networks>,
        <https://1145.am/db/2670700/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672497/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672513/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672581/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672582/Nokia_Siemens_Networks>,
        <https://1145.am/db/2673703/Nokia_Siemens_Networks>,
        <https://1145.am/db/2673757/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674536/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674934/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674950/Nokia_Siemens_Networks>,
        <https://1145.am/db/2675256/Nokia_Siemens_Networks>,
        <https://1145.am/db/2675276/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676115/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676312/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676415/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677266/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677518/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677609/Nokia_Siemens_Networks>,
        <https://1145.am/db/2678837/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679325/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679545/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679741/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679877/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680048/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680713/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680720/Nokia_Siemens_Networks>,
        <https://1145.am/db/2682371/Nokia_Siemens_Networks>,
        <https://1145.am/db/2683690/Nokia_Siemens_Networks>,
        <https://1145.am/db/2684551/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685124/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685394/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685508/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685558/Nokia_Siemens_Networks>,
        <https://1145.am/db/2686194/Nokia_Siemens_Networks> ;
    ns1:sourceName "Fierce Telecom" .

<https://1145.am/db/2669324/Verizon_Wireless> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York City" ;
    ns1:description "rumors and speculation" ;
    ns1:documentDate "2013-03-05T18:07:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Verizon wants to resolve Vodafone relationship in 2013" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-verizon-wants-to-resolve-vodafone-relationship-2013> ;
    ns1:foundName "Verizon Wireless" ;
    ns1:name "Verizon Wireless" ;
    ns1:sameAsHigh <https://1145.am/db/2669324/Verizon_Communications> ;
    ns1:sameAsMedium <https://1145.am/db/1698410/Verizon_Wireless>,
        <https://1145.am/db/1709073/Verizon_Wireless>,
        <https://1145.am/db/1713307/Verizon_Wireless>,
        <https://1145.am/db/1854000/Verizon_Wireless>,
        <https://1145.am/db/2175880/Verizon_Wireless>,
        <https://1145.am/db/2603175/Verizon_Wireless>,
        <https://1145.am/db/2607321/Verizon_Wireless>,
        <https://1145.am/db/2611521/Verizon_Wireless>,
        <https://1145.am/db/2615058/Verizon_Wireless>,
        <https://1145.am/db/2617844/Verizon_Wireless>,
        <https://1145.am/db/2623357/Verizon_Wireless>,
        <https://1145.am/db/2625944/Verizon_Wireless>,
        <https://1145.am/db/2626647/Verizon_Wireless>,
        <https://1145.am/db/2629075/Verizon_Wireless>,
        <https://1145.am/db/2630964/Verizon_Wireless>,
        <https://1145.am/db/2630966/Verizon_Wireless>,
        <https://1145.am/db/2631014/Verizon_Wireless>,
        <https://1145.am/db/2633169/Verizon_Wireless>,
        <https://1145.am/db/2636627/Verizon_Wireless>,
        <https://1145.am/db/2636649/Verizon_Wireless>,
        <https://1145.am/db/2637568/Verizon_Wireless>,
        <https://1145.am/db/2638447/Verizon_Wireless>,
        <https://1145.am/db/2638626/Verizon_Wireless>,
        <https://1145.am/db/2639565/Verizon_Wireless>,
        <https://1145.am/db/2640586/Verizon_Wireless>,
        <https://1145.am/db/2640627/Verizon_Wireless>,
        <https://1145.am/db/2640631/Verizon_Wireless>,
        <https://1145.am/db/2641133/Verizon_Wireless>,
        <https://1145.am/db/2641674/Verizon_Wireless>,
        <https://1145.am/db/2642638/Verizon_Wireless>,
        <https://1145.am/db/2643114/Verizon_Wireless>,
        <https://1145.am/db/2643151/Verizon_Wireless>,
        <https://1145.am/db/2644230/Verizon_Wireless>,
        <https://1145.am/db/2646605/Verizon_Wireless>,
        <https://1145.am/db/2647254/Verizon_Wireless>,
        <https://1145.am/db/2648489/Verizon_Wireless>,
        <https://1145.am/db/2648535/Verizon_Wireless>,
        <https://1145.am/db/2652646/Verizon_Wireless>,
        <https://1145.am/db/2653299/Verizon_Wireless>,
        <https://1145.am/db/2654246/Verizon_Wireless>,
        <https://1145.am/db/2655154/Verizon_Wireless>,
        <https://1145.am/db/2655158/Verizon_Wireless>,
        <https://1145.am/db/2658006/Verizon_Wireless>,
        <https://1145.am/db/2658043/Verizon_Wireless>,
        <https://1145.am/db/2659609/Verizon_Wireless>,
        <https://1145.am/db/2659966/Verizon_Wireless>,
        <https://1145.am/db/2660385/Verizon_Wireless>,
        <https://1145.am/db/2661771/Verizon_Wireless>,
        <https://1145.am/db/2663294/Verizon_Wireless>,
        <https://1145.am/db/2664359/Verizon_Wireless>,
        <https://1145.am/db/2665544/Verizon_Wireless>,
        <https://1145.am/db/2665564/Verizon_Wireless>,
        <https://1145.am/db/2666614/Verizon_Wireless>,
        <https://1145.am/db/2667132/Verizon_Wireless>,
        <https://1145.am/db/2667470/Verizon_Wireless>,
        <https://1145.am/db/2669935/Verizon_Wireless>,
        <https://1145.am/db/2669944/Verizon_Wireless>,
        <https://1145.am/db/2671406/Verizon_Wireless>,
        <https://1145.am/db/2671610/Verizon_Wireless>,
        <https://1145.am/db/2672183/Verizon_Wireless>,
        <https://1145.am/db/2672185/Verizon_Wireless>,
        <https://1145.am/db/2672228/Verizon_Wireless>,
        <https://1145.am/db/2672472/Verizon_Wireless>,
        <https://1145.am/db/2672778/Verizon_Wireless>,
        <https://1145.am/db/2672784/Verizon_Wireless>,
        <https://1145.am/db/2673608/Verizon_Wireless>,
        <https://1145.am/db/2673614/Verizon_Wireless>,
        <https://1145.am/db/2673622/Verizon_Wireless>,
        <https://1145.am/db/2673945/Verizon_Wireless>,
        <https://1145.am/db/2673958/Verizon_Wireless>,
        <https://1145.am/db/2676075/Verizon_Wireless>,
        <https://1145.am/db/2676100/Verizon_Wireless>,
        <https://1145.am/db/2679163/Verizon_Wireless>,
        <https://1145.am/db/2680403/Verizon_Wireless>,
        <https://1145.am/db/2680756/Verizon_Wireless>,
        <https://1145.am/db/2681282/Verizon_Wireless>,
        <https://1145.am/db/2681285/Verizon_Wireless>,
        <https://1145.am/db/2682721/Verizon_Wireless>,
        <https://1145.am/db/2683077/Verizon_Wireless>,
        <https://1145.am/db/2683135/Verizon_Wireless>,
        <https://1145.am/db/2683147/Verizon_Wireless>,
        <https://1145.am/db/2683432/Verizon_Wireless>,
        <https://1145.am/db/2683443/Verizon_Wireless>,
        <https://1145.am/db/2684478/Verizon_Wireless>,
        <https://1145.am/db/2684484/Verizon_Wireless>,
        <https://1145.am/db/2684691/Verizon_Wireless>,
        <https://1145.am/db/2684897/Verizon_Wireless>,
        <https://1145.am/db/2685047/Verizon_Wireless>,
        <https://1145.am/db/2685877/Verizon_Wireless>,
        <https://1145.am/db/2686087/Verizon_Wireless>,
        <https://1145.am/db/2686540/Verizon_Wireless> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2669324/Verizon_Wireless_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment",
        "merger" ;
    ns1:documentDate "2013-03-05T18:07:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Verizon Communications (NYSE: VZ) and Vodafone have held talks that range from a merger of the two giant phone companies to Verizon merely buying Vodafone's 45 percent stake in their Verizon Wireless joint venture, according to a Bloomberg report." ;
    ns1:documentTitle "Report: Verizon wants to resolve Vodafone relationship in 2013" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-verizon-wants-to-resolve-vodafone-relationship-2013> ;
    ns1:foundName "buying",
        "merger" ;
    ns1:name "buying",
        "merger" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped",
        "unknown" ;
    ns1:target <https://1145.am/db/2669324/Verizon_Wireless> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Verizon Wireless" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York City" .

<https://1145.am/db/2674215/Globul_Unit_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-05-01T09:56:35+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Deutsche Telekom, which owns 40 per cent of OTE, said last year it could buy Globul to help out the struggling Greek operator, if such a measure were required.",
        "Greek operator OTE said it will sell its Globul unit in Bulgaria to Norway's Telenor, and will use the proceeds to reduce debt and strengthen its competitive standing in recession-hit Greece." ;
    ns1:documentTitle "OTE sells Bulgarian unit to Telenor for 717M" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/ote-sells-bulgarian-unit-to-telenor-for-eu717m> ;
    ns1:foundName "buy",
        "sell" ;
    ns1:name "buy",
        "sell" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2674215/Globul> ;
    ns1:targetDetails "unit" ;
    ns1:targetName "Globul" ;
    ns1:vendor <https://1145.am/db/2674215/Ote> ;
    ns1:whenRaw "2012" ;
    ns1:whereGeoName "Republic of Bulgaria" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/732800/about.rdf> ;
    ns1:whereRaw "Bulgaria" .

<https://1145.am/db/2676599/CWC> a org:Organization ;
    ns1:basedInLowRaw "Monaco" ;
    ns1:description "business" ;
    ns1:documentDate "2013-05-22T14:42:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tiny Monaco thwarting CWC efforts to focus on pan-American strategy" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/tiny-monaco-thwarting-cwc-efforts-to-focus-pan-american-strategy> ;
    ns1:foundName "CWC" ;
    ns1:name "CWC" ;
    ns1:sameAsMedium <https://1145.am/db/2667523/CWC> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2676599/Compagnie_Monegasque_De_Communication_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-05-22T14:42:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CWC has already sold a 25 per cent stake in Compagnie Monegasque de Communication, which in turns owns 55 per cent of Monaco Telecom, to Batelco, with an option for Batelco to buy the other 75 per cent stake." ;
    ns1:documentTitle "Tiny Monaco thwarting CWC efforts to focus on pan-American strategy" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/tiny-monaco-thwarting-cwc-efforts-to-focus-pan-american-strategy> ;
    ns1:foundName "buy",
        "sold" ;
    ns1:name "buy",
        "sold" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2676599/CWC>,
        <https://1145.am/db/2676599/Compagnie_Monegasque_De_Communication> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Compagnie Monegasque de Communication" ;
    ns1:vendor <https://1145.am/db/2676599/CWC> ;
    ns1:whereGeoName "Principality of Monaco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2993457/about.rdf> ;
    ns1:whereRaw "Monaco" .

<https://1145.am/db/2676643/Merger_Rostelecom_Tele2_Russia_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "merger" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Expectations grow of a merger between Tele2 Russia and Rostelecom after a change of management at the VTB - owned operator." ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "merger" ;
    ns1:name "merger" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia" .

<https://1145.am/db/2676643/Orascom_Telecom> a org:Organization ;
    ns1:basedInHighGeoName "Arab Republic of Egypt" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/357994/about.rdf> ;
    ns1:basedInHighRaw "Egypt" ;
    ns1:documentDate "2013-05-31T14:35:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nokia's Indian tax appeal dismissed; TeliaSonera secures 800 MHz spectrum in Estonia" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/nokia-s-indian-tax-appeal-dismissed-teliasonera-secures-800-mhz-spectrum-estonia> ;
    ns1:foundName "Orascom Telecom" ;
    ns1:name "Orascom Telecom" ;
    ns1:sameAsMedium <https://1145.am/db/2654421/Orascom_Telecom>,
        <https://1145.am/db/2655203/Orascom_Telecom>,
        <https://1145.am/db/2656676/Orascom_Telecom>,
        <https://1145.am/db/2657740/Orascom_Telecom>,
        <https://1145.am/db/2660593/Orascom_Telecom>,
        <https://1145.am/db/2668326/Orascom_Telecom>,
        <https://1145.am/db/2671104/Orascom_Telecom>,
        <https://1145.am/db/2673027/Orascom_Telecom>,
        <https://1145.am/db/2675258/Orascom_Telecom>,
        <https://1145.am/db/2676888/Orascom_Telecom>,
        <https://1145.am/db/2678993/Orascom_Telecom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678993/Tele2_Russia> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:documentDate "2013-06-21T14:31:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "VimpelCom drops Wind Mobile bid; Free Mobile plans femtocell onslaught" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/vimpelcom-drops-wind-mobile-bid-free-mobile-plans-femtocell-onslaught> ;
    ns1:foundName "Tele2 Russia" ;
    ns1:name "Tele2 Russia" ;
    ns1:sameAsMedium <https://1145.am/db/2655910/Tele2_Russia>,
        <https://1145.am/db/2655942/Tele2_Russia>,
        <https://1145.am/db/2656799/Tele2_Russia>,
        <https://1145.am/db/2658919/Tele2_Russia>,
        <https://1145.am/db/2662068/Tele2_Russia>,
        <https://1145.am/db/2671855/Tele2_Russia>,
        <https://1145.am/db/2676643/Tele2_Russia> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2205089/Series_A_Investment_Claremont_Creek_Ventures_Life_Science_Angels_Lightspeed_Venture_Partners_Numedii_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-26T13:00:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NuMedii Receives $ 3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners.",
        "NuMedii, Inc. today announced that it has received $ 3.5M in a Series A funding led by Claremont Creek Ventures and Lightspeed Venture Partners, with participation by Life Science Angels and others." ;
    ns1:documentTitle "NuMedii Receives $3.5M in a Series A Financing from Claremont Creek Ventures and Lightspeed Venture Partners" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/numedii-receives-3-5m-a-series-a-financing-from-claremont-creek-ventures-and-lightspeed-venture> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2205089/Numedii> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 3.5M" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2223723/Growth_Investment_406_Ventures_Fidelity_Biosciences_Iora_Health_Polaris_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-17T11:00:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Iora Health Secures $ 14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh.",
        "Iora Health, a private healthcare company providing a radically different model of primary care, today announced that it has secured $ 14 million in series B growth financing." ;
    ns1:documentTitle "Iora Health Secures $14 Million in Series B Growth Financing; Investor Group Includes All Original Funders and Tony Hsieh" ;
    ns1:documentURL <https://www.fiercehealthcare.com/practices/iora-health-secures-14-million-series-b-growth-financing-investor-group-includes-all> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2223723/Iora_Health> ;
    ns1:targetDetails "Series B",
        "growth",
        "series B" ;
    ns1:valueRaw "$ 14 Million",
        "$ 14 million" .

<https://1145.am/db/2307564/Shangpharma_Corporation> a org:Organization ;
    ns1:basedInHighGeoName "Peoples Republic of China" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:basedInHighRaw "China" ;
    ns1:description "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:documentDate "2013-01-01T23:20:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ShangPharma Corporation Enters into Definitive Merger Agreement for Going Private Transaction" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/shangpharma-corporation-enters-into-definitive-merger-agreement-for-going-private-transaction> ;
    ns1:foundName "ShangPharma Corporation" ;
    ns1:industry "pharmaceutical and biotechnology research and development outsourcing company" ;
    ns1:name "ShangPharma Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2307564/Shangpharma_Holdings_Limited>,
        <https://1145.am/db/2307564/Shangpharma_Parent_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Corporation>,
        <https://1145.am/db/2310766/Shangpharma_Holdings_Limited>,
        <https://1145.am/db/2310766/Shangpharma_Parent_Limited>,
        <https://1145.am/db/2322854/Wuxi_Pharmatech>,
        <https://1145.am/db/2332973/Wuxi_Pharmatech>,
        <https://1145.am/db/2332977/Wuxi_Pharmatech>,
        <https://1145.am/db/2332992/Wuxi_Pharmatech>,
        <https://1145.am/db/2345752/Wuxi_Pharmatech>,
        <https://1145.am/db/2351337/Shangpharma_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2345830/Shangpharma_Corporation>,
        <https://1145.am/db/2536895/Shangpharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336944/Series_B_Investment_Clarus_Ventures_Heptares_Therapeutics_Stanley_Family_Foundation_Takeda_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-27T15:06:41+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Heptares Raises US $ 21 Million to Advance Novel GPCR Medicines into Clinical Development.",
        "Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced it has raised over US $ 21 million in a Series B financing to advance a clinical pipeline of novel drugs directed towards clinically validated targets for the treatment of neurological and psychiatric diseases." ;
    ns1:documentTitle "Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/heptares-raises-us-21-million-to-advance-novel-gpcr-medicines-into-clinical-development> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2336944/Heptares_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "US $ 21 Million",
        "over US $ 21 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "US" .

<https://1145.am/db/2336957/Investment_Ampliphi_Biosciences_Corp_Bioscience_Managers_Pty_Ltd_Ra_Capital_Management_Third_Security_Llc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-27T16:09:08+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AmpliPhi BioSciences Corp. (OTC: APHB) , the world leader in the development of bacteriophage - based antibacterial therapies to treat drug resistant infections, announced today the completion of a successful private placement of convertible preferred stock with gross proceeds of $ 7 million.",
        "Ampliphi Biosciences Corp: AmpliPhi Closes $ 7 Million Private Placement." ;
    ns1:documentTitle "Ampliphi Biosciences Corp : AmpliPhi Closes $7 Million Private Placement" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ampliphi-biosciences-corp-ampliphi-closes-7-million-private-placement> ;
    ns1:foundName "Private Placement",
        "private placement" ;
    ns1:name "Private Placement",
        "private placement" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336957/Ampliphi_Biosciences_Corp> ;
    ns1:valueRaw "$ 7 Million",
        "$ 7 million" ;
    ns1:when "2013-06-27T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "06/27/2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2338254/Series_C_Investment_Elcelyx_Therapeutics_Kleiner_Perkins_Caufield___Byers_Morgenthaler_Ventures_Technology_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-14T15:40:40+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Elcelyx Therapeutics Completes $ 20 Million Series C Financing to Advance NewMet and Lovidia.",
        "SAN DIEGO, Feb. 14, 2013 /PRNewswire/ - Elcelyx Therapeutics announced today the closing of a $ 20 million Series C financing to fund development of product candidates NewMet for Type 2 diabetes and Lovidia, an over-the-counter weight loss product." ;
    ns1:documentTitle "Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elcelyx-therapeutics-completes-20-million-series-c-financing-to-advance-newmet-and-lovidia> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2338254/Elcelyx_Therapeutics> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 20 Million",
        "$ 20 million" ;
    ns1:when "2013-02-14T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Feb. 14, 2013" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO" .

<https://1145.am/db/2339932/Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_New_Science_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-28T17:09:06+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Dutch biotech Dezima Pharma-which is working on developing new drugs in the field of dyslipidemia-raised a total of 14.2 million ($ 18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) along with earlier-stage dyslipidemia assets." ;
    ns1:documentTitle "Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-nabs-18-6m-venture-cash-aveo-gets-date-on-tivozanib-review> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2339932/Dezima_Pharma> ;
    ns1:valueRaw "$ 18.6 million",
        "14.2 million",
        "4.4 million" ;
    ns1:whereGeoName "Kingdom of the Netherlands" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:whereRaw "Netherlands" .

<https://1145.am/db/2352172/Bb_Biotech_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "BB Biotech Ventures" ;
    ns1:investor <https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> ;
    ns1:name "BB Biotech Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2292345/Bb_Biotech_Ventures>,
        <https://1145.am/db/2293270/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2297795/Bb_Biotech_Ventures>,
        <https://1145.am/db/2298049/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2303009/Bb_Biotech_Ventures>,
        <https://1145.am/db/2306873/Bb_Biotech_Ventures>,
        <https://1145.am/db/2308887/Bb_Biotech_Ventures>,
        <https://1145.am/db/2309845/Bb_Biotech_Ventures>,
        <https://1145.am/db/2311011/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315932/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315934/Bb_Biotech_Ventures>,
        <https://1145.am/db/2318778/Bb_Biotech_Ventures>,
        <https://1145.am/db/2331661/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2331670/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2346204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348506/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348523/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352203/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352216/Bb_Biotech_Ventures>,
        <https://1145.am/db/2358026/Bb_Biotech_Ventures>,
        <https://1145.am/db/2363907/Bb_Biotech_Ventures>,
        <https://1145.am/db/2367218/Bb_Biotech_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Baxter_Ventures> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Baxter Ventures" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Baxter Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2335936/Baxter_Ventures>,
        <https://1145.am/db/2352204/Baxter_Ventures>,
        <https://1145.am/db/2352349/Baxter_Ventures>,
        <https://1145.am/db/2352350/Baxter_Ventures>,
        <https://1145.am/db/2357487/Baxter_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2327046/Baxter_Ventures>,
        <https://1145.am/db/2350231/Baxter_Ventures>,
        <https://1145.am/db/2352216/Baxter_Ventures>,
        <https://1145.am/db/2357494/Baxter_Ventures>,
        <https://1145.am/db/2358541/Baxter_Ventures>,
        <https://1145.am/db/2371033/Baxter_Ventures>,
        <https://1145.am/db/2569831/Baxter_Ventures>,
        <https://1145.am/db/2580551/Baxter_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Bb_Biotech_Ventures> a org:Organization ;
    ns1:description "investing" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "BB Biotech Ventures" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "BB Biotech Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2297795/Bb_Biotech_Ventures>,
        <https://1145.am/db/2309845/Bb_Biotech_Ventures>,
        <https://1145.am/db/2325726/Tpg_Biotechnology>,
        <https://1145.am/db/2352204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2363907/Bb_Biotech_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2292345/Bb_Biotech_Ventures>,
        <https://1145.am/db/2293270/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2298049/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2303009/Bb_Biotech_Ventures>,
        <https://1145.am/db/2306873/Bb_Biotech_Ventures>,
        <https://1145.am/db/2308887/Bb_Biotech_Ventures>,
        <https://1145.am/db/2311011/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315932/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315934/Bb_Biotech_Ventures>,
        <https://1145.am/db/2318778/Bb_Biotech_Ventures>,
        <https://1145.am/db/2331661/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2331670/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2346204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348506/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348523/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352172/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352216/Bb_Biotech_Ventures>,
        <https://1145.am/db/2358026/Bb_Biotech_Ventures>,
        <https://1145.am/db/2367218/Bb_Biotech_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Opsona_Therapeutics_Limited> a org:Organization ;
    ns1:basedInLowRaw "Spain" ;
    ns1:description "Business" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Opsona Therapeutics Limited" ;
    ns1:industry "drug development" ;
    ns1:name "Opsona Therapeutics Limited" ;
    ns1:sameAsHigh <https://1145.am/db/2330711/Opsona_Therapeutics>,
        <https://1145.am/db/2331750/Opsona_Therapeutics>,
        <https://1145.am/db/2331751/Opsona_Therapeutics>,
        <https://1145.am/db/2352204/Opsona_Therapeutics>,
        <https://1145.am/db/2352216/Opsona_Therapeutics>,
        <https://1145.am/db/2366005/Opsona_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Roche_Venture_Fund> a org:Organization ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2308834/Roche_Investments_Usa_Inc>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Sunstone_Capital> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Sunstone Capital" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Sunstone Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1014186/Citylight_Vc>,
        <https://1145.am/db/1153338/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1272476/Cosmic_Venture_Partners>,
        <https://1145.am/db/1273257/Cosmic_Venture_Partners>,
        <https://1145.am/db/1327277/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1329603/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1386496/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1425749/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1488858/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1494028/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1575302/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1582024/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1704842/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1709168/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1714641/Brightpixel_Capital>,
        <https://1145.am/db/1717363/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1717968/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1719408/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1736514/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1738465/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1739484/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1742702/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1744313/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1744864/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1748678/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1751950/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1754997/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760367/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1760696/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1767037/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1775434/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1778667/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1782325/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1784577/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1788570/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795210/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795863/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1795934/Lightbank_Ventures>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1804458/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1809007/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1826922/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1827407/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1833389/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1835126/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1837800/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1841062/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1844140/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1845066/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1846040/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1854200/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1860644/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1862796/Rimlight_Capital>,
        <https://1145.am/db/1872837/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1881464/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1881748/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1883859/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1891664/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1918590/Lightspeed_Venture_Partners>,
        <https://1145.am/db/1927859/Blossom_Street_Ventures>,
        <https://1145.am/db/2003542/Starlight_Ventures>,
        <https://1145.am/db/2043018/Shine_Capital>,
        <https://1145.am/db/2044325/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2044393/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2075137/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2154438/Biostar_Ventures>,
        <https://1145.am/db/2190702/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2205089/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2297471/Biostar_Ventures>,
        <https://1145.am/db/2323746/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2393775/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2608620/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2629526/Lightspeed_Venture_Partners>,
        <https://1145.am/db/2791832/Lightspeed_Venture_Partners>,
        <https://1145.am/db/284996/Lightspeed_Venture_Partners>,
        <https://1145.am/db/402675/Lightspeed_Venture_Partners>,
        <https://1145.am/db/513305/Lightspeed_Venture_Partners>,
        <https://1145.am/db/531354/Lightspeed_Venture_Partners>,
        <https://1145.am/db/545196/Lightspeed_Venture_Partners>,
        <https://1145.am/db/576932/Lightspeed_Venture_Partners>,
        <https://1145.am/db/642123/Lightspeed_Venture_Partners>,
        <https://1145.am/db/676217/Lightship_Capital>,
        <https://1145.am/db/696051/Skyvision_Capital>,
        <https://1145.am/db/804799/Starlight_Ventures>,
        <https://1145.am/db/884806/Lightspeed_Venture_Partners>,
        <https://1145.am/db/922144/Lightspeed_Venture_Partners>,
        <https://1145.am/db/956106/Shine_Capital>,
        <https://1145.am/db/963185/Lightspeed_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1717714/Sunstone_Capital>,
        <https://1145.am/db/1791743/Sunstone_Capital>,
        <https://1145.am/db/1797413/Sunstone_Capital>,
        <https://1145.am/db/1803787/Sunstone_Capital>,
        <https://1145.am/db/1832434/Sunstone_Capital>,
        <https://1145.am/db/1833000/Sunstone_Capital>,
        <https://1145.am/db/1833646/Sunstone_Capital>,
        <https://1145.am/db/1850593/Sunstone_Capital>,
        <https://1145.am/db/1850760/Sunstone_Capital>,
        <https://1145.am/db/1854996/Sunstone_Capital>,
        <https://1145.am/db/1858818/Sunstone_Capital>,
        <https://1145.am/db/1868935/Sunstone_Capital>,
        <https://1145.am/db/1869517/Sunstone_Capital>,
        <https://1145.am/db/1870079/Sunstone_Capital>,
        <https://1145.am/db/1877786/Sunstone_Capital>,
        <https://1145.am/db/1885147/Sunstone_Capital>,
        <https://1145.am/db/1888954/Sunstone_Capital>,
        <https://1145.am/db/2323700/Sunstone_Capital>,
        <https://1145.am/db/2329919/Sunstone_Capital>,
        <https://1145.am/db/2336622/Sunstone_Capital>,
        <https://1145.am/db/2341942/Sunstone_Capital>,
        <https://1145.am/db/2347980/Sunstone_Capital>,
        <https://1145.am/db/2348003/Sunstone_Capital>,
        <https://1145.am/db/2352204/Sunstone_Capital>,
        <https://1145.am/db/2352216/Sunstone_Capital>,
        <https://1145.am/db/2355609/Sunstone_Capital>,
        <https://1145.am/db/2355841/Sunstone_Capital>,
        <https://1145.am/db/2360127/Sunstone_Capital>,
        <https://1145.am/db/2360922/Sunstone_Capital>,
        <https://1145.am/db/2367218/Sunstone_Capital>,
        <https://1145.am/db/2569491/Sunstone_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Baxter_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Baxter Ventures" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Baxter Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2335936/Baxter_Ventures>,
        <https://1145.am/db/2352203/Baxter_Ventures>,
        <https://1145.am/db/2352349/Baxter_Ventures>,
        <https://1145.am/db/2352350/Baxter_Ventures>,
        <https://1145.am/db/2357487/Baxter_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2327046/Baxter_Ventures>,
        <https://1145.am/db/2350231/Baxter_Ventures>,
        <https://1145.am/db/2352216/Baxter_Ventures>,
        <https://1145.am/db/2357494/Baxter_Ventures>,
        <https://1145.am/db/2358541/Baxter_Ventures>,
        <https://1145.am/db/2371033/Baxter_Ventures>,
        <https://1145.am/db/2569831/Baxter_Ventures>,
        <https://1145.am/db/2580551/Baxter_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Bb_Biotech_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "BB Biotech Ventures" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "BB Biotech Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2297795/Bb_Biotech_Ventures>,
        <https://1145.am/db/2309845/Bb_Biotech_Ventures>,
        <https://1145.am/db/2325726/Tpg_Biotechnology>,
        <https://1145.am/db/2352203/Bb_Biotech_Ventures>,
        <https://1145.am/db/2363907/Bb_Biotech_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2292345/Bb_Biotech_Ventures>,
        <https://1145.am/db/2293270/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2298049/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2303009/Bb_Biotech_Ventures>,
        <https://1145.am/db/2306873/Bb_Biotech_Ventures>,
        <https://1145.am/db/2308887/Bb_Biotech_Ventures>,
        <https://1145.am/db/2311011/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315932/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315934/Bb_Biotech_Ventures>,
        <https://1145.am/db/2318778/Bb_Biotech_Ventures>,
        <https://1145.am/db/2331661/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2331670/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2346204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348506/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348523/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352172/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352216/Bb_Biotech_Ventures>,
        <https://1145.am/db/2358026/Bb_Biotech_Ventures>,
        <https://1145.am/db/2367218/Bb_Biotech_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Opsona_Therapeutics> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:description "Biotech Ventures",
        "drug development" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Opsona",
        "Opsona Therapeutics",
        "Opsona Therapeutics Limited" ;
    ns1:industry "Biotech",
        "drug development" ;
    ns1:name "Opsona",
        "Opsona Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2330711/Opsona_Therapeutics>,
        <https://1145.am/db/2331750/Opsona_Therapeutics>,
        <https://1145.am/db/2331751/Opsona_Therapeutics>,
        <https://1145.am/db/2352203/Opsona_Therapeutics_Limited>,
        <https://1145.am/db/2352216/Opsona_Therapeutics>,
        <https://1145.am/db/2366005/Opsona_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Roche_Venture_Fund> a org:Organization ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2308834/Roche_Investments_Usa_Inc>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Baxter_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Baxter Ventures" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Baxter Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2327046/Baxter_Ventures>,
        <https://1145.am/db/2335936/Baxter_Ventures>,
        <https://1145.am/db/2350231/Baxter_Ventures>,
        <https://1145.am/db/2352203/Baxter_Ventures>,
        <https://1145.am/db/2352204/Baxter_Ventures>,
        <https://1145.am/db/2352349/Baxter_Ventures>,
        <https://1145.am/db/2352350/Baxter_Ventures>,
        <https://1145.am/db/2357487/Baxter_Ventures>,
        <https://1145.am/db/2357494/Baxter_Ventures>,
        <https://1145.am/db/2358541/Baxter_Ventures>,
        <https://1145.am/db/2371033/Baxter_Ventures>,
        <https://1145.am/db/2569831/Baxter_Ventures>,
        <https://1145.am/db/2580551/Baxter_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Bb_Biotech_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "BB Biotech Ventures" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "BB Biotech Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2292345/Bb_Biotech_Ventures>,
        <https://1145.am/db/2293270/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2297795/Bb_Biotech_Ventures>,
        <https://1145.am/db/2298049/Bb_Biotech_Ventures_Iii>,
        <https://1145.am/db/2303009/Bb_Biotech_Ventures>,
        <https://1145.am/db/2306873/Bb_Biotech_Ventures>,
        <https://1145.am/db/2308887/Bb_Biotech_Ventures>,
        <https://1145.am/db/2309845/Bb_Biotech_Ventures>,
        <https://1145.am/db/2311011/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315932/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315934/Bb_Biotech_Ventures>,
        <https://1145.am/db/2318778/Bb_Biotech_Ventures>,
        <https://1145.am/db/2331661/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2331670/Bb_Biotech_Ventures_Ii>,
        <https://1145.am/db/2346204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348506/Bb_Biotech_Ventures>,
        <https://1145.am/db/2348523/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352172/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352203/Bb_Biotech_Ventures>,
        <https://1145.am/db/2352204/Bb_Biotech_Ventures>,
        <https://1145.am/db/2358026/Bb_Biotech_Ventures>,
        <https://1145.am/db/2363907/Bb_Biotech_Ventures>,
        <https://1145.am/db/2367218/Bb_Biotech_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Opsona_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Dublin" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2964574/about.rdf> ;
    ns1:basedInHighRaw "Dublin" ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Opsona Therapeutics" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Opsona Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2330711/Opsona_Therapeutics>,
        <https://1145.am/db/2331750/Opsona_Therapeutics>,
        <https://1145.am/db/2331751/Opsona_Therapeutics>,
        <https://1145.am/db/2352203/Opsona_Therapeutics_Limited>,
        <https://1145.am/db/2352204/Opsona_Therapeutics>,
        <https://1145.am/db/2366005/Opsona_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Roche_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:description "Venture Capital" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2308834/Roche_Investments_Usa_Inc>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353241/Preferred_Stock_Investment_Danica_Pension_Novo_A_S_Pka_Symphogen_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-02T12:25:48+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced EUR100 million financing, attaining a total of a EUR141 million placement of preferred stock to a group of existing investors." ;
    ns1:documentTitle "Symphogen Expands Previous Private Equity Round, Reaching a Total of EUR 141 million (USD 185 Million)" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/symphogen-expands-previous-private-equity-round-reaching-a-total-of-eur-141-million-usd-185> ;
    ns1:foundName "financing",
        "investments" ;
    ns1:name "financing",
        "investments" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2353241/Symphogen> ;
    ns1:targetDetails "preferred stock" ;
    ns1:valueRaw "EUR100 million",
        "EUR141 million",
        "EUR20 million" ;
    ns1:whereRaw "Danica Pension" .

<https://1145.am/db/2355274/Series_A_Investment_Alta_Partners_Lumena_Pharmaceuticals_Pappas_Ventures_Rivervest_Venture_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-08T12:12:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "LUMENA PHARMACEUTICALS ANNOUNCES $ 23 MILLION SERIES A FINANCING.",
        "SAN DIEGO - May 8, 2013 - Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the company has secured $ 23 million in Series A financing." ;
    ns1:documentTitle "LUMENA PHARMACEUTICALS ANNOUNCES $23 MILLION SERIES A FINANCING" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/lumena-pharmaceuticals-announces-23-million-series-a-financing> ;
    ns1:foundName "FINANCING",
        "financing" ;
    ns1:name "FINANCING",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2355274/Lumena_Pharmaceuticals> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 23 MILLION",
        "$ 23 million" ;
    ns1:when "2013-05-08T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 8, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2360562/GSK> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:buyer <https://1145.am/db/2360562/Okairos_Acquisition> ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2013-05-29T15:31:16+00:00"^^xsd:dateTime ;
    ns1:documentTitle "J&J backs neurological disease research programs; AstraZeneca gains support for Parkinson's research work;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/j-j-backs-neurological-disease-research-programs-astrazeneca-gains-support-for-parkinson-s> ;
    ns1:foundName "GSK" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "GSK" ;
    ns1:sameAsHigh <https://1145.am/db/1002406/Glaxosmithkline_Plc>,
        <https://1145.am/db/1003861/Glaxosmithkline_Plc>,
        <https://1145.am/db/1018723/Pfizer_Inc>,
        <https://1145.am/db/1034874/Glaxosmithkline_Plc>,
        <https://1145.am/db/1035942/GSK>,
        <https://1145.am/db/1036772/Glaxosmithkline_Plc>,
        <https://1145.am/db/1037557/GSK>,
        <https://1145.am/db/1042002/Pfizer_Inc>,
        <https://1145.am/db/1045477/Pfizer_Inc>,
        <https://1145.am/db/1046923/Pfizer>,
        <https://1145.am/db/1053698/Pfizer>,
        <https://1145.am/db/1054558/Pfizer_Inc>,
        <https://1145.am/db/1065617/Pfizer_Inc>,
        <https://1145.am/db/1066444/Pfizer_Inc>,
        <https://1145.am/db/1097779/GSK>,
        <https://1145.am/db/1097915/GSK>,
        <https://1145.am/db/1097915/Pfizer>,
        <https://1145.am/db/1098950/GSK>,
        <https://1145.am/db/1123210/Pfizer_Inc>,
        <https://1145.am/db/1124362/Pfizer_Inc>,
        <https://1145.am/db/1138594/Pfizer_Inc>,
        <https://1145.am/db/118625/GSK>,
        <https://1145.am/db/1209318/Glaxosmithkline>,
        <https://1145.am/db/1258904/Pfizer_Inc>,
        <https://1145.am/db/1260932/Pfizer_Inc>,
        <https://1145.am/db/1261278/Pfizer_Inc>,
        <https://1145.am/db/1262347/Pfizer_Inc>,
        <https://1145.am/db/1262354/Pfizer_Inc>,
        <https://1145.am/db/1264461/Pfizer_Inc>,
        <https://1145.am/db/1264475/Pfizer_Inc>,
        <https://1145.am/db/1271008/Pfizer>,
        <https://1145.am/db/1361734/GSK>,
        <https://1145.am/db/1368193/GSK>,
        <https://1145.am/db/1369714/GSK>,
        <https://1145.am/db/1385939/Pfizer_Inc>,
        <https://1145.am/db/1390822/Pfizer_Inc>,
        <https://1145.am/db/1394279/Pfizer_Inc>,
        <https://1145.am/db/1395353/Pfizer_Inc>,
        <https://1145.am/db/1549114/Pfizer_Inc>,
        <https://1145.am/db/1550950/Pfizer_Inc>,
        <https://1145.am/db/1684001/Pfizer_Inc>,
        <https://1145.am/db/1936001/Pfizer_Inc>,
        <https://1145.am/db/1936167/Pfizer_Inc>,
        <https://1145.am/db/1952785/Pfizer_Inc>,
        <https://1145.am/db/1972441/GSK>,
        <https://1145.am/db/1983958/Gsk_Plc>,
        <https://1145.am/db/2009165/Pfizer_Inc>,
        <https://1145.am/db/2013022/Pfizer_Inc>,
        <https://1145.am/db/2057315/Pfizer>,
        <https://1145.am/db/2070468/Pfizer>,
        <https://1145.am/db/2088776/Pfizer>,
        <https://1145.am/db/2119099/Pfizer>,
        <https://1145.am/db/2137303/GSK>,
        <https://1145.am/db/2138577/GSK>,
        <https://1145.am/db/2152849/Pfizer>,
        <https://1145.am/db/2152862/Pfizer>,
        <https://1145.am/db/2153110/Glaxosmithkline>,
        <https://1145.am/db/2156284/Glaxosmithkline>,
        <https://1145.am/db/2190363/Glaxosmithkline>,
        <https://1145.am/db/2192331/Glaxosmithkline>,
        <https://1145.am/db/2207119/Pfizer_Inc>,
        <https://1145.am/db/2221589/Pfizer>,
        <https://1145.am/db/2224597/Glaxosmithkline>,
        <https://1145.am/db/2278803/GSK>,
        <https://1145.am/db/2279140/Pfizer>,
        <https://1145.am/db/2279371/Glaxosmithkline>,
        <https://1145.am/db/2280707/Pfizer>,
        <https://1145.am/db/2280718/Pfizer>,
        <https://1145.am/db/2280933/Pfizer>,
        <https://1145.am/db/2281080/GSK>,
        <https://1145.am/db/2281622/Pfizer>,
        <https://1145.am/db/2281629/Pfizer>,
        <https://1145.am/db/2281879/Pfizer>,
        <https://1145.am/db/2282253/Glaxosmithkline>,
        <https://1145.am/db/2282592/Glaxosmithkline>,
        <https://1145.am/db/2283867/GSK>,
        <https://1145.am/db/2284235/Pfizer>,
        <https://1145.am/db/2285463/Pfizer>,
        <https://1145.am/db/2285764/Pfizer>,
        <https://1145.am/db/2286031/Glaxosmithkline>,
        <https://1145.am/db/2287351/Glaxosmithkline>,
        <https://1145.am/db/2289482/Glaxosmithkline>,
        <https://1145.am/db/2289503/Pfizer>,
        <https://1145.am/db/2290507/Glaxosmithkline>,
        <https://1145.am/db/2291302/Glaxosmithkline>,
        <https://1145.am/db/2292884/Glaxosmithkline>,
        <https://1145.am/db/2293631/Glaxosmithkline>,
        <https://1145.am/db/2293980/Pfizer>,
        <https://1145.am/db/2294613/Pfizer>,
        <https://1145.am/db/2295427/Pfizer>,
        <https://1145.am/db/2295635/Glaxosmithkline>,
        <https://1145.am/db/2296000/Pfizer>,
        <https://1145.am/db/2297455/Pfizer>,
        <https://1145.am/db/2297477/Pfizer>,
        <https://1145.am/db/2298256/Pfizer>,
        <https://1145.am/db/2301922/Pfizer>,
        <https://1145.am/db/2302462/Glaxosmithkline>,
        <https://1145.am/db/2303242/Glaxosmithkline>,
        <https://1145.am/db/230344/GSK>,
        <https://1145.am/db/230344/Glaxosmithkline>,
        <https://1145.am/db/2303447/Pfizer>,
        <https://1145.am/db/2304647/Pfizer>,
        <https://1145.am/db/2305277/Glaxosmithkline>,
        <https://1145.am/db/2306213/Glaxosmithkline>,
        <https://1145.am/db/2306799/Glaxosmithkline>,
        <https://1145.am/db/2307723/Glaxosmithkline>,
        <https://1145.am/db/2308656/Pfizer>,
        <https://1145.am/db/2308807/Pfizer>,
        <https://1145.am/db/2309065/Pfizer>,
        <https://1145.am/db/2309488/P_g>,
        <https://1145.am/db/2310071/Pfizer_Inc>,
        <https://1145.am/db/2310072/Pfizer>,
        <https://1145.am/db/2310168/Pfizer>,
        <https://1145.am/db/2310192/Glaxosmithkline>,
        <https://1145.am/db/2310241/Pfizer>,
        <https://1145.am/db/2311347/Pfizer>,
        <https://1145.am/db/2311402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2311570/Pfizer_Inc>,
        <https://1145.am/db/2312131/Glaxosmithkline>,
        <https://1145.am/db/2312187/Glaxosmithkline>,
        <https://1145.am/db/2312314/Pfizer>,
        <https://1145.am/db/2312321/Pfizer_Inc>,
        <https://1145.am/db/2312656/Glaxosmithkline>,
        <https://1145.am/db/2312865/Pfizer>,
        <https://1145.am/db/2312994/Pfizer>,
        <https://1145.am/db/2312995/Pfizer_Inc>,
        <https://1145.am/db/2313289/Glaxosmithkline>,
        <https://1145.am/db/2313383/Pfizer_Inc>,
        <https://1145.am/db/2314928/Pfizer>,
        <https://1145.am/db/2315422/Glaxosmithkline>,
        <https://1145.am/db/2315552/Pfizer>,
        <https://1145.am/db/2316364/Glaxosmithkline>,
        <https://1145.am/db/2316517/Pfizer>,
        <https://1145.am/db/2316538/Pfizer_Inc>,
        <https://1145.am/db/2316660/Glaxosmithkline>,
        <https://1145.am/db/2316797/Glaxosmithkline>,
        <https://1145.am/db/2316843/Pfizer>,
        <https://1145.am/db/2317128/Pfizer-Wyeth>,
        <https://1145.am/db/2317846/Glaxosmithkline>,
        <https://1145.am/db/2317915/Pfizer>,
        <https://1145.am/db/2318310/Glaxosmithkline>,
        <https://1145.am/db/2318333/Pfizer>,
        <https://1145.am/db/2318644/Glaxosmithkline>,
        <https://1145.am/db/2318658/Glaxosmithkline_Plc>,
        <https://1145.am/db/2318681/Glaxosmithkline>,
        <https://1145.am/db/2318922/Pfizer>,
        <https://1145.am/db/2319763/Glaxosmithkline>,
        <https://1145.am/db/2319782/Glaxosmithkline>,
        <https://1145.am/db/2319892/Glaxosmithkline>,
        <https://1145.am/db/2320509/Pfizer>,
        <https://1145.am/db/2320824/Glaxosmithkline>,
        <https://1145.am/db/2320992/Glaxosmithkline>,
        <https://1145.am/db/2322306/Pfizer>,
        <https://1145.am/db/2322307/Pfizer>,
        <https://1145.am/db/2322620/Pfizer>,
        <https://1145.am/db/2322633/Pfizer_Inc>,
        <https://1145.am/db/2322733/Pfizer>,
        <https://1145.am/db/2322786/Pfizer>,
        <https://1145.am/db/2324128/Pfizer>,
        <https://1145.am/db/2324141/Glaxosmithkline>,
        <https://1145.am/db/2324155/Pfizer>,
        <https://1145.am/db/2325729/Glaxosmithkline_Plc>,
        <https://1145.am/db/2326266/Glaxosmithkline_(gsk)>,
        <https://1145.am/db/2326590/Glaxosmithkline>,
        <https://1145.am/db/2327507/Glaxosmithkline>,
        <https://1145.am/db/2327511/Pfizer_Inc>,
        <https://1145.am/db/2327656/Glaxosmithkline>,
        <https://1145.am/db/2328471/Glaxosmithkline>,
        <https://1145.am/db/2328637/Glaxosmithkline>,
        <https://1145.am/db/2328666/Glaxosmithkline>,
        <https://1145.am/db/2328681/GSK>,
        <https://1145.am/db/2328712/Pfizer>,
        <https://1145.am/db/2328981/Glaxosmithkline>,
        <https://1145.am/db/2329902/Pfizer>,
        <https://1145.am/db/2329920/Pfizer_Inc>,
        <https://1145.am/db/2330817/Pfizer_Inc>,
        <https://1145.am/db/2330955/Glaxosmithkline>,
        <https://1145.am/db/2330955/Pfizer>,
        <https://1145.am/db/2330986/Glaxosmithkline>,
        <https://1145.am/db/2331010/Glaxosmithkline>,
        <https://1145.am/db/2331823/Glaxosmithkline>,
        <https://1145.am/db/2332552/Pfizer>,
        <https://1145.am/db/2332660/Glaxosmithkline>,
        <https://1145.am/db/2332695/Glaxosmithkline>,
        <https://1145.am/db/2332767/Pfizer_Ltd>,
        <https://1145.am/db/2334133/Pfizer_Inc>,
        <https://1145.am/db/2335568/Glaxosmithkline>,
        <https://1145.am/db/2335573/GSK>,
        <https://1145.am/db/2335634/Pfizer>,
        <https://1145.am/db/2335717/Pfizer>,
        <https://1145.am/db/2336060/Glaxosmithkline>,
        <https://1145.am/db/2336333/Pfizer>,
        <https://1145.am/db/2336704/GSK>,
        <https://1145.am/db/2336990/Glaxosmithkline>,
        <https://1145.am/db/2337788/Pfizer>,
        <https://1145.am/db/2338296/Glaxosmithkline>,
        <https://1145.am/db/2339633/Pfizer_Inc>,
        <https://1145.am/db/2339979/Glaxosmithkline>,
        <https://1145.am/db/2340055/Pfizer>,
        <https://1145.am/db/2340071/Glaxosmithkline>,
        <https://1145.am/db/2340072/GSK>,
        <https://1145.am/db/2340260/Glaxosmithkline>,
        <https://1145.am/db/2340321/Pfizer_Inc>,
        <https://1145.am/db/2340324/Pfizer_Inc>,
        <https://1145.am/db/2340325/Pfizer_Inc>,
        <https://1145.am/db/2340331/Pfizer_Inc>,
        <https://1145.am/db/2340591/Glaxosmithkline>,
        <https://1145.am/db/2340890/Pfizer>,
        <https://1145.am/db/2341325/Pfizer>,
        <https://1145.am/db/2341516/Pfizer>,
        <https://1145.am/db/2342559/Pfizer_Inc>,
        <https://1145.am/db/2342876/Glaxosmithkline>,
        <https://1145.am/db/2343237/Pfizer_Inc>,
        <https://1145.am/db/2343273/Pfizer_Inc>,
        <https://1145.am/db/2343298/Pfizer_Inc>,
        <https://1145.am/db/2343344/Pfizer>,
        <https://1145.am/db/2343861/Glaxosmithkline>,
        <https://1145.am/db/2344023/Glaxosmithkline>,
        <https://1145.am/db/2345065/Pfizer>,
        <https://1145.am/db/2345251/GSK>,
        <https://1145.am/db/2345604/Glaxosmithkline>,
        <https://1145.am/db/2346602/Pfizer_Inc>,
        <https://1145.am/db/2347383/Pfizer_Inc>,
        <https://1145.am/db/2348510/Pfizer_Inc>,
        <https://1145.am/db/2348693/Glaxosmithkline>,
        <https://1145.am/db/2349724/GSK>,
        <https://1145.am/db/2349724/Glaxosmithkline_Biologicals>,
        <https://1145.am/db/2351730/Pfizer_Inc>,
        <https://1145.am/db/2352506/Glaxosmithkline_Plc>,
        <https://1145.am/db/2353039/Pfizer_Inc>,
        <https://1145.am/db/2353325/Pfizer>,
        <https://1145.am/db/2353326/Pfizer>,
        <https://1145.am/db/2353337/Pfizer>,
        <https://1145.am/db/2353364/Pfizer>,
        <https://1145.am/db/2353376/Pfizer>,
        <https://1145.am/db/2354567/Pfizer>,
        <https://1145.am/db/2355021/Pfizer>,
        <https://1145.am/db/2355025/Pfizer_Inc>,
        <https://1145.am/db/2355472/Pfizer_Inc>,
        <https://1145.am/db/2355587/Glaxosmithkline>,
        <https://1145.am/db/2355595/Glaxosmithkline>,
        <https://1145.am/db/2355641/GSK>,
        <https://1145.am/db/2355916/Pfizer_Inc>,
        <https://1145.am/db/2356124/Pfizer_Inc>,
        <https://1145.am/db/2356391/Glaxosmithkline>,
        <https://1145.am/db/2356559/Glaxosmithkline>,
        <https://1145.am/db/2356560/Glaxosmithkline>,
        <https://1145.am/db/2356597/Pfizer>,
        <https://1145.am/db/2356599/Pfizer>,
        <https://1145.am/db/2356639/Glaxosmithkline>,
        <https://1145.am/db/2356654/Glaxosmithkline>,
        <https://1145.am/db/2356811/GSK>,
        <https://1145.am/db/2357232/Pfizer>,
        <https://1145.am/db/2357308/Pfizer_Inc>,
        <https://1145.am/db/2357361/Glaxosmithkline_Plc>,
        <https://1145.am/db/2358128/Pfizer>,
        <https://1145.am/db/2359072/Glaxosmithkline>,
        <https://1145.am/db/2359697/Pfizer>,
        <https://1145.am/db/2359727/GSK>,
        <https://1145.am/db/2359727/Glaxosmithkline>,
        <https://1145.am/db/2359836/Glaxosmithkline>,
        <https://1145.am/db/2359838/Glaxosmithkline>,
        <https://1145.am/db/2359858/GSK>,
        <https://1145.am/db/2359858/Glaxosmithkline>,
        <https://1145.am/db/2360094/Glaxosmithkline>,
        <https://1145.am/db/2360371/Glaxosmithkline>,
        <https://1145.am/db/2360552/Glaxosmithkline>,
        <https://1145.am/db/2360647/Pfizer_Inc>,
        <https://1145.am/db/2361700/GSK>,
        <https://1145.am/db/2361705/GSK>,
        <https://1145.am/db/2362439/Pfizer_Inc>,
        <https://1145.am/db/2362851/Pfizer_Inc>,
        <https://1145.am/db/2363435/Gsk_Pfizer>,
        <https://1145.am/db/2363446/Pfizer_Inc>,
        <https://1145.am/db/2363896/Pfizer>,
        <https://1145.am/db/2364087/Pfizer_Inc>,
        <https://1145.am/db/2364813/Glaxosmithkline>,
        <https://1145.am/db/2364819/Glaxosmithkline>,
        <https://1145.am/db/2365103/Glaxosmithkline>,
        <https://1145.am/db/2366395/Pfizer_Inc>,
        <https://1145.am/db/2367283/Pfizer_Inc>,
        <https://1145.am/db/2367620/Glaxosmithkline>,
        <https://1145.am/db/2367621/Glaxosmithkline>,
        <https://1145.am/db/2367982/Pfizer>,
        <https://1145.am/db/2368146/Pfizer>,
        <https://1145.am/db/2368765/Glaxosmithkline>,
        <https://1145.am/db/2368770/Glaxosmithkline_Plc>,
        <https://1145.am/db/2369449/Glaxosmithkline>,
        <https://1145.am/db/2369451/Glaxosmithkline>,
        <https://1145.am/db/2369755/GSK>,
        <https://1145.am/db/2369761/Glaxosmithkline>,
        <https://1145.am/db/2369876/Pfizer>,
        <https://1145.am/db/2369909/Pfizer_Inc>,
        <https://1145.am/db/2370016/Pfizer>,
        <https://1145.am/db/2370635/GSK>,
        <https://1145.am/db/2370843/Glaxosmithkline>,
        <https://1145.am/db/238329/GSK>,
        <https://1145.am/db/2507041/Pfizer>,
        <https://1145.am/db/2536358/Pfizer_Inc>,
        <https://1145.am/db/2536361/Pfizer_Inc>,
        <https://1145.am/db/2536362/Pfizer_Inc>,
        <https://1145.am/db/2536365/Pfizer_Inc>,
        <https://1145.am/db/2536475/Pfizer>,
        <https://1145.am/db/2536493/Glaxosmithkline>,
        <https://1145.am/db/2536540/Glaxosmithkline>,
        <https://1145.am/db/2536585/Glaxosmithkline>,
        <https://1145.am/db/2536856/Pfizer>,
        <https://1145.am/db/2537054/Pfizer_Inc>,
        <https://1145.am/db/2537057/Pfizer_Inc>,
        <https://1145.am/db/2537064/Glaxosmithkline>,
        <https://1145.am/db/2537171/Pfizer>,
        <https://1145.am/db/2537597/Pfizer>,
        <https://1145.am/db/2537699/Glaxosmithkline>,
        <https://1145.am/db/2538568/Pfizer_Inc>,
        <https://1145.am/db/2538861/Pfizer>,
        <https://1145.am/db/2538924/Pfizer>,
        <https://1145.am/db/2539221/Glaxosmithkline>,
        <https://1145.am/db/2539308/Glaxosmithkline>,
        <https://1145.am/db/2539516/Pfizer>,
        <https://1145.am/db/2539695/GSK>,
        <https://1145.am/db/2540020/Glaxosmithkline>,
        <https://1145.am/db/2540091/Glaxosmithkline>,
        <https://1145.am/db/2540170/Glaxosmithkline>,
        <https://1145.am/db/2540172/Glaxosmithkline>,
        <https://1145.am/db/2540356/Pfizer>,
        <https://1145.am/db/2540527/Glaxosmithkline>,
        <https://1145.am/db/2541091/GSK>,
        <https://1145.am/db/2541139/Pfizer_Inc>,
        <https://1145.am/db/2541146/Pfizer>,
        <https://1145.am/db/2542064/GSK>,
        <https://1145.am/db/2542067/Pfizer_Inc>,
        <https://1145.am/db/2542072/Pfizer>,
        <https://1145.am/db/2542090/Glaxosmithkline>,
        <https://1145.am/db/2542192/GSK>,
        <https://1145.am/db/2542499/Pfizer>,
        <https://1145.am/db/2542506/Glaxosmithkline>,
        <https://1145.am/db/2543278/Pfizer>,
        <https://1145.am/db/2543533/Pfizer>,
        <https://1145.am/db/2543552/Glaxosmithkline>,
        <https://1145.am/db/2543826/Pfizer>,
        <https://1145.am/db/2543957/Pfizer>,
        <https://1145.am/db/2544062/Glaxosmithkline>,
        <https://1145.am/db/2544074/Pfizer>,
        <https://1145.am/db/2545023/Glaxosmithkline>,
        <https://1145.am/db/2545058/Pfizer>,
        <https://1145.am/db/2545122/Pfizer>,
        <https://1145.am/db/2545242/Glaxosmithkline>,
        <https://1145.am/db/2545284/Glaxosmithkline>,
        <https://1145.am/db/2545537/Glaxosmithkline>,
        <https://1145.am/db/2545618/Pfizer>,
        <https://1145.am/db/2545634/Pfizer>,
        <https://1145.am/db/2545818/Pfizer>,
        <https://1145.am/db/2545847/GSK>,
        <https://1145.am/db/2546136/Glaxosmithkline>,
        <https://1145.am/db/2546260/Glaxosmithkline>,
        <https://1145.am/db/2546574/Glaxosmithkline>,
        <https://1145.am/db/2546577/Glaxosmithkline>,
        <https://1145.am/db/2546583/Pfizer>,
        <https://1145.am/db/2546596/Pfizer>,
        <https://1145.am/db/2546616/Glaxosmithkline>,
        <https://1145.am/db/2547000/Pfizer>,
        <https://1145.am/db/2547142/Glaxosmithkline>,
        <https://1145.am/db/2547143/Glaxosmithkline>,
        <https://1145.am/db/2547653/Pfizer>,
        <https://1145.am/db/2547835/Glaxosmithkline>,
        <https://1145.am/db/2547954/Glaxosmithkline>,
        <https://1145.am/db/2548034/Glaxosmithkline>,
        <https://1145.am/db/2548208/Glaxosmithkline>,
        <https://1145.am/db/2548244/Pfizer_Inc>,
        <https://1145.am/db/2548523/Glaxosmithkline>,
        <https://1145.am/db/2548674/Pfizer>,
        <https://1145.am/db/2548752/GSK>,
        <https://1145.am/db/2548752/Pfizer>,
        <https://1145.am/db/2548986/Pfizer>,
        <https://1145.am/db/2549151/Pfizer>,
        <https://1145.am/db/2549598/Glaxosmithkline>,
        <https://1145.am/db/2549673/Pfizer>,
        <https://1145.am/db/2549694/Glaxosmithkline>,
        <https://1145.am/db/2549719/Pfizer>,
        <https://1145.am/db/2549876/Glaxosmithkline>,
        <https://1145.am/db/2550054/Glaxosmithkline>,
        <https://1145.am/db/2550445/Pfizer>,
        <https://1145.am/db/2550460/GSK>,
        <https://1145.am/db/2550662/Glaxosmithkline>,
        <https://1145.am/db/2550685/Pfizer>,
        <https://1145.am/db/2551402/Glaxosmithkline>,
        <https://1145.am/db/2551695/Glaxosmithkline>,
        <https://1145.am/db/2552165/Glaxosmithkline>,
        <https://1145.am/db/2552684/Pfizer>,
        <https://1145.am/db/2552794/Glaxosmithkline>,
        <https://1145.am/db/2553168/GSK>,
        <https://1145.am/db/2553974/Pfizer>,
        <https://1145.am/db/2554044/Glaxosmithkline>,
        <https://1145.am/db/2554578/Glaxosmithkline>,
        <https://1145.am/db/2554937/Pfizer>,
        <https://1145.am/db/2555012/Glaxosmithkline>,
        <https://1145.am/db/2555896/Pfizer>,
        <https://1145.am/db/2555992/Pfizer>,
        <https://1145.am/db/2556407/Glaxosmithkline>,
        <https://1145.am/db/2556820/Glaxosmithkline>,
        <https://1145.am/db/2556995/Glaxosmithkline>,
        <https://1145.am/db/2557064/Pfizer>,
        <https://1145.am/db/2557083/Pfizer>,
        <https://1145.am/db/2557221/Glaxosmithkline>,
        <https://1145.am/db/2557221/Pfizer>,
        <https://1145.am/db/2558268/Pfizer>,
        <https://1145.am/db/2558417/Pfizer>,
        <https://1145.am/db/2558464/Pfizer>,
        <https://1145.am/db/2558862/GSK>,
        <https://1145.am/db/2558862/Glaxosmithkline>,
        <https://1145.am/db/2558940/Glaxosmithkline>,
        <https://1145.am/db/2558970/Pfizer>,
        <https://1145.am/db/2558971/Pfizer>,
        <https://1145.am/db/2559649/Pfizer>,
        <https://1145.am/db/2560282/Pfizer>,
        <https://1145.am/db/2560633/Glaxosmithkline>,
        <https://1145.am/db/2560720/Pfizer>,
        <https://1145.am/db/2561231/Pfizer>,
        <https://1145.am/db/2561353/Glaxosmithkline>,
        <https://1145.am/db/2561599/Glaxosmithkline>,
        <https://1145.am/db/2561650/GSK>,
        <https://1145.am/db/2561650/Pfizer>,
        <https://1145.am/db/2562102/Pfizer_Inc>,
        <https://1145.am/db/2562701/Pfizer>,
        <https://1145.am/db/2562773/GSK>,
        <https://1145.am/db/2562951/Glaxosmithkline>,
        <https://1145.am/db/2563194/Glaxosmithkline>,
        <https://1145.am/db/2563381/Glaxosmithkline>,
        <https://1145.am/db/2563857/Pfizer>,
        <https://1145.am/db/2563889/Pfizer>,
        <https://1145.am/db/2564032/Pfizer>,
        <https://1145.am/db/2564238/Glaxosmithkline>,
        <https://1145.am/db/2564695/Glaxosmithkline>,
        <https://1145.am/db/2564786/Glaxosmithkline>,
        <https://1145.am/db/2564884/GSK>,
        <https://1145.am/db/2566186/GSK>,
        <https://1145.am/db/2566825/Glaxosmithkline>,
        <https://1145.am/db/2567104/GSK>,
        <https://1145.am/db/2568121/Pfizer>,
        <https://1145.am/db/2568519/Pfizer>,
        <https://1145.am/db/2568899/Pfizer>,
        <https://1145.am/db/2568968/Glaxosmithkline>,
        <https://1145.am/db/2568973/Glaxosmithkline>,
        <https://1145.am/db/2569734/Glaxosmithkline_Plc>,
        <https://1145.am/db/2569735/Glaxosmithkline_Plc>,
        <https://1145.am/db/2570369/Pfizer_Inc>,
        <https://1145.am/db/2570791/Glaxosmithkline>,
        <https://1145.am/db/2571798/Pfizer_Inc>,
        <https://1145.am/db/2572036/Pfizer>,
        <https://1145.am/db/2572429/Glaxosmithkline>,
        <https://1145.am/db/2572927/Pfizer>,
        <https://1145.am/db/2572963/Glaxosmithkline>,
        <https://1145.am/db/2573002/Glaxosmithkline>,
        <https://1145.am/db/2573173/Pfizer>,
        <https://1145.am/db/2573201/Glaxosmithkline>,
        <https://1145.am/db/2573463/Pfizer>,
        <https://1145.am/db/2573465/Pfizer_Inc>,
        <https://1145.am/db/2573466/Pfizer>,
        <https://1145.am/db/2573551/Pfizer_Inc>,
        <https://1145.am/db/2573558/Pfizer_Inc>,
        <https://1145.am/db/2573562/Pfizer>,
        <https://1145.am/db/2573585/Glaxosmithkline>,
        <https://1145.am/db/2573707/Pfizer>,
        <https://1145.am/db/2574332/Pfizer>,
        <https://1145.am/db/2574333/Glaxosmithkline>,
        <https://1145.am/db/2574459/Pfizer_Inc>,
        <https://1145.am/db/2574461/Pfizer_Inc>,
        <https://1145.am/db/2574687/Pfizer>,
        <https://1145.am/db/2574691/Pfizer_Inc>,
        <https://1145.am/db/2575139/Pfizer_Inc>,
        <https://1145.am/db/2575145/Pfizer_Inc>,
        <https://1145.am/db/2575289/Glaxosmithkline>,
        <https://1145.am/db/2575320/Pfizer>,
        <https://1145.am/db/2575471/Pfizer>,
        <https://1145.am/db/2575505/Pfizer_Inc>,
        <https://1145.am/db/2575575/Pfizer>,
        <https://1145.am/db/2575712/GSK>,
        <https://1145.am/db/2575723/Pfizer>,
        <https://1145.am/db/2576156/Glaxosmithkline>,
        <https://1145.am/db/2576230/Glaxosmithkline_Plc>,
        <https://1145.am/db/2576256/Glaxo>,
        <https://1145.am/db/2576263/Glaxosmithkline>,
        <https://1145.am/db/2576267/GSK>,
        <https://1145.am/db/2576267/Glaxosmithkline>,
        <https://1145.am/db/2576330/Pfizer_Inc>,
        <https://1145.am/db/2576526/Pfizer>,
        <https://1145.am/db/2576759/Pfizer>,
        <https://1145.am/db/2576762/Pfizer>,
        <https://1145.am/db/2577077/Pfizer>,
        <https://1145.am/db/2577226/Glaxosmithkline>,
        <https://1145.am/db/2577258/Pfizer_Inc>,
        <https://1145.am/db/2577655/Pfizer>,
        <https://1145.am/db/2577747/Glaxosmithkline>,
        <https://1145.am/db/2577778/Glaxosmithkline>,
        <https://1145.am/db/2578420/Glaxosmithkline>,
        <https://1145.am/db/2578528/GSK>,
        <https://1145.am/db/2579172/Glaxosmithkline>,
        <https://1145.am/db/2579177/Glaxosmithkline>,
        <https://1145.am/db/2579180/GSK>,
        <https://1145.am/db/2579205/Glaxosmithkline>,
        <https://1145.am/db/2579252/Pfizer>,
        <https://1145.am/db/2579709/Pfizer_Inc>,
        <https://1145.am/db/2579716/Pfizer>,
        <https://1145.am/db/2580047/Glaxosmithkline>,
        <https://1145.am/db/2580053/Glaxosmithkline>,
        <https://1145.am/db/2580140/Glaxosmithkline>,
        <https://1145.am/db/2580916/Glaxosmithkline>,
        <https://1145.am/db/2580940/Pfizer>,
        <https://1145.am/db/2581141/Glaxosmithkline_Plc>,
        <https://1145.am/db/2581145/Glaxosmithkline>,
        <https://1145.am/db/2581176/Glaxosmithkline>,
        <https://1145.am/db/2581331/Pfizer_Inc>,
        <https://1145.am/db/2581334/Pfizer_Inc>,
        <https://1145.am/db/2581339/Pfizer>,
        <https://1145.am/db/2581394/Pfizer>,
        <https://1145.am/db/2581659/GSK>,
        <https://1145.am/db/2581659/Pfizer>,
        <https://1145.am/db/2581661/Glaxosmithkline>,
        <https://1145.am/db/2581661/Pfizer_Inc>,
        <https://1145.am/db/2582158/Pfizer_Inc>,
        <https://1145.am/db/2582160/Pfizer_Inc>,
        <https://1145.am/db/2582233/Glaxosmithkline>,
        <https://1145.am/db/2582343/Pfizer_Inc>,
        <https://1145.am/db/2582879/Pfizer_Inc>,
        <https://1145.am/db/2583155/Pfizer_Inc>,
        <https://1145.am/db/2583163/Pfizer>,
        <https://1145.am/db/2583165/Pfizer_Inc>,
        <https://1145.am/db/2583172/Pfizer>,
        <https://1145.am/db/2583228/Glaxosmithkline_Plc>,
        <https://1145.am/db/2583242/Pfizer_Inc>,
        <https://1145.am/db/2583245/Pfizer_Inc>,
        <https://1145.am/db/2583281/Glaxosmithkline>,
        <https://1145.am/db/2583337/Pfizer_Inc>,
        <https://1145.am/db/2583584/Glaxosmithkline>,
        <https://1145.am/db/2583783/Pfizer>,
        <https://1145.am/db/2584085/Pfizer_Inc>,
        <https://1145.am/db/2584601/Pfizer_Inc>,
        <https://1145.am/db/2584968/Pfizer>,
        <https://1145.am/db/2585246/Glaxosmithkline_Plc>,
        <https://1145.am/db/2585700/Pfizer>,
        <https://1145.am/db/2585908/New_York-Pfizer_Inc>,
        <https://1145.am/db/2585908/Pfizer>,
        <https://1145.am/db/2585912/Pfizer>,
        <https://1145.am/db/2586034/Pfizer_Inc>,
        <https://1145.am/db/2586047/Pfizer_Inc>,
        <https://1145.am/db/2586099/Glaxosmithkline>,
        <https://1145.am/db/2586139/Glaxosmithkline>,
        <https://1145.am/db/2586802/GSK>,
        <https://1145.am/db/2586802/Glaxosmithkline>,
        <https://1145.am/db/2586804/GSK>,
        <https://1145.am/db/2587282/Glaxosmithkline>,
        <https://1145.am/db/2587387/Pfizer>,
        <https://1145.am/db/2587673/Pfizer>,
        <https://1145.am/db/2587770/Glaxosmithkline>,
        <https://1145.am/db/2587966/Glaxosmithkline>,
        <https://1145.am/db/2587967/GSK>,
        <https://1145.am/db/2587968/GSK>,
        <https://1145.am/db/2588134/Pfizer_Inc>,
        <https://1145.am/db/2588918/Glaxosmithkline>,
        <https://1145.am/db/2589035/Glaxosmithkline>,
        <https://1145.am/db/2589365/Pfizer>,
        <https://1145.am/db/2589642/Glaxosmithkline>,
        <https://1145.am/db/2589701/GSK>,
        <https://1145.am/db/2589701/Glaxosmithkline>,
        <https://1145.am/db/2590051/Glaxosmithkline>,
        <https://1145.am/db/2590549/Pfizer_Inc>,
        <https://1145.am/db/2590887/Pfizer>,
        <https://1145.am/db/2590988/Pfizer>,
        <https://1145.am/db/2590989/Pfizer>,
        <https://1145.am/db/2591081/Pfizer_Inc>,
        <https://1145.am/db/2591091/Pfizer>,
        <https://1145.am/db/2591092/Pfizer_Inc>,
        <https://1145.am/db/2591281/Pfizer>,
        <https://1145.am/db/2591652/Pfizer>,
        <https://1145.am/db/2591691/Pfizer>,
        <https://1145.am/db/2591733/Pfizer>,
        <https://1145.am/db/2592975/Pfizer_Inc>,
        <https://1145.am/db/2592977/Pfizer_Inc>,
        <https://1145.am/db/2592980/Pfizer>,
        <https://1145.am/db/2592987/Glaxosmithkline>,
        <https://1145.am/db/2592990/Pfizer_Inc>,
        <https://1145.am/db/2592992/Pfizer_Inc>,
        <https://1145.am/db/2593150/Pfizer>,
        <https://1145.am/db/2593710/Glaxosmithkline>,
        <https://1145.am/db/2593886/Pfizer>,
        <https://1145.am/db/2593961/Pfizer_Inc>,
        <https://1145.am/db/2594141/Pfizer_Inc>,
        <https://1145.am/db/2594208/Glaxosmithkline>,
        <https://1145.am/db/2594268/Pfizer_Inc>,
        <https://1145.am/db/2594422/Glaxosmithkline>,
        <https://1145.am/db/2594422/Pfizer>,
        <https://1145.am/db/2594489/Pfizer_Inc>,
        <https://1145.am/db/2594574/Pfizer>,
        <https://1145.am/db/2594581/Pfizer>,
        <https://1145.am/db/2594992/Pfizer>,
        <https://1145.am/db/2595001/Glaxosmithkline>,
        <https://1145.am/db/2595150/Glaxosmithkline>,
        <https://1145.am/db/2595320/Pfizer_Inc>,
        <https://1145.am/db/2595472/Pfizer>,
        <https://1145.am/db/2595499/Pfizer>,
        <https://1145.am/db/2596213/Glaxosmithkline>,
        <https://1145.am/db/2596344/Pfizer>,
        <https://1145.am/db/2596402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2596577/Glaxosmithkline>,
        <https://1145.am/db/2596754/Pfizer_Inc>,
        <https://1145.am/db/2596778/Pfizer>,
        <https://1145.am/db/2596835/Glaxosmithkline>,
        <https://1145.am/db/2596874/Pfizer>,
        <https://1145.am/db/2597004/GSK>,
        <https://1145.am/db/2597173/Pfizer>,
        <https://1145.am/db/2597183/Pfizer_Inc>,
        <https://1145.am/db/2597220/Glaxosmithkline>,
        <https://1145.am/db/2597554/Glaxosmithkline>,
        <https://1145.am/db/2597558/Glaxosmithkline_Pte>,
        <https://1145.am/db/2597643/Pfizer_Inc>,
        <https://1145.am/db/2597650/Pfizer>,
        <https://1145.am/db/2597651/Pfizer_Inc>,
        <https://1145.am/db/2597712/Pfizer>,
        <https://1145.am/db/2597960/Glaxosmithkline>,
        <https://1145.am/db/2598461/Glaxosmithkline>,
        <https://1145.am/db/274660/Pfizer_Inc>,
        <https://1145.am/db/274739/Pfizer_Inc>,
        <https://1145.am/db/2792911/Pfizer>,
        <https://1145.am/db/2797157/GSK>,
        <https://1145.am/db/286227/Glaxosmithkline>,
        <https://1145.am/db/318295/Pfizer_Inc>,
        <https://1145.am/db/338190/GSK>,
        <https://1145.am/db/338242/Glaxosmithkline>,
        <https://1145.am/db/377761/Glaxosmithkline>,
        <https://1145.am/db/377769/Glaxosmithkline>,
        <https://1145.am/db/385094/GSK>,
        <https://1145.am/db/385100/GSK>,
        <https://1145.am/db/422377/Pfizer_Inc>,
        <https://1145.am/db/422378/Pfizer_Inc>,
        <https://1145.am/db/423571/Pfizer_Inc>,
        <https://1145.am/db/424190/Pfizer_Inc>,
        <https://1145.am/db/424896/Pfizer_Inc>,
        <https://1145.am/db/425689/Pfizer_Inc>,
        <https://1145.am/db/426841/Pfizer_Inc>,
        <https://1145.am/db/428975/Pfizer_Inc>,
        <https://1145.am/db/446194/Glaxosmithkline>,
        <https://1145.am/db/494811/GSK>,
        <https://1145.am/db/576236/Glaxosmithkline>,
        <https://1145.am/db/582690/GSK>,
        <https://1145.am/db/582690/Glaxosmithkline>,
        <https://1145.am/db/626832/Pfizer_Inc>,
        <https://1145.am/db/627349/Pfizer_Inc>,
        <https://1145.am/db/631317/Pfizer_Inc>,
        <https://1145.am/db/635031/Pfizer>,
        <https://1145.am/db/661291/GSK>,
        <https://1145.am/db/692994/Pfizer_Inc>,
        <https://1145.am/db/694218/Pfizer_Inc>,
        <https://1145.am/db/694224/Pfizer_Inc>,
        <https://1145.am/db/696927/Pfizer_Inc>,
        <https://1145.am/db/699199/Pfizer>,
        <https://1145.am/db/702938/Glaxosmithkline>,
        <https://1145.am/db/704642/Glaxosmithkline_Plc>,
        <https://1145.am/db/76007/Pfizer>,
        <https://1145.am/db/761748/Glaxosmithkline>,
        <https://1145.am/db/761748/Pfizer>,
        <https://1145.am/db/764460/Pfizer>,
        <https://1145.am/db/797138/Pfizer_Inc>,
        <https://1145.am/db/800318/Pfizer_Inc>,
        <https://1145.am/db/87287/Glaxosmithkline>,
        <https://1145.am/db/896566/Pfizer_Inc>,
        <https://1145.am/db/897457/Pfizer_Inc>,
        <https://1145.am/db/962850/Pfizer_Inc>,
        <https://1145.am/db/962851/Pfizer_Inc>,
        <https://1145.am/db/962899/Pfizer_Inc>,
        <https://1145.am/db/965490/Pfizer_Inc>,
        <https://1145.am/db/968220/Pfizer_Inc>,
        <https://1145.am/db/970746/Glaxosmithkline>,
        <https://1145.am/db/971984/Pfizer_Inc>,
        <https://1145.am/db/973116/Glaxosmithkline>,
        <https://1145.am/db/977067/Glaxosmithkline> ;
    ns1:sameAsMedium <https://1145.am/db/118488/GSK>,
        <https://1145.am/db/1752832/GSK>,
        <https://1145.am/db/2040517/GSK>,
        <https://1145.am/db/2183506/GSK>,
        <https://1145.am/db/2314286/GSK>,
        <https://1145.am/db/2348686/GSK>,
        <https://1145.am/db/2541721/GSK>,
        <https://1145.am/db/2542065/GSK>,
        <https://1145.am/db/2561353/GSK>,
        <https://1145.am/db/2578705/GSK>,
        <https://1145.am/db/2587747/GSK>,
        <https://1145.am/db/2594208/GSK>,
        <https://1145.am/db/2597558/GSK>,
        <https://1145.am/db/766907/GSK>,
        <https://1145.am/db/977067/GSK> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360667/License_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "In addition, Solstice has acquired an exclusive license to University of California, San Diego intellectual property covering technology that enables RNA molecules to cross membranes of multiple cell types, a perplexing problem that has been a bottleneck in delivering on the therapeutic potential of RNA interference (RNAi) and microRNA.",
        "SAN FRANCISCO, Jan. 4, 2013 /PRNewswire/ - Solstice Biologics LLC, a company focused on solving the problem of targeting and delivery of nucleic acid therapeutics, today announced the completion of a $ 18 million Series A financing led by venBio and joined by Aeris Capital AG." ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "acquired",
        "financing" ;
    ns1:name "acquired",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2360667/Solstice_Biologics_Llc>,
        <https://1145.am/db/2360667/University_Of_California_San_Diego_Intellectual_Property_Covering> ;
    ns1:targetDetails "Series A",
        "license" ;
    ns1:targetName "University of California, San Diego intellectual property covering" ;
    ns1:valueRaw "$ 18 million" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "California",
        "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5332921/about.rdf>,
        <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "California",
        "San Diego" .

<https://1145.am/db/2360667/Solstice_Biologics_Llc> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:basedInLowRaw "San Diego" ;
    ns1:description "Biotechnology",
        "a company focused on solving the problem of targeting and delivery of nucleic acid therapeutics" ;
    ns1:documentDate "2013-01-04T13:37:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/solstice-biologics-secures-18-million-series-a-licenses-rnai-delivery-technology-from-uc> ;
    ns1:foundName "Solstice",
        "Solstice Biologics",
        "Solstice Biologics LLC" ;
    ns1:investor <https://1145.am/db/2360667/License_Investment_Aeris_Capital_Ag_Solstice_Biologics_Llc_University_Of_California_San_Diego_Intellectual_Property_Covering_Has_Not_Happened> ;
    ns1:name "Solstice Biologics",
        "Solstice Biologics LLC" ;
    ns1:sameAsHigh <https://1145.am/db/2575687/Solstice_Biologics_Llc> ;
    ns1:sameAsMedium <https://1145.am/db/2343608/Solstice_Biologics>,
        <https://1145.am/db/2343610/Solstice_Biologics_Llc>,
        <https://1145.am/db/2344628/Solstice_Biologics_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361581/Venture_Investment_Johnson___Johnson_Development_Corporation_Lilly_Ventures_Protagonist_Therapeutics_Starfish_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-04T11:33:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Menlo Park, Calif. (June 4, 2013) : Protagonist Therapeutics, Inc. today announced the completion of a $ 14 million Series B venture financing.",
        "Protagonist Therapeutics Raises $ 14 Million in Series B Venture Financing." ;
    ns1:documentTitle "Protagonist Therapeutics Raises $14 Million in Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/protagonist-therapeutics-raises-14-million-series-b-venture-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2361581/Protagonist_Therapeutics> ;
    ns1:targetDetails "Venture",
        "venture" ;
    ns1:valueRaw "$ 14 Million",
        "$ 14 million" ;
    ns1:when "2013-06-04T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 4, 2013" ;
    ns1:whereGeoName "Menlo Park" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5372223/about.rdf> ;
    ns1:whereRaw "Menlo Park" .

<https://1145.am/db/2362715/Roche_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2337974/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2667192/Nokia_Siemens_Networks> a org:Organization ;
    ns1:basedInLowRaw "Finland" ;
    ns1:buyer <https://1145.am/db/2667192/Nokia_Siemens_Networks_Stake_Acquisition> ;
    ns1:documentDate "2013-02-07T16:08:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: Nokia Siemens parents could use Alcatel-Lucent to exit JV" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-nokia-siemens-parents-could-use-alcatel-lucent-to-exit-jv> ;
    ns1:foundName "Nokia",
        "Nokia Siemens Networks" ;
    ns1:investor <https://1145.am/db/2667192/Nokia_Siemens_Networks_Stake_Acquisition> ;
    ns1:name "Nokia",
        "Nokia Siemens Networks" ;
    ns1:sameAsMedium <https://1145.am/db/1865517/Nokia_Siemens_Networks>,
        <https://1145.am/db/1866965/Nokia_Siemens_Networks>,
        <https://1145.am/db/1867044/Nokia_Siemens_Networks>,
        <https://1145.am/db/1893323/Nokia_Siemens_Networks>,
        <https://1145.am/db/2600044/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604319/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604506/Nokia_Siemens_Networks>,
        <https://1145.am/db/2604853/Nokia_Siemens_Networks>,
        <https://1145.am/db/2606778/Nokia_Siemens_Networks>,
        <https://1145.am/db/2607155/Nokia_Siemens_Networks>,
        <https://1145.am/db/2607408/Nokia_Siemens_Networks>,
        <https://1145.am/db/2608234/Nokia_Siemens_Networks>,
        <https://1145.am/db/2608675/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611268/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611280/Nokia_Siemens_Networks>,
        <https://1145.am/db/2611289/Nokia_Siemens_Networks>,
        <https://1145.am/db/2612831/Nokia_Siemens_Networks>,
        <https://1145.am/db/2613146/Nokia_Siemens_Networks>,
        <https://1145.am/db/2613169/Nokia_Siemens_Networks>,
        <https://1145.am/db/2614294/Nokia_Siemens_Networks>,
        <https://1145.am/db/2615021/Nokia_Siemens_Networks>,
        <https://1145.am/db/2616502/Nokia_Siemens_Networks>,
        <https://1145.am/db/2616957/Nokia_Siemens_Networks>,
        <https://1145.am/db/2616995/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617005/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617493/Nokia_Siemens_Networks>,
        <https://1145.am/db/2617657/Nokia_Siemens_Networks>,
        <https://1145.am/db/2618843/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619160/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619460/Nokia_Siemens_Networks>,
        <https://1145.am/db/2619788/Nokia_Siemens_Networks>,
        <https://1145.am/db/2622268/Nokia_Siemens_Networks>,
        <https://1145.am/db/2625103/Nokia_Siemens_Networks>,
        <https://1145.am/db/2625106/Nokia_Siemens_Networks>,
        <https://1145.am/db/2629903/Nokia_Siemens_Networks>,
        <https://1145.am/db/2630841/Nokia_Siemens_Networks>,
        <https://1145.am/db/2631730/Nokia_Siemens_Networks>,
        <https://1145.am/db/2635511/Nokia_Siemens_Networks>,
        <https://1145.am/db/2635545/Nokia_Siemens_Networks>,
        <https://1145.am/db/2636044/Nokia_Siemens_Networks>,
        <https://1145.am/db/2636463/Nokia_Siemens_Networks>,
        <https://1145.am/db/2637962/Nokia_Siemens_Networks>,
        <https://1145.am/db/2638937/Nokia_Siemens_Networks>,
        <https://1145.am/db/2638938/Nokia_Siemens_Networks>,
        <https://1145.am/db/2639419/Nokia_Siemens_Networks>,
        <https://1145.am/db/2639425/Nokia_Siemens_Networks>,
        <https://1145.am/db/2640432/Nokia_Siemens_Networks>,
        <https://1145.am/db/2642116/Nokia_Siemens_Networks>,
        <https://1145.am/db/2643132/Nokia_Siemens_Networks>,
        <https://1145.am/db/2643438/Nokia_Siemens_Networks>,
        <https://1145.am/db/2647326/Nokia_Siemens_Networks>,
        <https://1145.am/db/2648177/Nokia_Siemens_Networks>,
        <https://1145.am/db/2648187/Nokia_Siemens_Networks>,
        <https://1145.am/db/2650490/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651649/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651664/Nokia_Siemens_Networks>,
        <https://1145.am/db/2651668/Nokia_Siemens_Networks>,
        <https://1145.am/db/2652178/Nokia_Siemens_Networks>,
        <https://1145.am/db/2652962/Nokia_Siemens_Networks>,
        <https://1145.am/db/2653862/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654614/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654893/Nokia_Siemens_Networks>,
        <https://1145.am/db/2654922/Nokia_Siemens_Networks>,
        <https://1145.am/db/2656598/Nokia_Siemens_Networks>,
        <https://1145.am/db/2656673/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657431/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657486/Nokia_Siemens_Networks>,
        <https://1145.am/db/2657523/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659204/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659506/Nokia_Siemens_Networks>,
        <https://1145.am/db/2659682/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660228/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660248/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660256/Nokia_Siemens_Networks>,
        <https://1145.am/db/2660261/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662032/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662041/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662048/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662059/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662406/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662625/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662689/Nokia_Siemens_Networks>,
        <https://1145.am/db/2662865/Nokia_Siemens_Networks>,
        <https://1145.am/db/2663834/Nokia_Siemens_Networks>,
        <https://1145.am/db/2664171/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665073/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665681/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665701/Nokia_Siemens_Networks>,
        <https://1145.am/db/2665980/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666063/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666090/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666165/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666167/Nokia_Siemens_Networks>,
        <https://1145.am/db/2666782/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668320/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668329/Nokia_Siemens_Networks>,
        <https://1145.am/db/2668820/Nokia_Siemens_Networks>,
        <https://1145.am/db/2669368/Nokia_Siemens_Networks>,
        <https://1145.am/db/2670327/Nokia_Siemens_Networks>,
        <https://1145.am/db/2670700/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672497/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672513/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672581/Nokia_Siemens_Networks>,
        <https://1145.am/db/2672582/Nokia_Siemens_Networks>,
        <https://1145.am/db/2673703/Nokia_Siemens_Networks>,
        <https://1145.am/db/2673757/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674536/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674934/Nokia_Siemens_Networks>,
        <https://1145.am/db/2674950/Nokia_Siemens_Networks>,
        <https://1145.am/db/2675256/Nokia_Siemens_Networks>,
        <https://1145.am/db/2675276/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676115/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676312/Nokia_Siemens_Networks>,
        <https://1145.am/db/2676415/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677266/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677518/Nokia_Siemens_Networks>,
        <https://1145.am/db/2677609/Nokia_Siemens_Networks>,
        <https://1145.am/db/2678837/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679325/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679545/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679741/Nokia_Siemens_Networks>,
        <https://1145.am/db/2679877/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680048/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680713/Nokia_Siemens_Networks>,
        <https://1145.am/db/2680720/Nokia_Siemens_Networks>,
        <https://1145.am/db/2682371/Nokia_Siemens_Networks>,
        <https://1145.am/db/2683690/Nokia_Siemens_Networks>,
        <https://1145.am/db/2684551/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685124/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685394/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685508/Nokia_Siemens_Networks>,
        <https://1145.am/db/2685558/Nokia_Siemens_Networks>,
        <https://1145.am/db/2686194/Nokia_Siemens_Networks> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2206103/Investment_Buckhead_Investment_Partners_C___B_Capital_Council_Capital_Reach_Health_Silicon_Valley_Bank_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-27T12:00:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "REACH Health Secures $ 7.4 Million in Funding. < 0 > Laura Campbell & Associates for REACH HealthLaura Campbell, 615-579-6599 < /0 >",
        "REACH Health, Inc., the leading provider of telemedicine software solutions, announced today that it has secured $ 7.4 million in funding." ;
    ns1:documentTitle "REACH Health Secures $7.4 Million in Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/reach-health-secures-7-4-million-funding> ;
    ns1:foundName "financing",
        "funding" ;
    ns1:name "financing",
        "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2206103/Reach_Health> ;
    ns1:targetDetails "equity" ;
    ns1:valueRaw "$ 4.4 million",
        "$ 7.4 Million",
        "$ 7.4 million" ;
    ns1:whereGeoName "Tennessee" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4662168/about.rdf> ;
    ns1:whereRaw "Tennessee" .

<https://1145.am/db/2294893/Equity_Investment_3x5_Special_Opportunity_Fund_Ptv_Sciences_Rivervest_Venture_Partners_Spray_Venture_Partners_Tryton_Medical_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-07T16:11:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Tryton Medical has pulled in $ 24 million in equity financing, looping all its investors to pitch in as it prepares to seek FDA approval for its Side Branch Stent to treat bifurcated lesions.",
        "Tryton Medical raised $ 24 million to support its Side Branch Stent, which works where the coronary artery bifurcates.-courtesy of Tryton Medical." ;
    ns1:documentTitle "Tryton raises $24M to get stent on U.S. market" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/tryton-raises-24m-to-get-stent-u-s-market> ;
    ns1:foundName "approval",
        "financing" ;
    ns1:name "approval",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2294893/Tryton_Medical> ;
    ns1:targetDetails "Stent",
        "equity" ;
    ns1:valueRaw "$ 24 million" ;
    ns1:whereRaw "Tryton Medical" .

<https://1145.am/db/2307564/Shangpharma_Corporation_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2013-01-01T23:20:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SHANGHAI, China, Dec. 21, 2012 - ShangPharma Corporation (NYSE: SHP) (the \"Company\") , a leading China - based pharmaceutical and biotechnology research and development outsourcing company, today announced that the Company has entered into a definitive Agreement and Plan of Merger (the \"Merger Agreement\") with ShangPharma Holdings Limited (\"Holdings\") , ShangPharma Parent Limited (\"Parent\") and ShangPharma Merger Sub Limited (\"Merger Sub\") , pursuant to which Parent will acquire the Company for US $ 0.50 per ordinary share or US $ 9.00 per American Depositary Share, each representing eighteen ordinary shares (\"ADS\") ." ;
    ns1:documentTitle "ShangPharma Corporation Enters into Definitive Merger Agreement for Going Private Transaction" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/shangpharma-corporation-enters-into-definitive-merger-agreement-for-going-private-transaction> ;
    ns1:foundName "Merger",
        "acquire" ;
    ns1:name "Merger",
        "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2307564/Shangpharma_Corporation> ;
    ns1:targetName "ShangPharma Corporation" ;
    ns1:whereGeoName "Peoples Republic of China" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1814991/about.rdf> ;
    ns1:whereRaw "China" .

<https://1145.am/db/2307565/Venture_Investment_Aberdare_Ventures_Edbi_Qualcomm_Ventures_West_Health_Investment_Fund_Gobalto_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-01T22:16:15+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO, Dec. 27, 2012 - goBalto, Inc. (www.gobalto.com) announced today that it closed a $ 12 million round of venture financing, led by EDBI, the global investment arm of Singapore's Economic Development Board, with participation from new investor Qualcomm Life Fund, a $ 100 million investment allocation that is managed by Qualcomm Ventures, Qualcomm's investment group.",
        "The new round of funding brings goBalto's total financing to $ 21 million." ;
    ns1:documentTitle "goBalto Raises $12 Million in Series B Financing from EDBI and Qualcomm Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/cro/gobalto%E2%84%A2-raises-12-million-series-b-financing-from-edbi-and-qualcomm-ventures> ;
    ns1:foundName "financing",
        "funding" ;
    ns1:name "financing",
        "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2307565/Gobalto> ;
    ns1:targetDetails "venture" ;
    ns1:valueRaw "$ 100 million",
        "$ 12 million",
        "$ 21 million" ;
    ns1:whenRaw "2012" ;
    ns1:whereGeoName "San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:whereRaw "SAN FRANCISCO" .

<https://1145.am/db/2335936/Baxter_Ventures> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2013-01-29T13:20:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/zytoprotec-raises-eur-2-million-financing-from-baxter-ventures> ;
    ns1:foundName "Baxter Ventures" ;
    ns1:investor <https://1145.am/db/2335936/Series_A_Investment_Baxter_Ventures_Zytoprotec_Completed> ;
    ns1:name "Baxter Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2352203/Baxter_Ventures>,
        <https://1145.am/db/2352204/Baxter_Ventures>,
        <https://1145.am/db/2352349/Baxter_Ventures>,
        <https://1145.am/db/2352350/Baxter_Ventures>,
        <https://1145.am/db/2357487/Baxter_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2327046/Baxter_Ventures>,
        <https://1145.am/db/2350231/Baxter_Ventures>,
        <https://1145.am/db/2352216/Baxter_Ventures>,
        <https://1145.am/db/2357494/Baxter_Ventures>,
        <https://1145.am/db/2358541/Baxter_Ventures>,
        <https://1145.am/db/2371033/Baxter_Ventures>,
        <https://1145.am/db/2569831/Baxter_Ventures>,
        <https://1145.am/db/2580551/Baxter_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336410/Series_F_Investment_Bayern_Kapital_Entrepreneurs_Fund_Hanseatic_Asset_Management_Lbg_Heidelbergcapital_Private_Equity_Vasopharm_Gmbh_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-24T11:30:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Wuerzburg, Germany; June 24, 2013 - vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the successful completion of a Series F financing round totalling 5 million (~ US $ 6.5 million) .",
        "vasopharm Closes Series F Financing Round. - Company receives additional 5 million for preparation of Phase III study -" ;
    ns1:documentTitle "vasopharm Closes Series F Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/vasopharm-closes-series-f-financing-round> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336410/Vasopharm_Gmbh> ;
    ns1:targetDetails "Series F" ;
    ns1:valueRaw "~ US $ 6.5 million",
        "5 million" ;
    ns1:when "2013-06-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 24, 2013" ;
    ns1:whereGeoName "Federal Republic of Germany" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:whereRaw "Germany" .

<https://1145.am/db/2339933/Series_A_Investment_Biogeneration_Ventures_Dezima_Pharma_Forbion_Capital_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-02-28T17:12:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Dezima Pharma raises 14.2m ($ 18.6m) to develop its CETP inhibitor program DEZ-001.",
        "Dezima has raised 9.8m in a Series A funding round, led by Forbion Capital Partners (NL) and BioGeneration Ventures (NL) , with participation from New Science Ventures (USA) .",
        "Naarden, The Netherlands, 28 February 2013 - Dezima Pharma ('Dezima' ), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of 14.2m ($ 18.6m) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) and to develop additional earlier-stage dyslipidemia assets." ;
    ns1:documentTitle "Dezima Pharma raises 14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/dezima-pharma-raises-%E2%82%AC14-2m-18-6m-to-develop-its-cetp-inhibitor-program-dez-001> ;
    ns1:foundName "funding",
        "loan",
        "raised",
        "raises" ;
    ns1:name "funding",
        "loan",
        "raised",
        "raises" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2339933/Dezima_Pharma> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 18.6m",
        "14.2m",
        "4.4m",
        "9.8m" ;
    ns1:when "2013-02-28T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "28 February 2013" ;
    ns1:whereGeoName "Dejimamachi",
        "Pharma" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/10678659/about.rdf>,
        <https://sws.geonames.org/1864389/about.rdf> ;
    ns1:whereRaw "Dezima Pharma" .

<https://1145.am/db/2340819/Investment_Adage_Capital_Management_Brookside_Capital_Partners_Fund_Jennison_Associates_Llc_Longwood_Fund_Ptc_Therapeutics_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-08T12:59:41+00:00"^^xsd:dateTime ;
    ns1:documentExtract "PTC Therapeutics Closes $ 60 Million Private Financing.",
        "SOUTH PLAINFIELD, N.J., March 7, 2013 /PRNewswire/ - PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $ 60 million financing led by Brookside Capital Partners Fund, L.P." ;
    ns1:documentTitle "PTC Therapeutics Closes $60 Million Private Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-60-million-private-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2340819/Ptc_Therapeutics_Inc> ;
    ns1:valueRaw "$ 60 Million",
        "$ 60 million" ;
    ns1:when "2013-03-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 7, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2346988/Investment_Flagship_Ventures_Flybridge_Capital_Partners_Polaris_Partners_Taris_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-03T16:13:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has raised an additional $ 12.5 million financing round through its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners and Third Rock Ventures.",
        "TARIS Secures $ 12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate." ;
    ns1:documentTitle "TARIS Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/taris%C2%AE-secures-12-5-million-additional-financing-initiates-phase-2-trial-of-lead-product> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2346988/Taris> ;
    ns1:valueRaw "$ 12.5 Million",
        "$ 12.5 million" ;
    ns1:whereGeoName "Lexington" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4941935/about.rdf> ;
    ns1:whereRaw "LEXINGTON, Mass" .

<https://1145.am/db/2348066/Investment_Alexandria_Real_Estate_Equities_Cydan_New_Enterprise_Associates_Pfizer_Venture_Investments_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-11T02:23:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "- April 11, 2013 - Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced its launch with $ 16 million in financing led by New Enterprise Associates (NEA) and Pfizer Venture Investments, with participation from Alexandria Real Estate Equities, Inc.",
        "Cydan, a New Orphan Drug Accelerator, Launches with $ 16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities." ;
    ns1:documentTitle "Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cydan-a-new-orphan-drug-accelerator-launches-16-million-financing-from-leading-investors> ;
    ns1:foundName "Financing",
        "financing",
        "launch" ;
    ns1:name "Financing",
        "financing",
        "launch" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348066/Cydan> ;
    ns1:valueRaw "$ 16 Million",
        "$ 16 million" ;
    ns1:when "2013-04-11T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 11, 2013" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, Mass" .

<https://1145.am/db/2351192/Genticel> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:description "vaccine developer" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "Genticel" ;
    ns1:industry "life sciences" ;
    ns1:name "Genticel" ;
    ns1:sameAsHigh <https://1145.am/db/1009450/Biocompare>,
        <https://1145.am/db/1023985/Orgenesis_Inc>,
        <https://1145.am/db/1051761/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1066819/Biocentriq_Inc>,
        <https://1145.am/db/1088717/Biosynth>,
        <https://1145.am/db/1089921/Biosynth>,
        <https://1145.am/db/1116501/Alvotech_Sa>,
        <https://1145.am/db/1117630/Alvotech_Sa>,
        <https://1145.am/db/1124798/Accustem_Sciences>,
        <https://1145.am/db/1130652/Cogent_Biosciences>,
        <https://1145.am/db/1132106/Cogent_Biosciences>,
        <https://1145.am/db/1140693/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1142391/Cogent_Biosciences_Inc>,
        <https://1145.am/db/1143081/Bioinvent_International_Ab>,
        <https://1145.am/db/1154042/Applied_Biology>,
        <https://1145.am/db/1167874/Ensysce_Biosciences>,
        <https://1145.am/db/1174373/Biosynth>,
        <https://1145.am/db/1175242/Biosynth>,
        <https://1145.am/db/1179100/Ensysce_Biosciences>,
        <https://1145.am/db/1216524/Forbion>,
        <https://1145.am/db/1216997/180_Life_Sciences>,
        <https://1145.am/db/1222768/180_Life_Sciences_Corp>,
        <https://1145.am/db/1229517/Enveric_Biosciences>,
        <https://1145.am/db/1236975/Enveric_Biosciences>,
        <https://1145.am/db/1252190/Forbion>,
        <https://1145.am/db/1271538/Ensysce_Biosciences>,
        <https://1145.am/db/1278078/Monod_Bio>,
        <https://1145.am/db/1278479/Monod_Bio>,
        <https://1145.am/db/1293677/Biosion>,
        <https://1145.am/db/1295884/Brii_Biosciences_Limited>,
        <https://1145.am/db/1320133/Hc_Bioscience>,
        <https://1145.am/db/1336573/Hc_Bioscience>,
        <https://1145.am/db/1354619/Biogen>,
        <https://1145.am/db/1382711/Solid_Biosciences_Inc>,
        <https://1145.am/db/1386738/Vergent_Bioscience>,
        <https://1145.am/db/1387057/Vergent_Bioscience>,
        <https://1145.am/db/1408611/Alvotech>,
        <https://1145.am/db/1490000/Enavate_Sciences>,
        <https://1145.am/db/1506505/Biodesix>,
        <https://1145.am/db/1509205/Biodesix>,
        <https://1145.am/db/1522275/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1534347/Enveric_Biosciences>,
        <https://1145.am/db/1536048/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/1537082/Vergent_Bioscience>,
        <https://1145.am/db/1537788/Vergent_Bioscience>,
        <https://1145.am/db/1547927/Solid_Biosciences_Inc>,
        <https://1145.am/db/1548092/Innoforce>,
        <https://1145.am/db/1548093/Alvotech>,
        <https://1145.am/db/1553518/Solid_Biosciences_Inc>,
        <https://1145.am/db/1562950/Ensysce_Biosciences>,
        <https://1145.am/db/1577542/Bioasis>,
        <https://1145.am/db/1585988/Alvotech>,
        <https://1145.am/db/1585992/Alvotech>,
        <https://1145.am/db/1586236/Alvotech>,
        <https://1145.am/db/1586786/Bioasis>,
        <https://1145.am/db/1619665/Bioversys_Ag>,
        <https://1145.am/db/1630753/Solid_Biosciences_Inc>,
        <https://1145.am/db/1639462/Forte_Biosciences>,
        <https://1145.am/db/1640582/Forte_Biosciences>,
        <https://1145.am/db/1664988/Upstream_Bio>,
        <https://1145.am/db/1668597/Verily>,
        <https://1145.am/db/1685433/Enveric_Biosciences>,
        <https://1145.am/db/1696213/Genentech>,
        <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/1787025/Verily>,
        <https://1145.am/db/1821833/Verily>,
        <https://1145.am/db/1945850/Puretech>,
        <https://1145.am/db/2000772/Biosynth>,
        <https://1145.am/db/2010010/Iveric_Bio_Inc>,
        <https://1145.am/db/2019705/Eqt_Life_Sciences>,
        <https://1145.am/db/2023773/Genentech>,
        <https://1145.am/db/2032047/Enavate_Sciences>,
        <https://1145.am/db/2032047/Upstream_Bio>,
        <https://1145.am/db/2053399/Univercells_Technologies>,
        <https://1145.am/db/2061027/Roivant_Sciences>,
        <https://1145.am/db/2073555/Puretech_Scientific>,
        <https://1145.am/db/209111/Bioage>,
        <https://1145.am/db/2113176/Genentech>,
        <https://1145.am/db/2115362/2seventy_Bio>,
        <https://1145.am/db/2123899/Biosynth>,
        <https://1145.am/db/2152203/Osivax>,
        <https://1145.am/db/2152786/Aruvant_Sciences>,
        <https://1145.am/db/2152862/Therachon>,
        <https://1145.am/db/2152961/Arcus_Biosciences>,
        <https://1145.am/db/2153083/Arcus_Biosciences>,
        <https://1145.am/db/2153509/Or>,
        <https://1145.am/db/2154521/Baergic_Bio>,
        <https://1145.am/db/2154848/Brii_Biosciences>,
        <https://1145.am/db/2155108/Roivant_Sciences>,
        <https://1145.am/db/2155252/Bioagilytix>,
        <https://1145.am/db/2156304/Puretech>,
        <https://1145.am/db/2181432/Verily>,
        <https://1145.am/db/2188567/Verily_Life_Sciences>,
        <https://1145.am/db/2189613/Genapsys>,
        <https://1145.am/db/2198949/Cellectricon>,
        <https://1145.am/db/222920/Genapsys_Inc>,
        <https://1145.am/db/2230848/Bioohio>,
        <https://1145.am/db/2280215/Concentra_Biosciences>,
        <https://1145.am/db/2280734/Forte_Biosciences>,
        <https://1145.am/db/2281285/Locus_Biosciences>,
        <https://1145.am/db/2281875/Solid_Biosciences>,
        <https://1145.am/db/2282549/Coave>,
        <https://1145.am/db/2282760/Bioreliance>,
        <https://1145.am/db/2282760/Inotiv>,
        <https://1145.am/db/2283398/Sab>,
        <https://1145.am/db/2283480/Hcbioscience>,
        <https://1145.am/db/2285390/Cellarity>,
        <https://1145.am/db/2285399/Solid_Biosciences>,
        <https://1145.am/db/2285897/Hologic>,
        <https://1145.am/db/2285963/Iveric_Bio>,
        <https://1145.am/db/2286634/Therachon>,
        <https://1145.am/db/2286677/Roivant_Sciences>,
        <https://1145.am/db/2287185/Brii_Biosciences>,
        <https://1145.am/db/2290342/Biotech_Sector>,
        <https://1145.am/db/2290381/Life_Sciences>,
        <https://1145.am/db/2292237/Bioinvent>,
        <https://1145.am/db/2293367/Ascentage>,
        <https://1145.am/db/2293654/Eleven_Bio>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2295596/Roivant_Sciences>,
        <https://1145.am/db/2295654/Sv>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296584/Enterin>,
        <https://1145.am/db/2296692/Tp>,
        <https://1145.am/db/2297083/Biogen_Idec>,
        <https://1145.am/db/2297978/Ocugen>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298404/Bioz>,
        <https://1145.am/db/2298499/Inthera_Bioscience>,
        <https://1145.am/db/2298505/Inventisbio>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298866/Biosafe_Group>,
        <https://1145.am/db/2298948/Bioverativ>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299472/Aadi_Bioscience>,
        <https://1145.am/db/2300786/Axovant_Sciences>,
        <https://1145.am/db/2300790/Axovant_Sciences>,
        <https://1145.am/db/2301003/Roivant_Sciences>,
        <https://1145.am/db/2301684/Biogen_Idec_Inc>,
        <https://1145.am/db/2301979/Biogen_Idec_Inc>,
        <https://1145.am/db/2301983/Biogen_Idec>,
        <https://1145.am/db/2302002/Biogen_Idec>,
        <https://1145.am/db/2303130/Bioreliance_Corporation>,
        <https://1145.am/db/2303317/Applied_Biosystems>,
        <https://1145.am/db/2303604/Biogen_Idec>,
        <https://1145.am/db/2304650/Bioprocessors_Corp>,
        <https://1145.am/db/2304650/Life>,
        <https://1145.am/db/2305210/Biogen_Idec>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2306259/Bioanalab>,
        <https://1145.am/db/2306288/Bioanalab>,
        <https://1145.am/db/2308142/Biogen_Idec>,
        <https://1145.am/db/2310216/Biogen_Idec>,
        <https://1145.am/db/2310216/Genentech>,
        <https://1145.am/db/2310979/Cogenics>,
        <https://1145.am/db/2311995/Biovitrum>,
        <https://1145.am/db/2312238/Prometic_Life_Sciences>,
        <https://1145.am/db/2313533/Biosource_International>,
        <https://1145.am/db/2313760/Sistemic_Ltd>,
        <https://1145.am/db/2313762/Sistemic_Ltd>,
        <https://1145.am/db/2313763/Biomarin>,
        <https://1145.am/db/2314526/Bio-Rad>,
        <https://1145.am/db/2315615/Anormed>,
        <https://1145.am/db/2316066/Biogen_Idec>,
        <https://1145.am/db/2317136/Biogen_Idec_Inc>,
        <https://1145.am/db/2318537/Genomics>,
        <https://1145.am/db/2318657/Vaxinnate>,
        <https://1145.am/db/2319551/Medevol>,
        <https://1145.am/db/2319959/Progentech>,
        <https://1145.am/db/2320138/Biogen_Idec>,
        <https://1145.am/db/2320164/Anaptys_Biosciences>,
        <https://1145.am/db/2320435/Ym_Biosciences_Inc>,
        <https://1145.am/db/2322209/Genentech>,
        <https://1145.am/db/2322417/Bio-Quant>,
        <https://1145.am/db/2322417/Biotox_Sciences>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2325377/Celmed_Biosciences>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2326063/Biooutsource>,
        <https://1145.am/db/2327677/Fundamental_Applied_Biology>,
        <https://1145.am/db/2327982/Biovex_Inc>,
        <https://1145.am/db/2328028/Biotrove>,
        <https://1145.am/db/2328815/Fundamental_Applied_Biology>,
        <https://1145.am/db/2329870/Complex_Biosystems_Gmbh>,
        <https://1145.am/db/2330058/Bio-Quant>,
        <https://1145.am/db/2330348/Blaze_Bioscience>,
        <https://1145.am/db/2332771/S_*_Bio>,
        <https://1145.am/db/2333005/Genizon_Biosciences>,
        <https://1145.am/db/2334156/Genizon>,
        <https://1145.am/db/2335943/Genentech>,
        <https://1145.am/db/2336178/Biocon_Limited>,
        <https://1145.am/db/2336178/Biocon_Ltd>,
        <https://1145.am/db/2336383/Biocrates_Life_Sciences_Ag>,
        <https://1145.am/db/2336736/Coherus_Biosciences>,
        <https://1145.am/db/2336983/Biogen_Idec>,
        <https://1145.am/db/2337110/Bioutah>,
        <https://1145.am/db/2337412/Blaze_Bioscience>,
        <https://1145.am/db/2337664/Advent_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338837/Coherus_Biosciences>,
        <https://1145.am/db/2340502/Massbio>,
        <https://1145.am/db/2340513/Massbio>,
        <https://1145.am/db/2340560/Puretech>,
        <https://1145.am/db/2341443/Biosystems_International>,
        <https://1145.am/db/2341509/Epic_Sciences>,
        <https://1145.am/db/2341676/Bioforward>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343761/Ovascience>,
        <https://1145.am/db/2343777/Ovascience>,
        <https://1145.am/db/2343791/Bioniche_Life_Sciences_Inc>,
        <https://1145.am/db/2344638/Coherus_Biosciences>,
        <https://1145.am/db/2345112/Med_Biogene_Inc>,
        <https://1145.am/db/2345132/Biocon>,
        <https://1145.am/db/2345999/Biogen_Idec>,
        <https://1145.am/db/2346485/Pracinostat>,
        <https://1145.am/db/2347467/Theraclone_Sciences>,
        <https://1145.am/db/2347950/Epic_Sciences>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2349436/Ovascience>,
        <https://1145.am/db/2350267/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2350471/Biovex>,
        <https://1145.am/db/2350645/Biochrom_Ag>,
        <https://1145.am/db/2351312/Themis_Bioscience>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2351472/Mymetics>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2351921/Ovascience>,
        <https://1145.am/db/2352069/Biogen_Idec>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2354835/Biovex>,
        <https://1145.am/db/2355219/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355236/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355590/Intercell>,
        <https://1145.am/db/2356064/Frontline_Bioventures>,
        <https://1145.am/db/2356509/Inq_Biosciences_Corporation>,
        <https://1145.am/db/2357079/Techne_Corporation>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358296/Biogen_Idec>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2360075/Bionomics>,
        <https://1145.am/db/2360313/Engene>,
        <https://1145.am/db/2361502/Ovascience>,
        <https://1145.am/db/2362647/Bioqual>,
        <https://1145.am/db/2362737/Life_Sciences>,
        <https://1145.am/db/2363484/Bioscale>,
        <https://1145.am/db/2363485/Bioscale_Inc>,
        <https://1145.am/db/2363668/Ovasciencesm>,
        <https://1145.am/db/2364681/Biogen_Idec>,
        <https://1145.am/db/2366915/Biogen_Idec>,
        <https://1145.am/db/2368752/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/2369498/Genentech>,
        <https://1145.am/db/2370383/Prometic_Life_Sciences>,
        <https://1145.am/db/2370548/Bionovion>,
        <https://1145.am/db/2370549/Bionovion>,
        <https://1145.am/db/2370806/Alvotech>,
        <https://1145.am/db/2538197/Orgenesis>,
        <https://1145.am/db/2542617/Core_Biogenesis>,
        <https://1145.am/db/2542993/Biogen_Idec>,
        <https://1145.am/db/2550495/Bioatla>,
        <https://1145.am/db/2552636/Ark_Biosciences>,
        <https://1145.am/db/2553773/Mabxience>,
        <https://1145.am/db/2554400/Acambis>,
        <https://1145.am/db/2563996/Biocnd>,
        <https://1145.am/db/256464/Atai_Life_Sciences>,
        <https://1145.am/db/2566932/Exosomics>,
        <https://1145.am/db/2567231/Genentech>,
        <https://1145.am/db/2568479/Subintro>,
        <https://1145.am/db/2571023/Biochrom_Ag>,
        <https://1145.am/db/2577183/Biogen_Idec>,
        <https://1145.am/db/2577644/Presage_Biosciences>,
        <https://1145.am/db/2578308/Intermune>,
        <https://1145.am/db/2578528/Biogen_Idec>,
        <https://1145.am/db/2580665/Themis_Bioscience>,
        <https://1145.am/db/2580671/Themis_Bioscience>,
        <https://1145.am/db/2584538/Bionovion>,
        <https://1145.am/db/2594353/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2797140/Biotheus>,
        <https://1145.am/db/322594/Roivant_Sciences>,
        <https://1145.am/db/356493/Atai_Life_Sciences_Bv>,
        <https://1145.am/db/396787/Biotheryx>,
        <https://1145.am/db/417096/Solid_Biosciences_Inc>,
        <https://1145.am/db/417543/180_Life_Sciences_Corp>,
        <https://1145.am/db/417568/Ultivue>,
        <https://1145.am/db/425981/180_Life_Sciences_Corp>,
        <https://1145.am/db/436937/Triad_Life_Sciences>,
        <https://1145.am/db/471380/Insidescientific>,
        <https://1145.am/db/481671/Biolegend>,
        <https://1145.am/db/482988/Biolegend>,
        <https://1145.am/db/486391/Biolife_Solutions>,
        <https://1145.am/db/505292/Ensysce_Biosciences>,
        <https://1145.am/db/520363/Biohive>,
        <https://1145.am/db/521860/Tosoh_Bioscience_Llc>,
        <https://1145.am/db/523221/Biohive>,
        <https://1145.am/db/540091/Curative_Biotechnology_Inc>,
        <https://1145.am/db/540784/Coherus_Biosciences_Inc>,
        <https://1145.am/db/544370/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/591563/180_Life_Sciences>,
        <https://1145.am/db/624546/Ensysce_Biosciences>,
        <https://1145.am/db/730321/Biosion>,
        <https://1145.am/db/739185/Sqz_Biotechnologies>,
        <https://1145.am/db/767994/Biotech_Prokidney_Lp>,
        <https://1145.am/db/818850/Ensysce_Biosciences>,
        <https://1145.am/db/877317/Accustem_Sciences>,
        <https://1145.am/db/922807/Biolabs>,
        <https://1145.am/db/941576/Orgenesis_Inc>,
        <https://1145.am/db/948136/Ensysce_Biosciences_Inc>,
        <https://1145.am/db/958575/Biocompare>,
        <https://1145.am/db/958575/Scilan>,
        <https://1145.am/db/968301/Ansa_Biotechnologies>,
        <https://1145.am/db/972968/Ansa_Biotechnologies>,
        <https://1145.am/db/979663/Biostrand>,
        <https://1145.am/db/979842/Biostrand_Bv>,
        <https://1145.am/db/986828/Ensysce_Biosciences>,
        <https://1145.am/db/991347/Genovac> ;
    ns1:sameAsMedium <https://1145.am/db/2351191/Genticel>,
        <https://1145.am/db/2364536/Genticel> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352203/Novartis_Venture_Fund> a org:Organization ;
    ns1:description "Series C financing" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "Novartis Venture Fund" ;
    ns1:investor <https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Novartis Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/2153726/Novartis_Venture_Fund_And_Partners_Innovation_Fund>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2306568/Novartis_Bioventure_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2354770/Novartis_Bioventures>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2575232/Novartis_Bioventures>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352204/Novartis_Venture_Fund> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Novartis Venture Fund" ;
    ns1:investor <https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Novartis Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/2153726/Novartis_Venture_Fund_And_Partners_Innovation_Fund>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2306568/Novartis_Bioventure_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2324255/Novartis_Bioventures>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340615/Novartis>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2354770/Novartis_Bioventures>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2575232/Novartis_Bioventures>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/619955/Novartis>,
        <https://1145.am/db/623985/Novartis>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352216/Novartis_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "Dublin" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "Novartis Venture Fund" ;
    ns1:investor <https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> ;
    ns1:name "Novartis Venture Fund" ;
    ns1:sameAsMedium <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358430/Novartis_Venture_Funds> a org:Organization ;
    ns1:basedInLowRaw "San Diego" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Novartis Venture Funds" ;
    ns1:investor <https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> ;
    ns1:name "Novartis Venture Funds" ;
    ns1:sameAsMedium <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2361625/Series_C_Investment_Canaan_Partners_Sofinnova_Ventures_Domain_Associates_Foundation_Medical_Partners_Marinus_Pharmaceuticals_Inc_Rusnanomedinvest_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-07T17:06:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Marinus Pharmaceuticals Adds $ 21M Series C.",
        "Marinus Pharmaceuticals Inc., has added $ 21 million in Series C financing from Domain Associates, RusnanoMedInvest, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners.",
        "Marinus Pharmaceuticals, Inc. is pleased to announce $ 21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI) , and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners." ;
    ns1:documentTitle "Marinus Pharmaceuticals Adds $21M Series C" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/marinus-pharmaceuticals-adds-21m-series-c> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2361625/Marinus_Pharmaceuticals_Inc> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 21 million",
        "$ 21M" ;
    ns1:whereGeoName "Branford" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5283054/about.rdf> ;
    ns1:whereRaw "Branford, Conn." .

<https://1145.am/db/2362715/Novartis_Venture_Funds> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "Novartis Venture Funds" ;
    ns1:investor <https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> ;
    ns1:name "Novartis Venture Funds" ;
    ns1:sameAsMedium <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2348350/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2362736/C_Investment_Advent_Venture_Partners_Aisling_Capital_Index_Ventures_New_Leaf_Venture_Partners_Versartis_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-15T15:44:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Redwood City, CA - based startup Versartis has nailed a $ 25 million C round designed to fuel its journey into midstage work on a lead drug for endocrine disorders, leaving it positioned at the threshold of a late-stage program next year.",
        "Versartis landed a $ 21 million venture round just as it was headed into Phase I a year ago." ;
    ns1:documentTitle "Versartis pockets $25M C round as it looks to PhII growth hormone study" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/versartis-pockets-25m-c-round-as-it-looks-to-phii-growth-hormone-study> ;
    ns1:foundName "landed",
        "round" ;
    ns1:name "landed",
        "round" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2362736/Versartis> ;
    ns1:targetDetails "C",
        "venture" ;
    ns1:valueRaw "$ 21 million",
        "$ 25 million" ;
    ns1:whereGeoName "Redwood City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5386834/about.rdf> ;
    ns1:whereRaw "Redwood City" .

<https://1145.am/db/2362737/Series_C_Investment_Aisling_Capital_Index_Ventures_Life_Sciences_New_Leaf_Venture_Partners_Versartis_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-15T15:15:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "REDWOOD CITY, CA, Jan 15, 2013 (MARKETWIRE via COMTEX) - Versartis, Inc., an emerging biotechnology company developing novel therapeutics for patients with endocrine disorders, today announced completion of a $ 25 million Series C financing lead by new investor Aisling Capital.",
        "Versartis Closes $ 25 Million Series C Financing." ;
    ns1:documentTitle "Versartis Closes $25 Million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/versartis-closes-25-million-series-c-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2362737/Versartis> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 25 Million",
        "$ 25 million" ;
    ns1:when "2013-01-15T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Jan 15, 2013" ;
    ns1:whereGeoName "Redwood City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5386834/about.rdf> ;
    ns1:whereRaw "REDWOOD CITY, CA" .

<https://1145.am/db/2667192/Nokia_Siemens_Networks_Stake_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2013-02-07T16:08:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Nokia (NYSE: NOK) and Siemens are intensifying their talks to exit their Nokia Siemens Networks joint venture, according to a Bloomberg report, which cited unnamed sources familiar with the matter." ;
    ns1:documentTitle "Report: Nokia Siemens parents could use Alcatel-Lucent to exit JV" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/report-nokia-siemens-parents-could-use-alcatel-lucent-to-exit-jv> ;
    ns1:foundName "buy",
        "exit" ;
    ns1:name "buy",
        "exit" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2667192/Nokia_Siemens_Networks>,
        <https://1145.am/db/2667192/Siemens> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Nokia Siemens Networks",
        "Siemens" ;
    ns1:vendor <https://1145.am/db/2667192/Nokia_Siemens_Networks> .

<https://1145.am/db/2342842/Bioclinica_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment",
        "merger" ;
    ns1:documentDate "2013-03-14T16:17:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEWTOWN, Pa.- (BUSINESS WIRE) -Mar 14, 2013 - BioClinica, Inc., (NASDAQ: BIOC) , a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica." ;
    ns1:documentTitle "BioClinica and CoreLab Partners Are One" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bioclinica-and-corelab-partners-are-one> ;
    ns1:foundName "acquisition",
        "combined" ;
    ns1:name "acquisition",
        "combined" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2342842/Bioclinica> ;
    ns1:targetName "BioClinica" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "Newtown" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5203354/about.rdf> ;
    ns1:whereRaw "NEWTOWN, Pa" .

<https://1145.am/db/2342862/Series_A_Investment_Angeli_Parvi_Avitide_Inc_Borealis_Ventures_Orbimed_Advisors_Polaris_Venture_Partners_Sv_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-03-15T13:00:03+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology.",
        "LEBANON, N.H.- (BUSINESS WIRE) -Mar 15, 2013 - Avitide, Inc., a biotech company dedicated to the discovery and development of custom affinity purification solutions for the biopharmaceutical industry, announced the closing of their Series A financing." ;
    ns1:documentTitle "Avitide, Inc. Secures Series A Financing to Commercialize Novel Biopharmaceutical Affinity Purification Technology" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/avitide-inc-secures-series-a-financing-to-commercialize-novel-biopharmaceutical-affinity> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2342862/Avitide_Inc> ;
    ns1:targetDetails "Series A" ;
    ns1:when "2013-03-15T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2013-Mar-15" ;
    ns1:whereGeoName "New Hampshire" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5090174/about.rdf> ;
    ns1:whereRaw "N.H." .

<https://1145.am/db/2346978/Series_C_Investment_Aquinox_Pharmaceuticals_Inc_Augment_Investments_Ltd_Baker_Brothers_Investments_Johnson___Johnson_Development_Corporation_Pfizer_Venture_Investments_Ventures_West_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-03T15:24:10+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Aquinox Pharmaceuticals Completes US $ 18 million Series C Financing.",
        "VANCOUVER, BRITISH COLUMBIA- (Apr 3, 2013) - Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, announced today that it has secured U.S. $ 18 million in the close of a Series C financing led by Johnson & Johnson Development Corporation." ;
    ns1:documentTitle "Aquinox Pharmaceuticals Completes US $18 million Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aquinox-pharmaceuticals-completes-us-18-million-series-c-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2346978/Aquinox_Pharmaceuticals_Inc> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "U.S. $ 18 million",
        "US $ 18 million" ;
    ns1:when "2013-04-03T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2013-04-03" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "US" .

<https://1145.am/db/2360647/Pfizer_Inc> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "Pfizer",
        "Pfizer Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Pfizer",
        "Pfizer Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1018723/Pfizer_Inc>,
        <https://1145.am/db/1042002/Pfizer_Inc>,
        <https://1145.am/db/1045477/Pfizer_Inc>,
        <https://1145.am/db/1046923/Pfizer>,
        <https://1145.am/db/1053698/Pfizer>,
        <https://1145.am/db/1054558/Pfizer_Inc>,
        <https://1145.am/db/1065617/Pfizer_Inc>,
        <https://1145.am/db/1066444/Pfizer_Inc>,
        <https://1145.am/db/1097779/GSK>,
        <https://1145.am/db/1097915/GSK>,
        <https://1145.am/db/1097915/Pfizer>,
        <https://1145.am/db/1098950/GSK>,
        <https://1145.am/db/1123210/Pfizer_Inc>,
        <https://1145.am/db/1124362/Pfizer_Inc>,
        <https://1145.am/db/1138594/Pfizer_Inc>,
        <https://1145.am/db/1146707/Pfizer>,
        <https://1145.am/db/118625/GSK>,
        <https://1145.am/db/1209318/Glaxosmithkline>,
        <https://1145.am/db/1258904/Pfizer_Inc>,
        <https://1145.am/db/1260932/Pfizer_Inc>,
        <https://1145.am/db/1261278/Pfizer_Inc>,
        <https://1145.am/db/1262347/Pfizer_Inc>,
        <https://1145.am/db/1262354/Pfizer_Inc>,
        <https://1145.am/db/1262545/Pfizer_Inc>,
        <https://1145.am/db/1264461/Pfizer_Inc>,
        <https://1145.am/db/1264475/Pfizer_Inc>,
        <https://1145.am/db/1270781/Pfizer_Inc>,
        <https://1145.am/db/1271008/Pfizer>,
        <https://1145.am/db/1308148/Pfizer_Inc>,
        <https://1145.am/db/1308675/Pfizer_Inc>,
        <https://1145.am/db/1361734/GSK>,
        <https://1145.am/db/1369714/GSK>,
        <https://1145.am/db/1385939/Pfizer_Inc>,
        <https://1145.am/db/1390822/Pfizer_Inc>,
        <https://1145.am/db/1394279/Pfizer_Inc>,
        <https://1145.am/db/1395353/Pfizer_Inc>,
        <https://1145.am/db/1549114/Pfizer_Inc>,
        <https://1145.am/db/1550950/Pfizer_Inc>,
        <https://1145.am/db/1684001/Pfizer_Inc>,
        <https://1145.am/db/1936001/Pfizer_Inc>,
        <https://1145.am/db/1936167/Pfizer_Inc>,
        <https://1145.am/db/1952785/Pfizer_Inc>,
        <https://1145.am/db/1972441/GSK>,
        <https://1145.am/db/2007025/Pfizer_Inc>,
        <https://1145.am/db/2009165/Pfizer_Inc>,
        <https://1145.am/db/2009856/Pfizer>,
        <https://1145.am/db/2013022/Pfizer_Inc>,
        <https://1145.am/db/2057315/Pfizer>,
        <https://1145.am/db/2070468/Pfizer>,
        <https://1145.am/db/2088776/Pfizer>,
        <https://1145.am/db/2119099/Pfizer>,
        <https://1145.am/db/2137303/GSK>,
        <https://1145.am/db/2138577/GSK>,
        <https://1145.am/db/2152849/Pfizer>,
        <https://1145.am/db/2152862/Pfizer>,
        <https://1145.am/db/2207119/Pfizer_Inc>,
        <https://1145.am/db/2221589/Pfizer>,
        <https://1145.am/db/2278803/GSK>,
        <https://1145.am/db/2279140/Pfizer>,
        <https://1145.am/db/2280707/Pfizer>,
        <https://1145.am/db/2280718/Pfizer>,
        <https://1145.am/db/2280933/Pfizer>,
        <https://1145.am/db/2281080/GSK>,
        <https://1145.am/db/2281622/Pfizer>,
        <https://1145.am/db/2281629/Pfizer>,
        <https://1145.am/db/2281879/Pfizer>,
        <https://1145.am/db/2283867/GSK>,
        <https://1145.am/db/2284235/Pfizer>,
        <https://1145.am/db/2285463/Pfizer>,
        <https://1145.am/db/2285764/Pfizer>,
        <https://1145.am/db/2289503/Pfizer>,
        <https://1145.am/db/2290507/Glaxosmithkline>,
        <https://1145.am/db/2291302/Glaxosmithkline>,
        <https://1145.am/db/2293631/Glaxosmithkline>,
        <https://1145.am/db/2293980/Pfizer>,
        <https://1145.am/db/2294613/Pfizer>,
        <https://1145.am/db/2295427/Pfizer>,
        <https://1145.am/db/2295635/Glaxosmithkline>,
        <https://1145.am/db/2296000/Pfizer>,
        <https://1145.am/db/2297455/Pfizer>,
        <https://1145.am/db/2297477/Pfizer>,
        <https://1145.am/db/2298256/Pfizer>,
        <https://1145.am/db/2301922/Pfizer>,
        <https://1145.am/db/230344/GSK>,
        <https://1145.am/db/230344/Glaxosmithkline>,
        <https://1145.am/db/2303447/Pfizer>,
        <https://1145.am/db/2304647/Pfizer>,
        <https://1145.am/db/2306213/Glaxosmithkline>,
        <https://1145.am/db/2306799/Glaxosmithkline>,
        <https://1145.am/db/2308656/Pfizer>,
        <https://1145.am/db/2308807/Pfizer>,
        <https://1145.am/db/2309065/Pfizer>,
        <https://1145.am/db/2309488/P_g>,
        <https://1145.am/db/2310071/Pfizer_Inc>,
        <https://1145.am/db/2310072/Pfizer>,
        <https://1145.am/db/2310168/Pfizer>,
        <https://1145.am/db/2310241/Pfizer>,
        <https://1145.am/db/2311347/Pfizer>,
        <https://1145.am/db/2311570/Pfizer_Inc>,
        <https://1145.am/db/2312314/Pfizer>,
        <https://1145.am/db/2312321/Pfizer_Inc>,
        <https://1145.am/db/2312865/Pfizer>,
        <https://1145.am/db/2312994/Pfizer>,
        <https://1145.am/db/2312995/Pfizer_Inc>,
        <https://1145.am/db/2313383/Pfizer_Inc>,
        <https://1145.am/db/2314928/Pfizer>,
        <https://1145.am/db/2315552/Pfizer>,
        <https://1145.am/db/2316517/Pfizer>,
        <https://1145.am/db/2316538/Pfizer_Inc>,
        <https://1145.am/db/2316843/Pfizer>,
        <https://1145.am/db/2317128/Pfizer-Wyeth>,
        <https://1145.am/db/2317915/Pfizer>,
        <https://1145.am/db/2318333/Pfizer>,
        <https://1145.am/db/2318922/Pfizer>,
        <https://1145.am/db/2320509/Pfizer>,
        <https://1145.am/db/2322306/Pfizer>,
        <https://1145.am/db/2322307/Pfizer>,
        <https://1145.am/db/2322620/Pfizer>,
        <https://1145.am/db/2322633/Pfizer_Inc>,
        <https://1145.am/db/2322733/Pfizer>,
        <https://1145.am/db/2322786/Pfizer>,
        <https://1145.am/db/2324128/Pfizer>,
        <https://1145.am/db/2324155/Pfizer>,
        <https://1145.am/db/2325165/Pfizer_Inc>,
        <https://1145.am/db/2326266/Glaxosmithkline_(gsk)>,
        <https://1145.am/db/2327511/Pfizer_Inc>,
        <https://1145.am/db/2328681/GSK>,
        <https://1145.am/db/2328712/Pfizer>,
        <https://1145.am/db/2329902/Pfizer>,
        <https://1145.am/db/2329920/Pfizer_Inc>,
        <https://1145.am/db/2330817/Pfizer_Inc>,
        <https://1145.am/db/2330955/Pfizer>,
        <https://1145.am/db/2332552/Pfizer>,
        <https://1145.am/db/2332767/Pfizer_Ltd>,
        <https://1145.am/db/2334133/Pfizer_Inc>,
        <https://1145.am/db/2334165/Pfizer_Inc>,
        <https://1145.am/db/2335568/Glaxosmithkline>,
        <https://1145.am/db/2335573/GSK>,
        <https://1145.am/db/2335634/Pfizer>,
        <https://1145.am/db/2335717/Pfizer>,
        <https://1145.am/db/2336060/Glaxosmithkline>,
        <https://1145.am/db/2336333/Pfizer>,
        <https://1145.am/db/2336704/GSK>,
        <https://1145.am/db/2337788/Pfizer>,
        <https://1145.am/db/2339633/Pfizer_Inc>,
        <https://1145.am/db/2340055/Pfizer>,
        <https://1145.am/db/2340072/GSK>,
        <https://1145.am/db/2340260/Glaxosmithkline>,
        <https://1145.am/db/2340321/Pfizer_Inc>,
        <https://1145.am/db/2340324/Pfizer_Inc>,
        <https://1145.am/db/2340325/Pfizer_Inc>,
        <https://1145.am/db/2340331/Pfizer_Inc>,
        <https://1145.am/db/2340890/Pfizer>,
        <https://1145.am/db/2341325/Pfizer>,
        <https://1145.am/db/2341516/Pfizer>,
        <https://1145.am/db/2342559/Pfizer_Inc>,
        <https://1145.am/db/2343237/Pfizer_Inc>,
        <https://1145.am/db/2343273/Pfizer_Inc>,
        <https://1145.am/db/2343298/Pfizer_Inc>,
        <https://1145.am/db/2343344/Pfizer>,
        <https://1145.am/db/2343454/Pfizer_Inc>,
        <https://1145.am/db/2343861/Glaxosmithkline>,
        <https://1145.am/db/2344023/Glaxosmithkline>,
        <https://1145.am/db/2345065/Pfizer>,
        <https://1145.am/db/2345251/GSK>,
        <https://1145.am/db/2346602/Pfizer_Inc>,
        <https://1145.am/db/2347383/Pfizer_Inc>,
        <https://1145.am/db/2348510/Pfizer_Inc>,
        <https://1145.am/db/2351730/Pfizer_Inc>,
        <https://1145.am/db/2353039/Pfizer_Inc>,
        <https://1145.am/db/2353325/Pfizer>,
        <https://1145.am/db/2353326/Pfizer>,
        <https://1145.am/db/2353337/Pfizer>,
        <https://1145.am/db/2353364/Pfizer>,
        <https://1145.am/db/2353376/Pfizer>,
        <https://1145.am/db/2354567/Pfizer>,
        <https://1145.am/db/2355021/Pfizer>,
        <https://1145.am/db/2355025/Pfizer_Inc>,
        <https://1145.am/db/2355472/Pfizer_Inc>,
        <https://1145.am/db/2355641/GSK>,
        <https://1145.am/db/2355916/Pfizer_Inc>,
        <https://1145.am/db/2356124/Pfizer_Inc>,
        <https://1145.am/db/2356559/Glaxosmithkline>,
        <https://1145.am/db/2356597/Pfizer>,
        <https://1145.am/db/2356599/Pfizer>,
        <https://1145.am/db/2356811/GSK>,
        <https://1145.am/db/2357232/Pfizer>,
        <https://1145.am/db/2357308/Pfizer_Inc>,
        <https://1145.am/db/2358128/Pfizer>,
        <https://1145.am/db/2359697/Pfizer>,
        <https://1145.am/db/2359727/GSK>,
        <https://1145.am/db/2359727/Glaxosmithkline>,
        <https://1145.am/db/2359858/GSK>,
        <https://1145.am/db/2359858/Glaxosmithkline>,
        <https://1145.am/db/2360562/GSK>,
        <https://1145.am/db/2360633/Pfizer>,
        <https://1145.am/db/2361700/GSK>,
        <https://1145.am/db/2361705/GSK>,
        <https://1145.am/db/2362439/Pfizer_Inc>,
        <https://1145.am/db/2362851/Pfizer_Inc>,
        <https://1145.am/db/2363435/Gsk_Pfizer>,
        <https://1145.am/db/2363446/Pfizer_Inc>,
        <https://1145.am/db/2363896/Pfizer>,
        <https://1145.am/db/2364087/Pfizer_Inc>,
        <https://1145.am/db/2364813/Glaxosmithkline>,
        <https://1145.am/db/2365103/Glaxosmithkline>,
        <https://1145.am/db/2365171/Pfizer_Ventures>,
        <https://1145.am/db/2366395/Pfizer_Inc>,
        <https://1145.am/db/2367283/Pfizer_Inc>,
        <https://1145.am/db/2367982/Pfizer>,
        <https://1145.am/db/2368146/Pfizer>,
        <https://1145.am/db/2369451/Glaxosmithkline>,
        <https://1145.am/db/2369755/GSK>,
        <https://1145.am/db/2369761/Glaxosmithkline>,
        <https://1145.am/db/2369876/Pfizer>,
        <https://1145.am/db/2369909/Pfizer_Inc>,
        <https://1145.am/db/2370016/Pfizer>,
        <https://1145.am/db/2370635/GSK>,
        <https://1145.am/db/2370843/Glaxosmithkline>,
        <https://1145.am/db/2371512/Pfizer>,
        <https://1145.am/db/238329/GSK>,
        <https://1145.am/db/2507041/Pfizer>,
        <https://1145.am/db/2536358/Pfizer_Inc>,
        <https://1145.am/db/2536361/Pfizer_Inc>,
        <https://1145.am/db/2536362/Pfizer_Inc>,
        <https://1145.am/db/2536365/Pfizer_Inc>,
        <https://1145.am/db/2536475/Pfizer>,
        <https://1145.am/db/2536493/Glaxosmithkline>,
        <https://1145.am/db/2536856/Pfizer>,
        <https://1145.am/db/2537054/Pfizer_Inc>,
        <https://1145.am/db/2537057/Pfizer_Inc>,
        <https://1145.am/db/2537171/Pfizer>,
        <https://1145.am/db/2537597/Pfizer>,
        <https://1145.am/db/2537699/Glaxosmithkline>,
        <https://1145.am/db/2538568/Pfizer_Inc>,
        <https://1145.am/db/2538861/Pfizer>,
        <https://1145.am/db/2538915/Pfizer_Inc>,
        <https://1145.am/db/2538924/Pfizer>,
        <https://1145.am/db/2539516/Pfizer>,
        <https://1145.am/db/2539695/GSK>,
        <https://1145.am/db/2540020/Glaxosmithkline>,
        <https://1145.am/db/2540170/Glaxosmithkline>,
        <https://1145.am/db/2540356/Pfizer>,
        <https://1145.am/db/2541091/GSK>,
        <https://1145.am/db/2541139/Pfizer_Inc>,
        <https://1145.am/db/2541146/Pfizer>,
        <https://1145.am/db/2541721/Pfizer>,
        <https://1145.am/db/2542064/GSK>,
        <https://1145.am/db/2542067/Pfizer_Inc>,
        <https://1145.am/db/2542072/Pfizer>,
        <https://1145.am/db/2542499/Pfizer>,
        <https://1145.am/db/2543278/Pfizer>,
        <https://1145.am/db/2543533/Pfizer>,
        <https://1145.am/db/2543826/Pfizer>,
        <https://1145.am/db/2543957/Pfizer>,
        <https://1145.am/db/2544062/Glaxosmithkline>,
        <https://1145.am/db/2544074/Pfizer>,
        <https://1145.am/db/2545058/Pfizer>,
        <https://1145.am/db/2545122/Pfizer>,
        <https://1145.am/db/2545537/Glaxosmithkline>,
        <https://1145.am/db/2545618/Pfizer>,
        <https://1145.am/db/2545634/Pfizer>,
        <https://1145.am/db/2545818/Pfizer>,
        <https://1145.am/db/2545847/GSK>,
        <https://1145.am/db/2546136/Glaxosmithkline>,
        <https://1145.am/db/2546260/Glaxosmithkline>,
        <https://1145.am/db/2546577/Glaxosmithkline>,
        <https://1145.am/db/2546583/Pfizer>,
        <https://1145.am/db/2546596/Pfizer>,
        <https://1145.am/db/2547000/Pfizer>,
        <https://1145.am/db/2547653/Pfizer>,
        <https://1145.am/db/2547954/Glaxosmithkline>,
        <https://1145.am/db/2548244/Pfizer_Inc>,
        <https://1145.am/db/2548674/Pfizer>,
        <https://1145.am/db/2548752/GSK>,
        <https://1145.am/db/2548752/Pfizer>,
        <https://1145.am/db/2548986/Pfizer>,
        <https://1145.am/db/2549151/Pfizer>,
        <https://1145.am/db/2549598/Glaxosmithkline>,
        <https://1145.am/db/2549673/Pfizer>,
        <https://1145.am/db/2549694/Glaxosmithkline>,
        <https://1145.am/db/2549719/Pfizer>,
        <https://1145.am/db/2549876/Glaxosmithkline>,
        <https://1145.am/db/2550054/Glaxosmithkline>,
        <https://1145.am/db/2550445/Pfizer>,
        <https://1145.am/db/2550460/GSK>,
        <https://1145.am/db/2550662/Glaxosmithkline>,
        <https://1145.am/db/2550685/Pfizer>,
        <https://1145.am/db/2551402/Glaxosmithkline>,
        <https://1145.am/db/2552165/Glaxosmithkline>,
        <https://1145.am/db/2552684/Pfizer>,
        <https://1145.am/db/2552794/Glaxosmithkline>,
        <https://1145.am/db/2553974/Pfizer>,
        <https://1145.am/db/2554044/Glaxosmithkline>,
        <https://1145.am/db/2554937/Pfizer>,
        <https://1145.am/db/2554938/Pfizer>,
        <https://1145.am/db/2555012/Glaxosmithkline>,
        <https://1145.am/db/2555896/Pfizer>,
        <https://1145.am/db/2555992/Pfizer>,
        <https://1145.am/db/2556407/Glaxosmithkline>,
        <https://1145.am/db/2557064/Pfizer>,
        <https://1145.am/db/2557083/Pfizer>,
        <https://1145.am/db/2557221/Glaxosmithkline>,
        <https://1145.am/db/2557221/Pfizer>,
        <https://1145.am/db/2558268/Pfizer>,
        <https://1145.am/db/2558417/Pfizer>,
        <https://1145.am/db/2558464/Pfizer>,
        <https://1145.am/db/2558862/GSK>,
        <https://1145.am/db/2558970/Pfizer>,
        <https://1145.am/db/2558971/Pfizer>,
        <https://1145.am/db/2559649/Pfizer>,
        <https://1145.am/db/2560282/Pfizer>,
        <https://1145.am/db/2560633/Glaxosmithkline>,
        <https://1145.am/db/2560720/Pfizer>,
        <https://1145.am/db/2561231/Pfizer>,
        <https://1145.am/db/2561650/GSK>,
        <https://1145.am/db/2561650/Pfizer>,
        <https://1145.am/db/2562102/Pfizer_Inc>,
        <https://1145.am/db/2562701/Pfizer>,
        <https://1145.am/db/2562773/GSK>,
        <https://1145.am/db/2562951/Glaxosmithkline>,
        <https://1145.am/db/2563857/Pfizer>,
        <https://1145.am/db/2563889/Pfizer>,
        <https://1145.am/db/2564032/Pfizer>,
        <https://1145.am/db/2564695/Glaxosmithkline>,
        <https://1145.am/db/2564884/GSK>,
        <https://1145.am/db/2566186/GSK>,
        <https://1145.am/db/2568121/Pfizer>,
        <https://1145.am/db/2568519/Pfizer>,
        <https://1145.am/db/2568899/Pfizer>,
        <https://1145.am/db/2568973/Glaxosmithkline>,
        <https://1145.am/db/2569378/Pfizer>,
        <https://1145.am/db/2570369/Pfizer_Inc>,
        <https://1145.am/db/2570791/Glaxosmithkline>,
        <https://1145.am/db/2571798/Pfizer_Inc>,
        <https://1145.am/db/2572036/Pfizer>,
        <https://1145.am/db/2572429/Glaxosmithkline>,
        <https://1145.am/db/2572927/Pfizer>,
        <https://1145.am/db/2573173/Pfizer>,
        <https://1145.am/db/2573245/Pfizer_Inc>,
        <https://1145.am/db/2573463/Pfizer>,
        <https://1145.am/db/2573465/Pfizer_Inc>,
        <https://1145.am/db/2573466/Pfizer>,
        <https://1145.am/db/2573551/Pfizer_Inc>,
        <https://1145.am/db/2573558/Pfizer_Inc>,
        <https://1145.am/db/2573562/Pfizer>,
        <https://1145.am/db/2573707/Pfizer>,
        <https://1145.am/db/2574332/Pfizer>,
        <https://1145.am/db/2574459/Pfizer_Inc>,
        <https://1145.am/db/2574461/Pfizer_Inc>,
        <https://1145.am/db/2574687/Pfizer>,
        <https://1145.am/db/2574691/Pfizer_Inc>,
        <https://1145.am/db/2575139/Pfizer_Inc>,
        <https://1145.am/db/2575145/Pfizer_Inc>,
        <https://1145.am/db/2575320/Pfizer>,
        <https://1145.am/db/2575471/Pfizer>,
        <https://1145.am/db/2575505/Pfizer_Inc>,
        <https://1145.am/db/2575575/Pfizer>,
        <https://1145.am/db/2575712/GSK>,
        <https://1145.am/db/2575723/Pfizer>,
        <https://1145.am/db/2576330/Pfizer_Inc>,
        <https://1145.am/db/2576526/Pfizer>,
        <https://1145.am/db/2576759/Pfizer>,
        <https://1145.am/db/2576762/Pfizer>,
        <https://1145.am/db/2577077/Pfizer>,
        <https://1145.am/db/2577226/Glaxosmithkline>,
        <https://1145.am/db/2577258/Pfizer_Inc>,
        <https://1145.am/db/2577655/Pfizer>,
        <https://1145.am/db/2577778/Glaxosmithkline>,
        <https://1145.am/db/2578528/GSK>,
        <https://1145.am/db/2579205/Glaxosmithkline>,
        <https://1145.am/db/2579252/Pfizer>,
        <https://1145.am/db/2579709/Pfizer_Inc>,
        <https://1145.am/db/2579716/Pfizer>,
        <https://1145.am/db/2580940/Pfizer>,
        <https://1145.am/db/2581331/Pfizer_Inc>,
        <https://1145.am/db/2581334/Pfizer_Inc>,
        <https://1145.am/db/2581339/Pfizer>,
        <https://1145.am/db/2581394/Pfizer>,
        <https://1145.am/db/2581659/GSK>,
        <https://1145.am/db/2581659/Pfizer>,
        <https://1145.am/db/2581661/Pfizer_Inc>,
        <https://1145.am/db/2582158/Pfizer_Inc>,
        <https://1145.am/db/2582160/Pfizer_Inc>,
        <https://1145.am/db/2582233/Glaxosmithkline>,
        <https://1145.am/db/2582343/Pfizer_Inc>,
        <https://1145.am/db/2582879/Pfizer_Inc>,
        <https://1145.am/db/2583155/Pfizer_Inc>,
        <https://1145.am/db/2583163/Pfizer>,
        <https://1145.am/db/2583165/Pfizer_Inc>,
        <https://1145.am/db/2583172/Pfizer>,
        <https://1145.am/db/2583242/Pfizer_Inc>,
        <https://1145.am/db/2583245/Pfizer_Inc>,
        <https://1145.am/db/2583337/Pfizer_Inc>,
        <https://1145.am/db/2583783/Pfizer>,
        <https://1145.am/db/2584085/Pfizer_Inc>,
        <https://1145.am/db/2584258/Pfizer_Inc>,
        <https://1145.am/db/2584601/Pfizer_Inc>,
        <https://1145.am/db/2584968/Pfizer>,
        <https://1145.am/db/2585700/Pfizer>,
        <https://1145.am/db/2585908/New_York-Pfizer_Inc>,
        <https://1145.am/db/2585908/Pfizer>,
        <https://1145.am/db/2585912/Pfizer>,
        <https://1145.am/db/2586034/Pfizer_Inc>,
        <https://1145.am/db/2586047/Pfizer_Inc>,
        <https://1145.am/db/2586804/GSK>,
        <https://1145.am/db/2587282/Glaxosmithkline>,
        <https://1145.am/db/2587387/Pfizer>,
        <https://1145.am/db/2587673/Pfizer>,
        <https://1145.am/db/2587770/Glaxosmithkline>,
        <https://1145.am/db/2588134/Pfizer_Inc>,
        <https://1145.am/db/2589365/Pfizer>,
        <https://1145.am/db/2589701/GSK>,
        <https://1145.am/db/2590549/Pfizer_Inc>,
        <https://1145.am/db/2590887/Pfizer>,
        <https://1145.am/db/2590988/Pfizer>,
        <https://1145.am/db/2590989/Pfizer>,
        <https://1145.am/db/2591081/Pfizer_Inc>,
        <https://1145.am/db/2591091/Pfizer>,
        <https://1145.am/db/2591092/Pfizer_Inc>,
        <https://1145.am/db/2591281/Pfizer>,
        <https://1145.am/db/2591652/Pfizer>,
        <https://1145.am/db/2591691/Pfizer>,
        <https://1145.am/db/2591733/Pfizer>,
        <https://1145.am/db/2592975/Pfizer_Inc>,
        <https://1145.am/db/2592977/Pfizer_Inc>,
        <https://1145.am/db/2592980/Pfizer>,
        <https://1145.am/db/2592987/Glaxosmithkline>,
        <https://1145.am/db/2592990/Pfizer_Inc>,
        <https://1145.am/db/2592992/Pfizer_Inc>,
        <https://1145.am/db/2593150/Pfizer>,
        <https://1145.am/db/2593886/Pfizer>,
        <https://1145.am/db/2593961/Pfizer_Inc>,
        <https://1145.am/db/2594141/Pfizer_Inc>,
        <https://1145.am/db/2594268/Pfizer_Inc>,
        <https://1145.am/db/2594422/Pfizer>,
        <https://1145.am/db/2594489/Pfizer_Inc>,
        <https://1145.am/db/2594574/Pfizer>,
        <https://1145.am/db/2594581/Pfizer>,
        <https://1145.am/db/2594992/Pfizer>,
        <https://1145.am/db/2595320/Pfizer_Inc>,
        <https://1145.am/db/2595472/Pfizer>,
        <https://1145.am/db/2595499/Pfizer>,
        <https://1145.am/db/2596344/Pfizer>,
        <https://1145.am/db/2596754/Pfizer_Inc>,
        <https://1145.am/db/2596778/Pfizer>,
        <https://1145.am/db/2596874/Pfizer>,
        <https://1145.am/db/2596947/Pfizer>,
        <https://1145.am/db/2597173/Pfizer>,
        <https://1145.am/db/2597183/Pfizer_Inc>,
        <https://1145.am/db/2597220/Glaxosmithkline>,
        <https://1145.am/db/2597643/Pfizer_Inc>,
        <https://1145.am/db/2597650/Pfizer>,
        <https://1145.am/db/2597651/Pfizer_Inc>,
        <https://1145.am/db/2597712/Pfizer>,
        <https://1145.am/db/2598461/Glaxosmithkline>,
        <https://1145.am/db/274660/Pfizer_Inc>,
        <https://1145.am/db/274739/Pfizer_Inc>,
        <https://1145.am/db/2792911/Pfizer>,
        <https://1145.am/db/2797157/GSK>,
        <https://1145.am/db/286227/Glaxosmithkline>,
        <https://1145.am/db/318295/Pfizer_Inc>,
        <https://1145.am/db/338190/GSK>,
        <https://1145.am/db/338242/Glaxosmithkline>,
        <https://1145.am/db/377761/Glaxosmithkline>,
        <https://1145.am/db/377769/Glaxosmithkline>,
        <https://1145.am/db/385094/GSK>,
        <https://1145.am/db/385100/GSK>,
        <https://1145.am/db/422377/Pfizer_Inc>,
        <https://1145.am/db/422378/Pfizer_Inc>,
        <https://1145.am/db/423571/Pfizer_Inc>,
        <https://1145.am/db/424190/Pfizer_Inc>,
        <https://1145.am/db/424896/Pfizer_Inc>,
        <https://1145.am/db/425689/Pfizer_Inc>,
        <https://1145.am/db/426841/Pfizer_Inc>,
        <https://1145.am/db/428975/Pfizer_Inc>,
        <https://1145.am/db/494811/GSK>,
        <https://1145.am/db/582690/GSK>,
        <https://1145.am/db/582690/Glaxosmithkline>,
        <https://1145.am/db/626832/Pfizer_Inc>,
        <https://1145.am/db/627349/Pfizer_Inc>,
        <https://1145.am/db/631317/Pfizer_Inc>,
        <https://1145.am/db/635031/Pfizer>,
        <https://1145.am/db/661291/GSK>,
        <https://1145.am/db/692994/Pfizer_Inc>,
        <https://1145.am/db/694218/Pfizer_Inc>,
        <https://1145.am/db/694224/Pfizer_Inc>,
        <https://1145.am/db/696927/Pfizer_Inc>,
        <https://1145.am/db/699199/Pfizer>,
        <https://1145.am/db/704642/Glaxosmithkline_Plc>,
        <https://1145.am/db/76007/Pfizer>,
        <https://1145.am/db/761748/Pfizer>,
        <https://1145.am/db/764460/Pfizer>,
        <https://1145.am/db/797138/Pfizer_Inc>,
        <https://1145.am/db/800318/Pfizer_Inc>,
        <https://1145.am/db/87287/Glaxosmithkline>,
        <https://1145.am/db/896566/Pfizer_Inc>,
        <https://1145.am/db/897457/Pfizer_Inc>,
        <https://1145.am/db/962850/Pfizer_Inc>,
        <https://1145.am/db/962851/Pfizer_Inc>,
        <https://1145.am/db/962899/Pfizer_Inc>,
        <https://1145.am/db/965490/Pfizer_Inc>,
        <https://1145.am/db/968220/Pfizer_Inc>,
        <https://1145.am/db/971984/Pfizer_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1936264/Pfizer_Inc>,
        <https://1145.am/db/1983382/Pfizer_Inc>,
        <https://1145.am/db/2313175/Pfizer_Limited>,
        <https://1145.am/db/2327506/Pfizer>,
        <https://1145.am/db/2332830/Pfizer>,
        <https://1145.am/db/2350231/Pfizer>,
        <https://1145.am/db/2354370/Pfizer_Inc>,
        <https://1145.am/db/2539787/Pfizer>,
        <https://1145.am/db/2548137/Pfizer>,
        <https://1145.am/db/2550761/Pfizer>,
        <https://1145.am/db/2576064/Pfizer>,
        <https://1145.am/db/2595930/Pfizer>,
        <https://1145.am/db/2597185/Pfizer_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360647/Series_A_Investment_Canaan_Partners_Interwest_Partners_Labrys_Biologics_Inc_Labrys_Biologics_Inc_Pfizer_Inc_Sofinnova_Ventures_Venbio_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-03T13:28:19+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ - Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $ 31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures." ;
    ns1:documentTitle "Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/labrys-biologics-secures-31-million-series-a-financing-from-venture-capital-firms-acquires> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360647/Labrys_Biologics_Inc>,
        <https://1145.am/db/2360647/Pfizer_Inc> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 31 Million" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2351191/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-24T15:08:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding.",
        "Toulouse, France, April 24th 2013 - Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV) , announced today that it has raised EUR 18.2 million (USD 23,7 million) in additional capital." ;
    ns1:documentTitle "Genticel secures EUR 18.2 million (USD 23.7 million) in capital funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/genticel-secures-eur-18-2-million-usd-23-7-million-capital-funding> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2351191/Genticel> ;
    ns1:targetDetails "capital" ;
    ns1:valueRaw "EUR 18.2 million",
        "USD 23,7 million",
        "USD 23.7 million" ;
    ns1:when "2013-04-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 24th 2013" ;
    ns1:whereRaw "Genticel" .

<https://1145.am/db/2351192/Investment_Amundi_Private_Equity_Funds_Edmond_De_Rothschild_Investment_Partners_Genticel_Idinvest_Partners_Irdi_Innobio_Fund_Wellington_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-24T15:43:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Some top life sciences investors have backed France - based vaccine developer Genticel in an 18.2 million round of venture financing.",
        "Wellington Partners, headquartered in Munich, spearheaded Genticel's new venture round, which included all previous backers IDInvest Partners, Edmond de Rothschild Investment Partners, InnoBio fund, IRDI and Amundi Private Equity Funds, according to the biotech company." ;
    ns1:documentTitle "French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/french-biotech-genticel-lands-23-7m-for-blockbuster-hpv-vaccine-hopeful> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2351192/Genticel> ;
    ns1:targetDetails "venture" ;
    ns1:valueRaw "18.2 million" ;
    ns1:whenRaw "2012" ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "France" .

<https://1145.am/db/2352170/Preferred_Stock_Investment_Aisling_Capital_Alta_Partners_Arboretum_Ventures_Asset_Management_Domain_Associates_Esperion_Therapeutics_Longitude_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-25T14:20:21+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Esperion Therapeutics Completes $ 33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials.",
        "Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced that it has completed a $ 33 million preferred stock financing led by new investor Longitude Capital." ;
    ns1:documentTitle "Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/esperion-therapeutics-completes-33-million-preferred-financing-to-advance-its-novel-oral> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352170/Esperion_Therapeutics> ;
    ns1:targetDetails "Preferred",
        "preferred stock" ;
    ns1:valueRaw "$ 33 Million",
        "$ 33 million" .

<https://1145.am/db/2352172/Investment_Bb_Biotech_Ventures_Biotech_Growth_Nv_Brookside_Capital_F2_Biosciences_Iii_Lp_Mpm_Bio_Iv_Nvs_Strategic_Fund_Mpm_Capital_Radius_Health_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-25T15:15:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, MA- (Marketwired - Apr 25, 2013) - Radius Health, Inc. (\"Radius\") , a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it has completed a new equity financing of $ 43 million.",
        "Radius Health Completes $ 43 Million Financing to Advance BA058 for the Treatment of Osteoporosis." ;
    ns1:documentTitle "Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/radius-health-completes-43-million-financing-to-advance-ba058-for-treatment-of-osteoporosis> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352172/Radius_Health> ;
    ns1:targetDetails "equity" ;
    ns1:valueRaw "$ 43 Million",
        "$ 43 million" ;
    ns1:whenRaw "2013" ;
    ns1:whereGeoName "Health" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4114208/about.rdf> ;
    ns1:whereRaw "Radius Health" .

<https://1145.am/db/2362715/Series_D_Investment_Aileron_Therapeutics_Apple_Tree_Partners_Excel_Venture_Management_Lilly_Ventures_Novartis_Venture_Funds_Roche_Venture_Fund_Sr_One_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-01-14T14:22:38+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Aileron Therapeutics Secures $ 12 Million for First-Ever Stapled Peptide Clinical Trial.",
        "CAMBRIDGE, Mass., January 14, 2013 - Aileron Therapeutics, Inc. today announced that it secured the second tranche in its Series D financing, bringing the total round to $ 42 million." ;
    ns1:documentTitle "Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aileron-therapeutics-secures-12-million-for-first-ever-stapled-peptide-clinical-trial> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2362715/Aileron_Therapeutics> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 12 Million",
        "$ 42 Million",
        "$ 42 million" ;
    ns1:when "2013-01-14T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "January 14, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2358430/Series_A_Investment_Abingworth_Astellas_Venture_Management_Mission_Bay_Capital_Novartis_Venture_Funds_Osage_University_Partners_Sr_One_Us_Venture_Partners_Effector_Therapeutics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-05-20T11:30:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "San Diego, CA - May 20, 2013 - eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $ 45 million Series A financing.",
        "eFFECTOR Therapeutics Raises $ 45 Million in Series A Financing." ;
    ns1:documentTitle "eFFECTOR Therapeutics Raises $45 Million in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/venture-capital/effector-therapeutics-raises-45-million-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2358430/Effector_Therapeutics> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 45 Million",
        "$ 45 million" ;
    ns1:when "2013-05-20T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 20, 2013" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2336923/Series_B_Investment_Biotech_Fund_Flanders_Crp-Sant_Complix_Edmond_De_Rothschild_Investment_Partners_Gemma_Frisius_Fund_Trustcapital_Vinnof_Gimv_Gimv_Lrm_Omnes_Capital_Vesalius_Biocapital_Vinnof_Baekeland_Fund_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-06-26T15:58:16+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Complix Raises 12 Million (US $ 15.5 million) in Series B Round.",
        "Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies, a unique class of protein therapeutics active against intracellular disease targets, announces the successful closing of a 12 million (US $ 15.5 million) Series B equity financing roundfrom a syndicate of leading life sciences investors." ;
    ns1:documentTitle "Complix Raises 12 Million (US$15.5 million) in Series B Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/complix-raises-%E2%82%AC12-million-us-15-5-million-series-b-round> ;
    ns1:foundName "equity",
        "financing" ;
    ns1:name "equity",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336923/Complix> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "US $ 15.5 million",
        "12 Million",
        "12 million" ;
    ns1:whereGeoName "Republic of France" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:whereRaw "France" .

<https://1145.am/db/2352203/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Limited_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T11:00:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Opsona Therapeutics Limited ('Opsona' ), the innate immune drug development company, today announced that it has raised 33 million (US $ 43 million) in an oversubscribed Series C financing.",
        "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305." ;
    ns1:documentTitle "Opsona Therapeutics Limited raises 33 million (US $ 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-therapeutics-limited-raises-%E2%82%AC33-million-us-43-million-oversubscribed-series-c-equity> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352203/Opsona_Therapeutics_Limited> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "US $ 43 million",
        "33 million" .

<https://1145.am/db/2352204/Series_C_Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T11:26:23+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Opsona Raises 33 million. Posted on: April 29, 2013.",
        "Opsona Therapeutics Limited ('Opsona' ), the innate immune drug development company, today announced that it has raised 33 million (US $ 43 million) in an oversubscribed Series C financing.",
        "Opsona Therapeutics raised 33 million (US $ 43 million) in an oversubscribed Series C financing led by BB Biotech Ventures and Novartis Venture Fund." ;
    ns1:documentTitle "Opsona Raises 33 million" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/opsona-raises-%E2%82%AC33-million> ;
    ns1:foundName "Raises",
        "financing",
        "raised" ;
    ns1:name "Raises",
        "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352204/Opsona_Therapeutics> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "US $ 43 million",
        "33 million" ;
    ns1:whereGeoName "Kingdom of Spain" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2510769/about.rdf> ;
    ns1:whereRaw "Spain" .

<https://1145.am/db/2352216/Investment_Amgen_Ventures_Bb_Biotech_Ventures_Baxter_Ventures_Embl_Ventures_Fountain_Healthcare_Partners_Novartis_Venture_Fund_Opsona_Therapeutics_Roche_Venture_Fund_Seroba_Kernel_Life_Sciences_Sunstone_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2013-04-29T15:12:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Dublin - based Opsona Therapeutics has raised $ 43 million to fund a midstage study of its lead drug OPN-305." ;
    ns1:documentTitle "Pharma venture arms contribute to Opsona's $43M round; Heptares picks up Takeda payment; Oxford BioTherapeutics collaborates with Boehringer;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/pharma-venture-arms-contribute-to-opsona-s-43m-round-heptares-picks-up-takeda-payment> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352216/Opsona_Therapeutics> ;
    ns1:valueRaw "$ 43 million" ;
    ns1:whereGeoName "Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2963597/about.rdf> ;
    ns1:whereRaw "Ireland" .

